bio-datasets/bigbio-ner-merged · Datasets at Hugging Face

answer stringlengths 1 16.1k	id stringlengths 7 56	instruction stringlengths 106 72.6k	ner_tags list	text stringlengths 5 72.4k	tokens list	types list
Nuclear is a Entity, beta - catenin is a Protein, lymphoid enhancer factor 1 is a Protein, beta - catenin is a Protein, nucleus is a Entity, beta - catenin is a Protein, beta - catenin is a Protein, nucleus is a Entity, beta - catenin is a Protein, LEF-1 is a Protein, E - cadherin is a Protein, APC is a Protein, axin is a Protein, beta - catenin is a Protein, beta - catenin is a Protein, nucleus is a Entity, beta - Catenin is a Protein, LEF-1 is a Protein, nuclear is a Entity, nucleus is a Entity, beta - catenin is a Protein, VP16 is a Protein	10330189_task1	Sentence: Nuclear localization and formation of beta-catenin-lymphoid enhancer factor 1 complexes are not sufficient for activation of gene expression. In response to activation of the Wnt signaling pathway, beta-catenin accumulates in the nucleus, where it cooperates with LEF/TCF (for lymphoid enhancer factor and T-cell factor) transcription factors to activate gene expression. The mechanisms by which beta-catenin undergoes this shift in location and participates in activation of gene transcription are unknown. We demonstrate here that beta-catenin can be imported into the nucleus independently of LEF/TCF binding, and it may also be exported from nuclei. We have introduced a small deletion within beta-catenin (Delta19) that disrupts binding to LEF-1, E-cadherin, and APC but not axin. This Delta19 beta-catenin mutant localizes to the nucleus because it may not be efficiently sequestered in the cytoplasm. The nuclear localization of Delta19 definitively demonstrates that the mechanisms by which beta-catenin localizes in the nucleus are completely independent of LEF/TCF factors. beta-Catenin and LEF-1 complexes can activate reporter gene expression in a transformed T-lymphocyte cell line (Jurkat) but not in normal T lymphocytes, even though both factors are nuclear. Thus, localization of both factors to the nucleus is not sufficient for activation of gene expression. Excess beta-catenin can squelch reporter gene activation by LEF-1-beta-catenin complexes but not activation by the transcription factor VP16. Taken together, these data suggest that a third component is necessary for gene activation and that this third component may vary with cell type. Instructions: please typing these entity words according to sentence: Nuclear, beta - catenin, lymphoid enhancer factor 1, beta - catenin, nucleus, beta - catenin, beta - catenin, nucleus, beta - catenin, LEF-1, E - cadherin, APC, axin, beta - catenin, beta - catenin, nucleus, beta - Catenin, LEF-1, nuclear, nucleus, beta - catenin, VP16 Options: Entity, Protein	[ "B-Entity", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "B-Protein", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Nuclear localization and formation of beta-catenin-lymphoid enhancer factor 1 complexes are not sufficient for activation of gene expression. In response to activation of the Wnt signaling pathway, beta-catenin accumulates in the nucleus, where it cooperates with LEF/TCF (for lymphoid enhancer factor and T-cell factor) transcription factors to activate gene expression. The mechanisms by which beta-catenin undergoes this shift in location and participates in activation of gene transcription are unknown. We demonstrate here that beta-catenin can be imported into the nucleus independently of LEF/TCF binding, and it may also be exported from nuclei. We have introduced a small deletion within beta-catenin (Delta19) that disrupts binding to LEF-1, E-cadherin, and APC but not axin. This Delta19 beta-catenin mutant localizes to the nucleus because it may not be efficiently sequestered in the cytoplasm. The nuclear localization of Delta19 definitively demonstrates that the mechanisms by which beta-catenin localizes in the nucleus are completely independent of LEF/TCF factors. beta-Catenin and LEF-1 complexes can activate reporter gene expression in a transformed T-lymphocyte cell line (Jurkat) but not in normal T lymphocytes, even though both factors are nuclear. Thus, localization of both factors to the nucleus is not sufficient for activation of gene expression. Excess beta-catenin can squelch reporter gene activation by LEF-1-beta-catenin complexes but not activation by the transcription factor VP16. Taken together, these data suggest that a third component is necessary for gene activation and that this third component may vary with cell type.	[ "Nuclear", "localization", "and", "formation", "of", "beta", "-", "catenin", "-", "lymphoid", "enhancer", "factor", "1", "complexes", "are", "not", "sufficient", "for", "activation", "of", "gene", "expression", ".", "\n", "In", "response", "to", "activation", "of", "the", "Wnt", "signaling", "pathway", ",", "beta", "-", "catenin", "accumulates", "in", "the", "nucleus", ",", "where", "it", "cooperates", "with", "LEF", "/", "TCF", "(", "for", "lymphoid", "enhancer", "factor", "and", "T", "-", "cell", "factor", ")", "transcription", "factors", "to", "activate", "gene", "expression", ".", "The", "mechanisms", "by", "which", "beta", "-", "catenin", "undergoes", "this", "shift", "in", "location", "and", "participates", "in", "activation", "of", "gene", "transcription", "are", "unknown", ".", "We", "demonstrate", "here", "that", "beta", "-", "catenin", "can", "be", "imported", "into", "the", "nucleus", "independently", "of", "LEF", "/", "TCF", "binding", ",", "and", "it", "may", "also", "be", "exported", "from", "nuclei", ".", "We", "have", "introduced", "a", "small", "deletion", "within", "beta", "-", "catenin", "(", "Delta19", ")", "that", "disrupts", "binding", "to", "LEF-1", ",", "E", "-", "cadherin", ",", "and", "APC", "but", "not", "axin", ".", "This", "Delta19", "beta", "-", "catenin", "mutant", "localizes", "to", "the", "nucleus", "because", "it", "may", "not", "be", "efficiently", "sequestered", "in", "the", "cytoplasm", ".", "The", "nuclear", "localization", "of", "Delta19", "definitively", "demonstrates", "that", "the", "mechanisms", "by", "which", "beta", "-", "catenin", "localizes", "in", "the", "nucleus", "are", "completely", "independent", "of", "LEF", "/", "TCF", "factors", ".", "beta", "-", "Catenin", "and", "LEF-1", "complexes", "can", "activate", "reporter", "gene", "expression", "in", "a", "transformed", "T", "-", "lymphocyte", "cell", "line", "(", "Jurkat", ")", "but", "not", "in", "normal", "T", "lymphocytes", ",", "even", "though", "both", "factors", "are", "nuclear", ".", "Thus", ",", "localization", "of", "both", "factors", "to", "the", "nucleus", "is", "not", "sufficient", "for", "activation", "of", "gene", "expression", ".", "Excess", "beta", "-", "catenin", "can", "squelch", "reporter", "gene", "activation", "by", "LEF-1-beta", "-", "catenin", "complexes", "but", "not", "activation", "by", "the", "transcription", "factor", "VP16", ".", "Taken", "together", ",", "these", "data", "suggest", "that", "a", "third", "component", "is", "necessary", "for", "gene", "activation", "and", "that", "this", "third", "component", "may", "vary", "with", "cell", "type", "." ]	[ "Protein", "Entity" ]
Nuclear, beta - catenin, lymphoid enhancer factor 1, beta - catenin, nucleus, beta - catenin, beta - catenin, nucleus, beta - catenin, LEF-1, E - cadherin, APC, axin, beta - catenin, beta - catenin, nucleus, beta - Catenin, LEF-1, nuclear, nucleus, beta - catenin, VP16	10330189_task2	Sentence: Nuclear localization and formation of beta-catenin-lymphoid enhancer factor 1 complexes are not sufficient for activation of gene expression. In response to activation of the Wnt signaling pathway, beta-catenin accumulates in the nucleus, where it cooperates with LEF/TCF (for lymphoid enhancer factor and T-cell factor) transcription factors to activate gene expression. The mechanisms by which beta-catenin undergoes this shift in location and participates in activation of gene transcription are unknown. We demonstrate here that beta-catenin can be imported into the nucleus independently of LEF/TCF binding, and it may also be exported from nuclei. We have introduced a small deletion within beta-catenin (Delta19) that disrupts binding to LEF-1, E-cadherin, and APC but not axin. This Delta19 beta-catenin mutant localizes to the nucleus because it may not be efficiently sequestered in the cytoplasm. The nuclear localization of Delta19 definitively demonstrates that the mechanisms by which beta-catenin localizes in the nucleus are completely independent of LEF/TCF factors. beta-Catenin and LEF-1 complexes can activate reporter gene expression in a transformed T-lymphocyte cell line (Jurkat) but not in normal T lymphocytes, even though both factors are nuclear. Thus, localization of both factors to the nucleus is not sufficient for activation of gene expression. Excess beta-catenin can squelch reporter gene activation by LEF-1-beta-catenin complexes but not activation by the transcription factor VP16. Taken together, these data suggest that a third component is necessary for gene activation and that this third component may vary with cell type. Instructions: please extract entity words from the input sentence	[ "B-Entity", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "B-Protein", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Nuclear localization and formation of beta-catenin-lymphoid enhancer factor 1 complexes are not sufficient for activation of gene expression. In response to activation of the Wnt signaling pathway, beta-catenin accumulates in the nucleus, where it cooperates with LEF/TCF (for lymphoid enhancer factor and T-cell factor) transcription factors to activate gene expression. The mechanisms by which beta-catenin undergoes this shift in location and participates in activation of gene transcription are unknown. We demonstrate here that beta-catenin can be imported into the nucleus independently of LEF/TCF binding, and it may also be exported from nuclei. We have introduced a small deletion within beta-catenin (Delta19) that disrupts binding to LEF-1, E-cadherin, and APC but not axin. This Delta19 beta-catenin mutant localizes to the nucleus because it may not be efficiently sequestered in the cytoplasm. The nuclear localization of Delta19 definitively demonstrates that the mechanisms by which beta-catenin localizes in the nucleus are completely independent of LEF/TCF factors. beta-Catenin and LEF-1 complexes can activate reporter gene expression in a transformed T-lymphocyte cell line (Jurkat) but not in normal T lymphocytes, even though both factors are nuclear. Thus, localization of both factors to the nucleus is not sufficient for activation of gene expression. Excess beta-catenin can squelch reporter gene activation by LEF-1-beta-catenin complexes but not activation by the transcription factor VP16. Taken together, these data suggest that a third component is necessary for gene activation and that this third component may vary with cell type.	[ "Nuclear", "localization", "and", "formation", "of", "beta", "-", "catenin", "-", "lymphoid", "enhancer", "factor", "1", "complexes", "are", "not", "sufficient", "for", "activation", "of", "gene", "expression", ".", "\n", "In", "response", "to", "activation", "of", "the", "Wnt", "signaling", "pathway", ",", "beta", "-", "catenin", "accumulates", "in", "the", "nucleus", ",", "where", "it", "cooperates", "with", "LEF", "/", "TCF", "(", "for", "lymphoid", "enhancer", "factor", "and", "T", "-", "cell", "factor", ")", "transcription", "factors", "to", "activate", "gene", "expression", ".", "The", "mechanisms", "by", "which", "beta", "-", "catenin", "undergoes", "this", "shift", "in", "location", "and", "participates", "in", "activation", "of", "gene", "transcription", "are", "unknown", ".", "We", "demonstrate", "here", "that", "beta", "-", "catenin", "can", "be", "imported", "into", "the", "nucleus", "independently", "of", "LEF", "/", "TCF", "binding", ",", "and", "it", "may", "also", "be", "exported", "from", "nuclei", ".", "We", "have", "introduced", "a", "small", "deletion", "within", "beta", "-", "catenin", "(", "Delta19", ")", "that", "disrupts", "binding", "to", "LEF-1", ",", "E", "-", "cadherin", ",", "and", "APC", "but", "not", "axin", ".", "This", "Delta19", "beta", "-", "catenin", "mutant", "localizes", "to", "the", "nucleus", "because", "it", "may", "not", "be", "efficiently", "sequestered", "in", "the", "cytoplasm", ".", "The", "nuclear", "localization", "of", "Delta19", "definitively", "demonstrates", "that", "the", "mechanisms", "by", "which", "beta", "-", "catenin", "localizes", "in", "the", "nucleus", "are", "completely", "independent", "of", "LEF", "/", "TCF", "factors", ".", "beta", "-", "Catenin", "and", "LEF-1", "complexes", "can", "activate", "reporter", "gene", "expression", "in", "a", "transformed", "T", "-", "lymphocyte", "cell", "line", "(", "Jurkat", ")", "but", "not", "in", "normal", "T", "lymphocytes", ",", "even", "though", "both", "factors", "are", "nuclear", ".", "Thus", ",", "localization", "of", "both", "factors", "to", "the", "nucleus", "is", "not", "sufficient", "for", "activation", "of", "gene", "expression", ".", "Excess", "beta", "-", "catenin", "can", "squelch", "reporter", "gene", "activation", "by", "LEF-1-beta", "-", "catenin", "complexes", "but", "not", "activation", "by", "the", "transcription", "factor", "VP16", ".", "Taken", "together", ",", "these", "data", "suggest", "that", "a", "third", "component", "is", "necessary", "for", "gene", "activation", "and", "that", "this", "third", "component", "may", "vary", "with", "cell", "type", "." ]	[ "Protein", "Entity" ]
vitamin D3-binding protein is a Protein, alpha - N - acetylgalactosaminidase is a Protein, Gc is a Protein, vitamin D3-binding protein is a Protein, beta - galactosidase is a Protein, Gc is a Protein, Gc is a Protein, beta - galactosidase is a Protein, Gc is a Protein, Gc is a Protein, alpha - N - acetylgalactosaminidase is a Protein, alpha - N - acetylgalactosaminidase is a Protein, Gc is a Protein, Gc is a Protein, alpha - N - acetylgalactosaminidase is a Protein	570_task0	Sentence: Deglycosylation of serum vitamin D3-binding protein by alpha-N-acetylgalactosaminidase detected in the plasma of patients with systemic lupus erythematosus. A serum glycoprotein, Gc protein (vitamin D3-binding protein), can be converted by beta-galactosidase of B cells and sialidase of T cells to a potent macrophage-activating factor (MAF), a protein with N-acetylgalactosamine as the remaining sugar moiety. Thus, Gc protein is the precursor for MAF. Treatment of Gc protein with immobilized beta-galactosidase and sialidase generates a remarkably high titered macrophage-activating factor (GcMAF). When peripheral blood monocytes/ macrophages (designated macrophages) of 33 systemic lupus erythematosus patients were incubated with GcMAF (100 pg/ml), the macrophages of all patients were activated as determined by superoxide generation. However, the precursor activity of patient plasma Gc protein was lost or reduced in these patients. Loss of the precursor activity was the result of deglycosylation of plasma Gc protein by alpha-N-acetylgalactosaminidase activity found in the patient plasma. Levels of plasma alpha-N-acetylgalactosaminidase activity in individual patients had an inverse correlation with the MAF precursor activity of their plasma Gc protein. Deglycosylated Gc protein cannot be converted to macro-phage-activating factor. The resulting defect in macro-phage activation may lead to an inability to clear pathogenic immune complexes. Thus, elevated plasma alpha-N-acetylgalactosaminidase activity resulting in the loss of MAF precursor activity and reduced macro-phage activity may play a role in the pathogenesis of systemic lupus erythematosus. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein	[ "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Deglycosylation of serum vitamin D3-binding protein by alpha-N-acetylgalactosaminidase detected in the plasma of patients with systemic lupus erythematosus. A serum glycoprotein, Gc protein (vitamin D3-binding protein), can be converted by beta-galactosidase of B cells and sialidase of T cells to a potent macrophage-activating factor (MAF), a protein with N-acetylgalactosamine as the remaining sugar moiety. Thus, Gc protein is the precursor for MAF. Treatment of Gc protein with immobilized beta-galactosidase and sialidase generates a remarkably high titered macrophage-activating factor (GcMAF). When peripheral blood monocytes/ macrophages (designated macrophages) of 33 systemic lupus erythematosus patients were incubated with GcMAF (100 pg/ml), the macrophages of all patients were activated as determined by superoxide generation. However, the precursor activity of patient plasma Gc protein was lost or reduced in these patients. Loss of the precursor activity was the result of deglycosylation of plasma Gc protein by alpha-N-acetylgalactosaminidase activity found in the patient plasma. Levels of plasma alpha-N-acetylgalactosaminidase activity in individual patients had an inverse correlation with the MAF precursor activity of their plasma Gc protein. Deglycosylated Gc protein cannot be converted to macro-phage-activating factor. The resulting defect in macro-phage activation may lead to an inability to clear pathogenic immune complexes. Thus, elevated plasma alpha-N-acetylgalactosaminidase activity resulting in the loss of MAF precursor activity and reduced macro-phage activity may play a role in the pathogenesis of systemic lupus erythematosus.	[ "Deglycosylation", "of", "serum", "vitamin", "D3-binding", "protein", "by", "alpha", "-", "N", "-", "acetylgalactosaminidase", "detected", "in", "the", "plasma", "of", "patients", "with", "systemic", "lupus", "erythematosus", ".", "\n", "A", "serum", "glycoprotein", ",", "Gc", "protein", "(", "vitamin", "D3-binding", "protein", ")", ",", "can", "be", "converted", "by", "beta", "-", "galactosidase", "of", "B", "cells", "and", "sialidase", "of", "T", "cells", "to", "a", "potent", "macrophage", "-", "activating", "factor", "(", "MAF", ")", ",", "a", "protein", "with", "N", "-", "acetylgalactosamine", "as", "the", "remaining", "sugar", "moiety", ".", "Thus", ",", "Gc", "protein", "is", "the", "precursor", "for", "MAF", ".", "Treatment", "of", "Gc", "protein", "with", "immobilized", "beta", "-", "galactosidase", "and", "sialidase", "generates", "a", "remarkably", "high", "titered", "macrophage", "-", "activating", "factor", "(", "GcMAF", ")", ".", "When", "peripheral", "blood", "monocytes/", "macrophages", "(", "designated", "macrophages", ")", "of", "33", "systemic", "lupus", "erythematosus", "patients", "were", "incubated", "with", "GcMAF", "(", "100", "pg", "/", "ml", ")", ",", "the", "macrophages", "of", "all", "patients", "were", "activated", "as", "determined", "by", "superoxide", "generation", ".", "However", ",", "the", "precursor", "activity", "of", "patient", "plasma", "Gc", "protein", "was", "lost", "or", "reduced", "in", "these", "patients", ".", "Loss", "of", "the", "precursor", "activity", "was", "the", "result", "of", "deglycosylation", "of", "plasma", "Gc", "protein", "by", "alpha", "-", "N", "-", "acetylgalactosaminidase", "activity", "found", "in", "the", "patient", "plasma", ".", "Levels", "of", "plasma", "alpha", "-", "N", "-", "acetylgalactosaminidase", "activity", "in", "individual", "patients", "had", "an", "inverse", "correlation", "with", "the", "MAF", "precursor", "activity", "of", "their", "plasma", "Gc", "protein", ".", "Deglycosylated", "Gc", "protein", "cannot", "be", "converted", "to", "macro", "-", "phage", "-", "activating", "factor", ".", "The", "resulting", "defect", "in", "macro", "-", "phage", "activation", "may", "lead", "to", "an", "inability", "to", "clear", "pathogenic", "immune", "complexes", ".", "Thus", ",", "elevated", "plasma", "alpha", "-", "N", "-", "acetylgalactosaminidase", "activity", "resulting", "in", "the", "loss", "of", "MAF", "precursor", "activity", "and", "reduced", "macro", "-", "phage", "activity", "may", "play", "a", "role", "in", "the", "pathogenesis", "of", "systemic", "lupus", "erythematosus", ".", "\n" ]	[ "Protein" ]
vitamin D3-binding protein is a Protein, alpha - N - acetylgalactosaminidase is a Protein, Gc is a Protein, vitamin D3-binding protein is a Protein, beta - galactosidase is a Protein, Gc is a Protein, Gc is a Protein, beta - galactosidase is a Protein, Gc is a Protein, Gc is a Protein, alpha - N - acetylgalactosaminidase is a Protein, alpha - N - acetylgalactosaminidase is a Protein, Gc is a Protein, Gc is a Protein, alpha - N - acetylgalactosaminidase is a Protein	570_task1	Sentence: Deglycosylation of serum vitamin D3-binding protein by alpha-N-acetylgalactosaminidase detected in the plasma of patients with systemic lupus erythematosus. A serum glycoprotein, Gc protein (vitamin D3-binding protein), can be converted by beta-galactosidase of B cells and sialidase of T cells to a potent macrophage-activating factor (MAF), a protein with N-acetylgalactosamine as the remaining sugar moiety. Thus, Gc protein is the precursor for MAF. Treatment of Gc protein with immobilized beta-galactosidase and sialidase generates a remarkably high titered macrophage-activating factor (GcMAF). When peripheral blood monocytes/ macrophages (designated macrophages) of 33 systemic lupus erythematosus patients were incubated with GcMAF (100 pg/ml), the macrophages of all patients were activated as determined by superoxide generation. However, the precursor activity of patient plasma Gc protein was lost or reduced in these patients. Loss of the precursor activity was the result of deglycosylation of plasma Gc protein by alpha-N-acetylgalactosaminidase activity found in the patient plasma. Levels of plasma alpha-N-acetylgalactosaminidase activity in individual patients had an inverse correlation with the MAF precursor activity of their plasma Gc protein. Deglycosylated Gc protein cannot be converted to macro-phage-activating factor. The resulting defect in macro-phage activation may lead to an inability to clear pathogenic immune complexes. Thus, elevated plasma alpha-N-acetylgalactosaminidase activity resulting in the loss of MAF precursor activity and reduced macro-phage activity may play a role in the pathogenesis of systemic lupus erythematosus. Instructions: please typing these entity words according to sentence: vitamin D3-binding protein, alpha - N - acetylgalactosaminidase, Gc, vitamin D3-binding protein, beta - galactosidase, Gc, Gc, beta - galactosidase, Gc, Gc, alpha - N - acetylgalactosaminidase, alpha - N - acetylgalactosaminidase, Gc, Gc, alpha - N - acetylgalactosaminidase Options: Protein	[ "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Deglycosylation of serum vitamin D3-binding protein by alpha-N-acetylgalactosaminidase detected in the plasma of patients with systemic lupus erythematosus. A serum glycoprotein, Gc protein (vitamin D3-binding protein), can be converted by beta-galactosidase of B cells and sialidase of T cells to a potent macrophage-activating factor (MAF), a protein with N-acetylgalactosamine as the remaining sugar moiety. Thus, Gc protein is the precursor for MAF. Treatment of Gc protein with immobilized beta-galactosidase and sialidase generates a remarkably high titered macrophage-activating factor (GcMAF). When peripheral blood monocytes/ macrophages (designated macrophages) of 33 systemic lupus erythematosus patients were incubated with GcMAF (100 pg/ml), the macrophages of all patients were activated as determined by superoxide generation. However, the precursor activity of patient plasma Gc protein was lost or reduced in these patients. Loss of the precursor activity was the result of deglycosylation of plasma Gc protein by alpha-N-acetylgalactosaminidase activity found in the patient plasma. Levels of plasma alpha-N-acetylgalactosaminidase activity in individual patients had an inverse correlation with the MAF precursor activity of their plasma Gc protein. Deglycosylated Gc protein cannot be converted to macro-phage-activating factor. The resulting defect in macro-phage activation may lead to an inability to clear pathogenic immune complexes. Thus, elevated plasma alpha-N-acetylgalactosaminidase activity resulting in the loss of MAF precursor activity and reduced macro-phage activity may play a role in the pathogenesis of systemic lupus erythematosus.	[ "Deglycosylation", "of", "serum", "vitamin", "D3-binding", "protein", "by", "alpha", "-", "N", "-", "acetylgalactosaminidase", "detected", "in", "the", "plasma", "of", "patients", "with", "systemic", "lupus", "erythematosus", ".", "\n", "A", "serum", "glycoprotein", ",", "Gc", "protein", "(", "vitamin", "D3-binding", "protein", ")", ",", "can", "be", "converted", "by", "beta", "-", "galactosidase", "of", "B", "cells", "and", "sialidase", "of", "T", "cells", "to", "a", "potent", "macrophage", "-", "activating", "factor", "(", "MAF", ")", ",", "a", "protein", "with", "N", "-", "acetylgalactosamine", "as", "the", "remaining", "sugar", "moiety", ".", "Thus", ",", "Gc", "protein", "is", "the", "precursor", "for", "MAF", ".", "Treatment", "of", "Gc", "protein", "with", "immobilized", "beta", "-", "galactosidase", "and", "sialidase", "generates", "a", "remarkably", "high", "titered", "macrophage", "-", "activating", "factor", "(", "GcMAF", ")", ".", "When", "peripheral", "blood", "monocytes/", "macrophages", "(", "designated", "macrophages", ")", "of", "33", "systemic", "lupus", "erythematosus", "patients", "were", "incubated", "with", "GcMAF", "(", "100", "pg", "/", "ml", ")", ",", "the", "macrophages", "of", "all", "patients", "were", "activated", "as", "determined", "by", "superoxide", "generation", ".", "However", ",", "the", "precursor", "activity", "of", "patient", "plasma", "Gc", "protein", "was", "lost", "or", "reduced", "in", "these", "patients", ".", "Loss", "of", "the", "precursor", "activity", "was", "the", "result", "of", "deglycosylation", "of", "plasma", "Gc", "protein", "by", "alpha", "-", "N", "-", "acetylgalactosaminidase", "activity", "found", "in", "the", "patient", "plasma", ".", "Levels", "of", "plasma", "alpha", "-", "N", "-", "acetylgalactosaminidase", "activity", "in", "individual", "patients", "had", "an", "inverse", "correlation", "with", "the", "MAF", "precursor", "activity", "of", "their", "plasma", "Gc", "protein", ".", "Deglycosylated", "Gc", "protein", "cannot", "be", "converted", "to", "macro", "-", "phage", "-", "activating", "factor", ".", "The", "resulting", "defect", "in", "macro", "-", "phage", "activation", "may", "lead", "to", "an", "inability", "to", "clear", "pathogenic", "immune", "complexes", ".", "Thus", ",", "elevated", "plasma", "alpha", "-", "N", "-", "acetylgalactosaminidase", "activity", "resulting", "in", "the", "loss", "of", "MAF", "precursor", "activity", "and", "reduced", "macro", "-", "phage", "activity", "may", "play", "a", "role", "in", "the", "pathogenesis", "of", "systemic", "lupus", "erythematosus", ".", "\n" ]	[ "Protein" ]
vitamin D3-binding protein, alpha - N - acetylgalactosaminidase, Gc, vitamin D3-binding protein, beta - galactosidase, Gc, Gc, beta - galactosidase, Gc, Gc, alpha - N - acetylgalactosaminidase, alpha - N - acetylgalactosaminidase, Gc, Gc, alpha - N - acetylgalactosaminidase	570_task2	Sentence: Deglycosylation of serum vitamin D3-binding protein by alpha-N-acetylgalactosaminidase detected in the plasma of patients with systemic lupus erythematosus. A serum glycoprotein, Gc protein (vitamin D3-binding protein), can be converted by beta-galactosidase of B cells and sialidase of T cells to a potent macrophage-activating factor (MAF), a protein with N-acetylgalactosamine as the remaining sugar moiety. Thus, Gc protein is the precursor for MAF. Treatment of Gc protein with immobilized beta-galactosidase and sialidase generates a remarkably high titered macrophage-activating factor (GcMAF). When peripheral blood monocytes/ macrophages (designated macrophages) of 33 systemic lupus erythematosus patients were incubated with GcMAF (100 pg/ml), the macrophages of all patients were activated as determined by superoxide generation. However, the precursor activity of patient plasma Gc protein was lost or reduced in these patients. Loss of the precursor activity was the result of deglycosylation of plasma Gc protein by alpha-N-acetylgalactosaminidase activity found in the patient plasma. Levels of plasma alpha-N-acetylgalactosaminidase activity in individual patients had an inverse correlation with the MAF precursor activity of their plasma Gc protein. Deglycosylated Gc protein cannot be converted to macro-phage-activating factor. The resulting defect in macro-phage activation may lead to an inability to clear pathogenic immune complexes. Thus, elevated plasma alpha-N-acetylgalactosaminidase activity resulting in the loss of MAF precursor activity and reduced macro-phage activity may play a role in the pathogenesis of systemic lupus erythematosus. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Deglycosylation of serum vitamin D3-binding protein by alpha-N-acetylgalactosaminidase detected in the plasma of patients with systemic lupus erythematosus. A serum glycoprotein, Gc protein (vitamin D3-binding protein), can be converted by beta-galactosidase of B cells and sialidase of T cells to a potent macrophage-activating factor (MAF), a protein with N-acetylgalactosamine as the remaining sugar moiety. Thus, Gc protein is the precursor for MAF. Treatment of Gc protein with immobilized beta-galactosidase and sialidase generates a remarkably high titered macrophage-activating factor (GcMAF). When peripheral blood monocytes/ macrophages (designated macrophages) of 33 systemic lupus erythematosus patients were incubated with GcMAF (100 pg/ml), the macrophages of all patients were activated as determined by superoxide generation. However, the precursor activity of patient plasma Gc protein was lost or reduced in these patients. Loss of the precursor activity was the result of deglycosylation of plasma Gc protein by alpha-N-acetylgalactosaminidase activity found in the patient plasma. Levels of plasma alpha-N-acetylgalactosaminidase activity in individual patients had an inverse correlation with the MAF precursor activity of their plasma Gc protein. Deglycosylated Gc protein cannot be converted to macro-phage-activating factor. The resulting defect in macro-phage activation may lead to an inability to clear pathogenic immune complexes. Thus, elevated plasma alpha-N-acetylgalactosaminidase activity resulting in the loss of MAF precursor activity and reduced macro-phage activity may play a role in the pathogenesis of systemic lupus erythematosus.	[ "Deglycosylation", "of", "serum", "vitamin", "D3-binding", "protein", "by", "alpha", "-", "N", "-", "acetylgalactosaminidase", "detected", "in", "the", "plasma", "of", "patients", "with", "systemic", "lupus", "erythematosus", ".", "\n", "A", "serum", "glycoprotein", ",", "Gc", "protein", "(", "vitamin", "D3-binding", "protein", ")", ",", "can", "be", "converted", "by", "beta", "-", "galactosidase", "of", "B", "cells", "and", "sialidase", "of", "T", "cells", "to", "a", "potent", "macrophage", "-", "activating", "factor", "(", "MAF", ")", ",", "a", "protein", "with", "N", "-", "acetylgalactosamine", "as", "the", "remaining", "sugar", "moiety", ".", "Thus", ",", "Gc", "protein", "is", "the", "precursor", "for", "MAF", ".", "Treatment", "of", "Gc", "protein", "with", "immobilized", "beta", "-", "galactosidase", "and", "sialidase", "generates", "a", "remarkably", "high", "titered", "macrophage", "-", "activating", "factor", "(", "GcMAF", ")", ".", "When", "peripheral", "blood", "monocytes/", "macrophages", "(", "designated", "macrophages", ")", "of", "33", "systemic", "lupus", "erythematosus", "patients", "were", "incubated", "with", "GcMAF", "(", "100", "pg", "/", "ml", ")", ",", "the", "macrophages", "of", "all", "patients", "were", "activated", "as", "determined", "by", "superoxide", "generation", ".", "However", ",", "the", "precursor", "activity", "of", "patient", "plasma", "Gc", "protein", "was", "lost", "or", "reduced", "in", "these", "patients", ".", "Loss", "of", "the", "precursor", "activity", "was", "the", "result", "of", "deglycosylation", "of", "plasma", "Gc", "protein", "by", "alpha", "-", "N", "-", "acetylgalactosaminidase", "activity", "found", "in", "the", "patient", "plasma", ".", "Levels", "of", "plasma", "alpha", "-", "N", "-", "acetylgalactosaminidase", "activity", "in", "individual", "patients", "had", "an", "inverse", "correlation", "with", "the", "MAF", "precursor", "activity", "of", "their", "plasma", "Gc", "protein", ".", "Deglycosylated", "Gc", "protein", "cannot", "be", "converted", "to", "macro", "-", "phage", "-", "activating", "factor", ".", "The", "resulting", "defect", "in", "macro", "-", "phage", "activation", "may", "lead", "to", "an", "inability", "to", "clear", "pathogenic", "immune", "complexes", ".", "Thus", ",", "elevated", "plasma", "alpha", "-", "N", "-", "acetylgalactosaminidase", "activity", "resulting", "in", "the", "loss", "of", "MAF", "precursor", "activity", "and", "reduced", "macro", "-", "phage", "activity", "may", "play", "a", "role", "in", "the", "pathogenesis", "of", "systemic", "lupus", "erythematosus", ".", "\n" ]	[ "Protein" ]
amprenavir is a DRUG, rifabutin is a DRUG, rifampin is a DRUG, amprenavir is a DRUG, rifabutin is a DRUG, rifampin is a DRUG, amprenavir is a DRUG, rifabutin is a DRUG, rifampin is a DRUG, amprenavir is a DRUG, rifabutin is a DRUG, amprenavir is a DRUG, rifampin is a DRUG, amprenavir is a DRUG, rifabutin is a DRUG, rifampin is a DRUG, 25-O - desacetyl metabolites is a DRUG_N, Rifabutin is a DRUG, amprenavir is a DRUG, Amprenavir is a DRUG, rifabutin is a DRUG, 25-O - desacetylrifabutin is a DRUG_N, Rifampin is a DRUG, amprenavir is a DRUG, amprenavir is a DRUG, rifampin is a DRUG, Amprenavir is a DRUG, rifabutin is a DRUG, rifampin is a DRUG, Amprenavir is a DRUG, rifampin is a DRUG, Amprenavir is a DRUG, rifabutin is a DRUG, Rifampin is a DRUG, amprenavir is a DRUG, Amprenavir is a DRUG, rifabutin is a DRUG, 25-O - desacetylrifabutin is a DRUG_N, Amprenavir is a DRUG, rifampin is a DRUG, rifabutin is a DRUG	11158747_task0	Sentence: Pharmacokinetic Interaction between amprenavir and rifabutin or rifampin in healthy males. The objective of this study was to determine if there is a pharmacokinetic interaction when amprenavir is given with rifabutin or rifampin and to determine the effects of these drugs on the erythromycin breath test (ERMBT). Twenty-four healthy male subjects were randomized to one of two cohorts. All subjects received amprenavir (1,200 mg twice a day) for 4 days, followed by a 7-day washout period, followed by either rifabutin (300 mg once a day [QD]) (cohort 1) or rifampin (600 mg QD) (cohort 2) for 14 days. Cohort 1 then received amprenavir plus rifabutin for 10 days, and cohort 2 received amprenavir plus rifampin for 4 days. Serial plasma and urine samples for measurement of amprenavir, rifabutin, and rifampin and their 25-O-desacetyl metabolites, were measured by high-performance liquid chromatography. Rifabutin did not significantly affect amprenavir's pharmacokinetics. Amprenavir significantly increased the area under the curve at steady state (AUC(ss)) of rifabutin by 2.93-fold and the AUC(ss) of 25-O-desacetylrifabutin by 13.3-fold. Rifampin significantly decreased the AUC(ss) of amprenavir by 82%, but amprenavir had no effect on rifampin pharmacokinetics. Amprenavir decreased the results of the ERMBT by 83%. The results of the ERMBT after 2 weeks of rifabutin and rifampin therapy were increased 187 and 156%, respectively. Amprenavir plus rifampin was well tolerated. Amprenavir plus rifabutin was poorly tolerated, and 5 of 11 subjects discontinued therapy. Rifampin markedly increases the metabolic clearance of amprenavir, and coadministration is contraindicated. Amprenavir significantly decreases clearance of rifabutin and 25-O-desacetylrifabutin, and the combination is poorly tolerated. Amprenavir inhibits the ERMBT, and rifampin and rifabutin are equipotent inducers of the ERMBT. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: DRUG_N, DRUG	[ "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "O", "B-DRUG_N", "I-DRUG_N", "I-DRUG_N", "I-DRUG_N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "B-DRUG_N", "I-DRUG_N", "I-DRUG_N", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG_N", "I-DRUG_N", "I-DRUG_N", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O" ]	Pharmacokinetic Interaction between amprenavir and rifabutin or rifampin in healthy males. The objective of this study was to determine if there is a pharmacokinetic interaction when amprenavir is given with rifabutin or rifampin and to determine the effects of these drugs on the erythromycin breath test (ERMBT). Twenty-four healthy male subjects were randomized to one of two cohorts. All subjects received amprenavir (1,200 mg twice a day) for 4 days, followed by a 7-day washout period, followed by either rifabutin (300 mg once a day [QD]) (cohort 1) or rifampin (600 mg QD) (cohort 2) for 14 days. Cohort 1 then received amprenavir plus rifabutin for 10 days, and cohort 2 received amprenavir plus rifampin for 4 days. Serial plasma and urine samples for measurement of amprenavir, rifabutin, and rifampin and their 25-O-desacetyl metabolites, were measured by high-performance liquid chromatography. Rifabutin did not significantly affect amprenavir's pharmacokinetics. Amprenavir significantly increased the area under the curve at steady state (AUC(ss)) of rifabutin by 2.93-fold and the AUC(ss) of 25-O-desacetylrifabutin by 13.3-fold. Rifampin significantly decreased the AUC(ss) of amprenavir by 82%, but amprenavir had no effect on rifampin pharmacokinetics. Amprenavir decreased the results of the ERMBT by 83%. The results of the ERMBT after 2 weeks of rifabutin and rifampin therapy were increased 187 and 156%, respectively. Amprenavir plus rifampin was well tolerated. Amprenavir plus rifabutin was poorly tolerated, and 5 of 11 subjects discontinued therapy. Rifampin markedly increases the metabolic clearance of amprenavir, and coadministration is contraindicated. Amprenavir significantly decreases clearance of rifabutin and 25-O-desacetylrifabutin, and the combination is poorly tolerated. Amprenavir inhibits the ERMBT, and rifampin and rifabutin are equipotent inducers of the ERMBT.	[ "Pharmacokinetic", "Interaction", "between", "amprenavir", "and", "rifabutin", "or", "rifampin", "in", "healthy", "males", ".", "The", "objective", "of", "this", "study", "was", "to", "determine", "if", "there", "is", "a", "pharmacokinetic", "interaction", "when", "amprenavir", "is", "given", "with", "rifabutin", "or", "rifampin", "and", "to", "determine", "the", "effects", "of", "these", "drugs", "on", "the", "erythromycin", "breath", "test", "(", "ERMBT", ")", ".", "Twenty", "-", "four", "healthy", "male", "subjects", "were", "randomized", "to", "one", "of", "two", "cohorts", ".", "All", "subjects", "received", "amprenavir", "(", "1,200", "mg", "twice", "a", "day", ")", "for", "4", "days", ",", "followed", "by", "a", "7-day", "washout", "period", ",", "followed", "by", "either", "rifabutin", "(", "300", "mg", "once", "a", "day", "[", "QD", "]", ")", "(", "cohort", "1", ")", "or", "rifampin", "(", "600", "mg", "QD", ")", "(", "cohort", "2", ")", "for", "14", "days", ".", "Cohort", "1", "then", "received", "amprenavir", "plus", "rifabutin", "for", "10", "days", ",", "and", "cohort", "2", "received", "amprenavir", "plus", "rifampin", "for", "4", "days", ".", "Serial", "plasma", "and", "urine", "samples", "for", "measurement", "of", "amprenavir", ",", "rifabutin", ",", "and", "rifampin", "and", "their", "25-O", "-", "desacetyl", "metabolites", ",", "were", "measured", "by", "high", "-", "performance", "liquid", "chromatography", ".", "Rifabutin", "did", "not", "significantly", "affect", "amprenavir", "'s", "pharmacokinetics", ".", "Amprenavir", "significantly", "increased", "the", "area", "under", "the", "curve", "at", "steady", "state", "(", "AUC(ss", ")", ")", "of", "rifabutin", "by", "2.93-fold", "and", "the", "AUC(ss", ")", "of", "25-O", "-", "desacetylrifabutin", "by", "13.3-fold", ".", "Rifampin", "significantly", "decreased", "the", "AUC(ss", ")", "of", "amprenavir", "by", "82", "%", ",", "but", "amprenavir", "had", "no", "effect", "on", "rifampin", "pharmacokinetics", ".", "Amprenavir", "decreased", "the", "results", "of", "the", "ERMBT", "by", "83", "%", ".", "The", "results", "of", "the", "ERMBT", "after", "2", "weeks", "of", "rifabutin", "and", "rifampin", "therapy", "were", "increased", "187", "and", "156", "%", ",", "respectively", ".", "Amprenavir", "plus", "rifampin", "was", "well", "tolerated", ".", "Amprenavir", "plus", "rifabutin", "was", "poorly", "tolerated", ",", "and", "5", "of", "11", "subjects", "discontinued", "therapy", ".", "Rifampin", "markedly", "increases", "the", "metabolic", "clearance", "of", "amprenavir", ",", "and", "coadministration", "is", "contraindicated", ".", "Amprenavir", "significantly", "decreases", "clearance", "of", "rifabutin", "and", "25-O", "-", "desacetylrifabutin", ",", "and", "the", "combination", "is", "poorly", "tolerated", ".", "Amprenavir", "inhibits", "the", "ERMBT", ",", "and", "rifampin", "and", "rifabutin", "are", "equipotent", "inducers", "of", "the", "ERMBT", "." ]	[ "DRUG_N", "DRUG" ]
amprenavir is a DRUG, rifabutin is a DRUG, rifampin is a DRUG, amprenavir is a DRUG, rifabutin is a DRUG, rifampin is a DRUG, amprenavir is a DRUG, rifabutin is a DRUG, rifampin is a DRUG, amprenavir is a DRUG, rifabutin is a DRUG, amprenavir is a DRUG, rifampin is a DRUG, amprenavir is a DRUG, rifabutin is a DRUG, rifampin is a DRUG, 25-O - desacetyl metabolites is a DRUG_N, Rifabutin is a DRUG, amprenavir is a DRUG, Amprenavir is a DRUG, rifabutin is a DRUG, 25-O - desacetylrifabutin is a DRUG_N, Rifampin is a DRUG, amprenavir is a DRUG, amprenavir is a DRUG, rifampin is a DRUG, Amprenavir is a DRUG, rifabutin is a DRUG, rifampin is a DRUG, Amprenavir is a DRUG, rifampin is a DRUG, Amprenavir is a DRUG, rifabutin is a DRUG, Rifampin is a DRUG, amprenavir is a DRUG, Amprenavir is a DRUG, rifabutin is a DRUG, 25-O - desacetylrifabutin is a DRUG_N, Amprenavir is a DRUG, rifampin is a DRUG, rifabutin is a DRUG	11158747_task1	Sentence: Pharmacokinetic Interaction between amprenavir and rifabutin or rifampin in healthy males. The objective of this study was to determine if there is a pharmacokinetic interaction when amprenavir is given with rifabutin or rifampin and to determine the effects of these drugs on the erythromycin breath test (ERMBT). Twenty-four healthy male subjects were randomized to one of two cohorts. All subjects received amprenavir (1,200 mg twice a day) for 4 days, followed by a 7-day washout period, followed by either rifabutin (300 mg once a day [QD]) (cohort 1) or rifampin (600 mg QD) (cohort 2) for 14 days. Cohort 1 then received amprenavir plus rifabutin for 10 days, and cohort 2 received amprenavir plus rifampin for 4 days. Serial plasma and urine samples for measurement of amprenavir, rifabutin, and rifampin and their 25-O-desacetyl metabolites, were measured by high-performance liquid chromatography. Rifabutin did not significantly affect amprenavir's pharmacokinetics. Amprenavir significantly increased the area under the curve at steady state (AUC(ss)) of rifabutin by 2.93-fold and the AUC(ss) of 25-O-desacetylrifabutin by 13.3-fold. Rifampin significantly decreased the AUC(ss) of amprenavir by 82%, but amprenavir had no effect on rifampin pharmacokinetics. Amprenavir decreased the results of the ERMBT by 83%. The results of the ERMBT after 2 weeks of rifabutin and rifampin therapy were increased 187 and 156%, respectively. Amprenavir plus rifampin was well tolerated. Amprenavir plus rifabutin was poorly tolerated, and 5 of 11 subjects discontinued therapy. Rifampin markedly increases the metabolic clearance of amprenavir, and coadministration is contraindicated. Amprenavir significantly decreases clearance of rifabutin and 25-O-desacetylrifabutin, and the combination is poorly tolerated. Amprenavir inhibits the ERMBT, and rifampin and rifabutin are equipotent inducers of the ERMBT. Instructions: please typing these entity words according to sentence: amprenavir, rifabutin, rifampin, amprenavir, rifabutin, rifampin, amprenavir, rifabutin, rifampin, amprenavir, rifabutin, amprenavir, rifampin, amprenavir, rifabutin, rifampin, 25-O - desacetyl metabolites, Rifabutin, amprenavir, Amprenavir, rifabutin, 25-O - desacetylrifabutin, Rifampin, amprenavir, amprenavir, rifampin, Amprenavir, rifabutin, rifampin, Amprenavir, rifampin, Amprenavir, rifabutin, Rifampin, amprenavir, Amprenavir, rifabutin, 25-O - desacetylrifabutin, Amprenavir, rifampin, rifabutin Options: DRUG_N, DRUG	[ "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "O", "B-DRUG_N", "I-DRUG_N", "I-DRUG_N", "I-DRUG_N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "B-DRUG_N", "I-DRUG_N", "I-DRUG_N", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG_N", "I-DRUG_N", "I-DRUG_N", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O" ]	Pharmacokinetic Interaction between amprenavir and rifabutin or rifampin in healthy males. The objective of this study was to determine if there is a pharmacokinetic interaction when amprenavir is given with rifabutin or rifampin and to determine the effects of these drugs on the erythromycin breath test (ERMBT). Twenty-four healthy male subjects were randomized to one of two cohorts. All subjects received amprenavir (1,200 mg twice a day) for 4 days, followed by a 7-day washout period, followed by either rifabutin (300 mg once a day [QD]) (cohort 1) or rifampin (600 mg QD) (cohort 2) for 14 days. Cohort 1 then received amprenavir plus rifabutin for 10 days, and cohort 2 received amprenavir plus rifampin for 4 days. Serial plasma and urine samples for measurement of amprenavir, rifabutin, and rifampin and their 25-O-desacetyl metabolites, were measured by high-performance liquid chromatography. Rifabutin did not significantly affect amprenavir's pharmacokinetics. Amprenavir significantly increased the area under the curve at steady state (AUC(ss)) of rifabutin by 2.93-fold and the AUC(ss) of 25-O-desacetylrifabutin by 13.3-fold. Rifampin significantly decreased the AUC(ss) of amprenavir by 82%, but amprenavir had no effect on rifampin pharmacokinetics. Amprenavir decreased the results of the ERMBT by 83%. The results of the ERMBT after 2 weeks of rifabutin and rifampin therapy were increased 187 and 156%, respectively. Amprenavir plus rifampin was well tolerated. Amprenavir plus rifabutin was poorly tolerated, and 5 of 11 subjects discontinued therapy. Rifampin markedly increases the metabolic clearance of amprenavir, and coadministration is contraindicated. Amprenavir significantly decreases clearance of rifabutin and 25-O-desacetylrifabutin, and the combination is poorly tolerated. Amprenavir inhibits the ERMBT, and rifampin and rifabutin are equipotent inducers of the ERMBT.	[ "Pharmacokinetic", "Interaction", "between", "amprenavir", "and", "rifabutin", "or", "rifampin", "in", "healthy", "males", ".", "The", "objective", "of", "this", "study", "was", "to", "determine", "if", "there", "is", "a", "pharmacokinetic", "interaction", "when", "amprenavir", "is", "given", "with", "rifabutin", "or", "rifampin", "and", "to", "determine", "the", "effects", "of", "these", "drugs", "on", "the", "erythromycin", "breath", "test", "(", "ERMBT", ")", ".", "Twenty", "-", "four", "healthy", "male", "subjects", "were", "randomized", "to", "one", "of", "two", "cohorts", ".", "All", "subjects", "received", "amprenavir", "(", "1,200", "mg", "twice", "a", "day", ")", "for", "4", "days", ",", "followed", "by", "a", "7-day", "washout", "period", ",", "followed", "by", "either", "rifabutin", "(", "300", "mg", "once", "a", "day", "[", "QD", "]", ")", "(", "cohort", "1", ")", "or", "rifampin", "(", "600", "mg", "QD", ")", "(", "cohort", "2", ")", "for", "14", "days", ".", "Cohort", "1", "then", "received", "amprenavir", "plus", "rifabutin", "for", "10", "days", ",", "and", "cohort", "2", "received", "amprenavir", "plus", "rifampin", "for", "4", "days", ".", "Serial", "plasma", "and", "urine", "samples", "for", "measurement", "of", "amprenavir", ",", "rifabutin", ",", "and", "rifampin", "and", "their", "25-O", "-", "desacetyl", "metabolites", ",", "were", "measured", "by", "high", "-", "performance", "liquid", "chromatography", ".", "Rifabutin", "did", "not", "significantly", "affect", "amprenavir", "'s", "pharmacokinetics", ".", "Amprenavir", "significantly", "increased", "the", "area", "under", "the", "curve", "at", "steady", "state", "(", "AUC(ss", ")", ")", "of", "rifabutin", "by", "2.93-fold", "and", "the", "AUC(ss", ")", "of", "25-O", "-", "desacetylrifabutin", "by", "13.3-fold", ".", "Rifampin", "significantly", "decreased", "the", "AUC(ss", ")", "of", "amprenavir", "by", "82", "%", ",", "but", "amprenavir", "had", "no", "effect", "on", "rifampin", "pharmacokinetics", ".", "Amprenavir", "decreased", "the", "results", "of", "the", "ERMBT", "by", "83", "%", ".", "The", "results", "of", "the", "ERMBT", "after", "2", "weeks", "of", "rifabutin", "and", "rifampin", "therapy", "were", "increased", "187", "and", "156", "%", ",", "respectively", ".", "Amprenavir", "plus", "rifampin", "was", "well", "tolerated", ".", "Amprenavir", "plus", "rifabutin", "was", "poorly", "tolerated", ",", "and", "5", "of", "11", "subjects", "discontinued", "therapy", ".", "Rifampin", "markedly", "increases", "the", "metabolic", "clearance", "of", "amprenavir", ",", "and", "coadministration", "is", "contraindicated", ".", "Amprenavir", "significantly", "decreases", "clearance", "of", "rifabutin", "and", "25-O", "-", "desacetylrifabutin", ",", "and", "the", "combination", "is", "poorly", "tolerated", ".", "Amprenavir", "inhibits", "the", "ERMBT", ",", "and", "rifampin", "and", "rifabutin", "are", "equipotent", "inducers", "of", "the", "ERMBT", "." ]	[ "DRUG_N", "DRUG" ]
amprenavir, rifabutin, rifampin, amprenavir, rifabutin, rifampin, amprenavir, rifabutin, rifampin, amprenavir, rifabutin, amprenavir, rifampin, amprenavir, rifabutin, rifampin, 25-O - desacetyl metabolites, Rifabutin, amprenavir, Amprenavir, rifabutin, 25-O - desacetylrifabutin, Rifampin, amprenavir, amprenavir, rifampin, Amprenavir, rifabutin, rifampin, Amprenavir, rifampin, Amprenavir, rifabutin, Rifampin, amprenavir, Amprenavir, rifabutin, 25-O - desacetylrifabutin, Amprenavir, rifampin, rifabutin	11158747_task2	Sentence: Pharmacokinetic Interaction between amprenavir and rifabutin or rifampin in healthy males. The objective of this study was to determine if there is a pharmacokinetic interaction when amprenavir is given with rifabutin or rifampin and to determine the effects of these drugs on the erythromycin breath test (ERMBT). Twenty-four healthy male subjects were randomized to one of two cohorts. All subjects received amprenavir (1,200 mg twice a day) for 4 days, followed by a 7-day washout period, followed by either rifabutin (300 mg once a day [QD]) (cohort 1) or rifampin (600 mg QD) (cohort 2) for 14 days. Cohort 1 then received amprenavir plus rifabutin for 10 days, and cohort 2 received amprenavir plus rifampin for 4 days. Serial plasma and urine samples for measurement of amprenavir, rifabutin, and rifampin and their 25-O-desacetyl metabolites, were measured by high-performance liquid chromatography. Rifabutin did not significantly affect amprenavir's pharmacokinetics. Amprenavir significantly increased the area under the curve at steady state (AUC(ss)) of rifabutin by 2.93-fold and the AUC(ss) of 25-O-desacetylrifabutin by 13.3-fold. Rifampin significantly decreased the AUC(ss) of amprenavir by 82%, but amprenavir had no effect on rifampin pharmacokinetics. Amprenavir decreased the results of the ERMBT by 83%. The results of the ERMBT after 2 weeks of rifabutin and rifampin therapy were increased 187 and 156%, respectively. Amprenavir plus rifampin was well tolerated. Amprenavir plus rifabutin was poorly tolerated, and 5 of 11 subjects discontinued therapy. Rifampin markedly increases the metabolic clearance of amprenavir, and coadministration is contraindicated. Amprenavir significantly decreases clearance of rifabutin and 25-O-desacetylrifabutin, and the combination is poorly tolerated. Amprenavir inhibits the ERMBT, and rifampin and rifabutin are equipotent inducers of the ERMBT. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "O", "B-DRUG_N", "I-DRUG_N", "I-DRUG_N", "I-DRUG_N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "B-DRUG_N", "I-DRUG_N", "I-DRUG_N", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG_N", "I-DRUG_N", "I-DRUG_N", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O" ]	Pharmacokinetic Interaction between amprenavir and rifabutin or rifampin in healthy males. The objective of this study was to determine if there is a pharmacokinetic interaction when amprenavir is given with rifabutin or rifampin and to determine the effects of these drugs on the erythromycin breath test (ERMBT). Twenty-four healthy male subjects were randomized to one of two cohorts. All subjects received amprenavir (1,200 mg twice a day) for 4 days, followed by a 7-day washout period, followed by either rifabutin (300 mg once a day [QD]) (cohort 1) or rifampin (600 mg QD) (cohort 2) for 14 days. Cohort 1 then received amprenavir plus rifabutin for 10 days, and cohort 2 received amprenavir plus rifampin for 4 days. Serial plasma and urine samples for measurement of amprenavir, rifabutin, and rifampin and their 25-O-desacetyl metabolites, were measured by high-performance liquid chromatography. Rifabutin did not significantly affect amprenavir's pharmacokinetics. Amprenavir significantly increased the area under the curve at steady state (AUC(ss)) of rifabutin by 2.93-fold and the AUC(ss) of 25-O-desacetylrifabutin by 13.3-fold. Rifampin significantly decreased the AUC(ss) of amprenavir by 82%, but amprenavir had no effect on rifampin pharmacokinetics. Amprenavir decreased the results of the ERMBT by 83%. The results of the ERMBT after 2 weeks of rifabutin and rifampin therapy were increased 187 and 156%, respectively. Amprenavir plus rifampin was well tolerated. Amprenavir plus rifabutin was poorly tolerated, and 5 of 11 subjects discontinued therapy. Rifampin markedly increases the metabolic clearance of amprenavir, and coadministration is contraindicated. Amprenavir significantly decreases clearance of rifabutin and 25-O-desacetylrifabutin, and the combination is poorly tolerated. Amprenavir inhibits the ERMBT, and rifampin and rifabutin are equipotent inducers of the ERMBT.	[ "Pharmacokinetic", "Interaction", "between", "amprenavir", "and", "rifabutin", "or", "rifampin", "in", "healthy", "males", ".", "The", "objective", "of", "this", "study", "was", "to", "determine", "if", "there", "is", "a", "pharmacokinetic", "interaction", "when", "amprenavir", "is", "given", "with", "rifabutin", "or", "rifampin", "and", "to", "determine", "the", "effects", "of", "these", "drugs", "on", "the", "erythromycin", "breath", "test", "(", "ERMBT", ")", ".", "Twenty", "-", "four", "healthy", "male", "subjects", "were", "randomized", "to", "one", "of", "two", "cohorts", ".", "All", "subjects", "received", "amprenavir", "(", "1,200", "mg", "twice", "a", "day", ")", "for", "4", "days", ",", "followed", "by", "a", "7-day", "washout", "period", ",", "followed", "by", "either", "rifabutin", "(", "300", "mg", "once", "a", "day", "[", "QD", "]", ")", "(", "cohort", "1", ")", "or", "rifampin", "(", "600", "mg", "QD", ")", "(", "cohort", "2", ")", "for", "14", "days", ".", "Cohort", "1", "then", "received", "amprenavir", "plus", "rifabutin", "for", "10", "days", ",", "and", "cohort", "2", "received", "amprenavir", "plus", "rifampin", "for", "4", "days", ".", "Serial", "plasma", "and", "urine", "samples", "for", "measurement", "of", "amprenavir", ",", "rifabutin", ",", "and", "rifampin", "and", "their", "25-O", "-", "desacetyl", "metabolites", ",", "were", "measured", "by", "high", "-", "performance", "liquid", "chromatography", ".", "Rifabutin", "did", "not", "significantly", "affect", "amprenavir", "'s", "pharmacokinetics", ".", "Amprenavir", "significantly", "increased", "the", "area", "under", "the", "curve", "at", "steady", "state", "(", "AUC(ss", ")", ")", "of", "rifabutin", "by", "2.93-fold", "and", "the", "AUC(ss", ")", "of", "25-O", "-", "desacetylrifabutin", "by", "13.3-fold", ".", "Rifampin", "significantly", "decreased", "the", "AUC(ss", ")", "of", "amprenavir", "by", "82", "%", ",", "but", "amprenavir", "had", "no", "effect", "on", "rifampin", "pharmacokinetics", ".", "Amprenavir", "decreased", "the", "results", "of", "the", "ERMBT", "by", "83", "%", ".", "The", "results", "of", "the", "ERMBT", "after", "2", "weeks", "of", "rifabutin", "and", "rifampin", "therapy", "were", "increased", "187", "and", "156", "%", ",", "respectively", ".", "Amprenavir", "plus", "rifampin", "was", "well", "tolerated", ".", "Amprenavir", "plus", "rifabutin", "was", "poorly", "tolerated", ",", "and", "5", "of", "11", "subjects", "discontinued", "therapy", ".", "Rifampin", "markedly", "increases", "the", "metabolic", "clearance", "of", "amprenavir", ",", "and", "coadministration", "is", "contraindicated", ".", "Amprenavir", "significantly", "decreases", "clearance", "of", "rifabutin", "and", "25-O", "-", "desacetylrifabutin", ",", "and", "the", "combination", "is", "poorly", "tolerated", ".", "Amprenavir", "inhibits", "the", "ERMBT", ",", "and", "rifampin", "and", "rifabutin", "are", "equipotent", "inducers", "of", "the", "ERMBT", "." ]	[ "DRUG_N", "DRUG" ]
profilin is a Individual_protein, actin is a Individual_protein	487_task0	Sentence: Involvement of profilin in the actin-based motility of L. monocytogenes in cells and in cell-free extracts. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Individual_protein	[ "O", "O", "B-Individual_protein", "O", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Involvement of profilin in the actin-based motility of L. monocytogenes in cells and in cell-free extracts.	[ "Involvement", "of", "profilin", "in", "the", "actin", "-", "based", "motility", "of", "L.", "monocytogenes", "in", "cells", "and", "in", "cell", "-", "free", "extracts", "." ]	[ "Individual_protein" ]
profilin is a Individual_protein, actin is a Individual_protein	487_task1	Sentence: Involvement of profilin in the actin-based motility of L. monocytogenes in cells and in cell-free extracts. Instructions: please typing these entity words according to sentence: profilin, actin Options: Individual_protein	[ "O", "O", "B-Individual_protein", "O", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Involvement of profilin in the actin-based motility of L. monocytogenes in cells and in cell-free extracts.	[ "Involvement", "of", "profilin", "in", "the", "actin", "-", "based", "motility", "of", "L.", "monocytogenes", "in", "cells", "and", "in", "cell", "-", "free", "extracts", "." ]	[ "Individual_protein" ]
profilin, actin	487_task2	Sentence: Involvement of profilin in the actin-based motility of L. monocytogenes in cells and in cell-free extracts. Instructions: please extract entity words from the input sentence	[ "O", "O", "B-Individual_protein", "O", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Involvement of profilin in the actin-based motility of L. monocytogenes in cells and in cell-free extracts.	[ "Involvement", "of", "profilin", "in", "the", "actin", "-", "based", "motility", "of", "L.", "monocytogenes", "in", "cells", "and", "in", "cell", "-", "free", "extracts", "." ]	[ "Individual_protein" ]
L - Carnitine is a Simple_chemical, methotrexate is a Simple_chemical, organ is a Organ, leukocyte is a Cell, Methotrexate is a Simple_chemical, MTX is a Simple_chemical, folic acid is a Simple_chemical, tumors is a Cancer, normal tissues is a Tissue, hematopoietic cells is a Cell, bone marrow is a Multi-tissue_structure, gastrointestinal mucosal cells is a Cell, leukocytes is a Cell, MTX is a Simple_chemical, organ is a Organ, L - carnitine is a Simple_chemical, L - Car is a Simple_chemical, Wistar albino rats is a Organism, MTX is a Simple_chemical, saline is a Simple_chemical, L - Car is a Simple_chemical, rats is a Organism, trunk blood is a Organism_substance, ileum is a Multi-tissue_structure, liver is a Organ, kidney is a Organ, malondialdehyde is a Simple_chemical, MDA is a Simple_chemical, glutathione is a Simple_chemical, GSH is a Simple_chemical, myeloperoxidase is a Simple_chemical, MPO is a Simple_chemical, collagen is a Gene_or_gene_product, MTX is a Simple_chemical, MDA is a Simple_chemical, MPO is a Simple_chemical, collagen is a Gene_or_gene_product, GSH is a Simple_chemical, tissues is a Tissue, L - Car is a Simple_chemical, serum is a Organism_substance, TNF - alpha is a Gene_or_gene_product, MTX is a Simple_chemical, L - Car is a Simple_chemical, neutrophils is a Cell, Annexin V is a Gene_or_gene_product, saline is a Simple_chemical, MTX is a Simple_chemical, L - Car is a Simple_chemical, leukocyte is a Cell, MTX is a Simple_chemical, L - Car is a Simple_chemical, intestinal mucosa is a Multi-tissue_structure, liver parenchyma is a Multi-tissue_structure, glomerular is a Tissue, tubular epithelium is a Tissue, saline is a Simple_chemical, MTX is a Simple_chemical, L - Car is a Simple_chemical, L - Car is a Simple_chemical, MTX is a Simple_chemical, organ is a Organ, leukocyte is a Cell, L - Carnitine is a Simple_chemical	63_task0	Sentence: L-Carnitine ameliorates methotrexate-induced oxidative organ injury and inhibits leukocyte death. Methotrexate (MTX), a folic acid antagonist widely used for the treatment of a variety of tumors and inflammatory diseases, affects normal tissues that have a high rate of proliferation, including the hematopoietic cells of the bone marrow and the gastrointestinal mucosal cells. To elucidate the role of free radicals and leukocytes in MTX-induced oxidative organ damage and the putative protective effect of L-carnitine (L-Car), Wistar albino rats were administered a single dose of MTX (20 mg/kg) followed by either saline or L-Car (500 mg/kg) for 5 days. After decapitation of the rats, trunk blood was obtained, and the ileum, liver, and kidney were removed for histological examination and for the measurement of malondialdehyde (MDA) and glutathione (GSH) levels, myeloperoxidase (MPO) activity, and collagen content. Our results showed that MTX administration increased the MDA and MPO activities and collagen content and decreased GSH levels in all tissues, while these alterations were reversed in L-Car-treated group. The elevated serum TNF-alpha level observed following MTX treatment was depressed with L-Car. The oxidative burst of neutrophils stimulated by Annexin V was reduced in the saline-treated MTX group, while L-Car abolished this inhibition. Similarly, flow cytometric measurements revealed that leukocyte apoptosis was increased in MTX-treated animals, while L-Car reversed these effects. Severe degeneration of the intestinal mucosa, liver parenchyma, and glomerular and tubular epithelium observed in the saline-treated MTX group was improved by L-Car treatment. These results suggest that L-Car, possibly via its free radical scavenging and antioxidant properties, ameliorates MTX-induced oxidative organ injury and inhibits leukocyte apoptosis. Thus, supplementation with L-Carnitine as an adjuvant therapy may be promising in alleviating the systemic side-effects of chemotherapeutics. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Tissue, Organ, Organism_substance, Gene_or_gene_product, Organism, Simple_chemical, Cancer, Multi-tissue_structure, Cell	[ "B-Simple_chemical", "I-Simple_chemical", "I-Simple_chemical", "O", "B-Simple_chemical", "O", "O", "O", "B-Organ", "O", "O", "O", "B-Cell", "O", "O", "O", "B-Simple_chemical", "O", "B-Simple_chemical", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "B-Tissue", "I-Tissue", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "B-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "B-Simple_chemical", "O", "O", "O", "B-Organ", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "I-Simple_chemical", "O", "B-Simple_chemical", "I-Simple_chemical", "I-Simple_chemical", "O", "O", "B-Organism", "I-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "B-Simple_chemical", "I-Simple_chemical", "I-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "B-Organism_substance", "I-Organism_substance", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "B-Organ", "O", "O", "B-Organ", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "B-Simple_chemical", "O", "O", "B-Simple_chemical", "O", "B-Simple_chemical", "O", "O", "O", "B-Simple_chemical", "O", "B-Simple_chemical", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "B-Simple_chemical", "O", "B-Simple_chemical", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "B-Tissue", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "I-Simple_chemical", "O", "O", "O", "O", "O", "O", "B-Organism_substance", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "I-Simple_chemical", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "B-Simple_chemical", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "I-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "I-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "B-Tissue", "O", "B-Tissue", "I-Tissue", "O", "O", "O", "B-Simple_chemical", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "I-Simple_chemical", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "I-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "B-Organ", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "I-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	L-Carnitine ameliorates methotrexate-induced oxidative organ injury and inhibits leukocyte death. Methotrexate (MTX), a folic acid antagonist widely used for the treatment of a variety of tumors and inflammatory diseases, affects normal tissues that have a high rate of proliferation, including the hematopoietic cells of the bone marrow and the gastrointestinal mucosal cells. To elucidate the role of free radicals and leukocytes in MTX-induced oxidative organ damage and the putative protective effect of L-carnitine (L-Car), Wistar albino rats were administered a single dose of MTX (20 mg/kg) followed by either saline or L-Car (500 mg/kg) for 5 days. After decapitation of the rats, trunk blood was obtained, and the ileum, liver, and kidney were removed for histological examination and for the measurement of malondialdehyde (MDA) and glutathione (GSH) levels, myeloperoxidase (MPO) activity, and collagen content. Our results showed that MTX administration increased the MDA and MPO activities and collagen content and decreased GSH levels in all tissues, while these alterations were reversed in L-Car-treated group. The elevated serum TNF-alpha level observed following MTX treatment was depressed with L-Car. The oxidative burst of neutrophils stimulated by Annexin V was reduced in the saline-treated MTX group, while L-Car abolished this inhibition. Similarly, flow cytometric measurements revealed that leukocyte apoptosis was increased in MTX-treated animals, while L-Car reversed these effects. Severe degeneration of the intestinal mucosa, liver parenchyma, and glomerular and tubular epithelium observed in the saline-treated MTX group was improved by L-Car treatment. These results suggest that L-Car, possibly via its free radical scavenging and antioxidant properties, ameliorates MTX-induced oxidative organ injury and inhibits leukocyte apoptosis. Thus, supplementation with L-Carnitine as an adjuvant therapy may be promising in alleviating the systemic side-effects of chemotherapeutics.	[ "L", "-", "Carnitine", "ameliorates", "methotrexate", "-", "induced", "oxidative", "organ", "injury", "and", "inhibits", "leukocyte", "death", ".", "\n", "Methotrexate", "(", "MTX", ")", ",", "a", "folic", "acid", "antagonist", "widely", "used", "for", "the", "treatment", "of", "a", "variety", "of", "tumors", "and", "inflammatory", "diseases", ",", "affects", "normal", "tissues", "that", "have", "a", "high", "rate", "of", "proliferation", ",", "including", "the", "hematopoietic", "cells", "of", "the", "bone", "marrow", "and", "the", "gastrointestinal", "mucosal", "cells", ".", "To", "elucidate", "the", "role", "of", "free", "radicals", "and", "leukocytes", "in", "MTX", "-", "induced", "oxidative", "organ", "damage", "and", "the", "putative", "protective", "effect", "of", "L", "-", "carnitine", "(", "L", "-", "Car", ")", ",", "Wistar", "albino", "rats", "were", "administered", "a", "single", "dose", "of", "MTX", "(", "20", "mg", "/", "kg", ")", "followed", "by", "either", "saline", "or", "L", "-", "Car", "(", "500", "mg", "/", "kg", ")", "for", "5", "days", ".", "After", "decapitation", "of", "the", "rats", ",", "trunk", "blood", "was", "obtained", ",", "and", "the", "ileum", ",", "liver", ",", "and", "kidney", "were", "removed", "for", "histological", "examination", "and", "for", "the", "measurement", "of", "malondialdehyde", "(", "MDA", ")", "and", "glutathione", "(", "GSH", ")", "levels", ",", "myeloperoxidase", "(", "MPO", ")", "activity", ",", "and", "collagen", "content", ".", "Our", "results", "showed", "that", "MTX", "administration", "increased", "the", "MDA", "and", "MPO", "activities", "and", "collagen", "content", "and", "decreased", "GSH", "levels", "in", "all", "tissues", ",", "while", "these", "alterations", "were", "reversed", "in", "L", "-", "Car", "-", "treated", "group", ".", "The", "elevated", "serum", "TNF", "-", "alpha", "level", "observed", "following", "MTX", "treatment", "was", "depressed", "with", "L", "-", "Car", ".", "The", "oxidative", "burst", "of", "neutrophils", "stimulated", "by", "Annexin", "V", "was", "reduced", "in", "the", "saline", "-", "treated", "MTX", "group", ",", "while", "L", "-", "Car", "abolished", "this", "inhibition", ".", "Similarly", ",", "flow", "cytometric", "measurements", "revealed", "that", "leukocyte", "apoptosis", "was", "increased", "in", "MTX", "-", "treated", "animals", ",", "while", "L", "-", "Car", "reversed", "these", "effects", ".", "Severe", "degeneration", "of", "the", "intestinal", "mucosa", ",", "liver", "parenchyma", ",", "and", "glomerular", "and", "tubular", "epithelium", "observed", "in", "the", "saline", "-", "treated", "MTX", "group", "was", "improved", "by", "L", "-", "Car", "treatment", ".", "These", "results", "suggest", "that", "L", "-", "Car", ",", "possibly", "via", "its", "free", "radical", "scavenging", "and", "antioxidant", "properties", ",", "ameliorates", "MTX", "-", "induced", "oxidative", "organ", "injury", "and", "inhibits", "leukocyte", "apoptosis", ".", "Thus", ",", "supplementation", "with", "L", "-", "Carnitine", "as", "an", "adjuvant", "therapy", "may", "be", "promising", "in", "alleviating", "the", "systemic", "side", "-", "effects", "of", "chemotherapeutics", ".", "\n" ]	[ "Cell", "Organism", "Tissue", "Multi-tissue_structure", "Simple_chemical", "Organism_substance", "Gene_or_gene_product", "Cancer", "Organ" ]
L - Carnitine is a Simple_chemical, methotrexate is a Simple_chemical, organ is a Organ, leukocyte is a Cell, Methotrexate is a Simple_chemical, MTX is a Simple_chemical, folic acid is a Simple_chemical, tumors is a Cancer, normal tissues is a Tissue, hematopoietic cells is a Cell, bone marrow is a Multi-tissue_structure, gastrointestinal mucosal cells is a Cell, leukocytes is a Cell, MTX is a Simple_chemical, organ is a Organ, L - carnitine is a Simple_chemical, L - Car is a Simple_chemical, Wistar albino rats is a Organism, MTX is a Simple_chemical, saline is a Simple_chemical, L - Car is a Simple_chemical, rats is a Organism, trunk blood is a Organism_substance, ileum is a Multi-tissue_structure, liver is a Organ, kidney is a Organ, malondialdehyde is a Simple_chemical, MDA is a Simple_chemical, glutathione is a Simple_chemical, GSH is a Simple_chemical, myeloperoxidase is a Simple_chemical, MPO is a Simple_chemical, collagen is a Gene_or_gene_product, MTX is a Simple_chemical, MDA is a Simple_chemical, MPO is a Simple_chemical, collagen is a Gene_or_gene_product, GSH is a Simple_chemical, tissues is a Tissue, L - Car is a Simple_chemical, serum is a Organism_substance, TNF - alpha is a Gene_or_gene_product, MTX is a Simple_chemical, L - Car is a Simple_chemical, neutrophils is a Cell, Annexin V is a Gene_or_gene_product, saline is a Simple_chemical, MTX is a Simple_chemical, L - Car is a Simple_chemical, leukocyte is a Cell, MTX is a Simple_chemical, L - Car is a Simple_chemical, intestinal mucosa is a Multi-tissue_structure, liver parenchyma is a Multi-tissue_structure, glomerular is a Tissue, tubular epithelium is a Tissue, saline is a Simple_chemical, MTX is a Simple_chemical, L - Car is a Simple_chemical, L - Car is a Simple_chemical, MTX is a Simple_chemical, organ is a Organ, leukocyte is a Cell, L - Carnitine is a Simple_chemical	63_task1	Sentence: L-Carnitine ameliorates methotrexate-induced oxidative organ injury and inhibits leukocyte death. Methotrexate (MTX), a folic acid antagonist widely used for the treatment of a variety of tumors and inflammatory diseases, affects normal tissues that have a high rate of proliferation, including the hematopoietic cells of the bone marrow and the gastrointestinal mucosal cells. To elucidate the role of free radicals and leukocytes in MTX-induced oxidative organ damage and the putative protective effect of L-carnitine (L-Car), Wistar albino rats were administered a single dose of MTX (20 mg/kg) followed by either saline or L-Car (500 mg/kg) for 5 days. After decapitation of the rats, trunk blood was obtained, and the ileum, liver, and kidney were removed for histological examination and for the measurement of malondialdehyde (MDA) and glutathione (GSH) levels, myeloperoxidase (MPO) activity, and collagen content. Our results showed that MTX administration increased the MDA and MPO activities and collagen content and decreased GSH levels in all tissues, while these alterations were reversed in L-Car-treated group. The elevated serum TNF-alpha level observed following MTX treatment was depressed with L-Car. The oxidative burst of neutrophils stimulated by Annexin V was reduced in the saline-treated MTX group, while L-Car abolished this inhibition. Similarly, flow cytometric measurements revealed that leukocyte apoptosis was increased in MTX-treated animals, while L-Car reversed these effects. Severe degeneration of the intestinal mucosa, liver parenchyma, and glomerular and tubular epithelium observed in the saline-treated MTX group was improved by L-Car treatment. These results suggest that L-Car, possibly via its free radical scavenging and antioxidant properties, ameliorates MTX-induced oxidative organ injury and inhibits leukocyte apoptosis. Thus, supplementation with L-Carnitine as an adjuvant therapy may be promising in alleviating the systemic side-effects of chemotherapeutics. Instructions: please typing these entity words according to sentence: L - Carnitine, methotrexate, organ, leukocyte, Methotrexate, MTX, folic acid, tumors, normal tissues, hematopoietic cells, bone marrow, gastrointestinal mucosal cells, leukocytes, MTX, organ, L - carnitine, L - Car, Wistar albino rats, MTX, saline, L - Car, rats, trunk blood, ileum, liver, kidney, malondialdehyde, MDA, glutathione, GSH, myeloperoxidase, MPO, collagen, MTX, MDA, MPO, collagen, GSH, tissues, L - Car, serum, TNF - alpha, MTX, L - Car, neutrophils, Annexin V, saline, MTX, L - Car, leukocyte, MTX, L - Car, intestinal mucosa, liver parenchyma, glomerular, tubular epithelium, saline, MTX, L - Car, L - Car, MTX, organ, leukocyte, L - Carnitine Options: Tissue, Organ, Organism_substance, Gene_or_gene_product, Organism, Simple_chemical, Cancer, Multi-tissue_structure, Cell	[ "B-Simple_chemical", "I-Simple_chemical", "I-Simple_chemical", "O", "B-Simple_chemical", "O", "O", "O", "B-Organ", "O", "O", "O", "B-Cell", "O", "O", "O", "B-Simple_chemical", "O", "B-Simple_chemical", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "B-Tissue", "I-Tissue", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "B-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "B-Simple_chemical", "O", "O", "O", "B-Organ", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "I-Simple_chemical", "O", "B-Simple_chemical", "I-Simple_chemical", "I-Simple_chemical", "O", "O", "B-Organism", "I-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "B-Simple_chemical", "I-Simple_chemical", "I-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "B-Organism_substance", "I-Organism_substance", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "B-Organ", "O", "O", "B-Organ", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "B-Simple_chemical", "O", "O", "B-Simple_chemical", "O", "B-Simple_chemical", "O", "O", "O", "B-Simple_chemical", "O", "B-Simple_chemical", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "B-Simple_chemical", "O", "B-Simple_chemical", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "B-Tissue", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "I-Simple_chemical", "O", "O", "O", "O", "O", "O", "B-Organism_substance", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "I-Simple_chemical", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "B-Simple_chemical", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "I-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "I-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "B-Tissue", "O", "B-Tissue", "I-Tissue", "O", "O", "O", "B-Simple_chemical", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "I-Simple_chemical", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "I-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "B-Organ", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "I-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	L-Carnitine ameliorates methotrexate-induced oxidative organ injury and inhibits leukocyte death. Methotrexate (MTX), a folic acid antagonist widely used for the treatment of a variety of tumors and inflammatory diseases, affects normal tissues that have a high rate of proliferation, including the hematopoietic cells of the bone marrow and the gastrointestinal mucosal cells. To elucidate the role of free radicals and leukocytes in MTX-induced oxidative organ damage and the putative protective effect of L-carnitine (L-Car), Wistar albino rats were administered a single dose of MTX (20 mg/kg) followed by either saline or L-Car (500 mg/kg) for 5 days. After decapitation of the rats, trunk blood was obtained, and the ileum, liver, and kidney were removed for histological examination and for the measurement of malondialdehyde (MDA) and glutathione (GSH) levels, myeloperoxidase (MPO) activity, and collagen content. Our results showed that MTX administration increased the MDA and MPO activities and collagen content and decreased GSH levels in all tissues, while these alterations were reversed in L-Car-treated group. The elevated serum TNF-alpha level observed following MTX treatment was depressed with L-Car. The oxidative burst of neutrophils stimulated by Annexin V was reduced in the saline-treated MTX group, while L-Car abolished this inhibition. Similarly, flow cytometric measurements revealed that leukocyte apoptosis was increased in MTX-treated animals, while L-Car reversed these effects. Severe degeneration of the intestinal mucosa, liver parenchyma, and glomerular and tubular epithelium observed in the saline-treated MTX group was improved by L-Car treatment. These results suggest that L-Car, possibly via its free radical scavenging and antioxidant properties, ameliorates MTX-induced oxidative organ injury and inhibits leukocyte apoptosis. Thus, supplementation with L-Carnitine as an adjuvant therapy may be promising in alleviating the systemic side-effects of chemotherapeutics.	[ "L", "-", "Carnitine", "ameliorates", "methotrexate", "-", "induced", "oxidative", "organ", "injury", "and", "inhibits", "leukocyte", "death", ".", "\n", "Methotrexate", "(", "MTX", ")", ",", "a", "folic", "acid", "antagonist", "widely", "used", "for", "the", "treatment", "of", "a", "variety", "of", "tumors", "and", "inflammatory", "diseases", ",", "affects", "normal", "tissues", "that", "have", "a", "high", "rate", "of", "proliferation", ",", "including", "the", "hematopoietic", "cells", "of", "the", "bone", "marrow", "and", "the", "gastrointestinal", "mucosal", "cells", ".", "To", "elucidate", "the", "role", "of", "free", "radicals", "and", "leukocytes", "in", "MTX", "-", "induced", "oxidative", "organ", "damage", "and", "the", "putative", "protective", "effect", "of", "L", "-", "carnitine", "(", "L", "-", "Car", ")", ",", "Wistar", "albino", "rats", "were", "administered", "a", "single", "dose", "of", "MTX", "(", "20", "mg", "/", "kg", ")", "followed", "by", "either", "saline", "or", "L", "-", "Car", "(", "500", "mg", "/", "kg", ")", "for", "5", "days", ".", "After", "decapitation", "of", "the", "rats", ",", "trunk", "blood", "was", "obtained", ",", "and", "the", "ileum", ",", "liver", ",", "and", "kidney", "were", "removed", "for", "histological", "examination", "and", "for", "the", "measurement", "of", "malondialdehyde", "(", "MDA", ")", "and", "glutathione", "(", "GSH", ")", "levels", ",", "myeloperoxidase", "(", "MPO", ")", "activity", ",", "and", "collagen", "content", ".", "Our", "results", "showed", "that", "MTX", "administration", "increased", "the", "MDA", "and", "MPO", "activities", "and", "collagen", "content", "and", "decreased", "GSH", "levels", "in", "all", "tissues", ",", "while", "these", "alterations", "were", "reversed", "in", "L", "-", "Car", "-", "treated", "group", ".", "The", "elevated", "serum", "TNF", "-", "alpha", "level", "observed", "following", "MTX", "treatment", "was", "depressed", "with", "L", "-", "Car", ".", "The", "oxidative", "burst", "of", "neutrophils", "stimulated", "by", "Annexin", "V", "was", "reduced", "in", "the", "saline", "-", "treated", "MTX", "group", ",", "while", "L", "-", "Car", "abolished", "this", "inhibition", ".", "Similarly", ",", "flow", "cytometric", "measurements", "revealed", "that", "leukocyte", "apoptosis", "was", "increased", "in", "MTX", "-", "treated", "animals", ",", "while", "L", "-", "Car", "reversed", "these", "effects", ".", "Severe", "degeneration", "of", "the", "intestinal", "mucosa", ",", "liver", "parenchyma", ",", "and", "glomerular", "and", "tubular", "epithelium", "observed", "in", "the", "saline", "-", "treated", "MTX", "group", "was", "improved", "by", "L", "-", "Car", "treatment", ".", "These", "results", "suggest", "that", "L", "-", "Car", ",", "possibly", "via", "its", "free", "radical", "scavenging", "and", "antioxidant", "properties", ",", "ameliorates", "MTX", "-", "induced", "oxidative", "organ", "injury", "and", "inhibits", "leukocyte", "apoptosis", ".", "Thus", ",", "supplementation", "with", "L", "-", "Carnitine", "as", "an", "adjuvant", "therapy", "may", "be", "promising", "in", "alleviating", "the", "systemic", "side", "-", "effects", "of", "chemotherapeutics", ".", "\n" ]	[ "Cell", "Organism", "Tissue", "Multi-tissue_structure", "Simple_chemical", "Organism_substance", "Gene_or_gene_product", "Cancer", "Organ" ]
L - Carnitine, methotrexate, organ, leukocyte, Methotrexate, MTX, folic acid, tumors, normal tissues, hematopoietic cells, bone marrow, gastrointestinal mucosal cells, leukocytes, MTX, organ, L - carnitine, L - Car, Wistar albino rats, MTX, saline, L - Car, rats, trunk blood, ileum, liver, kidney, malondialdehyde, MDA, glutathione, GSH, myeloperoxidase, MPO, collagen, MTX, MDA, MPO, collagen, GSH, tissues, L - Car, serum, TNF - alpha, MTX, L - Car, neutrophils, Annexin V, saline, MTX, L - Car, leukocyte, MTX, L - Car, intestinal mucosa, liver parenchyma, glomerular, tubular epithelium, saline, MTX, L - Car, L - Car, MTX, organ, leukocyte, L - Carnitine	63_task2	Sentence: L-Carnitine ameliorates methotrexate-induced oxidative organ injury and inhibits leukocyte death. Methotrexate (MTX), a folic acid antagonist widely used for the treatment of a variety of tumors and inflammatory diseases, affects normal tissues that have a high rate of proliferation, including the hematopoietic cells of the bone marrow and the gastrointestinal mucosal cells. To elucidate the role of free radicals and leukocytes in MTX-induced oxidative organ damage and the putative protective effect of L-carnitine (L-Car), Wistar albino rats were administered a single dose of MTX (20 mg/kg) followed by either saline or L-Car (500 mg/kg) for 5 days. After decapitation of the rats, trunk blood was obtained, and the ileum, liver, and kidney were removed for histological examination and for the measurement of malondialdehyde (MDA) and glutathione (GSH) levels, myeloperoxidase (MPO) activity, and collagen content. Our results showed that MTX administration increased the MDA and MPO activities and collagen content and decreased GSH levels in all tissues, while these alterations were reversed in L-Car-treated group. The elevated serum TNF-alpha level observed following MTX treatment was depressed with L-Car. The oxidative burst of neutrophils stimulated by Annexin V was reduced in the saline-treated MTX group, while L-Car abolished this inhibition. Similarly, flow cytometric measurements revealed that leukocyte apoptosis was increased in MTX-treated animals, while L-Car reversed these effects. Severe degeneration of the intestinal mucosa, liver parenchyma, and glomerular and tubular epithelium observed in the saline-treated MTX group was improved by L-Car treatment. These results suggest that L-Car, possibly via its free radical scavenging and antioxidant properties, ameliorates MTX-induced oxidative organ injury and inhibits leukocyte apoptosis. Thus, supplementation with L-Carnitine as an adjuvant therapy may be promising in alleviating the systemic side-effects of chemotherapeutics. Instructions: please extract entity words from the input sentence	[ "B-Simple_chemical", "I-Simple_chemical", "I-Simple_chemical", "O", "B-Simple_chemical", "O", "O", "O", "B-Organ", "O", "O", "O", "B-Cell", "O", "O", "O", "B-Simple_chemical", "O", "B-Simple_chemical", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "B-Tissue", "I-Tissue", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "B-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "B-Simple_chemical", "O", "O", "O", "B-Organ", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "I-Simple_chemical", "O", "B-Simple_chemical", "I-Simple_chemical", "I-Simple_chemical", "O", "O", "B-Organism", "I-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "B-Simple_chemical", "I-Simple_chemical", "I-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "B-Organism_substance", "I-Organism_substance", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "B-Organ", "O", "O", "B-Organ", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "B-Simple_chemical", "O", "O", "B-Simple_chemical", "O", "B-Simple_chemical", "O", "O", "O", "B-Simple_chemical", "O", "B-Simple_chemical", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "B-Simple_chemical", "O", "B-Simple_chemical", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "B-Tissue", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "I-Simple_chemical", "O", "O", "O", "O", "O", "O", "B-Organism_substance", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "I-Simple_chemical", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "B-Simple_chemical", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "I-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "I-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "B-Tissue", "O", "B-Tissue", "I-Tissue", "O", "O", "O", "B-Simple_chemical", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "I-Simple_chemical", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "I-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "B-Organ", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "I-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	L-Carnitine ameliorates methotrexate-induced oxidative organ injury and inhibits leukocyte death. Methotrexate (MTX), a folic acid antagonist widely used for the treatment of a variety of tumors and inflammatory diseases, affects normal tissues that have a high rate of proliferation, including the hematopoietic cells of the bone marrow and the gastrointestinal mucosal cells. To elucidate the role of free radicals and leukocytes in MTX-induced oxidative organ damage and the putative protective effect of L-carnitine (L-Car), Wistar albino rats were administered a single dose of MTX (20 mg/kg) followed by either saline or L-Car (500 mg/kg) for 5 days. After decapitation of the rats, trunk blood was obtained, and the ileum, liver, and kidney were removed for histological examination and for the measurement of malondialdehyde (MDA) and glutathione (GSH) levels, myeloperoxidase (MPO) activity, and collagen content. Our results showed that MTX administration increased the MDA and MPO activities and collagen content and decreased GSH levels in all tissues, while these alterations were reversed in L-Car-treated group. The elevated serum TNF-alpha level observed following MTX treatment was depressed with L-Car. The oxidative burst of neutrophils stimulated by Annexin V was reduced in the saline-treated MTX group, while L-Car abolished this inhibition. Similarly, flow cytometric measurements revealed that leukocyte apoptosis was increased in MTX-treated animals, while L-Car reversed these effects. Severe degeneration of the intestinal mucosa, liver parenchyma, and glomerular and tubular epithelium observed in the saline-treated MTX group was improved by L-Car treatment. These results suggest that L-Car, possibly via its free radical scavenging and antioxidant properties, ameliorates MTX-induced oxidative organ injury and inhibits leukocyte apoptosis. Thus, supplementation with L-Carnitine as an adjuvant therapy may be promising in alleviating the systemic side-effects of chemotherapeutics.	[ "L", "-", "Carnitine", "ameliorates", "methotrexate", "-", "induced", "oxidative", "organ", "injury", "and", "inhibits", "leukocyte", "death", ".", "\n", "Methotrexate", "(", "MTX", ")", ",", "a", "folic", "acid", "antagonist", "widely", "used", "for", "the", "treatment", "of", "a", "variety", "of", "tumors", "and", "inflammatory", "diseases", ",", "affects", "normal", "tissues", "that", "have", "a", "high", "rate", "of", "proliferation", ",", "including", "the", "hematopoietic", "cells", "of", "the", "bone", "marrow", "and", "the", "gastrointestinal", "mucosal", "cells", ".", "To", "elucidate", "the", "role", "of", "free", "radicals", "and", "leukocytes", "in", "MTX", "-", "induced", "oxidative", "organ", "damage", "and", "the", "putative", "protective", "effect", "of", "L", "-", "carnitine", "(", "L", "-", "Car", ")", ",", "Wistar", "albino", "rats", "were", "administered", "a", "single", "dose", "of", "MTX", "(", "20", "mg", "/", "kg", ")", "followed", "by", "either", "saline", "or", "L", "-", "Car", "(", "500", "mg", "/", "kg", ")", "for", "5", "days", ".", "After", "decapitation", "of", "the", "rats", ",", "trunk", "blood", "was", "obtained", ",", "and", "the", "ileum", ",", "liver", ",", "and", "kidney", "were", "removed", "for", "histological", "examination", "and", "for", "the", "measurement", "of", "malondialdehyde", "(", "MDA", ")", "and", "glutathione", "(", "GSH", ")", "levels", ",", "myeloperoxidase", "(", "MPO", ")", "activity", ",", "and", "collagen", "content", ".", "Our", "results", "showed", "that", "MTX", "administration", "increased", "the", "MDA", "and", "MPO", "activities", "and", "collagen", "content", "and", "decreased", "GSH", "levels", "in", "all", "tissues", ",", "while", "these", "alterations", "were", "reversed", "in", "L", "-", "Car", "-", "treated", "group", ".", "The", "elevated", "serum", "TNF", "-", "alpha", "level", "observed", "following", "MTX", "treatment", "was", "depressed", "with", "L", "-", "Car", ".", "The", "oxidative", "burst", "of", "neutrophils", "stimulated", "by", "Annexin", "V", "was", "reduced", "in", "the", "saline", "-", "treated", "MTX", "group", ",", "while", "L", "-", "Car", "abolished", "this", "inhibition", ".", "Similarly", ",", "flow", "cytometric", "measurements", "revealed", "that", "leukocyte", "apoptosis", "was", "increased", "in", "MTX", "-", "treated", "animals", ",", "while", "L", "-", "Car", "reversed", "these", "effects", ".", "Severe", "degeneration", "of", "the", "intestinal", "mucosa", ",", "liver", "parenchyma", ",", "and", "glomerular", "and", "tubular", "epithelium", "observed", "in", "the", "saline", "-", "treated", "MTX", "group", "was", "improved", "by", "L", "-", "Car", "treatment", ".", "These", "results", "suggest", "that", "L", "-", "Car", ",", "possibly", "via", "its", "free", "radical", "scavenging", "and", "antioxidant", "properties", ",", "ameliorates", "MTX", "-", "induced", "oxidative", "organ", "injury", "and", "inhibits", "leukocyte", "apoptosis", ".", "Thus", ",", "supplementation", "with", "L", "-", "Carnitine", "as", "an", "adjuvant", "therapy", "may", "be", "promising", "in", "alleviating", "the", "systemic", "side", "-", "effects", "of", "chemotherapeutics", ".", "\n" ]	[ "Cell", "Organism", "Tissue", "Multi-tissue_structure", "Simple_chemical", "Organism_substance", "Gene_or_gene_product", "Cancer", "Organ" ]
Clinically significant is a Qualifier, new is a Qualifier, illness is a Condition, within 1 month before randomization is a Temporal, may affect the participant 's ability to fulfill the study requirements or significantly confound the assessments is a Scope, cannot swallow is a Observation, investigational products is a Drug, T2DM is a Condition, hypoglycemia unawareness is a Condition, Aortic regurgitation is a Condition, mild or greater is a Qualifier, Mitral regurgitation is a Condition, moderate or greater is a Qualifier, Mitral or aortic valve stenosis greater than mild is a Scope, aortic stenosis : jet > 3.0 meters per second [ m / s ] , mean gradient > 25 millimeters of mercury [ mmHg ] , and aortic valve area < 1.5 centimeters squared [ cm^2 ] ; mitral stenosis : mean gradient > 5 mmHg and mitral valve area < 1.5 cm^2 is a Scope, Systolic pulmonary artery pressure ( SPAP ) is a Measurement, > 40 mmHg is a Value, tricuspid regurgitation [ TR ] jet velocity is a Measurement, > 2.9 m / s is a Value, RVOTAT is a Measurement, = 100 milliseconds ( msec ) is a Value, Left ventricular ejection fraction is a Measurement, < 45 % is a Value, Intracardiac mass is a Condition, tumor is a Condition, thrombus is a Condition, Evidence of is a Mood, congenital heart disease is a Condition, Clinically significant is a Qualifier, pericardial effusion is a Condition, moderate or larger or with hemodynamic compromise is a Scope, Significant is a Qualifier, renal or hepatic disease is a Scope, serum creatinine greater than 1.5× upper limit of normal ( ULN ) , serum transaminases greater than 3× ULN , or total bilirubin greater than 1.5× ULN in absence of Gilbert 's syndrome is a Scope, suicidal ideation is a Condition, with intent is a Qualifier, with or without a plan is a Scope, at the time of or within 6 months of Screening is a Scope, Yes is a Value, questions 4 or 5 is a Scope, Suicidal Ideation section of the Columbia - Suicide Severity Rating Scale ( C - SSRS ) is a Procedure, suicidal behavior is a Condition, in the past is a Temporal, C - SSRS is a Procedure, history is a Observation, anorexia or bulimia is a Scope, within 2 years before Screening is a Temporal, Attention Deficit Hyperactivity Disorder is a Condition, Diagnostic and Statistical Manual of Mental Disorders , 5th Edition is a Qualifier, depressive disorder , bipolar disorder , or schizophrenia is a Scope, secondary causes ( genetic , endocrine , or metabolic ) for obesity is a Scope, Prader - Willi syndrome , Bardet Biedl syndrome , Down 's Syndrome , untreated hypothyroidism , Cushing 's syndrome , daily systemic corticosteroid exposure for longer than 30 days , history of significant exposure to corticosteroids for chronic illness during the past year ; inhaled steroids will be allowed is a Scope, products intended for weight loss is a Drug, prescription drugs , over - the - counter ( OTC ) drugs , and herbal is a Scope, within 1 month before Screening is a Temporal, selective serotonin reuptake inhibitors is a Drug, serotonin norepinephrine reuptake inhibitors is a Drug, tricyclic antidepressants is a Drug, bupropion is a Drug, triptans is a Drug, St . John 's Wort is a Drug, tryptophan is a Drug, linezolid is a Drug, dextromethorphan is a Drug, any form is a Qualifier, lithium is a Drug, tramadol is a Drug, antipsychotics is a Drug, dopamine antagonists is a Drug, antiseizure medications is a Drug, valproic acid , zonisamide , topiramate , and lamotrigine is a Scope, oral steroids is a Drug, topical and inhaled steroids is a Scope, acceptable is a Negation, stimulant medications is a Drug, Ritalin , Concerta , Biphetamine , and Dexedrine is a Scope, benzodiazepines is a Drug, drugs known to increase the risk for cardiac valvulopathy is a Scope, within 6 months before Screening is a Temporal, pergolide , ergotamine , methysergide , and cabergoline is a Scope, History or evidence of clinically significant disease is a Scope, malignancy ; cardiac , respiratory , gastrointestinal , renal , or psychiatric disease is a Scope, other than is a Negation, prediabetes is a Condition, impaired fasting glucose or impaired glucose tolerance ) is a Scope, type 2 diabetes is a Condition, oral anti - diabetic agents ( excluding sulfonylurea ) or non - insulin injectable antidiabetic agents is a Scope, obstructive sleep apnea is a Condition, dyslipidemia is a Condition, nonalcoholic fatty liver disease is a Condition, within 6 months before Screening is a Temporal, hypersensitivity is a Condition, Belviq XR is a Drug, or any of the excipients is a Qualifier, Significant is a Qualifier, change in diet or level of physical activity is a Scope, within 1 month before dosing is a Temporal, change in weight is a Observation, more than 5 kg is a Value, within 3 months before Screening is a Temporal, < 1000 calories / day is a Value, within 6 months before Screening is a Temporal, History is a Observation, alcohol or drug dependence or abuse is a Scope, Recreational drug use is a Observation, within 2 years before Screening is a Temporal, human immunodeficiency virus positive is a Condition, active is a Qualifier, viral hepatitis is a Condition, B or C is a Scope, Malignancy is a Condition, within 5 years before Screening is a Temporal, Unable to attend scheduled visits is a Observation, lack of transportation is a Observation, lack of a caregiver is a Observation, Special needs is a Observation, unable to comprehend study - related instructions is a Scope, mild to profound mental retardation [ intelligence quotient < 70 ] , moderate to severe cognitive developmental delay , pervasive development disorders , autism is a Scope, Ongoing is a Temporal, epilepsy is a Condition, other is a Qualifier, medications is a Drug, seizure disorder is a Condition, within 6 months of screening or any time between screening and randomization is a Scope, blood pressure is a Measurement, 95th percentile or greater is a Value, for age is a Qualifier, 2 separate readings is a Multiplier, 2 separate days is a Qualifier, Currently is a Temporal, another is a Qualifier, investigational drug or device is a Scope, within 30 days before providing informed consent is a Temporal, Planned is a Mood, bariatric surgery is a Procedure, during the study is a Temporal, prior is a Temporal, bariatric surgical procedures is a Procedure, the study is a Reference_point, Female is a Person, breastfeeding or pregnant is a Scope, at Screening or Baseline is a Scope, positive beta - human chorionic gonadotropin test is a Scope, separate Baseline assessment is required if a negative screening pregnancy test was obtained more than 72 hours before the first dose of study drug is a Scope, unprotected sexual intercourse is a Condition, within 30 days before study entry is a Temporal, do not agree is a Observation, highly effective method of contraception is a Scope, total abstinence , an intrauterine device , a double - barrier method [ such as condom plus diaphragm with spermicide ] , a contraceptive implant , an oral contraceptive , or have a vasectomized partner with confirmed azoospermia is a Scope, throughout the entire study period is a Temporal, for 28 days after study drug discontinuation is a Temporal, currently is a Temporal, abstinent is a Condition, do not agree is a Observation, double - barrier method ( as described above ) or refrain from sexual activity is a Scope, during the study period and for 28 days after study drug discontinuation is a Scope, hormonal contraceptives is a Drug, not is a Negation, stable dose is a Qualifier, hormonal contraceptive is a Drug, for at least 4 weeks before dosing is a Temporal, do not agree is a Observation, the same is a Qualifier, contraceptive is a Drug, during the study is a Temporal, for 28 days after study drug discontinuation is a Temporal	NCT03338296_exc_task0	Sentence: Clinically significant new illness within 1 month before randomization that may affect the participant's ability to fulfill the study requirements or significantly confound the assessments Participants who cannot swallow investigational products Participants with T2DM who have hypoglycemia unawareness Aortic regurgitation mild or greater Mitral regurgitation moderate or greater Mitral or aortic valve stenosis greater than mild (ie, aortic stenosis: jet >3.0 meters per second [m/s], mean gradient >25 millimeters of mercury [mmHg], and aortic valve area <1.5 centimeters squared [cm^2]; mitral stenosis: mean gradient >5 mmHg and mitral valve area <1.5 cm^2) Systolic pulmonary artery pressure (SPAP) >40 mmHg (and/or tricuspid regurgitation [TR] jet velocity >2.9 m/s) In cases where an actual SPAP value is not measurable due to lack of adequate TR jet, the pulmonary flow acceleration time measured at the right ventricular outflow tract (RVOTAT) will be used to assess eligibility. Participants with a RVOTAT =100 milliseconds (msec) will be excluded, suggesting an elevated mean SPAP; eligibility for the those participants with RVOTAT between 100 and 120 msec will be determined based on combined assessment of the TR jet, septal motion, and right ventricular size. Left ventricular ejection fraction <45% Intracardiac mass, tumor, or thrombus Evidence of congenital heart disease Clinically significant pericardial effusion (eg, moderate or larger or with hemodynamic compromise) Significant renal or hepatic disease as evidenced by a serum creatinine greater than 1.5× upper limit of normal (ULN), serum transaminases greater than 3× ULN, or total bilirubin greater than 1.5× ULN in absence of Gilbert's syndrome Any suicidal ideation with intent with or without a plan, at the time of or within 6 months of Screening, as indicated by answering "Yes" to questions 4 or 5 on the Suicidal Ideation section of the Columbia-Suicide Severity Rating Scale (C-SSRS) Any suicidal behavior in the past based on the C-SSRS Any history of anorexia or bulimia within 2 years before Screening, Attention Deficit Hyperactivity Disorder, any Diagnostic and Statistical Manual of Mental Disorders, 5th Edition depressive disorder, bipolar disorder, or schizophrenia Known secondary causes (genetic, endocrine, or metabolic) for obesity (eg, Prader-Willi syndrome, Bardet Biedl syndrome, Down's Syndrome, untreated hypothyroidism, Cushing's syndrome, daily systemic corticosteroid exposure for longer than 30 days, history of significant exposure to corticosteroids for chronic illness during the past year; inhaled steroids will be allowed) Use of other products intended for weight loss including prescription drugs, over-the-counter (OTC) drugs, and herbal preparations within 1 month before Screening selective serotonin reuptake inhibitors serotonin norepinephrine reuptake inhibitors tricyclic antidepressants bupropion triptans St. John's Wort tryptophan linezolid dextromethorphan in any form (eg, OTC cold medicines) lithium tramadol antipsychotics or other dopamine antagonists antiseizure medications including valproic acid, zonisamide, topiramate, and lamotrigine oral steroids (topical and inhaled steroids are acceptable) stimulant medications (eg, Ritalin, Concerta, Biphetamine, and Dexedrine) benzodiazepines Use of drugs known to increase the risk for cardiac valvulopathy within 6 months before Screening, including but not limited to pergolide, ergotamine, methysergide, and cabergoline History or evidence of clinically significant disease (eg, malignancy; cardiac, respiratory, gastrointestinal, renal, or psychiatric disease) other than prediabetes (impaired fasting glucose or impaired glucose tolerance), type 2 diabetes treated with oral anti-diabetic agents (excluding sulfonylurea) or non-insulin injectable antidiabetic agents, obstructive sleep apnea, dyslipidemia, and nonalcoholic fatty liver disease Use of Belviq XR within 6 months before Screening or hypersensitivity to Belviq XR or any of the excipients Significant change in diet or level of physical activity within 1 month before dosing or change in weight of more than 5 kg within 3 months before Screening Any use of a very-low-calorie (<1000 calories/day) weight loss diet within 6 months before Screening History of alcohol or drug dependence or abuse Recreational drug use within 2 years before Screening Known to be human immunodeficiency virus positive Known to have active viral hepatitis (B or C) Malignancy within 5 years before Screening Unable to attend scheduled visits (eg, lack of transportation) or lack of a caregiver or guardian to supervise study participation Special needs participants who are unable to comprehend study-related instructions (eg, mild to profound mental retardation [intelligence quotient <70], moderate to severe cognitive developmental delay, pervasive development disorders, autism) Ongoing epilepsy or other seizure disorder, or use of medications for a seizure disorder within 6 months of screening or any time between screening and randomization Participants with a blood pressure in the 95th percentile or greater for age, sex, and height on 2 separate readings recorded on 2 separate days. Those participants who had uncontrolled hypertension at Screening can be rescreened more than 1 month after initiation or adjustment of antihypertensive therapy 1 time. Currently enrolled in another clinical study or has used any investigational drug or device within 30 days before providing informed consent Planned bariatric surgery during the study or prior bariatric surgical procedures Not suitable to participate in the study in the opinion of the investigator, including consideration of any existing physical, medical, or mental condition that prevents compliance with the protocol Female participants who are breastfeeding or pregnant at Screening or Baseline (as documented by a positive beta-human chorionic gonadotropin test). A separate Baseline assessment is required if a negative screening pregnancy test was obtained more than 72 hours before the first dose of study drug. Had unprotected sexual intercourse within 30 days before study entry and who do not agree to use a highly effective method of contraception (eg, total abstinence, an intrauterine device, a double-barrier method [such as condom plus diaphragm with spermicide], a contraceptive implant, an oral contraceptive, or have a vasectomized partner with confirmed azoospermia) throughout the entire study period and for 28 days after study drug discontinuation Are currently abstinent and do not agree to use a double-barrier method (as described above) or refrain from sexual activity during the study period and for 28 days after study drug discontinuation Are using hormonal contraceptives, but are not on a stable dose of the same hormonal contraceptive product for at least 4 weeks before dosing and who do not agree to use the same contraceptive during the study and for 28 days after study drug discontinuation (Note: All female participants will be considered to be of childbearing potential unless they have been sterilized surgically [ie, bilateral tubal ligation, total hysterectomy, or bilateral oophorectomy, all with surgery at least 1 month before dosing]). Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Temporal, Condition, Qualifier, Value, Person, Observation, Multiplier, Procedure, Negation, Reference_point, Scope, Measurement, Mood, Drug	[ "B-Qualifier", "I-Qualifier", "B-Qualifier", "B-Condition", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Observation", "I-Observation", "B-Drug", "I-Drug", "O", "O", "O", "B-Condition", "O", "O", "B-Condition", "I-Condition", "O", "B-Condition", "I-Condition", "B-Qualifier", "I-Qualifier", "I-Qualifier", "O", "B-Condition", "I-Condition", "B-Qualifier", "I-Qualifier", "I-Qualifier", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "O", "O", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "O", "B-Condition", "I-Condition", "O", "B-Condition", "O", "O", "B-Condition", "O", "B-Mood", "I-Mood", "B-Condition", "I-Condition", "I-Condition", "O", "B-Qualifier", "I-Qualifier", "B-Condition", "I-Condition", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Qualifier", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Condition", "I-Condition", "B-Qualifier", "I-Qualifier", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "B-Value", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "O", "O", "B-Condition", "I-Condition", "B-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "B-Procedure", "I-Procedure", "I-Procedure", "O", "O", "B-Observation", "O", "B-Scope", "I-Scope", "I-Scope", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "O", "O", "B-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "B-Drug", "I-Drug", "I-Drug", "I-Drug", "I-Drug", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Drug", "I-Drug", "I-Drug", "I-Drug", "O", "B-Drug", "I-Drug", "I-Drug", "I-Drug", "O", "B-Drug", "I-Drug", "O", "B-Drug", "O", "B-Drug", "O", "B-Drug", "I-Drug", "I-Drug", "I-Drug", "I-Drug", "O", "B-Drug", "O", "B-Drug", "O", "B-Drug", "O", "B-Qualifier", "I-Qualifier", "O", "O", "O", "O", "O", "O", "O", "O", "B-Drug", "O", "B-Drug", "O", "B-Drug", "O", "O", "B-Drug", "I-Drug", "O", "B-Drug", "I-Drug", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Drug", "I-Drug", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Negation", "O", "O", "B-Drug", "I-Drug", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Drug", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Negation", "I-Negation", "B-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Condition", "I-Condition", "I-Condition", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Condition", "I-Condition", "I-Condition", "O", "B-Condition", "O", "O", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "O", "O", "O", "O", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Condition", "O", "B-Drug", "I-Drug", "B-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "O", "B-Qualifier", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Observation", "I-Observation", "I-Observation", "O", "B-Value", "I-Value", "I-Value", "I-Value", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "O", "O", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Observation", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Observation", "I-Observation", "I-Observation", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "O", "O", "O", "O", "B-Qualifier", "B-Condition", "I-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "O", "O", "B-Condition", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Observation", "I-Observation", "I-Observation", "I-Observation", "I-Observation", "O", "O", "O", "B-Observation", "I-Observation", "I-Observation", "O", "O", "B-Observation", "I-Observation", "I-Observation", "I-Observation", "O", "O", "O", "O", "O", "O", "O", "B-Observation", "I-Observation", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Temporal", "B-Condition", "O", "B-Qualifier", "O", "O", "O", "O", "O", "O", "B-Drug", "O", "O", "B-Condition", "I-Condition", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "B-Measurement", "I-Measurement", "O", "O", "B-Value", "I-Value", "I-Value", "I-Value", "B-Qualifier", "I-Qualifier", "O", "O", "O", "O", "O", "O", "B-Multiplier", "I-Multiplier", "I-Multiplier", "O", "O", "B-Qualifier", "I-Qualifier", "I-Qualifier", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Temporal", "O", "O", "B-Qualifier", "O", "O", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Mood", "B-Procedure", "I-Procedure", "B-Temporal", "I-Temporal", "I-Temporal", "O", "B-Temporal", "B-Procedure", "I-Procedure", "I-Procedure", "O", "O", "O", "O", "O", "O", "B-Reference_point", "I-Reference_point", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Person", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Condition", "I-Condition", "I-Condition", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "B-Observation", "I-Observation", "I-Observation", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "B-Temporal", "B-Condition", "O", "B-Observation", "I-Observation", "I-Observation", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Drug", "I-Drug", "O", "O", "O", "B-Negation", "O", "O", "B-Qualifier", "I-Qualifier", "O", "O", "O", "B-Drug", "I-Drug", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "B-Observation", "I-Observation", "I-Observation", "O", "O", "B-Qualifier", "I-Qualifier", "B-Drug", "B-Temporal", "I-Temporal", "I-Temporal", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Clinically significant new illness within 1 month before randomization that may affect the participant's ability to fulfill the study requirements or significantly confound the assessments Participants who cannot swallow investigational products Participants with T2DM who have hypoglycemia unawareness Aortic regurgitation mild or greater Mitral regurgitation moderate or greater Mitral or aortic valve stenosis greater than mild (ie, aortic stenosis: jet >3.0 meters per second [m/s], mean gradient >25 millimeters of mercury [mmHg], and aortic valve area <1.5 centimeters squared [cm^2]; mitral stenosis: mean gradient >5 mmHg and mitral valve area <1.5 cm^2) Systolic pulmonary artery pressure (SPAP) >40 mmHg (and/or tricuspid regurgitation [TR] jet velocity >2.9 m/s) In cases where an actual SPAP value is not measurable due to lack of adequate TR jet, the pulmonary flow acceleration time measured at the right ventricular outflow tract (RVOTAT) will be used to assess eligibility. Participants with a RVOTAT =100 milliseconds (msec) will be excluded, suggesting an elevated mean SPAP; eligibility for the those participants with RVOTAT between 100 and 120 msec will be determined based on combined assessment of the TR jet, septal motion, and right ventricular size. Left ventricular ejection fraction <45% Intracardiac mass, tumor, or thrombus Evidence of congenital heart disease Clinically significant pericardial effusion (eg, moderate or larger or with hemodynamic compromise) Significant renal or hepatic disease as evidenced by a serum creatinine greater than 1.5× upper limit of normal (ULN), serum transaminases greater than 3× ULN, or total bilirubin greater than 1.5× ULN in absence of Gilbert's syndrome Any suicidal ideation with intent with or without a plan, at the time of or within 6 months of Screening, as indicated by answering "Yes" to questions 4 or 5 on the Suicidal Ideation section of the Columbia-Suicide Severity Rating Scale (C-SSRS) Any suicidal behavior in the past based on the C-SSRS Any history of anorexia or bulimia within 2 years before Screening, Attention Deficit Hyperactivity Disorder, any Diagnostic and Statistical Manual of Mental Disorders, 5th Edition depressive disorder, bipolar disorder, or schizophrenia Known secondary causes (genetic, endocrine, or metabolic) for obesity (eg, Prader-Willi syndrome, Bardet Biedl syndrome, Down's Syndrome, untreated hypothyroidism, Cushing's syndrome, daily systemic corticosteroid exposure for longer than 30 days, history of significant exposure to corticosteroids for chronic illness during the past year; inhaled steroids will be allowed) Use of other products intended for weight loss including prescription drugs, over-the-counter (OTC) drugs, and herbal preparations within 1 month before Screening selective serotonin reuptake inhibitors serotonin norepinephrine reuptake inhibitors tricyclic antidepressants bupropion triptans St. John's Wort tryptophan linezolid dextromethorphan in any form (eg, OTC cold medicines) lithium tramadol antipsychotics or other dopamine antagonists antiseizure medications including valproic acid, zonisamide, topiramate, and lamotrigine oral steroids (topical and inhaled steroids are acceptable) stimulant medications (eg, Ritalin, Concerta, Biphetamine, and Dexedrine) benzodiazepines Use of drugs known to increase the risk for cardiac valvulopathy within 6 months before Screening, including but not limited to pergolide, ergotamine, methysergide, and cabergoline History or evidence of clinically significant disease (eg, malignancy; cardiac, respiratory, gastrointestinal, renal, or psychiatric disease) other than prediabetes (impaired fasting glucose or impaired glucose tolerance), type 2 diabetes treated with oral anti-diabetic agents (excluding sulfonylurea) or non-insulin injectable antidiabetic agents, obstructive sleep apnea, dyslipidemia, and nonalcoholic fatty liver disease Use of Belviq XR within 6 months before Screening or hypersensitivity to Belviq XR or any of the excipients Significant change in diet or level of physical activity within 1 month before dosing or change in weight of more than 5 kg within 3 months before Screening Any use of a very-low-calorie (<1000 calories/day) weight loss diet within 6 months before Screening History of alcohol or drug dependence or abuse Recreational drug use within 2 years before Screening Known to be human immunodeficiency virus positive Known to have active viral hepatitis (B or C) Malignancy within 5 years before Screening Unable to attend scheduled visits (eg, lack of transportation) or lack of a caregiver or guardian to supervise study participation Special needs participants who are unable to comprehend study-related instructions (eg, mild to profound mental retardation [intelligence quotient <70], moderate to severe cognitive developmental delay, pervasive development disorders, autism) Ongoing epilepsy or other seizure disorder, or use of medications for a seizure disorder within 6 months of screening or any time between screening and randomization Participants with a blood pressure in the 95th percentile or greater for age, sex, and height on 2 separate readings recorded on 2 separate days. Those participants who had uncontrolled hypertension at Screening can be rescreened more than 1 month after initiation or adjustment of antihypertensive therapy 1 time. Currently enrolled in another clinical study or has used any investigational drug or device within 30 days before providing informed consent Planned bariatric surgery during the study or prior bariatric surgical procedures Not suitable to participate in the study in the opinion of the investigator, including consideration of any existing physical, medical, or mental condition that prevents compliance with the protocol Female participants who are breastfeeding or pregnant at Screening or Baseline (as documented by a positive beta-human chorionic gonadotropin test). A separate Baseline assessment is required if a negative screening pregnancy test was obtained more than 72 hours before the first dose of study drug. Had unprotected sexual intercourse within 30 days before study entry and who do not agree to use a highly effective method of contraception (eg, total abstinence, an intrauterine device, a double-barrier method [such as condom plus diaphragm with spermicide], a contraceptive implant, an oral contraceptive, or have a vasectomized partner with confirmed azoospermia) throughout the entire study period and for 28 days after study drug discontinuation Are currently abstinent and do not agree to use a double-barrier method (as described above) or refrain from sexual activity during the study period and for 28 days after study drug discontinuation Are using hormonal contraceptives, but are not on a stable dose of the same hormonal contraceptive product for at least 4 weeks before dosing and who do not agree to use the same contraceptive during the study and for 28 days after study drug discontinuation (Note: All female participants will be considered to be of childbearing potential unless they have been sterilized surgically [ie, bilateral tubal ligation, total hysterectomy, or bilateral oophorectomy, all with surgery at least 1 month before dosing]).	[ "Clinically", "significant", "new", "illness", "within", "1", "month", "before", "randomization", "that", "may", "affect", "the", "participant", "'s", "ability", "to", "fulfill", "the", "study", "requirements", "or", "significantly", "confound", "the", "assessments", "\n", "Participants", "who", "cannot", "swallow", "investigational", "products", "\n", "Participants", "with", "T2DM", "who", "have", "hypoglycemia", "unawareness", "\n", "Aortic", "regurgitation", "mild", "or", "greater", "\n", "Mitral", "regurgitation", "moderate", "or", "greater", "\n", "Mitral", "or", "aortic", "valve", "stenosis", "greater", "than", "mild", "(", "ie", ",", "aortic", "stenosis", ":", "jet", ">", "3.0", "meters", "per", "second", "[", "m", "/", "s", "]", ",", "mean", "gradient", ">", "25", "millimeters", "of", "mercury", "[", "mmHg", "]", ",", "and", "aortic", "valve", "area", "<", "1.5", "centimeters", "squared", "[", "cm^2", "]", ";", "mitral", "stenosis", ":", "mean", "gradient", ">", "5", "mmHg", "and", "mitral", "valve", "area", "<", "1.5", "cm^2", ")", "\n", "Systolic", "pulmonary", "artery", "pressure", "(", "SPAP", ")", ">", "40", "mmHg", "(", "and", "/", "or", "tricuspid", "regurgitation", "[", "TR", "]", "jet", "velocity", ">", "2.9", "m", "/", "s", ")", "In", "cases", "where", "an", "actual", "SPAP", "value", "is", "not", "measurable", "due", "to", "lack", "of", "adequate", "TR", "jet", ",", "the", "pulmonary", "flow", "acceleration", "time", "measured", "at", "the", "right", "ventricular", "outflow", "tract", "(", "RVOTAT", ")", "will", "be", "used", "to", "assess", "eligibility", ".", "Participants", "with", "a", "RVOTAT", "=", "100", "milliseconds", "(", "msec", ")", "will", "be", "excluded", ",", "suggesting", "an", "elevated", "mean", "SPAP", ";", "eligibility", "for", "the", "those", "participants", "with", "RVOTAT", "between", "100", "and", "120", "msec", "will", "be", "determined", "based", "on", "combined", "assessment", "of", "the", "TR", "jet", ",", "septal", "motion", ",", "and", "right", "ventricular", "size", ".", "\n", "Left", "ventricular", "ejection", "fraction", "<", "45", "%", "\n", "Intracardiac", "mass", ",", "tumor", ",", "or", "thrombus", "\n", "Evidence", "of", "congenital", "heart", "disease", "\n", "Clinically", "significant", "pericardial", "effusion", "(", "eg", ",", "moderate", "or", "larger", "or", "with", "hemodynamic", "compromise", ")", "\n", "Significant", "renal", "or", "hepatic", "disease", "as", "evidenced", "by", "a", "serum", "creatinine", "greater", "than", "1.5×", "upper", "limit", "of", "normal", "(", "ULN", ")", ",", "serum", "transaminases", "greater", "than", "3×", "ULN", ",", "or", "total", "bilirubin", "greater", "than", "1.5×", "ULN", "in", "absence", "of", "Gilbert", "'s", "syndrome", "\n", "Any", "suicidal", "ideation", "with", "intent", "with", "or", "without", "a", "plan", ",", "at", "the", "time", "of", "or", "within", "6", "months", "of", "Screening", ",", "as", "indicated", "by", "answering", "\"", "Yes", "\"", "to", "questions", "4", "or", "5", "on", "the", "Suicidal", "Ideation", "section", "of", "the", "Columbia", "-", "Suicide", "Severity", "Rating", "Scale", "(", "C", "-", "SSRS", ")", "\n", "Any", "suicidal", "behavior", "in", "the", "past", "based", "on", "the", "C", "-", "SSRS", "\n", "Any", "history", "of", "anorexia", "or", "bulimia", "within", "2", "years", "before", "Screening", ",", "Attention", "Deficit", "Hyperactivity", "Disorder", ",", "any", "Diagnostic", "and", "Statistical", "Manual", "of", "Mental", "Disorders", ",", "5th", "Edition", "depressive", "disorder", ",", "bipolar", "disorder", ",", "or", "schizophrenia", "\n", "Known", "secondary", "causes", "(", "genetic", ",", "endocrine", ",", "or", "metabolic", ")", "for", "obesity", "(", "eg", ",", "Prader", "-", "Willi", "syndrome", ",", "Bardet", "Biedl", "syndrome", ",", "Down", "'s", "Syndrome", ",", "untreated", "hypothyroidism", ",", "Cushing", "'s", "syndrome", ",", "daily", "systemic", "corticosteroid", "exposure", "for", "longer", "than", "30", "days", ",", "history", "of", "significant", "exposure", "to", "corticosteroids", "for", "chronic", "illness", "during", "the", "past", "year", ";", "inhaled", "steroids", "will", "be", "allowed", ")", "\n", "Use", "of", "other", "products", "intended", "for", "weight", "loss", "including", "prescription", "drugs", ",", "over", "-", "the", "-", "counter", "(", "OTC", ")", "drugs", ",", "and", "herbal", "preparations", "within", "1", "month", "before", "Screening", "\n", "selective", "serotonin", "reuptake", "inhibitors", "\n", "serotonin", "norepinephrine", "reuptake", "inhibitors", "\n", "tricyclic", "antidepressants", "\n", "bupropion", "\n", "triptans", "\n", "St", ".", "John", "'s", "Wort", "\n", "tryptophan", "\n", "linezolid", "\n", "dextromethorphan", "in", "any", "form", "(", "eg", ",", "OTC", "cold", "medicines", ")", "\n", "lithium", "\n", "tramadol", "\n", "antipsychotics", "or", "other", "dopamine", "antagonists", "\t\n", "antiseizure", "medications", "including", "valproic", "acid", ",", "zonisamide", ",", "topiramate", ",", "and", "lamotrigine", "\n", "oral", "steroids", "(", "topical", "and", "inhaled", "steroids", "are", "acceptable", ")", "\n", "stimulant", "medications", "(", "eg", ",", "Ritalin", ",", "Concerta", ",", "Biphetamine", ",", "and", "Dexedrine", ")", "\n", "benzodiazepines", "\n", "Use", "of", "drugs", "known", "to", "increase", "the", "risk", "for", "cardiac", "valvulopathy", "within", "6", "months", "before", "Screening", ",", "including", "but", "not", "limited", "to", "pergolide", ",", "ergotamine", ",", "methysergide", ",", "and", "cabergoline", "\n", "History", "or", "evidence", "of", "clinically", "significant", "disease", "(", "eg", ",", "malignancy", ";", "cardiac", ",", "respiratory", ",", "gastrointestinal", ",", "renal", ",", "or", "psychiatric", "disease", ")", "other", "than", "prediabetes", "(", "impaired", "fasting", "glucose", "or", "impaired", "glucose", "tolerance", ")", ",", "type", "2", "diabetes", "treated", "with", "oral", "anti", "-", "diabetic", "agents", "(", "excluding", "sulfonylurea", ")", "or", "non", "-", "insulin", "injectable", "antidiabetic", "agents", ",", "obstructive", "sleep", "apnea", ",", "dyslipidemia", ",", "and", "nonalcoholic", "fatty", "liver", "disease", "\n", "Use", "of", "Belviq", "XR", "within", "6", "months", "before", "Screening", "or", "hypersensitivity", "to", "Belviq", "XR", "or", "any", "of", "the", "excipients", "\n", "Significant", "change", "in", "diet", "or", "level", "of", "physical", "activity", "within", "1", "month", "before", "dosing", "or", "change", "in", "weight", "of", "more", "than", "5", "kg", "within", "3", "months", "before", "Screening", "\n", "Any", "use", "of", "a", "very", "-", "low", "-", "calorie", "(", "<", "1000", "calories", "/", "day", ")", "weight", "loss", "diet", "within", "6", "months", "before", "Screening", "\n", "History", "of", "alcohol", "or", "drug", "dependence", "or", "abuse", "\n", "Recreational", "drug", "use", "within", "2", "years", "before", "Screening", "\n", "Known", "to", "be", "human", "immunodeficiency", "virus", "positive", "\n", "Known", "to", "have", "active", "viral", "hepatitis", "(", "B", "or", "C", ")", "\n", "Malignancy", "within", "5", "years", "before", "Screening", "\n", "Unable", "to", "attend", "scheduled", "visits", "(", "eg", ",", "lack", "of", "transportation", ")", "or", "lack", "of", "a", "caregiver", "or", "guardian", "to", "supervise", "study", "participation", "\n", "Special", "needs", "participants", "who", "are", "unable", "to", "comprehend", "study", "-", "related", "instructions", "(", "eg", ",", "mild", "to", "profound", "mental", "retardation", "[", "intelligence", "quotient", "<", "70", "]", ",", "moderate", "to", "severe", "cognitive", "developmental", "delay", ",", "pervasive", "development", "disorders", ",", "autism", ")", "\n", "Ongoing", "epilepsy", "or", "other", "seizure", "disorder", ",", "or", "use", "of", "medications", "for", "a", "seizure", "disorder", "within", "6", "months", "of", "screening", "or", "any", "time", "between", "screening", "and", "randomization", "\n", "Participants", "with", "a", "blood", "pressure", "in", "the", "95th", "percentile", "or", "greater", "for", "age", ",", "sex", ",", "and", "height", "on", "2", "separate", "readings", "recorded", "on", "2", "separate", "days", ".", "Those", "participants", "who", "had", "uncontrolled", "hypertension", "at", "Screening", "can", "be", "rescreened", "more", "than", "1", "month", "after", "initiation", "or", "adjustment", "of", "antihypertensive", "therapy", "1", "time", ".", "\n", "Currently", "enrolled", "in", "another", "clinical", "study", "or", "has", "used", "any", "investigational", "drug", "or", "device", "within", "30", "days", "before", "providing", "informed", "consent", "\n", "Planned", "bariatric", "surgery", "during", "the", "study", "or", "prior", "bariatric", "surgical", "procedures", "\n", "Not", "suitable", "to", "participate", "in", "the", "study", "in", "the", "opinion", "of", "the", "investigator", ",", "including", "consideration", "of", "any", "existing", "physical", ",", "medical", ",", "or", "mental", "condition", "that", "prevents", "compliance", "with", "the", "protocol", "\n", "Female", "participants", "who", "are", "breastfeeding", "or", "pregnant", "at", "Screening", "or", "Baseline", "(", "as", "documented", "by", "a", "positive", "beta", "-", "human", "chorionic", "gonadotropin", "test", ")", ".", "A", "separate", "Baseline", "assessment", "is", "required", "if", "a", "negative", "screening", "pregnancy", "test", "was", "obtained", "more", "than", "72", "hours", "before", "the", "first", "dose", "of", "study", "drug", ".", "\n", "Had", "unprotected", "sexual", "intercourse", "within", "30", "days", "before", "study", "entry", "and", "who", "do", "not", "agree", "to", "use", "a", "highly", "effective", "method", "of", "contraception", "(", "eg", ",", "total", "abstinence", ",", "an", "intrauterine", "device", ",", "a", "double", "-", "barrier", "method", "[", "such", "as", "condom", "plus", "diaphragm", "with", "spermicide", "]", ",", "a", "contraceptive", "implant", ",", "an", "oral", "contraceptive", ",", "or", "have", "a", "vasectomized", "partner", "with", "confirmed", "azoospermia", ")", "throughout", "the", "entire", "study", "period", "and", "for", "28", "days", "after", "study", "drug", "discontinuation", "\n", "Are", "currently", "abstinent", "and", "do", "not", "agree", "to", "use", "a", "double", "-", "barrier", "method", "(", "as", "described", "above", ")", "or", "refrain", "from", "sexual", "activity", "during", "the", "study", "period", "and", "for", "28", "days", "after", "study", "drug", "discontinuation", "\n", "Are", "using", "hormonal", "contraceptives", ",", "but", "are", "not", "on", "a", "stable", "dose", "of", "the", "same", "hormonal", "contraceptive", "product", "for", "at", "least", "4", "weeks", "before", "dosing", "and", "who", "do", "not", "agree", "to", "use", "the", "same", "contraceptive", "during", "the", "study", "and", "for", "28", "days", "after", "study", "drug", "discontinuation", "(", "Note", ":", "All", "female", "participants", "will", "be", "considered", "to", "be", "of", "childbearing", "potential", "unless", "they", "have", "been", "sterilized", "surgically", "[", "ie", ",", "bilateral", "tubal", "ligation", ",", "total", "hysterectomy", ",", "or", "bilateral", "oophorectomy", ",", "all", "with", "surgery", "at", "least", "1", "month", "before", "dosing", "]", ")", ".", "\n" ]	[ "Scope", "Procedure", "Observation", "Qualifier", "Temporal", "Value", "Drug", "Measurement", "Condition", "Reference_point", "Device", "Multiplier", "Mood", "Negation", "Person" ]
Clinically significant is a Qualifier, new is a Qualifier, illness is a Condition, within 1 month before randomization is a Temporal, may affect the participant 's ability to fulfill the study requirements or significantly confound the assessments is a Scope, cannot swallow is a Observation, investigational products is a Drug, T2DM is a Condition, hypoglycemia unawareness is a Condition, Aortic regurgitation is a Condition, mild or greater is a Qualifier, Mitral regurgitation is a Condition, moderate or greater is a Qualifier, Mitral or aortic valve stenosis greater than mild is a Scope, aortic stenosis : jet > 3.0 meters per second [ m / s ] , mean gradient > 25 millimeters of mercury [ mmHg ] , and aortic valve area < 1.5 centimeters squared [ cm^2 ] ; mitral stenosis : mean gradient > 5 mmHg and mitral valve area < 1.5 cm^2 is a Scope, Systolic pulmonary artery pressure ( SPAP ) is a Measurement, > 40 mmHg is a Value, tricuspid regurgitation [ TR ] jet velocity is a Measurement, > 2.9 m / s is a Value, RVOTAT is a Measurement, = 100 milliseconds ( msec ) is a Value, Left ventricular ejection fraction is a Measurement, < 45 % is a Value, Intracardiac mass is a Condition, tumor is a Condition, thrombus is a Condition, Evidence of is a Mood, congenital heart disease is a Condition, Clinically significant is a Qualifier, pericardial effusion is a Condition, moderate or larger or with hemodynamic compromise is a Scope, Significant is a Qualifier, renal or hepatic disease is a Scope, serum creatinine greater than 1.5× upper limit of normal ( ULN ) , serum transaminases greater than 3× ULN , or total bilirubin greater than 1.5× ULN in absence of Gilbert 's syndrome is a Scope, suicidal ideation is a Condition, with intent is a Qualifier, with or without a plan is a Scope, at the time of or within 6 months of Screening is a Scope, Yes is a Value, questions 4 or 5 is a Scope, Suicidal Ideation section of the Columbia - Suicide Severity Rating Scale ( C - SSRS ) is a Procedure, suicidal behavior is a Condition, in the past is a Temporal, C - SSRS is a Procedure, history is a Observation, anorexia or bulimia is a Scope, within 2 years before Screening is a Temporal, Attention Deficit Hyperactivity Disorder is a Condition, Diagnostic and Statistical Manual of Mental Disorders , 5th Edition is a Qualifier, depressive disorder , bipolar disorder , or schizophrenia is a Scope, secondary causes ( genetic , endocrine , or metabolic ) for obesity is a Scope, Prader - Willi syndrome , Bardet Biedl syndrome , Down 's Syndrome , untreated hypothyroidism , Cushing 's syndrome , daily systemic corticosteroid exposure for longer than 30 days , history of significant exposure to corticosteroids for chronic illness during the past year ; inhaled steroids will be allowed is a Scope, products intended for weight loss is a Drug, prescription drugs , over - the - counter ( OTC ) drugs , and herbal is a Scope, within 1 month before Screening is a Temporal, selective serotonin reuptake inhibitors is a Drug, serotonin norepinephrine reuptake inhibitors is a Drug, tricyclic antidepressants is a Drug, bupropion is a Drug, triptans is a Drug, St . John 's Wort is a Drug, tryptophan is a Drug, linezolid is a Drug, dextromethorphan is a Drug, any form is a Qualifier, lithium is a Drug, tramadol is a Drug, antipsychotics is a Drug, dopamine antagonists is a Drug, antiseizure medications is a Drug, valproic acid , zonisamide , topiramate , and lamotrigine is a Scope, oral steroids is a Drug, topical and inhaled steroids is a Scope, acceptable is a Negation, stimulant medications is a Drug, Ritalin , Concerta , Biphetamine , and Dexedrine is a Scope, benzodiazepines is a Drug, drugs known to increase the risk for cardiac valvulopathy is a Scope, within 6 months before Screening is a Temporal, pergolide , ergotamine , methysergide , and cabergoline is a Scope, History or evidence of clinically significant disease is a Scope, malignancy ; cardiac , respiratory , gastrointestinal , renal , or psychiatric disease is a Scope, other than is a Negation, prediabetes is a Condition, impaired fasting glucose or impaired glucose tolerance ) is a Scope, type 2 diabetes is a Condition, oral anti - diabetic agents ( excluding sulfonylurea ) or non - insulin injectable antidiabetic agents is a Scope, obstructive sleep apnea is a Condition, dyslipidemia is a Condition, nonalcoholic fatty liver disease is a Condition, within 6 months before Screening is a Temporal, hypersensitivity is a Condition, Belviq XR is a Drug, or any of the excipients is a Qualifier, Significant is a Qualifier, change in diet or level of physical activity is a Scope, within 1 month before dosing is a Temporal, change in weight is a Observation, more than 5 kg is a Value, within 3 months before Screening is a Temporal, < 1000 calories / day is a Value, within 6 months before Screening is a Temporal, History is a Observation, alcohol or drug dependence or abuse is a Scope, Recreational drug use is a Observation, within 2 years before Screening is a Temporal, human immunodeficiency virus positive is a Condition, active is a Qualifier, viral hepatitis is a Condition, B or C is a Scope, Malignancy is a Condition, within 5 years before Screening is a Temporal, Unable to attend scheduled visits is a Observation, lack of transportation is a Observation, lack of a caregiver is a Observation, Special needs is a Observation, unable to comprehend study - related instructions is a Scope, mild to profound mental retardation [ intelligence quotient < 70 ] , moderate to severe cognitive developmental delay , pervasive development disorders , autism is a Scope, Ongoing is a Temporal, epilepsy is a Condition, other is a Qualifier, medications is a Drug, seizure disorder is a Condition, within 6 months of screening or any time between screening and randomization is a Scope, blood pressure is a Measurement, 95th percentile or greater is a Value, for age is a Qualifier, 2 separate readings is a Multiplier, 2 separate days is a Qualifier, Currently is a Temporal, another is a Qualifier, investigational drug or device is a Scope, within 30 days before providing informed consent is a Temporal, Planned is a Mood, bariatric surgery is a Procedure, during the study is a Temporal, prior is a Temporal, bariatric surgical procedures is a Procedure, the study is a Reference_point, Female is a Person, breastfeeding or pregnant is a Scope, at Screening or Baseline is a Scope, positive beta - human chorionic gonadotropin test is a Scope, separate Baseline assessment is required if a negative screening pregnancy test was obtained more than 72 hours before the first dose of study drug is a Scope, unprotected sexual intercourse is a Condition, within 30 days before study entry is a Temporal, do not agree is a Observation, highly effective method of contraception is a Scope, total abstinence , an intrauterine device , a double - barrier method [ such as condom plus diaphragm with spermicide ] , a contraceptive implant , an oral contraceptive , or have a vasectomized partner with confirmed azoospermia is a Scope, throughout the entire study period is a Temporal, for 28 days after study drug discontinuation is a Temporal, currently is a Temporal, abstinent is a Condition, do not agree is a Observation, double - barrier method ( as described above ) or refrain from sexual activity is a Scope, during the study period and for 28 days after study drug discontinuation is a Scope, hormonal contraceptives is a Drug, not is a Negation, stable dose is a Qualifier, hormonal contraceptive is a Drug, for at least 4 weeks before dosing is a Temporal, do not agree is a Observation, the same is a Qualifier, contraceptive is a Drug, during the study is a Temporal, for 28 days after study drug discontinuation is a Temporal	NCT03338296_exc_task1	Sentence: Clinically significant new illness within 1 month before randomization that may affect the participant's ability to fulfill the study requirements or significantly confound the assessments Participants who cannot swallow investigational products Participants with T2DM who have hypoglycemia unawareness Aortic regurgitation mild or greater Mitral regurgitation moderate or greater Mitral or aortic valve stenosis greater than mild (ie, aortic stenosis: jet >3.0 meters per second [m/s], mean gradient >25 millimeters of mercury [mmHg], and aortic valve area <1.5 centimeters squared [cm^2]; mitral stenosis: mean gradient >5 mmHg and mitral valve area <1.5 cm^2) Systolic pulmonary artery pressure (SPAP) >40 mmHg (and/or tricuspid regurgitation [TR] jet velocity >2.9 m/s) In cases where an actual SPAP value is not measurable due to lack of adequate TR jet, the pulmonary flow acceleration time measured at the right ventricular outflow tract (RVOTAT) will be used to assess eligibility. Participants with a RVOTAT =100 milliseconds (msec) will be excluded, suggesting an elevated mean SPAP; eligibility for the those participants with RVOTAT between 100 and 120 msec will be determined based on combined assessment of the TR jet, septal motion, and right ventricular size. Left ventricular ejection fraction <45% Intracardiac mass, tumor, or thrombus Evidence of congenital heart disease Clinically significant pericardial effusion (eg, moderate or larger or with hemodynamic compromise) Significant renal or hepatic disease as evidenced by a serum creatinine greater than 1.5× upper limit of normal (ULN), serum transaminases greater than 3× ULN, or total bilirubin greater than 1.5× ULN in absence of Gilbert's syndrome Any suicidal ideation with intent with or without a plan, at the time of or within 6 months of Screening, as indicated by answering "Yes" to questions 4 or 5 on the Suicidal Ideation section of the Columbia-Suicide Severity Rating Scale (C-SSRS) Any suicidal behavior in the past based on the C-SSRS Any history of anorexia or bulimia within 2 years before Screening, Attention Deficit Hyperactivity Disorder, any Diagnostic and Statistical Manual of Mental Disorders, 5th Edition depressive disorder, bipolar disorder, or schizophrenia Known secondary causes (genetic, endocrine, or metabolic) for obesity (eg, Prader-Willi syndrome, Bardet Biedl syndrome, Down's Syndrome, untreated hypothyroidism, Cushing's syndrome, daily systemic corticosteroid exposure for longer than 30 days, history of significant exposure to corticosteroids for chronic illness during the past year; inhaled steroids will be allowed) Use of other products intended for weight loss including prescription drugs, over-the-counter (OTC) drugs, and herbal preparations within 1 month before Screening selective serotonin reuptake inhibitors serotonin norepinephrine reuptake inhibitors tricyclic antidepressants bupropion triptans St. John's Wort tryptophan linezolid dextromethorphan in any form (eg, OTC cold medicines) lithium tramadol antipsychotics or other dopamine antagonists antiseizure medications including valproic acid, zonisamide, topiramate, and lamotrigine oral steroids (topical and inhaled steroids are acceptable) stimulant medications (eg, Ritalin, Concerta, Biphetamine, and Dexedrine) benzodiazepines Use of drugs known to increase the risk for cardiac valvulopathy within 6 months before Screening, including but not limited to pergolide, ergotamine, methysergide, and cabergoline History or evidence of clinically significant disease (eg, malignancy; cardiac, respiratory, gastrointestinal, renal, or psychiatric disease) other than prediabetes (impaired fasting glucose or impaired glucose tolerance), type 2 diabetes treated with oral anti-diabetic agents (excluding sulfonylurea) or non-insulin injectable antidiabetic agents, obstructive sleep apnea, dyslipidemia, and nonalcoholic fatty liver disease Use of Belviq XR within 6 months before Screening or hypersensitivity to Belviq XR or any of the excipients Significant change in diet or level of physical activity within 1 month before dosing or change in weight of more than 5 kg within 3 months before Screening Any use of a very-low-calorie (<1000 calories/day) weight loss diet within 6 months before Screening History of alcohol or drug dependence or abuse Recreational drug use within 2 years before Screening Known to be human immunodeficiency virus positive Known to have active viral hepatitis (B or C) Malignancy within 5 years before Screening Unable to attend scheduled visits (eg, lack of transportation) or lack of a caregiver or guardian to supervise study participation Special needs participants who are unable to comprehend study-related instructions (eg, mild to profound mental retardation [intelligence quotient <70], moderate to severe cognitive developmental delay, pervasive development disorders, autism) Ongoing epilepsy or other seizure disorder, or use of medications for a seizure disorder within 6 months of screening or any time between screening and randomization Participants with a blood pressure in the 95th percentile or greater for age, sex, and height on 2 separate readings recorded on 2 separate days. Those participants who had uncontrolled hypertension at Screening can be rescreened more than 1 month after initiation or adjustment of antihypertensive therapy 1 time. Currently enrolled in another clinical study or has used any investigational drug or device within 30 days before providing informed consent Planned bariatric surgery during the study or prior bariatric surgical procedures Not suitable to participate in the study in the opinion of the investigator, including consideration of any existing physical, medical, or mental condition that prevents compliance with the protocol Female participants who are breastfeeding or pregnant at Screening or Baseline (as documented by a positive beta-human chorionic gonadotropin test). A separate Baseline assessment is required if a negative screening pregnancy test was obtained more than 72 hours before the first dose of study drug. Had unprotected sexual intercourse within 30 days before study entry and who do not agree to use a highly effective method of contraception (eg, total abstinence, an intrauterine device, a double-barrier method [such as condom plus diaphragm with spermicide], a contraceptive implant, an oral contraceptive, or have a vasectomized partner with confirmed azoospermia) throughout the entire study period and for 28 days after study drug discontinuation Are currently abstinent and do not agree to use a double-barrier method (as described above) or refrain from sexual activity during the study period and for 28 days after study drug discontinuation Are using hormonal contraceptives, but are not on a stable dose of the same hormonal contraceptive product for at least 4 weeks before dosing and who do not agree to use the same contraceptive during the study and for 28 days after study drug discontinuation (Note: All female participants will be considered to be of childbearing potential unless they have been sterilized surgically [ie, bilateral tubal ligation, total hysterectomy, or bilateral oophorectomy, all with surgery at least 1 month before dosing]). Instructions: please typing these entity words according to sentence: Clinically significant, new, illness, within 1 month before randomization, may affect the participant 's ability to fulfill the study requirements or significantly confound the assessments, cannot swallow, investigational products, T2DM, hypoglycemia unawareness, Aortic regurgitation, mild or greater, Mitral regurgitation, moderate or greater, Mitral or aortic valve stenosis greater than mild, aortic stenosis : jet > 3.0 meters per second [ m / s ] , mean gradient > 25 millimeters of mercury [ mmHg ] , and aortic valve area < 1.5 centimeters squared [ cm^2 ] ; mitral stenosis : mean gradient > 5 mmHg and mitral valve area < 1.5 cm^2, Systolic pulmonary artery pressure ( SPAP ), > 40 mmHg, tricuspid regurgitation [ TR ] jet velocity, > 2.9 m / s, RVOTAT, = 100 milliseconds ( msec ), Left ventricular ejection fraction, < 45 %, Intracardiac mass, tumor, thrombus, Evidence of, congenital heart disease, Clinically significant, pericardial effusion, moderate or larger or with hemodynamic compromise, Significant, renal or hepatic disease, serum creatinine greater than 1.5× upper limit of normal ( ULN ) , serum transaminases greater than 3× ULN , or total bilirubin greater than 1.5× ULN in absence of Gilbert 's syndrome, suicidal ideation, with intent, with or without a plan, at the time of or within 6 months of Screening, Yes, questions 4 or 5, Suicidal Ideation section of the Columbia - Suicide Severity Rating Scale ( C - SSRS ), suicidal behavior, in the past, C - SSRS, history, anorexia or bulimia, within 2 years before Screening, Attention Deficit Hyperactivity Disorder, Diagnostic and Statistical Manual of Mental Disorders , 5th Edition, depressive disorder , bipolar disorder , or schizophrenia, secondary causes ( genetic , endocrine , or metabolic ) for obesity, Prader - Willi syndrome , Bardet Biedl syndrome , Down 's Syndrome , untreated hypothyroidism , Cushing 's syndrome , daily systemic corticosteroid exposure for longer than 30 days , history of significant exposure to corticosteroids for chronic illness during the past year ; inhaled steroids will be allowed, products intended for weight loss, prescription drugs , over - the - counter ( OTC ) drugs , and herbal, within 1 month before Screening, selective serotonin reuptake inhibitors, serotonin norepinephrine reuptake inhibitors, tricyclic antidepressants, bupropion, triptans, St . John 's Wort, tryptophan, linezolid, dextromethorphan, any form, lithium, tramadol, antipsychotics, dopamine antagonists, antiseizure medications, valproic acid , zonisamide , topiramate , and lamotrigine, oral steroids, topical and inhaled steroids, acceptable, stimulant medications, Ritalin , Concerta , Biphetamine , and Dexedrine, benzodiazepines, drugs known to increase the risk for cardiac valvulopathy, within 6 months before Screening, pergolide , ergotamine , methysergide , and cabergoline, History or evidence of clinically significant disease, malignancy ; cardiac , respiratory , gastrointestinal , renal , or psychiatric disease, other than, prediabetes, impaired fasting glucose or impaired glucose tolerance ), type 2 diabetes, oral anti - diabetic agents ( excluding sulfonylurea ) or non - insulin injectable antidiabetic agents, obstructive sleep apnea, dyslipidemia, nonalcoholic fatty liver disease, within 6 months before Screening, hypersensitivity, Belviq XR, or any of the excipients, Significant, change in diet or level of physical activity, within 1 month before dosing, change in weight, more than 5 kg, within 3 months before Screening, < 1000 calories / day, within 6 months before Screening, History, alcohol or drug dependence or abuse, Recreational drug use, within 2 years before Screening, human immunodeficiency virus positive, active, viral hepatitis, B or C, Malignancy, within 5 years before Screening, Unable to attend scheduled visits, lack of transportation, lack of a caregiver, Special needs, unable to comprehend study - related instructions, mild to profound mental retardation [ intelligence quotient < 70 ] , moderate to severe cognitive developmental delay , pervasive development disorders , autism, Ongoing, epilepsy, other, medications, seizure disorder, within 6 months of screening or any time between screening and randomization, blood pressure, 95th percentile or greater, for age, 2 separate readings, 2 separate days, Currently, another, investigational drug or device, within 30 days before providing informed consent, Planned, bariatric surgery, during the study, prior, bariatric surgical procedures, the study, Female, breastfeeding or pregnant, at Screening or Baseline, positive beta - human chorionic gonadotropin test, separate Baseline assessment is required if a negative screening pregnancy test was obtained more than 72 hours before the first dose of study drug, unprotected sexual intercourse, within 30 days before study entry, do not agree, highly effective method of contraception, total abstinence , an intrauterine device , a double - barrier method [ such as condom plus diaphragm with spermicide ] , a contraceptive implant , an oral contraceptive , or have a vasectomized partner with confirmed azoospermia, throughout the entire study period, for 28 days after study drug discontinuation, currently, abstinent, do not agree, double - barrier method ( as described above ) or refrain from sexual activity, during the study period and for 28 days after study drug discontinuation, hormonal contraceptives, not, stable dose, hormonal contraceptive, for at least 4 weeks before dosing, do not agree, the same, contraceptive, during the study, for 28 days after study drug discontinuation Options: Temporal, Condition, Qualifier, Value, Person, Observation, Multiplier, Procedure, Negation, Reference_point, Scope, Measurement, Mood, Drug	[ "B-Qualifier", "I-Qualifier", "B-Qualifier", "B-Condition", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Observation", "I-Observation", "B-Drug", "I-Drug", "O", "O", "O", "B-Condition", "O", "O", "B-Condition", "I-Condition", "O", "B-Condition", "I-Condition", "B-Qualifier", "I-Qualifier", "I-Qualifier", "O", "B-Condition", "I-Condition", "B-Qualifier", "I-Qualifier", "I-Qualifier", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "O", "O", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "O", "B-Condition", "I-Condition", "O", "B-Condition", "O", "O", "B-Condition", "O", "B-Mood", "I-Mood", "B-Condition", "I-Condition", "I-Condition", "O", "B-Qualifier", "I-Qualifier", "B-Condition", "I-Condition", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Qualifier", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Condition", "I-Condition", "B-Qualifier", "I-Qualifier", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "B-Value", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "O", "O", "B-Condition", "I-Condition", "B-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "B-Procedure", "I-Procedure", "I-Procedure", "O", "O", "B-Observation", "O", "B-Scope", "I-Scope", "I-Scope", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "O", "O", "B-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "B-Drug", "I-Drug", "I-Drug", "I-Drug", "I-Drug", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Drug", "I-Drug", "I-Drug", "I-Drug", "O", "B-Drug", "I-Drug", "I-Drug", "I-Drug", "O", "B-Drug", "I-Drug", "O", "B-Drug", "O", "B-Drug", "O", "B-Drug", "I-Drug", "I-Drug", "I-Drug", "I-Drug", "O", "B-Drug", "O", "B-Drug", "O", "B-Drug", "O", "B-Qualifier", "I-Qualifier", "O", "O", "O", "O", "O", "O", "O", "O", "B-Drug", "O", "B-Drug", "O", "B-Drug", "O", "O", "B-Drug", "I-Drug", "O", "B-Drug", "I-Drug", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Drug", "I-Drug", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Negation", "O", "O", "B-Drug", "I-Drug", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Drug", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Negation", "I-Negation", "B-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Condition", "I-Condition", "I-Condition", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Condition", "I-Condition", "I-Condition", "O", "B-Condition", "O", "O", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "O", "O", "O", "O", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Condition", "O", "B-Drug", "I-Drug", "B-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "O", "B-Qualifier", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Observation", "I-Observation", "I-Observation", "O", "B-Value", "I-Value", "I-Value", "I-Value", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "O", "O", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Observation", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Observation", "I-Observation", "I-Observation", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "O", "O", "O", "O", "B-Qualifier", "B-Condition", "I-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "O", "O", "B-Condition", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Observation", "I-Observation", "I-Observation", "I-Observation", "I-Observation", "O", "O", "O", "B-Observation", "I-Observation", "I-Observation", "O", "O", "B-Observation", "I-Observation", "I-Observation", "I-Observation", "O", "O", "O", "O", "O", "O", "O", "B-Observation", "I-Observation", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Temporal", "B-Condition", "O", "B-Qualifier", "O", "O", "O", "O", "O", "O", "B-Drug", "O", "O", "B-Condition", "I-Condition", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "B-Measurement", "I-Measurement", "O", "O", "B-Value", "I-Value", "I-Value", "I-Value", "B-Qualifier", "I-Qualifier", "O", "O", "O", "O", "O", "O", "B-Multiplier", "I-Multiplier", "I-Multiplier", "O", "O", "B-Qualifier", "I-Qualifier", "I-Qualifier", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Temporal", "O", "O", "B-Qualifier", "O", "O", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Mood", "B-Procedure", "I-Procedure", "B-Temporal", "I-Temporal", "I-Temporal", "O", "B-Temporal", "B-Procedure", "I-Procedure", "I-Procedure", "O", "O", "O", "O", "O", "O", "B-Reference_point", "I-Reference_point", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Person", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Condition", "I-Condition", "I-Condition", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "B-Observation", "I-Observation", "I-Observation", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "B-Temporal", "B-Condition", "O", "B-Observation", "I-Observation", "I-Observation", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Drug", "I-Drug", "O", "O", "O", "B-Negation", "O", "O", "B-Qualifier", "I-Qualifier", "O", "O", "O", "B-Drug", "I-Drug", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "B-Observation", "I-Observation", "I-Observation", "O", "O", "B-Qualifier", "I-Qualifier", "B-Drug", "B-Temporal", "I-Temporal", "I-Temporal", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Clinically significant new illness within 1 month before randomization that may affect the participant's ability to fulfill the study requirements or significantly confound the assessments Participants who cannot swallow investigational products Participants with T2DM who have hypoglycemia unawareness Aortic regurgitation mild or greater Mitral regurgitation moderate or greater Mitral or aortic valve stenosis greater than mild (ie, aortic stenosis: jet >3.0 meters per second [m/s], mean gradient >25 millimeters of mercury [mmHg], and aortic valve area <1.5 centimeters squared [cm^2]; mitral stenosis: mean gradient >5 mmHg and mitral valve area <1.5 cm^2) Systolic pulmonary artery pressure (SPAP) >40 mmHg (and/or tricuspid regurgitation [TR] jet velocity >2.9 m/s) In cases where an actual SPAP value is not measurable due to lack of adequate TR jet, the pulmonary flow acceleration time measured at the right ventricular outflow tract (RVOTAT) will be used to assess eligibility. Participants with a RVOTAT =100 milliseconds (msec) will be excluded, suggesting an elevated mean SPAP; eligibility for the those participants with RVOTAT between 100 and 120 msec will be determined based on combined assessment of the TR jet, septal motion, and right ventricular size. Left ventricular ejection fraction <45% Intracardiac mass, tumor, or thrombus Evidence of congenital heart disease Clinically significant pericardial effusion (eg, moderate or larger or with hemodynamic compromise) Significant renal or hepatic disease as evidenced by a serum creatinine greater than 1.5× upper limit of normal (ULN), serum transaminases greater than 3× ULN, or total bilirubin greater than 1.5× ULN in absence of Gilbert's syndrome Any suicidal ideation with intent with or without a plan, at the time of or within 6 months of Screening, as indicated by answering "Yes" to questions 4 or 5 on the Suicidal Ideation section of the Columbia-Suicide Severity Rating Scale (C-SSRS) Any suicidal behavior in the past based on the C-SSRS Any history of anorexia or bulimia within 2 years before Screening, Attention Deficit Hyperactivity Disorder, any Diagnostic and Statistical Manual of Mental Disorders, 5th Edition depressive disorder, bipolar disorder, or schizophrenia Known secondary causes (genetic, endocrine, or metabolic) for obesity (eg, Prader-Willi syndrome, Bardet Biedl syndrome, Down's Syndrome, untreated hypothyroidism, Cushing's syndrome, daily systemic corticosteroid exposure for longer than 30 days, history of significant exposure to corticosteroids for chronic illness during the past year; inhaled steroids will be allowed) Use of other products intended for weight loss including prescription drugs, over-the-counter (OTC) drugs, and herbal preparations within 1 month before Screening selective serotonin reuptake inhibitors serotonin norepinephrine reuptake inhibitors tricyclic antidepressants bupropion triptans St. John's Wort tryptophan linezolid dextromethorphan in any form (eg, OTC cold medicines) lithium tramadol antipsychotics or other dopamine antagonists antiseizure medications including valproic acid, zonisamide, topiramate, and lamotrigine oral steroids (topical and inhaled steroids are acceptable) stimulant medications (eg, Ritalin, Concerta, Biphetamine, and Dexedrine) benzodiazepines Use of drugs known to increase the risk for cardiac valvulopathy within 6 months before Screening, including but not limited to pergolide, ergotamine, methysergide, and cabergoline History or evidence of clinically significant disease (eg, malignancy; cardiac, respiratory, gastrointestinal, renal, or psychiatric disease) other than prediabetes (impaired fasting glucose or impaired glucose tolerance), type 2 diabetes treated with oral anti-diabetic agents (excluding sulfonylurea) or non-insulin injectable antidiabetic agents, obstructive sleep apnea, dyslipidemia, and nonalcoholic fatty liver disease Use of Belviq XR within 6 months before Screening or hypersensitivity to Belviq XR or any of the excipients Significant change in diet or level of physical activity within 1 month before dosing or change in weight of more than 5 kg within 3 months before Screening Any use of a very-low-calorie (<1000 calories/day) weight loss diet within 6 months before Screening History of alcohol or drug dependence or abuse Recreational drug use within 2 years before Screening Known to be human immunodeficiency virus positive Known to have active viral hepatitis (B or C) Malignancy within 5 years before Screening Unable to attend scheduled visits (eg, lack of transportation) or lack of a caregiver or guardian to supervise study participation Special needs participants who are unable to comprehend study-related instructions (eg, mild to profound mental retardation [intelligence quotient <70], moderate to severe cognitive developmental delay, pervasive development disorders, autism) Ongoing epilepsy or other seizure disorder, or use of medications for a seizure disorder within 6 months of screening or any time between screening and randomization Participants with a blood pressure in the 95th percentile or greater for age, sex, and height on 2 separate readings recorded on 2 separate days. Those participants who had uncontrolled hypertension at Screening can be rescreened more than 1 month after initiation or adjustment of antihypertensive therapy 1 time. Currently enrolled in another clinical study or has used any investigational drug or device within 30 days before providing informed consent Planned bariatric surgery during the study or prior bariatric surgical procedures Not suitable to participate in the study in the opinion of the investigator, including consideration of any existing physical, medical, or mental condition that prevents compliance with the protocol Female participants who are breastfeeding or pregnant at Screening or Baseline (as documented by a positive beta-human chorionic gonadotropin test). A separate Baseline assessment is required if a negative screening pregnancy test was obtained more than 72 hours before the first dose of study drug. Had unprotected sexual intercourse within 30 days before study entry and who do not agree to use a highly effective method of contraception (eg, total abstinence, an intrauterine device, a double-barrier method [such as condom plus diaphragm with spermicide], a contraceptive implant, an oral contraceptive, or have a vasectomized partner with confirmed azoospermia) throughout the entire study period and for 28 days after study drug discontinuation Are currently abstinent and do not agree to use a double-barrier method (as described above) or refrain from sexual activity during the study period and for 28 days after study drug discontinuation Are using hormonal contraceptives, but are not on a stable dose of the same hormonal contraceptive product for at least 4 weeks before dosing and who do not agree to use the same contraceptive during the study and for 28 days after study drug discontinuation (Note: All female participants will be considered to be of childbearing potential unless they have been sterilized surgically [ie, bilateral tubal ligation, total hysterectomy, or bilateral oophorectomy, all with surgery at least 1 month before dosing]).	[ "Clinically", "significant", "new", "illness", "within", "1", "month", "before", "randomization", "that", "may", "affect", "the", "participant", "'s", "ability", "to", "fulfill", "the", "study", "requirements", "or", "significantly", "confound", "the", "assessments", "\n", "Participants", "who", "cannot", "swallow", "investigational", "products", "\n", "Participants", "with", "T2DM", "who", "have", "hypoglycemia", "unawareness", "\n", "Aortic", "regurgitation", "mild", "or", "greater", "\n", "Mitral", "regurgitation", "moderate", "or", "greater", "\n", "Mitral", "or", "aortic", "valve", "stenosis", "greater", "than", "mild", "(", "ie", ",", "aortic", "stenosis", ":", "jet", ">", "3.0", "meters", "per", "second", "[", "m", "/", "s", "]", ",", "mean", "gradient", ">", "25", "millimeters", "of", "mercury", "[", "mmHg", "]", ",", "and", "aortic", "valve", "area", "<", "1.5", "centimeters", "squared", "[", "cm^2", "]", ";", "mitral", "stenosis", ":", "mean", "gradient", ">", "5", "mmHg", "and", "mitral", "valve", "area", "<", "1.5", "cm^2", ")", "\n", "Systolic", "pulmonary", "artery", "pressure", "(", "SPAP", ")", ">", "40", "mmHg", "(", "and", "/", "or", "tricuspid", "regurgitation", "[", "TR", "]", "jet", "velocity", ">", "2.9", "m", "/", "s", ")", "In", "cases", "where", "an", "actual", "SPAP", "value", "is", "not", "measurable", "due", "to", "lack", "of", "adequate", "TR", "jet", ",", "the", "pulmonary", "flow", "acceleration", "time", "measured", "at", "the", "right", "ventricular", "outflow", "tract", "(", "RVOTAT", ")", "will", "be", "used", "to", "assess", "eligibility", ".", "Participants", "with", "a", "RVOTAT", "=", "100", "milliseconds", "(", "msec", ")", "will", "be", "excluded", ",", "suggesting", "an", "elevated", "mean", "SPAP", ";", "eligibility", "for", "the", "those", "participants", "with", "RVOTAT", "between", "100", "and", "120", "msec", "will", "be", "determined", "based", "on", "combined", "assessment", "of", "the", "TR", "jet", ",", "septal", "motion", ",", "and", "right", "ventricular", "size", ".", "\n", "Left", "ventricular", "ejection", "fraction", "<", "45", "%", "\n", "Intracardiac", "mass", ",", "tumor", ",", "or", "thrombus", "\n", "Evidence", "of", "congenital", "heart", "disease", "\n", "Clinically", "significant", "pericardial", "effusion", "(", "eg", ",", "moderate", "or", "larger", "or", "with", "hemodynamic", "compromise", ")", "\n", "Significant", "renal", "or", "hepatic", "disease", "as", "evidenced", "by", "a", "serum", "creatinine", "greater", "than", "1.5×", "upper", "limit", "of", "normal", "(", "ULN", ")", ",", "serum", "transaminases", "greater", "than", "3×", "ULN", ",", "or", "total", "bilirubin", "greater", "than", "1.5×", "ULN", "in", "absence", "of", "Gilbert", "'s", "syndrome", "\n", "Any", "suicidal", "ideation", "with", "intent", "with", "or", "without", "a", "plan", ",", "at", "the", "time", "of", "or", "within", "6", "months", "of", "Screening", ",", "as", "indicated", "by", "answering", "\"", "Yes", "\"", "to", "questions", "4", "or", "5", "on", "the", "Suicidal", "Ideation", "section", "of", "the", "Columbia", "-", "Suicide", "Severity", "Rating", "Scale", "(", "C", "-", "SSRS", ")", "\n", "Any", "suicidal", "behavior", "in", "the", "past", "based", "on", "the", "C", "-", "SSRS", "\n", "Any", "history", "of", "anorexia", "or", "bulimia", "within", "2", "years", "before", "Screening", ",", "Attention", "Deficit", "Hyperactivity", "Disorder", ",", "any", "Diagnostic", "and", "Statistical", "Manual", "of", "Mental", "Disorders", ",", "5th", "Edition", "depressive", "disorder", ",", "bipolar", "disorder", ",", "or", "schizophrenia", "\n", "Known", "secondary", "causes", "(", "genetic", ",", "endocrine", ",", "or", "metabolic", ")", "for", "obesity", "(", "eg", ",", "Prader", "-", "Willi", "syndrome", ",", "Bardet", "Biedl", "syndrome", ",", "Down", "'s", "Syndrome", ",", "untreated", "hypothyroidism", ",", "Cushing", "'s", "syndrome", ",", "daily", "systemic", "corticosteroid", "exposure", "for", "longer", "than", "30", "days", ",", "history", "of", "significant", "exposure", "to", "corticosteroids", "for", "chronic", "illness", "during", "the", "past", "year", ";", "inhaled", "steroids", "will", "be", "allowed", ")", "\n", "Use", "of", "other", "products", "intended", "for", "weight", "loss", "including", "prescription", "drugs", ",", "over", "-", "the", "-", "counter", "(", "OTC", ")", "drugs", ",", "and", "herbal", "preparations", "within", "1", "month", "before", "Screening", "\n", "selective", "serotonin", "reuptake", "inhibitors", "\n", "serotonin", "norepinephrine", "reuptake", "inhibitors", "\n", "tricyclic", "antidepressants", "\n", "bupropion", "\n", "triptans", "\n", "St", ".", "John", "'s", "Wort", "\n", "tryptophan", "\n", "linezolid", "\n", "dextromethorphan", "in", "any", "form", "(", "eg", ",", "OTC", "cold", "medicines", ")", "\n", "lithium", "\n", "tramadol", "\n", "antipsychotics", "or", "other", "dopamine", "antagonists", "\t\n", "antiseizure", "medications", "including", "valproic", "acid", ",", "zonisamide", ",", "topiramate", ",", "and", "lamotrigine", "\n", "oral", "steroids", "(", "topical", "and", "inhaled", "steroids", "are", "acceptable", ")", "\n", "stimulant", "medications", "(", "eg", ",", "Ritalin", ",", "Concerta", ",", "Biphetamine", ",", "and", "Dexedrine", ")", "\n", "benzodiazepines", "\n", "Use", "of", "drugs", "known", "to", "increase", "the", "risk", "for", "cardiac", "valvulopathy", "within", "6", "months", "before", "Screening", ",", "including", "but", "not", "limited", "to", "pergolide", ",", "ergotamine", ",", "methysergide", ",", "and", "cabergoline", "\n", "History", "or", "evidence", "of", "clinically", "significant", "disease", "(", "eg", ",", "malignancy", ";", "cardiac", ",", "respiratory", ",", "gastrointestinal", ",", "renal", ",", "or", "psychiatric", "disease", ")", "other", "than", "prediabetes", "(", "impaired", "fasting", "glucose", "or", "impaired", "glucose", "tolerance", ")", ",", "type", "2", "diabetes", "treated", "with", "oral", "anti", "-", "diabetic", "agents", "(", "excluding", "sulfonylurea", ")", "or", "non", "-", "insulin", "injectable", "antidiabetic", "agents", ",", "obstructive", "sleep", "apnea", ",", "dyslipidemia", ",", "and", "nonalcoholic", "fatty", "liver", "disease", "\n", "Use", "of", "Belviq", "XR", "within", "6", "months", "before", "Screening", "or", "hypersensitivity", "to", "Belviq", "XR", "or", "any", "of", "the", "excipients", "\n", "Significant", "change", "in", "diet", "or", "level", "of", "physical", "activity", "within", "1", "month", "before", "dosing", "or", "change", "in", "weight", "of", "more", "than", "5", "kg", "within", "3", "months", "before", "Screening", "\n", "Any", "use", "of", "a", "very", "-", "low", "-", "calorie", "(", "<", "1000", "calories", "/", "day", ")", "weight", "loss", "diet", "within", "6", "months", "before", "Screening", "\n", "History", "of", "alcohol", "or", "drug", "dependence", "or", "abuse", "\n", "Recreational", "drug", "use", "within", "2", "years", "before", "Screening", "\n", "Known", "to", "be", "human", "immunodeficiency", "virus", "positive", "\n", "Known", "to", "have", "active", "viral", "hepatitis", "(", "B", "or", "C", ")", "\n", "Malignancy", "within", "5", "years", "before", "Screening", "\n", "Unable", "to", "attend", "scheduled", "visits", "(", "eg", ",", "lack", "of", "transportation", ")", "or", "lack", "of", "a", "caregiver", "or", "guardian", "to", "supervise", "study", "participation", "\n", "Special", "needs", "participants", "who", "are", "unable", "to", "comprehend", "study", "-", "related", "instructions", "(", "eg", ",", "mild", "to", "profound", "mental", "retardation", "[", "intelligence", "quotient", "<", "70", "]", ",", "moderate", "to", "severe", "cognitive", "developmental", "delay", ",", "pervasive", "development", "disorders", ",", "autism", ")", "\n", "Ongoing", "epilepsy", "or", "other", "seizure", "disorder", ",", "or", "use", "of", "medications", "for", "a", "seizure", "disorder", "within", "6", "months", "of", "screening", "or", "any", "time", "between", "screening", "and", "randomization", "\n", "Participants", "with", "a", "blood", "pressure", "in", "the", "95th", "percentile", "or", "greater", "for", "age", ",", "sex", ",", "and", "height", "on", "2", "separate", "readings", "recorded", "on", "2", "separate", "days", ".", "Those", "participants", "who", "had", "uncontrolled", "hypertension", "at", "Screening", "can", "be", "rescreened", "more", "than", "1", "month", "after", "initiation", "or", "adjustment", "of", "antihypertensive", "therapy", "1", "time", ".", "\n", "Currently", "enrolled", "in", "another", "clinical", "study", "or", "has", "used", "any", "investigational", "drug", "or", "device", "within", "30", "days", "before", "providing", "informed", "consent", "\n", "Planned", "bariatric", "surgery", "during", "the", "study", "or", "prior", "bariatric", "surgical", "procedures", "\n", "Not", "suitable", "to", "participate", "in", "the", "study", "in", "the", "opinion", "of", "the", "investigator", ",", "including", "consideration", "of", "any", "existing", "physical", ",", "medical", ",", "or", "mental", "condition", "that", "prevents", "compliance", "with", "the", "protocol", "\n", "Female", "participants", "who", "are", "breastfeeding", "or", "pregnant", "at", "Screening", "or", "Baseline", "(", "as", "documented", "by", "a", "positive", "beta", "-", "human", "chorionic", "gonadotropin", "test", ")", ".", "A", "separate", "Baseline", "assessment", "is", "required", "if", "a", "negative", "screening", "pregnancy", "test", "was", "obtained", "more", "than", "72", "hours", "before", "the", "first", "dose", "of", "study", "drug", ".", "\n", "Had", "unprotected", "sexual", "intercourse", "within", "30", "days", "before", "study", "entry", "and", "who", "do", "not", "agree", "to", "use", "a", "highly", "effective", "method", "of", "contraception", "(", "eg", ",", "total", "abstinence", ",", "an", "intrauterine", "device", ",", "a", "double", "-", "barrier", "method", "[", "such", "as", "condom", "plus", "diaphragm", "with", "spermicide", "]", ",", "a", "contraceptive", "implant", ",", "an", "oral", "contraceptive", ",", "or", "have", "a", "vasectomized", "partner", "with", "confirmed", "azoospermia", ")", "throughout", "the", "entire", "study", "period", "and", "for", "28", "days", "after", "study", "drug", "discontinuation", "\n", "Are", "currently", "abstinent", "and", "do", "not", "agree", "to", "use", "a", "double", "-", "barrier", "method", "(", "as", "described", "above", ")", "or", "refrain", "from", "sexual", "activity", "during", "the", "study", "period", "and", "for", "28", "days", "after", "study", "drug", "discontinuation", "\n", "Are", "using", "hormonal", "contraceptives", ",", "but", "are", "not", "on", "a", "stable", "dose", "of", "the", "same", "hormonal", "contraceptive", "product", "for", "at", "least", "4", "weeks", "before", "dosing", "and", "who", "do", "not", "agree", "to", "use", "the", "same", "contraceptive", "during", "the", "study", "and", "for", "28", "days", "after", "study", "drug", "discontinuation", "(", "Note", ":", "All", "female", "participants", "will", "be", "considered", "to", "be", "of", "childbearing", "potential", "unless", "they", "have", "been", "sterilized", "surgically", "[", "ie", ",", "bilateral", "tubal", "ligation", ",", "total", "hysterectomy", ",", "or", "bilateral", "oophorectomy", ",", "all", "with", "surgery", "at", "least", "1", "month", "before", "dosing", "]", ")", ".", "\n" ]	[ "Scope", "Procedure", "Observation", "Qualifier", "Temporal", "Value", "Drug", "Measurement", "Condition", "Reference_point", "Device", "Multiplier", "Mood", "Negation", "Person" ]
Clinically significant, new, illness, within 1 month before randomization, may affect the participant 's ability to fulfill the study requirements or significantly confound the assessments, cannot swallow, investigational products, T2DM, hypoglycemia unawareness, Aortic regurgitation, mild or greater, Mitral regurgitation, moderate or greater, Mitral or aortic valve stenosis greater than mild, aortic stenosis : jet > 3.0 meters per second [ m / s ] , mean gradient > 25 millimeters of mercury [ mmHg ] , and aortic valve area < 1.5 centimeters squared [ cm^2 ] ; mitral stenosis : mean gradient > 5 mmHg and mitral valve area < 1.5 cm^2, Systolic pulmonary artery pressure ( SPAP ), > 40 mmHg, tricuspid regurgitation [ TR ] jet velocity, > 2.9 m / s, RVOTAT, = 100 milliseconds ( msec ), Left ventricular ejection fraction, < 45 %, Intracardiac mass, tumor, thrombus, Evidence of, congenital heart disease, Clinically significant, pericardial effusion, moderate or larger or with hemodynamic compromise, Significant, renal or hepatic disease, serum creatinine greater than 1.5× upper limit of normal ( ULN ) , serum transaminases greater than 3× ULN , or total bilirubin greater than 1.5× ULN in absence of Gilbert 's syndrome, suicidal ideation, with intent, with or without a plan, at the time of or within 6 months of Screening, Yes, questions 4 or 5, Suicidal Ideation section of the Columbia - Suicide Severity Rating Scale ( C - SSRS ), suicidal behavior, in the past, C - SSRS, history, anorexia or bulimia, within 2 years before Screening, Attention Deficit Hyperactivity Disorder, Diagnostic and Statistical Manual of Mental Disorders , 5th Edition, depressive disorder , bipolar disorder , or schizophrenia, secondary causes ( genetic , endocrine , or metabolic ) for obesity, Prader - Willi syndrome , Bardet Biedl syndrome , Down 's Syndrome , untreated hypothyroidism , Cushing 's syndrome , daily systemic corticosteroid exposure for longer than 30 days , history of significant exposure to corticosteroids for chronic illness during the past year ; inhaled steroids will be allowed, products intended for weight loss, prescription drugs , over - the - counter ( OTC ) drugs , and herbal, within 1 month before Screening, selective serotonin reuptake inhibitors, serotonin norepinephrine reuptake inhibitors, tricyclic antidepressants, bupropion, triptans, St . John 's Wort, tryptophan, linezolid, dextromethorphan, any form, lithium, tramadol, antipsychotics, dopamine antagonists, antiseizure medications, valproic acid , zonisamide , topiramate , and lamotrigine, oral steroids, topical and inhaled steroids, acceptable, stimulant medications, Ritalin , Concerta , Biphetamine , and Dexedrine, benzodiazepines, drugs known to increase the risk for cardiac valvulopathy, within 6 months before Screening, pergolide , ergotamine , methysergide , and cabergoline, History or evidence of clinically significant disease, malignancy ; cardiac , respiratory , gastrointestinal , renal , or psychiatric disease, other than, prediabetes, impaired fasting glucose or impaired glucose tolerance ), type 2 diabetes, oral anti - diabetic agents ( excluding sulfonylurea ) or non - insulin injectable antidiabetic agents, obstructive sleep apnea, dyslipidemia, nonalcoholic fatty liver disease, within 6 months before Screening, hypersensitivity, Belviq XR, or any of the excipients, Significant, change in diet or level of physical activity, within 1 month before dosing, change in weight, more than 5 kg, within 3 months before Screening, < 1000 calories / day, within 6 months before Screening, History, alcohol or drug dependence or abuse, Recreational drug use, within 2 years before Screening, human immunodeficiency virus positive, active, viral hepatitis, B or C, Malignancy, within 5 years before Screening, Unable to attend scheduled visits, lack of transportation, lack of a caregiver, Special needs, unable to comprehend study - related instructions, mild to profound mental retardation [ intelligence quotient < 70 ] , moderate to severe cognitive developmental delay , pervasive development disorders , autism, Ongoing, epilepsy, other, medications, seizure disorder, within 6 months of screening or any time between screening and randomization, blood pressure, 95th percentile or greater, for age, 2 separate readings, 2 separate days, Currently, another, investigational drug or device, within 30 days before providing informed consent, Planned, bariatric surgery, during the study, prior, bariatric surgical procedures, the study, Female, breastfeeding or pregnant, at Screening or Baseline, positive beta - human chorionic gonadotropin test, separate Baseline assessment is required if a negative screening pregnancy test was obtained more than 72 hours before the first dose of study drug, unprotected sexual intercourse, within 30 days before study entry, do not agree, highly effective method of contraception, total abstinence , an intrauterine device , a double - barrier method [ such as condom plus diaphragm with spermicide ] , a contraceptive implant , an oral contraceptive , or have a vasectomized partner with confirmed azoospermia, throughout the entire study period, for 28 days after study drug discontinuation, currently, abstinent, do not agree, double - barrier method ( as described above ) or refrain from sexual activity, during the study period and for 28 days after study drug discontinuation, hormonal contraceptives, not, stable dose, hormonal contraceptive, for at least 4 weeks before dosing, do not agree, the same, contraceptive, during the study, for 28 days after study drug discontinuation	NCT03338296_exc_task2	Sentence: Clinically significant new illness within 1 month before randomization that may affect the participant's ability to fulfill the study requirements or significantly confound the assessments Participants who cannot swallow investigational products Participants with T2DM who have hypoglycemia unawareness Aortic regurgitation mild or greater Mitral regurgitation moderate or greater Mitral or aortic valve stenosis greater than mild (ie, aortic stenosis: jet >3.0 meters per second [m/s], mean gradient >25 millimeters of mercury [mmHg], and aortic valve area <1.5 centimeters squared [cm^2]; mitral stenosis: mean gradient >5 mmHg and mitral valve area <1.5 cm^2) Systolic pulmonary artery pressure (SPAP) >40 mmHg (and/or tricuspid regurgitation [TR] jet velocity >2.9 m/s) In cases where an actual SPAP value is not measurable due to lack of adequate TR jet, the pulmonary flow acceleration time measured at the right ventricular outflow tract (RVOTAT) will be used to assess eligibility. Participants with a RVOTAT =100 milliseconds (msec) will be excluded, suggesting an elevated mean SPAP; eligibility for the those participants with RVOTAT between 100 and 120 msec will be determined based on combined assessment of the TR jet, septal motion, and right ventricular size. Left ventricular ejection fraction <45% Intracardiac mass, tumor, or thrombus Evidence of congenital heart disease Clinically significant pericardial effusion (eg, moderate or larger or with hemodynamic compromise) Significant renal or hepatic disease as evidenced by a serum creatinine greater than 1.5× upper limit of normal (ULN), serum transaminases greater than 3× ULN, or total bilirubin greater than 1.5× ULN in absence of Gilbert's syndrome Any suicidal ideation with intent with or without a plan, at the time of or within 6 months of Screening, as indicated by answering "Yes" to questions 4 or 5 on the Suicidal Ideation section of the Columbia-Suicide Severity Rating Scale (C-SSRS) Any suicidal behavior in the past based on the C-SSRS Any history of anorexia or bulimia within 2 years before Screening, Attention Deficit Hyperactivity Disorder, any Diagnostic and Statistical Manual of Mental Disorders, 5th Edition depressive disorder, bipolar disorder, or schizophrenia Known secondary causes (genetic, endocrine, or metabolic) for obesity (eg, Prader-Willi syndrome, Bardet Biedl syndrome, Down's Syndrome, untreated hypothyroidism, Cushing's syndrome, daily systemic corticosteroid exposure for longer than 30 days, history of significant exposure to corticosteroids for chronic illness during the past year; inhaled steroids will be allowed) Use of other products intended for weight loss including prescription drugs, over-the-counter (OTC) drugs, and herbal preparations within 1 month before Screening selective serotonin reuptake inhibitors serotonin norepinephrine reuptake inhibitors tricyclic antidepressants bupropion triptans St. John's Wort tryptophan linezolid dextromethorphan in any form (eg, OTC cold medicines) lithium tramadol antipsychotics or other dopamine antagonists antiseizure medications including valproic acid, zonisamide, topiramate, and lamotrigine oral steroids (topical and inhaled steroids are acceptable) stimulant medications (eg, Ritalin, Concerta, Biphetamine, and Dexedrine) benzodiazepines Use of drugs known to increase the risk for cardiac valvulopathy within 6 months before Screening, including but not limited to pergolide, ergotamine, methysergide, and cabergoline History or evidence of clinically significant disease (eg, malignancy; cardiac, respiratory, gastrointestinal, renal, or psychiatric disease) other than prediabetes (impaired fasting glucose or impaired glucose tolerance), type 2 diabetes treated with oral anti-diabetic agents (excluding sulfonylurea) or non-insulin injectable antidiabetic agents, obstructive sleep apnea, dyslipidemia, and nonalcoholic fatty liver disease Use of Belviq XR within 6 months before Screening or hypersensitivity to Belviq XR or any of the excipients Significant change in diet or level of physical activity within 1 month before dosing or change in weight of more than 5 kg within 3 months before Screening Any use of a very-low-calorie (<1000 calories/day) weight loss diet within 6 months before Screening History of alcohol or drug dependence or abuse Recreational drug use within 2 years before Screening Known to be human immunodeficiency virus positive Known to have active viral hepatitis (B or C) Malignancy within 5 years before Screening Unable to attend scheduled visits (eg, lack of transportation) or lack of a caregiver or guardian to supervise study participation Special needs participants who are unable to comprehend study-related instructions (eg, mild to profound mental retardation [intelligence quotient <70], moderate to severe cognitive developmental delay, pervasive development disorders, autism) Ongoing epilepsy or other seizure disorder, or use of medications for a seizure disorder within 6 months of screening or any time between screening and randomization Participants with a blood pressure in the 95th percentile or greater for age, sex, and height on 2 separate readings recorded on 2 separate days. Those participants who had uncontrolled hypertension at Screening can be rescreened more than 1 month after initiation or adjustment of antihypertensive therapy 1 time. Currently enrolled in another clinical study or has used any investigational drug or device within 30 days before providing informed consent Planned bariatric surgery during the study or prior bariatric surgical procedures Not suitable to participate in the study in the opinion of the investigator, including consideration of any existing physical, medical, or mental condition that prevents compliance with the protocol Female participants who are breastfeeding or pregnant at Screening or Baseline (as documented by a positive beta-human chorionic gonadotropin test). A separate Baseline assessment is required if a negative screening pregnancy test was obtained more than 72 hours before the first dose of study drug. Had unprotected sexual intercourse within 30 days before study entry and who do not agree to use a highly effective method of contraception (eg, total abstinence, an intrauterine device, a double-barrier method [such as condom plus diaphragm with spermicide], a contraceptive implant, an oral contraceptive, or have a vasectomized partner with confirmed azoospermia) throughout the entire study period and for 28 days after study drug discontinuation Are currently abstinent and do not agree to use a double-barrier method (as described above) or refrain from sexual activity during the study period and for 28 days after study drug discontinuation Are using hormonal contraceptives, but are not on a stable dose of the same hormonal contraceptive product for at least 4 weeks before dosing and who do not agree to use the same contraceptive during the study and for 28 days after study drug discontinuation (Note: All female participants will be considered to be of childbearing potential unless they have been sterilized surgically [ie, bilateral tubal ligation, total hysterectomy, or bilateral oophorectomy, all with surgery at least 1 month before dosing]). Instructions: please extract entity words from the input sentence	[ "B-Qualifier", "I-Qualifier", "B-Qualifier", "B-Condition", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Observation", "I-Observation", "B-Drug", "I-Drug", "O", "O", "O", "B-Condition", "O", "O", "B-Condition", "I-Condition", "O", "B-Condition", "I-Condition", "B-Qualifier", "I-Qualifier", "I-Qualifier", "O", "B-Condition", "I-Condition", "B-Qualifier", "I-Qualifier", "I-Qualifier", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "O", "O", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "O", "B-Condition", "I-Condition", "O", "B-Condition", "O", "O", "B-Condition", "O", "B-Mood", "I-Mood", "B-Condition", "I-Condition", "I-Condition", "O", "B-Qualifier", "I-Qualifier", "B-Condition", "I-Condition", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Qualifier", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Condition", "I-Condition", "B-Qualifier", "I-Qualifier", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "B-Value", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "O", "O", "B-Condition", "I-Condition", "B-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "B-Procedure", "I-Procedure", "I-Procedure", "O", "O", "B-Observation", "O", "B-Scope", "I-Scope", "I-Scope", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "O", "O", "B-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "B-Drug", "I-Drug", "I-Drug", "I-Drug", "I-Drug", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Drug", "I-Drug", "I-Drug", "I-Drug", "O", "B-Drug", "I-Drug", "I-Drug", "I-Drug", "O", "B-Drug", "I-Drug", "O", "B-Drug", "O", "B-Drug", "O", "B-Drug", "I-Drug", "I-Drug", "I-Drug", "I-Drug", "O", "B-Drug", "O", "B-Drug", "O", "B-Drug", "O", "B-Qualifier", "I-Qualifier", "O", "O", "O", "O", "O", "O", "O", "O", "B-Drug", "O", "B-Drug", "O", "B-Drug", "O", "O", "B-Drug", "I-Drug", "O", "B-Drug", "I-Drug", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Drug", "I-Drug", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Negation", "O", "O", "B-Drug", "I-Drug", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Drug", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Negation", "I-Negation", "B-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Condition", "I-Condition", "I-Condition", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Condition", "I-Condition", "I-Condition", "O", "B-Condition", "O", "O", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "O", "O", "O", "O", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Condition", "O", "B-Drug", "I-Drug", "B-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "O", "B-Qualifier", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Observation", "I-Observation", "I-Observation", "O", "B-Value", "I-Value", "I-Value", "I-Value", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "O", "O", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Observation", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Observation", "I-Observation", "I-Observation", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "O", "O", "O", "O", "B-Qualifier", "B-Condition", "I-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "O", "O", "B-Condition", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Observation", "I-Observation", "I-Observation", "I-Observation", "I-Observation", "O", "O", "O", "B-Observation", "I-Observation", "I-Observation", "O", "O", "B-Observation", "I-Observation", "I-Observation", "I-Observation", "O", "O", "O", "O", "O", "O", "O", "B-Observation", "I-Observation", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Temporal", "B-Condition", "O", "B-Qualifier", "O", "O", "O", "O", "O", "O", "B-Drug", "O", "O", "B-Condition", "I-Condition", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "B-Measurement", "I-Measurement", "O", "O", "B-Value", "I-Value", "I-Value", "I-Value", "B-Qualifier", "I-Qualifier", "O", "O", "O", "O", "O", "O", "B-Multiplier", "I-Multiplier", "I-Multiplier", "O", "O", "B-Qualifier", "I-Qualifier", "I-Qualifier", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Temporal", "O", "O", "B-Qualifier", "O", "O", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Mood", "B-Procedure", "I-Procedure", "B-Temporal", "I-Temporal", "I-Temporal", "O", "B-Temporal", "B-Procedure", "I-Procedure", "I-Procedure", "O", "O", "O", "O", "O", "O", "B-Reference_point", "I-Reference_point", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Person", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Condition", "I-Condition", "I-Condition", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "B-Observation", "I-Observation", "I-Observation", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "B-Temporal", "B-Condition", "O", "B-Observation", "I-Observation", "I-Observation", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Drug", "I-Drug", "O", "O", "O", "B-Negation", "O", "O", "B-Qualifier", "I-Qualifier", "O", "O", "O", "B-Drug", "I-Drug", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "B-Observation", "I-Observation", "I-Observation", "O", "O", "B-Qualifier", "I-Qualifier", "B-Drug", "B-Temporal", "I-Temporal", "I-Temporal", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Clinically significant new illness within 1 month before randomization that may affect the participant's ability to fulfill the study requirements or significantly confound the assessments Participants who cannot swallow investigational products Participants with T2DM who have hypoglycemia unawareness Aortic regurgitation mild or greater Mitral regurgitation moderate or greater Mitral or aortic valve stenosis greater than mild (ie, aortic stenosis: jet >3.0 meters per second [m/s], mean gradient >25 millimeters of mercury [mmHg], and aortic valve area <1.5 centimeters squared [cm^2]; mitral stenosis: mean gradient >5 mmHg and mitral valve area <1.5 cm^2) Systolic pulmonary artery pressure (SPAP) >40 mmHg (and/or tricuspid regurgitation [TR] jet velocity >2.9 m/s) In cases where an actual SPAP value is not measurable due to lack of adequate TR jet, the pulmonary flow acceleration time measured at the right ventricular outflow tract (RVOTAT) will be used to assess eligibility. Participants with a RVOTAT =100 milliseconds (msec) will be excluded, suggesting an elevated mean SPAP; eligibility for the those participants with RVOTAT between 100 and 120 msec will be determined based on combined assessment of the TR jet, septal motion, and right ventricular size. Left ventricular ejection fraction <45% Intracardiac mass, tumor, or thrombus Evidence of congenital heart disease Clinically significant pericardial effusion (eg, moderate or larger or with hemodynamic compromise) Significant renal or hepatic disease as evidenced by a serum creatinine greater than 1.5× upper limit of normal (ULN), serum transaminases greater than 3× ULN, or total bilirubin greater than 1.5× ULN in absence of Gilbert's syndrome Any suicidal ideation with intent with or without a plan, at the time of or within 6 months of Screening, as indicated by answering "Yes" to questions 4 or 5 on the Suicidal Ideation section of the Columbia-Suicide Severity Rating Scale (C-SSRS) Any suicidal behavior in the past based on the C-SSRS Any history of anorexia or bulimia within 2 years before Screening, Attention Deficit Hyperactivity Disorder, any Diagnostic and Statistical Manual of Mental Disorders, 5th Edition depressive disorder, bipolar disorder, or schizophrenia Known secondary causes (genetic, endocrine, or metabolic) for obesity (eg, Prader-Willi syndrome, Bardet Biedl syndrome, Down's Syndrome, untreated hypothyroidism, Cushing's syndrome, daily systemic corticosteroid exposure for longer than 30 days, history of significant exposure to corticosteroids for chronic illness during the past year; inhaled steroids will be allowed) Use of other products intended for weight loss including prescription drugs, over-the-counter (OTC) drugs, and herbal preparations within 1 month before Screening selective serotonin reuptake inhibitors serotonin norepinephrine reuptake inhibitors tricyclic antidepressants bupropion triptans St. John's Wort tryptophan linezolid dextromethorphan in any form (eg, OTC cold medicines) lithium tramadol antipsychotics or other dopamine antagonists antiseizure medications including valproic acid, zonisamide, topiramate, and lamotrigine oral steroids (topical and inhaled steroids are acceptable) stimulant medications (eg, Ritalin, Concerta, Biphetamine, and Dexedrine) benzodiazepines Use of drugs known to increase the risk for cardiac valvulopathy within 6 months before Screening, including but not limited to pergolide, ergotamine, methysergide, and cabergoline History or evidence of clinically significant disease (eg, malignancy; cardiac, respiratory, gastrointestinal, renal, or psychiatric disease) other than prediabetes (impaired fasting glucose or impaired glucose tolerance), type 2 diabetes treated with oral anti-diabetic agents (excluding sulfonylurea) or non-insulin injectable antidiabetic agents, obstructive sleep apnea, dyslipidemia, and nonalcoholic fatty liver disease Use of Belviq XR within 6 months before Screening or hypersensitivity to Belviq XR or any of the excipients Significant change in diet or level of physical activity within 1 month before dosing or change in weight of more than 5 kg within 3 months before Screening Any use of a very-low-calorie (<1000 calories/day) weight loss diet within 6 months before Screening History of alcohol or drug dependence or abuse Recreational drug use within 2 years before Screening Known to be human immunodeficiency virus positive Known to have active viral hepatitis (B or C) Malignancy within 5 years before Screening Unable to attend scheduled visits (eg, lack of transportation) or lack of a caregiver or guardian to supervise study participation Special needs participants who are unable to comprehend study-related instructions (eg, mild to profound mental retardation [intelligence quotient <70], moderate to severe cognitive developmental delay, pervasive development disorders, autism) Ongoing epilepsy or other seizure disorder, or use of medications for a seizure disorder within 6 months of screening or any time between screening and randomization Participants with a blood pressure in the 95th percentile or greater for age, sex, and height on 2 separate readings recorded on 2 separate days. Those participants who had uncontrolled hypertension at Screening can be rescreened more than 1 month after initiation or adjustment of antihypertensive therapy 1 time. Currently enrolled in another clinical study or has used any investigational drug or device within 30 days before providing informed consent Planned bariatric surgery during the study or prior bariatric surgical procedures Not suitable to participate in the study in the opinion of the investigator, including consideration of any existing physical, medical, or mental condition that prevents compliance with the protocol Female participants who are breastfeeding or pregnant at Screening or Baseline (as documented by a positive beta-human chorionic gonadotropin test). A separate Baseline assessment is required if a negative screening pregnancy test was obtained more than 72 hours before the first dose of study drug. Had unprotected sexual intercourse within 30 days before study entry and who do not agree to use a highly effective method of contraception (eg, total abstinence, an intrauterine device, a double-barrier method [such as condom plus diaphragm with spermicide], a contraceptive implant, an oral contraceptive, or have a vasectomized partner with confirmed azoospermia) throughout the entire study period and for 28 days after study drug discontinuation Are currently abstinent and do not agree to use a double-barrier method (as described above) or refrain from sexual activity during the study period and for 28 days after study drug discontinuation Are using hormonal contraceptives, but are not on a stable dose of the same hormonal contraceptive product for at least 4 weeks before dosing and who do not agree to use the same contraceptive during the study and for 28 days after study drug discontinuation (Note: All female participants will be considered to be of childbearing potential unless they have been sterilized surgically [ie, bilateral tubal ligation, total hysterectomy, or bilateral oophorectomy, all with surgery at least 1 month before dosing]).	[ "Clinically", "significant", "new", "illness", "within", "1", "month", "before", "randomization", "that", "may", "affect", "the", "participant", "'s", "ability", "to", "fulfill", "the", "study", "requirements", "or", "significantly", "confound", "the", "assessments", "\n", "Participants", "who", "cannot", "swallow", "investigational", "products", "\n", "Participants", "with", "T2DM", "who", "have", "hypoglycemia", "unawareness", "\n", "Aortic", "regurgitation", "mild", "or", "greater", "\n", "Mitral", "regurgitation", "moderate", "or", "greater", "\n", "Mitral", "or", "aortic", "valve", "stenosis", "greater", "than", "mild", "(", "ie", ",", "aortic", "stenosis", ":", "jet", ">", "3.0", "meters", "per", "second", "[", "m", "/", "s", "]", ",", "mean", "gradient", ">", "25", "millimeters", "of", "mercury", "[", "mmHg", "]", ",", "and", "aortic", "valve", "area", "<", "1.5", "centimeters", "squared", "[", "cm^2", "]", ";", "mitral", "stenosis", ":", "mean", "gradient", ">", "5", "mmHg", "and", "mitral", "valve", "area", "<", "1.5", "cm^2", ")", "\n", "Systolic", "pulmonary", "artery", "pressure", "(", "SPAP", ")", ">", "40", "mmHg", "(", "and", "/", "or", "tricuspid", "regurgitation", "[", "TR", "]", "jet", "velocity", ">", "2.9", "m", "/", "s", ")", "In", "cases", "where", "an", "actual", "SPAP", "value", "is", "not", "measurable", "due", "to", "lack", "of", "adequate", "TR", "jet", ",", "the", "pulmonary", "flow", "acceleration", "time", "measured", "at", "the", "right", "ventricular", "outflow", "tract", "(", "RVOTAT", ")", "will", "be", "used", "to", "assess", "eligibility", ".", "Participants", "with", "a", "RVOTAT", "=", "100", "milliseconds", "(", "msec", ")", "will", "be", "excluded", ",", "suggesting", "an", "elevated", "mean", "SPAP", ";", "eligibility", "for", "the", "those", "participants", "with", "RVOTAT", "between", "100", "and", "120", "msec", "will", "be", "determined", "based", "on", "combined", "assessment", "of", "the", "TR", "jet", ",", "septal", "motion", ",", "and", "right", "ventricular", "size", ".", "\n", "Left", "ventricular", "ejection", "fraction", "<", "45", "%", "\n", "Intracardiac", "mass", ",", "tumor", ",", "or", "thrombus", "\n", "Evidence", "of", "congenital", "heart", "disease", "\n", "Clinically", "significant", "pericardial", "effusion", "(", "eg", ",", "moderate", "or", "larger", "or", "with", "hemodynamic", "compromise", ")", "\n", "Significant", "renal", "or", "hepatic", "disease", "as", "evidenced", "by", "a", "serum", "creatinine", "greater", "than", "1.5×", "upper", "limit", "of", "normal", "(", "ULN", ")", ",", "serum", "transaminases", "greater", "than", "3×", "ULN", ",", "or", "total", "bilirubin", "greater", "than", "1.5×", "ULN", "in", "absence", "of", "Gilbert", "'s", "syndrome", "\n", "Any", "suicidal", "ideation", "with", "intent", "with", "or", "without", "a", "plan", ",", "at", "the", "time", "of", "or", "within", "6", "months", "of", "Screening", ",", "as", "indicated", "by", "answering", "\"", "Yes", "\"", "to", "questions", "4", "or", "5", "on", "the", "Suicidal", "Ideation", "section", "of", "the", "Columbia", "-", "Suicide", "Severity", "Rating", "Scale", "(", "C", "-", "SSRS", ")", "\n", "Any", "suicidal", "behavior", "in", "the", "past", "based", "on", "the", "C", "-", "SSRS", "\n", "Any", "history", "of", "anorexia", "or", "bulimia", "within", "2", "years", "before", "Screening", ",", "Attention", "Deficit", "Hyperactivity", "Disorder", ",", "any", "Diagnostic", "and", "Statistical", "Manual", "of", "Mental", "Disorders", ",", "5th", "Edition", "depressive", "disorder", ",", "bipolar", "disorder", ",", "or", "schizophrenia", "\n", "Known", "secondary", "causes", "(", "genetic", ",", "endocrine", ",", "or", "metabolic", ")", "for", "obesity", "(", "eg", ",", "Prader", "-", "Willi", "syndrome", ",", "Bardet", "Biedl", "syndrome", ",", "Down", "'s", "Syndrome", ",", "untreated", "hypothyroidism", ",", "Cushing", "'s", "syndrome", ",", "daily", "systemic", "corticosteroid", "exposure", "for", "longer", "than", "30", "days", ",", "history", "of", "significant", "exposure", "to", "corticosteroids", "for", "chronic", "illness", "during", "the", "past", "year", ";", "inhaled", "steroids", "will", "be", "allowed", ")", "\n", "Use", "of", "other", "products", "intended", "for", "weight", "loss", "including", "prescription", "drugs", ",", "over", "-", "the", "-", "counter", "(", "OTC", ")", "drugs", ",", "and", "herbal", "preparations", "within", "1", "month", "before", "Screening", "\n", "selective", "serotonin", "reuptake", "inhibitors", "\n", "serotonin", "norepinephrine", "reuptake", "inhibitors", "\n", "tricyclic", "antidepressants", "\n", "bupropion", "\n", "triptans", "\n", "St", ".", "John", "'s", "Wort", "\n", "tryptophan", "\n", "linezolid", "\n", "dextromethorphan", "in", "any", "form", "(", "eg", ",", "OTC", "cold", "medicines", ")", "\n", "lithium", "\n", "tramadol", "\n", "antipsychotics", "or", "other", "dopamine", "antagonists", "\t\n", "antiseizure", "medications", "including", "valproic", "acid", ",", "zonisamide", ",", "topiramate", ",", "and", "lamotrigine", "\n", "oral", "steroids", "(", "topical", "and", "inhaled", "steroids", "are", "acceptable", ")", "\n", "stimulant", "medications", "(", "eg", ",", "Ritalin", ",", "Concerta", ",", "Biphetamine", ",", "and", "Dexedrine", ")", "\n", "benzodiazepines", "\n", "Use", "of", "drugs", "known", "to", "increase", "the", "risk", "for", "cardiac", "valvulopathy", "within", "6", "months", "before", "Screening", ",", "including", "but", "not", "limited", "to", "pergolide", ",", "ergotamine", ",", "methysergide", ",", "and", "cabergoline", "\n", "History", "or", "evidence", "of", "clinically", "significant", "disease", "(", "eg", ",", "malignancy", ";", "cardiac", ",", "respiratory", ",", "gastrointestinal", ",", "renal", ",", "or", "psychiatric", "disease", ")", "other", "than", "prediabetes", "(", "impaired", "fasting", "glucose", "or", "impaired", "glucose", "tolerance", ")", ",", "type", "2", "diabetes", "treated", "with", "oral", "anti", "-", "diabetic", "agents", "(", "excluding", "sulfonylurea", ")", "or", "non", "-", "insulin", "injectable", "antidiabetic", "agents", ",", "obstructive", "sleep", "apnea", ",", "dyslipidemia", ",", "and", "nonalcoholic", "fatty", "liver", "disease", "\n", "Use", "of", "Belviq", "XR", "within", "6", "months", "before", "Screening", "or", "hypersensitivity", "to", "Belviq", "XR", "or", "any", "of", "the", "excipients", "\n", "Significant", "change", "in", "diet", "or", "level", "of", "physical", "activity", "within", "1", "month", "before", "dosing", "or", "change", "in", "weight", "of", "more", "than", "5", "kg", "within", "3", "months", "before", "Screening", "\n", "Any", "use", "of", "a", "very", "-", "low", "-", "calorie", "(", "<", "1000", "calories", "/", "day", ")", "weight", "loss", "diet", "within", "6", "months", "before", "Screening", "\n", "History", "of", "alcohol", "or", "drug", "dependence", "or", "abuse", "\n", "Recreational", "drug", "use", "within", "2", "years", "before", "Screening", "\n", "Known", "to", "be", "human", "immunodeficiency", "virus", "positive", "\n", "Known", "to", "have", "active", "viral", "hepatitis", "(", "B", "or", "C", ")", "\n", "Malignancy", "within", "5", "years", "before", "Screening", "\n", "Unable", "to", "attend", "scheduled", "visits", "(", "eg", ",", "lack", "of", "transportation", ")", "or", "lack", "of", "a", "caregiver", "or", "guardian", "to", "supervise", "study", "participation", "\n", "Special", "needs", "participants", "who", "are", "unable", "to", "comprehend", "study", "-", "related", "instructions", "(", "eg", ",", "mild", "to", "profound", "mental", "retardation", "[", "intelligence", "quotient", "<", "70", "]", ",", "moderate", "to", "severe", "cognitive", "developmental", "delay", ",", "pervasive", "development", "disorders", ",", "autism", ")", "\n", "Ongoing", "epilepsy", "or", "other", "seizure", "disorder", ",", "or", "use", "of", "medications", "for", "a", "seizure", "disorder", "within", "6", "months", "of", "screening", "or", "any", "time", "between", "screening", "and", "randomization", "\n", "Participants", "with", "a", "blood", "pressure", "in", "the", "95th", "percentile", "or", "greater", "for", "age", ",", "sex", ",", "and", "height", "on", "2", "separate", "readings", "recorded", "on", "2", "separate", "days", ".", "Those", "participants", "who", "had", "uncontrolled", "hypertension", "at", "Screening", "can", "be", "rescreened", "more", "than", "1", "month", "after", "initiation", "or", "adjustment", "of", "antihypertensive", "therapy", "1", "time", ".", "\n", "Currently", "enrolled", "in", "another", "clinical", "study", "or", "has", "used", "any", "investigational", "drug", "or", "device", "within", "30", "days", "before", "providing", "informed", "consent", "\n", "Planned", "bariatric", "surgery", "during", "the", "study", "or", "prior", "bariatric", "surgical", "procedures", "\n", "Not", "suitable", "to", "participate", "in", "the", "study", "in", "the", "opinion", "of", "the", "investigator", ",", "including", "consideration", "of", "any", "existing", "physical", ",", "medical", ",", "or", "mental", "condition", "that", "prevents", "compliance", "with", "the", "protocol", "\n", "Female", "participants", "who", "are", "breastfeeding", "or", "pregnant", "at", "Screening", "or", "Baseline", "(", "as", "documented", "by", "a", "positive", "beta", "-", "human", "chorionic", "gonadotropin", "test", ")", ".", "A", "separate", "Baseline", "assessment", "is", "required", "if", "a", "negative", "screening", "pregnancy", "test", "was", "obtained", "more", "than", "72", "hours", "before", "the", "first", "dose", "of", "study", "drug", ".", "\n", "Had", "unprotected", "sexual", "intercourse", "within", "30", "days", "before", "study", "entry", "and", "who", "do", "not", "agree", "to", "use", "a", "highly", "effective", "method", "of", "contraception", "(", "eg", ",", "total", "abstinence", ",", "an", "intrauterine", "device", ",", "a", "double", "-", "barrier", "method", "[", "such", "as", "condom", "plus", "diaphragm", "with", "spermicide", "]", ",", "a", "contraceptive", "implant", ",", "an", "oral", "contraceptive", ",", "or", "have", "a", "vasectomized", "partner", "with", "confirmed", "azoospermia", ")", "throughout", "the", "entire", "study", "period", "and", "for", "28", "days", "after", "study", "drug", "discontinuation", "\n", "Are", "currently", "abstinent", "and", "do", "not", "agree", "to", "use", "a", "double", "-", "barrier", "method", "(", "as", "described", "above", ")", "or", "refrain", "from", "sexual", "activity", "during", "the", "study", "period", "and", "for", "28", "days", "after", "study", "drug", "discontinuation", "\n", "Are", "using", "hormonal", "contraceptives", ",", "but", "are", "not", "on", "a", "stable", "dose", "of", "the", "same", "hormonal", "contraceptive", "product", "for", "at", "least", "4", "weeks", "before", "dosing", "and", "who", "do", "not", "agree", "to", "use", "the", "same", "contraceptive", "during", "the", "study", "and", "for", "28", "days", "after", "study", "drug", "discontinuation", "(", "Note", ":", "All", "female", "participants", "will", "be", "considered", "to", "be", "of", "childbearing", "potential", "unless", "they", "have", "been", "sterilized", "surgically", "[", "ie", ",", "bilateral", "tubal", "ligation", ",", "total", "hysterectomy", ",", "or", "bilateral", "oophorectomy", ",", "all", "with", "surgery", "at", "least", "1", "month", "before", "dosing", "]", ")", ".", "\n" ]	[ "Scope", "Procedure", "Observation", "Qualifier", "Temporal", "Value", "Drug", "Measurement", "Condition", "Reference_point", "Device", "Multiplier", "Mood", "Negation", "Person" ]
Ca2 + is a CHEMICAL	20566645_task0	Sentence: Predicting cardiomyopathic phenotypes by altering Ca2+ affinity of cardiac troponin C. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: CHEMICAL	[ "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O" ]	Predicting cardiomyopathic phenotypes by altering Ca2+ affinity of cardiac troponin C.	[ "Predicting", "cardiomyopathic", "phenotypes", "by", "altering", "Ca2", "+", "affinity", "of", "cardiac", "troponin", "C." ]	[ "GENE-Y", "GENE-N", "CHEMICAL" ]
Ca2 + is a CHEMICAL	20566645_task1	Sentence: Predicting cardiomyopathic phenotypes by altering Ca2+ affinity of cardiac troponin C. Instructions: please typing these entity words according to sentence: Ca2 + Options: CHEMICAL	[ "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O" ]	Predicting cardiomyopathic phenotypes by altering Ca2+ affinity of cardiac troponin C.	[ "Predicting", "cardiomyopathic", "phenotypes", "by", "altering", "Ca2", "+", "affinity", "of", "cardiac", "troponin", "C." ]	[ "GENE-Y", "GENE-N", "CHEMICAL" ]
Ca2 +	20566645_task2	Sentence: Predicting cardiomyopathic phenotypes by altering Ca2+ affinity of cardiac troponin C. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O" ]	Predicting cardiomyopathic phenotypes by altering Ca2+ affinity of cardiac troponin C.	[ "Predicting", "cardiomyopathic", "phenotypes", "by", "altering", "Ca2", "+", "affinity", "of", "cardiac", "troponin", "C." ]	[ "GENE-Y", "GENE-N", "CHEMICAL" ]
placebo - controlled is a Intervention_Control, melatonin treatment is a Intervention_Pharmacological, delayed sleep phase syndrome is a Participant_Condition, impaired sleep maintenance is a Outcome_Physical, children is a Participant_Age, neurodevelopmental disabilities is a Participant_Condition, efficacy is a Outcome_Other, autistic spectrum disorders is a Participant_Condition, CR melatonin is a Intervention_Pharmacological, Sleep characteristics is a Outcome_Physical, Clinician rating is a Outcome_Other, caregiver ratings is a Outcome_Other, Fifty - one is a Participant_Sample-size, children ( age range 2 - 18 years ) is a Participant_Age, total night - time sleep is a Outcome_Physical, sleep latency is a Outcome_Physical, clinician and parent ratings . is a Outcome_Other, open - label somnolog measures is a Outcome_Physical, sleep efficiency is a Outcome_Physical, the longest sleep episode is a Outcome_Physical, improved the sleep is a Outcome_Physical, effective in reducing family stress is a Outcome_Mental, Children is a Participant_Age, treatment resistant chronic delayed sleep phase syndrome is a Outcome_Physical, melatonin therapy . is a Intervention_Pharmacological	33945_task0	Sentence: A randomized , placebo-controlled trial of controlled release melatonin treatment of delayed sleep phase syndrome and impaired sleep maintenance in children with neurodevelopmental disabilities . The purpose of this study was to determine the efficacy of controlled-release ( CR ) melatonin in the treatment of delayed sleep phase syndrome and impaired sleep maintenance of children with neurodevelopmental disabilities including autistic spectrum disorders . A randomized double-blind , placebo-controlled crossover trial of CR melatonin ( 5 mg ) followed by a 3-month open-label study was conducted during which the dose was gradually increased until the therapy showed optimal beneficial effects . Sleep characteristics were measured by caregiver who completed somnologs and wrist actigraphs . Clinician rating of severity of the sleep disorder and improvement from baseline , along with caregiver ratings of global functioning and family stress were also obtained . Fifty-one children ( age range 2-18 years ) who did not respond to sleep hygiene intervention were enrolled . Fifty patients completed the crossover trial and 47 completed the open-label phase . Recordings of total night-time sleep and sleep latency showed significant improvement of approximately 30 min . Similarly , significant improvement was observed in clinician and parent ratings . There was additional improvement in the open-label somnolog measures of sleep efficiency and the longest sleep episode in the open-label phase . Overall , the therapy improved the sleep of 47 children and was effective in reducing family stress . Children with neurodevelopmental disabilities , who had treatment resistant chronic delayed sleep phase syndrome and impaired sleep maintenance , showed improvement in melatonin therapy . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Participant_Condition, Intervention_Control, Participant_Age, Outcome_Physical, Participant_Sample-size, Outcome_Other, Outcome_Mental	[ "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Participant_Age", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "B-Participant_Age", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological" ]	A randomized , placebo-controlled trial of controlled release melatonin treatment of delayed sleep phase syndrome and impaired sleep maintenance in children with neurodevelopmental disabilities . The purpose of this study was to determine the efficacy of controlled-release ( CR ) melatonin in the treatment of delayed sleep phase syndrome and impaired sleep maintenance of children with neurodevelopmental disabilities including autistic spectrum disorders . A randomized double-blind , placebo-controlled crossover trial of CR melatonin ( 5 mg ) followed by a 3-month open-label study was conducted during which the dose was gradually increased until the therapy showed optimal beneficial effects . Sleep characteristics were measured by caregiver who completed somnologs and wrist actigraphs . Clinician rating of severity of the sleep disorder and improvement from baseline , along with caregiver ratings of global functioning and family stress were also obtained . Fifty-one children ( age range 2-18 years ) who did not respond to sleep hygiene intervention were enrolled . Fifty patients completed the crossover trial and 47 completed the open-label phase . Recordings of total night-time sleep and sleep latency showed significant improvement of approximately 30 min . Similarly , significant improvement was observed in clinician and parent ratings . There was additional improvement in the open-label somnolog measures of sleep efficiency and the longest sleep episode in the open-label phase . Overall , the therapy improved the sleep of 47 children and was effective in reducing family stress . Children with neurodevelopmental disabilities , who had treatment resistant chronic delayed sleep phase syndrome and impaired sleep maintenance , showed improvement in melatonin therapy .	[ "A", "randomized", ",", "placebo", "-", "controlled", "trial", "of", "controlled", "release", "melatonin", "treatment", "of", "delayed", "sleep", "phase", "syndrome", "and", "impaired", "sleep", "maintenance", "in", "children", "with", "neurodevelopmental", "disabilities", ".", "The", "purpose", "of", "this", "study", "was", "to", "determine", "the", "efficacy", "of", "controlled", "-", "release", "(", "CR", ")", "melatonin", "in", "the", "treatment", "of", "delayed", "sleep", "phase", "syndrome", "and", "impaired", "sleep", "maintenance", "of", "children", "with", "neurodevelopmental", "disabilities", "including", "autistic", "spectrum", "disorders", ".", "A", "randomized", "double", "-", "blind", ",", "placebo", "-", "controlled", "crossover", "trial", "of", "CR", "melatonin", "(", "5", "mg", ")", "followed", "by", "a", "3-month", "open", "-", "label", "study", "was", "conducted", "during", "which", "the", "dose", "was", "gradually", "increased", "until", "the", "therapy", "showed", "optimal", "beneficial", "effects", ".", "Sleep", "characteristics", "were", "measured", "by", "caregiver", "who", "completed", "somnologs", "and", "wrist", "actigraphs", ".", "Clinician", "rating", "of", "severity", "of", "the", "sleep", "disorder", "and", "improvement", "from", "baseline", ",", "along", "with", "caregiver", "ratings", "of", "global", "functioning", "and", "family", "stress", "were", "also", "obtained", ".", "Fifty", "-", "one", "children", "(", "age", "range", "2", "-", "18", "years", ")", "who", "did", "not", "respond", "to", "sleep", "hygiene", "intervention", "were", "enrolled", ".", "Fifty", "patients", "completed", "the", "crossover", "trial", "and", "47", "completed", "the", "open", "-", "label", "phase", ".", "Recordings", "of", "total", "night", "-", "time", "sleep", "and", "sleep", "latency", "showed", "significant", "improvement", "of", "approximately", "30", "min", ".", "Similarly", ",", "significant", "improvement", "was", "observed", "in", "clinician", "and", "parent", "ratings", ".", "There", "was", "additional", "improvement", "in", "the", "open", "-", "label", "somnolog", "measures", "of", "sleep", "efficiency", "and", "the", "longest", "sleep", "episode", "in", "the", "open", "-", "label", "phase", ".", "Overall", ",", "the", "therapy", "improved", "the", "sleep", "of", "47", "children", "and", "was", "effective", "in", "reducing", "family", "stress", ".", "Children", "with", "neurodevelopmental", "disabilities", ",", "who", "had", "treatment", "resistant", "chronic", "delayed", "sleep", "phase", "syndrome", "and", "impaired", "sleep", "maintenance", ",", "showed", "improvement", "in", "melatonin", "therapy", "." ]	[ "Outcome_Physical", "Participant_Condition", "Outcome_Mental", "Participant_Age", "Outcome_Other", "Intervention_Pharmacological", "Intervention_Control", "Participant_Sample-size" ]
placebo - controlled is a Intervention_Control, melatonin treatment is a Intervention_Pharmacological, delayed sleep phase syndrome is a Participant_Condition, impaired sleep maintenance is a Outcome_Physical, children is a Participant_Age, neurodevelopmental disabilities is a Participant_Condition, efficacy is a Outcome_Other, autistic spectrum disorders is a Participant_Condition, CR melatonin is a Intervention_Pharmacological, Sleep characteristics is a Outcome_Physical, Clinician rating is a Outcome_Other, caregiver ratings is a Outcome_Other, Fifty - one is a Participant_Sample-size, children ( age range 2 - 18 years ) is a Participant_Age, total night - time sleep is a Outcome_Physical, sleep latency is a Outcome_Physical, clinician and parent ratings . is a Outcome_Other, open - label somnolog measures is a Outcome_Physical, sleep efficiency is a Outcome_Physical, the longest sleep episode is a Outcome_Physical, improved the sleep is a Outcome_Physical, effective in reducing family stress is a Outcome_Mental, Children is a Participant_Age, treatment resistant chronic delayed sleep phase syndrome is a Outcome_Physical, melatonin therapy . is a Intervention_Pharmacological	33945_task1	Sentence: A randomized , placebo-controlled trial of controlled release melatonin treatment of delayed sleep phase syndrome and impaired sleep maintenance in children with neurodevelopmental disabilities . The purpose of this study was to determine the efficacy of controlled-release ( CR ) melatonin in the treatment of delayed sleep phase syndrome and impaired sleep maintenance of children with neurodevelopmental disabilities including autistic spectrum disorders . A randomized double-blind , placebo-controlled crossover trial of CR melatonin ( 5 mg ) followed by a 3-month open-label study was conducted during which the dose was gradually increased until the therapy showed optimal beneficial effects . Sleep characteristics were measured by caregiver who completed somnologs and wrist actigraphs . Clinician rating of severity of the sleep disorder and improvement from baseline , along with caregiver ratings of global functioning and family stress were also obtained . Fifty-one children ( age range 2-18 years ) who did not respond to sleep hygiene intervention were enrolled . Fifty patients completed the crossover trial and 47 completed the open-label phase . Recordings of total night-time sleep and sleep latency showed significant improvement of approximately 30 min . Similarly , significant improvement was observed in clinician and parent ratings . There was additional improvement in the open-label somnolog measures of sleep efficiency and the longest sleep episode in the open-label phase . Overall , the therapy improved the sleep of 47 children and was effective in reducing family stress . Children with neurodevelopmental disabilities , who had treatment resistant chronic delayed sleep phase syndrome and impaired sleep maintenance , showed improvement in melatonin therapy . Instructions: please typing these entity words according to sentence: placebo - controlled, melatonin treatment, delayed sleep phase syndrome, impaired sleep maintenance, children, neurodevelopmental disabilities, efficacy, autistic spectrum disorders, CR melatonin, Sleep characteristics, Clinician rating, caregiver ratings, Fifty - one, children ( age range 2 - 18 years ), total night - time sleep, sleep latency, clinician and parent ratings ., open - label somnolog measures, sleep efficiency, the longest sleep episode, improved the sleep, effective in reducing family stress, Children, treatment resistant chronic delayed sleep phase syndrome, melatonin therapy . Options: Intervention_Pharmacological, Participant_Condition, Intervention_Control, Participant_Age, Outcome_Physical, Participant_Sample-size, Outcome_Other, Outcome_Mental	[ "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Participant_Age", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "B-Participant_Age", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological" ]	A randomized , placebo-controlled trial of controlled release melatonin treatment of delayed sleep phase syndrome and impaired sleep maintenance in children with neurodevelopmental disabilities . The purpose of this study was to determine the efficacy of controlled-release ( CR ) melatonin in the treatment of delayed sleep phase syndrome and impaired sleep maintenance of children with neurodevelopmental disabilities including autistic spectrum disorders . A randomized double-blind , placebo-controlled crossover trial of CR melatonin ( 5 mg ) followed by a 3-month open-label study was conducted during which the dose was gradually increased until the therapy showed optimal beneficial effects . Sleep characteristics were measured by caregiver who completed somnologs and wrist actigraphs . Clinician rating of severity of the sleep disorder and improvement from baseline , along with caregiver ratings of global functioning and family stress were also obtained . Fifty-one children ( age range 2-18 years ) who did not respond to sleep hygiene intervention were enrolled . Fifty patients completed the crossover trial and 47 completed the open-label phase . Recordings of total night-time sleep and sleep latency showed significant improvement of approximately 30 min . Similarly , significant improvement was observed in clinician and parent ratings . There was additional improvement in the open-label somnolog measures of sleep efficiency and the longest sleep episode in the open-label phase . Overall , the therapy improved the sleep of 47 children and was effective in reducing family stress . Children with neurodevelopmental disabilities , who had treatment resistant chronic delayed sleep phase syndrome and impaired sleep maintenance , showed improvement in melatonin therapy .	[ "A", "randomized", ",", "placebo", "-", "controlled", "trial", "of", "controlled", "release", "melatonin", "treatment", "of", "delayed", "sleep", "phase", "syndrome", "and", "impaired", "sleep", "maintenance", "in", "children", "with", "neurodevelopmental", "disabilities", ".", "The", "purpose", "of", "this", "study", "was", "to", "determine", "the", "efficacy", "of", "controlled", "-", "release", "(", "CR", ")", "melatonin", "in", "the", "treatment", "of", "delayed", "sleep", "phase", "syndrome", "and", "impaired", "sleep", "maintenance", "of", "children", "with", "neurodevelopmental", "disabilities", "including", "autistic", "spectrum", "disorders", ".", "A", "randomized", "double", "-", "blind", ",", "placebo", "-", "controlled", "crossover", "trial", "of", "CR", "melatonin", "(", "5", "mg", ")", "followed", "by", "a", "3-month", "open", "-", "label", "study", "was", "conducted", "during", "which", "the", "dose", "was", "gradually", "increased", "until", "the", "therapy", "showed", "optimal", "beneficial", "effects", ".", "Sleep", "characteristics", "were", "measured", "by", "caregiver", "who", "completed", "somnologs", "and", "wrist", "actigraphs", ".", "Clinician", "rating", "of", "severity", "of", "the", "sleep", "disorder", "and", "improvement", "from", "baseline", ",", "along", "with", "caregiver", "ratings", "of", "global", "functioning", "and", "family", "stress", "were", "also", "obtained", ".", "Fifty", "-", "one", "children", "(", "age", "range", "2", "-", "18", "years", ")", "who", "did", "not", "respond", "to", "sleep", "hygiene", "intervention", "were", "enrolled", ".", "Fifty", "patients", "completed", "the", "crossover", "trial", "and", "47", "completed", "the", "open", "-", "label", "phase", ".", "Recordings", "of", "total", "night", "-", "time", "sleep", "and", "sleep", "latency", "showed", "significant", "improvement", "of", "approximately", "30", "min", ".", "Similarly", ",", "significant", "improvement", "was", "observed", "in", "clinician", "and", "parent", "ratings", ".", "There", "was", "additional", "improvement", "in", "the", "open", "-", "label", "somnolog", "measures", "of", "sleep", "efficiency", "and", "the", "longest", "sleep", "episode", "in", "the", "open", "-", "label", "phase", ".", "Overall", ",", "the", "therapy", "improved", "the", "sleep", "of", "47", "children", "and", "was", "effective", "in", "reducing", "family", "stress", ".", "Children", "with", "neurodevelopmental", "disabilities", ",", "who", "had", "treatment", "resistant", "chronic", "delayed", "sleep", "phase", "syndrome", "and", "impaired", "sleep", "maintenance", ",", "showed", "improvement", "in", "melatonin", "therapy", "." ]	[ "Outcome_Physical", "Participant_Condition", "Outcome_Mental", "Participant_Age", "Outcome_Other", "Intervention_Pharmacological", "Intervention_Control", "Participant_Sample-size" ]
placebo - controlled, melatonin treatment, delayed sleep phase syndrome, impaired sleep maintenance, children, neurodevelopmental disabilities, efficacy, autistic spectrum disorders, CR melatonin, Sleep characteristics, Clinician rating, caregiver ratings, Fifty - one, children ( age range 2 - 18 years ), total night - time sleep, sleep latency, clinician and parent ratings ., open - label somnolog measures, sleep efficiency, the longest sleep episode, improved the sleep, effective in reducing family stress, Children, treatment resistant chronic delayed sleep phase syndrome, melatonin therapy .	33945_task2	Sentence: A randomized , placebo-controlled trial of controlled release melatonin treatment of delayed sleep phase syndrome and impaired sleep maintenance in children with neurodevelopmental disabilities . The purpose of this study was to determine the efficacy of controlled-release ( CR ) melatonin in the treatment of delayed sleep phase syndrome and impaired sleep maintenance of children with neurodevelopmental disabilities including autistic spectrum disorders . A randomized double-blind , placebo-controlled crossover trial of CR melatonin ( 5 mg ) followed by a 3-month open-label study was conducted during which the dose was gradually increased until the therapy showed optimal beneficial effects . Sleep characteristics were measured by caregiver who completed somnologs and wrist actigraphs . Clinician rating of severity of the sleep disorder and improvement from baseline , along with caregiver ratings of global functioning and family stress were also obtained . Fifty-one children ( age range 2-18 years ) who did not respond to sleep hygiene intervention were enrolled . Fifty patients completed the crossover trial and 47 completed the open-label phase . Recordings of total night-time sleep and sleep latency showed significant improvement of approximately 30 min . Similarly , significant improvement was observed in clinician and parent ratings . There was additional improvement in the open-label somnolog measures of sleep efficiency and the longest sleep episode in the open-label phase . Overall , the therapy improved the sleep of 47 children and was effective in reducing family stress . Children with neurodevelopmental disabilities , who had treatment resistant chronic delayed sleep phase syndrome and impaired sleep maintenance , showed improvement in melatonin therapy . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Participant_Age", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "B-Participant_Age", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological" ]	A randomized , placebo-controlled trial of controlled release melatonin treatment of delayed sleep phase syndrome and impaired sleep maintenance in children with neurodevelopmental disabilities . The purpose of this study was to determine the efficacy of controlled-release ( CR ) melatonin in the treatment of delayed sleep phase syndrome and impaired sleep maintenance of children with neurodevelopmental disabilities including autistic spectrum disorders . A randomized double-blind , placebo-controlled crossover trial of CR melatonin ( 5 mg ) followed by a 3-month open-label study was conducted during which the dose was gradually increased until the therapy showed optimal beneficial effects . Sleep characteristics were measured by caregiver who completed somnologs and wrist actigraphs . Clinician rating of severity of the sleep disorder and improvement from baseline , along with caregiver ratings of global functioning and family stress were also obtained . Fifty-one children ( age range 2-18 years ) who did not respond to sleep hygiene intervention were enrolled . Fifty patients completed the crossover trial and 47 completed the open-label phase . Recordings of total night-time sleep and sleep latency showed significant improvement of approximately 30 min . Similarly , significant improvement was observed in clinician and parent ratings . There was additional improvement in the open-label somnolog measures of sleep efficiency and the longest sleep episode in the open-label phase . Overall , the therapy improved the sleep of 47 children and was effective in reducing family stress . Children with neurodevelopmental disabilities , who had treatment resistant chronic delayed sleep phase syndrome and impaired sleep maintenance , showed improvement in melatonin therapy .	[ "A", "randomized", ",", "placebo", "-", "controlled", "trial", "of", "controlled", "release", "melatonin", "treatment", "of", "delayed", "sleep", "phase", "syndrome", "and", "impaired", "sleep", "maintenance", "in", "children", "with", "neurodevelopmental", "disabilities", ".", "The", "purpose", "of", "this", "study", "was", "to", "determine", "the", "efficacy", "of", "controlled", "-", "release", "(", "CR", ")", "melatonin", "in", "the", "treatment", "of", "delayed", "sleep", "phase", "syndrome", "and", "impaired", "sleep", "maintenance", "of", "children", "with", "neurodevelopmental", "disabilities", "including", "autistic", "spectrum", "disorders", ".", "A", "randomized", "double", "-", "blind", ",", "placebo", "-", "controlled", "crossover", "trial", "of", "CR", "melatonin", "(", "5", "mg", ")", "followed", "by", "a", "3-month", "open", "-", "label", "study", "was", "conducted", "during", "which", "the", "dose", "was", "gradually", "increased", "until", "the", "therapy", "showed", "optimal", "beneficial", "effects", ".", "Sleep", "characteristics", "were", "measured", "by", "caregiver", "who", "completed", "somnologs", "and", "wrist", "actigraphs", ".", "Clinician", "rating", "of", "severity", "of", "the", "sleep", "disorder", "and", "improvement", "from", "baseline", ",", "along", "with", "caregiver", "ratings", "of", "global", "functioning", "and", "family", "stress", "were", "also", "obtained", ".", "Fifty", "-", "one", "children", "(", "age", "range", "2", "-", "18", "years", ")", "who", "did", "not", "respond", "to", "sleep", "hygiene", "intervention", "were", "enrolled", ".", "Fifty", "patients", "completed", "the", "crossover", "trial", "and", "47", "completed", "the", "open", "-", "label", "phase", ".", "Recordings", "of", "total", "night", "-", "time", "sleep", "and", "sleep", "latency", "showed", "significant", "improvement", "of", "approximately", "30", "min", ".", "Similarly", ",", "significant", "improvement", "was", "observed", "in", "clinician", "and", "parent", "ratings", ".", "There", "was", "additional", "improvement", "in", "the", "open", "-", "label", "somnolog", "measures", "of", "sleep", "efficiency", "and", "the", "longest", "sleep", "episode", "in", "the", "open", "-", "label", "phase", ".", "Overall", ",", "the", "therapy", "improved", "the", "sleep", "of", "47", "children", "and", "was", "effective", "in", "reducing", "family", "stress", ".", "Children", "with", "neurodevelopmental", "disabilities", ",", "who", "had", "treatment", "resistant", "chronic", "delayed", "sleep", "phase", "syndrome", "and", "impaired", "sleep", "maintenance", ",", "showed", "improvement", "in", "melatonin", "therapy", "." ]	[ "Outcome_Physical", "Participant_Condition", "Outcome_Mental", "Participant_Age", "Outcome_Other", "Intervention_Pharmacological", "Intervention_Control", "Participant_Sample-size" ]
PDGF(B ) is a Protein, c - fos is a Protein, c - jun is a Protein, EGR2 is a Protein, platelet - derived growth factor B subunit is a Protein, PDGF[B ] is a Protein, transforming growth factor - beta is a Protein, TGF - beta is a Protein, PDGF(B ) is a Protein, TGF - beta is a Protein, PDGF(B ) is a Protein, PDGF(B ) is a Protein, fibronectin is a Protein, PDGF(B ) is a Protein, PDGF(B ) is a Protein, c - fos is a Protein, c - jun is a Protein, EGR2 is a Protein, c - jun is a Protein, EGR2 is a Protein, c - fos is a Protein, c - fos is a Protein, c - jun is a Protein, EGR2 is a Protein, PDGF(B ) is a Protein, c - jun is a Protein, EGR2 is a Protein, PDGF(B ) is a Protein	328_task0	Sentence: Adherence-dependent increase in human monocyte PDGF(B) mRNA is associated with increases in c-fos, c-jun, and EGR2 mRNA. Adherence is an important initial step in the transition of a circulating monocyte to a tissue macrophage. This differentiation is accompanied by an augmented capacity to generate growth factors. We hypothesized that adherence itself might be an important trigger for a sequence of gene activation culminating in cells with increased mRNA encoding profibrotic growth factors such as platelet-derived growth factor B subunit (PDGF[B]) and transforming growth factor-beta (TGF-beta). After in vitro adherence, human monocytes had a biphasic increase in PDGF(B) mRNA with peaks at 6 h and 13 d. No increase in TGF-beta mRNA was observed. The 6-h increase in PDGF(B) mRNA was adherence dependent, and in addition, was abrogated when the cytoskeletal integrity was compromised by cytochalasin D. The 6-h increase in PDGF(B) mRNA was unaltered by adherence in the presence of the monocyte stimulus lipopolysaccharide. Adherence to either fibronectin or collagen-coated plastic had little consistent effect on PDGF(B) mRNA accumulation. The increased PDGF(B) mRNA observed in adherent monocytes was accompanied by increases in mRNAs of the early growth response genes c-fos (maximal at 20 min), c-jun, and EGR2 (maximal at 6-24 h). The increase in c-jun and EGR2, but not c-fos, mRNA was also abrogated by cytochalasin D. These observations suggest that adherence results in increases of c-fos, c-jun, EGR2, and PDGF(B) mRNA. In addition, the increases in c-jun, EGR2, and PDGF(B) may depend on cytoskeletal rearrangement. Modulation of these events at the time of adherence offers a mechanism by which differential priming of the cells may be accomplished. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein	[ "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Adherence-dependent increase in human monocyte PDGF(B) mRNA is associated with increases in c-fos, c-jun, and EGR2 mRNA. Adherence is an important initial step in the transition of a circulating monocyte to a tissue macrophage. This differentiation is accompanied by an augmented capacity to generate growth factors. We hypothesized that adherence itself might be an important trigger for a sequence of gene activation culminating in cells with increased mRNA encoding profibrotic growth factors such as platelet-derived growth factor B subunit (PDGF[B]) and transforming growth factor-beta (TGF-beta). After in vitro adherence, human monocytes had a biphasic increase in PDGF(B) mRNA with peaks at 6 h and 13 d. No increase in TGF-beta mRNA was observed. The 6-h increase in PDGF(B) mRNA was adherence dependent, and in addition, was abrogated when the cytoskeletal integrity was compromised by cytochalasin D. The 6-h increase in PDGF(B) mRNA was unaltered by adherence in the presence of the monocyte stimulus lipopolysaccharide. Adherence to either fibronectin or collagen-coated plastic had little consistent effect on PDGF(B) mRNA accumulation. The increased PDGF(B) mRNA observed in adherent monocytes was accompanied by increases in mRNAs of the early growth response genes c-fos (maximal at 20 min), c-jun, and EGR2 (maximal at 6-24 h). The increase in c-jun and EGR2, but not c-fos, mRNA was also abrogated by cytochalasin D. These observations suggest that adherence results in increases of c-fos, c-jun, EGR2, and PDGF(B) mRNA. In addition, the increases in c-jun, EGR2, and PDGF(B) may depend on cytoskeletal rearrangement. Modulation of these events at the time of adherence offers a mechanism by which differential priming of the cells may be accomplished.	[ "Adherence", "-", "dependent", "increase", "in", "human", "monocyte", "PDGF(B", ")", "mRNA", "is", "associated", "with", "increases", "in", "c", "-", "fos", ",", "c", "-", "jun", ",", "and", "EGR2", "mRNA", ".", "\n", "Adherence", "is", "an", "important", "initial", "step", "in", "the", "transition", "of", "a", "circulating", "monocyte", "to", "a", "tissue", "macrophage", ".", "This", "differentiation", "is", "accompanied", "by", "an", "augmented", "capacity", "to", "generate", "growth", "factors", ".", "We", "hypothesized", "that", "adherence", "itself", "might", "be", "an", "important", "trigger", "for", "a", "sequence", "of", "gene", "activation", "culminating", "in", "cells", "with", "increased", "mRNA", "encoding", "profibrotic", "growth", "factors", "such", "as", "platelet", "-", "derived", "growth", "factor", "B", "subunit", "(", "PDGF[B", "]", ")", "and", "transforming", "growth", "factor", "-", "beta", "(", "TGF", "-", "beta", ")", ".", "After", "in", "vitro", "adherence", ",", "human", "monocytes", "had", "a", "biphasic", "increase", "in", "PDGF(B", ")", "mRNA", "with", "peaks", "at", "6", "h", "and", "13", "d.", "No", "increase", "in", "TGF", "-", "beta", "mRNA", "was", "observed", ".", "The", "6-h", "increase", "in", "PDGF(B", ")", "mRNA", "was", "adherence", "dependent", ",", "and", "in", "addition", ",", "was", "abrogated", "when", "the", "cytoskeletal", "integrity", "was", "compromised", "by", "cytochalasin", "D.", "The", "6-h", "increase", "in", "PDGF(B", ")", "mRNA", "was", "unaltered", "by", "adherence", "in", "the", "presence", "of", "the", "monocyte", "stimulus", "lipopolysaccharide", ".", "Adherence", "to", "either", "fibronectin", "or", "collagen", "-", "coated", "plastic", "had", "little", "consistent", "effect", "on", "PDGF(B", ")", "mRNA", "accumulation", ".", "The", "increased", "PDGF(B", ")", "mRNA", "observed", "in", "adherent", "monocytes", "was", "accompanied", "by", "increases", "in", "mRNAs", "of", "the", "early", "growth", "response", "genes", "c", "-", "fos", "(", "maximal", "at", "20", "min", ")", ",", "c", "-", "jun", ",", "and", "EGR2", "(", "maximal", "at", "6", "-", "24", "h", ")", ".", "The", "increase", "in", "c", "-", "jun", "and", "EGR2", ",", "but", "not", "c", "-", "fos", ",", "mRNA", "was", "also", "abrogated", "by", "cytochalasin", "D.", "These", "observations", "suggest", "that", "adherence", "results", "in", "increases", "of", "c", "-", "fos", ",", "c", "-", "jun", ",", "EGR2", ",", "and", "PDGF(B", ")", "mRNA", ".", "In", "addition", ",", "the", "increases", "in", "c", "-", "jun", ",", "EGR2", ",", "and", "PDGF(B", ")", "may", "depend", "on", "cytoskeletal", "rearrangement", ".", "Modulation", "of", "these", "events", "at", "the", "time", "of", "adherence", "offers", "a", "mechanism", "by", "which", "differential", "priming", "of", "the", "cells", "may", "be", "accomplished", "." ]	[ "Protein" ]
PDGF(B ) is a Protein, c - fos is a Protein, c - jun is a Protein, EGR2 is a Protein, platelet - derived growth factor B subunit is a Protein, PDGF[B ] is a Protein, transforming growth factor - beta is a Protein, TGF - beta is a Protein, PDGF(B ) is a Protein, TGF - beta is a Protein, PDGF(B ) is a Protein, PDGF(B ) is a Protein, fibronectin is a Protein, PDGF(B ) is a Protein, PDGF(B ) is a Protein, c - fos is a Protein, c - jun is a Protein, EGR2 is a Protein, c - jun is a Protein, EGR2 is a Protein, c - fos is a Protein, c - fos is a Protein, c - jun is a Protein, EGR2 is a Protein, PDGF(B ) is a Protein, c - jun is a Protein, EGR2 is a Protein, PDGF(B ) is a Protein	328_task1	Sentence: Adherence-dependent increase in human monocyte PDGF(B) mRNA is associated with increases in c-fos, c-jun, and EGR2 mRNA. Adherence is an important initial step in the transition of a circulating monocyte to a tissue macrophage. This differentiation is accompanied by an augmented capacity to generate growth factors. We hypothesized that adherence itself might be an important trigger for a sequence of gene activation culminating in cells with increased mRNA encoding profibrotic growth factors such as platelet-derived growth factor B subunit (PDGF[B]) and transforming growth factor-beta (TGF-beta). After in vitro adherence, human monocytes had a biphasic increase in PDGF(B) mRNA with peaks at 6 h and 13 d. No increase in TGF-beta mRNA was observed. The 6-h increase in PDGF(B) mRNA was adherence dependent, and in addition, was abrogated when the cytoskeletal integrity was compromised by cytochalasin D. The 6-h increase in PDGF(B) mRNA was unaltered by adherence in the presence of the monocyte stimulus lipopolysaccharide. Adherence to either fibronectin or collagen-coated plastic had little consistent effect on PDGF(B) mRNA accumulation. The increased PDGF(B) mRNA observed in adherent monocytes was accompanied by increases in mRNAs of the early growth response genes c-fos (maximal at 20 min), c-jun, and EGR2 (maximal at 6-24 h). The increase in c-jun and EGR2, but not c-fos, mRNA was also abrogated by cytochalasin D. These observations suggest that adherence results in increases of c-fos, c-jun, EGR2, and PDGF(B) mRNA. In addition, the increases in c-jun, EGR2, and PDGF(B) may depend on cytoskeletal rearrangement. Modulation of these events at the time of adherence offers a mechanism by which differential priming of the cells may be accomplished. Instructions: please typing these entity words according to sentence: PDGF(B ), c - fos, c - jun, EGR2, platelet - derived growth factor B subunit, PDGF[B ], transforming growth factor - beta, TGF - beta, PDGF(B ), TGF - beta, PDGF(B ), PDGF(B ), fibronectin, PDGF(B ), PDGF(B ), c - fos, c - jun, EGR2, c - jun, EGR2, c - fos, c - fos, c - jun, EGR2, PDGF(B ), c - jun, EGR2, PDGF(B ) Options: Protein	[ "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Adherence-dependent increase in human monocyte PDGF(B) mRNA is associated with increases in c-fos, c-jun, and EGR2 mRNA. Adherence is an important initial step in the transition of a circulating monocyte to a tissue macrophage. This differentiation is accompanied by an augmented capacity to generate growth factors. We hypothesized that adherence itself might be an important trigger for a sequence of gene activation culminating in cells with increased mRNA encoding profibrotic growth factors such as platelet-derived growth factor B subunit (PDGF[B]) and transforming growth factor-beta (TGF-beta). After in vitro adherence, human monocytes had a biphasic increase in PDGF(B) mRNA with peaks at 6 h and 13 d. No increase in TGF-beta mRNA was observed. The 6-h increase in PDGF(B) mRNA was adherence dependent, and in addition, was abrogated when the cytoskeletal integrity was compromised by cytochalasin D. The 6-h increase in PDGF(B) mRNA was unaltered by adherence in the presence of the monocyte stimulus lipopolysaccharide. Adherence to either fibronectin or collagen-coated plastic had little consistent effect on PDGF(B) mRNA accumulation. The increased PDGF(B) mRNA observed in adherent monocytes was accompanied by increases in mRNAs of the early growth response genes c-fos (maximal at 20 min), c-jun, and EGR2 (maximal at 6-24 h). The increase in c-jun and EGR2, but not c-fos, mRNA was also abrogated by cytochalasin D. These observations suggest that adherence results in increases of c-fos, c-jun, EGR2, and PDGF(B) mRNA. In addition, the increases in c-jun, EGR2, and PDGF(B) may depend on cytoskeletal rearrangement. Modulation of these events at the time of adherence offers a mechanism by which differential priming of the cells may be accomplished.	[ "Adherence", "-", "dependent", "increase", "in", "human", "monocyte", "PDGF(B", ")", "mRNA", "is", "associated", "with", "increases", "in", "c", "-", "fos", ",", "c", "-", "jun", ",", "and", "EGR2", "mRNA", ".", "\n", "Adherence", "is", "an", "important", "initial", "step", "in", "the", "transition", "of", "a", "circulating", "monocyte", "to", "a", "tissue", "macrophage", ".", "This", "differentiation", "is", "accompanied", "by", "an", "augmented", "capacity", "to", "generate", "growth", "factors", ".", "We", "hypothesized", "that", "adherence", "itself", "might", "be", "an", "important", "trigger", "for", "a", "sequence", "of", "gene", "activation", "culminating", "in", "cells", "with", "increased", "mRNA", "encoding", "profibrotic", "growth", "factors", "such", "as", "platelet", "-", "derived", "growth", "factor", "B", "subunit", "(", "PDGF[B", "]", ")", "and", "transforming", "growth", "factor", "-", "beta", "(", "TGF", "-", "beta", ")", ".", "After", "in", "vitro", "adherence", ",", "human", "monocytes", "had", "a", "biphasic", "increase", "in", "PDGF(B", ")", "mRNA", "with", "peaks", "at", "6", "h", "and", "13", "d.", "No", "increase", "in", "TGF", "-", "beta", "mRNA", "was", "observed", ".", "The", "6-h", "increase", "in", "PDGF(B", ")", "mRNA", "was", "adherence", "dependent", ",", "and", "in", "addition", ",", "was", "abrogated", "when", "the", "cytoskeletal", "integrity", "was", "compromised", "by", "cytochalasin", "D.", "The", "6-h", "increase", "in", "PDGF(B", ")", "mRNA", "was", "unaltered", "by", "adherence", "in", "the", "presence", "of", "the", "monocyte", "stimulus", "lipopolysaccharide", ".", "Adherence", "to", "either", "fibronectin", "or", "collagen", "-", "coated", "plastic", "had", "little", "consistent", "effect", "on", "PDGF(B", ")", "mRNA", "accumulation", ".", "The", "increased", "PDGF(B", ")", "mRNA", "observed", "in", "adherent", "monocytes", "was", "accompanied", "by", "increases", "in", "mRNAs", "of", "the", "early", "growth", "response", "genes", "c", "-", "fos", "(", "maximal", "at", "20", "min", ")", ",", "c", "-", "jun", ",", "and", "EGR2", "(", "maximal", "at", "6", "-", "24", "h", ")", ".", "The", "increase", "in", "c", "-", "jun", "and", "EGR2", ",", "but", "not", "c", "-", "fos", ",", "mRNA", "was", "also", "abrogated", "by", "cytochalasin", "D.", "These", "observations", "suggest", "that", "adherence", "results", "in", "increases", "of", "c", "-", "fos", ",", "c", "-", "jun", ",", "EGR2", ",", "and", "PDGF(B", ")", "mRNA", ".", "In", "addition", ",", "the", "increases", "in", "c", "-", "jun", ",", "EGR2", ",", "and", "PDGF(B", ")", "may", "depend", "on", "cytoskeletal", "rearrangement", ".", "Modulation", "of", "these", "events", "at", "the", "time", "of", "adherence", "offers", "a", "mechanism", "by", "which", "differential", "priming", "of", "the", "cells", "may", "be", "accomplished", "." ]	[ "Protein" ]
PDGF(B ), c - fos, c - jun, EGR2, platelet - derived growth factor B subunit, PDGF[B ], transforming growth factor - beta, TGF - beta, PDGF(B ), TGF - beta, PDGF(B ), PDGF(B ), fibronectin, PDGF(B ), PDGF(B ), c - fos, c - jun, EGR2, c - jun, EGR2, c - fos, c - fos, c - jun, EGR2, PDGF(B ), c - jun, EGR2, PDGF(B )	328_task2	Sentence: Adherence-dependent increase in human monocyte PDGF(B) mRNA is associated with increases in c-fos, c-jun, and EGR2 mRNA. Adherence is an important initial step in the transition of a circulating monocyte to a tissue macrophage. This differentiation is accompanied by an augmented capacity to generate growth factors. We hypothesized that adherence itself might be an important trigger for a sequence of gene activation culminating in cells with increased mRNA encoding profibrotic growth factors such as platelet-derived growth factor B subunit (PDGF[B]) and transforming growth factor-beta (TGF-beta). After in vitro adherence, human monocytes had a biphasic increase in PDGF(B) mRNA with peaks at 6 h and 13 d. No increase in TGF-beta mRNA was observed. The 6-h increase in PDGF(B) mRNA was adherence dependent, and in addition, was abrogated when the cytoskeletal integrity was compromised by cytochalasin D. The 6-h increase in PDGF(B) mRNA was unaltered by adherence in the presence of the monocyte stimulus lipopolysaccharide. Adherence to either fibronectin or collagen-coated plastic had little consistent effect on PDGF(B) mRNA accumulation. The increased PDGF(B) mRNA observed in adherent monocytes was accompanied by increases in mRNAs of the early growth response genes c-fos (maximal at 20 min), c-jun, and EGR2 (maximal at 6-24 h). The increase in c-jun and EGR2, but not c-fos, mRNA was also abrogated by cytochalasin D. These observations suggest that adherence results in increases of c-fos, c-jun, EGR2, and PDGF(B) mRNA. In addition, the increases in c-jun, EGR2, and PDGF(B) may depend on cytoskeletal rearrangement. Modulation of these events at the time of adherence offers a mechanism by which differential priming of the cells may be accomplished. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Adherence-dependent increase in human monocyte PDGF(B) mRNA is associated with increases in c-fos, c-jun, and EGR2 mRNA. Adherence is an important initial step in the transition of a circulating monocyte to a tissue macrophage. This differentiation is accompanied by an augmented capacity to generate growth factors. We hypothesized that adherence itself might be an important trigger for a sequence of gene activation culminating in cells with increased mRNA encoding profibrotic growth factors such as platelet-derived growth factor B subunit (PDGF[B]) and transforming growth factor-beta (TGF-beta). After in vitro adherence, human monocytes had a biphasic increase in PDGF(B) mRNA with peaks at 6 h and 13 d. No increase in TGF-beta mRNA was observed. The 6-h increase in PDGF(B) mRNA was adherence dependent, and in addition, was abrogated when the cytoskeletal integrity was compromised by cytochalasin D. The 6-h increase in PDGF(B) mRNA was unaltered by adherence in the presence of the monocyte stimulus lipopolysaccharide. Adherence to either fibronectin or collagen-coated plastic had little consistent effect on PDGF(B) mRNA accumulation. The increased PDGF(B) mRNA observed in adherent monocytes was accompanied by increases in mRNAs of the early growth response genes c-fos (maximal at 20 min), c-jun, and EGR2 (maximal at 6-24 h). The increase in c-jun and EGR2, but not c-fos, mRNA was also abrogated by cytochalasin D. These observations suggest that adherence results in increases of c-fos, c-jun, EGR2, and PDGF(B) mRNA. In addition, the increases in c-jun, EGR2, and PDGF(B) may depend on cytoskeletal rearrangement. Modulation of these events at the time of adherence offers a mechanism by which differential priming of the cells may be accomplished.	[ "Adherence", "-", "dependent", "increase", "in", "human", "monocyte", "PDGF(B", ")", "mRNA", "is", "associated", "with", "increases", "in", "c", "-", "fos", ",", "c", "-", "jun", ",", "and", "EGR2", "mRNA", ".", "\n", "Adherence", "is", "an", "important", "initial", "step", "in", "the", "transition", "of", "a", "circulating", "monocyte", "to", "a", "tissue", "macrophage", ".", "This", "differentiation", "is", "accompanied", "by", "an", "augmented", "capacity", "to", "generate", "growth", "factors", ".", "We", "hypothesized", "that", "adherence", "itself", "might", "be", "an", "important", "trigger", "for", "a", "sequence", "of", "gene", "activation", "culminating", "in", "cells", "with", "increased", "mRNA", "encoding", "profibrotic", "growth", "factors", "such", "as", "platelet", "-", "derived", "growth", "factor", "B", "subunit", "(", "PDGF[B", "]", ")", "and", "transforming", "growth", "factor", "-", "beta", "(", "TGF", "-", "beta", ")", ".", "After", "in", "vitro", "adherence", ",", "human", "monocytes", "had", "a", "biphasic", "increase", "in", "PDGF(B", ")", "mRNA", "with", "peaks", "at", "6", "h", "and", "13", "d.", "No", "increase", "in", "TGF", "-", "beta", "mRNA", "was", "observed", ".", "The", "6-h", "increase", "in", "PDGF(B", ")", "mRNA", "was", "adherence", "dependent", ",", "and", "in", "addition", ",", "was", "abrogated", "when", "the", "cytoskeletal", "integrity", "was", "compromised", "by", "cytochalasin", "D.", "The", "6-h", "increase", "in", "PDGF(B", ")", "mRNA", "was", "unaltered", "by", "adherence", "in", "the", "presence", "of", "the", "monocyte", "stimulus", "lipopolysaccharide", ".", "Adherence", "to", "either", "fibronectin", "or", "collagen", "-", "coated", "plastic", "had", "little", "consistent", "effect", "on", "PDGF(B", ")", "mRNA", "accumulation", ".", "The", "increased", "PDGF(B", ")", "mRNA", "observed", "in", "adherent", "monocytes", "was", "accompanied", "by", "increases", "in", "mRNAs", "of", "the", "early", "growth", "response", "genes", "c", "-", "fos", "(", "maximal", "at", "20", "min", ")", ",", "c", "-", "jun", ",", "and", "EGR2", "(", "maximal", "at", "6", "-", "24", "h", ")", ".", "The", "increase", "in", "c", "-", "jun", "and", "EGR2", ",", "but", "not", "c", "-", "fos", ",", "mRNA", "was", "also", "abrogated", "by", "cytochalasin", "D.", "These", "observations", "suggest", "that", "adherence", "results", "in", "increases", "of", "c", "-", "fos", ",", "c", "-", "jun", ",", "EGR2", ",", "and", "PDGF(B", ")", "mRNA", ".", "In", "addition", ",", "the", "increases", "in", "c", "-", "jun", ",", "EGR2", ",", "and", "PDGF(B", ")", "may", "depend", "on", "cytoskeletal", "rearrangement", ".", "Modulation", "of", "these", "events", "at", "the", "time", "of", "adherence", "offers", "a", "mechanism", "by", "which", "differential", "priming", "of", "the", "cells", "may", "be", "accomplished", "." ]	[ "Protein" ]
benefit / disadvantage is a Outcome_Other, granulocyte colony - stimulating factor therapy is a Intervention_Pharmacological, children is a Participant_Age, PBSCT is a Intervention_Pharmacological, 74 is a Participant_Sample-size, high - dose chemotherapy is a Intervention_Pharmacological, autologous peripheral blood stem cell transplantation ( PBSCT ) is a Participant_Condition, effectiveness is a Outcome_Other, G - CSF is a Intervention_Pharmacological, hematopoietic recovery is a Outcome_Physical, acute lymphoblastic leukemia is a Participant_Condition, 27 is a Participant_Sample-size, neuroblastoma is a Participant_Condition, 29 is a Participant_Sample-size, miscellaneous solid tumors is a Participant_Condition, 18 is a Participant_Sample-size, primary PBSCT is a Intervention_Pharmacological, chemotherapy - responsive disease is a Participant_Condition, collected cell number > 1 x 10 ( 5 ) colony - forming unit - granulocyte - macrophage ( CFU - GM ) /kg and > 1 x 10 ( 6 ) CD34 ( + ) cells / kg is a Participant_Condition, 11 is a Participant_Sample-size, 63 is a Participant_Sample-size, 32 is a Participant_Sample-size, control group is a Intervention_Control, high - dose regimens without total body irradiation consisted of the MCVAC regimen using ranimustine ( MCNU , 450 mg / m2 ) , cytosine arabinoside ( 16 g / m2 ) , etoposide ( 1.6 g / m2 ) , and cyclophosphamide is a Intervention_Pharmacological, Hi - MEC regimen using melphalan is a Intervention_Pharmacological, carboplatinum is a Intervention_Pharmacological, Five is a Participant_Sample-size, two is a Participant_Sample-size, three is a Participant_Sample-size, survived is a Outcome_Mortality, median numbers of transfused mononuclear cells ( MNC ) is a Outcome_Physical, time to achieve an absolute neutrophil count ( ANC ) of > 0.5 x 10 ( 9 ) /L is a Outcome_Other, duration of febrile days is a Outcome_Other, platelet recovery to > 20 x 10 ( 9 ) /L is a Outcome_Other, platelet transfusion - dependent days is a Outcome_Other, engraftment kinetics is a Outcome_Physical, recovery of granulocytes is a Outcome_Physical, recovery of platelets . is a Outcome_Physical	93229_task0	Sentence: Marginal benefit/disadvantage of granulocyte colony-stimulating factor therapy after autologous blood stem cell transplantation in children : results of a prospective randomized trial . The Japanese Cooperative Study Group of PBSCT . In this prospective trial , a total of 74 children who were scheduled to undergo high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation ( PBSCT ) were prospectively randomized at diagnosis to evaluate the effectiveness of exogenous granulocyte colony-stimulating factor ( G-CSF ) treatment in accelerating hematopoietic recovery after PBSCT . The diagnosis included acute lymphoblastic leukemia ( ALL ) ( n = 27 ) , neuroblastoma ( n = 29 ) , and miscellaneous solid tumors ( n = 18 ) . Eligibility criteria included ( 1 ) primary PBSCT , ( 2 ) chemotherapy-responsive disease , and ( 3 ) collected cell number > 1 x 10 ( 5 ) colony-forming unit-granulocyte-macrophage ( CFU-GM ) /kg and > 1 x 10 ( 6 ) CD34 ( + ) cells/kg patient 's body weight . After applying the above criteria , 11 patients were excluded due to disease progression before PBSCT ( n = 6 ) or a low number of harvested cells ( n = 5 ) , leaving 63 patients for analysis ; 32 patients in the treatment group ( 300 microg/m2 of G-CSF intravenously over 1 hour from day 1 of PBSCT ) and 31 in the control group without treatment . Two distinct disease-oriented high-dose regimens without total body irradiation consisted of the MCVAC regimen using ranimustine ( MCNU , 450 mg/m2 ) , cytosine arabinoside ( 16 g/m2 ) , etoposide ( 1.6 g/m2 ) , and cyclophosphamide ( 100 mg/kg ) for patients with ALL , and the Hi-MEC regimen using melphalan ( 180 mg/m2 ) , etoposide ( 1.6 g/m2 ) , and carboplatinum ( 1.6 g/m2 ) for those with solid tumors . Five patients ( two in the treatment group and three in the control group ) were subsequently removed due to protocol violations . All patients survived PBSCT . The median numbers of transfused mononuclear cells ( MNC ) , CD34 ( + ) cells , and CFU-GM were , respectively , 4.5 ( range , 1 to 19 ) x 10 ( 8 ) /kg , 8.0 ( 1.1 to 25 ) x 10 ( 6 ) /kg , and 3.7 ( 1.2 to 23 ) x 10 ( 5 ) /kg in the treatment group ( n = 30 ) and 2.9 ( 0.8 to 21 ) x 10 ( 8 ) /kg , 6.3 ( 1.1 to 34 ) x 10 ( 6 ) /kg , and 5.5 ( 1.3 to 37 ) x 10 ( 5 ) /kg , respectively , in the control group ( n = 28 ) , with no significant difference . After PBSCT , the time to achieve an absolute neutrophil count ( ANC ) of > 0.5 x 10 ( 9 ) /L in the treatment group was less than that in the control group ( median , 11 v 12 days ; the log-rank test , P =.046 ) , although the last day of red blood cell ( RBC ) transfusion ( day 11 v day 10 ) and the duration of febrile days ( > 38 degrees C ) after PBSCT ( 4 v 4 days ) were identical in both groups . However , platelet recovery to > 20 x 10 ( 9 ) /L was significantly longer in treatment group than control group ( 26 v 16 days ; P =.009 ) and > 50 x 10 ( 9 ) /L tended to take longer in the treatment group ( 29 v 26 days ; P =.126 ) , with significantly more platelet transfusion-dependent days ( 27 v 13 days ; t-test , P =.037 ) . When patients were divided into two different disease cohorts , ALL patients showed no difference in engraftment kinetics between the G-CSF treatment and control groups , while differences were seen in those with solid tumors . We concluded that the marginal clinical benefit of 1 day earlier recovery of granulocytes could be offset by the delayed recovery of platelets . We recommend that the routine application of costly G-CSF therapy in children undergoing PBSCT should be seriously reconsidered . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Participant_Condition, Intervention_Control, Outcome_Mortality, Participant_Age, Outcome_Physical, Participant_Sample-size, Outcome_Other	[ "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "B-Participant_Condition", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Marginal benefit/disadvantage of granulocyte colony-stimulating factor therapy after autologous blood stem cell transplantation in children : results of a prospective randomized trial . The Japanese Cooperative Study Group of PBSCT . In this prospective trial , a total of 74 children who were scheduled to undergo high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation ( PBSCT ) were prospectively randomized at diagnosis to evaluate the effectiveness of exogenous granulocyte colony-stimulating factor ( G-CSF ) treatment in accelerating hematopoietic recovery after PBSCT . The diagnosis included acute lymphoblastic leukemia ( ALL ) ( n = 27 ) , neuroblastoma ( n = 29 ) , and miscellaneous solid tumors ( n = 18 ) . Eligibility criteria included ( 1 ) primary PBSCT , ( 2 ) chemotherapy-responsive disease , and ( 3 ) collected cell number > 1 x 10 ( 5 ) colony-forming unit-granulocyte-macrophage ( CFU-GM ) /kg and > 1 x 10 ( 6 ) CD34 ( + ) cells/kg patient 's body weight . After applying the above criteria , 11 patients were excluded due to disease progression before PBSCT ( n = 6 ) or a low number of harvested cells ( n = 5 ) , leaving 63 patients for analysis ; 32 patients in the treatment group ( 300 microg/m2 of G-CSF intravenously over 1 hour from day 1 of PBSCT ) and 31 in the control group without treatment . Two distinct disease-oriented high-dose regimens without total body irradiation consisted of the MCVAC regimen using ranimustine ( MCNU , 450 mg/m2 ) , cytosine arabinoside ( 16 g/m2 ) , etoposide ( 1.6 g/m2 ) , and cyclophosphamide ( 100 mg/kg ) for patients with ALL , and the Hi-MEC regimen using melphalan ( 180 mg/m2 ) , etoposide ( 1.6 g/m2 ) , and carboplatinum ( 1.6 g/m2 ) for those with solid tumors . Five patients ( two in the treatment group and three in the control group ) were subsequently removed due to protocol violations . All patients survived PBSCT . The median numbers of transfused mononuclear cells ( MNC ) , CD34 ( + ) cells , and CFU-GM were , respectively , 4.5 ( range , 1 to 19 ) x 10 ( 8 ) /kg , 8.0 ( 1.1 to 25 ) x 10 ( 6 ) /kg , and 3.7 ( 1.2 to 23 ) x 10 ( 5 ) /kg in the treatment group ( n = 30 ) and 2.9 ( 0.8 to 21 ) x 10 ( 8 ) /kg , 6.3 ( 1.1 to 34 ) x 10 ( 6 ) /kg , and 5.5 ( 1.3 to 37 ) x 10 ( 5 ) /kg , respectively , in the control group ( n = 28 ) , with no significant difference . After PBSCT , the time to achieve an absolute neutrophil count ( ANC ) of > 0.5 x 10 ( 9 ) /L in the treatment group was less than that in the control group ( median , 11 v 12 days ; the log-rank test , P =.046 ) , although the last day of red blood cell ( RBC ) transfusion ( day 11 v day 10 ) and the duration of febrile days ( > 38 degrees C ) after PBSCT ( 4 v 4 days ) were identical in both groups . However , platelet recovery to > 20 x 10 ( 9 ) /L was significantly longer in treatment group than control group ( 26 v 16 days ; P =.009 ) and > 50 x 10 ( 9 ) /L tended to take longer in the treatment group ( 29 v 26 days ; P =.126 ) , with significantly more platelet transfusion-dependent days ( 27 v 13 days ; t-test , P =.037 ) . When patients were divided into two different disease cohorts , ALL patients showed no difference in engraftment kinetics between the G-CSF treatment and control groups , while differences were seen in those with solid tumors . We concluded that the marginal clinical benefit of 1 day earlier recovery of granulocytes could be offset by the delayed recovery of platelets . We recommend that the routine application of costly G-CSF therapy in children undergoing PBSCT should be seriously reconsidered .	[ "Marginal", "benefit", "/", "disadvantage", "of", "granulocyte", "colony", "-", "stimulating", "factor", "therapy", "after", "autologous", "blood", "stem", "cell", "transplantation", "in", "children", ":", "results", "of", "a", "prospective", "randomized", "trial", ".", "The", "Japanese", "Cooperative", "Study", "Group", "of", "PBSCT", ".", "In", "this", "prospective", "trial", ",", "a", "total", "of", "74", "children", "who", "were", "scheduled", "to", "undergo", "high", "-", "dose", "chemotherapy", "followed", "by", "autologous", "peripheral", "blood", "stem", "cell", "transplantation", "(", "PBSCT", ")", "were", "prospectively", "randomized", "at", "diagnosis", "to", "evaluate", "the", "effectiveness", "of", "exogenous", "granulocyte", "colony", "-", "stimulating", "factor", "(", "G", "-", "CSF", ")", "treatment", "in", "accelerating", "hematopoietic", "recovery", "after", "PBSCT", ".", "The", "diagnosis", "included", "acute", "lymphoblastic", "leukemia", "(", "ALL", ")", "(", "n", "=", "27", ")", ",", "neuroblastoma", "(", "n", "=", "29", ")", ",", "and", "miscellaneous", "solid", "tumors", "(", "n", "=", "18", ")", ".", "Eligibility", "criteria", "included", "(", "1", ")", "primary", "PBSCT", ",", "(", "2", ")", "chemotherapy", "-", "responsive", "disease", ",", "and", "(", "3", ")", "collected", "cell", "number", ">", "1", "x", "10", "(", "5", ")", "colony", "-", "forming", "unit", "-", "granulocyte", "-", "macrophage", "(", "CFU", "-", "GM", ")", "/kg", "and", ">", "1", "x", "10", "(", "6", ")", "CD34", "(", "+", ")", "cells", "/", "kg", "patient", "'", "s", "body", "weight", ".", "After", "applying", "the", "above", "criteria", ",", "11", "patients", "were", "excluded", "due", "to", "disease", "progression", "before", "PBSCT", "(", "n", "=", "6", ")", "or", "a", "low", "number", "of", "harvested", "cells", "(", "n", "=", "5", ")", ",", "leaving", "63", "patients", "for", "analysis", ";", "32", "patients", "in", "the", "treatment", "group", "(", "300", "microg", "/", "m2", "of", "G", "-", "CSF", "intravenously", "over", "1", "hour", "from", "day", "1", "of", "PBSCT", ")", "and", "31", "in", "the", "control", "group", "without", "treatment", ".", "Two", "distinct", "disease", "-", "oriented", "high", "-", "dose", "regimens", "without", "total", "body", "irradiation", "consisted", "of", "the", "MCVAC", "regimen", "using", "ranimustine", "(", "MCNU", ",", "450", "mg", "/", "m2", ")", ",", "cytosine", "arabinoside", "(", "16", "g", "/", "m2", ")", ",", "etoposide", "(", "1.6", "g", "/", "m2", ")", ",", "and", "cyclophosphamide", "(", "100", "mg", "/", "kg", ")", "for", "patients", "with", "ALL", ",", "and", "the", "Hi", "-", "MEC", "regimen", "using", "melphalan", "(", "180", "mg", "/", "m2", ")", ",", "etoposide", "(", "1.6", "g", "/", "m2", ")", ",", "and", "carboplatinum", "(", "1.6", "g", "/", "m2", ")", "for", "those", "with", "solid", "tumors", ".", "Five", "patients", "(", "two", "in", "the", "treatment", "group", "and", "three", "in", "the", "control", "group", ")", "were", "subsequently", "removed", "due", "to", "protocol", "violations", ".", "All", "patients", "survived", "PBSCT", ".", "The", "median", "numbers", "of", "transfused", "mononuclear", "cells", "(", "MNC", ")", ",", "CD34", "(", "+", ")", "cells", ",", "and", "CFU", "-", "GM", "were", ",", "respectively", ",", "4.5", "(", "range", ",", "1", "to", "19", ")", "x", "10", "(", "8", ")", "/kg", ",", "8.0", "(", "1.1", "to", "25", ")", "x", "10", "(", "6", ")", "/kg", ",", "and", "3.7", "(", "1.2", "to", "23", ")", "x", "10", "(", "5", ")", "/kg", "in", "the", "treatment", "group", "(", "n", "=", "30", ")", "and", "2.9", "(", "0.8", "to", "21", ")", "x", "10", "(", "8", ")", "/kg", ",", "6.3", "(", "1.1", "to", "34", ")", "x", "10", "(", "6", ")", "/kg", ",", "and", "5.5", "(", "1.3", "to", "37", ")", "x", "10", "(", "5", ")", "/kg", ",", "respectively", ",", "in", "the", "control", "group", "(", "n", "=", "28", ")", ",", "with", "no", "significant", "difference", ".", "After", "PBSCT", ",", "the", "time", "to", "achieve", "an", "absolute", "neutrophil", "count", "(", "ANC", ")", "of", ">", "0.5", "x", "10", "(", "9", ")", "/L", "in", "the", "treatment", "group", "was", "less", "than", "that", "in", "the", "control", "group", "(", "median", ",", "11", "v", "12", "days", ";", "the", "log", "-", "rank", "test", ",", "P", "=", ".046", ")", ",", "although", "the", "last", "day", "of", "red", "blood", "cell", "(", "RBC", ")", "transfusion", "(", "day", "11", "v", "day", "10", ")", "and", "the", "duration", "of", "febrile", "days", "(", ">", "38", "degrees", "C", ")", "after", "PBSCT", "(", "4", "v", "4", "days", ")", "were", "identical", "in", "both", "groups", ".", "However", ",", "platelet", "recovery", "to", ">", "20", "x", "10", "(", "9", ")", "/L", "was", "significantly", "longer", "in", "treatment", "group", "than", "control", "group", "(", "26", "v", "16", "days", ";", "P", "=", ".009", ")", "and", ">", "50", "x", "10", "(", "9", ")", "/L", "tended", "to", "take", "longer", "in", "the", "treatment", "group", "(", "29", "v", "26", "days", ";", "P", "=", ".126", ")", ",", "with", "significantly", "more", "platelet", "transfusion", "-", "dependent", "days", "(", "27", "v", "13", "days", ";", "t", "-", "test", ",", "P", "=", ".037", ")", ".", "When", "patients", "were", "divided", "into", "two", "different", "disease", "cohorts", ",", "ALL", "patients", "showed", "no", "difference", "in", "engraftment", "kinetics", "between", "the", "G", "-", "CSF", "treatment", "and", "control", "groups", ",", "while", "differences", "were", "seen", "in", "those", "with", "solid", "tumors", ".", "We", "concluded", "that", "the", "marginal", "clinical", "benefit", "of", "1", "day", "earlier", "recovery", "of", "granulocytes", "could", "be", "offset", "by", "the", "delayed", "recovery", "of", "platelets", ".", "We", "recommend", "that", "the", "routine", "application", "of", "costly", "G", "-", "CSF", "therapy", "in", "children", "undergoing", "PBSCT", "should", "be", "seriously", "reconsidered", "." ]	[ "Intervention_Pharmacological", "Participant_Condition", "Outcome_Other", "Outcome_Physical", "Intervention_Control", "Outcome_Mortality", "Participant_Age", "Participant_Sample-size" ]
benefit / disadvantage is a Outcome_Other, granulocyte colony - stimulating factor therapy is a Intervention_Pharmacological, children is a Participant_Age, PBSCT is a Intervention_Pharmacological, 74 is a Participant_Sample-size, high - dose chemotherapy is a Intervention_Pharmacological, autologous peripheral blood stem cell transplantation ( PBSCT ) is a Participant_Condition, effectiveness is a Outcome_Other, G - CSF is a Intervention_Pharmacological, hematopoietic recovery is a Outcome_Physical, acute lymphoblastic leukemia is a Participant_Condition, 27 is a Participant_Sample-size, neuroblastoma is a Participant_Condition, 29 is a Participant_Sample-size, miscellaneous solid tumors is a Participant_Condition, 18 is a Participant_Sample-size, primary PBSCT is a Intervention_Pharmacological, chemotherapy - responsive disease is a Participant_Condition, collected cell number > 1 x 10 ( 5 ) colony - forming unit - granulocyte - macrophage ( CFU - GM ) /kg and > 1 x 10 ( 6 ) CD34 ( + ) cells / kg is a Participant_Condition, 11 is a Participant_Sample-size, 63 is a Participant_Sample-size, 32 is a Participant_Sample-size, control group is a Intervention_Control, high - dose regimens without total body irradiation consisted of the MCVAC regimen using ranimustine ( MCNU , 450 mg / m2 ) , cytosine arabinoside ( 16 g / m2 ) , etoposide ( 1.6 g / m2 ) , and cyclophosphamide is a Intervention_Pharmacological, Hi - MEC regimen using melphalan is a Intervention_Pharmacological, carboplatinum is a Intervention_Pharmacological, Five is a Participant_Sample-size, two is a Participant_Sample-size, three is a Participant_Sample-size, survived is a Outcome_Mortality, median numbers of transfused mononuclear cells ( MNC ) is a Outcome_Physical, time to achieve an absolute neutrophil count ( ANC ) of > 0.5 x 10 ( 9 ) /L is a Outcome_Other, duration of febrile days is a Outcome_Other, platelet recovery to > 20 x 10 ( 9 ) /L is a Outcome_Other, platelet transfusion - dependent days is a Outcome_Other, engraftment kinetics is a Outcome_Physical, recovery of granulocytes is a Outcome_Physical, recovery of platelets . is a Outcome_Physical	93229_task1	Sentence: Marginal benefit/disadvantage of granulocyte colony-stimulating factor therapy after autologous blood stem cell transplantation in children : results of a prospective randomized trial . The Japanese Cooperative Study Group of PBSCT . In this prospective trial , a total of 74 children who were scheduled to undergo high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation ( PBSCT ) were prospectively randomized at diagnosis to evaluate the effectiveness of exogenous granulocyte colony-stimulating factor ( G-CSF ) treatment in accelerating hematopoietic recovery after PBSCT . The diagnosis included acute lymphoblastic leukemia ( ALL ) ( n = 27 ) , neuroblastoma ( n = 29 ) , and miscellaneous solid tumors ( n = 18 ) . Eligibility criteria included ( 1 ) primary PBSCT , ( 2 ) chemotherapy-responsive disease , and ( 3 ) collected cell number > 1 x 10 ( 5 ) colony-forming unit-granulocyte-macrophage ( CFU-GM ) /kg and > 1 x 10 ( 6 ) CD34 ( + ) cells/kg patient 's body weight . After applying the above criteria , 11 patients were excluded due to disease progression before PBSCT ( n = 6 ) or a low number of harvested cells ( n = 5 ) , leaving 63 patients for analysis ; 32 patients in the treatment group ( 300 microg/m2 of G-CSF intravenously over 1 hour from day 1 of PBSCT ) and 31 in the control group without treatment . Two distinct disease-oriented high-dose regimens without total body irradiation consisted of the MCVAC regimen using ranimustine ( MCNU , 450 mg/m2 ) , cytosine arabinoside ( 16 g/m2 ) , etoposide ( 1.6 g/m2 ) , and cyclophosphamide ( 100 mg/kg ) for patients with ALL , and the Hi-MEC regimen using melphalan ( 180 mg/m2 ) , etoposide ( 1.6 g/m2 ) , and carboplatinum ( 1.6 g/m2 ) for those with solid tumors . Five patients ( two in the treatment group and three in the control group ) were subsequently removed due to protocol violations . All patients survived PBSCT . The median numbers of transfused mononuclear cells ( MNC ) , CD34 ( + ) cells , and CFU-GM were , respectively , 4.5 ( range , 1 to 19 ) x 10 ( 8 ) /kg , 8.0 ( 1.1 to 25 ) x 10 ( 6 ) /kg , and 3.7 ( 1.2 to 23 ) x 10 ( 5 ) /kg in the treatment group ( n = 30 ) and 2.9 ( 0.8 to 21 ) x 10 ( 8 ) /kg , 6.3 ( 1.1 to 34 ) x 10 ( 6 ) /kg , and 5.5 ( 1.3 to 37 ) x 10 ( 5 ) /kg , respectively , in the control group ( n = 28 ) , with no significant difference . After PBSCT , the time to achieve an absolute neutrophil count ( ANC ) of > 0.5 x 10 ( 9 ) /L in the treatment group was less than that in the control group ( median , 11 v 12 days ; the log-rank test , P =.046 ) , although the last day of red blood cell ( RBC ) transfusion ( day 11 v day 10 ) and the duration of febrile days ( > 38 degrees C ) after PBSCT ( 4 v 4 days ) were identical in both groups . However , platelet recovery to > 20 x 10 ( 9 ) /L was significantly longer in treatment group than control group ( 26 v 16 days ; P =.009 ) and > 50 x 10 ( 9 ) /L tended to take longer in the treatment group ( 29 v 26 days ; P =.126 ) , with significantly more platelet transfusion-dependent days ( 27 v 13 days ; t-test , P =.037 ) . When patients were divided into two different disease cohorts , ALL patients showed no difference in engraftment kinetics between the G-CSF treatment and control groups , while differences were seen in those with solid tumors . We concluded that the marginal clinical benefit of 1 day earlier recovery of granulocytes could be offset by the delayed recovery of platelets . We recommend that the routine application of costly G-CSF therapy in children undergoing PBSCT should be seriously reconsidered . Instructions: please typing these entity words according to sentence: benefit / disadvantage, granulocyte colony - stimulating factor therapy, children, PBSCT, 74, high - dose chemotherapy, autologous peripheral blood stem cell transplantation ( PBSCT ), effectiveness, G - CSF, hematopoietic recovery, acute lymphoblastic leukemia, 27, neuroblastoma, 29, miscellaneous solid tumors, 18, primary PBSCT, chemotherapy - responsive disease, collected cell number > 1 x 10 ( 5 ) colony - forming unit - granulocyte - macrophage ( CFU - GM ) /kg and > 1 x 10 ( 6 ) CD34 ( + ) cells / kg, 11, 63, 32, control group, high - dose regimens without total body irradiation consisted of the MCVAC regimen using ranimustine ( MCNU , 450 mg / m2 ) , cytosine arabinoside ( 16 g / m2 ) , etoposide ( 1.6 g / m2 ) , and cyclophosphamide, Hi - MEC regimen using melphalan, carboplatinum, Five, two, three, survived, median numbers of transfused mononuclear cells ( MNC ), time to achieve an absolute neutrophil count ( ANC ) of > 0.5 x 10 ( 9 ) /L, duration of febrile days, platelet recovery to > 20 x 10 ( 9 ) /L, platelet transfusion - dependent days, engraftment kinetics, recovery of granulocytes, recovery of platelets . Options: Intervention_Pharmacological, Participant_Condition, Intervention_Control, Outcome_Mortality, Participant_Age, Outcome_Physical, Participant_Sample-size, Outcome_Other	[ "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "B-Participant_Condition", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Marginal benefit/disadvantage of granulocyte colony-stimulating factor therapy after autologous blood stem cell transplantation in children : results of a prospective randomized trial . The Japanese Cooperative Study Group of PBSCT . In this prospective trial , a total of 74 children who were scheduled to undergo high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation ( PBSCT ) were prospectively randomized at diagnosis to evaluate the effectiveness of exogenous granulocyte colony-stimulating factor ( G-CSF ) treatment in accelerating hematopoietic recovery after PBSCT . The diagnosis included acute lymphoblastic leukemia ( ALL ) ( n = 27 ) , neuroblastoma ( n = 29 ) , and miscellaneous solid tumors ( n = 18 ) . Eligibility criteria included ( 1 ) primary PBSCT , ( 2 ) chemotherapy-responsive disease , and ( 3 ) collected cell number > 1 x 10 ( 5 ) colony-forming unit-granulocyte-macrophage ( CFU-GM ) /kg and > 1 x 10 ( 6 ) CD34 ( + ) cells/kg patient 's body weight . After applying the above criteria , 11 patients were excluded due to disease progression before PBSCT ( n = 6 ) or a low number of harvested cells ( n = 5 ) , leaving 63 patients for analysis ; 32 patients in the treatment group ( 300 microg/m2 of G-CSF intravenously over 1 hour from day 1 of PBSCT ) and 31 in the control group without treatment . Two distinct disease-oriented high-dose regimens without total body irradiation consisted of the MCVAC regimen using ranimustine ( MCNU , 450 mg/m2 ) , cytosine arabinoside ( 16 g/m2 ) , etoposide ( 1.6 g/m2 ) , and cyclophosphamide ( 100 mg/kg ) for patients with ALL , and the Hi-MEC regimen using melphalan ( 180 mg/m2 ) , etoposide ( 1.6 g/m2 ) , and carboplatinum ( 1.6 g/m2 ) for those with solid tumors . Five patients ( two in the treatment group and three in the control group ) were subsequently removed due to protocol violations . All patients survived PBSCT . The median numbers of transfused mononuclear cells ( MNC ) , CD34 ( + ) cells , and CFU-GM were , respectively , 4.5 ( range , 1 to 19 ) x 10 ( 8 ) /kg , 8.0 ( 1.1 to 25 ) x 10 ( 6 ) /kg , and 3.7 ( 1.2 to 23 ) x 10 ( 5 ) /kg in the treatment group ( n = 30 ) and 2.9 ( 0.8 to 21 ) x 10 ( 8 ) /kg , 6.3 ( 1.1 to 34 ) x 10 ( 6 ) /kg , and 5.5 ( 1.3 to 37 ) x 10 ( 5 ) /kg , respectively , in the control group ( n = 28 ) , with no significant difference . After PBSCT , the time to achieve an absolute neutrophil count ( ANC ) of > 0.5 x 10 ( 9 ) /L in the treatment group was less than that in the control group ( median , 11 v 12 days ; the log-rank test , P =.046 ) , although the last day of red blood cell ( RBC ) transfusion ( day 11 v day 10 ) and the duration of febrile days ( > 38 degrees C ) after PBSCT ( 4 v 4 days ) were identical in both groups . However , platelet recovery to > 20 x 10 ( 9 ) /L was significantly longer in treatment group than control group ( 26 v 16 days ; P =.009 ) and > 50 x 10 ( 9 ) /L tended to take longer in the treatment group ( 29 v 26 days ; P =.126 ) , with significantly more platelet transfusion-dependent days ( 27 v 13 days ; t-test , P =.037 ) . When patients were divided into two different disease cohorts , ALL patients showed no difference in engraftment kinetics between the G-CSF treatment and control groups , while differences were seen in those with solid tumors . We concluded that the marginal clinical benefit of 1 day earlier recovery of granulocytes could be offset by the delayed recovery of platelets . We recommend that the routine application of costly G-CSF therapy in children undergoing PBSCT should be seriously reconsidered .	[ "Marginal", "benefit", "/", "disadvantage", "of", "granulocyte", "colony", "-", "stimulating", "factor", "therapy", "after", "autologous", "blood", "stem", "cell", "transplantation", "in", "children", ":", "results", "of", "a", "prospective", "randomized", "trial", ".", "The", "Japanese", "Cooperative", "Study", "Group", "of", "PBSCT", ".", "In", "this", "prospective", "trial", ",", "a", "total", "of", "74", "children", "who", "were", "scheduled", "to", "undergo", "high", "-", "dose", "chemotherapy", "followed", "by", "autologous", "peripheral", "blood", "stem", "cell", "transplantation", "(", "PBSCT", ")", "were", "prospectively", "randomized", "at", "diagnosis", "to", "evaluate", "the", "effectiveness", "of", "exogenous", "granulocyte", "colony", "-", "stimulating", "factor", "(", "G", "-", "CSF", ")", "treatment", "in", "accelerating", "hematopoietic", "recovery", "after", "PBSCT", ".", "The", "diagnosis", "included", "acute", "lymphoblastic", "leukemia", "(", "ALL", ")", "(", "n", "=", "27", ")", ",", "neuroblastoma", "(", "n", "=", "29", ")", ",", "and", "miscellaneous", "solid", "tumors", "(", "n", "=", "18", ")", ".", "Eligibility", "criteria", "included", "(", "1", ")", "primary", "PBSCT", ",", "(", "2", ")", "chemotherapy", "-", "responsive", "disease", ",", "and", "(", "3", ")", "collected", "cell", "number", ">", "1", "x", "10", "(", "5", ")", "colony", "-", "forming", "unit", "-", "granulocyte", "-", "macrophage", "(", "CFU", "-", "GM", ")", "/kg", "and", ">", "1", "x", "10", "(", "6", ")", "CD34", "(", "+", ")", "cells", "/", "kg", "patient", "'", "s", "body", "weight", ".", "After", "applying", "the", "above", "criteria", ",", "11", "patients", "were", "excluded", "due", "to", "disease", "progression", "before", "PBSCT", "(", "n", "=", "6", ")", "or", "a", "low", "number", "of", "harvested", "cells", "(", "n", "=", "5", ")", ",", "leaving", "63", "patients", "for", "analysis", ";", "32", "patients", "in", "the", "treatment", "group", "(", "300", "microg", "/", "m2", "of", "G", "-", "CSF", "intravenously", "over", "1", "hour", "from", "day", "1", "of", "PBSCT", ")", "and", "31", "in", "the", "control", "group", "without", "treatment", ".", "Two", "distinct", "disease", "-", "oriented", "high", "-", "dose", "regimens", "without", "total", "body", "irradiation", "consisted", "of", "the", "MCVAC", "regimen", "using", "ranimustine", "(", "MCNU", ",", "450", "mg", "/", "m2", ")", ",", "cytosine", "arabinoside", "(", "16", "g", "/", "m2", ")", ",", "etoposide", "(", "1.6", "g", "/", "m2", ")", ",", "and", "cyclophosphamide", "(", "100", "mg", "/", "kg", ")", "for", "patients", "with", "ALL", ",", "and", "the", "Hi", "-", "MEC", "regimen", "using", "melphalan", "(", "180", "mg", "/", "m2", ")", ",", "etoposide", "(", "1.6", "g", "/", "m2", ")", ",", "and", "carboplatinum", "(", "1.6", "g", "/", "m2", ")", "for", "those", "with", "solid", "tumors", ".", "Five", "patients", "(", "two", "in", "the", "treatment", "group", "and", "three", "in", "the", "control", "group", ")", "were", "subsequently", "removed", "due", "to", "protocol", "violations", ".", "All", "patients", "survived", "PBSCT", ".", "The", "median", "numbers", "of", "transfused", "mononuclear", "cells", "(", "MNC", ")", ",", "CD34", "(", "+", ")", "cells", ",", "and", "CFU", "-", "GM", "were", ",", "respectively", ",", "4.5", "(", "range", ",", "1", "to", "19", ")", "x", "10", "(", "8", ")", "/kg", ",", "8.0", "(", "1.1", "to", "25", ")", "x", "10", "(", "6", ")", "/kg", ",", "and", "3.7", "(", "1.2", "to", "23", ")", "x", "10", "(", "5", ")", "/kg", "in", "the", "treatment", "group", "(", "n", "=", "30", ")", "and", "2.9", "(", "0.8", "to", "21", ")", "x", "10", "(", "8", ")", "/kg", ",", "6.3", "(", "1.1", "to", "34", ")", "x", "10", "(", "6", ")", "/kg", ",", "and", "5.5", "(", "1.3", "to", "37", ")", "x", "10", "(", "5", ")", "/kg", ",", "respectively", ",", "in", "the", "control", "group", "(", "n", "=", "28", ")", ",", "with", "no", "significant", "difference", ".", "After", "PBSCT", ",", "the", "time", "to", "achieve", "an", "absolute", "neutrophil", "count", "(", "ANC", ")", "of", ">", "0.5", "x", "10", "(", "9", ")", "/L", "in", "the", "treatment", "group", "was", "less", "than", "that", "in", "the", "control", "group", "(", "median", ",", "11", "v", "12", "days", ";", "the", "log", "-", "rank", "test", ",", "P", "=", ".046", ")", ",", "although", "the", "last", "day", "of", "red", "blood", "cell", "(", "RBC", ")", "transfusion", "(", "day", "11", "v", "day", "10", ")", "and", "the", "duration", "of", "febrile", "days", "(", ">", "38", "degrees", "C", ")", "after", "PBSCT", "(", "4", "v", "4", "days", ")", "were", "identical", "in", "both", "groups", ".", "However", ",", "platelet", "recovery", "to", ">", "20", "x", "10", "(", "9", ")", "/L", "was", "significantly", "longer", "in", "treatment", "group", "than", "control", "group", "(", "26", "v", "16", "days", ";", "P", "=", ".009", ")", "and", ">", "50", "x", "10", "(", "9", ")", "/L", "tended", "to", "take", "longer", "in", "the", "treatment", "group", "(", "29", "v", "26", "days", ";", "P", "=", ".126", ")", ",", "with", "significantly", "more", "platelet", "transfusion", "-", "dependent", "days", "(", "27", "v", "13", "days", ";", "t", "-", "test", ",", "P", "=", ".037", ")", ".", "When", "patients", "were", "divided", "into", "two", "different", "disease", "cohorts", ",", "ALL", "patients", "showed", "no", "difference", "in", "engraftment", "kinetics", "between", "the", "G", "-", "CSF", "treatment", "and", "control", "groups", ",", "while", "differences", "were", "seen", "in", "those", "with", "solid", "tumors", ".", "We", "concluded", "that", "the", "marginal", "clinical", "benefit", "of", "1", "day", "earlier", "recovery", "of", "granulocytes", "could", "be", "offset", "by", "the", "delayed", "recovery", "of", "platelets", ".", "We", "recommend", "that", "the", "routine", "application", "of", "costly", "G", "-", "CSF", "therapy", "in", "children", "undergoing", "PBSCT", "should", "be", "seriously", "reconsidered", "." ]	[ "Intervention_Pharmacological", "Participant_Condition", "Outcome_Other", "Outcome_Physical", "Intervention_Control", "Outcome_Mortality", "Participant_Age", "Participant_Sample-size" ]
benefit / disadvantage, granulocyte colony - stimulating factor therapy, children, PBSCT, 74, high - dose chemotherapy, autologous peripheral blood stem cell transplantation ( PBSCT ), effectiveness, G - CSF, hematopoietic recovery, acute lymphoblastic leukemia, 27, neuroblastoma, 29, miscellaneous solid tumors, 18, primary PBSCT, chemotherapy - responsive disease, collected cell number > 1 x 10 ( 5 ) colony - forming unit - granulocyte - macrophage ( CFU - GM ) /kg and > 1 x 10 ( 6 ) CD34 ( + ) cells / kg, 11, 63, 32, control group, high - dose regimens without total body irradiation consisted of the MCVAC regimen using ranimustine ( MCNU , 450 mg / m2 ) , cytosine arabinoside ( 16 g / m2 ) , etoposide ( 1.6 g / m2 ) , and cyclophosphamide, Hi - MEC regimen using melphalan, carboplatinum, Five, two, three, survived, median numbers of transfused mononuclear cells ( MNC ), time to achieve an absolute neutrophil count ( ANC ) of > 0.5 x 10 ( 9 ) /L, duration of febrile days, platelet recovery to > 20 x 10 ( 9 ) /L, platelet transfusion - dependent days, engraftment kinetics, recovery of granulocytes, recovery of platelets .	93229_task2	Sentence: Marginal benefit/disadvantage of granulocyte colony-stimulating factor therapy after autologous blood stem cell transplantation in children : results of a prospective randomized trial . The Japanese Cooperative Study Group of PBSCT . In this prospective trial , a total of 74 children who were scheduled to undergo high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation ( PBSCT ) were prospectively randomized at diagnosis to evaluate the effectiveness of exogenous granulocyte colony-stimulating factor ( G-CSF ) treatment in accelerating hematopoietic recovery after PBSCT . The diagnosis included acute lymphoblastic leukemia ( ALL ) ( n = 27 ) , neuroblastoma ( n = 29 ) , and miscellaneous solid tumors ( n = 18 ) . Eligibility criteria included ( 1 ) primary PBSCT , ( 2 ) chemotherapy-responsive disease , and ( 3 ) collected cell number > 1 x 10 ( 5 ) colony-forming unit-granulocyte-macrophage ( CFU-GM ) /kg and > 1 x 10 ( 6 ) CD34 ( + ) cells/kg patient 's body weight . After applying the above criteria , 11 patients were excluded due to disease progression before PBSCT ( n = 6 ) or a low number of harvested cells ( n = 5 ) , leaving 63 patients for analysis ; 32 patients in the treatment group ( 300 microg/m2 of G-CSF intravenously over 1 hour from day 1 of PBSCT ) and 31 in the control group without treatment . Two distinct disease-oriented high-dose regimens without total body irradiation consisted of the MCVAC regimen using ranimustine ( MCNU , 450 mg/m2 ) , cytosine arabinoside ( 16 g/m2 ) , etoposide ( 1.6 g/m2 ) , and cyclophosphamide ( 100 mg/kg ) for patients with ALL , and the Hi-MEC regimen using melphalan ( 180 mg/m2 ) , etoposide ( 1.6 g/m2 ) , and carboplatinum ( 1.6 g/m2 ) for those with solid tumors . Five patients ( two in the treatment group and three in the control group ) were subsequently removed due to protocol violations . All patients survived PBSCT . The median numbers of transfused mononuclear cells ( MNC ) , CD34 ( + ) cells , and CFU-GM were , respectively , 4.5 ( range , 1 to 19 ) x 10 ( 8 ) /kg , 8.0 ( 1.1 to 25 ) x 10 ( 6 ) /kg , and 3.7 ( 1.2 to 23 ) x 10 ( 5 ) /kg in the treatment group ( n = 30 ) and 2.9 ( 0.8 to 21 ) x 10 ( 8 ) /kg , 6.3 ( 1.1 to 34 ) x 10 ( 6 ) /kg , and 5.5 ( 1.3 to 37 ) x 10 ( 5 ) /kg , respectively , in the control group ( n = 28 ) , with no significant difference . After PBSCT , the time to achieve an absolute neutrophil count ( ANC ) of > 0.5 x 10 ( 9 ) /L in the treatment group was less than that in the control group ( median , 11 v 12 days ; the log-rank test , P =.046 ) , although the last day of red blood cell ( RBC ) transfusion ( day 11 v day 10 ) and the duration of febrile days ( > 38 degrees C ) after PBSCT ( 4 v 4 days ) were identical in both groups . However , platelet recovery to > 20 x 10 ( 9 ) /L was significantly longer in treatment group than control group ( 26 v 16 days ; P =.009 ) and > 50 x 10 ( 9 ) /L tended to take longer in the treatment group ( 29 v 26 days ; P =.126 ) , with significantly more platelet transfusion-dependent days ( 27 v 13 days ; t-test , P =.037 ) . When patients were divided into two different disease cohorts , ALL patients showed no difference in engraftment kinetics between the G-CSF treatment and control groups , while differences were seen in those with solid tumors . We concluded that the marginal clinical benefit of 1 day earlier recovery of granulocytes could be offset by the delayed recovery of platelets . We recommend that the routine application of costly G-CSF therapy in children undergoing PBSCT should be seriously reconsidered . Instructions: please extract entity words from the input sentence	[ "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "B-Participant_Condition", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Marginal benefit/disadvantage of granulocyte colony-stimulating factor therapy after autologous blood stem cell transplantation in children : results of a prospective randomized trial . The Japanese Cooperative Study Group of PBSCT . In this prospective trial , a total of 74 children who were scheduled to undergo high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation ( PBSCT ) were prospectively randomized at diagnosis to evaluate the effectiveness of exogenous granulocyte colony-stimulating factor ( G-CSF ) treatment in accelerating hematopoietic recovery after PBSCT . The diagnosis included acute lymphoblastic leukemia ( ALL ) ( n = 27 ) , neuroblastoma ( n = 29 ) , and miscellaneous solid tumors ( n = 18 ) . Eligibility criteria included ( 1 ) primary PBSCT , ( 2 ) chemotherapy-responsive disease , and ( 3 ) collected cell number > 1 x 10 ( 5 ) colony-forming unit-granulocyte-macrophage ( CFU-GM ) /kg and > 1 x 10 ( 6 ) CD34 ( + ) cells/kg patient 's body weight . After applying the above criteria , 11 patients were excluded due to disease progression before PBSCT ( n = 6 ) or a low number of harvested cells ( n = 5 ) , leaving 63 patients for analysis ; 32 patients in the treatment group ( 300 microg/m2 of G-CSF intravenously over 1 hour from day 1 of PBSCT ) and 31 in the control group without treatment . Two distinct disease-oriented high-dose regimens without total body irradiation consisted of the MCVAC regimen using ranimustine ( MCNU , 450 mg/m2 ) , cytosine arabinoside ( 16 g/m2 ) , etoposide ( 1.6 g/m2 ) , and cyclophosphamide ( 100 mg/kg ) for patients with ALL , and the Hi-MEC regimen using melphalan ( 180 mg/m2 ) , etoposide ( 1.6 g/m2 ) , and carboplatinum ( 1.6 g/m2 ) for those with solid tumors . Five patients ( two in the treatment group and three in the control group ) were subsequently removed due to protocol violations . All patients survived PBSCT . The median numbers of transfused mononuclear cells ( MNC ) , CD34 ( + ) cells , and CFU-GM were , respectively , 4.5 ( range , 1 to 19 ) x 10 ( 8 ) /kg , 8.0 ( 1.1 to 25 ) x 10 ( 6 ) /kg , and 3.7 ( 1.2 to 23 ) x 10 ( 5 ) /kg in the treatment group ( n = 30 ) and 2.9 ( 0.8 to 21 ) x 10 ( 8 ) /kg , 6.3 ( 1.1 to 34 ) x 10 ( 6 ) /kg , and 5.5 ( 1.3 to 37 ) x 10 ( 5 ) /kg , respectively , in the control group ( n = 28 ) , with no significant difference . After PBSCT , the time to achieve an absolute neutrophil count ( ANC ) of > 0.5 x 10 ( 9 ) /L in the treatment group was less than that in the control group ( median , 11 v 12 days ; the log-rank test , P =.046 ) , although the last day of red blood cell ( RBC ) transfusion ( day 11 v day 10 ) and the duration of febrile days ( > 38 degrees C ) after PBSCT ( 4 v 4 days ) were identical in both groups . However , platelet recovery to > 20 x 10 ( 9 ) /L was significantly longer in treatment group than control group ( 26 v 16 days ; P =.009 ) and > 50 x 10 ( 9 ) /L tended to take longer in the treatment group ( 29 v 26 days ; P =.126 ) , with significantly more platelet transfusion-dependent days ( 27 v 13 days ; t-test , P =.037 ) . When patients were divided into two different disease cohorts , ALL patients showed no difference in engraftment kinetics between the G-CSF treatment and control groups , while differences were seen in those with solid tumors . We concluded that the marginal clinical benefit of 1 day earlier recovery of granulocytes could be offset by the delayed recovery of platelets . We recommend that the routine application of costly G-CSF therapy in children undergoing PBSCT should be seriously reconsidered .	[ "Marginal", "benefit", "/", "disadvantage", "of", "granulocyte", "colony", "-", "stimulating", "factor", "therapy", "after", "autologous", "blood", "stem", "cell", "transplantation", "in", "children", ":", "results", "of", "a", "prospective", "randomized", "trial", ".", "The", "Japanese", "Cooperative", "Study", "Group", "of", "PBSCT", ".", "In", "this", "prospective", "trial", ",", "a", "total", "of", "74", "children", "who", "were", "scheduled", "to", "undergo", "high", "-", "dose", "chemotherapy", "followed", "by", "autologous", "peripheral", "blood", "stem", "cell", "transplantation", "(", "PBSCT", ")", "were", "prospectively", "randomized", "at", "diagnosis", "to", "evaluate", "the", "effectiveness", "of", "exogenous", "granulocyte", "colony", "-", "stimulating", "factor", "(", "G", "-", "CSF", ")", "treatment", "in", "accelerating", "hematopoietic", "recovery", "after", "PBSCT", ".", "The", "diagnosis", "included", "acute", "lymphoblastic", "leukemia", "(", "ALL", ")", "(", "n", "=", "27", ")", ",", "neuroblastoma", "(", "n", "=", "29", ")", ",", "and", "miscellaneous", "solid", "tumors", "(", "n", "=", "18", ")", ".", "Eligibility", "criteria", "included", "(", "1", ")", "primary", "PBSCT", ",", "(", "2", ")", "chemotherapy", "-", "responsive", "disease", ",", "and", "(", "3", ")", "collected", "cell", "number", ">", "1", "x", "10", "(", "5", ")", "colony", "-", "forming", "unit", "-", "granulocyte", "-", "macrophage", "(", "CFU", "-", "GM", ")", "/kg", "and", ">", "1", "x", "10", "(", "6", ")", "CD34", "(", "+", ")", "cells", "/", "kg", "patient", "'", "s", "body", "weight", ".", "After", "applying", "the", "above", "criteria", ",", "11", "patients", "were", "excluded", "due", "to", "disease", "progression", "before", "PBSCT", "(", "n", "=", "6", ")", "or", "a", "low", "number", "of", "harvested", "cells", "(", "n", "=", "5", ")", ",", "leaving", "63", "patients", "for", "analysis", ";", "32", "patients", "in", "the", "treatment", "group", "(", "300", "microg", "/", "m2", "of", "G", "-", "CSF", "intravenously", "over", "1", "hour", "from", "day", "1", "of", "PBSCT", ")", "and", "31", "in", "the", "control", "group", "without", "treatment", ".", "Two", "distinct", "disease", "-", "oriented", "high", "-", "dose", "regimens", "without", "total", "body", "irradiation", "consisted", "of", "the", "MCVAC", "regimen", "using", "ranimustine", "(", "MCNU", ",", "450", "mg", "/", "m2", ")", ",", "cytosine", "arabinoside", "(", "16", "g", "/", "m2", ")", ",", "etoposide", "(", "1.6", "g", "/", "m2", ")", ",", "and", "cyclophosphamide", "(", "100", "mg", "/", "kg", ")", "for", "patients", "with", "ALL", ",", "and", "the", "Hi", "-", "MEC", "regimen", "using", "melphalan", "(", "180", "mg", "/", "m2", ")", ",", "etoposide", "(", "1.6", "g", "/", "m2", ")", ",", "and", "carboplatinum", "(", "1.6", "g", "/", "m2", ")", "for", "those", "with", "solid", "tumors", ".", "Five", "patients", "(", "two", "in", "the", "treatment", "group", "and", "three", "in", "the", "control", "group", ")", "were", "subsequently", "removed", "due", "to", "protocol", "violations", ".", "All", "patients", "survived", "PBSCT", ".", "The", "median", "numbers", "of", "transfused", "mononuclear", "cells", "(", "MNC", ")", ",", "CD34", "(", "+", ")", "cells", ",", "and", "CFU", "-", "GM", "were", ",", "respectively", ",", "4.5", "(", "range", ",", "1", "to", "19", ")", "x", "10", "(", "8", ")", "/kg", ",", "8.0", "(", "1.1", "to", "25", ")", "x", "10", "(", "6", ")", "/kg", ",", "and", "3.7", "(", "1.2", "to", "23", ")", "x", "10", "(", "5", ")", "/kg", "in", "the", "treatment", "group", "(", "n", "=", "30", ")", "and", "2.9", "(", "0.8", "to", "21", ")", "x", "10", "(", "8", ")", "/kg", ",", "6.3", "(", "1.1", "to", "34", ")", "x", "10", "(", "6", ")", "/kg", ",", "and", "5.5", "(", "1.3", "to", "37", ")", "x", "10", "(", "5", ")", "/kg", ",", "respectively", ",", "in", "the", "control", "group", "(", "n", "=", "28", ")", ",", "with", "no", "significant", "difference", ".", "After", "PBSCT", ",", "the", "time", "to", "achieve", "an", "absolute", "neutrophil", "count", "(", "ANC", ")", "of", ">", "0.5", "x", "10", "(", "9", ")", "/L", "in", "the", "treatment", "group", "was", "less", "than", "that", "in", "the", "control", "group", "(", "median", ",", "11", "v", "12", "days", ";", "the", "log", "-", "rank", "test", ",", "P", "=", ".046", ")", ",", "although", "the", "last", "day", "of", "red", "blood", "cell", "(", "RBC", ")", "transfusion", "(", "day", "11", "v", "day", "10", ")", "and", "the", "duration", "of", "febrile", "days", "(", ">", "38", "degrees", "C", ")", "after", "PBSCT", "(", "4", "v", "4", "days", ")", "were", "identical", "in", "both", "groups", ".", "However", ",", "platelet", "recovery", "to", ">", "20", "x", "10", "(", "9", ")", "/L", "was", "significantly", "longer", "in", "treatment", "group", "than", "control", "group", "(", "26", "v", "16", "days", ";", "P", "=", ".009", ")", "and", ">", "50", "x", "10", "(", "9", ")", "/L", "tended", "to", "take", "longer", "in", "the", "treatment", "group", "(", "29", "v", "26", "days", ";", "P", "=", ".126", ")", ",", "with", "significantly", "more", "platelet", "transfusion", "-", "dependent", "days", "(", "27", "v", "13", "days", ";", "t", "-", "test", ",", "P", "=", ".037", ")", ".", "When", "patients", "were", "divided", "into", "two", "different", "disease", "cohorts", ",", "ALL", "patients", "showed", "no", "difference", "in", "engraftment", "kinetics", "between", "the", "G", "-", "CSF", "treatment", "and", "control", "groups", ",", "while", "differences", "were", "seen", "in", "those", "with", "solid", "tumors", ".", "We", "concluded", "that", "the", "marginal", "clinical", "benefit", "of", "1", "day", "earlier", "recovery", "of", "granulocytes", "could", "be", "offset", "by", "the", "delayed", "recovery", "of", "platelets", ".", "We", "recommend", "that", "the", "routine", "application", "of", "costly", "G", "-", "CSF", "therapy", "in", "children", "undergoing", "PBSCT", "should", "be", "seriously", "reconsidered", "." ]	[ "Intervention_Pharmacological", "Participant_Condition", "Outcome_Other", "Outcome_Physical", "Intervention_Control", "Outcome_Mortality", "Participant_Age", "Participant_Sample-size" ]
Jedet is a NOMBRE_SUJETO_ASISTENCIA, Sanchez Garcia is a NOMBRE_SUJETO_ASISTENCIA, 7845123 is a ID_SUJETO_ASISTENCIA, 23 56487946 12 is a ID_ASEGURAMIENTO, Girona is a TERRITORIO, 17002 is a TERRITORIO, 14/09/1986 is a FECHAS, España is a PAIS, 31 años is a EDAD_SUJETO_ASISTENCIA, 11/12/2017 is a FECHAS, Paula Ortiz Ballujera is a NOMBRE_PERSONAL_SANITARIO, 17 17 85236 is a ID_TITULACION_PERSONAL_SANITARIO, varón is a SEXO_SUJETO_ASISTENCIA, 31 años is a EDAD_SUJETO_ASISTENCIA, Paula Ortiz Ballujera is a NOMBRE_PERSONAL_SANITARIO, Hospital Universitari de Girona Doctor Josep Trueta is a HOSPITAL, 17007 is a TERRITORIO, Girona is a TERRITORIO, España is a PAIS, ballujera@hotmail.com is a CORREO_ELECTRONICO	97_task0	Sentence: Nombre: Jedet. Apellidos: Sanchez Garcia. NHC: 7845123. NASS: 23 56487946 12. Domicilio: Carrer del Dr. Castany 28, 8A. Localidad/ Provincia: Girona. CP: 17002. Datos asistenciales. Fecha de nacimiento: 14/09/1986. País: España. Edad: 31 años Sexo: H. Fecha de Ingreso: 11/12/2017. Servicio: Medicina intensiva. Médico:Paula Ortiz Ballujera NºCol: 17 17 85236. Historia Actual: El paciente era un varón de 31 años de edad que sufrió un accidente de motocicleta. La radiografía de tórax mostraba un ensanchamiento mediastínico. La TACHT al ingreso mostró un seudoaneurisma de aorta torácica distal a la salida de la arteria subclavia izquierda con un importante hematoma periaórtico y mediastínico asociado con hemotórax bilateral. Ingresó en la UCI, donde se consiguió un control estricto de la tensión arterial. A las 8 horas del traumatismo se colocó una endoprótesis en la aorta torácica descendente por vía ilíaca izquierda. La arteria subclavia izquierda quedó parcialmente ocluida sin repercusión clínica. A las 24 horas fue dado de alta a planta y a la semana se le dio el alta hospitalaria, ya que estaba asintomático. Remitido por: Dirección para correspondencia: Dra. Paula Ortiz Ballujera. Servicio de Medicina Intensiva (UCI). Hospital Universitari de Girona Doctor Josep Trueta. Avda. de França, s/n. 17007 Girona. España. Correo electrónico: ballujera@hotmail.com Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: TERRITORIO, SEXO_SUJETO_ASISTENCIA, ID_SUJETO_ASISTENCIA, FECHAS, HOSPITAL, CORREO_ELECTRONICO, PAIS, EDAD_SUJETO_ASISTENCIA, ID_ASEGURAMIENTO, ID_TITULACION_PERSONAL_SANITARIO, NOMBRE_SUJETO_ASISTENCIA, NOMBRE_PERSONAL_SANITARIO	[ "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "B-TERRITORIO", "O", "B-PAIS", "O", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]	Nombre: Jedet. Apellidos: Sanchez Garcia. NHC: 7845123. NASS: 23 56487946 12. Domicilio: Carrer del Dr. Castany 28, 8A. Localidad/ Provincia: Girona. CP: 17002. Datos asistenciales. Fecha de nacimiento: 14/09/1986. País: España. Edad: 31 años Sexo: H. Fecha de Ingreso: 11/12/2017. Servicio: Medicina intensiva. Médico:Paula Ortiz Ballujera NºCol: 17 17 85236. Historia Actual: El paciente era un varón de 31 años de edad que sufrió un accidente de motocicleta. La radiografía de tórax mostraba un ensanchamiento mediastínico. La TACHT al ingreso mostró un seudoaneurisma de aorta torácica distal a la salida de la arteria subclavia izquierda con un importante hematoma periaórtico y mediastínico asociado con hemotórax bilateral. Ingresó en la UCI, donde se consiguió un control estricto de la tensión arterial. A las 8 horas del traumatismo se colocó una endoprótesis en la aorta torácica descendente por vía ilíaca izquierda. La arteria subclavia izquierda quedó parcialmente ocluida sin repercusión clínica. A las 24 horas fue dado de alta a planta y a la semana se le dio el alta hospitalaria, ya que estaba asintomático. Remitido por: Dirección para correspondencia: Dra. Paula Ortiz Ballujera. Servicio de Medicina Intensiva (UCI). Hospital Universitari de Girona Doctor Josep Trueta. Avda. de França, s/n. 17007 Girona. España. Correo electrónico: ballujera@hotmail.com	[ "Nombre", ":", "Jedet", ".", "\n", "Apellidos", ":", "Sanchez", "Garcia", ".", "\n", "NHC", ":", "7845123", ".", "\n", "NASS", ":", "23", "56487946", "12", ".", "\n", "Domicilio", ":", "Carrer", "del", "Dr", ".", "Castany", "28", ",", "8A.", "\n", "Localidad/", "Provincia", ":", "Girona", ".", "\n", "CP", ":", "17002", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "14/09/1986", ".", "\n", "País", ":", "España", ".", "\n", "Edad", ":", "31", "años", "Sexo", ":", "H.", "\n", "Fecha", "de", "Ingreso", ":", "11/12/2017", ".", "\n", "Servicio", ":", "Medicina", "intensiva", ".", "\n", "Médico", ":", "Paula", "Ortiz", "Ballujera", "NºCol", ":", "17", "17", "85236", ".", "\n", "Historia", "Actual", ":", "El", "paciente", "era", "un", "varón", "de", "31", "años", "de", "edad", "que", "sufrió", "un", "accidente", "de", "motocicleta", ".", "La", "radiografía", "de", "tórax", "mostraba", "un", "ensanchamiento", "mediastínico", ".", "La", "TACHT", "al", "ingreso", "mostró", "un", "seudoaneurisma", "de", "aorta", "torácica", "distal", "a", "la", "salida", "de", "la", "arteria", "subclavia", "izquierda", "con", "un", "importante", "hematoma", "periaórtico", "y", "mediastínico", "asociado", "con", "hemotórax", "bilateral", ".", "\n", "Ingresó", "en", "la", "UCI", ",", "donde", "se", "consiguió", "un", "control", "estricto", "de", "la", "tensión", "arterial", ".", "A", "las", "8", "horas", "del", "traumatismo", "se", "colocó", "una", "endoprótesis", "en", "la", "aorta", "torácica", "descendente", "por", "vía", "ilíaca", "izquierda", ".", "La", "arteria", "subclavia", "izquierda", "quedó", "parcialmente", "ocluida", "sin", "repercusión", "clínica", ".", "A", "las", "24", "horas", "fue", "dado", "de", "alta", "a", "planta", "y", "a", "la", "semana", "se", "le", "dio", "el", "alta", "hospitalaria", ",", "ya", "que", "estaba", "asintomático", ".", "\n", "Remitido", "por", ":", "Dirección", "para", "correspondencia", ":", "Dra", ".", "Paula", "Ortiz", "Ballujera", ".", "Servicio", "de", "Medicina", "Intensiva", "(", "UCI", ")", ".", "Hospital", "Universitari", "de", "Girona", "Doctor", "Josep", "Trueta", ".", "Avda", ".", "de", "França", ",", "s", "/", "n.", "17007", "Girona", ".", "España", ".", "Correo", "electrónico", ":", "ballujera@hotmail.com", "\n" ]	[ "HOSPITAL", "CALLE", "CORREO_ELECTRONICO", "NOMBRE_PERSONAL_SANITARIO", "ID_ASEGURAMIENTO", "NOMBRE_SUJETO_ASISTENCIA", "ID_TITULACION_PERSONAL_SANITARIO", "FECHAS", "EDAD_SUJETO_ASISTENCIA", "ID_SUJETO_ASISTENCIA", "PAIS", "TERRITORIO", "SEXO_SUJETO_ASISTENCIA" ]
Jedet is a NOMBRE_SUJETO_ASISTENCIA, Sanchez Garcia is a NOMBRE_SUJETO_ASISTENCIA, 7845123 is a ID_SUJETO_ASISTENCIA, 23 56487946 12 is a ID_ASEGURAMIENTO, Girona is a TERRITORIO, 17002 is a TERRITORIO, 14/09/1986 is a FECHAS, España is a PAIS, 31 años is a EDAD_SUJETO_ASISTENCIA, 11/12/2017 is a FECHAS, Paula Ortiz Ballujera is a NOMBRE_PERSONAL_SANITARIO, 17 17 85236 is a ID_TITULACION_PERSONAL_SANITARIO, varón is a SEXO_SUJETO_ASISTENCIA, 31 años is a EDAD_SUJETO_ASISTENCIA, Paula Ortiz Ballujera is a NOMBRE_PERSONAL_SANITARIO, Hospital Universitari de Girona Doctor Josep Trueta is a HOSPITAL, 17007 is a TERRITORIO, Girona is a TERRITORIO, España is a PAIS, ballujera@hotmail.com is a CORREO_ELECTRONICO	97_task1	Sentence: Nombre: Jedet. Apellidos: Sanchez Garcia. NHC: 7845123. NASS: 23 56487946 12. Domicilio: Carrer del Dr. Castany 28, 8A. Localidad/ Provincia: Girona. CP: 17002. Datos asistenciales. Fecha de nacimiento: 14/09/1986. País: España. Edad: 31 años Sexo: H. Fecha de Ingreso: 11/12/2017. Servicio: Medicina intensiva. Médico:Paula Ortiz Ballujera NºCol: 17 17 85236. Historia Actual: El paciente era un varón de 31 años de edad que sufrió un accidente de motocicleta. La radiografía de tórax mostraba un ensanchamiento mediastínico. La TACHT al ingreso mostró un seudoaneurisma de aorta torácica distal a la salida de la arteria subclavia izquierda con un importante hematoma periaórtico y mediastínico asociado con hemotórax bilateral. Ingresó en la UCI, donde se consiguió un control estricto de la tensión arterial. A las 8 horas del traumatismo se colocó una endoprótesis en la aorta torácica descendente por vía ilíaca izquierda. La arteria subclavia izquierda quedó parcialmente ocluida sin repercusión clínica. A las 24 horas fue dado de alta a planta y a la semana se le dio el alta hospitalaria, ya que estaba asintomático. Remitido por: Dirección para correspondencia: Dra. Paula Ortiz Ballujera. Servicio de Medicina Intensiva (UCI). Hospital Universitari de Girona Doctor Josep Trueta. Avda. de França, s/n. 17007 Girona. España. Correo electrónico: ballujera@hotmail.com Instructions: please typing these entity words according to sentence: Jedet, Sanchez Garcia, 7845123, 23 56487946 12, Girona, 17002, 14/09/1986, España, 31 años, 11/12/2017, Paula Ortiz Ballujera, 17 17 85236, varón, 31 años, Paula Ortiz Ballujera, Hospital Universitari de Girona Doctor Josep Trueta, 17007, Girona, España, ballujera@hotmail.com Options: TERRITORIO, SEXO_SUJETO_ASISTENCIA, ID_SUJETO_ASISTENCIA, FECHAS, HOSPITAL, CORREO_ELECTRONICO, PAIS, EDAD_SUJETO_ASISTENCIA, ID_ASEGURAMIENTO, ID_TITULACION_PERSONAL_SANITARIO, NOMBRE_SUJETO_ASISTENCIA, NOMBRE_PERSONAL_SANITARIO	[ "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "B-TERRITORIO", "O", "B-PAIS", "O", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]	Nombre: Jedet. Apellidos: Sanchez Garcia. NHC: 7845123. NASS: 23 56487946 12. Domicilio: Carrer del Dr. Castany 28, 8A. Localidad/ Provincia: Girona. CP: 17002. Datos asistenciales. Fecha de nacimiento: 14/09/1986. País: España. Edad: 31 años Sexo: H. Fecha de Ingreso: 11/12/2017. Servicio: Medicina intensiva. Médico:Paula Ortiz Ballujera NºCol: 17 17 85236. Historia Actual: El paciente era un varón de 31 años de edad que sufrió un accidente de motocicleta. La radiografía de tórax mostraba un ensanchamiento mediastínico. La TACHT al ingreso mostró un seudoaneurisma de aorta torácica distal a la salida de la arteria subclavia izquierda con un importante hematoma periaórtico y mediastínico asociado con hemotórax bilateral. Ingresó en la UCI, donde se consiguió un control estricto de la tensión arterial. A las 8 horas del traumatismo se colocó una endoprótesis en la aorta torácica descendente por vía ilíaca izquierda. La arteria subclavia izquierda quedó parcialmente ocluida sin repercusión clínica. A las 24 horas fue dado de alta a planta y a la semana se le dio el alta hospitalaria, ya que estaba asintomático. Remitido por: Dirección para correspondencia: Dra. Paula Ortiz Ballujera. Servicio de Medicina Intensiva (UCI). Hospital Universitari de Girona Doctor Josep Trueta. Avda. de França, s/n. 17007 Girona. España. Correo electrónico: ballujera@hotmail.com	[ "Nombre", ":", "Jedet", ".", "\n", "Apellidos", ":", "Sanchez", "Garcia", ".", "\n", "NHC", ":", "7845123", ".", "\n", "NASS", ":", "23", "56487946", "12", ".", "\n", "Domicilio", ":", "Carrer", "del", "Dr", ".", "Castany", "28", ",", "8A.", "\n", "Localidad/", "Provincia", ":", "Girona", ".", "\n", "CP", ":", "17002", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "14/09/1986", ".", "\n", "País", ":", "España", ".", "\n", "Edad", ":", "31", "años", "Sexo", ":", "H.", "\n", "Fecha", "de", "Ingreso", ":", "11/12/2017", ".", "\n", "Servicio", ":", "Medicina", "intensiva", ".", "\n", "Médico", ":", "Paula", "Ortiz", "Ballujera", "NºCol", ":", "17", "17", "85236", ".", "\n", "Historia", "Actual", ":", "El", "paciente", "era", "un", "varón", "de", "31", "años", "de", "edad", "que", "sufrió", "un", "accidente", "de", "motocicleta", ".", "La", "radiografía", "de", "tórax", "mostraba", "un", "ensanchamiento", "mediastínico", ".", "La", "TACHT", "al", "ingreso", "mostró", "un", "seudoaneurisma", "de", "aorta", "torácica", "distal", "a", "la", "salida", "de", "la", "arteria", "subclavia", "izquierda", "con", "un", "importante", "hematoma", "periaórtico", "y", "mediastínico", "asociado", "con", "hemotórax", "bilateral", ".", "\n", "Ingresó", "en", "la", "UCI", ",", "donde", "se", "consiguió", "un", "control", "estricto", "de", "la", "tensión", "arterial", ".", "A", "las", "8", "horas", "del", "traumatismo", "se", "colocó", "una", "endoprótesis", "en", "la", "aorta", "torácica", "descendente", "por", "vía", "ilíaca", "izquierda", ".", "La", "arteria", "subclavia", "izquierda", "quedó", "parcialmente", "ocluida", "sin", "repercusión", "clínica", ".", "A", "las", "24", "horas", "fue", "dado", "de", "alta", "a", "planta", "y", "a", "la", "semana", "se", "le", "dio", "el", "alta", "hospitalaria", ",", "ya", "que", "estaba", "asintomático", ".", "\n", "Remitido", "por", ":", "Dirección", "para", "correspondencia", ":", "Dra", ".", "Paula", "Ortiz", "Ballujera", ".", "Servicio", "de", "Medicina", "Intensiva", "(", "UCI", ")", ".", "Hospital", "Universitari", "de", "Girona", "Doctor", "Josep", "Trueta", ".", "Avda", ".", "de", "França", ",", "s", "/", "n.", "17007", "Girona", ".", "España", ".", "Correo", "electrónico", ":", "ballujera@hotmail.com", "\n" ]	[ "HOSPITAL", "CALLE", "CORREO_ELECTRONICO", "NOMBRE_PERSONAL_SANITARIO", "ID_ASEGURAMIENTO", "NOMBRE_SUJETO_ASISTENCIA", "ID_TITULACION_PERSONAL_SANITARIO", "FECHAS", "EDAD_SUJETO_ASISTENCIA", "ID_SUJETO_ASISTENCIA", "PAIS", "TERRITORIO", "SEXO_SUJETO_ASISTENCIA" ]
Jedet, Sanchez Garcia, 7845123, 23 56487946 12, Girona, 17002, 14/09/1986, España, 31 años, 11/12/2017, Paula Ortiz Ballujera, 17 17 85236, varón, 31 años, Paula Ortiz Ballujera, Hospital Universitari de Girona Doctor Josep Trueta, 17007, Girona, España, ballujera@hotmail.com	97_task2	Sentence: Nombre: Jedet. Apellidos: Sanchez Garcia. NHC: 7845123. NASS: 23 56487946 12. Domicilio: Carrer del Dr. Castany 28, 8A. Localidad/ Provincia: Girona. CP: 17002. Datos asistenciales. Fecha de nacimiento: 14/09/1986. País: España. Edad: 31 años Sexo: H. Fecha de Ingreso: 11/12/2017. Servicio: Medicina intensiva. Médico:Paula Ortiz Ballujera NºCol: 17 17 85236. Historia Actual: El paciente era un varón de 31 años de edad que sufrió un accidente de motocicleta. La radiografía de tórax mostraba un ensanchamiento mediastínico. La TACHT al ingreso mostró un seudoaneurisma de aorta torácica distal a la salida de la arteria subclavia izquierda con un importante hematoma periaórtico y mediastínico asociado con hemotórax bilateral. Ingresó en la UCI, donde se consiguió un control estricto de la tensión arterial. A las 8 horas del traumatismo se colocó una endoprótesis en la aorta torácica descendente por vía ilíaca izquierda. La arteria subclavia izquierda quedó parcialmente ocluida sin repercusión clínica. A las 24 horas fue dado de alta a planta y a la semana se le dio el alta hospitalaria, ya que estaba asintomático. Remitido por: Dirección para correspondencia: Dra. Paula Ortiz Ballujera. Servicio de Medicina Intensiva (UCI). Hospital Universitari de Girona Doctor Josep Trueta. Avda. de França, s/n. 17007 Girona. España. Correo electrónico: ballujera@hotmail.com Instructions: please extract entity words from the input sentence	[ "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "B-TERRITORIO", "O", "B-PAIS", "O", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]	Nombre: Jedet. Apellidos: Sanchez Garcia. NHC: 7845123. NASS: 23 56487946 12. Domicilio: Carrer del Dr. Castany 28, 8A. Localidad/ Provincia: Girona. CP: 17002. Datos asistenciales. Fecha de nacimiento: 14/09/1986. País: España. Edad: 31 años Sexo: H. Fecha de Ingreso: 11/12/2017. Servicio: Medicina intensiva. Médico:Paula Ortiz Ballujera NºCol: 17 17 85236. Historia Actual: El paciente era un varón de 31 años de edad que sufrió un accidente de motocicleta. La radiografía de tórax mostraba un ensanchamiento mediastínico. La TACHT al ingreso mostró un seudoaneurisma de aorta torácica distal a la salida de la arteria subclavia izquierda con un importante hematoma periaórtico y mediastínico asociado con hemotórax bilateral. Ingresó en la UCI, donde se consiguió un control estricto de la tensión arterial. A las 8 horas del traumatismo se colocó una endoprótesis en la aorta torácica descendente por vía ilíaca izquierda. La arteria subclavia izquierda quedó parcialmente ocluida sin repercusión clínica. A las 24 horas fue dado de alta a planta y a la semana se le dio el alta hospitalaria, ya que estaba asintomático. Remitido por: Dirección para correspondencia: Dra. Paula Ortiz Ballujera. Servicio de Medicina Intensiva (UCI). Hospital Universitari de Girona Doctor Josep Trueta. Avda. de França, s/n. 17007 Girona. España. Correo electrónico: ballujera@hotmail.com	[ "Nombre", ":", "Jedet", ".", "\n", "Apellidos", ":", "Sanchez", "Garcia", ".", "\n", "NHC", ":", "7845123", ".", "\n", "NASS", ":", "23", "56487946", "12", ".", "\n", "Domicilio", ":", "Carrer", "del", "Dr", ".", "Castany", "28", ",", "8A.", "\n", "Localidad/", "Provincia", ":", "Girona", ".", "\n", "CP", ":", "17002", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "14/09/1986", ".", "\n", "País", ":", "España", ".", "\n", "Edad", ":", "31", "años", "Sexo", ":", "H.", "\n", "Fecha", "de", "Ingreso", ":", "11/12/2017", ".", "\n", "Servicio", ":", "Medicina", "intensiva", ".", "\n", "Médico", ":", "Paula", "Ortiz", "Ballujera", "NºCol", ":", "17", "17", "85236", ".", "\n", "Historia", "Actual", ":", "El", "paciente", "era", "un", "varón", "de", "31", "años", "de", "edad", "que", "sufrió", "un", "accidente", "de", "motocicleta", ".", "La", "radiografía", "de", "tórax", "mostraba", "un", "ensanchamiento", "mediastínico", ".", "La", "TACHT", "al", "ingreso", "mostró", "un", "seudoaneurisma", "de", "aorta", "torácica", "distal", "a", "la", "salida", "de", "la", "arteria", "subclavia", "izquierda", "con", "un", "importante", "hematoma", "periaórtico", "y", "mediastínico", "asociado", "con", "hemotórax", "bilateral", ".", "\n", "Ingresó", "en", "la", "UCI", ",", "donde", "se", "consiguió", "un", "control", "estricto", "de", "la", "tensión", "arterial", ".", "A", "las", "8", "horas", "del", "traumatismo", "se", "colocó", "una", "endoprótesis", "en", "la", "aorta", "torácica", "descendente", "por", "vía", "ilíaca", "izquierda", ".", "La", "arteria", "subclavia", "izquierda", "quedó", "parcialmente", "ocluida", "sin", "repercusión", "clínica", ".", "A", "las", "24", "horas", "fue", "dado", "de", "alta", "a", "planta", "y", "a", "la", "semana", "se", "le", "dio", "el", "alta", "hospitalaria", ",", "ya", "que", "estaba", "asintomático", ".", "\n", "Remitido", "por", ":", "Dirección", "para", "correspondencia", ":", "Dra", ".", "Paula", "Ortiz", "Ballujera", ".", "Servicio", "de", "Medicina", "Intensiva", "(", "UCI", ")", ".", "Hospital", "Universitari", "de", "Girona", "Doctor", "Josep", "Trueta", ".", "Avda", ".", "de", "França", ",", "s", "/", "n.", "17007", "Girona", ".", "España", ".", "Correo", "electrónico", ":", "ballujera@hotmail.com", "\n" ]	[ "HOSPITAL", "CALLE", "CORREO_ELECTRONICO", "NOMBRE_PERSONAL_SANITARIO", "ID_ASEGURAMIENTO", "NOMBRE_SUJETO_ASISTENCIA", "ID_TITULACION_PERSONAL_SANITARIO", "FECHAS", "EDAD_SUJETO_ASISTENCIA", "ID_SUJETO_ASISTENCIA", "PAIS", "TERRITORIO", "SEXO_SUJETO_ASISTENCIA" ]
review is an umlsterm, pediatrics is an umlsterm, war is an umlsterm, touch is an umlsterm, pediatrics is an umlsterm, standard is an umlsterm, the changing is an umlsterm, needs is an umlsterm, pediatrics is an umlsterm, pediatrics is an umlsterm, economic is an umlsterm, National is an umlsterm, population is an umlsterm, preventive is an umlsterm, care is an umlsterm, program is an umlsterm, public health is an umlsterm, plan is an umlsterm, need is an umlsterm, evaluation is an umlsterm, program is an umlsterm, need is an umlsterm, communication is an umlsterm	MonatsschriftKinderheilkunde.01480573.eng.abstr_task0	Sentence: This review summarizes some aspects of German pediatrics as it developed after world war II . Having lost its touch with international pediatrics regained its high standard during the late forties and fifties and now develops in concordance with the changing needs and the advances of pediatrics in a highly industialoized nation . As in other countries , the practice and structure of pediatrics have been influenced by changes in social attidudes and expectations , and by economic restrictions . National specifics are the high number of practicing pediatric population and emphasis on a highly structured and formalized preventive care program under a public health plan . The need for critical evaluation of this program is emphasized as is the need for better communication among subspecialties . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O" ]	This review summarizes some aspects of German pediatrics as it developed after world war II . Having lost its touch with international pediatrics regained its high standard during the late forties and fifties and now develops in concordance with the changing needs and the advances of pediatrics in a highly industialoized nation . As in other countries , the practice and structure of pediatrics have been influenced by changes in social attidudes and expectations , and by economic restrictions . National specifics are the high number of practicing pediatric population and emphasis on a highly structured and formalized preventive care program under a public health plan . The need for critical evaluation of this program is emphasized as is the need for better communication among subspecialties .	[ "This", "review", "summarizes", "some", "aspects", "of", "German", "pediatrics", "as", "it", "developed", "after", "world", "war", "II", ".", "Having", "lost", "its", "touch", "with", "international", "pediatrics", "regained", "its", "high", "standard", "during", "the", "late", "forties", "and", "fifties", "and", "now", "develops", "in", "concordance", "with", "the", "changing", "needs", "and", "the", "advances", "of", "pediatrics", "in", "a", "highly", "industialoized", "nation", ".", "As", "in", "other", "countries", ",", "the", "practice", "and", "structure", "of", "pediatrics", "have", "been", "influenced", "by", "changes", "in", "social", "attidudes", "and", "expectations", ",", "and", "by", "economic", "restrictions", ".", "National", "specifics", "are", "the", "high", "number", "of", "practicing", "pediatric", "population", "and", "emphasis", "on", "a", "highly", "structured", "and", "formalized", "preventive", "care", "program", "under", "a", "public", "health", "plan", ".", "The", "need", "for", "critical", "evaluation", "of", "this", "program", "is", "emphasized", "as", "is", "the", "need", "for", "better", "communication", "among", "subspecialties", "." ]	[ "umlsterm" ]
review is an umlsterm, pediatrics is an umlsterm, war is an umlsterm, touch is an umlsterm, pediatrics is an umlsterm, standard is an umlsterm, the changing is an umlsterm, needs is an umlsterm, pediatrics is an umlsterm, pediatrics is an umlsterm, economic is an umlsterm, National is an umlsterm, population is an umlsterm, preventive is an umlsterm, care is an umlsterm, program is an umlsterm, public health is an umlsterm, plan is an umlsterm, need is an umlsterm, evaluation is an umlsterm, program is an umlsterm, need is an umlsterm, communication is an umlsterm	MonatsschriftKinderheilkunde.01480573.eng.abstr_task1	Sentence: This review summarizes some aspects of German pediatrics as it developed after world war II . Having lost its touch with international pediatrics regained its high standard during the late forties and fifties and now develops in concordance with the changing needs and the advances of pediatrics in a highly industialoized nation . As in other countries , the practice and structure of pediatrics have been influenced by changes in social attidudes and expectations , and by economic restrictions . National specifics are the high number of practicing pediatric population and emphasis on a highly structured and formalized preventive care program under a public health plan . The need for critical evaluation of this program is emphasized as is the need for better communication among subspecialties . Instructions: please typing these entity words according to sentence: review, pediatrics, war, touch, pediatrics, standard, the changing, needs, pediatrics, pediatrics, economic, National, population, preventive, care, program, public health, plan, need, evaluation, program, need, communication Options: umlsterm	[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O" ]	This review summarizes some aspects of German pediatrics as it developed after world war II . Having lost its touch with international pediatrics regained its high standard during the late forties and fifties and now develops in concordance with the changing needs and the advances of pediatrics in a highly industialoized nation . As in other countries , the practice and structure of pediatrics have been influenced by changes in social attidudes and expectations , and by economic restrictions . National specifics are the high number of practicing pediatric population and emphasis on a highly structured and formalized preventive care program under a public health plan . The need for critical evaluation of this program is emphasized as is the need for better communication among subspecialties .	[ "This", "review", "summarizes", "some", "aspects", "of", "German", "pediatrics", "as", "it", "developed", "after", "world", "war", "II", ".", "Having", "lost", "its", "touch", "with", "international", "pediatrics", "regained", "its", "high", "standard", "during", "the", "late", "forties", "and", "fifties", "and", "now", "develops", "in", "concordance", "with", "the", "changing", "needs", "and", "the", "advances", "of", "pediatrics", "in", "a", "highly", "industialoized", "nation", ".", "As", "in", "other", "countries", ",", "the", "practice", "and", "structure", "of", "pediatrics", "have", "been", "influenced", "by", "changes", "in", "social", "attidudes", "and", "expectations", ",", "and", "by", "economic", "restrictions", ".", "National", "specifics", "are", "the", "high", "number", "of", "practicing", "pediatric", "population", "and", "emphasis", "on", "a", "highly", "structured", "and", "formalized", "preventive", "care", "program", "under", "a", "public", "health", "plan", ".", "The", "need", "for", "critical", "evaluation", "of", "this", "program", "is", "emphasized", "as", "is", "the", "need", "for", "better", "communication", "among", "subspecialties", "." ]	[ "umlsterm" ]
review, pediatrics, war, touch, pediatrics, standard, the changing, needs, pediatrics, pediatrics, economic, National, population, preventive, care, program, public health, plan, need, evaluation, program, need, communication	MonatsschriftKinderheilkunde.01480573.eng.abstr_task2	Sentence: This review summarizes some aspects of German pediatrics as it developed after world war II . Having lost its touch with international pediatrics regained its high standard during the late forties and fifties and now develops in concordance with the changing needs and the advances of pediatrics in a highly industialoized nation . As in other countries , the practice and structure of pediatrics have been influenced by changes in social attidudes and expectations , and by economic restrictions . National specifics are the high number of practicing pediatric population and emphasis on a highly structured and formalized preventive care program under a public health plan . The need for critical evaluation of this program is emphasized as is the need for better communication among subspecialties . Instructions: please extract entity words from the input sentence	[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O" ]	This review summarizes some aspects of German pediatrics as it developed after world war II . Having lost its touch with international pediatrics regained its high standard during the late forties and fifties and now develops in concordance with the changing needs and the advances of pediatrics in a highly industialoized nation . As in other countries , the practice and structure of pediatrics have been influenced by changes in social attidudes and expectations , and by economic restrictions . National specifics are the high number of practicing pediatric population and emphasis on a highly structured and formalized preventive care program under a public health plan . The need for critical evaluation of this program is emphasized as is the need for better communication among subspecialties .	[ "This", "review", "summarizes", "some", "aspects", "of", "German", "pediatrics", "as", "it", "developed", "after", "world", "war", "II", ".", "Having", "lost", "its", "touch", "with", "international", "pediatrics", "regained", "its", "high", "standard", "during", "the", "late", "forties", "and", "fifties", "and", "now", "develops", "in", "concordance", "with", "the", "changing", "needs", "and", "the", "advances", "of", "pediatrics", "in", "a", "highly", "industialoized", "nation", ".", "As", "in", "other", "countries", ",", "the", "practice", "and", "structure", "of", "pediatrics", "have", "been", "influenced", "by", "changes", "in", "social", "attidudes", "and", "expectations", ",", "and", "by", "economic", "restrictions", ".", "National", "specifics", "are", "the", "high", "number", "of", "practicing", "pediatric", "population", "and", "emphasis", "on", "a", "highly", "structured", "and", "formalized", "preventive", "care", "program", "under", "a", "public", "health", "plan", ".", "The", "need", "for", "critical", "evaluation", "of", "this", "program", "is", "emphasized", "as", "is", "the", "need", "for", "better", "communication", "among", "subspecialties", "." ]	[ "umlsterm" ]
patients is an umlsterm, operations is an umlsterm, arthritis is an umlsterm, os calcis is an umlsterm, fracture is an umlsterm, evaluation is an umlsterm, overall is an umlsterm, Outcome - questionnaire is an umlsterm, severity - symptom is an umlsterm, scale is an umlsterm, Carpaltunnel - syndrome is an umlsterm, evaluation is an umlsterm, analysis of variance is an umlsterm, ANOVA is an umlsterm, Pearson 's is an umlsterm, Os calcis is an umlsterm, fracture is an umlsterm, cause is an umlsterm, arthritis is an umlsterm, patients is an umlsterm, males is an umlsterm, females is an umlsterm, treatment is an umlsterm, fracture is an umlsterm, patients is an umlsterm, patients is an umlsterm, open is an umlsterm, plate is an umlsterm, trauma is an umlsterm, age is an umlsterm, time is an umlsterm, pain is an umlsterm, patients is an umlsterm, range of motion is an umlsterm, ankle joint is an umlsterm, patients is an umlsterm, evaluation is an umlsterm, arthritis is an umlsterm, ankle joint is an umlsterm, joint is an umlsterm, patients is an umlsterm, joint is an umlsterm, patients is an umlsterm, analysis is an umlsterm, os calcis is an umlsterm, fracture is an umlsterm, evaluation is an umlsterm, clinical - radiological is an umlsterm, evaluation is an umlsterm	DerUnfallchirurg.91020013.eng.abstr_task0	Sentence: In a long-term follow-up we evaluated 40 patients out of 55 ( 73 % ) with a subtalar fusion . The operations took place from 5/84 to 5/91 . In all cases the indication for the fusion was a post-traumatic arthritis after an intra-articular os calcis fracture . The evaluation of the overall results was carried out with three different scoring systems : a. The Hannover Scoring System . b. The Outcome-questionnaire , rating patient's complaints and the functional status based on the severity-symptom scale and functional status described for Carpaltunnel-syndrome by Levine et al. c . The clinical rating system ( CRS ) described by Kitaoka et al. The statistical evaluation was performed by analysis of variance ( ANOVA ) . Level of significance was based on P = 0.05 and calculation of Pearson's correlation coefficient . The Os calcis fracture was the cause for the subtalar arthritis in all 40 patients ( 33 males and 7 females ) . The primary treatment of the calcaneal fracture was conservative ( cons . ) using a plaster in 23 patients ( 57.5 % ) , while 17 patients ( 42.5 % ) underwent open reduction and plate fixation ( op . ) . The interval between trauma and subtalar fusion averaged 3.5 years ( 3 months to 20 years ) . The interval between subtalar fusion and follow-up averaged 5.2 years ( 4-14 years ) . The mean age at the time of reexamination was 47 years ( 26-61 years ) . In the present study , complete pain relief could be achieved in 21 ( 52.5 % ; 58 % op . , 50 % cons . ) patients . A relevant restriction in the range of motion in the ankle joint was found in 26 ( 65 % ; 76 % op . , 58 % cons . ) . In 23 patients ( 62 % ; 65 % op . , 59 % cons . ) the radiological evaluation revealed a grade 1 ° arthritis of the ankle joint , in the talonavicular joint in 17 patients ( 42.5 % ; 41 % op . , 45 % cons . ) , and in the calcaneo-cuboid joint in 14 patients ( 35 % ; 47 % . , 27 % cons . ) . The statistical analysis revealed a better outcome in the operative group compared with the conservative group , although the operated os calcis fractures in the majority were the more severe fracture types . In all evaluation systems a score between 61 and 69 points could be achieved with no significant difference between the operatively and conservatively treated groups and between the newly developed questionaire and the clinical-radiological scoring systems . For the questionaire this fulfills the requirements for a reliable outcome evaluation . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]	In a long-term follow-up we evaluated 40 patients out of 55 ( 73 % ) with a subtalar fusion . The operations took place from 5/84 to 5/91 . In all cases the indication for the fusion was a post-traumatic arthritis after an intra-articular os calcis fracture . The evaluation of the overall results was carried out with three different scoring systems : a. The Hannover Scoring System . b. The Outcome-questionnaire , rating patient's complaints and the functional status based on the severity-symptom scale and functional status described for Carpaltunnel-syndrome by Levine et al. c . The clinical rating system ( CRS ) described by Kitaoka et al. The statistical evaluation was performed by analysis of variance ( ANOVA ) . Level of significance was based on P = 0.05 and calculation of Pearson's correlation coefficient . The Os calcis fracture was the cause for the subtalar arthritis in all 40 patients ( 33 males and 7 females ) . The primary treatment of the calcaneal fracture was conservative ( cons . ) using a plaster in 23 patients ( 57.5 % ) , while 17 patients ( 42.5 % ) underwent open reduction and plate fixation ( op . ) . The interval between trauma and subtalar fusion averaged 3.5 years ( 3 months to 20 years ) . The interval between subtalar fusion and follow-up averaged 5.2 years ( 4-14 years ) . The mean age at the time of reexamination was 47 years ( 26-61 years ) . In the present study , complete pain relief could be achieved in 21 ( 52.5 % ; 58 % op . , 50 % cons . ) patients . A relevant restriction in the range of motion in the ankle joint was found in 26 ( 65 % ; 76 % op . , 58 % cons . ) . In 23 patients ( 62 % ; 65 % op . , 59 % cons . ) the radiological evaluation revealed a grade 1 ° arthritis of the ankle joint , in the talonavicular joint in 17 patients ( 42.5 % ; 41 % op . , 45 % cons . ) , and in the calcaneo-cuboid joint in 14 patients ( 35 % ; 47 % . , 27 % cons . ) . The statistical analysis revealed a better outcome in the operative group compared with the conservative group , although the operated os calcis fractures in the majority were the more severe fracture types . In all evaluation systems a score between 61 and 69 points could be achieved with no significant difference between the operatively and conservatively treated groups and between the newly developed questionaire and the clinical-radiological scoring systems . For the questionaire this fulfills the requirements for a reliable outcome evaluation .	[ "In", "a", "long", "-", "term", "follow", "-", "up", "we", "evaluated", "40", "patients", "out", "of", "55", "(", "73", "%", ")", "with", "a", "subtalar", "fusion", ".", "The", "operations", "took", "place", "from", "5/84", "to", "5/91", ".", "In", "all", "cases", "the", "indication", "for", "the", "fusion", "was", "a", "post", "-", "traumatic", "arthritis", "after", "an", "intra", "-", "articular", "os", "calcis", "fracture", ".", "The", "evaluation", "of", "the", "overall", "results", "was", "carried", "out", "with", "three", "different", "scoring", "systems", ":", "a.", "The", "Hannover", "Scoring", "System", ".", "b.", "The", "Outcome", "-", "questionnaire", ",", "rating", "patient", "'s", "complaints", "and", "the", "functional", "status", "based", "on", "the", "severity", "-", "symptom", "scale", "and", "functional", "status", "described", "for", "Carpaltunnel", "-", "syndrome", "by", "Levine", "et", "al", ".", "c", ".", "The", "clinical", "rating", "system", "(", "CRS", ")", "described", "by", "Kitaoka", "et", "al", ".", "The", "statistical", "evaluation", "was", "performed", "by", "analysis", "of", "variance", "(", "ANOVA", ")", ".", "Level", "of", "significance", "was", "based", "on", "P", "=", "0.05", "and", "calculation", "of", "Pearson", "'s", "correlation", "coefficient", ".", "The", "Os", "calcis", "fracture", "was", "the", "cause", "for", "the", "subtalar", "arthritis", "in", "all", "40", "patients", "(", "33", "males", "and", "7", "females", ")", ".", "The", "primary", "treatment", "of", "the", "calcaneal", "fracture", "was", "conservative", "(", "cons", ".", ")", "using", "a", "plaster", "in", "23", "patients", "(", "57.5", "%", ")", ",", "while", "17", "patients", "(", "42.5", "%", ")", "underwent", "open", "reduction", "and", "plate", "fixation", "(", "op", ".", ")", ".", "The", "interval", "between", "trauma", "and", "subtalar", "fusion", "averaged", "3.5", "years", "(", "3", "months", "to", "20", "years", ")", ".", "The", "interval", "between", "subtalar", "fusion", "and", "follow", "-", "up", "averaged", "5.2", "years", "(", "4", "-", "14", "years", ")", ".", "The", "mean", "age", "at", "the", "time", "of", "reexamination", "was", "47", "years", "(", "26", "-", "61", "years", ")", ".", "In", "the", "present", "study", ",", "complete", "pain", "relief", "could", "be", "achieved", "in", "21", "(", "52.5", "%", ";", "58", "%", "op", ".", ",", "50", "%", "cons", ".", ")", "patients", ".", "A", "relevant", "restriction", "in", "the", "range", "of", "motion", "in", "the", "ankle", "joint", "was", "found", "in", "26", "(", "65", "%", ";", "76", "%", "op", ".", ",", "58", "%", "cons", ".", ")", ".", "In", "23", "patients", "(", "62", "%", ";", "65", "%", "op", ".", ",", "59", "%", "cons", ".", ")", "the", "radiological", "evaluation", "revealed", "a", "grade", "1", "°", "arthritis", "of", "the", "ankle", "joint", ",", "in", "the", "talonavicular", "joint", "in", "17", "patients", "(", "42.5", "%", ";", "41", "%", "op", ".", ",", "45", "%", "cons", ".", ")", ",", "and", "in", "the", "calcaneo", "-", "cuboid", "joint", "in", "14", "patients", "(", "35", "%", ";", "47", "%", ".", ",", "27", "%", "cons", ".", ")", ".", "The", "statistical", "analysis", "revealed", "a", "better", "outcome", "in", "the", "operative", "group", "compared", "with", "the", "conservative", "group", ",", "although", "the", "operated", "os", "calcis", "fractures", "in", "the", "majority", "were", "the", "more", "severe", "fracture", "types", ".", "In", "all", "evaluation", "systems", "a", "score", "between", "61", "and", "69", "points", "could", "be", "achieved", "with", "no", "significant", "difference", "between", "the", "operatively", "and", "conservatively", "treated", "groups", "and", "between", "the", "newly", "developed", "questionaire", "and", "the", "clinical", "-", "radiological", "scoring", "systems", ".", "For", "the", "questionaire", "this", "fulfills", "the", "requirements", "for", "a", "reliable", "outcome", "evaluation", "." ]	[ "umlsterm" ]
patients is an umlsterm, operations is an umlsterm, arthritis is an umlsterm, os calcis is an umlsterm, fracture is an umlsterm, evaluation is an umlsterm, overall is an umlsterm, Outcome - questionnaire is an umlsterm, severity - symptom is an umlsterm, scale is an umlsterm, Carpaltunnel - syndrome is an umlsterm, evaluation is an umlsterm, analysis of variance is an umlsterm, ANOVA is an umlsterm, Pearson 's is an umlsterm, Os calcis is an umlsterm, fracture is an umlsterm, cause is an umlsterm, arthritis is an umlsterm, patients is an umlsterm, males is an umlsterm, females is an umlsterm, treatment is an umlsterm, fracture is an umlsterm, patients is an umlsterm, patients is an umlsterm, open is an umlsterm, plate is an umlsterm, trauma is an umlsterm, age is an umlsterm, time is an umlsterm, pain is an umlsterm, patients is an umlsterm, range of motion is an umlsterm, ankle joint is an umlsterm, patients is an umlsterm, evaluation is an umlsterm, arthritis is an umlsterm, ankle joint is an umlsterm, joint is an umlsterm, patients is an umlsterm, joint is an umlsterm, patients is an umlsterm, analysis is an umlsterm, os calcis is an umlsterm, fracture is an umlsterm, evaluation is an umlsterm, clinical - radiological is an umlsterm, evaluation is an umlsterm	DerUnfallchirurg.91020013.eng.abstr_task1	Sentence: In a long-term follow-up we evaluated 40 patients out of 55 ( 73 % ) with a subtalar fusion . The operations took place from 5/84 to 5/91 . In all cases the indication for the fusion was a post-traumatic arthritis after an intra-articular os calcis fracture . The evaluation of the overall results was carried out with three different scoring systems : a. The Hannover Scoring System . b. The Outcome-questionnaire , rating patient's complaints and the functional status based on the severity-symptom scale and functional status described for Carpaltunnel-syndrome by Levine et al. c . The clinical rating system ( CRS ) described by Kitaoka et al. The statistical evaluation was performed by analysis of variance ( ANOVA ) . Level of significance was based on P = 0.05 and calculation of Pearson's correlation coefficient . The Os calcis fracture was the cause for the subtalar arthritis in all 40 patients ( 33 males and 7 females ) . The primary treatment of the calcaneal fracture was conservative ( cons . ) using a plaster in 23 patients ( 57.5 % ) , while 17 patients ( 42.5 % ) underwent open reduction and plate fixation ( op . ) . The interval between trauma and subtalar fusion averaged 3.5 years ( 3 months to 20 years ) . The interval between subtalar fusion and follow-up averaged 5.2 years ( 4-14 years ) . The mean age at the time of reexamination was 47 years ( 26-61 years ) . In the present study , complete pain relief could be achieved in 21 ( 52.5 % ; 58 % op . , 50 % cons . ) patients . A relevant restriction in the range of motion in the ankle joint was found in 26 ( 65 % ; 76 % op . , 58 % cons . ) . In 23 patients ( 62 % ; 65 % op . , 59 % cons . ) the radiological evaluation revealed a grade 1 ° arthritis of the ankle joint , in the talonavicular joint in 17 patients ( 42.5 % ; 41 % op . , 45 % cons . ) , and in the calcaneo-cuboid joint in 14 patients ( 35 % ; 47 % . , 27 % cons . ) . The statistical analysis revealed a better outcome in the operative group compared with the conservative group , although the operated os calcis fractures in the majority were the more severe fracture types . In all evaluation systems a score between 61 and 69 points could be achieved with no significant difference between the operatively and conservatively treated groups and between the newly developed questionaire and the clinical-radiological scoring systems . For the questionaire this fulfills the requirements for a reliable outcome evaluation . Instructions: please typing these entity words according to sentence: patients, operations, arthritis, os calcis, fracture, evaluation, overall, Outcome - questionnaire, severity - symptom, scale, Carpaltunnel - syndrome, evaluation, analysis of variance, ANOVA, Pearson 's, Os calcis, fracture, cause, arthritis, patients, males, females, treatment, fracture, patients, patients, open, plate, trauma, age, time, pain, patients, range of motion, ankle joint, patients, evaluation, arthritis, ankle joint, joint, patients, joint, patients, analysis, os calcis, fracture, evaluation, clinical - radiological, evaluation Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]	In a long-term follow-up we evaluated 40 patients out of 55 ( 73 % ) with a subtalar fusion . The operations took place from 5/84 to 5/91 . In all cases the indication for the fusion was a post-traumatic arthritis after an intra-articular os calcis fracture . The evaluation of the overall results was carried out with three different scoring systems : a. The Hannover Scoring System . b. The Outcome-questionnaire , rating patient's complaints and the functional status based on the severity-symptom scale and functional status described for Carpaltunnel-syndrome by Levine et al. c . The clinical rating system ( CRS ) described by Kitaoka et al. The statistical evaluation was performed by analysis of variance ( ANOVA ) . Level of significance was based on P = 0.05 and calculation of Pearson's correlation coefficient . The Os calcis fracture was the cause for the subtalar arthritis in all 40 patients ( 33 males and 7 females ) . The primary treatment of the calcaneal fracture was conservative ( cons . ) using a plaster in 23 patients ( 57.5 % ) , while 17 patients ( 42.5 % ) underwent open reduction and plate fixation ( op . ) . The interval between trauma and subtalar fusion averaged 3.5 years ( 3 months to 20 years ) . The interval between subtalar fusion and follow-up averaged 5.2 years ( 4-14 years ) . The mean age at the time of reexamination was 47 years ( 26-61 years ) . In the present study , complete pain relief could be achieved in 21 ( 52.5 % ; 58 % op . , 50 % cons . ) patients . A relevant restriction in the range of motion in the ankle joint was found in 26 ( 65 % ; 76 % op . , 58 % cons . ) . In 23 patients ( 62 % ; 65 % op . , 59 % cons . ) the radiological evaluation revealed a grade 1 ° arthritis of the ankle joint , in the talonavicular joint in 17 patients ( 42.5 % ; 41 % op . , 45 % cons . ) , and in the calcaneo-cuboid joint in 14 patients ( 35 % ; 47 % . , 27 % cons . ) . The statistical analysis revealed a better outcome in the operative group compared with the conservative group , although the operated os calcis fractures in the majority were the more severe fracture types . In all evaluation systems a score between 61 and 69 points could be achieved with no significant difference between the operatively and conservatively treated groups and between the newly developed questionaire and the clinical-radiological scoring systems . For the questionaire this fulfills the requirements for a reliable outcome evaluation .	[ "In", "a", "long", "-", "term", "follow", "-", "up", "we", "evaluated", "40", "patients", "out", "of", "55", "(", "73", "%", ")", "with", "a", "subtalar", "fusion", ".", "The", "operations", "took", "place", "from", "5/84", "to", "5/91", ".", "In", "all", "cases", "the", "indication", "for", "the", "fusion", "was", "a", "post", "-", "traumatic", "arthritis", "after", "an", "intra", "-", "articular", "os", "calcis", "fracture", ".", "The", "evaluation", "of", "the", "overall", "results", "was", "carried", "out", "with", "three", "different", "scoring", "systems", ":", "a.", "The", "Hannover", "Scoring", "System", ".", "b.", "The", "Outcome", "-", "questionnaire", ",", "rating", "patient", "'s", "complaints", "and", "the", "functional", "status", "based", "on", "the", "severity", "-", "symptom", "scale", "and", "functional", "status", "described", "for", "Carpaltunnel", "-", "syndrome", "by", "Levine", "et", "al", ".", "c", ".", "The", "clinical", "rating", "system", "(", "CRS", ")", "described", "by", "Kitaoka", "et", "al", ".", "The", "statistical", "evaluation", "was", "performed", "by", "analysis", "of", "variance", "(", "ANOVA", ")", ".", "Level", "of", "significance", "was", "based", "on", "P", "=", "0.05", "and", "calculation", "of", "Pearson", "'s", "correlation", "coefficient", ".", "The", "Os", "calcis", "fracture", "was", "the", "cause", "for", "the", "subtalar", "arthritis", "in", "all", "40", "patients", "(", "33", "males", "and", "7", "females", ")", ".", "The", "primary", "treatment", "of", "the", "calcaneal", "fracture", "was", "conservative", "(", "cons", ".", ")", "using", "a", "plaster", "in", "23", "patients", "(", "57.5", "%", ")", ",", "while", "17", "patients", "(", "42.5", "%", ")", "underwent", "open", "reduction", "and", "plate", "fixation", "(", "op", ".", ")", ".", "The", "interval", "between", "trauma", "and", "subtalar", "fusion", "averaged", "3.5", "years", "(", "3", "months", "to", "20", "years", ")", ".", "The", "interval", "between", "subtalar", "fusion", "and", "follow", "-", "up", "averaged", "5.2", "years", "(", "4", "-", "14", "years", ")", ".", "The", "mean", "age", "at", "the", "time", "of", "reexamination", "was", "47", "years", "(", "26", "-", "61", "years", ")", ".", "In", "the", "present", "study", ",", "complete", "pain", "relief", "could", "be", "achieved", "in", "21", "(", "52.5", "%", ";", "58", "%", "op", ".", ",", "50", "%", "cons", ".", ")", "patients", ".", "A", "relevant", "restriction", "in", "the", "range", "of", "motion", "in", "the", "ankle", "joint", "was", "found", "in", "26", "(", "65", "%", ";", "76", "%", "op", ".", ",", "58", "%", "cons", ".", ")", ".", "In", "23", "patients", "(", "62", "%", ";", "65", "%", "op", ".", ",", "59", "%", "cons", ".", ")", "the", "radiological", "evaluation", "revealed", "a", "grade", "1", "°", "arthritis", "of", "the", "ankle", "joint", ",", "in", "the", "talonavicular", "joint", "in", "17", "patients", "(", "42.5", "%", ";", "41", "%", "op", ".", ",", "45", "%", "cons", ".", ")", ",", "and", "in", "the", "calcaneo", "-", "cuboid", "joint", "in", "14", "patients", "(", "35", "%", ";", "47", "%", ".", ",", "27", "%", "cons", ".", ")", ".", "The", "statistical", "analysis", "revealed", "a", "better", "outcome", "in", "the", "operative", "group", "compared", "with", "the", "conservative", "group", ",", "although", "the", "operated", "os", "calcis", "fractures", "in", "the", "majority", "were", "the", "more", "severe", "fracture", "types", ".", "In", "all", "evaluation", "systems", "a", "score", "between", "61", "and", "69", "points", "could", "be", "achieved", "with", "no", "significant", "difference", "between", "the", "operatively", "and", "conservatively", "treated", "groups", "and", "between", "the", "newly", "developed", "questionaire", "and", "the", "clinical", "-", "radiological", "scoring", "systems", ".", "For", "the", "questionaire", "this", "fulfills", "the", "requirements", "for", "a", "reliable", "outcome", "evaluation", "." ]	[ "umlsterm" ]
patients, operations, arthritis, os calcis, fracture, evaluation, overall, Outcome - questionnaire, severity - symptom, scale, Carpaltunnel - syndrome, evaluation, analysis of variance, ANOVA, Pearson 's, Os calcis, fracture, cause, arthritis, patients, males, females, treatment, fracture, patients, patients, open, plate, trauma, age, time, pain, patients, range of motion, ankle joint, patients, evaluation, arthritis, ankle joint, joint, patients, joint, patients, analysis, os calcis, fracture, evaluation, clinical - radiological, evaluation	DerUnfallchirurg.91020013.eng.abstr_task2	Sentence: In a long-term follow-up we evaluated 40 patients out of 55 ( 73 % ) with a subtalar fusion . The operations took place from 5/84 to 5/91 . In all cases the indication for the fusion was a post-traumatic arthritis after an intra-articular os calcis fracture . The evaluation of the overall results was carried out with three different scoring systems : a. The Hannover Scoring System . b. The Outcome-questionnaire , rating patient's complaints and the functional status based on the severity-symptom scale and functional status described for Carpaltunnel-syndrome by Levine et al. c . The clinical rating system ( CRS ) described by Kitaoka et al. The statistical evaluation was performed by analysis of variance ( ANOVA ) . Level of significance was based on P = 0.05 and calculation of Pearson's correlation coefficient . The Os calcis fracture was the cause for the subtalar arthritis in all 40 patients ( 33 males and 7 females ) . The primary treatment of the calcaneal fracture was conservative ( cons . ) using a plaster in 23 patients ( 57.5 % ) , while 17 patients ( 42.5 % ) underwent open reduction and plate fixation ( op . ) . The interval between trauma and subtalar fusion averaged 3.5 years ( 3 months to 20 years ) . The interval between subtalar fusion and follow-up averaged 5.2 years ( 4-14 years ) . The mean age at the time of reexamination was 47 years ( 26-61 years ) . In the present study , complete pain relief could be achieved in 21 ( 52.5 % ; 58 % op . , 50 % cons . ) patients . A relevant restriction in the range of motion in the ankle joint was found in 26 ( 65 % ; 76 % op . , 58 % cons . ) . In 23 patients ( 62 % ; 65 % op . , 59 % cons . ) the radiological evaluation revealed a grade 1 ° arthritis of the ankle joint , in the talonavicular joint in 17 patients ( 42.5 % ; 41 % op . , 45 % cons . ) , and in the calcaneo-cuboid joint in 14 patients ( 35 % ; 47 % . , 27 % cons . ) . The statistical analysis revealed a better outcome in the operative group compared with the conservative group , although the operated os calcis fractures in the majority were the more severe fracture types . In all evaluation systems a score between 61 and 69 points could be achieved with no significant difference between the operatively and conservatively treated groups and between the newly developed questionaire and the clinical-radiological scoring systems . For the questionaire this fulfills the requirements for a reliable outcome evaluation . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]	In a long-term follow-up we evaluated 40 patients out of 55 ( 73 % ) with a subtalar fusion . The operations took place from 5/84 to 5/91 . In all cases the indication for the fusion was a post-traumatic arthritis after an intra-articular os calcis fracture . The evaluation of the overall results was carried out with three different scoring systems : a. The Hannover Scoring System . b. The Outcome-questionnaire , rating patient's complaints and the functional status based on the severity-symptom scale and functional status described for Carpaltunnel-syndrome by Levine et al. c . The clinical rating system ( CRS ) described by Kitaoka et al. The statistical evaluation was performed by analysis of variance ( ANOVA ) . Level of significance was based on P = 0.05 and calculation of Pearson's correlation coefficient . The Os calcis fracture was the cause for the subtalar arthritis in all 40 patients ( 33 males and 7 females ) . The primary treatment of the calcaneal fracture was conservative ( cons . ) using a plaster in 23 patients ( 57.5 % ) , while 17 patients ( 42.5 % ) underwent open reduction and plate fixation ( op . ) . The interval between trauma and subtalar fusion averaged 3.5 years ( 3 months to 20 years ) . The interval between subtalar fusion and follow-up averaged 5.2 years ( 4-14 years ) . The mean age at the time of reexamination was 47 years ( 26-61 years ) . In the present study , complete pain relief could be achieved in 21 ( 52.5 % ; 58 % op . , 50 % cons . ) patients . A relevant restriction in the range of motion in the ankle joint was found in 26 ( 65 % ; 76 % op . , 58 % cons . ) . In 23 patients ( 62 % ; 65 % op . , 59 % cons . ) the radiological evaluation revealed a grade 1 ° arthritis of the ankle joint , in the talonavicular joint in 17 patients ( 42.5 % ; 41 % op . , 45 % cons . ) , and in the calcaneo-cuboid joint in 14 patients ( 35 % ; 47 % . , 27 % cons . ) . The statistical analysis revealed a better outcome in the operative group compared with the conservative group , although the operated os calcis fractures in the majority were the more severe fracture types . In all evaluation systems a score between 61 and 69 points could be achieved with no significant difference between the operatively and conservatively treated groups and between the newly developed questionaire and the clinical-radiological scoring systems . For the questionaire this fulfills the requirements for a reliable outcome evaluation .	[ "In", "a", "long", "-", "term", "follow", "-", "up", "we", "evaluated", "40", "patients", "out", "of", "55", "(", "73", "%", ")", "with", "a", "subtalar", "fusion", ".", "The", "operations", "took", "place", "from", "5/84", "to", "5/91", ".", "In", "all", "cases", "the", "indication", "for", "the", "fusion", "was", "a", "post", "-", "traumatic", "arthritis", "after", "an", "intra", "-", "articular", "os", "calcis", "fracture", ".", "The", "evaluation", "of", "the", "overall", "results", "was", "carried", "out", "with", "three", "different", "scoring", "systems", ":", "a.", "The", "Hannover", "Scoring", "System", ".", "b.", "The", "Outcome", "-", "questionnaire", ",", "rating", "patient", "'s", "complaints", "and", "the", "functional", "status", "based", "on", "the", "severity", "-", "symptom", "scale", "and", "functional", "status", "described", "for", "Carpaltunnel", "-", "syndrome", "by", "Levine", "et", "al", ".", "c", ".", "The", "clinical", "rating", "system", "(", "CRS", ")", "described", "by", "Kitaoka", "et", "al", ".", "The", "statistical", "evaluation", "was", "performed", "by", "analysis", "of", "variance", "(", "ANOVA", ")", ".", "Level", "of", "significance", "was", "based", "on", "P", "=", "0.05", "and", "calculation", "of", "Pearson", "'s", "correlation", "coefficient", ".", "The", "Os", "calcis", "fracture", "was", "the", "cause", "for", "the", "subtalar", "arthritis", "in", "all", "40", "patients", "(", "33", "males", "and", "7", "females", ")", ".", "The", "primary", "treatment", "of", "the", "calcaneal", "fracture", "was", "conservative", "(", "cons", ".", ")", "using", "a", "plaster", "in", "23", "patients", "(", "57.5", "%", ")", ",", "while", "17", "patients", "(", "42.5", "%", ")", "underwent", "open", "reduction", "and", "plate", "fixation", "(", "op", ".", ")", ".", "The", "interval", "between", "trauma", "and", "subtalar", "fusion", "averaged", "3.5", "years", "(", "3", "months", "to", "20", "years", ")", ".", "The", "interval", "between", "subtalar", "fusion", "and", "follow", "-", "up", "averaged", "5.2", "years", "(", "4", "-", "14", "years", ")", ".", "The", "mean", "age", "at", "the", "time", "of", "reexamination", "was", "47", "years", "(", "26", "-", "61", "years", ")", ".", "In", "the", "present", "study", ",", "complete", "pain", "relief", "could", "be", "achieved", "in", "21", "(", "52.5", "%", ";", "58", "%", "op", ".", ",", "50", "%", "cons", ".", ")", "patients", ".", "A", "relevant", "restriction", "in", "the", "range", "of", "motion", "in", "the", "ankle", "joint", "was", "found", "in", "26", "(", "65", "%", ";", "76", "%", "op", ".", ",", "58", "%", "cons", ".", ")", ".", "In", "23", "patients", "(", "62", "%", ";", "65", "%", "op", ".", ",", "59", "%", "cons", ".", ")", "the", "radiological", "evaluation", "revealed", "a", "grade", "1", "°", "arthritis", "of", "the", "ankle", "joint", ",", "in", "the", "talonavicular", "joint", "in", "17", "patients", "(", "42.5", "%", ";", "41", "%", "op", ".", ",", "45", "%", "cons", ".", ")", ",", "and", "in", "the", "calcaneo", "-", "cuboid", "joint", "in", "14", "patients", "(", "35", "%", ";", "47", "%", ".", ",", "27", "%", "cons", ".", ")", ".", "The", "statistical", "analysis", "revealed", "a", "better", "outcome", "in", "the", "operative", "group", "compared", "with", "the", "conservative", "group", ",", "although", "the", "operated", "os", "calcis", "fractures", "in", "the", "majority", "were", "the", "more", "severe", "fracture", "types", ".", "In", "all", "evaluation", "systems", "a", "score", "between", "61", "and", "69", "points", "could", "be", "achieved", "with", "no", "significant", "difference", "between", "the", "operatively", "and", "conservatively", "treated", "groups", "and", "between", "the", "newly", "developed", "questionaire", "and", "the", "clinical", "-", "radiological", "scoring", "systems", ".", "For", "the", "questionaire", "this", "fulfills", "the", "requirements", "for", "a", "reliable", "outcome", "evaluation", "." ]	[ "umlsterm" ]
2,3-dihydrobenzofuran is a IUPAC, analogues is a MODIFIER, amphetamines is a FAMILY, LSD tartrate is a IUPAC, [ 125I]-(R)-DOI is a IUPAC, ( 125I]-(R)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane ) is a IUPAC, 1-(5-methoxy-2,3-dihydrobenzofuran-4-yl)-2-aminopropane is a IUPAC, 7-brominated is a PARTIUPAC, analogue is a MODIFIER, 1-(2,5-dimethoxyphenyl)-2-aminopropane is a IUPAC, 4-bromo is a PARTIUPAC, derivative is a MODIFIER, DOB is a ABBREVIATION, dihydrofuran is a TRIVIAL, 5-methoxy is a PARTIUPAC, groups is a MODIFIER, bromine is a TRIVIAL, bromine is a TRIVIAL, atom is a MODIFIER, 5-methoxy is a PARTIUPAC	example-61_task0	Sentence: Two 2,3-dihydrobenzofuran analogues of hallucinogenic amphetamines were prepared and evaluated for activity in the two-lever drug-discrimination paradigm in rats trained to discriminate saline from LSD tartrate (0.08 mg/kg) and for the ability to displace [125I]-(R)-DOI [( 125I]-(R)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane) from rat cortical homogenate 5-HT2 receptors. The compounds, 1-(5-methoxy-2,3-dihydrobenzofuran-4-yl)-2-aminopropane (6a) and its 7-brominated analogue 6b, possessed activity comparable to their conformationally flexible counterparts 1-(2,5-dimethoxyphenyl)-2-aminopropane (3) and its 4-bromo derivative DOB (5), respectively. The results suggest that the dihydrofuran ring in 6a and 6b models the active conformation of the 5-methoxy groups in 3 and 5. Free energy of binding, derived from radioligand displacement KA values, indicated that addition of the bromine in either series contributes 2.4-3.2 kcal/mol of binding energy. On the basis of surface area of the bromine atom, this value is 2-3 times higher than would be expected on the basis of hydrophobic binding. Thus, hydrophobicity of the para substituent alone cannot account for the dramatic enhancement of hallucinogenic activity. Although this substituent may play a minor role in orienting the conformation of the 5-methoxy groupin derivatives such as 4 and 5, there appears to be some other, as yet unknown, critical receptor interaction. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: IUPAC, TRIVIAL, FAMILY, PARTIUPAC, MODIFIER, ABBREVIATION	[ "O", "B-IUPAC", "B-MODIFIER", "O", "O", "B-FAMILY", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-IUPAC", "I-IUPAC", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-IUPAC", "I-IUPAC", "O", "B-IUPAC", "I-IUPAC", "I-IUPAC", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-IUPAC", "O", "O", "O", "O", "O", "B-PARTIUPAC", "B-MODIFIER", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-IUPAC", "O", "O", "O", "O", "O", "B-PARTIUPAC", "B-MODIFIER", "B-ABBREVIATION", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PARTIUPAC", "B-MODIFIER", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "B-MODIFIER", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PARTIUPAC", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Two 2,3-dihydrobenzofuran analogues of hallucinogenic amphetamines were prepared and evaluated for activity in the two-lever drug-discrimination paradigm in rats trained to discriminate saline from LSD tartrate (0.08 mg/kg) and for the ability to displace [125I]-(R)-DOI [( 125I]-(R)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane) from rat cortical homogenate 5-HT2 receptors. The compounds, 1-(5-methoxy-2,3-dihydrobenzofuran-4-yl)-2-aminopropane (6a) and its 7-brominated analogue 6b, possessed activity comparable to their conformationally flexible counterparts 1-(2,5-dimethoxyphenyl)-2-aminopropane (3) and its 4-bromo derivative DOB (5), respectively. The results suggest that the dihydrofuran ring in 6a and 6b models the active conformation of the 5-methoxy groups in 3 and 5. Free energy of binding, derived from radioligand displacement KA values, indicated that addition of the bromine in either series contributes 2.4-3.2 kcal/mol of binding energy. On the basis of surface area of the bromine atom, this value is 2-3 times higher than would be expected on the basis of hydrophobic binding. Thus, hydrophobicity of the para substituent alone cannot account for the dramatic enhancement of hallucinogenic activity. Although this substituent may play a minor role in orienting the conformation of the 5-methoxy groupin derivatives such as 4 and 5, there appears to be some other, as yet unknown, critical receptor interaction.	[ "Two", "2,3-dihydrobenzofuran", "analogues", "of", "hallucinogenic", "amphetamines", "were", "prepared", "and", "evaluated", "for", "activity", "in", "the", "two", "-", "lever", "drug", "-", "discrimination", "paradigm", "in", "rats", "trained", "to", "discriminate", "saline", "from", "LSD", "tartrate", "(", "0.08", "mg", "/", "kg", ")", "and", "for", "the", "ability", "to", "displace", "[", "125I]-(R)-DOI", "[", "(", "125I]-(R)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane", ")", "from", "rat", "cortical", "homogenate", "5-HT2", "receptors", ".", "The", "compounds", ",", "1-(5-methoxy-2,3-dihydrobenzofuran-4-yl)-2-aminopropane", "(", "6a", ")", "and", "its", "7-brominated", "analogue", "6b", ",", "possessed", "activity", "comparable", "to", "their", "conformationally", "flexible", "counterparts", "1-(2,5-dimethoxyphenyl)-2-aminopropane", "(", "3", ")", "and", "its", "4-bromo", "derivative", "DOB", "(", "5", ")", ",", "respectively", ".", "The", "results", "suggest", "that", "the", "dihydrofuran", "ring", "in", "6a", "and", "6b", "models", "the", "active", "conformation", "of", "the", "5-methoxy", "groups", "in", "3", "and", "5", ".", "Free", "energy", "of", "binding", ",", "derived", "from", "radioligand", "displacement", "KA", "values", ",", "indicated", "that", "addition", "of", "the", "bromine", "in", "either", "series", "contributes", "2.4", "-", "3.2", "kcal", "/", "mol", "of", "binding", "energy", ".", "On", "the", "basis", "of", "surface", "area", "of", "the", "bromine", "atom", ",", "this", "value", "is", "2", "-", "3", "times", "higher", "than", "would", "be", "expected", "on", "the", "basis", "of", "hydrophobic", "binding", ".", "Thus", ",", "hydrophobicity", "of", "the", "para", "substituent", "alone", "cannot", "account", "for", "the", "dramatic", "enhancement", "of", "hallucinogenic", "activity", ".", "Although", "this", "substituent", "may", "play", "a", "minor", "role", "in", "orienting", "the", "conformation", "of", "the", "5-methoxy", "groupin", " ", "derivatives", "such", "as", "4", "and", "5", ",", "there", "appears", "to", "be", "some", "other", ",", "as", "yet", "unknown", ",", "critical", "receptor", "interaction", "." ]	[ "IUPAC", "FAMILY", "PARTIUPAC", "TRIVIAL", "MODIFIER", "ABBREVIATION" ]
2,3-dihydrobenzofuran is a IUPAC, analogues is a MODIFIER, amphetamines is a FAMILY, LSD tartrate is a IUPAC, [ 125I]-(R)-DOI is a IUPAC, ( 125I]-(R)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane ) is a IUPAC, 1-(5-methoxy-2,3-dihydrobenzofuran-4-yl)-2-aminopropane is a IUPAC, 7-brominated is a PARTIUPAC, analogue is a MODIFIER, 1-(2,5-dimethoxyphenyl)-2-aminopropane is a IUPAC, 4-bromo is a PARTIUPAC, derivative is a MODIFIER, DOB is a ABBREVIATION, dihydrofuran is a TRIVIAL, 5-methoxy is a PARTIUPAC, groups is a MODIFIER, bromine is a TRIVIAL, bromine is a TRIVIAL, atom is a MODIFIER, 5-methoxy is a PARTIUPAC	example-61_task1	Sentence: Two 2,3-dihydrobenzofuran analogues of hallucinogenic amphetamines were prepared and evaluated for activity in the two-lever drug-discrimination paradigm in rats trained to discriminate saline from LSD tartrate (0.08 mg/kg) and for the ability to displace [125I]-(R)-DOI [( 125I]-(R)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane) from rat cortical homogenate 5-HT2 receptors. The compounds, 1-(5-methoxy-2,3-dihydrobenzofuran-4-yl)-2-aminopropane (6a) and its 7-brominated analogue 6b, possessed activity comparable to their conformationally flexible counterparts 1-(2,5-dimethoxyphenyl)-2-aminopropane (3) and its 4-bromo derivative DOB (5), respectively. The results suggest that the dihydrofuran ring in 6a and 6b models the active conformation of the 5-methoxy groups in 3 and 5. Free energy of binding, derived from radioligand displacement KA values, indicated that addition of the bromine in either series contributes 2.4-3.2 kcal/mol of binding energy. On the basis of surface area of the bromine atom, this value is 2-3 times higher than would be expected on the basis of hydrophobic binding. Thus, hydrophobicity of the para substituent alone cannot account for the dramatic enhancement of hallucinogenic activity. Although this substituent may play a minor role in orienting the conformation of the 5-methoxy groupin derivatives such as 4 and 5, there appears to be some other, as yet unknown, critical receptor interaction. Instructions: please typing these entity words according to sentence: 2,3-dihydrobenzofuran, analogues, amphetamines, LSD tartrate, [ 125I]-(R)-DOI, ( 125I]-(R)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane ), 1-(5-methoxy-2,3-dihydrobenzofuran-4-yl)-2-aminopropane, 7-brominated, analogue, 1-(2,5-dimethoxyphenyl)-2-aminopropane, 4-bromo, derivative, DOB, dihydrofuran, 5-methoxy, groups, bromine, bromine, atom, 5-methoxy Options: IUPAC, TRIVIAL, FAMILY, PARTIUPAC, MODIFIER, ABBREVIATION	[ "O", "B-IUPAC", "B-MODIFIER", "O", "O", "B-FAMILY", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-IUPAC", "I-IUPAC", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-IUPAC", "I-IUPAC", "O", "B-IUPAC", "I-IUPAC", "I-IUPAC", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-IUPAC", "O", "O", "O", "O", "O", "B-PARTIUPAC", "B-MODIFIER", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-IUPAC", "O", "O", "O", "O", "O", "B-PARTIUPAC", "B-MODIFIER", "B-ABBREVIATION", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PARTIUPAC", "B-MODIFIER", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "B-MODIFIER", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PARTIUPAC", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Two 2,3-dihydrobenzofuran analogues of hallucinogenic amphetamines were prepared and evaluated for activity in the two-lever drug-discrimination paradigm in rats trained to discriminate saline from LSD tartrate (0.08 mg/kg) and for the ability to displace [125I]-(R)-DOI [( 125I]-(R)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane) from rat cortical homogenate 5-HT2 receptors. The compounds, 1-(5-methoxy-2,3-dihydrobenzofuran-4-yl)-2-aminopropane (6a) and its 7-brominated analogue 6b, possessed activity comparable to their conformationally flexible counterparts 1-(2,5-dimethoxyphenyl)-2-aminopropane (3) and its 4-bromo derivative DOB (5), respectively. The results suggest that the dihydrofuran ring in 6a and 6b models the active conformation of the 5-methoxy groups in 3 and 5. Free energy of binding, derived from radioligand displacement KA values, indicated that addition of the bromine in either series contributes 2.4-3.2 kcal/mol of binding energy. On the basis of surface area of the bromine atom, this value is 2-3 times higher than would be expected on the basis of hydrophobic binding. Thus, hydrophobicity of the para substituent alone cannot account for the dramatic enhancement of hallucinogenic activity. Although this substituent may play a minor role in orienting the conformation of the 5-methoxy groupin derivatives such as 4 and 5, there appears to be some other, as yet unknown, critical receptor interaction.	[ "Two", "2,3-dihydrobenzofuran", "analogues", "of", "hallucinogenic", "amphetamines", "were", "prepared", "and", "evaluated", "for", "activity", "in", "the", "two", "-", "lever", "drug", "-", "discrimination", "paradigm", "in", "rats", "trained", "to", "discriminate", "saline", "from", "LSD", "tartrate", "(", "0.08", "mg", "/", "kg", ")", "and", "for", "the", "ability", "to", "displace", "[", "125I]-(R)-DOI", "[", "(", "125I]-(R)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane", ")", "from", "rat", "cortical", "homogenate", "5-HT2", "receptors", ".", "The", "compounds", ",", "1-(5-methoxy-2,3-dihydrobenzofuran-4-yl)-2-aminopropane", "(", "6a", ")", "and", "its", "7-brominated", "analogue", "6b", ",", "possessed", "activity", "comparable", "to", "their", "conformationally", "flexible", "counterparts", "1-(2,5-dimethoxyphenyl)-2-aminopropane", "(", "3", ")", "and", "its", "4-bromo", "derivative", "DOB", "(", "5", ")", ",", "respectively", ".", "The", "results", "suggest", "that", "the", "dihydrofuran", "ring", "in", "6a", "and", "6b", "models", "the", "active", "conformation", "of", "the", "5-methoxy", "groups", "in", "3", "and", "5", ".", "Free", "energy", "of", "binding", ",", "derived", "from", "radioligand", "displacement", "KA", "values", ",", "indicated", "that", "addition", "of", "the", "bromine", "in", "either", "series", "contributes", "2.4", "-", "3.2", "kcal", "/", "mol", "of", "binding", "energy", ".", "On", "the", "basis", "of", "surface", "area", "of", "the", "bromine", "atom", ",", "this", "value", "is", "2", "-", "3", "times", "higher", "than", "would", "be", "expected", "on", "the", "basis", "of", "hydrophobic", "binding", ".", "Thus", ",", "hydrophobicity", "of", "the", "para", "substituent", "alone", "cannot", "account", "for", "the", "dramatic", "enhancement", "of", "hallucinogenic", "activity", ".", "Although", "this", "substituent", "may", "play", "a", "minor", "role", "in", "orienting", "the", "conformation", "of", "the", "5-methoxy", "groupin", " ", "derivatives", "such", "as", "4", "and", "5", ",", "there", "appears", "to", "be", "some", "other", ",", "as", "yet", "unknown", ",", "critical", "receptor", "interaction", "." ]	[ "IUPAC", "FAMILY", "PARTIUPAC", "TRIVIAL", "MODIFIER", "ABBREVIATION" ]
2,3-dihydrobenzofuran, analogues, amphetamines, LSD tartrate, [ 125I]-(R)-DOI, ( 125I]-(R)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane ), 1-(5-methoxy-2,3-dihydrobenzofuran-4-yl)-2-aminopropane, 7-brominated, analogue, 1-(2,5-dimethoxyphenyl)-2-aminopropane, 4-bromo, derivative, DOB, dihydrofuran, 5-methoxy, groups, bromine, bromine, atom, 5-methoxy	example-61_task2	Sentence: Two 2,3-dihydrobenzofuran analogues of hallucinogenic amphetamines were prepared and evaluated for activity in the two-lever drug-discrimination paradigm in rats trained to discriminate saline from LSD tartrate (0.08 mg/kg) and for the ability to displace [125I]-(R)-DOI [( 125I]-(R)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane) from rat cortical homogenate 5-HT2 receptors. The compounds, 1-(5-methoxy-2,3-dihydrobenzofuran-4-yl)-2-aminopropane (6a) and its 7-brominated analogue 6b, possessed activity comparable to their conformationally flexible counterparts 1-(2,5-dimethoxyphenyl)-2-aminopropane (3) and its 4-bromo derivative DOB (5), respectively. The results suggest that the dihydrofuran ring in 6a and 6b models the active conformation of the 5-methoxy groups in 3 and 5. Free energy of binding, derived from radioligand displacement KA values, indicated that addition of the bromine in either series contributes 2.4-3.2 kcal/mol of binding energy. On the basis of surface area of the bromine atom, this value is 2-3 times higher than would be expected on the basis of hydrophobic binding. Thus, hydrophobicity of the para substituent alone cannot account for the dramatic enhancement of hallucinogenic activity. Although this substituent may play a minor role in orienting the conformation of the 5-methoxy groupin derivatives such as 4 and 5, there appears to be some other, as yet unknown, critical receptor interaction. Instructions: please extract entity words from the input sentence	[ "O", "B-IUPAC", "B-MODIFIER", "O", "O", "B-FAMILY", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-IUPAC", "I-IUPAC", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-IUPAC", "I-IUPAC", "O", "B-IUPAC", "I-IUPAC", "I-IUPAC", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-IUPAC", "O", "O", "O", "O", "O", "B-PARTIUPAC", "B-MODIFIER", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-IUPAC", "O", "O", "O", "O", "O", "B-PARTIUPAC", "B-MODIFIER", "B-ABBREVIATION", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PARTIUPAC", "B-MODIFIER", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "B-MODIFIER", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PARTIUPAC", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Two 2,3-dihydrobenzofuran analogues of hallucinogenic amphetamines were prepared and evaluated for activity in the two-lever drug-discrimination paradigm in rats trained to discriminate saline from LSD tartrate (0.08 mg/kg) and for the ability to displace [125I]-(R)-DOI [( 125I]-(R)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane) from rat cortical homogenate 5-HT2 receptors. The compounds, 1-(5-methoxy-2,3-dihydrobenzofuran-4-yl)-2-aminopropane (6a) and its 7-brominated analogue 6b, possessed activity comparable to their conformationally flexible counterparts 1-(2,5-dimethoxyphenyl)-2-aminopropane (3) and its 4-bromo derivative DOB (5), respectively. The results suggest that the dihydrofuran ring in 6a and 6b models the active conformation of the 5-methoxy groups in 3 and 5. Free energy of binding, derived from radioligand displacement KA values, indicated that addition of the bromine in either series contributes 2.4-3.2 kcal/mol of binding energy. On the basis of surface area of the bromine atom, this value is 2-3 times higher than would be expected on the basis of hydrophobic binding. Thus, hydrophobicity of the para substituent alone cannot account for the dramatic enhancement of hallucinogenic activity. Although this substituent may play a minor role in orienting the conformation of the 5-methoxy groupin derivatives such as 4 and 5, there appears to be some other, as yet unknown, critical receptor interaction.	[ "Two", "2,3-dihydrobenzofuran", "analogues", "of", "hallucinogenic", "amphetamines", "were", "prepared", "and", "evaluated", "for", "activity", "in", "the", "two", "-", "lever", "drug", "-", "discrimination", "paradigm", "in", "rats", "trained", "to", "discriminate", "saline", "from", "LSD", "tartrate", "(", "0.08", "mg", "/", "kg", ")", "and", "for", "the", "ability", "to", "displace", "[", "125I]-(R)-DOI", "[", "(", "125I]-(R)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane", ")", "from", "rat", "cortical", "homogenate", "5-HT2", "receptors", ".", "The", "compounds", ",", "1-(5-methoxy-2,3-dihydrobenzofuran-4-yl)-2-aminopropane", "(", "6a", ")", "and", "its", "7-brominated", "analogue", "6b", ",", "possessed", "activity", "comparable", "to", "their", "conformationally", "flexible", "counterparts", "1-(2,5-dimethoxyphenyl)-2-aminopropane", "(", "3", ")", "and", "its", "4-bromo", "derivative", "DOB", "(", "5", ")", ",", "respectively", ".", "The", "results", "suggest", "that", "the", "dihydrofuran", "ring", "in", "6a", "and", "6b", "models", "the", "active", "conformation", "of", "the", "5-methoxy", "groups", "in", "3", "and", "5", ".", "Free", "energy", "of", "binding", ",", "derived", "from", "radioligand", "displacement", "KA", "values", ",", "indicated", "that", "addition", "of", "the", "bromine", "in", "either", "series", "contributes", "2.4", "-", "3.2", "kcal", "/", "mol", "of", "binding", "energy", ".", "On", "the", "basis", "of", "surface", "area", "of", "the", "bromine", "atom", ",", "this", "value", "is", "2", "-", "3", "times", "higher", "than", "would", "be", "expected", "on", "the", "basis", "of", "hydrophobic", "binding", ".", "Thus", ",", "hydrophobicity", "of", "the", "para", "substituent", "alone", "cannot", "account", "for", "the", "dramatic", "enhancement", "of", "hallucinogenic", "activity", ".", "Although", "this", "substituent", "may", "play", "a", "minor", "role", "in", "orienting", "the", "conformation", "of", "the", "5-methoxy", "groupin", " ", "derivatives", "such", "as", "4", "and", "5", ",", "there", "appears", "to", "be", "some", "other", ",", "as", "yet", "unknown", ",", "critical", "receptor", "interaction", "." ]	[ "IUPAC", "FAMILY", "PARTIUPAC", "TRIVIAL", "MODIFIER", "ABBREVIATION" ]
pseudoexfoliation syndrome is an umlsterm, Evaluation is an umlsterm, cell is an umlsterm, cataract extraction is an umlsterm, eyes is an umlsterm	DerOpthalmologe.70940332.eng.abstr_task0	Sentence: Introduction : Corneal endothelial involvement can be found in pseudoexfoliation syndrome ( PEX ) . Evaluation of possible differences in endothelial cell loss following cataract extraction was compared to normal eyes . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O" ]	Introduction : Corneal endothelial involvement can be found in pseudoexfoliation syndrome ( PEX ) . Evaluation of possible differences in endothelial cell loss following cataract extraction was compared to normal eyes .	[ "Introduction", ":", "Corneal", "endothelial", "involvement", "can", "be", "found", "in", "pseudoexfoliation", "syndrome", "(", "PEX", ")", ".", "Evaluation", "of", "possible", "differences", "in", "endothelial", "cell", "loss", "following", "cataract", "extraction", "was", "compared", "to", "normal", "eyes", "." ]	[ "umlsterm" ]
pseudoexfoliation syndrome is an umlsterm, Evaluation is an umlsterm, cell is an umlsterm, cataract extraction is an umlsterm, eyes is an umlsterm	DerOpthalmologe.70940332.eng.abstr_task1	Sentence: Introduction : Corneal endothelial involvement can be found in pseudoexfoliation syndrome ( PEX ) . Evaluation of possible differences in endothelial cell loss following cataract extraction was compared to normal eyes . Instructions: please typing these entity words according to sentence: pseudoexfoliation syndrome, Evaluation, cell, cataract extraction, eyes Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O" ]	Introduction : Corneal endothelial involvement can be found in pseudoexfoliation syndrome ( PEX ) . Evaluation of possible differences in endothelial cell loss following cataract extraction was compared to normal eyes .	[ "Introduction", ":", "Corneal", "endothelial", "involvement", "can", "be", "found", "in", "pseudoexfoliation", "syndrome", "(", "PEX", ")", ".", "Evaluation", "of", "possible", "differences", "in", "endothelial", "cell", "loss", "following", "cataract", "extraction", "was", "compared", "to", "normal", "eyes", "." ]	[ "umlsterm" ]
pseudoexfoliation syndrome, Evaluation, cell, cataract extraction, eyes	DerOpthalmologe.70940332.eng.abstr_task2	Sentence: Introduction : Corneal endothelial involvement can be found in pseudoexfoliation syndrome ( PEX ) . Evaluation of possible differences in endothelial cell loss following cataract extraction was compared to normal eyes . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O" ]	Introduction : Corneal endothelial involvement can be found in pseudoexfoliation syndrome ( PEX ) . Evaluation of possible differences in endothelial cell loss following cataract extraction was compared to normal eyes .	[ "Introduction", ":", "Corneal", "endothelial", "involvement", "can", "be", "found", "in", "pseudoexfoliation", "syndrome", "(", "PEX", ")", ".", "Evaluation", "of", "possible", "differences", "in", "endothelial", "cell", "loss", "following", "cataract", "extraction", "was", "compared", "to", "normal", "eyes", "." ]	[ "umlsterm" ]
DICO is a CHEMICAL, flavonoid is a CHEMICAL	23567243_task0	Sentence: DICO, a novel nonaromatic B-ring flavonoid, induces G2/M cell cycle arrest and apoptosis in human hepatoma cells. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: CHEMICAL	[ "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	DICO, a novel nonaromatic B-ring flavonoid, induces G2/M cell cycle arrest and apoptosis in human hepatoma cells.	[ "DICO", ",", "a", "novel", "nonaromatic", "B", "-", "ring", "flavonoid", ",", "induces", "G2", "/", "M", "cell", "cycle", "arrest", "and", "apoptosis", "in", "human", "hepatoma", "cells", "." ]	[ "GENE-N", "GENE-Y", "CHEMICAL" ]
DICO is a CHEMICAL, flavonoid is a CHEMICAL	23567243_task1	Sentence: DICO, a novel nonaromatic B-ring flavonoid, induces G2/M cell cycle arrest and apoptosis in human hepatoma cells. Instructions: please typing these entity words according to sentence: DICO, flavonoid Options: CHEMICAL	[ "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	DICO, a novel nonaromatic B-ring flavonoid, induces G2/M cell cycle arrest and apoptosis in human hepatoma cells.	[ "DICO", ",", "a", "novel", "nonaromatic", "B", "-", "ring", "flavonoid", ",", "induces", "G2", "/", "M", "cell", "cycle", "arrest", "and", "apoptosis", "in", "human", "hepatoma", "cells", "." ]	[ "GENE-N", "GENE-Y", "CHEMICAL" ]
DICO, flavonoid	23567243_task2	Sentence: DICO, a novel nonaromatic B-ring flavonoid, induces G2/M cell cycle arrest and apoptosis in human hepatoma cells. Instructions: please extract entity words from the input sentence	[ "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	DICO, a novel nonaromatic B-ring flavonoid, induces G2/M cell cycle arrest and apoptosis in human hepatoma cells.	[ "DICO", ",", "a", "novel", "nonaromatic", "B", "-", "ring", "flavonoid", ",", "induces", "G2", "/", "M", "cell", "cycle", "arrest", "and", "apoptosis", "in", "human", "hepatoma", "cells", "." ]	[ "GENE-N", "GENE-Y", "CHEMICAL" ]
PU.1 is a Protein, spi-1 is a Protein, promoter is a Entity, PU.1 is a Protein, spi-1 is a Protein, PU.1 is a Protein, promoter is a Entity, PU.1 is a Protein, PU.1 is a Protein, Oct-1 is a Protein, Oct-2 is a Protein, Sp1 is a Protein, PU.1 is a Protein, OBF-1 is a Protein, Bob1 is a Protein, OCA - B is a Protein, OBF-1 is a Protein, Bob1 is a Protein, OCA - B is a Protein, PU.1 is a Protein, promoter is a Entity, PU.1 is a Protein	8663022_task0	Sentence: Octamer binding factors and their coactivator can activate the murine PU.1 (spi-1) promoter. PU.1 (spi-1), a member of the Ets transcription factor family, is predominantly expressed in myeloid and B cells, activates many B cell and myeloid genes, and is critical for development of both of these lineages. Our previous studies (Chen, H.M., Ray-Gallet, D., Zhang, P., Hetherington, C.J., Gonzalez, D.A., Zhang, D.-E., Moreau-Gachelin, F., and Tenen, D.G.(1995) Oncogene 11, 1549-1560) demonstrate that the PU.1 promoter directs cell type-specific reporter gene expression in myeloid cell lines, and that PU.1 activates its own promoter in an autoregulatory loop. Here we show that the murine PU.1 promoter is also specifically and highly functional in B cell lines as well. Oct-1 and Oct-2 can bind specifically to a site at base pair -55 in vitro, and this site is specifically protected in B cells in vivo. We also demonstrate that two other sites contribute to promoter activity in B cells; an Sp1 binding site adjacent to the octamer site, and the PU.1 autoregulatory site. Finally, we show that the B cell coactivator OBF-1/Bob1/OCA-B is only expressed in B cells and not in myeloid cells, and that OBF-1/Bob1/OCA-B can transactivate the PU.1 promoter in HeLa and myeloid cells. This B cell restricted coactivator may be responsible for the B cell specific expression of PU.1 mediated by the octamer site. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "B-Entity", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O" ]	Octamer binding factors and their coactivator can activate the murine PU.1 (spi-1) promoter. PU.1 (spi-1), a member of the Ets transcription factor family, is predominantly expressed in myeloid and B cells, activates many B cell and myeloid genes, and is critical for development of both of these lineages. Our previous studies (Chen, H.M., Ray-Gallet, D., Zhang, P., Hetherington, C.J., Gonzalez, D.A., Zhang, D.-E., Moreau-Gachelin, F., and Tenen, D.G.(1995) Oncogene 11, 1549-1560) demonstrate that the PU.1 promoter directs cell type-specific reporter gene expression in myeloid cell lines, and that PU.1 activates its own promoter in an autoregulatory loop. Here we show that the murine PU.1 promoter is also specifically and highly functional in B cell lines as well. Oct-1 and Oct-2 can bind specifically to a site at base pair -55 in vitro, and this site is specifically protected in B cells in vivo. We also demonstrate that two other sites contribute to promoter activity in B cells; an Sp1 binding site adjacent to the octamer site, and the PU.1 autoregulatory site. Finally, we show that the B cell coactivator OBF-1/Bob1/OCA-B is only expressed in B cells and not in myeloid cells, and that OBF-1/Bob1/OCA-B can transactivate the PU.1 promoter in HeLa and myeloid cells. This B cell restricted coactivator may be responsible for the B cell specific expression of PU.1 mediated by the octamer site.	[ "Octamer", "binding", "factors", "and", "their", "coactivator", "can", "activate", "the", "murine", "PU.1", "(", "spi-1", ")", "promoter", ".", "\n", "PU.1", "(", "spi-1", ")", ",", "a", "member", "of", "the", "Ets", "transcription", "factor", "family", ",", "is", "predominantly", "expressed", "in", "myeloid", "and", "B", "cells", ",", "activates", "many", "B", "cell", "and", "myeloid", "genes", ",", "and", "is", "critical", "for", "development", "of", "both", "of", "these", "lineages", ".", "Our", "previous", "studies", "(", "Chen", ",", "H.M.", ",", "Ray", "-", "Gallet", ",", "D.", ",", "Zhang", ",", "P.", ",", "Hetherington", ",", "C.J.", ",", "Gonzalez", ",", "D.A.", ",", "Zhang", ",", "D.-E.", ",", "Moreau", "-", "Gachelin", ",", "F.", ",", "and", "Tenen", ",", "D.G.(1995", ")", "Oncogene", "11", ",", "1549", "-", "1560", ")", "demonstrate", "that", "the", "PU.1", "promoter", "directs", "cell", "type", "-", "specific", "reporter", "gene", "expression", "in", "myeloid", "cell", "lines", ",", "and", "that", "PU.1", "activates", "its", "own", "promoter", "in", "an", "autoregulatory", "loop", ".", "Here", "we", "show", "that", "the", "murine", "PU.1", "promoter", "is", "also", "specifically", "and", "highly", "functional", "in", "B", "cell", "lines", "as", "well", ".", "Oct-1", "and", "Oct-2", "can", "bind", "specifically", "to", "a", "site", "at", "base", "pair", "-55", "in", "vitro", ",", "and", "this", "site", "is", "specifically", "protected", "in", "B", "cells", "in", "vivo", ".", "We", "also", "demonstrate", "that", "two", "other", "sites", "contribute", "to", "promoter", "activity", "in", "B", "cells", ";", "an", "Sp1", "binding", "site", "adjacent", "to", "the", "octamer", "site", ",", "and", "the", "PU.1", "autoregulatory", "site", ".", "Finally", ",", "we", "show", "that", "the", "B", "cell", "coactivator", "OBF-1", "/", "Bob1", "/", "OCA", "-", "B", "is", "only", "expressed", "in", "B", "cells", "and", "not", "in", "myeloid", "cells", ",", "and", "that", "OBF-1", "/", "Bob1", "/", "OCA", "-", "B", "can", "transactivate", "the", "PU.1", "promoter", "in", "HeLa", "and", "myeloid", "cells", ".", "This", "B", "cell", "restricted", "coactivator", "may", "be", "responsible", "for", "the", "B", "cell", "specific", "expression", "of", "PU.1", "mediated", "by", "the", "octamer", "site", "." ]	[ "Entity", "Protein" ]
PU.1 is a Protein, spi-1 is a Protein, promoter is a Entity, PU.1 is a Protein, spi-1 is a Protein, PU.1 is a Protein, promoter is a Entity, PU.1 is a Protein, PU.1 is a Protein, Oct-1 is a Protein, Oct-2 is a Protein, Sp1 is a Protein, PU.1 is a Protein, OBF-1 is a Protein, Bob1 is a Protein, OCA - B is a Protein, OBF-1 is a Protein, Bob1 is a Protein, OCA - B is a Protein, PU.1 is a Protein, promoter is a Entity, PU.1 is a Protein	8663022_task1	Sentence: Octamer binding factors and their coactivator can activate the murine PU.1 (spi-1) promoter. PU.1 (spi-1), a member of the Ets transcription factor family, is predominantly expressed in myeloid and B cells, activates many B cell and myeloid genes, and is critical for development of both of these lineages. Our previous studies (Chen, H.M., Ray-Gallet, D., Zhang, P., Hetherington, C.J., Gonzalez, D.A., Zhang, D.-E., Moreau-Gachelin, F., and Tenen, D.G.(1995) Oncogene 11, 1549-1560) demonstrate that the PU.1 promoter directs cell type-specific reporter gene expression in myeloid cell lines, and that PU.1 activates its own promoter in an autoregulatory loop. Here we show that the murine PU.1 promoter is also specifically and highly functional in B cell lines as well. Oct-1 and Oct-2 can bind specifically to a site at base pair -55 in vitro, and this site is specifically protected in B cells in vivo. We also demonstrate that two other sites contribute to promoter activity in B cells; an Sp1 binding site adjacent to the octamer site, and the PU.1 autoregulatory site. Finally, we show that the B cell coactivator OBF-1/Bob1/OCA-B is only expressed in B cells and not in myeloid cells, and that OBF-1/Bob1/OCA-B can transactivate the PU.1 promoter in HeLa and myeloid cells. This B cell restricted coactivator may be responsible for the B cell specific expression of PU.1 mediated by the octamer site. Instructions: please typing these entity words according to sentence: PU.1, spi-1, promoter, PU.1, spi-1, PU.1, promoter, PU.1, PU.1, Oct-1, Oct-2, Sp1, PU.1, OBF-1, Bob1, OCA - B, OBF-1, Bob1, OCA - B, PU.1, promoter, PU.1 Options: Entity, Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "B-Entity", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O" ]	Octamer binding factors and their coactivator can activate the murine PU.1 (spi-1) promoter. PU.1 (spi-1), a member of the Ets transcription factor family, is predominantly expressed in myeloid and B cells, activates many B cell and myeloid genes, and is critical for development of both of these lineages. Our previous studies (Chen, H.M., Ray-Gallet, D., Zhang, P., Hetherington, C.J., Gonzalez, D.A., Zhang, D.-E., Moreau-Gachelin, F., and Tenen, D.G.(1995) Oncogene 11, 1549-1560) demonstrate that the PU.1 promoter directs cell type-specific reporter gene expression in myeloid cell lines, and that PU.1 activates its own promoter in an autoregulatory loop. Here we show that the murine PU.1 promoter is also specifically and highly functional in B cell lines as well. Oct-1 and Oct-2 can bind specifically to a site at base pair -55 in vitro, and this site is specifically protected in B cells in vivo. We also demonstrate that two other sites contribute to promoter activity in B cells; an Sp1 binding site adjacent to the octamer site, and the PU.1 autoregulatory site. Finally, we show that the B cell coactivator OBF-1/Bob1/OCA-B is only expressed in B cells and not in myeloid cells, and that OBF-1/Bob1/OCA-B can transactivate the PU.1 promoter in HeLa and myeloid cells. This B cell restricted coactivator may be responsible for the B cell specific expression of PU.1 mediated by the octamer site.	[ "Octamer", "binding", "factors", "and", "their", "coactivator", "can", "activate", "the", "murine", "PU.1", "(", "spi-1", ")", "promoter", ".", "\n", "PU.1", "(", "spi-1", ")", ",", "a", "member", "of", "the", "Ets", "transcription", "factor", "family", ",", "is", "predominantly", "expressed", "in", "myeloid", "and", "B", "cells", ",", "activates", "many", "B", "cell", "and", "myeloid", "genes", ",", "and", "is", "critical", "for", "development", "of", "both", "of", "these", "lineages", ".", "Our", "previous", "studies", "(", "Chen", ",", "H.M.", ",", "Ray", "-", "Gallet", ",", "D.", ",", "Zhang", ",", "P.", ",", "Hetherington", ",", "C.J.", ",", "Gonzalez", ",", "D.A.", ",", "Zhang", ",", "D.-E.", ",", "Moreau", "-", "Gachelin", ",", "F.", ",", "and", "Tenen", ",", "D.G.(1995", ")", "Oncogene", "11", ",", "1549", "-", "1560", ")", "demonstrate", "that", "the", "PU.1", "promoter", "directs", "cell", "type", "-", "specific", "reporter", "gene", "expression", "in", "myeloid", "cell", "lines", ",", "and", "that", "PU.1", "activates", "its", "own", "promoter", "in", "an", "autoregulatory", "loop", ".", "Here", "we", "show", "that", "the", "murine", "PU.1", "promoter", "is", "also", "specifically", "and", "highly", "functional", "in", "B", "cell", "lines", "as", "well", ".", "Oct-1", "and", "Oct-2", "can", "bind", "specifically", "to", "a", "site", "at", "base", "pair", "-55", "in", "vitro", ",", "and", "this", "site", "is", "specifically", "protected", "in", "B", "cells", "in", "vivo", ".", "We", "also", "demonstrate", "that", "two", "other", "sites", "contribute", "to", "promoter", "activity", "in", "B", "cells", ";", "an", "Sp1", "binding", "site", "adjacent", "to", "the", "octamer", "site", ",", "and", "the", "PU.1", "autoregulatory", "site", ".", "Finally", ",", "we", "show", "that", "the", "B", "cell", "coactivator", "OBF-1", "/", "Bob1", "/", "OCA", "-", "B", "is", "only", "expressed", "in", "B", "cells", "and", "not", "in", "myeloid", "cells", ",", "and", "that", "OBF-1", "/", "Bob1", "/", "OCA", "-", "B", "can", "transactivate", "the", "PU.1", "promoter", "in", "HeLa", "and", "myeloid", "cells", ".", "This", "B", "cell", "restricted", "coactivator", "may", "be", "responsible", "for", "the", "B", "cell", "specific", "expression", "of", "PU.1", "mediated", "by", "the", "octamer", "site", "." ]	[ "Entity", "Protein" ]
PU.1, spi-1, promoter, PU.1, spi-1, PU.1, promoter, PU.1, PU.1, Oct-1, Oct-2, Sp1, PU.1, OBF-1, Bob1, OCA - B, OBF-1, Bob1, OCA - B, PU.1, promoter, PU.1	8663022_task2	Sentence: Octamer binding factors and their coactivator can activate the murine PU.1 (spi-1) promoter. PU.1 (spi-1), a member of the Ets transcription factor family, is predominantly expressed in myeloid and B cells, activates many B cell and myeloid genes, and is critical for development of both of these lineages. Our previous studies (Chen, H.M., Ray-Gallet, D., Zhang, P., Hetherington, C.J., Gonzalez, D.A., Zhang, D.-E., Moreau-Gachelin, F., and Tenen, D.G.(1995) Oncogene 11, 1549-1560) demonstrate that the PU.1 promoter directs cell type-specific reporter gene expression in myeloid cell lines, and that PU.1 activates its own promoter in an autoregulatory loop. Here we show that the murine PU.1 promoter is also specifically and highly functional in B cell lines as well. Oct-1 and Oct-2 can bind specifically to a site at base pair -55 in vitro, and this site is specifically protected in B cells in vivo. We also demonstrate that two other sites contribute to promoter activity in B cells; an Sp1 binding site adjacent to the octamer site, and the PU.1 autoregulatory site. Finally, we show that the B cell coactivator OBF-1/Bob1/OCA-B is only expressed in B cells and not in myeloid cells, and that OBF-1/Bob1/OCA-B can transactivate the PU.1 promoter in HeLa and myeloid cells. This B cell restricted coactivator may be responsible for the B cell specific expression of PU.1 mediated by the octamer site. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "B-Entity", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O" ]	Octamer binding factors and their coactivator can activate the murine PU.1 (spi-1) promoter. PU.1 (spi-1), a member of the Ets transcription factor family, is predominantly expressed in myeloid and B cells, activates many B cell and myeloid genes, and is critical for development of both of these lineages. Our previous studies (Chen, H.M., Ray-Gallet, D., Zhang, P., Hetherington, C.J., Gonzalez, D.A., Zhang, D.-E., Moreau-Gachelin, F., and Tenen, D.G.(1995) Oncogene 11, 1549-1560) demonstrate that the PU.1 promoter directs cell type-specific reporter gene expression in myeloid cell lines, and that PU.1 activates its own promoter in an autoregulatory loop. Here we show that the murine PU.1 promoter is also specifically and highly functional in B cell lines as well. Oct-1 and Oct-2 can bind specifically to a site at base pair -55 in vitro, and this site is specifically protected in B cells in vivo. We also demonstrate that two other sites contribute to promoter activity in B cells; an Sp1 binding site adjacent to the octamer site, and the PU.1 autoregulatory site. Finally, we show that the B cell coactivator OBF-1/Bob1/OCA-B is only expressed in B cells and not in myeloid cells, and that OBF-1/Bob1/OCA-B can transactivate the PU.1 promoter in HeLa and myeloid cells. This B cell restricted coactivator may be responsible for the B cell specific expression of PU.1 mediated by the octamer site.	[ "Octamer", "binding", "factors", "and", "their", "coactivator", "can", "activate", "the", "murine", "PU.1", "(", "spi-1", ")", "promoter", ".", "\n", "PU.1", "(", "spi-1", ")", ",", "a", "member", "of", "the", "Ets", "transcription", "factor", "family", ",", "is", "predominantly", "expressed", "in", "myeloid", "and", "B", "cells", ",", "activates", "many", "B", "cell", "and", "myeloid", "genes", ",", "and", "is", "critical", "for", "development", "of", "both", "of", "these", "lineages", ".", "Our", "previous", "studies", "(", "Chen", ",", "H.M.", ",", "Ray", "-", "Gallet", ",", "D.", ",", "Zhang", ",", "P.", ",", "Hetherington", ",", "C.J.", ",", "Gonzalez", ",", "D.A.", ",", "Zhang", ",", "D.-E.", ",", "Moreau", "-", "Gachelin", ",", "F.", ",", "and", "Tenen", ",", "D.G.(1995", ")", "Oncogene", "11", ",", "1549", "-", "1560", ")", "demonstrate", "that", "the", "PU.1", "promoter", "directs", "cell", "type", "-", "specific", "reporter", "gene", "expression", "in", "myeloid", "cell", "lines", ",", "and", "that", "PU.1", "activates", "its", "own", "promoter", "in", "an", "autoregulatory", "loop", ".", "Here", "we", "show", "that", "the", "murine", "PU.1", "promoter", "is", "also", "specifically", "and", "highly", "functional", "in", "B", "cell", "lines", "as", "well", ".", "Oct-1", "and", "Oct-2", "can", "bind", "specifically", "to", "a", "site", "at", "base", "pair", "-55", "in", "vitro", ",", "and", "this", "site", "is", "specifically", "protected", "in", "B", "cells", "in", "vivo", ".", "We", "also", "demonstrate", "that", "two", "other", "sites", "contribute", "to", "promoter", "activity", "in", "B", "cells", ";", "an", "Sp1", "binding", "site", "adjacent", "to", "the", "octamer", "site", ",", "and", "the", "PU.1", "autoregulatory", "site", ".", "Finally", ",", "we", "show", "that", "the", "B", "cell", "coactivator", "OBF-1", "/", "Bob1", "/", "OCA", "-", "B", "is", "only", "expressed", "in", "B", "cells", "and", "not", "in", "myeloid", "cells", ",", "and", "that", "OBF-1", "/", "Bob1", "/", "OCA", "-", "B", "can", "transactivate", "the", "PU.1", "promoter", "in", "HeLa", "and", "myeloid", "cells", ".", "This", "B", "cell", "restricted", "coactivator", "may", "be", "responsible", "for", "the", "B", "cell", "specific", "expression", "of", "PU.1", "mediated", "by", "the", "octamer", "site", "." ]	[ "Entity", "Protein" ]
vessels is a Multi-tissue_structure, tissue is a Tissue, Vascular is a Multi-tissue_structure, arterial is a Multi-tissue_structure, venous is a Multi-tissue_structure, stroma is a Tissue, tissues is a Tissue, hierarchic network is a Tissue, pericytes is a Cell, arterial is a Multi-tissue_structure, extracellular is a Immaterial_anatomical_entity, vascular is a Multi-tissue_structure, vessels is a Multi-tissue_structure, caliber is a Immaterial_anatomical_entity, vessel lumen is a Immaterial_anatomical_entity, pericyte is a Cell, vascular is a Multi-tissue_structure, vascular is a Multi-tissue_structure, tumor is a Cancer, tumor is a Cancer, tumors is a Cancer	PMID-17311993_task0	Sentence: Inhibition of Dll4-mediated signaling induces proliferation of immature vessels and results in poor tissue perfusion. Vascular development is dependent on various growth factors and certain modifiers critical for providing arterial or venous identity, interaction with the surrounding stroma and tissues, hierarchic network formation, and recruitment of pericytes. Notch receptors and ligands (Jagged and Delta-like) play a critical role in this process in addition to VEGF. Dll4 is one of the Notch ligands that regulates arterial specification and maturation events. In the current study, we have shown that loss of function by either targeted allele deletion or use of a soluble form of Dll4 extracellular domain leads to inhibition of Notch signaling, resulting in increased vascular proliferation but defective maturation. Newly forming vessels have thin caliber, a markedly reduced vessel lumen, markedly reduced pericyte recruitment, and deficient vascular perfusion. sDll4 similarly induced defective vascular response in tumor implants leading to reduced tumor growth. Interference with Dll4-Notch signaling may be particularly desirable in tumors that have highly induced Dll4-Notch pathway. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Tissue, Immaterial_anatomical_entity, Cancer, Multi-tissue_structure, Cell	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "O", "O", "B-Tissue", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "B-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "B-Tissue", "O", "B-Tissue", "O", "B-Tissue", "I-Tissue", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Immaterial_anatomical_entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "B-Immaterial_anatomical_entity", "O", "O", "O", "O", "B-Immaterial_anatomical_entity", "I-Immaterial_anatomical_entity", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "B-Cancer", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O" ]	Inhibition of Dll4-mediated signaling induces proliferation of immature vessels and results in poor tissue perfusion. Vascular development is dependent on various growth factors and certain modifiers critical for providing arterial or venous identity, interaction with the surrounding stroma and tissues, hierarchic network formation, and recruitment of pericytes. Notch receptors and ligands (Jagged and Delta-like) play a critical role in this process in addition to VEGF. Dll4 is one of the Notch ligands that regulates arterial specification and maturation events. In the current study, we have shown that loss of function by either targeted allele deletion or use of a soluble form of Dll4 extracellular domain leads to inhibition of Notch signaling, resulting in increased vascular proliferation but defective maturation. Newly forming vessels have thin caliber, a markedly reduced vessel lumen, markedly reduced pericyte recruitment, and deficient vascular perfusion. sDll4 similarly induced defective vascular response in tumor implants leading to reduced tumor growth. Interference with Dll4-Notch signaling may be particularly desirable in tumors that have highly induced Dll4-Notch pathway.	[ "Inhibition", "of", "Dll4-mediated", "signaling", "induces", "proliferation", "of", "immature", "vessels", "and", "results", "in", "poor", "tissue", "perfusion", ".", "\n", "Vascular", "development", "is", "dependent", "on", "various", "growth", "factors", "and", "certain", "modifiers", "critical", "for", "providing", "arterial", "or", "venous", "identity", ",", "interaction", "with", "the", "surrounding", "stroma", "and", "tissues", ",", "hierarchic", "network", "formation", ",", "and", "recruitment", "of", "pericytes", ".", "Notch", "receptors", "and", "ligands", "(", "Jagged", "and", "Delta", "-", "like", ")", "play", "a", "critical", "role", "in", "this", "process", "in", "addition", "to", "VEGF", ".", "Dll4", "is", "one", "of", "the", "Notch", "ligands", "that", "regulates", "arterial", "specification", "and", "maturation", "events", ".", "In", "the", "current", "study", ",", "we", "have", "shown", "that", "loss", "of", "function", "by", "either", "targeted", "allele", "deletion", "or", "use", "of", "a", "soluble", "form", "of", "Dll4", "extracellular", "domain", "leads", "to", "inhibition", "of", "Notch", "signaling", ",", "resulting", "in", "increased", "vascular", "proliferation", "but", "defective", "maturation", ".", "Newly", "forming", "vessels", "have", "thin", "caliber", ",", "a", "markedly", "reduced", "vessel", "lumen", ",", "markedly", "reduced", "pericyte", "recruitment", ",", "and", "deficient", "vascular", "perfusion", ".", "sDll4", "similarly", "induced", "defective", "vascular", "response", "in", "tumor", "implants", "leading", "to", "reduced", "tumor", "growth", ".", "Interference", "with", "Dll4-Notch", "signaling", "may", "be", "particularly", "desirable", "in", "tumors", "that", "have", "highly", "induced", "Dll4-Notch", "pathway", ".", "\n" ]	[ "Tissue", "Immaterial_anatomical_entity", "Cell", "Multi-tissue_structure", "Cancer" ]
vessels is a Multi-tissue_structure, tissue is a Tissue, Vascular is a Multi-tissue_structure, arterial is a Multi-tissue_structure, venous is a Multi-tissue_structure, stroma is a Tissue, tissues is a Tissue, hierarchic network is a Tissue, pericytes is a Cell, arterial is a Multi-tissue_structure, extracellular is a Immaterial_anatomical_entity, vascular is a Multi-tissue_structure, vessels is a Multi-tissue_structure, caliber is a Immaterial_anatomical_entity, vessel lumen is a Immaterial_anatomical_entity, pericyte is a Cell, vascular is a Multi-tissue_structure, vascular is a Multi-tissue_structure, tumor is a Cancer, tumor is a Cancer, tumors is a Cancer	PMID-17311993_task1	Sentence: Inhibition of Dll4-mediated signaling induces proliferation of immature vessels and results in poor tissue perfusion. Vascular development is dependent on various growth factors and certain modifiers critical for providing arterial or venous identity, interaction with the surrounding stroma and tissues, hierarchic network formation, and recruitment of pericytes. Notch receptors and ligands (Jagged and Delta-like) play a critical role in this process in addition to VEGF. Dll4 is one of the Notch ligands that regulates arterial specification and maturation events. In the current study, we have shown that loss of function by either targeted allele deletion or use of a soluble form of Dll4 extracellular domain leads to inhibition of Notch signaling, resulting in increased vascular proliferation but defective maturation. Newly forming vessels have thin caliber, a markedly reduced vessel lumen, markedly reduced pericyte recruitment, and deficient vascular perfusion. sDll4 similarly induced defective vascular response in tumor implants leading to reduced tumor growth. Interference with Dll4-Notch signaling may be particularly desirable in tumors that have highly induced Dll4-Notch pathway. Instructions: please typing these entity words according to sentence: vessels, tissue, Vascular, arterial, venous, stroma, tissues, hierarchic network, pericytes, arterial, extracellular, vascular, vessels, caliber, vessel lumen, pericyte, vascular, vascular, tumor, tumor, tumors Options: Tissue, Immaterial_anatomical_entity, Cancer, Multi-tissue_structure, Cell	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "O", "O", "B-Tissue", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "B-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "B-Tissue", "O", "B-Tissue", "O", "B-Tissue", "I-Tissue", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Immaterial_anatomical_entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "B-Immaterial_anatomical_entity", "O", "O", "O", "O", "B-Immaterial_anatomical_entity", "I-Immaterial_anatomical_entity", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "B-Cancer", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O" ]	Inhibition of Dll4-mediated signaling induces proliferation of immature vessels and results in poor tissue perfusion. Vascular development is dependent on various growth factors and certain modifiers critical for providing arterial or venous identity, interaction with the surrounding stroma and tissues, hierarchic network formation, and recruitment of pericytes. Notch receptors and ligands (Jagged and Delta-like) play a critical role in this process in addition to VEGF. Dll4 is one of the Notch ligands that regulates arterial specification and maturation events. In the current study, we have shown that loss of function by either targeted allele deletion or use of a soluble form of Dll4 extracellular domain leads to inhibition of Notch signaling, resulting in increased vascular proliferation but defective maturation. Newly forming vessels have thin caliber, a markedly reduced vessel lumen, markedly reduced pericyte recruitment, and deficient vascular perfusion. sDll4 similarly induced defective vascular response in tumor implants leading to reduced tumor growth. Interference with Dll4-Notch signaling may be particularly desirable in tumors that have highly induced Dll4-Notch pathway.	[ "Inhibition", "of", "Dll4-mediated", "signaling", "induces", "proliferation", "of", "immature", "vessels", "and", "results", "in", "poor", "tissue", "perfusion", ".", "\n", "Vascular", "development", "is", "dependent", "on", "various", "growth", "factors", "and", "certain", "modifiers", "critical", "for", "providing", "arterial", "or", "venous", "identity", ",", "interaction", "with", "the", "surrounding", "stroma", "and", "tissues", ",", "hierarchic", "network", "formation", ",", "and", "recruitment", "of", "pericytes", ".", "Notch", "receptors", "and", "ligands", "(", "Jagged", "and", "Delta", "-", "like", ")", "play", "a", "critical", "role", "in", "this", "process", "in", "addition", "to", "VEGF", ".", "Dll4", "is", "one", "of", "the", "Notch", "ligands", "that", "regulates", "arterial", "specification", "and", "maturation", "events", ".", "In", "the", "current", "study", ",", "we", "have", "shown", "that", "loss", "of", "function", "by", "either", "targeted", "allele", "deletion", "or", "use", "of", "a", "soluble", "form", "of", "Dll4", "extracellular", "domain", "leads", "to", "inhibition", "of", "Notch", "signaling", ",", "resulting", "in", "increased", "vascular", "proliferation", "but", "defective", "maturation", ".", "Newly", "forming", "vessels", "have", "thin", "caliber", ",", "a", "markedly", "reduced", "vessel", "lumen", ",", "markedly", "reduced", "pericyte", "recruitment", ",", "and", "deficient", "vascular", "perfusion", ".", "sDll4", "similarly", "induced", "defective", "vascular", "response", "in", "tumor", "implants", "leading", "to", "reduced", "tumor", "growth", ".", "Interference", "with", "Dll4-Notch", "signaling", "may", "be", "particularly", "desirable", "in", "tumors", "that", "have", "highly", "induced", "Dll4-Notch", "pathway", ".", "\n" ]	[ "Tissue", "Immaterial_anatomical_entity", "Cell", "Multi-tissue_structure", "Cancer" ]
vessels, tissue, Vascular, arterial, venous, stroma, tissues, hierarchic network, pericytes, arterial, extracellular, vascular, vessels, caliber, vessel lumen, pericyte, vascular, vascular, tumor, tumor, tumors	PMID-17311993_task2	Sentence: Inhibition of Dll4-mediated signaling induces proliferation of immature vessels and results in poor tissue perfusion. Vascular development is dependent on various growth factors and certain modifiers critical for providing arterial or venous identity, interaction with the surrounding stroma and tissues, hierarchic network formation, and recruitment of pericytes. Notch receptors and ligands (Jagged and Delta-like) play a critical role in this process in addition to VEGF. Dll4 is one of the Notch ligands that regulates arterial specification and maturation events. In the current study, we have shown that loss of function by either targeted allele deletion or use of a soluble form of Dll4 extracellular domain leads to inhibition of Notch signaling, resulting in increased vascular proliferation but defective maturation. Newly forming vessels have thin caliber, a markedly reduced vessel lumen, markedly reduced pericyte recruitment, and deficient vascular perfusion. sDll4 similarly induced defective vascular response in tumor implants leading to reduced tumor growth. Interference with Dll4-Notch signaling may be particularly desirable in tumors that have highly induced Dll4-Notch pathway. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "O", "O", "B-Tissue", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "B-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "B-Tissue", "O", "B-Tissue", "O", "B-Tissue", "I-Tissue", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Immaterial_anatomical_entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "B-Immaterial_anatomical_entity", "O", "O", "O", "O", "B-Immaterial_anatomical_entity", "I-Immaterial_anatomical_entity", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "B-Cancer", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O" ]	Inhibition of Dll4-mediated signaling induces proliferation of immature vessels and results in poor tissue perfusion. Vascular development is dependent on various growth factors and certain modifiers critical for providing arterial or venous identity, interaction with the surrounding stroma and tissues, hierarchic network formation, and recruitment of pericytes. Notch receptors and ligands (Jagged and Delta-like) play a critical role in this process in addition to VEGF. Dll4 is one of the Notch ligands that regulates arterial specification and maturation events. In the current study, we have shown that loss of function by either targeted allele deletion or use of a soluble form of Dll4 extracellular domain leads to inhibition of Notch signaling, resulting in increased vascular proliferation but defective maturation. Newly forming vessels have thin caliber, a markedly reduced vessel lumen, markedly reduced pericyte recruitment, and deficient vascular perfusion. sDll4 similarly induced defective vascular response in tumor implants leading to reduced tumor growth. Interference with Dll4-Notch signaling may be particularly desirable in tumors that have highly induced Dll4-Notch pathway.	[ "Inhibition", "of", "Dll4-mediated", "signaling", "induces", "proliferation", "of", "immature", "vessels", "and", "results", "in", "poor", "tissue", "perfusion", ".", "\n", "Vascular", "development", "is", "dependent", "on", "various", "growth", "factors", "and", "certain", "modifiers", "critical", "for", "providing", "arterial", "or", "venous", "identity", ",", "interaction", "with", "the", "surrounding", "stroma", "and", "tissues", ",", "hierarchic", "network", "formation", ",", "and", "recruitment", "of", "pericytes", ".", "Notch", "receptors", "and", "ligands", "(", "Jagged", "and", "Delta", "-", "like", ")", "play", "a", "critical", "role", "in", "this", "process", "in", "addition", "to", "VEGF", ".", "Dll4", "is", "one", "of", "the", "Notch", "ligands", "that", "regulates", "arterial", "specification", "and", "maturation", "events", ".", "In", "the", "current", "study", ",", "we", "have", "shown", "that", "loss", "of", "function", "by", "either", "targeted", "allele", "deletion", "or", "use", "of", "a", "soluble", "form", "of", "Dll4", "extracellular", "domain", "leads", "to", "inhibition", "of", "Notch", "signaling", ",", "resulting", "in", "increased", "vascular", "proliferation", "but", "defective", "maturation", ".", "Newly", "forming", "vessels", "have", "thin", "caliber", ",", "a", "markedly", "reduced", "vessel", "lumen", ",", "markedly", "reduced", "pericyte", "recruitment", ",", "and", "deficient", "vascular", "perfusion", ".", "sDll4", "similarly", "induced", "defective", "vascular", "response", "in", "tumor", "implants", "leading", "to", "reduced", "tumor", "growth", ".", "Interference", "with", "Dll4-Notch", "signaling", "may", "be", "particularly", "desirable", "in", "tumors", "that", "have", "highly", "induced", "Dll4-Notch", "pathway", ".", "\n" ]	[ "Tissue", "Immaterial_anatomical_entity", "Cell", "Multi-tissue_structure", "Cancer" ]
Porphyrine is an umlsterm, Tumoren is an umlsterm, Arbeit is an umlsterm, Melanomen is an umlsterm, Hauttumors is an umlsterm	DerRadiologe.90390422.ger.abstr_task0	Sentence: Ziel : Fuer Porphyrine wird eine selektive Anreicherung in malignen Tumoren beschrieben . In dieser Arbeit soll mittels der hochaufloesenden MRT das Enhancement in melanotischen Melanomen nach Applikation von Mn-TPPS4 untersucht werden , um eine bessere Charakterisierung dieses malignen Hauttumors zu erreichen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]	Ziel : Fuer Porphyrine wird eine selektive Anreicherung in malignen Tumoren beschrieben . In dieser Arbeit soll mittels der hochaufloesenden MRT das Enhancement in melanotischen Melanomen nach Applikation von Mn-TPPS4 untersucht werden , um eine bessere Charakterisierung dieses malignen Hauttumors zu erreichen .	[ "Ziel", ":", "Fuer", "Porphyrine", "wird", "eine", "selektive", "Anreicherung", "in", "malignen", "Tumoren", "beschrieben", ".", "In", "dieser", "Arbeit", "soll", "mittels", "der", "hochaufloesenden", "MRT", "das", "Enhancement", "in", "melanotischen", "Melanomen", "nach", "Applikation", "von", "Mn", "-", "TPPS4", "untersucht", "werden", ",", "um", "eine", "bessere", "Charakterisierung", "dieses", "malignen", "Hauttumors", "zu", "erreichen", "." ]	[ "umlsterm" ]
Porphyrine is an umlsterm, Tumoren is an umlsterm, Arbeit is an umlsterm, Melanomen is an umlsterm, Hauttumors is an umlsterm	DerRadiologe.90390422.ger.abstr_task1	Sentence: Ziel : Fuer Porphyrine wird eine selektive Anreicherung in malignen Tumoren beschrieben . In dieser Arbeit soll mittels der hochaufloesenden MRT das Enhancement in melanotischen Melanomen nach Applikation von Mn-TPPS4 untersucht werden , um eine bessere Charakterisierung dieses malignen Hauttumors zu erreichen . Instructions: please typing these entity words according to sentence: Porphyrine, Tumoren, Arbeit, Melanomen, Hauttumors Options: umlsterm	[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]	Ziel : Fuer Porphyrine wird eine selektive Anreicherung in malignen Tumoren beschrieben . In dieser Arbeit soll mittels der hochaufloesenden MRT das Enhancement in melanotischen Melanomen nach Applikation von Mn-TPPS4 untersucht werden , um eine bessere Charakterisierung dieses malignen Hauttumors zu erreichen .	[ "Ziel", ":", "Fuer", "Porphyrine", "wird", "eine", "selektive", "Anreicherung", "in", "malignen", "Tumoren", "beschrieben", ".", "In", "dieser", "Arbeit", "soll", "mittels", "der", "hochaufloesenden", "MRT", "das", "Enhancement", "in", "melanotischen", "Melanomen", "nach", "Applikation", "von", "Mn", "-", "TPPS4", "untersucht", "werden", ",", "um", "eine", "bessere", "Charakterisierung", "dieses", "malignen", "Hauttumors", "zu", "erreichen", "." ]	[ "umlsterm" ]
Porphyrine, Tumoren, Arbeit, Melanomen, Hauttumors	DerRadiologe.90390422.ger.abstr_task2	Sentence: Ziel : Fuer Porphyrine wird eine selektive Anreicherung in malignen Tumoren beschrieben . In dieser Arbeit soll mittels der hochaufloesenden MRT das Enhancement in melanotischen Melanomen nach Applikation von Mn-TPPS4 untersucht werden , um eine bessere Charakterisierung dieses malignen Hauttumors zu erreichen . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]	Ziel : Fuer Porphyrine wird eine selektive Anreicherung in malignen Tumoren beschrieben . In dieser Arbeit soll mittels der hochaufloesenden MRT das Enhancement in melanotischen Melanomen nach Applikation von Mn-TPPS4 untersucht werden , um eine bessere Charakterisierung dieses malignen Hauttumors zu erreichen .	[ "Ziel", ":", "Fuer", "Porphyrine", "wird", "eine", "selektive", "Anreicherung", "in", "malignen", "Tumoren", "beschrieben", ".", "In", "dieser", "Arbeit", "soll", "mittels", "der", "hochaufloesenden", "MRT", "das", "Enhancement", "in", "melanotischen", "Melanomen", "nach", "Applikation", "von", "Mn", "-", "TPPS4", "untersucht", "werden", ",", "um", "eine", "bessere", "Charakterisierung", "dieses", "malignen", "Hauttumors", "zu", "erreichen", "." ]	[ "umlsterm" ]
Peptid is an umlsterm, Patienten is an umlsterm	DerAnaesthesist.90480395.ger.abstr_task0	Sentence: Der Syntheseort fuer das inflammatorische Peptid Procalcitonin ( PCT ) ist bisher nicht bekannt . In der vorliegenden Studie wurde bei kardiochirurgischen Patienten nach Hinweisen fuer einen Syntheseort nach extrakorporaler Zirkulation ( EKZ ) gesucht . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Der Syntheseort fuer das inflammatorische Peptid Procalcitonin ( PCT ) ist bisher nicht bekannt . In der vorliegenden Studie wurde bei kardiochirurgischen Patienten nach Hinweisen fuer einen Syntheseort nach extrakorporaler Zirkulation ( EKZ ) gesucht .	[ "Der", "Syntheseort", "fuer", "das", "inflammatorische", "Peptid", "Procalcitonin", "(", "PCT", ")", "ist", "bisher", "nicht", "bekannt", ".", "In", "der", "vorliegenden", "Studie", "wurde", "bei", "kardiochirurgischen", "Patienten", "nach", "Hinweisen", "fuer", "einen", "Syntheseort", "nach", "extrakorporaler", "Zirkulation", "(", "EKZ", ")", "gesucht", "." ]	[ "umlsterm" ]
Peptid is an umlsterm, Patienten is an umlsterm	DerAnaesthesist.90480395.ger.abstr_task1	Sentence: Der Syntheseort fuer das inflammatorische Peptid Procalcitonin ( PCT ) ist bisher nicht bekannt . In der vorliegenden Studie wurde bei kardiochirurgischen Patienten nach Hinweisen fuer einen Syntheseort nach extrakorporaler Zirkulation ( EKZ ) gesucht . Instructions: please typing these entity words according to sentence: Peptid, Patienten Options: umlsterm	[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Der Syntheseort fuer das inflammatorische Peptid Procalcitonin ( PCT ) ist bisher nicht bekannt . In der vorliegenden Studie wurde bei kardiochirurgischen Patienten nach Hinweisen fuer einen Syntheseort nach extrakorporaler Zirkulation ( EKZ ) gesucht .	[ "Der", "Syntheseort", "fuer", "das", "inflammatorische", "Peptid", "Procalcitonin", "(", "PCT", ")", "ist", "bisher", "nicht", "bekannt", ".", "In", "der", "vorliegenden", "Studie", "wurde", "bei", "kardiochirurgischen", "Patienten", "nach", "Hinweisen", "fuer", "einen", "Syntheseort", "nach", "extrakorporaler", "Zirkulation", "(", "EKZ", ")", "gesucht", "." ]	[ "umlsterm" ]
Peptid, Patienten	DerAnaesthesist.90480395.ger.abstr_task2	Sentence: Der Syntheseort fuer das inflammatorische Peptid Procalcitonin ( PCT ) ist bisher nicht bekannt . In der vorliegenden Studie wurde bei kardiochirurgischen Patienten nach Hinweisen fuer einen Syntheseort nach extrakorporaler Zirkulation ( EKZ ) gesucht . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Der Syntheseort fuer das inflammatorische Peptid Procalcitonin ( PCT ) ist bisher nicht bekannt . In der vorliegenden Studie wurde bei kardiochirurgischen Patienten nach Hinweisen fuer einen Syntheseort nach extrakorporaler Zirkulation ( EKZ ) gesucht .	[ "Der", "Syntheseort", "fuer", "das", "inflammatorische", "Peptid", "Procalcitonin", "(", "PCT", ")", "ist", "bisher", "nicht", "bekannt", ".", "In", "der", "vorliegenden", "Studie", "wurde", "bei", "kardiochirurgischen", "Patienten", "nach", "Hinweisen", "fuer", "einen", "Syntheseort", "nach", "extrakorporaler", "Zirkulation", "(", "EKZ", ")", "gesucht", "." ]	[ "umlsterm" ]
Progesterone is a compound, microtubule - associated protein 2 is a protein, MAP2 is a protein	DS.d395_task0	Sentence: Progesterone effects on neuronal ultrastructure and expression of microtubule-associated protein 2 (MAP2) in rats with acute spinal cord injury. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: compound, protein	[ "B-compound", "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "I-protein", "I-protein", "I-protein", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Progesterone effects on neuronal ultrastructure and expression of microtubule-associated protein 2 (MAP2) in rats with acute spinal cord injury.	[ "Progesterone", "effects", "on", "neuronal", "ultrastructure", "and", "expression", "of", "microtubule", "-", "associated", "protein", "2", "(", "MAP2", ")", "in", "rats", "with", "acute", "spinal", "cord", "injury", "." ]	[ "protein", "compound" ]
Progesterone is a compound, microtubule - associated protein 2 is a protein, MAP2 is a protein	DS.d395_task1	Sentence: Progesterone effects on neuronal ultrastructure and expression of microtubule-associated protein 2 (MAP2) in rats with acute spinal cord injury. Instructions: please typing these entity words according to sentence: Progesterone, microtubule - associated protein 2, MAP2 Options: compound, protein	[ "B-compound", "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "I-protein", "I-protein", "I-protein", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Progesterone effects on neuronal ultrastructure and expression of microtubule-associated protein 2 (MAP2) in rats with acute spinal cord injury.	[ "Progesterone", "effects", "on", "neuronal", "ultrastructure", "and", "expression", "of", "microtubule", "-", "associated", "protein", "2", "(", "MAP2", ")", "in", "rats", "with", "acute", "spinal", "cord", "injury", "." ]	[ "protein", "compound" ]
Progesterone, microtubule - associated protein 2, MAP2	DS.d395_task2	Sentence: Progesterone effects on neuronal ultrastructure and expression of microtubule-associated protein 2 (MAP2) in rats with acute spinal cord injury. Instructions: please extract entity words from the input sentence	[ "B-compound", "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "I-protein", "I-protein", "I-protein", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Progesterone effects on neuronal ultrastructure and expression of microtubule-associated protein 2 (MAP2) in rats with acute spinal cord injury.	[ "Progesterone", "effects", "on", "neuronal", "ultrastructure", "and", "expression", "of", "microtubule", "-", "associated", "protein", "2", "(", "MAP2", ")", "in", "rats", "with", "acute", "spinal", "cord", "injury", "." ]	[ "protein", "compound" ]
diabetes mellitus according to World Health Organization criteria is a Scope, treatment with insulin or an oral hypoglycemic agent , twice random glucose measurements major than 200 mg / dl , or a fasting glucose major than 140 mg / dl is a Scope, Ulcer is a Condition, legs or feet is a Scope, stage is a Measurement, III or IV is a Value, Wagner Classification System is a Qualifier	NCT02742233_inc_task0	Sentence: Diagnosis of diabetes mellitus according to World Health Organization criteria ( treatment with insulin or an oral hypoglycemic agent, twice random glucose measurements major than 200 mg/dl, or a fasting glucose major than 140 mg/dl) Ulcer located on the legs or feet, stage III or IV (Wagner Classification System) The subject agrees to comply with study protocol requirements and all follow up visit requirements. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Condition, Qualifier, Value, Scope, Measurement	[ "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Condition", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "O", "B-Measurement", "B-Value", "I-Value", "I-Value", "O", "B-Qualifier", "I-Qualifier", "I-Qualifier", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Diagnosis of diabetes mellitus according to World Health Organization criteria ( treatment with insulin or an oral hypoglycemic agent, twice random glucose measurements major than 200 mg/dl, or a fasting glucose major than 140 mg/dl) Ulcer located on the legs or feet, stage III or IV (Wagner Classification System) The subject agrees to comply with study protocol requirements and all follow up visit requirements.	[ "Diagnosis", "of", "diabetes", "mellitus", "according", "to", "World", "Health", "Organization", "criteria", "(", "treatment", "with", "insulin", "or", "an", "oral", "hypoglycemic", "agent", ",", "twice", "random", "glucose", "measurements", "major", "than", "200", "mg", "/", "dl", ",", "or", "a", "fasting", "glucose", "major", "than", "140", "mg", "/", "dl", ")", "\n", "Ulcer", "located", "on", "the", "legs", "or", "feet", ",", "stage", "III", "or", "IV", "(", "Wagner", "Classification", "System", ")", "\n", "The", "subject", "agrees", "to", "comply", "with", "study", "protocol", "requirements", "and", "all", "follow", "up", "visit", "requirements", ".", "\n" ]	[ "Scope", "Qualifier", "Measurement", "Drug", "Value", "Condition", "Procedure", "Multiplier" ]
diabetes mellitus according to World Health Organization criteria is a Scope, treatment with insulin or an oral hypoglycemic agent , twice random glucose measurements major than 200 mg / dl , or a fasting glucose major than 140 mg / dl is a Scope, Ulcer is a Condition, legs or feet is a Scope, stage is a Measurement, III or IV is a Value, Wagner Classification System is a Qualifier	NCT02742233_inc_task1	Sentence: Diagnosis of diabetes mellitus according to World Health Organization criteria ( treatment with insulin or an oral hypoglycemic agent, twice random glucose measurements major than 200 mg/dl, or a fasting glucose major than 140 mg/dl) Ulcer located on the legs or feet, stage III or IV (Wagner Classification System) The subject agrees to comply with study protocol requirements and all follow up visit requirements. Instructions: please typing these entity words according to sentence: diabetes mellitus according to World Health Organization criteria, treatment with insulin or an oral hypoglycemic agent , twice random glucose measurements major than 200 mg / dl , or a fasting glucose major than 140 mg / dl, Ulcer, legs or feet, stage, III or IV, Wagner Classification System Options: Condition, Qualifier, Value, Scope, Measurement	[ "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Condition", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "O", "B-Measurement", "B-Value", "I-Value", "I-Value", "O", "B-Qualifier", "I-Qualifier", "I-Qualifier", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Diagnosis of diabetes mellitus according to World Health Organization criteria ( treatment with insulin or an oral hypoglycemic agent, twice random glucose measurements major than 200 mg/dl, or a fasting glucose major than 140 mg/dl) Ulcer located on the legs or feet, stage III or IV (Wagner Classification System) The subject agrees to comply with study protocol requirements and all follow up visit requirements.	[ "Diagnosis", "of", "diabetes", "mellitus", "according", "to", "World", "Health", "Organization", "criteria", "(", "treatment", "with", "insulin", "or", "an", "oral", "hypoglycemic", "agent", ",", "twice", "random", "glucose", "measurements", "major", "than", "200", "mg", "/", "dl", ",", "or", "a", "fasting", "glucose", "major", "than", "140", "mg", "/", "dl", ")", "\n", "Ulcer", "located", "on", "the", "legs", "or", "feet", ",", "stage", "III", "or", "IV", "(", "Wagner", "Classification", "System", ")", "\n", "The", "subject", "agrees", "to", "comply", "with", "study", "protocol", "requirements", "and", "all", "follow", "up", "visit", "requirements", ".", "\n" ]	[ "Scope", "Qualifier", "Measurement", "Drug", "Value", "Condition", "Procedure", "Multiplier" ]
diabetes mellitus according to World Health Organization criteria, treatment with insulin or an oral hypoglycemic agent , twice random glucose measurements major than 200 mg / dl , or a fasting glucose major than 140 mg / dl, Ulcer, legs or feet, stage, III or IV, Wagner Classification System	NCT02742233_inc_task2	Sentence: Diagnosis of diabetes mellitus according to World Health Organization criteria ( treatment with insulin or an oral hypoglycemic agent, twice random glucose measurements major than 200 mg/dl, or a fasting glucose major than 140 mg/dl) Ulcer located on the legs or feet, stage III or IV (Wagner Classification System) The subject agrees to comply with study protocol requirements and all follow up visit requirements. Instructions: please extract entity words from the input sentence	[ "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Condition", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "O", "B-Measurement", "B-Value", "I-Value", "I-Value", "O", "B-Qualifier", "I-Qualifier", "I-Qualifier", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Diagnosis of diabetes mellitus according to World Health Organization criteria ( treatment with insulin or an oral hypoglycemic agent, twice random glucose measurements major than 200 mg/dl, or a fasting glucose major than 140 mg/dl) Ulcer located on the legs or feet, stage III or IV (Wagner Classification System) The subject agrees to comply with study protocol requirements and all follow up visit requirements.	[ "Diagnosis", "of", "diabetes", "mellitus", "according", "to", "World", "Health", "Organization", "criteria", "(", "treatment", "with", "insulin", "or", "an", "oral", "hypoglycemic", "agent", ",", "twice", "random", "glucose", "measurements", "major", "than", "200", "mg", "/", "dl", ",", "or", "a", "fasting", "glucose", "major", "than", "140", "mg", "/", "dl", ")", "\n", "Ulcer", "located", "on", "the", "legs", "or", "feet", ",", "stage", "III", "or", "IV", "(", "Wagner", "Classification", "System", ")", "\n", "The", "subject", "agrees", "to", "comply", "with", "study", "protocol", "requirements", "and", "all", "follow", "up", "visit", "requirements", ".", "\n" ]	[ "Scope", "Qualifier", "Measurement", "Drug", "Value", "Condition", "Procedure", "Multiplier" ]
Osteoporose is an umlsterm, Knochenmassenverlust is an umlsterm, Knochenstruktur is an umlsterm, Frakturgefaehrdung is an umlsterm, Osteoporosediagnostik is an umlsterm, bildgebende is an umlsterm, Computertomographie is an umlsterm, Magnetresonanztomographie is an umlsterm, Knochendichte is an umlsterm, Knochenstabilitaet is an umlsterm, Patienten is an umlsterm, Frakturen is an umlsterm	DerRadiologe.80380853.ger.abstr_task0	Sentence: Bei der Osteoporose kommt es zu einem Knochenmassenverlust und zu einem Umbau der trabekulaeren Knochenstruktur mit erhoehter Frakturgefaehrdung . Ziel der vorliegenden Uebersicht ist es , den Stellenwert strukturanalytischer Verfahren im Rahmen der Osteoporosediagnostik zu analysieren . Als bildgebende Verfahren zur Strukturanalyse wurden konventionelle Radiographie , hochaufloesende Computertomographie ( HR-CT ) und hochaufloesende Magnetresonanztomographie ( HR-MRT ) eingesetzt . Die besten Ergebnisse wurden mit hochaufloesenden tomographischen Verfahren erzielt , wobei die hochaufloesende MRT die beste Ortsaufloesung erzielte . Die vorliegenden Untersuchungen zeigen , dass Texturparameter und Knochendichte sich komplementaer zueinander verhalten . Die Kombination beider Verfahren erzielt die beste Praediktion der biomechanisch bestimmten Knochenstabilitaet und die beste Differenzierung von Patienten mit und ohne osteoporotische Frakturen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O" ]	Bei der Osteoporose kommt es zu einem Knochenmassenverlust und zu einem Umbau der trabekulaeren Knochenstruktur mit erhoehter Frakturgefaehrdung . Ziel der vorliegenden Uebersicht ist es , den Stellenwert strukturanalytischer Verfahren im Rahmen der Osteoporosediagnostik zu analysieren . Als bildgebende Verfahren zur Strukturanalyse wurden konventionelle Radiographie , hochaufloesende Computertomographie ( HR-CT ) und hochaufloesende Magnetresonanztomographie ( HR-MRT ) eingesetzt . Die besten Ergebnisse wurden mit hochaufloesenden tomographischen Verfahren erzielt , wobei die hochaufloesende MRT die beste Ortsaufloesung erzielte . Die vorliegenden Untersuchungen zeigen , dass Texturparameter und Knochendichte sich komplementaer zueinander verhalten . Die Kombination beider Verfahren erzielt die beste Praediktion der biomechanisch bestimmten Knochenstabilitaet und die beste Differenzierung von Patienten mit und ohne osteoporotische Frakturen .	[ "Bei", "der", "Osteoporose", "kommt", "es", "zu", "einem", "Knochenmassenverlust", "und", "zu", "einem", "Umbau", "der", "trabekulaeren", "Knochenstruktur", "mit", "erhoehter", "Frakturgefaehrdung", ".", "Ziel", "der", "vorliegenden", "Uebersicht", "ist", "es", ",", "den", "Stellenwert", "strukturanalytischer", "Verfahren", "im", "Rahmen", "der", "Osteoporosediagnostik", "zu", "analysieren", ".", "Als", "bildgebende", "Verfahren", "zur", "Strukturanalyse", "wurden", "konventionelle", "Radiographie", ",", "hochaufloesende", "Computertomographie", "(", "HR", "-", "CT", ")", "und", "hochaufloesende", "Magnetresonanztomographie", "(", "HR", "-", "MRT", ")", "eingesetzt", ".", "Die", "besten", "Ergebnisse", "wurden", "mit", "hochaufloesenden", "tomographischen", "Verfahren", "erzielt", ",", "wobei", "die", "hochaufloesende", "MRT", "die", "beste", "Ortsaufloesung", "erzielte", ".", "Die", "vorliegenden", "Untersuchungen", "zeigen", ",", "dass", "Texturparameter", "und", "Knochendichte", "sich", "komplementaer", "zueinander", "verhalten", ".", "Die", "Kombination", "beider", "Verfahren", "erzielt", "die", "beste", "Praediktion", "der", "biomechanisch", "bestimmten", "Knochenstabilitaet", "und", "die", "beste", "Differenzierung", "von", "Patienten", "mit", "und", "ohne", "osteoporotische", "Frakturen", "." ]	[ "umlsterm" ]
Osteoporose is an umlsterm, Knochenmassenverlust is an umlsterm, Knochenstruktur is an umlsterm, Frakturgefaehrdung is an umlsterm, Osteoporosediagnostik is an umlsterm, bildgebende is an umlsterm, Computertomographie is an umlsterm, Magnetresonanztomographie is an umlsterm, Knochendichte is an umlsterm, Knochenstabilitaet is an umlsterm, Patienten is an umlsterm, Frakturen is an umlsterm	DerRadiologe.80380853.ger.abstr_task1	Sentence: Bei der Osteoporose kommt es zu einem Knochenmassenverlust und zu einem Umbau der trabekulaeren Knochenstruktur mit erhoehter Frakturgefaehrdung . Ziel der vorliegenden Uebersicht ist es , den Stellenwert strukturanalytischer Verfahren im Rahmen der Osteoporosediagnostik zu analysieren . Als bildgebende Verfahren zur Strukturanalyse wurden konventionelle Radiographie , hochaufloesende Computertomographie ( HR-CT ) und hochaufloesende Magnetresonanztomographie ( HR-MRT ) eingesetzt . Die besten Ergebnisse wurden mit hochaufloesenden tomographischen Verfahren erzielt , wobei die hochaufloesende MRT die beste Ortsaufloesung erzielte . Die vorliegenden Untersuchungen zeigen , dass Texturparameter und Knochendichte sich komplementaer zueinander verhalten . Die Kombination beider Verfahren erzielt die beste Praediktion der biomechanisch bestimmten Knochenstabilitaet und die beste Differenzierung von Patienten mit und ohne osteoporotische Frakturen . Instructions: please typing these entity words according to sentence: Osteoporose, Knochenmassenverlust, Knochenstruktur, Frakturgefaehrdung, Osteoporosediagnostik, bildgebende, Computertomographie, Magnetresonanztomographie, Knochendichte, Knochenstabilitaet, Patienten, Frakturen Options: umlsterm	[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O" ]	Bei der Osteoporose kommt es zu einem Knochenmassenverlust und zu einem Umbau der trabekulaeren Knochenstruktur mit erhoehter Frakturgefaehrdung . Ziel der vorliegenden Uebersicht ist es , den Stellenwert strukturanalytischer Verfahren im Rahmen der Osteoporosediagnostik zu analysieren . Als bildgebende Verfahren zur Strukturanalyse wurden konventionelle Radiographie , hochaufloesende Computertomographie ( HR-CT ) und hochaufloesende Magnetresonanztomographie ( HR-MRT ) eingesetzt . Die besten Ergebnisse wurden mit hochaufloesenden tomographischen Verfahren erzielt , wobei die hochaufloesende MRT die beste Ortsaufloesung erzielte . Die vorliegenden Untersuchungen zeigen , dass Texturparameter und Knochendichte sich komplementaer zueinander verhalten . Die Kombination beider Verfahren erzielt die beste Praediktion der biomechanisch bestimmten Knochenstabilitaet und die beste Differenzierung von Patienten mit und ohne osteoporotische Frakturen .	[ "Bei", "der", "Osteoporose", "kommt", "es", "zu", "einem", "Knochenmassenverlust", "und", "zu", "einem", "Umbau", "der", "trabekulaeren", "Knochenstruktur", "mit", "erhoehter", "Frakturgefaehrdung", ".", "Ziel", "der", "vorliegenden", "Uebersicht", "ist", "es", ",", "den", "Stellenwert", "strukturanalytischer", "Verfahren", "im", "Rahmen", "der", "Osteoporosediagnostik", "zu", "analysieren", ".", "Als", "bildgebende", "Verfahren", "zur", "Strukturanalyse", "wurden", "konventionelle", "Radiographie", ",", "hochaufloesende", "Computertomographie", "(", "HR", "-", "CT", ")", "und", "hochaufloesende", "Magnetresonanztomographie", "(", "HR", "-", "MRT", ")", "eingesetzt", ".", "Die", "besten", "Ergebnisse", "wurden", "mit", "hochaufloesenden", "tomographischen", "Verfahren", "erzielt", ",", "wobei", "die", "hochaufloesende", "MRT", "die", "beste", "Ortsaufloesung", "erzielte", ".", "Die", "vorliegenden", "Untersuchungen", "zeigen", ",", "dass", "Texturparameter", "und", "Knochendichte", "sich", "komplementaer", "zueinander", "verhalten", ".", "Die", "Kombination", "beider", "Verfahren", "erzielt", "die", "beste", "Praediktion", "der", "biomechanisch", "bestimmten", "Knochenstabilitaet", "und", "die", "beste", "Differenzierung", "von", "Patienten", "mit", "und", "ohne", "osteoporotische", "Frakturen", "." ]	[ "umlsterm" ]
Osteoporose, Knochenmassenverlust, Knochenstruktur, Frakturgefaehrdung, Osteoporosediagnostik, bildgebende, Computertomographie, Magnetresonanztomographie, Knochendichte, Knochenstabilitaet, Patienten, Frakturen	DerRadiologe.80380853.ger.abstr_task2	Sentence: Bei der Osteoporose kommt es zu einem Knochenmassenverlust und zu einem Umbau der trabekulaeren Knochenstruktur mit erhoehter Frakturgefaehrdung . Ziel der vorliegenden Uebersicht ist es , den Stellenwert strukturanalytischer Verfahren im Rahmen der Osteoporosediagnostik zu analysieren . Als bildgebende Verfahren zur Strukturanalyse wurden konventionelle Radiographie , hochaufloesende Computertomographie ( HR-CT ) und hochaufloesende Magnetresonanztomographie ( HR-MRT ) eingesetzt . Die besten Ergebnisse wurden mit hochaufloesenden tomographischen Verfahren erzielt , wobei die hochaufloesende MRT die beste Ortsaufloesung erzielte . Die vorliegenden Untersuchungen zeigen , dass Texturparameter und Knochendichte sich komplementaer zueinander verhalten . Die Kombination beider Verfahren erzielt die beste Praediktion der biomechanisch bestimmten Knochenstabilitaet und die beste Differenzierung von Patienten mit und ohne osteoporotische Frakturen . Instructions: please extract entity words from the input sentence	[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O" ]	Bei der Osteoporose kommt es zu einem Knochenmassenverlust und zu einem Umbau der trabekulaeren Knochenstruktur mit erhoehter Frakturgefaehrdung . Ziel der vorliegenden Uebersicht ist es , den Stellenwert strukturanalytischer Verfahren im Rahmen der Osteoporosediagnostik zu analysieren . Als bildgebende Verfahren zur Strukturanalyse wurden konventionelle Radiographie , hochaufloesende Computertomographie ( HR-CT ) und hochaufloesende Magnetresonanztomographie ( HR-MRT ) eingesetzt . Die besten Ergebnisse wurden mit hochaufloesenden tomographischen Verfahren erzielt , wobei die hochaufloesende MRT die beste Ortsaufloesung erzielte . Die vorliegenden Untersuchungen zeigen , dass Texturparameter und Knochendichte sich komplementaer zueinander verhalten . Die Kombination beider Verfahren erzielt die beste Praediktion der biomechanisch bestimmten Knochenstabilitaet und die beste Differenzierung von Patienten mit und ohne osteoporotische Frakturen .	[ "Bei", "der", "Osteoporose", "kommt", "es", "zu", "einem", "Knochenmassenverlust", "und", "zu", "einem", "Umbau", "der", "trabekulaeren", "Knochenstruktur", "mit", "erhoehter", "Frakturgefaehrdung", ".", "Ziel", "der", "vorliegenden", "Uebersicht", "ist", "es", ",", "den", "Stellenwert", "strukturanalytischer", "Verfahren", "im", "Rahmen", "der", "Osteoporosediagnostik", "zu", "analysieren", ".", "Als", "bildgebende", "Verfahren", "zur", "Strukturanalyse", "wurden", "konventionelle", "Radiographie", ",", "hochaufloesende", "Computertomographie", "(", "HR", "-", "CT", ")", "und", "hochaufloesende", "Magnetresonanztomographie", "(", "HR", "-", "MRT", ")", "eingesetzt", ".", "Die", "besten", "Ergebnisse", "wurden", "mit", "hochaufloesenden", "tomographischen", "Verfahren", "erzielt", ",", "wobei", "die", "hochaufloesende", "MRT", "die", "beste", "Ortsaufloesung", "erzielte", ".", "Die", "vorliegenden", "Untersuchungen", "zeigen", ",", "dass", "Texturparameter", "und", "Knochendichte", "sich", "komplementaer", "zueinander", "verhalten", ".", "Die", "Kombination", "beider", "Verfahren", "erzielt", "die", "beste", "Praediktion", "der", "biomechanisch", "bestimmten", "Knochenstabilitaet", "und", "die", "beste", "Differenzierung", "von", "Patienten", "mit", "und", "ohne", "osteoporotische", "Frakturen", "." ]	[ "umlsterm" ]
Gliclazide is a compound, gliclazide is a compound, CYP2C9 is a protein, CYP2C19 is a protein	DS.d305_task0	Sentence: Gliclazide can change the conformation of the active sites and decrease obviously the affinities between gliclazide in the active site and enzymes when it is docked in the second active sites in CYP2C9 and CYP2C19. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: compound, protein	[ "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "B-protein", "O" ]	Gliclazide can change the conformation of the active sites and decrease obviously the affinities between gliclazide in the active site and enzymes when it is docked in the second active sites in CYP2C9 and CYP2C19.	[ "Gliclazide", "can", "change", "the", "conformation", "of", "the", "active", "sites", "and", "decrease", "obviously", "the", "affinities", "between", "gliclazide", "in", "the", "active", "site", "and", "enzymes", "when", "it", "is", "docked", "in", "the", "second", "active", "sites", "in", "CYP2C9", "and", "CYP2C19", "." ]	[ "compound", "protein" ]
Gliclazide is a compound, gliclazide is a compound, CYP2C9 is a protein, CYP2C19 is a protein	DS.d305_task1	Sentence: Gliclazide can change the conformation of the active sites and decrease obviously the affinities between gliclazide in the active site and enzymes when it is docked in the second active sites in CYP2C9 and CYP2C19. Instructions: please typing these entity words according to sentence: Gliclazide, gliclazide, CYP2C9, CYP2C19 Options: compound, protein	[ "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "B-protein", "O" ]	Gliclazide can change the conformation of the active sites and decrease obviously the affinities between gliclazide in the active site and enzymes when it is docked in the second active sites in CYP2C9 and CYP2C19.	[ "Gliclazide", "can", "change", "the", "conformation", "of", "the", "active", "sites", "and", "decrease", "obviously", "the", "affinities", "between", "gliclazide", "in", "the", "active", "site", "and", "enzymes", "when", "it", "is", "docked", "in", "the", "second", "active", "sites", "in", "CYP2C9", "and", "CYP2C19", "." ]	[ "compound", "protein" ]
Gliclazide, gliclazide, CYP2C9, CYP2C19	DS.d305_task2	Sentence: Gliclazide can change the conformation of the active sites and decrease obviously the affinities between gliclazide in the active site and enzymes when it is docked in the second active sites in CYP2C9 and CYP2C19. Instructions: please extract entity words from the input sentence	[ "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "B-protein", "O" ]	Gliclazide can change the conformation of the active sites and decrease obviously the affinities between gliclazide in the active site and enzymes when it is docked in the second active sites in CYP2C9 and CYP2C19.	[ "Gliclazide", "can", "change", "the", "conformation", "of", "the", "active", "sites", "and", "decrease", "obviously", "the", "affinities", "between", "gliclazide", "in", "the", "active", "site", "and", "enzymes", "when", "it", "is", "docked", "in", "the", "second", "active", "sites", "in", "CYP2C9", "and", "CYP2C19", "." ]	[ "compound", "protein" ]
supine BP is a Measurement, > 140 mm Hg systolic or > 90 mm Hg diastolic or < 100 mm Hg systolic or < 60 mm Hg diastolic is a Scope, Serum potassium is a Measurement, > = 5.1 mmol / L or < 3.5 mmol / L is a Scope, at screening is a Temporal, Estimated GFR is a Measurement, < 60 mL / min/1.73 m2 is a Value, Cockcroft - Gault formula is a Observation	NCT01314898_exc_task0	Sentence: Subjects with a supine BP >140 mm Hg systolic or >90 mm Hg diastolic or <100 mm Hg systolic or <60 mm Hg diastolic based on the average of the triplicate Serum potassium >=5.1 mmol/L or <3.5 mmol/L at screening, confirmed by a single repeat if deemed necessary. Estimated GFR <60 mL/min/1.73 m2 using the Cockcroft-Gault formula measurement of the individual parameters following at least 5 minutes of rest at Screening. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Temporal, Value, Observation, Scope, Measurement	[ "O", "O", "O", "B-Measurement", "I-Measurement", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "O", "O", "B-Measurement", "I-Measurement", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "O", "B-Observation", "I-Observation", "I-Observation", "I-Observation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Subjects with a supine BP >140 mm Hg systolic or >90 mm Hg diastolic or <100 mm Hg systolic or <60 mm Hg diastolic based on the average of the triplicate Serum potassium >=5.1 mmol/L or <3.5 mmol/L at screening, confirmed by a single repeat if deemed necessary. Estimated GFR <60 mL/min/1.73 m2 using the Cockcroft-Gault formula measurement of the individual parameters following at least 5 minutes of rest at Screening.	[ "Subjects", "with", "a", "supine", "BP", ">", "140", "mm", "Hg", "systolic", "or", ">", "90", "mm", "Hg", "diastolic", "or", "<", "100", "mm", "Hg", "systolic", "or", "<", "60", "mm", "Hg", "diastolic", "based", "on", "the", "average", "of", "the", "triplicate", "\n", "Serum", "potassium", ">", "=", "5.1", "mmol", "/", "L", "or", "<", "3.5", "mmol", "/", "L", "at", "screening", ",", "confirmed", "by", "a", "single", "repeat", "if", "deemed", "necessary", ".", "\n", "Estimated", "GFR", "<", "60", "mL", "/", "min/1.73", "m2", "using", "the", "Cockcroft", "-", "Gault", "formula", "measurement", "of", "the", "individual", "parameters", "following", "at", "least", "5", "minutes", "of", "rest", "at", "Screening", ".", " \n \n" ]	[ "Scope", "Observation", "Value", "Measurement", "Temporal" ]
supine BP is a Measurement, > 140 mm Hg systolic or > 90 mm Hg diastolic or < 100 mm Hg systolic or < 60 mm Hg diastolic is a Scope, Serum potassium is a Measurement, > = 5.1 mmol / L or < 3.5 mmol / L is a Scope, at screening is a Temporal, Estimated GFR is a Measurement, < 60 mL / min/1.73 m2 is a Value, Cockcroft - Gault formula is a Observation	NCT01314898_exc_task1	Sentence: Subjects with a supine BP >140 mm Hg systolic or >90 mm Hg diastolic or <100 mm Hg systolic or <60 mm Hg diastolic based on the average of the triplicate Serum potassium >=5.1 mmol/L or <3.5 mmol/L at screening, confirmed by a single repeat if deemed necessary. Estimated GFR <60 mL/min/1.73 m2 using the Cockcroft-Gault formula measurement of the individual parameters following at least 5 minutes of rest at Screening. Instructions: please typing these entity words according to sentence: supine BP, > 140 mm Hg systolic or > 90 mm Hg diastolic or < 100 mm Hg systolic or < 60 mm Hg diastolic, Serum potassium, > = 5.1 mmol / L or < 3.5 mmol / L, at screening, Estimated GFR, < 60 mL / min/1.73 m2, Cockcroft - Gault formula Options: Temporal, Value, Observation, Scope, Measurement	[ "O", "O", "O", "B-Measurement", "I-Measurement", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "O", "O", "B-Measurement", "I-Measurement", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "O", "B-Observation", "I-Observation", "I-Observation", "I-Observation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Subjects with a supine BP >140 mm Hg systolic or >90 mm Hg diastolic or <100 mm Hg systolic or <60 mm Hg diastolic based on the average of the triplicate Serum potassium >=5.1 mmol/L or <3.5 mmol/L at screening, confirmed by a single repeat if deemed necessary. Estimated GFR <60 mL/min/1.73 m2 using the Cockcroft-Gault formula measurement of the individual parameters following at least 5 minutes of rest at Screening.	[ "Subjects", "with", "a", "supine", "BP", ">", "140", "mm", "Hg", "systolic", "or", ">", "90", "mm", "Hg", "diastolic", "or", "<", "100", "mm", "Hg", "systolic", "or", "<", "60", "mm", "Hg", "diastolic", "based", "on", "the", "average", "of", "the", "triplicate", "\n", "Serum", "potassium", ">", "=", "5.1", "mmol", "/", "L", "or", "<", "3.5", "mmol", "/", "L", "at", "screening", ",", "confirmed", "by", "a", "single", "repeat", "if", "deemed", "necessary", ".", "\n", "Estimated", "GFR", "<", "60", "mL", "/", "min/1.73", "m2", "using", "the", "Cockcroft", "-", "Gault", "formula", "measurement", "of", "the", "individual", "parameters", "following", "at", "least", "5", "minutes", "of", "rest", "at", "Screening", ".", " \n \n" ]	[ "Scope", "Observation", "Value", "Measurement", "Temporal" ]
supine BP, > 140 mm Hg systolic or > 90 mm Hg diastolic or < 100 mm Hg systolic or < 60 mm Hg diastolic, Serum potassium, > = 5.1 mmol / L or < 3.5 mmol / L, at screening, Estimated GFR, < 60 mL / min/1.73 m2, Cockcroft - Gault formula	NCT01314898_exc_task2	Sentence: Subjects with a supine BP >140 mm Hg systolic or >90 mm Hg diastolic or <100 mm Hg systolic or <60 mm Hg diastolic based on the average of the triplicate Serum potassium >=5.1 mmol/L or <3.5 mmol/L at screening, confirmed by a single repeat if deemed necessary. Estimated GFR <60 mL/min/1.73 m2 using the Cockcroft-Gault formula measurement of the individual parameters following at least 5 minutes of rest at Screening. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-Measurement", "I-Measurement", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "O", "O", "B-Measurement", "I-Measurement", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "O", "B-Observation", "I-Observation", "I-Observation", "I-Observation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Subjects with a supine BP >140 mm Hg systolic or >90 mm Hg diastolic or <100 mm Hg systolic or <60 mm Hg diastolic based on the average of the triplicate Serum potassium >=5.1 mmol/L or <3.5 mmol/L at screening, confirmed by a single repeat if deemed necessary. Estimated GFR <60 mL/min/1.73 m2 using the Cockcroft-Gault formula measurement of the individual parameters following at least 5 minutes of rest at Screening.	[ "Subjects", "with", "a", "supine", "BP", ">", "140", "mm", "Hg", "systolic", "or", ">", "90", "mm", "Hg", "diastolic", "or", "<", "100", "mm", "Hg", "systolic", "or", "<", "60", "mm", "Hg", "diastolic", "based", "on", "the", "average", "of", "the", "triplicate", "\n", "Serum", "potassium", ">", "=", "5.1", "mmol", "/", "L", "or", "<", "3.5", "mmol", "/", "L", "at", "screening", ",", "confirmed", "by", "a", "single", "repeat", "if", "deemed", "necessary", ".", "\n", "Estimated", "GFR", "<", "60", "mL", "/", "min/1.73", "m2", "using", "the", "Cockcroft", "-", "Gault", "formula", "measurement", "of", "the", "individual", "parameters", "following", "at", "least", "5", "minutes", "of", "rest", "at", "Screening", ".", " \n \n" ]	[ "Scope", "Observation", "Value", "Measurement", "Temporal" ]
Zehe is an umlsterm, Druckstellen is an umlsterm, Schuhversorgung is an umlsterm	OperativeOrthopaedie.00120068.ger.abstr_task0	Sentence: Das Problem Sechsjaehriger Junge mit einseitigem Spaltfuss vom Typ II mit Oligodaktylie und Klinodaktylie der zweiten Zehe . Wegen ungewoehnlicher Vorfussbreite bestehen schmerzhafte Druckstellen und grosse Schwierigkeiten bei der Schuhversorgung . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]	Das Problem Sechsjaehriger Junge mit einseitigem Spaltfuss vom Typ II mit Oligodaktylie und Klinodaktylie der zweiten Zehe . Wegen ungewoehnlicher Vorfussbreite bestehen schmerzhafte Druckstellen und grosse Schwierigkeiten bei der Schuhversorgung .	[ "Das", "Problem", "Sechsjaehriger", "Junge", "mit", "einseitigem", "Spaltfuss", "vom", "Typ", "II", "mit", "Oligodaktylie", "und", "Klinodaktylie", "der", "zweiten", "Zehe", ".", "Wegen", "ungewoehnlicher", "Vorfussbreite", "bestehen", "schmerzhafte", "Druckstellen", "und", "grosse", "Schwierigkeiten", "bei", "der", "Schuhversorgung", "." ]	[ "umlsterm" ]
Zehe is an umlsterm, Druckstellen is an umlsterm, Schuhversorgung is an umlsterm	OperativeOrthopaedie.00120068.ger.abstr_task1	Sentence: Das Problem Sechsjaehriger Junge mit einseitigem Spaltfuss vom Typ II mit Oligodaktylie und Klinodaktylie der zweiten Zehe . Wegen ungewoehnlicher Vorfussbreite bestehen schmerzhafte Druckstellen und grosse Schwierigkeiten bei der Schuhversorgung . Instructions: please typing these entity words according to sentence: Zehe, Druckstellen, Schuhversorgung Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]	Das Problem Sechsjaehriger Junge mit einseitigem Spaltfuss vom Typ II mit Oligodaktylie und Klinodaktylie der zweiten Zehe . Wegen ungewoehnlicher Vorfussbreite bestehen schmerzhafte Druckstellen und grosse Schwierigkeiten bei der Schuhversorgung .	[ "Das", "Problem", "Sechsjaehriger", "Junge", "mit", "einseitigem", "Spaltfuss", "vom", "Typ", "II", "mit", "Oligodaktylie", "und", "Klinodaktylie", "der", "zweiten", "Zehe", ".", "Wegen", "ungewoehnlicher", "Vorfussbreite", "bestehen", "schmerzhafte", "Druckstellen", "und", "grosse", "Schwierigkeiten", "bei", "der", "Schuhversorgung", "." ]	[ "umlsterm" ]
Zehe, Druckstellen, Schuhversorgung	OperativeOrthopaedie.00120068.ger.abstr_task2	Sentence: Das Problem Sechsjaehriger Junge mit einseitigem Spaltfuss vom Typ II mit Oligodaktylie und Klinodaktylie der zweiten Zehe . Wegen ungewoehnlicher Vorfussbreite bestehen schmerzhafte Druckstellen und grosse Schwierigkeiten bei der Schuhversorgung . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]	Das Problem Sechsjaehriger Junge mit einseitigem Spaltfuss vom Typ II mit Oligodaktylie und Klinodaktylie der zweiten Zehe . Wegen ungewoehnlicher Vorfussbreite bestehen schmerzhafte Druckstellen und grosse Schwierigkeiten bei der Schuhversorgung .	[ "Das", "Problem", "Sechsjaehriger", "Junge", "mit", "einseitigem", "Spaltfuss", "vom", "Typ", "II", "mit", "Oligodaktylie", "und", "Klinodaktylie", "der", "zweiten", "Zehe", ".", "Wegen", "ungewoehnlicher", "Vorfussbreite", "bestehen", "schmerzhafte", "Druckstellen", "und", "grosse", "Schwierigkeiten", "bei", "der", "Schuhversorgung", "." ]	[ "umlsterm" ]
Myc is a Protein, Max is a Protein, heterodimer is a Entity, antisense oligonucleotides is a Entity, c - Myc is a Protein, c - Myc is a Protein, Max is a Protein, Myc is a Protein, heterodimers is a Entity, Max is a Protein, Myc is a Protein, Max is a Protein	610_task0	Sentence: Functional Myc-Max heterodimer is required for activation-induced apoptosis in T cell hybridomas. T cell hybridomas respond to activation signals by undergoing apoptotic cell death, and this is likely to represent comparable events related to tolerance induction in immature and mature T cells in vivo. Previous studies using antisense oligonucleotides implicated the c-Myc protein in the phenomenon of activation-induced apoptosis. This role for c-Myc in apoptosis is now confirmed in studies using a dominant negative form of its heterodimeric binding partner, Max, which we show here inhibits activation-induced apoptosis. Further, coexpression of a reciprocally mutant Myc protein capable of forming functional heterodimers with the mutant Max can compensate for the dominant negative activity and restore activation-induced apoptosis. These results imply that Myc promotes activation-induced apoptosis by obligatory heterodimerization with Max, and therefore, by regulating gene transcription. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein	[ "O", "B-Protein", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Functional Myc-Max heterodimer is required for activation-induced apoptosis in T cell hybridomas. T cell hybridomas respond to activation signals by undergoing apoptotic cell death, and this is likely to represent comparable events related to tolerance induction in immature and mature T cells in vivo. Previous studies using antisense oligonucleotides implicated the c-Myc protein in the phenomenon of activation-induced apoptosis. This role for c-Myc in apoptosis is now confirmed in studies using a dominant negative form of its heterodimeric binding partner, Max, which we show here inhibits activation-induced apoptosis. Further, coexpression of a reciprocally mutant Myc protein capable of forming functional heterodimers with the mutant Max can compensate for the dominant negative activity and restore activation-induced apoptosis. These results imply that Myc promotes activation-induced apoptosis by obligatory heterodimerization with Max, and therefore, by regulating gene transcription.	[ "Functional", "Myc", "-", "Max", "heterodimer", "is", "required", "for", "activation", "-", "induced", "apoptosis", "in", "T", "cell", "hybridomas", ".", "\n", "T", "cell", "hybridomas", "respond", "to", "activation", "signals", "by", "undergoing", "apoptotic", "cell", "death", ",", "and", "this", "is", "likely", "to", "represent", "comparable", "events", "related", "to", "tolerance", "induction", "in", "immature", "and", "mature", "T", "cells", "in", "vivo", ".", "Previous", "studies", "using", "antisense", "oligonucleotides", "implicated", "the", "c", "-", "Myc", "protein", "in", "the", "phenomenon", "of", "activation", "-", "induced", "apoptosis", ".", "This", "role", "for", "c", "-", "Myc", "in", "apoptosis", "is", "now", "confirmed", "in", "studies", "using", "a", "dominant", "negative", "form", "of", "its", "heterodimeric", "binding", "partner", ",", "Max", ",", "which", "we", "show", "here", "inhibits", "activation", "-", "induced", "apoptosis", ".", "Further", ",", "coexpression", "of", "a", "reciprocally", "mutant", "Myc", "protein", "capable", "of", "forming", "functional", "heterodimers", "with", "the", "mutant", "Max", "can", "compensate", "for", "the", "dominant", "negative", "activity", "and", "restore", "activation", "-", "induced", "apoptosis", ".", "These", "results", "imply", "that", "Myc", "promotes", "activation", "-", "induced", "apoptosis", "by", "obligatory", "heterodimerization", "with", "Max", ",", "and", "therefore", ",", "by", "regulating", "gene", "transcription", ".", "\n" ]	[ "Entity", "Protein" ]
Myc is a Protein, Max is a Protein, heterodimer is a Entity, antisense oligonucleotides is a Entity, c - Myc is a Protein, c - Myc is a Protein, Max is a Protein, Myc is a Protein, heterodimers is a Entity, Max is a Protein, Myc is a Protein, Max is a Protein	610_task1	Sentence: Functional Myc-Max heterodimer is required for activation-induced apoptosis in T cell hybridomas. T cell hybridomas respond to activation signals by undergoing apoptotic cell death, and this is likely to represent comparable events related to tolerance induction in immature and mature T cells in vivo. Previous studies using antisense oligonucleotides implicated the c-Myc protein in the phenomenon of activation-induced apoptosis. This role for c-Myc in apoptosis is now confirmed in studies using a dominant negative form of its heterodimeric binding partner, Max, which we show here inhibits activation-induced apoptosis. Further, coexpression of a reciprocally mutant Myc protein capable of forming functional heterodimers with the mutant Max can compensate for the dominant negative activity and restore activation-induced apoptosis. These results imply that Myc promotes activation-induced apoptosis by obligatory heterodimerization with Max, and therefore, by regulating gene transcription. Instructions: please typing these entity words according to sentence: Myc, Max, heterodimer, antisense oligonucleotides, c - Myc, c - Myc, Max, Myc, heterodimers, Max, Myc, Max Options: Entity, Protein	[ "O", "B-Protein", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Functional Myc-Max heterodimer is required for activation-induced apoptosis in T cell hybridomas. T cell hybridomas respond to activation signals by undergoing apoptotic cell death, and this is likely to represent comparable events related to tolerance induction in immature and mature T cells in vivo. Previous studies using antisense oligonucleotides implicated the c-Myc protein in the phenomenon of activation-induced apoptosis. This role for c-Myc in apoptosis is now confirmed in studies using a dominant negative form of its heterodimeric binding partner, Max, which we show here inhibits activation-induced apoptosis. Further, coexpression of a reciprocally mutant Myc protein capable of forming functional heterodimers with the mutant Max can compensate for the dominant negative activity and restore activation-induced apoptosis. These results imply that Myc promotes activation-induced apoptosis by obligatory heterodimerization with Max, and therefore, by regulating gene transcription.	[ "Functional", "Myc", "-", "Max", "heterodimer", "is", "required", "for", "activation", "-", "induced", "apoptosis", "in", "T", "cell", "hybridomas", ".", "\n", "T", "cell", "hybridomas", "respond", "to", "activation", "signals", "by", "undergoing", "apoptotic", "cell", "death", ",", "and", "this", "is", "likely", "to", "represent", "comparable", "events", "related", "to", "tolerance", "induction", "in", "immature", "and", "mature", "T", "cells", "in", "vivo", ".", "Previous", "studies", "using", "antisense", "oligonucleotides", "implicated", "the", "c", "-", "Myc", "protein", "in", "the", "phenomenon", "of", "activation", "-", "induced", "apoptosis", ".", "This", "role", "for", "c", "-", "Myc", "in", "apoptosis", "is", "now", "confirmed", "in", "studies", "using", "a", "dominant", "negative", "form", "of", "its", "heterodimeric", "binding", "partner", ",", "Max", ",", "which", "we", "show", "here", "inhibits", "activation", "-", "induced", "apoptosis", ".", "Further", ",", "coexpression", "of", "a", "reciprocally", "mutant", "Myc", "protein", "capable", "of", "forming", "functional", "heterodimers", "with", "the", "mutant", "Max", "can", "compensate", "for", "the", "dominant", "negative", "activity", "and", "restore", "activation", "-", "induced", "apoptosis", ".", "These", "results", "imply", "that", "Myc", "promotes", "activation", "-", "induced", "apoptosis", "by", "obligatory", "heterodimerization", "with", "Max", ",", "and", "therefore", ",", "by", "regulating", "gene", "transcription", ".", "\n" ]	[ "Entity", "Protein" ]
Myc, Max, heterodimer, antisense oligonucleotides, c - Myc, c - Myc, Max, Myc, heterodimers, Max, Myc, Max	610_task2	Sentence: Functional Myc-Max heterodimer is required for activation-induced apoptosis in T cell hybridomas. T cell hybridomas respond to activation signals by undergoing apoptotic cell death, and this is likely to represent comparable events related to tolerance induction in immature and mature T cells in vivo. Previous studies using antisense oligonucleotides implicated the c-Myc protein in the phenomenon of activation-induced apoptosis. This role for c-Myc in apoptosis is now confirmed in studies using a dominant negative form of its heterodimeric binding partner, Max, which we show here inhibits activation-induced apoptosis. Further, coexpression of a reciprocally mutant Myc protein capable of forming functional heterodimers with the mutant Max can compensate for the dominant negative activity and restore activation-induced apoptosis. These results imply that Myc promotes activation-induced apoptosis by obligatory heterodimerization with Max, and therefore, by regulating gene transcription. Instructions: please extract entity words from the input sentence	[ "O", "B-Protein", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Functional Myc-Max heterodimer is required for activation-induced apoptosis in T cell hybridomas. T cell hybridomas respond to activation signals by undergoing apoptotic cell death, and this is likely to represent comparable events related to tolerance induction in immature and mature T cells in vivo. Previous studies using antisense oligonucleotides implicated the c-Myc protein in the phenomenon of activation-induced apoptosis. This role for c-Myc in apoptosis is now confirmed in studies using a dominant negative form of its heterodimeric binding partner, Max, which we show here inhibits activation-induced apoptosis. Further, coexpression of a reciprocally mutant Myc protein capable of forming functional heterodimers with the mutant Max can compensate for the dominant negative activity and restore activation-induced apoptosis. These results imply that Myc promotes activation-induced apoptosis by obligatory heterodimerization with Max, and therefore, by regulating gene transcription.	[ "Functional", "Myc", "-", "Max", "heterodimer", "is", "required", "for", "activation", "-", "induced", "apoptosis", "in", "T", "cell", "hybridomas", ".", "\n", "T", "cell", "hybridomas", "respond", "to", "activation", "signals", "by", "undergoing", "apoptotic", "cell", "death", ",", "and", "this", "is", "likely", "to", "represent", "comparable", "events", "related", "to", "tolerance", "induction", "in", "immature", "and", "mature", "T", "cells", "in", "vivo", ".", "Previous", "studies", "using", "antisense", "oligonucleotides", "implicated", "the", "c", "-", "Myc", "protein", "in", "the", "phenomenon", "of", "activation", "-", "induced", "apoptosis", ".", "This", "role", "for", "c", "-", "Myc", "in", "apoptosis", "is", "now", "confirmed", "in", "studies", "using", "a", "dominant", "negative", "form", "of", "its", "heterodimeric", "binding", "partner", ",", "Max", ",", "which", "we", "show", "here", "inhibits", "activation", "-", "induced", "apoptosis", ".", "Further", ",", "coexpression", "of", "a", "reciprocally", "mutant", "Myc", "protein", "capable", "of", "forming", "functional", "heterodimers", "with", "the", "mutant", "Max", "can", "compensate", "for", "the", "dominant", "negative", "activity", "and", "restore", "activation", "-", "induced", "apoptosis", ".", "These", "results", "imply", "that", "Myc", "promotes", "activation", "-", "induced", "apoptosis", "by", "obligatory", "heterodimerization", "with", "Max", ",", "and", "therefore", ",", "by", "regulating", "gene", "transcription", ".", "\n" ]	[ "Entity", "Protein" ]
Methicillin - resistant is an umlsterm, S. aureus is an umlsterm, cause is an umlsterm, infection is an umlsterm, patients is an umlsterm, Germany is an umlsterm, nosocomial infections is an umlsterm, elderly is an umlsterm, patients is an umlsterm, chronic illnesses is an umlsterm, risk of is an umlsterm, epidemiology is an umlsterm, therapy is an umlsterm, recommendations is an umlsterm, prevention is an umlsterm, hospitals is an umlsterm, nursing homes is an umlsterm	ZfuerGerontologie+Geriatrie.00330367.eng.abstr_task0	Sentence: Methicillin-resistant S. aureus ( MRSA ) has become an important cause of severe infection in hospitalized patients all over the world . In Germany a significant increase of nosocomial infections due to MRSA has occurred during the last 10 years . Especially elderly patients with chronic illnesses are at increased risk of becoming colonized or infected with MRSA . This report focuses on epidemiology and therapy of MRSA , and on the recommendations concerning management and prevention of spread of MRSA in hospitals and nursing homes . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O" ]	Methicillin-resistant S. aureus ( MRSA ) has become an important cause of severe infection in hospitalized patients all over the world . In Germany a significant increase of nosocomial infections due to MRSA has occurred during the last 10 years . Especially elderly patients with chronic illnesses are at increased risk of becoming colonized or infected with MRSA . This report focuses on epidemiology and therapy of MRSA , and on the recommendations concerning management and prevention of spread of MRSA in hospitals and nursing homes .	[ "Methicillin", "-", "resistant", "S.", "aureus", "(", "MRSA", ")", "has", "become", "an", "important", "cause", "of", "severe", "infection", "in", "hospitalized", "patients", "all", "over", "the", "world", ".", "In", "Germany", "a", "significant", "increase", "of", "nosocomial", "infections", "due", "to", "MRSA", "has", "occurred", "during", "the", "last", "10", "years", ".", "Especially", "elderly", "patients", "with", "chronic", "illnesses", "are", "at", "increased", "risk", "of", "becoming", "colonized", "or", "infected", "with", "MRSA", ".", "This", "report", "focuses", "on", "epidemiology", "and", "therapy", "of", "MRSA", ",", "and", "on", "the", "recommendations", "concerning", "management", "and", "prevention", "of", "spread", "of", "MRSA", "in", "hospitals", "and", "nursing", "homes", "." ]	[ "umlsterm" ]
Methicillin - resistant is an umlsterm, S. aureus is an umlsterm, cause is an umlsterm, infection is an umlsterm, patients is an umlsterm, Germany is an umlsterm, nosocomial infections is an umlsterm, elderly is an umlsterm, patients is an umlsterm, chronic illnesses is an umlsterm, risk of is an umlsterm, epidemiology is an umlsterm, therapy is an umlsterm, recommendations is an umlsterm, prevention is an umlsterm, hospitals is an umlsterm, nursing homes is an umlsterm	ZfuerGerontologie+Geriatrie.00330367.eng.abstr_task1	Sentence: Methicillin-resistant S. aureus ( MRSA ) has become an important cause of severe infection in hospitalized patients all over the world . In Germany a significant increase of nosocomial infections due to MRSA has occurred during the last 10 years . Especially elderly patients with chronic illnesses are at increased risk of becoming colonized or infected with MRSA . This report focuses on epidemiology and therapy of MRSA , and on the recommendations concerning management and prevention of spread of MRSA in hospitals and nursing homes . Instructions: please typing these entity words according to sentence: Methicillin - resistant, S. aureus, cause, infection, patients, Germany, nosocomial infections, elderly, patients, chronic illnesses, risk of, epidemiology, therapy, recommendations, prevention, hospitals, nursing homes Options: umlsterm	[ "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O" ]	Methicillin-resistant S. aureus ( MRSA ) has become an important cause of severe infection in hospitalized patients all over the world . In Germany a significant increase of nosocomial infections due to MRSA has occurred during the last 10 years . Especially elderly patients with chronic illnesses are at increased risk of becoming colonized or infected with MRSA . This report focuses on epidemiology and therapy of MRSA , and on the recommendations concerning management and prevention of spread of MRSA in hospitals and nursing homes .	[ "Methicillin", "-", "resistant", "S.", "aureus", "(", "MRSA", ")", "has", "become", "an", "important", "cause", "of", "severe", "infection", "in", "hospitalized", "patients", "all", "over", "the", "world", ".", "In", "Germany", "a", "significant", "increase", "of", "nosocomial", "infections", "due", "to", "MRSA", "has", "occurred", "during", "the", "last", "10", "years", ".", "Especially", "elderly", "patients", "with", "chronic", "illnesses", "are", "at", "increased", "risk", "of", "becoming", "colonized", "or", "infected", "with", "MRSA", ".", "This", "report", "focuses", "on", "epidemiology", "and", "therapy", "of", "MRSA", ",", "and", "on", "the", "recommendations", "concerning", "management", "and", "prevention", "of", "spread", "of", "MRSA", "in", "hospitals", "and", "nursing", "homes", "." ]	[ "umlsterm" ]
Methicillin - resistant, S. aureus, cause, infection, patients, Germany, nosocomial infections, elderly, patients, chronic illnesses, risk of, epidemiology, therapy, recommendations, prevention, hospitals, nursing homes	ZfuerGerontologie+Geriatrie.00330367.eng.abstr_task2	Sentence: Methicillin-resistant S. aureus ( MRSA ) has become an important cause of severe infection in hospitalized patients all over the world . In Germany a significant increase of nosocomial infections due to MRSA has occurred during the last 10 years . Especially elderly patients with chronic illnesses are at increased risk of becoming colonized or infected with MRSA . This report focuses on epidemiology and therapy of MRSA , and on the recommendations concerning management and prevention of spread of MRSA in hospitals and nursing homes . Instructions: please extract entity words from the input sentence	[ "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O" ]	Methicillin-resistant S. aureus ( MRSA ) has become an important cause of severe infection in hospitalized patients all over the world . In Germany a significant increase of nosocomial infections due to MRSA has occurred during the last 10 years . Especially elderly patients with chronic illnesses are at increased risk of becoming colonized or infected with MRSA . This report focuses on epidemiology and therapy of MRSA , and on the recommendations concerning management and prevention of spread of MRSA in hospitals and nursing homes .	[ "Methicillin", "-", "resistant", "S.", "aureus", "(", "MRSA", ")", "has", "become", "an", "important", "cause", "of", "severe", "infection", "in", "hospitalized", "patients", "all", "over", "the", "world", ".", "In", "Germany", "a", "significant", "increase", "of", "nosocomial", "infections", "due", "to", "MRSA", "has", "occurred", "during", "the", "last", "10", "years", ".", "Especially", "elderly", "patients", "with", "chronic", "illnesses", "are", "at", "increased", "risk", "of", "becoming", "colonized", "or", "infected", "with", "MRSA", ".", "This", "report", "focuses", "on", "epidemiology", "and", "therapy", "of", "MRSA", ",", "and", "on", "the", "recommendations", "concerning", "management", "and", "prevention", "of", "spread", "of", "MRSA", "in", "hospitals", "and", "nursing", "homes", "." ]	[ "umlsterm" ]
history is an umlsterm, patients is an umlsterm, surgical treatment is an umlsterm, face is an umlsterm, surgical is an umlsterm, flap is an umlsterm, skin grafting is an umlsterm, techniques is an umlsterm, nose is an umlsterm, eyelids is an umlsterm, skin is an umlsterm, defect is an umlsterm, histologic is an umlsterm, control is an umlsterm, tumor is an umlsterm, tumor is an umlsterm, judgement is an umlsterm, procedure is an umlsterm, repair is an umlsterm, Recurrences is an umlsterm, histologic is an umlsterm, growth is an umlsterm, predisposition is an umlsterm, time is an umlsterm, surgical is an umlsterm, face is an umlsterm, techniques is an umlsterm	DerChirurg.90700265.eng.abstr_task0	Sentence: The present investigation reviews the history of 673 patients having undergone surgical treatment for 1301 BCC of the face between 1977 and 1992 at our department . Based on this series the features with bearing on the surgical strategy , such as type , size and location of the lesions , will be outlined . Emphasis is put on the variants of local flap reconstruction and skin grafting techniques , particularly in the problem zones of the nose and eyelids , where no excess skin for closure of the defect is available . Throughout the whole series histologic control of the adequacy of marginal and deep tumor resection was performed . It became obvious that the required ranges for clearance to tumor edges and removal in depth cannot be predefined arbitrarily or on pure clinical judgement . Frequently a two-stage procedure of resection and repair will be necessitated . Recurrences during the mandatory follow-up were thoroughly reassessed to identify the reason for failure ( e . g . accuracy of histologic category , multifocal growth , predisposition ) and related to the time span from primary excision . Our series confirms that morphologically controlled surgical excision of the BCC of the face and subsequent application of reconstructive techniques produces both safe oncologic and esthetic results . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O" ]	The present investigation reviews the history of 673 patients having undergone surgical treatment for 1301 BCC of the face between 1977 and 1992 at our department . Based on this series the features with bearing on the surgical strategy , such as type , size and location of the lesions , will be outlined . Emphasis is put on the variants of local flap reconstruction and skin grafting techniques , particularly in the problem zones of the nose and eyelids , where no excess skin for closure of the defect is available . Throughout the whole series histologic control of the adequacy of marginal and deep tumor resection was performed . It became obvious that the required ranges for clearance to tumor edges and removal in depth cannot be predefined arbitrarily or on pure clinical judgement . Frequently a two-stage procedure of resection and repair will be necessitated . Recurrences during the mandatory follow-up were thoroughly reassessed to identify the reason for failure ( e . g . accuracy of histologic category , multifocal growth , predisposition ) and related to the time span from primary excision . Our series confirms that morphologically controlled surgical excision of the BCC of the face and subsequent application of reconstructive techniques produces both safe oncologic and esthetic results .	[ "The", "present", "investigation", "reviews", "the", "history", "of", "673", "patients", "having", "undergone", "surgical", "treatment", "for", "1301", "BCC", "of", "the", "face", "between", "1977", "and", "1992", "at", "our", "department", ".", "Based", "on", "this", "series", "the", "features", "with", "bearing", "on", "the", "surgical", "strategy", ",", "such", "as", "type", ",", "size", "and", "location", "of", "the", "lesions", ",", "will", "be", "outlined", ".", "Emphasis", "is", "put", "on", "the", "variants", "of", "local", "flap", "reconstruction", "and", "skin", "grafting", "techniques", ",", "particularly", "in", "the", "problem", "zones", "of", "the", "nose", "and", "eyelids", ",", "where", "no", "excess", "skin", "for", "closure", "of", "the", "defect", "is", "available", ".", "Throughout", "the", "whole", "series", "histologic", "control", "of", "the", "adequacy", "of", "marginal", "and", "deep", "tumor", "resection", "was", "performed", ".", "It", "became", "obvious", "that", "the", "required", "ranges", "for", "clearance", "to", "tumor", "edges", "and", "removal", "in", "depth", "cannot", "be", "predefined", "arbitrarily", "or", "on", "pure", "clinical", "judgement", ".", "Frequently", "a", "two", "-", "stage", "procedure", "of", "resection", "and", "repair", "will", "be", "necessitated", ".", "Recurrences", "during", "the", "mandatory", "follow", "-", "up", "were", "thoroughly", "reassessed", "to", "identify", "the", "reason", "for", "failure", "(", "e", ".", "g", ".", "accuracy", "of", "histologic", "category", ",", "multifocal", "growth", ",", "predisposition", ")", "and", "related", "to", "the", "time", "span", "from", "primary", "excision", ".", "Our", "series", "confirms", "that", "morphologically", "controlled", "surgical", "excision", "of", "the", "BCC", "of", "the", "face", "and", "subsequent", "application", "of", "reconstructive", "techniques", "produces", "both", "safe", "oncologic", "and", "esthetic", "results", "." ]	[ "umlsterm" ]
history is an umlsterm, patients is an umlsterm, surgical treatment is an umlsterm, face is an umlsterm, surgical is an umlsterm, flap is an umlsterm, skin grafting is an umlsterm, techniques is an umlsterm, nose is an umlsterm, eyelids is an umlsterm, skin is an umlsterm, defect is an umlsterm, histologic is an umlsterm, control is an umlsterm, tumor is an umlsterm, tumor is an umlsterm, judgement is an umlsterm, procedure is an umlsterm, repair is an umlsterm, Recurrences is an umlsterm, histologic is an umlsterm, growth is an umlsterm, predisposition is an umlsterm, time is an umlsterm, surgical is an umlsterm, face is an umlsterm, techniques is an umlsterm	DerChirurg.90700265.eng.abstr_task1	Sentence: The present investigation reviews the history of 673 patients having undergone surgical treatment for 1301 BCC of the face between 1977 and 1992 at our department . Based on this series the features with bearing on the surgical strategy , such as type , size and location of the lesions , will be outlined . Emphasis is put on the variants of local flap reconstruction and skin grafting techniques , particularly in the problem zones of the nose and eyelids , where no excess skin for closure of the defect is available . Throughout the whole series histologic control of the adequacy of marginal and deep tumor resection was performed . It became obvious that the required ranges for clearance to tumor edges and removal in depth cannot be predefined arbitrarily or on pure clinical judgement . Frequently a two-stage procedure of resection and repair will be necessitated . Recurrences during the mandatory follow-up were thoroughly reassessed to identify the reason for failure ( e . g . accuracy of histologic category , multifocal growth , predisposition ) and related to the time span from primary excision . Our series confirms that morphologically controlled surgical excision of the BCC of the face and subsequent application of reconstructive techniques produces both safe oncologic and esthetic results . Instructions: please typing these entity words according to sentence: history, patients, surgical treatment, face, surgical, flap, skin grafting, techniques, nose, eyelids, skin, defect, histologic, control, tumor, tumor, judgement, procedure, repair, Recurrences, histologic, growth, predisposition, time, surgical, face, techniques Options: umlsterm	[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O" ]	The present investigation reviews the history of 673 patients having undergone surgical treatment for 1301 BCC of the face between 1977 and 1992 at our department . Based on this series the features with bearing on the surgical strategy , such as type , size and location of the lesions , will be outlined . Emphasis is put on the variants of local flap reconstruction and skin grafting techniques , particularly in the problem zones of the nose and eyelids , where no excess skin for closure of the defect is available . Throughout the whole series histologic control of the adequacy of marginal and deep tumor resection was performed . It became obvious that the required ranges for clearance to tumor edges and removal in depth cannot be predefined arbitrarily or on pure clinical judgement . Frequently a two-stage procedure of resection and repair will be necessitated . Recurrences during the mandatory follow-up were thoroughly reassessed to identify the reason for failure ( e . g . accuracy of histologic category , multifocal growth , predisposition ) and related to the time span from primary excision . Our series confirms that morphologically controlled surgical excision of the BCC of the face and subsequent application of reconstructive techniques produces both safe oncologic and esthetic results .	[ "The", "present", "investigation", "reviews", "the", "history", "of", "673", "patients", "having", "undergone", "surgical", "treatment", "for", "1301", "BCC", "of", "the", "face", "between", "1977", "and", "1992", "at", "our", "department", ".", "Based", "on", "this", "series", "the", "features", "with", "bearing", "on", "the", "surgical", "strategy", ",", "such", "as", "type", ",", "size", "and", "location", "of", "the", "lesions", ",", "will", "be", "outlined", ".", "Emphasis", "is", "put", "on", "the", "variants", "of", "local", "flap", "reconstruction", "and", "skin", "grafting", "techniques", ",", "particularly", "in", "the", "problem", "zones", "of", "the", "nose", "and", "eyelids", ",", "where", "no", "excess", "skin", "for", "closure", "of", "the", "defect", "is", "available", ".", "Throughout", "the", "whole", "series", "histologic", "control", "of", "the", "adequacy", "of", "marginal", "and", "deep", "tumor", "resection", "was", "performed", ".", "It", "became", "obvious", "that", "the", "required", "ranges", "for", "clearance", "to", "tumor", "edges", "and", "removal", "in", "depth", "cannot", "be", "predefined", "arbitrarily", "or", "on", "pure", "clinical", "judgement", ".", "Frequently", "a", "two", "-", "stage", "procedure", "of", "resection", "and", "repair", "will", "be", "necessitated", ".", "Recurrences", "during", "the", "mandatory", "follow", "-", "up", "were", "thoroughly", "reassessed", "to", "identify", "the", "reason", "for", "failure", "(", "e", ".", "g", ".", "accuracy", "of", "histologic", "category", ",", "multifocal", "growth", ",", "predisposition", ")", "and", "related", "to", "the", "time", "span", "from", "primary", "excision", ".", "Our", "series", "confirms", "that", "morphologically", "controlled", "surgical", "excision", "of", "the", "BCC", "of", "the", "face", "and", "subsequent", "application", "of", "reconstructive", "techniques", "produces", "both", "safe", "oncologic", "and", "esthetic", "results", "." ]	[ "umlsterm" ]
history, patients, surgical treatment, face, surgical, flap, skin grafting, techniques, nose, eyelids, skin, defect, histologic, control, tumor, tumor, judgement, procedure, repair, Recurrences, histologic, growth, predisposition, time, surgical, face, techniques	DerChirurg.90700265.eng.abstr_task2	Sentence: The present investigation reviews the history of 673 patients having undergone surgical treatment for 1301 BCC of the face between 1977 and 1992 at our department . Based on this series the features with bearing on the surgical strategy , such as type , size and location of the lesions , will be outlined . Emphasis is put on the variants of local flap reconstruction and skin grafting techniques , particularly in the problem zones of the nose and eyelids , where no excess skin for closure of the defect is available . Throughout the whole series histologic control of the adequacy of marginal and deep tumor resection was performed . It became obvious that the required ranges for clearance to tumor edges and removal in depth cannot be predefined arbitrarily or on pure clinical judgement . Frequently a two-stage procedure of resection and repair will be necessitated . Recurrences during the mandatory follow-up were thoroughly reassessed to identify the reason for failure ( e . g . accuracy of histologic category , multifocal growth , predisposition ) and related to the time span from primary excision . Our series confirms that morphologically controlled surgical excision of the BCC of the face and subsequent application of reconstructive techniques produces both safe oncologic and esthetic results . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O" ]	The present investigation reviews the history of 673 patients having undergone surgical treatment for 1301 BCC of the face between 1977 and 1992 at our department . Based on this series the features with bearing on the surgical strategy , such as type , size and location of the lesions , will be outlined . Emphasis is put on the variants of local flap reconstruction and skin grafting techniques , particularly in the problem zones of the nose and eyelids , where no excess skin for closure of the defect is available . Throughout the whole series histologic control of the adequacy of marginal and deep tumor resection was performed . It became obvious that the required ranges for clearance to tumor edges and removal in depth cannot be predefined arbitrarily or on pure clinical judgement . Frequently a two-stage procedure of resection and repair will be necessitated . Recurrences during the mandatory follow-up were thoroughly reassessed to identify the reason for failure ( e . g . accuracy of histologic category , multifocal growth , predisposition ) and related to the time span from primary excision . Our series confirms that morphologically controlled surgical excision of the BCC of the face and subsequent application of reconstructive techniques produces both safe oncologic and esthetic results .	[ "The", "present", "investigation", "reviews", "the", "history", "of", "673", "patients", "having", "undergone", "surgical", "treatment", "for", "1301", "BCC", "of", "the", "face", "between", "1977", "and", "1992", "at", "our", "department", ".", "Based", "on", "this", "series", "the", "features", "with", "bearing", "on", "the", "surgical", "strategy", ",", "such", "as", "type", ",", "size", "and", "location", "of", "the", "lesions", ",", "will", "be", "outlined", ".", "Emphasis", "is", "put", "on", "the", "variants", "of", "local", "flap", "reconstruction", "and", "skin", "grafting", "techniques", ",", "particularly", "in", "the", "problem", "zones", "of", "the", "nose", "and", "eyelids", ",", "where", "no", "excess", "skin", "for", "closure", "of", "the", "defect", "is", "available", ".", "Throughout", "the", "whole", "series", "histologic", "control", "of", "the", "adequacy", "of", "marginal", "and", "deep", "tumor", "resection", "was", "performed", ".", "It", "became", "obvious", "that", "the", "required", "ranges", "for", "clearance", "to", "tumor", "edges", "and", "removal", "in", "depth", "cannot", "be", "predefined", "arbitrarily", "or", "on", "pure", "clinical", "judgement", ".", "Frequently", "a", "two", "-", "stage", "procedure", "of", "resection", "and", "repair", "will", "be", "necessitated", ".", "Recurrences", "during", "the", "mandatory", "follow", "-", "up", "were", "thoroughly", "reassessed", "to", "identify", "the", "reason", "for", "failure", "(", "e", ".", "g", ".", "accuracy", "of", "histologic", "category", ",", "multifocal", "growth", ",", "predisposition", ")", "and", "related", "to", "the", "time", "span", "from", "primary", "excision", ".", "Our", "series", "confirms", "that", "morphologically", "controlled", "surgical", "excision", "of", "the", "BCC", "of", "the", "face", "and", "subsequent", "application", "of", "reconstructive", "techniques", "produces", "both", "safe", "oncologic", "and", "esthetic", "results", "." ]	[ "umlsterm" ]
diagnosis is an umlsterm, neonate is an umlsterm, neonatal hypotonia is an umlsterm, asphyxia is an umlsterm, Craniofacial abnormalities is an umlsterm, fissures is an umlsterm, mouth is an umlsterm, treatment is an umlsterm, Hypogonadism is an umlsterm, cryptorchism is an umlsterm, signs is an umlsterm, age is an umlsterm, obesity is an umlsterm, hyperphagia is an umlsterm, hands is an umlsterm, feet is an umlsterm, neonate is an umlsterm, Diagnostic is an umlsterm, criteria is an umlsterm, therapeutic is an umlsterm, Hydrops fetalis is an umlsterm	MonatsschriftKinderheilkunde.71450515.eng.abstr_task0	Sentence: The diagnosis Prader-Willi-Syndrome ( PWS ) in the neonate is difficult because features like neonatal hypotonia and feeding problems are easily misdiagnosed as a consequence of peripartal asphyxia . Craniofacial abnormalities like narrow bifrontal diameter , almond shaped palpebral fissures and openend downturned mouth are underdiagnosed especially if respiratory treatment is necessary . Hypogonadism in girls and in milder expression in boys ( for example cryptorchism ) are common and unspecific signs at that age . Typical features like obesity and hyperphagia , small hands and feet and small stature are not expressed until the second year . The clinical course of PWS in the neonate is demonstrated in two cases . Diagnostic criteria and therapeutic intervention are discussed . Hydrops fetalis as a seldom feature in PWS has to be taken into consideration . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	The diagnosis Prader-Willi-Syndrome ( PWS ) in the neonate is difficult because features like neonatal hypotonia and feeding problems are easily misdiagnosed as a consequence of peripartal asphyxia . Craniofacial abnormalities like narrow bifrontal diameter , almond shaped palpebral fissures and openend downturned mouth are underdiagnosed especially if respiratory treatment is necessary . Hypogonadism in girls and in milder expression in boys ( for example cryptorchism ) are common and unspecific signs at that age . Typical features like obesity and hyperphagia , small hands and feet and small stature are not expressed until the second year . The clinical course of PWS in the neonate is demonstrated in two cases . Diagnostic criteria and therapeutic intervention are discussed . Hydrops fetalis as a seldom feature in PWS has to be taken into consideration .	[ "The", "diagnosis", "Prader", "-", "Willi", "-", "Syndrome", "(", "PWS", ")", "in", "the", "neonate", "is", "difficult", "because", "features", "like", "neonatal", "hypotonia", "and", "feeding", "problems", "are", "easily", "misdiagnosed", "as", "a", "consequence", "of", "peripartal", "asphyxia", ".", "Craniofacial", "abnormalities", "like", "narrow", "bifrontal", "diameter", ",", "almond", "shaped", "palpebral", "fissures", "and", "openend", "downturned", "mouth", "are", "underdiagnosed", "especially", "if", "respiratory", "treatment", "is", "necessary", ".", "Hypogonadism", "in", "girls", "and", "in", "milder", "expression", "in", "boys", "(", "for", "example", "cryptorchism", ")", "are", "common", "and", "unspecific", "signs", "at", "that", "age", ".", "Typical", "features", "like", "obesity", "and", "hyperphagia", ",", "small", "hands", "and", "feet", "and", "small", "stature", "are", "not", "expressed", "until", "the", "second", "year", ".", "The", "clinical", "course", "of", "PWS", "in", "the", "neonate", "is", "demonstrated", "in", "two", "cases", ".", "Diagnostic", "criteria", "and", "therapeutic", "intervention", "are", "discussed", ".", "Hydrops", "fetalis", "as", "a", "seldom", "feature", "in", "PWS", "has", "to", "be", "taken", "into", "consideration", "." ]	[ "umlsterm" ]
diagnosis is an umlsterm, neonate is an umlsterm, neonatal hypotonia is an umlsterm, asphyxia is an umlsterm, Craniofacial abnormalities is an umlsterm, fissures is an umlsterm, mouth is an umlsterm, treatment is an umlsterm, Hypogonadism is an umlsterm, cryptorchism is an umlsterm, signs is an umlsterm, age is an umlsterm, obesity is an umlsterm, hyperphagia is an umlsterm, hands is an umlsterm, feet is an umlsterm, neonate is an umlsterm, Diagnostic is an umlsterm, criteria is an umlsterm, therapeutic is an umlsterm, Hydrops fetalis is an umlsterm	MonatsschriftKinderheilkunde.71450515.eng.abstr_task1	Sentence: The diagnosis Prader-Willi-Syndrome ( PWS ) in the neonate is difficult because features like neonatal hypotonia and feeding problems are easily misdiagnosed as a consequence of peripartal asphyxia . Craniofacial abnormalities like narrow bifrontal diameter , almond shaped palpebral fissures and openend downturned mouth are underdiagnosed especially if respiratory treatment is necessary . Hypogonadism in girls and in milder expression in boys ( for example cryptorchism ) are common and unspecific signs at that age . Typical features like obesity and hyperphagia , small hands and feet and small stature are not expressed until the second year . The clinical course of PWS in the neonate is demonstrated in two cases . Diagnostic criteria and therapeutic intervention are discussed . Hydrops fetalis as a seldom feature in PWS has to be taken into consideration . Instructions: please typing these entity words according to sentence: diagnosis, neonate, neonatal hypotonia, asphyxia, Craniofacial abnormalities, fissures, mouth, treatment, Hypogonadism, cryptorchism, signs, age, obesity, hyperphagia, hands, feet, neonate, Diagnostic, criteria, therapeutic, Hydrops fetalis Options: umlsterm	[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	The diagnosis Prader-Willi-Syndrome ( PWS ) in the neonate is difficult because features like neonatal hypotonia and feeding problems are easily misdiagnosed as a consequence of peripartal asphyxia . Craniofacial abnormalities like narrow bifrontal diameter , almond shaped palpebral fissures and openend downturned mouth are underdiagnosed especially if respiratory treatment is necessary . Hypogonadism in girls and in milder expression in boys ( for example cryptorchism ) are common and unspecific signs at that age . Typical features like obesity and hyperphagia , small hands and feet and small stature are not expressed until the second year . The clinical course of PWS in the neonate is demonstrated in two cases . Diagnostic criteria and therapeutic intervention are discussed . Hydrops fetalis as a seldom feature in PWS has to be taken into consideration .	[ "The", "diagnosis", "Prader", "-", "Willi", "-", "Syndrome", "(", "PWS", ")", "in", "the", "neonate", "is", "difficult", "because", "features", "like", "neonatal", "hypotonia", "and", "feeding", "problems", "are", "easily", "misdiagnosed", "as", "a", "consequence", "of", "peripartal", "asphyxia", ".", "Craniofacial", "abnormalities", "like", "narrow", "bifrontal", "diameter", ",", "almond", "shaped", "palpebral", "fissures", "and", "openend", "downturned", "mouth", "are", "underdiagnosed", "especially", "if", "respiratory", "treatment", "is", "necessary", ".", "Hypogonadism", "in", "girls", "and", "in", "milder", "expression", "in", "boys", "(", "for", "example", "cryptorchism", ")", "are", "common", "and", "unspecific", "signs", "at", "that", "age", ".", "Typical", "features", "like", "obesity", "and", "hyperphagia", ",", "small", "hands", "and", "feet", "and", "small", "stature", "are", "not", "expressed", "until", "the", "second", "year", ".", "The", "clinical", "course", "of", "PWS", "in", "the", "neonate", "is", "demonstrated", "in", "two", "cases", ".", "Diagnostic", "criteria", "and", "therapeutic", "intervention", "are", "discussed", ".", "Hydrops", "fetalis", "as", "a", "seldom", "feature", "in", "PWS", "has", "to", "be", "taken", "into", "consideration", "." ]	[ "umlsterm" ]
diagnosis, neonate, neonatal hypotonia, asphyxia, Craniofacial abnormalities, fissures, mouth, treatment, Hypogonadism, cryptorchism, signs, age, obesity, hyperphagia, hands, feet, neonate, Diagnostic, criteria, therapeutic, Hydrops fetalis	MonatsschriftKinderheilkunde.71450515.eng.abstr_task2	Sentence: The diagnosis Prader-Willi-Syndrome ( PWS ) in the neonate is difficult because features like neonatal hypotonia and feeding problems are easily misdiagnosed as a consequence of peripartal asphyxia . Craniofacial abnormalities like narrow bifrontal diameter , almond shaped palpebral fissures and openend downturned mouth are underdiagnosed especially if respiratory treatment is necessary . Hypogonadism in girls and in milder expression in boys ( for example cryptorchism ) are common and unspecific signs at that age . Typical features like obesity and hyperphagia , small hands and feet and small stature are not expressed until the second year . The clinical course of PWS in the neonate is demonstrated in two cases . Diagnostic criteria and therapeutic intervention are discussed . Hydrops fetalis as a seldom feature in PWS has to be taken into consideration . Instructions: please extract entity words from the input sentence	[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	The diagnosis Prader-Willi-Syndrome ( PWS ) in the neonate is difficult because features like neonatal hypotonia and feeding problems are easily misdiagnosed as a consequence of peripartal asphyxia . Craniofacial abnormalities like narrow bifrontal diameter , almond shaped palpebral fissures and openend downturned mouth are underdiagnosed especially if respiratory treatment is necessary . Hypogonadism in girls and in milder expression in boys ( for example cryptorchism ) are common and unspecific signs at that age . Typical features like obesity and hyperphagia , small hands and feet and small stature are not expressed until the second year . The clinical course of PWS in the neonate is demonstrated in two cases . Diagnostic criteria and therapeutic intervention are discussed . Hydrops fetalis as a seldom feature in PWS has to be taken into consideration .	[ "The", "diagnosis", "Prader", "-", "Willi", "-", "Syndrome", "(", "PWS", ")", "in", "the", "neonate", "is", "difficult", "because", "features", "like", "neonatal", "hypotonia", "and", "feeding", "problems", "are", "easily", "misdiagnosed", "as", "a", "consequence", "of", "peripartal", "asphyxia", ".", "Craniofacial", "abnormalities", "like", "narrow", "bifrontal", "diameter", ",", "almond", "shaped", "palpebral", "fissures", "and", "openend", "downturned", "mouth", "are", "underdiagnosed", "especially", "if", "respiratory", "treatment", "is", "necessary", ".", "Hypogonadism", "in", "girls", "and", "in", "milder", "expression", "in", "boys", "(", "for", "example", "cryptorchism", ")", "are", "common", "and", "unspecific", "signs", "at", "that", "age", ".", "Typical", "features", "like", "obesity", "and", "hyperphagia", ",", "small", "hands", "and", "feet", "and", "small", "stature", "are", "not", "expressed", "until", "the", "second", "year", ".", "The", "clinical", "course", "of", "PWS", "in", "the", "neonate", "is", "demonstrated", "in", "two", "cases", ".", "Diagnostic", "criteria", "and", "therapeutic", "intervention", "are", "discussed", ".", "Hydrops", "fetalis", "as", "a", "seldom", "feature", "in", "PWS", "has", "to", "be", "taken", "into", "consideration", "." ]	[ "umlsterm" ]
15S)-HPETE is a compound, 15S)-HETE is a compound, Fas ligand is a protein, FADD is a protein, BH3-interacting domain death agonist is a protein, cytochrome c is a protein, PARP-1 is a protein	DS.d237_task0	Sentence: The cells exposed to 10 microM (15S)-HPETE for 3 h or to 40 microM (15S)-HETE for 6 h showed increased expression of Fas ligand and FADD (Fas-associated death domain), caspase 8 activation, Bid (BH3-interacting domain death agonist) cleavage, decrease in mitochondrial membrane potential, cytochrome c release, caspase 3 activation, PARP-1 (poly(ADP-ribose) polymerase-1) cleavage and DNA fragmentation, suggesting the involvement of both extrinsic and intrinsic death pathways. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: compound, protein	[ "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "I-protein", "I-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	The cells exposed to 10 microM (15S)-HPETE for 3 h or to 40 microM (15S)-HETE for 6 h showed increased expression of Fas ligand and FADD (Fas-associated death domain), caspase 8 activation, Bid (BH3-interacting domain death agonist) cleavage, decrease in mitochondrial membrane potential, cytochrome c release, caspase 3 activation, PARP-1 (poly(ADP-ribose) polymerase-1) cleavage and DNA fragmentation, suggesting the involvement of both extrinsic and intrinsic death pathways.	[ "The", "cells", "exposed", "to", "10", "microM", "(", "15S)-HPETE", "for", "3", "h", "or", "to", "40", "microM", "(", "15S)-HETE", "for", "6", "h", "showed", "increased", "expression", "of", "Fas", "ligand", "and", "FADD", "(", "Fas", "-", "associated", "death", "domain", ")", ",", "caspase", "8", "activation", ",", "Bid", "(", "BH3-interacting", "domain", "death", "agonist", ")", "cleavage", ",", "decrease", "in", "mitochondrial", "membrane", "potential", ",", "cytochrome", "c", "release", ",", "caspase", "3", "activation", ",", "PARP-1", "(", "poly(ADP", "-", "ribose", ")", "polymerase-1", ")", "cleavage", "and", "DNA", "fragmentation", ",", "suggesting", "the", "involvement", "of", "both", "extrinsic", "and", "intrinsic", "death", "pathways", "." ]	[ "protein", "compound" ]
15S)-HPETE is a compound, 15S)-HETE is a compound, Fas ligand is a protein, FADD is a protein, BH3-interacting domain death agonist is a protein, cytochrome c is a protein, PARP-1 is a protein	DS.d237_task1	Sentence: The cells exposed to 10 microM (15S)-HPETE for 3 h or to 40 microM (15S)-HETE for 6 h showed increased expression of Fas ligand and FADD (Fas-associated death domain), caspase 8 activation, Bid (BH3-interacting domain death agonist) cleavage, decrease in mitochondrial membrane potential, cytochrome c release, caspase 3 activation, PARP-1 (poly(ADP-ribose) polymerase-1) cleavage and DNA fragmentation, suggesting the involvement of both extrinsic and intrinsic death pathways. Instructions: please typing these entity words according to sentence: 15S)-HPETE, 15S)-HETE, Fas ligand, FADD, BH3-interacting domain death agonist, cytochrome c, PARP-1 Options: compound, protein	[ "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "I-protein", "I-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	The cells exposed to 10 microM (15S)-HPETE for 3 h or to 40 microM (15S)-HETE for 6 h showed increased expression of Fas ligand and FADD (Fas-associated death domain), caspase 8 activation, Bid (BH3-interacting domain death agonist) cleavage, decrease in mitochondrial membrane potential, cytochrome c release, caspase 3 activation, PARP-1 (poly(ADP-ribose) polymerase-1) cleavage and DNA fragmentation, suggesting the involvement of both extrinsic and intrinsic death pathways.	[ "The", "cells", "exposed", "to", "10", "microM", "(", "15S)-HPETE", "for", "3", "h", "or", "to", "40", "microM", "(", "15S)-HETE", "for", "6", "h", "showed", "increased", "expression", "of", "Fas", "ligand", "and", "FADD", "(", "Fas", "-", "associated", "death", "domain", ")", ",", "caspase", "8", "activation", ",", "Bid", "(", "BH3-interacting", "domain", "death", "agonist", ")", "cleavage", ",", "decrease", "in", "mitochondrial", "membrane", "potential", ",", "cytochrome", "c", "release", ",", "caspase", "3", "activation", ",", "PARP-1", "(", "poly(ADP", "-", "ribose", ")", "polymerase-1", ")", "cleavage", "and", "DNA", "fragmentation", ",", "suggesting", "the", "involvement", "of", "both", "extrinsic", "and", "intrinsic", "death", "pathways", "." ]	[ "protein", "compound" ]
15S)-HPETE, 15S)-HETE, Fas ligand, FADD, BH3-interacting domain death agonist, cytochrome c, PARP-1	DS.d237_task2	Sentence: The cells exposed to 10 microM (15S)-HPETE for 3 h or to 40 microM (15S)-HETE for 6 h showed increased expression of Fas ligand and FADD (Fas-associated death domain), caspase 8 activation, Bid (BH3-interacting domain death agonist) cleavage, decrease in mitochondrial membrane potential, cytochrome c release, caspase 3 activation, PARP-1 (poly(ADP-ribose) polymerase-1) cleavage and DNA fragmentation, suggesting the involvement of both extrinsic and intrinsic death pathways. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "I-protein", "I-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	The cells exposed to 10 microM (15S)-HPETE for 3 h or to 40 microM (15S)-HETE for 6 h showed increased expression of Fas ligand and FADD (Fas-associated death domain), caspase 8 activation, Bid (BH3-interacting domain death agonist) cleavage, decrease in mitochondrial membrane potential, cytochrome c release, caspase 3 activation, PARP-1 (poly(ADP-ribose) polymerase-1) cleavage and DNA fragmentation, suggesting the involvement of both extrinsic and intrinsic death pathways.	[ "The", "cells", "exposed", "to", "10", "microM", "(", "15S)-HPETE", "for", "3", "h", "or", "to", "40", "microM", "(", "15S)-HETE", "for", "6", "h", "showed", "increased", "expression", "of", "Fas", "ligand", "and", "FADD", "(", "Fas", "-", "associated", "death", "domain", ")", ",", "caspase", "8", "activation", ",", "Bid", "(", "BH3-interacting", "domain", "death", "agonist", ")", "cleavage", ",", "decrease", "in", "mitochondrial", "membrane", "potential", ",", "cytochrome", "c", "release", ",", "caspase", "3", "activation", ",", "PARP-1", "(", "poly(ADP", "-", "ribose", ")", "polymerase-1", ")", "cleavage", "and", "DNA", "fragmentation", ",", "suggesting", "the", "involvement", "of", "both", "extrinsic", "and", "intrinsic", "death", "pathways", "." ]	[ "protein", "compound" ]
fumarylacetoacetate hydrolase is a Gene, FAH is a Gene, G158D is a SNP, P261L is a SNP, F405H is a SNP, DEL366S is a SNP, IVS2 + 1(g - t ) is a SNP, IVS6 - 1(g - c ) is a SNP, IVS8 - 1(g - c ) is a SNP, IVS6 - 1(g - t ) is a SNP, IVS12 + 5(g - a ) is a SNP	487_task0	Sentence: Spectrum of mutations in the fumarylacetoacetate hydrolase gene of tyrosinemia type 1 patients in northwestern Europe and Mediterranean countries. Hereditary tyrosinemia type 1 (HT1) is a rare metabolic disease caused by a deficient activity of the enzyme fumarylacetoacetase (FAH). To investigate the molecular heterogeneity of tyrosinemia, the geographic distribution and the genotype-phenotype relationship, we have analyzed the FAH genotype of 25 HT1 patients. Mutation screening was performed by PCR amplification of exons 1-14 of the FAH gene, followed by SSCP analysis and direct sequencing of the amplified exons. Fourteen different mutations were found, of which seven were novel, viz. three missense mutations (G158D, P261L, F405H), a deletion of three nucleotides causing a deletion of serine (DEL366S) and three splice site mutations: IVS2+1(g-t), IVS6-1(g-c), IVS8-1(g-c). The splice site mutations IVS6-1(g-t) and IVS12+5(g-a) were frequently found in countries around the Mediterranean and northwestern Europe, respectively. No clear correlation between the genotype and the three major HT1 subtypes could be established. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Gene, SNP	[ "O", "O", "O", "O", "O", "B-Gene", "I-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-SNP", "O", "B-SNP", "O", "B-SNP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-SNP", "O", "O", "O", "O", "O", "O", "O", "B-SNP", "I-SNP", "I-SNP", "I-SNP", "I-SNP", "I-SNP", "O", "B-SNP", "I-SNP", "I-SNP", "I-SNP", "I-SNP", "I-SNP", "O", "B-SNP", "I-SNP", "I-SNP", "I-SNP", "I-SNP", "I-SNP", "O", "O", "O", "O", "O", "B-SNP", "I-SNP", "I-SNP", "I-SNP", "I-SNP", "I-SNP", "O", "B-SNP", "I-SNP", "I-SNP", "I-SNP", "I-SNP", "I-SNP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Spectrum of mutations in the fumarylacetoacetate hydrolase gene of tyrosinemia type 1 patients in northwestern Europe and Mediterranean countries. Hereditary tyrosinemia type 1 (HT1) is a rare metabolic disease caused by a deficient activity of the enzyme fumarylacetoacetase (FAH). To investigate the molecular heterogeneity of tyrosinemia, the geographic distribution and the genotype-phenotype relationship, we have analyzed the FAH genotype of 25 HT1 patients. Mutation screening was performed by PCR amplification of exons 1-14 of the FAH gene, followed by SSCP analysis and direct sequencing of the amplified exons. Fourteen different mutations were found, of which seven were novel, viz. three missense mutations (G158D, P261L, F405H), a deletion of three nucleotides causing a deletion of serine (DEL366S) and three splice site mutations: IVS2+1(g-t), IVS6-1(g-c), IVS8-1(g-c). The splice site mutations IVS6-1(g-t) and IVS12+5(g-a) were frequently found in countries around the Mediterranean and northwestern Europe, respectively. No clear correlation between the genotype and the three major HT1 subtypes could be established.	[ "Spectrum", "of", "mutations", "in", "the", "fumarylacetoacetate", "hydrolase", "gene", "of", "tyrosinemia", "type", "1", "patients", "in", "northwestern", "Europe", "and", "Mediterranean", "countries", ".", "Hereditary", "tyrosinemia", "type", "1", "(", "HT1", ")", "is", "a", "rare", "metabolic", "disease", "caused", "by", "a", "deficient", "activity", "of", "the", "enzyme", "fumarylacetoacetase", "(", "FAH", ")", ".", "To", "investigate", "the", "molecular", "heterogeneity", "of", "tyrosinemia", ",", "the", "geographic", "distribution", "and", "the", "genotype", "-", "phenotype", "relationship", ",", "we", "have", "analyzed", "the", "FAH", "genotype", "of", "25", "HT1", "patients", ".", "Mutation", "screening", "was", "performed", "by", "PCR", "amplification", "of", "exons", "1", "-", "14", "of", "the", "FAH", "gene", ",", "followed", "by", "SSCP", "analysis", "and", "direct", "sequencing", "of", "the", "amplified", "exons", ".", "Fourteen", "different", "mutations", "were", "found", ",", "of", "which", "seven", "were", "novel", ",", "viz", ".", "three", "missense", "mutations", "(", "G158D", ",", "P261L", ",", "F405H", ")", ",", "a", "deletion", "of", "three", "nucleotides", "causing", "a", "deletion", "of", "serine", "(", "DEL366S", ")", "and", "three", "splice", "site", "mutations", ":", "IVS2", "+", "1(g", "-", "t", ")", ",", "IVS6", "-", "1(g", "-", "c", ")", ",", "IVS8", "-", "1(g", "-", "c", ")", ".", "The", "splice", "site", "mutations", "IVS6", "-", "1(g", "-", "t", ")", "and", "IVS12", "+", "5(g", "-", "a", ")", "were", "frequently", "found", "in", "countries", "around", "the", "Mediterranean", "and", "northwestern", "Europe", ",", "respectively", ".", "No", "clear", "correlation", "between", "the", "genotype", "and", "the", "three", "major", "HT1", "subtypes", "could", "be", "established", ".", "\n" ]	[ "Gene", "SNP" ]
fumarylacetoacetate hydrolase is a Gene, FAH is a Gene, G158D is a SNP, P261L is a SNP, F405H is a SNP, DEL366S is a SNP, IVS2 + 1(g - t ) is a SNP, IVS6 - 1(g - c ) is a SNP, IVS8 - 1(g - c ) is a SNP, IVS6 - 1(g - t ) is a SNP, IVS12 + 5(g - a ) is a SNP	487_task1	Sentence: Spectrum of mutations in the fumarylacetoacetate hydrolase gene of tyrosinemia type 1 patients in northwestern Europe and Mediterranean countries. Hereditary tyrosinemia type 1 (HT1) is a rare metabolic disease caused by a deficient activity of the enzyme fumarylacetoacetase (FAH). To investigate the molecular heterogeneity of tyrosinemia, the geographic distribution and the genotype-phenotype relationship, we have analyzed the FAH genotype of 25 HT1 patients. Mutation screening was performed by PCR amplification of exons 1-14 of the FAH gene, followed by SSCP analysis and direct sequencing of the amplified exons. Fourteen different mutations were found, of which seven were novel, viz. three missense mutations (G158D, P261L, F405H), a deletion of three nucleotides causing a deletion of serine (DEL366S) and three splice site mutations: IVS2+1(g-t), IVS6-1(g-c), IVS8-1(g-c). The splice site mutations IVS6-1(g-t) and IVS12+5(g-a) were frequently found in countries around the Mediterranean and northwestern Europe, respectively. No clear correlation between the genotype and the three major HT1 subtypes could be established. Instructions: please typing these entity words according to sentence: fumarylacetoacetate hydrolase, FAH, G158D, P261L, F405H, DEL366S, IVS2 + 1(g - t ), IVS6 - 1(g - c ), IVS8 - 1(g - c ), IVS6 - 1(g - t ), IVS12 + 5(g - a ) Options: Gene, SNP	[ "O", "O", "O", "O", "O", "B-Gene", "I-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-SNP", "O", "B-SNP", "O", "B-SNP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-SNP", "O", "O", "O", "O", "O", "O", "O", "B-SNP", "I-SNP", "I-SNP", "I-SNP", "I-SNP", "I-SNP", "O", "B-SNP", "I-SNP", "I-SNP", "I-SNP", "I-SNP", "I-SNP", "O", "B-SNP", "I-SNP", "I-SNP", "I-SNP", "I-SNP", "I-SNP", "O", "O", "O", "O", "O", "B-SNP", "I-SNP", "I-SNP", "I-SNP", "I-SNP", "I-SNP", "O", "B-SNP", "I-SNP", "I-SNP", "I-SNP", "I-SNP", "I-SNP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Spectrum of mutations in the fumarylacetoacetate hydrolase gene of tyrosinemia type 1 patients in northwestern Europe and Mediterranean countries. Hereditary tyrosinemia type 1 (HT1) is a rare metabolic disease caused by a deficient activity of the enzyme fumarylacetoacetase (FAH). To investigate the molecular heterogeneity of tyrosinemia, the geographic distribution and the genotype-phenotype relationship, we have analyzed the FAH genotype of 25 HT1 patients. Mutation screening was performed by PCR amplification of exons 1-14 of the FAH gene, followed by SSCP analysis and direct sequencing of the amplified exons. Fourteen different mutations were found, of which seven were novel, viz. three missense mutations (G158D, P261L, F405H), a deletion of three nucleotides causing a deletion of serine (DEL366S) and three splice site mutations: IVS2+1(g-t), IVS6-1(g-c), IVS8-1(g-c). The splice site mutations IVS6-1(g-t) and IVS12+5(g-a) were frequently found in countries around the Mediterranean and northwestern Europe, respectively. No clear correlation between the genotype and the three major HT1 subtypes could be established.	[ "Spectrum", "of", "mutations", "in", "the", "fumarylacetoacetate", "hydrolase", "gene", "of", "tyrosinemia", "type", "1", "patients", "in", "northwestern", "Europe", "and", "Mediterranean", "countries", ".", "Hereditary", "tyrosinemia", "type", "1", "(", "HT1", ")", "is", "a", "rare", "metabolic", "disease", "caused", "by", "a", "deficient", "activity", "of", "the", "enzyme", "fumarylacetoacetase", "(", "FAH", ")", ".", "To", "investigate", "the", "molecular", "heterogeneity", "of", "tyrosinemia", ",", "the", "geographic", "distribution", "and", "the", "genotype", "-", "phenotype", "relationship", ",", "we", "have", "analyzed", "the", "FAH", "genotype", "of", "25", "HT1", "patients", ".", "Mutation", "screening", "was", "performed", "by", "PCR", "amplification", "of", "exons", "1", "-", "14", "of", "the", "FAH", "gene", ",", "followed", "by", "SSCP", "analysis", "and", "direct", "sequencing", "of", "the", "amplified", "exons", ".", "Fourteen", "different", "mutations", "were", "found", ",", "of", "which", "seven", "were", "novel", ",", "viz", ".", "three", "missense", "mutations", "(", "G158D", ",", "P261L", ",", "F405H", ")", ",", "a", "deletion", "of", "three", "nucleotides", "causing", "a", "deletion", "of", "serine", "(", "DEL366S", ")", "and", "three", "splice", "site", "mutations", ":", "IVS2", "+", "1(g", "-", "t", ")", ",", "IVS6", "-", "1(g", "-", "c", ")", ",", "IVS8", "-", "1(g", "-", "c", ")", ".", "The", "splice", "site", "mutations", "IVS6", "-", "1(g", "-", "t", ")", "and", "IVS12", "+", "5(g", "-", "a", ")", "were", "frequently", "found", "in", "countries", "around", "the", "Mediterranean", "and", "northwestern", "Europe", ",", "respectively", ".", "No", "clear", "correlation", "between", "the", "genotype", "and", "the", "three", "major", "HT1", "subtypes", "could", "be", "established", ".", "\n" ]	[ "Gene", "SNP" ]
fumarylacetoacetate hydrolase, FAH, G158D, P261L, F405H, DEL366S, IVS2 + 1(g - t ), IVS6 - 1(g - c ), IVS8 - 1(g - c ), IVS6 - 1(g - t ), IVS12 + 5(g - a )	487_task2	Sentence: Spectrum of mutations in the fumarylacetoacetate hydrolase gene of tyrosinemia type 1 patients in northwestern Europe and Mediterranean countries. Hereditary tyrosinemia type 1 (HT1) is a rare metabolic disease caused by a deficient activity of the enzyme fumarylacetoacetase (FAH). To investigate the molecular heterogeneity of tyrosinemia, the geographic distribution and the genotype-phenotype relationship, we have analyzed the FAH genotype of 25 HT1 patients. Mutation screening was performed by PCR amplification of exons 1-14 of the FAH gene, followed by SSCP analysis and direct sequencing of the amplified exons. Fourteen different mutations were found, of which seven were novel, viz. three missense mutations (G158D, P261L, F405H), a deletion of three nucleotides causing a deletion of serine (DEL366S) and three splice site mutations: IVS2+1(g-t), IVS6-1(g-c), IVS8-1(g-c). The splice site mutations IVS6-1(g-t) and IVS12+5(g-a) were frequently found in countries around the Mediterranean and northwestern Europe, respectively. No clear correlation between the genotype and the three major HT1 subtypes could be established. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "B-Gene", "I-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-SNP", "O", "B-SNP", "O", "B-SNP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-SNP", "O", "O", "O", "O", "O", "O", "O", "B-SNP", "I-SNP", "I-SNP", "I-SNP", "I-SNP", "I-SNP", "O", "B-SNP", "I-SNP", "I-SNP", "I-SNP", "I-SNP", "I-SNP", "O", "B-SNP", "I-SNP", "I-SNP", "I-SNP", "I-SNP", "I-SNP", "O", "O", "O", "O", "O", "B-SNP", "I-SNP", "I-SNP", "I-SNP", "I-SNP", "I-SNP", "O", "B-SNP", "I-SNP", "I-SNP", "I-SNP", "I-SNP", "I-SNP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Spectrum of mutations in the fumarylacetoacetate hydrolase gene of tyrosinemia type 1 patients in northwestern Europe and Mediterranean countries. Hereditary tyrosinemia type 1 (HT1) is a rare metabolic disease caused by a deficient activity of the enzyme fumarylacetoacetase (FAH). To investigate the molecular heterogeneity of tyrosinemia, the geographic distribution and the genotype-phenotype relationship, we have analyzed the FAH genotype of 25 HT1 patients. Mutation screening was performed by PCR amplification of exons 1-14 of the FAH gene, followed by SSCP analysis and direct sequencing of the amplified exons. Fourteen different mutations were found, of which seven were novel, viz. three missense mutations (G158D, P261L, F405H), a deletion of three nucleotides causing a deletion of serine (DEL366S) and three splice site mutations: IVS2+1(g-t), IVS6-1(g-c), IVS8-1(g-c). The splice site mutations IVS6-1(g-t) and IVS12+5(g-a) were frequently found in countries around the Mediterranean and northwestern Europe, respectively. No clear correlation between the genotype and the three major HT1 subtypes could be established.	[ "Spectrum", "of", "mutations", "in", "the", "fumarylacetoacetate", "hydrolase", "gene", "of", "tyrosinemia", "type", "1", "patients", "in", "northwestern", "Europe", "and", "Mediterranean", "countries", ".", "Hereditary", "tyrosinemia", "type", "1", "(", "HT1", ")", "is", "a", "rare", "metabolic", "disease", "caused", "by", "a", "deficient", "activity", "of", "the", "enzyme", "fumarylacetoacetase", "(", "FAH", ")", ".", "To", "investigate", "the", "molecular", "heterogeneity", "of", "tyrosinemia", ",", "the", "geographic", "distribution", "and", "the", "genotype", "-", "phenotype", "relationship", ",", "we", "have", "analyzed", "the", "FAH", "genotype", "of", "25", "HT1", "patients", ".", "Mutation", "screening", "was", "performed", "by", "PCR", "amplification", "of", "exons", "1", "-", "14", "of", "the", "FAH", "gene", ",", "followed", "by", "SSCP", "analysis", "and", "direct", "sequencing", "of", "the", "amplified", "exons", ".", "Fourteen", "different", "mutations", "were", "found", ",", "of", "which", "seven", "were", "novel", ",", "viz", ".", "three", "missense", "mutations", "(", "G158D", ",", "P261L", ",", "F405H", ")", ",", "a", "deletion", "of", "three", "nucleotides", "causing", "a", "deletion", "of", "serine", "(", "DEL366S", ")", "and", "three", "splice", "site", "mutations", ":", "IVS2", "+", "1(g", "-", "t", ")", ",", "IVS6", "-", "1(g", "-", "c", ")", ",", "IVS8", "-", "1(g", "-", "c", ")", ".", "The", "splice", "site", "mutations", "IVS6", "-", "1(g", "-", "t", ")", "and", "IVS12", "+", "5(g", "-", "a", ")", "were", "frequently", "found", "in", "countries", "around", "the", "Mediterranean", "and", "northwestern", "Europe", ",", "respectively", ".", "No", "clear", "correlation", "between", "the", "genotype", "and", "the", "three", "major", "HT1", "subtypes", "could", "be", "established", ".", "\n" ]	[ "Gene", "SNP" ]
maennliche is an umlsterm, Patienten is an umlsterm, Diagnose is an umlsterm, Aortenisthmusstenose is an umlsterm, Patienten is an umlsterm, lebensbedrohlichen is an umlsterm, Komplikation is an umlsterm, Aortenisthmusstenose is an umlsterm, Subarachnoidalblutung is an umlsterm, zerebrales Aneurysma is an umlsterm, Patienten is an umlsterm, Aortenruptur is an umlsterm, Erweiterung is an umlsterm, Aorta ascendens is an umlsterm, Patienten is an umlsterm, Ruptur is an umlsterm, Aorta descendens is an umlsterm, Oesophagus is an umlsterm, Patienten is an umlsterm, Diagnose is an umlsterm, Diagnose is an umlsterm, Aortenisthmusstenose is an umlsterm	MonatsschriftKinderheilkunde.71450477.ger.abstr_task0	Sentence: Wir berichten ueber 4 maennliche Patienten im Alter zwischen 11 Jahren und 14 Jahren , 9 Monaten , bei denen verspaetet die Diagnose einer Aortenisthmusstenose gestellt wurde . Drei der Patienten kamen primaer mit einer lebensbedrohlichen Komplikation der zuvor nicht erkannten Aortenisthmusstenose zur stationaeren Aufnahme . Es handelte sich hierbei 1 mal um eine Subarachnoidalblutung durch ein rupturiertes zerebrales Aneurysma , bei 1 anderen Patienten um eine Aortenruptur bei aneurysmatischer Erweiterung der Aorta ascendens , die von einer Aortendissektion gefolgt wurde sowie bei 1 Patienten um die Ruptur eines poststenotischen Aneurysmas der Aorta descendens in den Oesophagus . Alle 4 Patienten konnten erfolgreich operiert werden . Der postoperative Verlauf war jedoch immer durch einen schwer einstellbaren Hypertonus gekennzeichnet . Diskussion : Die verspaetete Diagnose dieser Aortenisthmusstenosen ist auf die fehlende Symptomatik zurueckzufuehren , die auf der Entwicklung eines meist ausgepraegten Kollateralkreislaufs beruht . Prognostisch entscheidend ist die fruehzeitige Diagnose . Die Korrekturoperation der asymptomatischen Aortenisthmusstenose sollte im 2. Lebensjahr erfolgen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O" ]	Wir berichten ueber 4 maennliche Patienten im Alter zwischen 11 Jahren und 14 Jahren , 9 Monaten , bei denen verspaetet die Diagnose einer Aortenisthmusstenose gestellt wurde . Drei der Patienten kamen primaer mit einer lebensbedrohlichen Komplikation der zuvor nicht erkannten Aortenisthmusstenose zur stationaeren Aufnahme . Es handelte sich hierbei 1 mal um eine Subarachnoidalblutung durch ein rupturiertes zerebrales Aneurysma , bei 1 anderen Patienten um eine Aortenruptur bei aneurysmatischer Erweiterung der Aorta ascendens , die von einer Aortendissektion gefolgt wurde sowie bei 1 Patienten um die Ruptur eines poststenotischen Aneurysmas der Aorta descendens in den Oesophagus . Alle 4 Patienten konnten erfolgreich operiert werden . Der postoperative Verlauf war jedoch immer durch einen schwer einstellbaren Hypertonus gekennzeichnet . Diskussion : Die verspaetete Diagnose dieser Aortenisthmusstenosen ist auf die fehlende Symptomatik zurueckzufuehren , die auf der Entwicklung eines meist ausgepraegten Kollateralkreislaufs beruht . Prognostisch entscheidend ist die fruehzeitige Diagnose . Die Korrekturoperation der asymptomatischen Aortenisthmusstenose sollte im 2. Lebensjahr erfolgen .	[ "Wir", "berichten", "ueber", "4", "maennliche", "Patienten", "im", "Alter", "zwischen", "11", "Jahren", "und", "14", "Jahren", ",", "9", "Monaten", ",", "bei", "denen", "verspaetet", "die", "Diagnose", "einer", "Aortenisthmusstenose", "gestellt", "wurde", ".", "Drei", "der", "Patienten", "kamen", "primaer", "mit", "einer", "lebensbedrohlichen", "Komplikation", "der", "zuvor", "nicht", "erkannten", "Aortenisthmusstenose", "zur", "stationaeren", "Aufnahme", ".", "Es", "handelte", "sich", "hierbei", "1", "mal", "um", "eine", "Subarachnoidalblutung", "durch", "ein", "rupturiertes", "zerebrales", "Aneurysma", ",", "bei", "1", "anderen", "Patienten", "um", "eine", "Aortenruptur", "bei", "aneurysmatischer", "Erweiterung", "der", "Aorta", "ascendens", ",", "die", "von", "einer", "Aortendissektion", "gefolgt", "wurde", "sowie", "bei", "1", "Patienten", "um", "die", "Ruptur", "eines", "poststenotischen", "Aneurysmas", "der", "Aorta", "descendens", "in", "den", "Oesophagus", ".", "Alle", "4", "Patienten", "konnten", "erfolgreich", "operiert", "werden", ".", "Der", "postoperative", "Verlauf", "war", "jedoch", "immer", "durch", "einen", "schwer", "einstellbaren", "Hypertonus", "gekennzeichnet", ".", "Diskussion", ":", "Die", "verspaetete", "Diagnose", "dieser", "Aortenisthmusstenosen", "ist", "auf", "die", "fehlende", "Symptomatik", "zurueckzufuehren", ",", "die", "auf", "der", "Entwicklung", "eines", "meist", "ausgepraegten", "Kollateralkreislaufs", "beruht", ".", "Prognostisch", "entscheidend", "ist", "die", "fruehzeitige", "Diagnose", ".", "Die", "Korrekturoperation", "der", "asymptomatischen", "Aortenisthmusstenose", "sollte", "im", "2", ".", "Lebensjahr", "erfolgen", "." ]	[ "umlsterm" ]
maennliche is an umlsterm, Patienten is an umlsterm, Diagnose is an umlsterm, Aortenisthmusstenose is an umlsterm, Patienten is an umlsterm, lebensbedrohlichen is an umlsterm, Komplikation is an umlsterm, Aortenisthmusstenose is an umlsterm, Subarachnoidalblutung is an umlsterm, zerebrales Aneurysma is an umlsterm, Patienten is an umlsterm, Aortenruptur is an umlsterm, Erweiterung is an umlsterm, Aorta ascendens is an umlsterm, Patienten is an umlsterm, Ruptur is an umlsterm, Aorta descendens is an umlsterm, Oesophagus is an umlsterm, Patienten is an umlsterm, Diagnose is an umlsterm, Diagnose is an umlsterm, Aortenisthmusstenose is an umlsterm	MonatsschriftKinderheilkunde.71450477.ger.abstr_task1	Sentence: Wir berichten ueber 4 maennliche Patienten im Alter zwischen 11 Jahren und 14 Jahren , 9 Monaten , bei denen verspaetet die Diagnose einer Aortenisthmusstenose gestellt wurde . Drei der Patienten kamen primaer mit einer lebensbedrohlichen Komplikation der zuvor nicht erkannten Aortenisthmusstenose zur stationaeren Aufnahme . Es handelte sich hierbei 1 mal um eine Subarachnoidalblutung durch ein rupturiertes zerebrales Aneurysma , bei 1 anderen Patienten um eine Aortenruptur bei aneurysmatischer Erweiterung der Aorta ascendens , die von einer Aortendissektion gefolgt wurde sowie bei 1 Patienten um die Ruptur eines poststenotischen Aneurysmas der Aorta descendens in den Oesophagus . Alle 4 Patienten konnten erfolgreich operiert werden . Der postoperative Verlauf war jedoch immer durch einen schwer einstellbaren Hypertonus gekennzeichnet . Diskussion : Die verspaetete Diagnose dieser Aortenisthmusstenosen ist auf die fehlende Symptomatik zurueckzufuehren , die auf der Entwicklung eines meist ausgepraegten Kollateralkreislaufs beruht . Prognostisch entscheidend ist die fruehzeitige Diagnose . Die Korrekturoperation der asymptomatischen Aortenisthmusstenose sollte im 2. Lebensjahr erfolgen . Instructions: please typing these entity words according to sentence: maennliche, Patienten, Diagnose, Aortenisthmusstenose, Patienten, lebensbedrohlichen, Komplikation, Aortenisthmusstenose, Subarachnoidalblutung, zerebrales Aneurysma, Patienten, Aortenruptur, Erweiterung, Aorta ascendens, Patienten, Ruptur, Aorta descendens, Oesophagus, Patienten, Diagnose, Diagnose, Aortenisthmusstenose Options: umlsterm	[ "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O" ]	Wir berichten ueber 4 maennliche Patienten im Alter zwischen 11 Jahren und 14 Jahren , 9 Monaten , bei denen verspaetet die Diagnose einer Aortenisthmusstenose gestellt wurde . Drei der Patienten kamen primaer mit einer lebensbedrohlichen Komplikation der zuvor nicht erkannten Aortenisthmusstenose zur stationaeren Aufnahme . Es handelte sich hierbei 1 mal um eine Subarachnoidalblutung durch ein rupturiertes zerebrales Aneurysma , bei 1 anderen Patienten um eine Aortenruptur bei aneurysmatischer Erweiterung der Aorta ascendens , die von einer Aortendissektion gefolgt wurde sowie bei 1 Patienten um die Ruptur eines poststenotischen Aneurysmas der Aorta descendens in den Oesophagus . Alle 4 Patienten konnten erfolgreich operiert werden . Der postoperative Verlauf war jedoch immer durch einen schwer einstellbaren Hypertonus gekennzeichnet . Diskussion : Die verspaetete Diagnose dieser Aortenisthmusstenosen ist auf die fehlende Symptomatik zurueckzufuehren , die auf der Entwicklung eines meist ausgepraegten Kollateralkreislaufs beruht . Prognostisch entscheidend ist die fruehzeitige Diagnose . Die Korrekturoperation der asymptomatischen Aortenisthmusstenose sollte im 2. Lebensjahr erfolgen .	[ "Wir", "berichten", "ueber", "4", "maennliche", "Patienten", "im", "Alter", "zwischen", "11", "Jahren", "und", "14", "Jahren", ",", "9", "Monaten", ",", "bei", "denen", "verspaetet", "die", "Diagnose", "einer", "Aortenisthmusstenose", "gestellt", "wurde", ".", "Drei", "der", "Patienten", "kamen", "primaer", "mit", "einer", "lebensbedrohlichen", "Komplikation", "der", "zuvor", "nicht", "erkannten", "Aortenisthmusstenose", "zur", "stationaeren", "Aufnahme", ".", "Es", "handelte", "sich", "hierbei", "1", "mal", "um", "eine", "Subarachnoidalblutung", "durch", "ein", "rupturiertes", "zerebrales", "Aneurysma", ",", "bei", "1", "anderen", "Patienten", "um", "eine", "Aortenruptur", "bei", "aneurysmatischer", "Erweiterung", "der", "Aorta", "ascendens", ",", "die", "von", "einer", "Aortendissektion", "gefolgt", "wurde", "sowie", "bei", "1", "Patienten", "um", "die", "Ruptur", "eines", "poststenotischen", "Aneurysmas", "der", "Aorta", "descendens", "in", "den", "Oesophagus", ".", "Alle", "4", "Patienten", "konnten", "erfolgreich", "operiert", "werden", ".", "Der", "postoperative", "Verlauf", "war", "jedoch", "immer", "durch", "einen", "schwer", "einstellbaren", "Hypertonus", "gekennzeichnet", ".", "Diskussion", ":", "Die", "verspaetete", "Diagnose", "dieser", "Aortenisthmusstenosen", "ist", "auf", "die", "fehlende", "Symptomatik", "zurueckzufuehren", ",", "die", "auf", "der", "Entwicklung", "eines", "meist", "ausgepraegten", "Kollateralkreislaufs", "beruht", ".", "Prognostisch", "entscheidend", "ist", "die", "fruehzeitige", "Diagnose", ".", "Die", "Korrekturoperation", "der", "asymptomatischen", "Aortenisthmusstenose", "sollte", "im", "2", ".", "Lebensjahr", "erfolgen", "." ]	[ "umlsterm" ]
maennliche, Patienten, Diagnose, Aortenisthmusstenose, Patienten, lebensbedrohlichen, Komplikation, Aortenisthmusstenose, Subarachnoidalblutung, zerebrales Aneurysma, Patienten, Aortenruptur, Erweiterung, Aorta ascendens, Patienten, Ruptur, Aorta descendens, Oesophagus, Patienten, Diagnose, Diagnose, Aortenisthmusstenose	MonatsschriftKinderheilkunde.71450477.ger.abstr_task2	Sentence: Wir berichten ueber 4 maennliche Patienten im Alter zwischen 11 Jahren und 14 Jahren , 9 Monaten , bei denen verspaetet die Diagnose einer Aortenisthmusstenose gestellt wurde . Drei der Patienten kamen primaer mit einer lebensbedrohlichen Komplikation der zuvor nicht erkannten Aortenisthmusstenose zur stationaeren Aufnahme . Es handelte sich hierbei 1 mal um eine Subarachnoidalblutung durch ein rupturiertes zerebrales Aneurysma , bei 1 anderen Patienten um eine Aortenruptur bei aneurysmatischer Erweiterung der Aorta ascendens , die von einer Aortendissektion gefolgt wurde sowie bei 1 Patienten um die Ruptur eines poststenotischen Aneurysmas der Aorta descendens in den Oesophagus . Alle 4 Patienten konnten erfolgreich operiert werden . Der postoperative Verlauf war jedoch immer durch einen schwer einstellbaren Hypertonus gekennzeichnet . Diskussion : Die verspaetete Diagnose dieser Aortenisthmusstenosen ist auf die fehlende Symptomatik zurueckzufuehren , die auf der Entwicklung eines meist ausgepraegten Kollateralkreislaufs beruht . Prognostisch entscheidend ist die fruehzeitige Diagnose . Die Korrekturoperation der asymptomatischen Aortenisthmusstenose sollte im 2. Lebensjahr erfolgen . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O" ]	Wir berichten ueber 4 maennliche Patienten im Alter zwischen 11 Jahren und 14 Jahren , 9 Monaten , bei denen verspaetet die Diagnose einer Aortenisthmusstenose gestellt wurde . Drei der Patienten kamen primaer mit einer lebensbedrohlichen Komplikation der zuvor nicht erkannten Aortenisthmusstenose zur stationaeren Aufnahme . Es handelte sich hierbei 1 mal um eine Subarachnoidalblutung durch ein rupturiertes zerebrales Aneurysma , bei 1 anderen Patienten um eine Aortenruptur bei aneurysmatischer Erweiterung der Aorta ascendens , die von einer Aortendissektion gefolgt wurde sowie bei 1 Patienten um die Ruptur eines poststenotischen Aneurysmas der Aorta descendens in den Oesophagus . Alle 4 Patienten konnten erfolgreich operiert werden . Der postoperative Verlauf war jedoch immer durch einen schwer einstellbaren Hypertonus gekennzeichnet . Diskussion : Die verspaetete Diagnose dieser Aortenisthmusstenosen ist auf die fehlende Symptomatik zurueckzufuehren , die auf der Entwicklung eines meist ausgepraegten Kollateralkreislaufs beruht . Prognostisch entscheidend ist die fruehzeitige Diagnose . Die Korrekturoperation der asymptomatischen Aortenisthmusstenose sollte im 2. Lebensjahr erfolgen .	[ "Wir", "berichten", "ueber", "4", "maennliche", "Patienten", "im", "Alter", "zwischen", "11", "Jahren", "und", "14", "Jahren", ",", "9", "Monaten", ",", "bei", "denen", "verspaetet", "die", "Diagnose", "einer", "Aortenisthmusstenose", "gestellt", "wurde", ".", "Drei", "der", "Patienten", "kamen", "primaer", "mit", "einer", "lebensbedrohlichen", "Komplikation", "der", "zuvor", "nicht", "erkannten", "Aortenisthmusstenose", "zur", "stationaeren", "Aufnahme", ".", "Es", "handelte", "sich", "hierbei", "1", "mal", "um", "eine", "Subarachnoidalblutung", "durch", "ein", "rupturiertes", "zerebrales", "Aneurysma", ",", "bei", "1", "anderen", "Patienten", "um", "eine", "Aortenruptur", "bei", "aneurysmatischer", "Erweiterung", "der", "Aorta", "ascendens", ",", "die", "von", "einer", "Aortendissektion", "gefolgt", "wurde", "sowie", "bei", "1", "Patienten", "um", "die", "Ruptur", "eines", "poststenotischen", "Aneurysmas", "der", "Aorta", "descendens", "in", "den", "Oesophagus", ".", "Alle", "4", "Patienten", "konnten", "erfolgreich", "operiert", "werden", ".", "Der", "postoperative", "Verlauf", "war", "jedoch", "immer", "durch", "einen", "schwer", "einstellbaren", "Hypertonus", "gekennzeichnet", ".", "Diskussion", ":", "Die", "verspaetete", "Diagnose", "dieser", "Aortenisthmusstenosen", "ist", "auf", "die", "fehlende", "Symptomatik", "zurueckzufuehren", ",", "die", "auf", "der", "Entwicklung", "eines", "meist", "ausgepraegten", "Kollateralkreislaufs", "beruht", ".", "Prognostisch", "entscheidend", "ist", "die", "fruehzeitige", "Diagnose", ".", "Die", "Korrekturoperation", "der", "asymptomatischen", "Aortenisthmusstenose", "sollte", "im", "2", ".", "Lebensjahr", "erfolgen", "." ]	[ "umlsterm" ]
Pedro is a NOMBRE_SUJETO_ASISTENCIA, Iglesias Pastor is a NOMBRE_SUJETO_ASISTENCIA, 1149404 is a ID_SUJETO_ASISTENCIA, 343551107164 is a ID_ASEGURAMIENTO, A Coruña is a TERRITORIO, 15003 is a TERRITORIO, 09/05/1945 is a FECHAS, España is a PAIS, 67 años is a EDAD_SUJETO_ASISTENCIA, 02/04/2013 is a FECHAS, 1287103 is a ID_CONTACTO_ASISTENCIAL, José Manuel Janeiro Pais is a NOMBRE_PERSONAL_SANITARIO, 15 15 65203 is a ID_TITULACION_PERSONAL_SANITARIO, Varón is a SEXO_SUJETO_ASISTENCIA, 67 años is a EDAD_SUJETO_ASISTENCIA, José Manuel Janeiro Pais is a NOMBRE_PERSONAL_SANITARIO, Avda . Lázaro Cárdenas , 23 - 1ºE is a CALLE, 15009 is a TERRITORIO, La Coruña is a TERRITORIO, España is a PAIS, janeiropais@canalejo.org is a CORREO_ELECTRONICO	185_task0	Sentence: Datos del paciente. Nombre: Pedro . Apellidos: Iglesias Pastor. NHC: 1149404. NASS: 343551107164. Domicilio: Rúa Comandante Fontanes, 19, 2 B. Localidad/ Provincia: A Coruña. CP: 15003. Datos asistenciales. Fecha de nacimiento: 09/05/1945. País de nacimiento: España. Edad: 67 años Sexo: H. Fecha de Ingreso: 02/04/2013. Episodio: 1287103. Médico: José Manuel Janeiro Pais NºCol: 15 15 65203. Informe clínico del paciente: Varón, de 67 años, con agudeza visual de 0,6 y 0,5 con cataratas nucleares grado 3 en ambos ojos. El ojo izquierdo mostraba un pterigión nasal grado I y diversas lesiones con forma de islotes corneales epiteliales con distribución semicircular inferior, no afectando al eje visual. No presentaba signos inflamatorios en el segmento anterior y el resto de la exploración es normal. Se instauró tratamiento con Mitomicina-C 0,02% preoperatorio (1), con reducción de la lesión a 1/3 de su tamaño. Se realizó intervención de cataratas en ambos ojos mediante técnica MICS, exéresis del pterigión del ojo izquierdo y exéresis de la lesión corneal, remitiéndose a estudio anatomopatológico, el cual informa: epitelio conjuntival con focos de atipia leve de las células de la capa basal, llegando a ocupar la atipia, a nivel del limbo, hasta 2/3 del espesor total, observándose escaso pleomorfismo. Degeneración elastótica actínica del corión y escaso infiltrado inflamatorio crónico linfocitario subepitelial. A los 6 meses se evidenció la presencia de islotes aislados recidivantes, tratándose nuevamente con Mitomicina-C, regresando la lesión, no evidenciándose nuevas recidivas en su seguimiento durante 1 año. Responsable clínico: Dr. José Manuel Janeiro Pais, Avda. Lázaro Cárdenas, 23 - 1ºE 15009 La Coruña (España). janeiropais@canalejo.org Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: TERRITORIO, SEXO_SUJETO_ASISTENCIA, ID_SUJETO_ASISTENCIA, FECHAS, CALLE, CORREO_ELECTRONICO, PAIS, EDAD_SUJETO_ASISTENCIA, ID_CONTACTO_ASISTENCIAL, ID_ASEGURAMIENTO, ID_TITULACION_PERSONAL_SANITARIO, NOMBRE_SUJETO_ASISTENCIA, NOMBRE_PERSONAL_SANITARIO	[ "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_ASEGURAMIENTO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "I-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-ID_CONTACTO_ASISTENCIAL", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "B-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "B-TERRITORIO", "B-TERRITORIO", "I-TERRITORIO", "O", "B-PAIS", "O", "O", "B-CORREO_ELECTRONICO", "O" ]	Datos del paciente. Nombre: Pedro . Apellidos: Iglesias Pastor. NHC: 1149404. NASS: 343551107164. Domicilio: Rúa Comandante Fontanes, 19, 2 B. Localidad/ Provincia: A Coruña. CP: 15003. Datos asistenciales. Fecha de nacimiento: 09/05/1945. País de nacimiento: España. Edad: 67 años Sexo: H. Fecha de Ingreso: 02/04/2013. Episodio: 1287103. Médico: José Manuel Janeiro Pais NºCol: 15 15 65203. Informe clínico del paciente: Varón, de 67 años, con agudeza visual de 0,6 y 0,5 con cataratas nucleares grado 3 en ambos ojos. El ojo izquierdo mostraba un pterigión nasal grado I y diversas lesiones con forma de islotes corneales epiteliales con distribución semicircular inferior, no afectando al eje visual. No presentaba signos inflamatorios en el segmento anterior y el resto de la exploración es normal. Se instauró tratamiento con Mitomicina-C 0,02% preoperatorio (1), con reducción de la lesión a 1/3 de su tamaño. Se realizó intervención de cataratas en ambos ojos mediante técnica MICS, exéresis del pterigión del ojo izquierdo y exéresis de la lesión corneal, remitiéndose a estudio anatomopatológico, el cual informa: epitelio conjuntival con focos de atipia leve de las células de la capa basal, llegando a ocupar la atipia, a nivel del limbo, hasta 2/3 del espesor total, observándose escaso pleomorfismo. Degeneración elastótica actínica del corión y escaso infiltrado inflamatorio crónico linfocitario subepitelial. A los 6 meses se evidenció la presencia de islotes aislados recidivantes, tratándose nuevamente con Mitomicina-C, regresando la lesión, no evidenciándose nuevas recidivas en su seguimiento durante 1 año. Responsable clínico: Dr. José Manuel Janeiro Pais, Avda. Lázaro Cárdenas, 23 - 1ºE 15009 La Coruña (España). janeiropais@canalejo.org	[ "Datos", "del", "paciente", ".", "\n", "Nombre", ":", "Pedro", ".", "\n", "Apellidos", ":", "Iglesias", "Pastor", ".", "\n", "NHC", ":", "1149404", ".", "\n", "NASS", ":", "343551107164", ".", "\n", "Domicilio", ":", "Rúa", "Comandante", "Fontanes", ",", "19", ",", "2", "B.", "\n", "Localidad/", "Provincia", ":", "A", "Coruña", ".", "\n", "CP", ":", "15003", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "09/05/1945", ".", "\n", "País", "de", "nacimiento", ":", "España", ".", "\n", "Edad", ":", "67", "años", "Sexo", ":", "H.", "\n", "Fecha", "de", "Ingreso", ":", "02/04/2013", ".", "\n", "Episodio", ":", "1287103", ".", "\n", "Médico", ":", "José", "Manuel", "Janeiro", "Pais", " ", "NºCol", ":", "15", "15", "65203", ".", "\n", "Informe", "clínico", "del", "paciente", ":", "Varón", ",", "de", "67", "años", ",", "con", "agudeza", "visual", "de", "0,6", "y", "0,5", "con", "cataratas", "nucleares", "grado", "3", "en", "ambos", "ojos", ".", "El", "ojo", "izquierdo", "mostraba", "un", "pterigión", "nasal", "grado", "I", "y", "diversas", "lesiones", "con", "forma", "de", "islotes", "corneales", "epiteliales", "con", "distribución", "semicircular", "inferior", ",", "no", "afectando", "al", "eje", "visual", ".", "No", "presentaba", "signos", "inflamatorios", "en", "el", "segmento", "anterior", "y", "el", "resto", "de", "la", "exploración", "es", "normal", ".", "\n", "Se", "instauró", "tratamiento", "con", "Mitomicina", "-", "C", "0,02", "%", "preoperatorio", "(", "1", ")", ",", "con", "reducción", "de", "la", "lesión", "a", "1/3", "de", "su", "tamaño", ".", "\n", "Se", "realizó", "intervención", "de", "cataratas", "en", "ambos", "ojos", "mediante", "técnica", "MICS", ",", "exéresis", "del", "pterigión", "del", "ojo", "izquierdo", "y", "exéresis", "de", "la", "lesión", "corneal", ",", "remitiéndose", "a", "estudio", "anatomopatológico", ",", "el", "cual", "informa", ":", "epitelio", "conjuntival", "con", "focos", "de", "atipia", "leve", "de", "las", "células", "de", "la", "capa", "basal", ",", "llegando", "a", "ocupar", "la", "atipia", ",", "a", "nivel", "del", "limbo", ",", "hasta", "2/3", "del", "espesor", "total", ",", "observándose", "escaso", "pleomorfismo", ".", "Degeneración", "elastótica", "actínica", "del", "corión", "y", "escaso", "infiltrado", "inflamatorio", "crónico", "linfocitario", "subepitelial", ".", "\n", "A", "los", "6", "meses", "se", "evidenció", "la", "presencia", "de", "islotes", "aislados", "recidivantes", ",", "tratándose", "nuevamente", "con", "Mitomicina", "-", "C", ",", "regresando", "la", "lesión", ",", "no", "evidenciándose", "nuevas", "recidivas", "en", "su", "seguimiento", "durante", "1", "año", ".", "\n", "Responsable", "clínico", ":", "Dr", ".", "José", "Manuel", "Janeiro", "Pais", ",", "Avda", ".", "Lázaro", "Cárdenas", ",", "23", "-", "1ºE", "15009", "La", "Coruña", "(", "España", ")", ".", "janeiropais@canalejo.org", "\n" ]	[ "CALLE", "CORREO_ELECTRONICO", "NOMBRE_PERSONAL_SANITARIO", "NOMBRE_SUJETO_ASISTENCIA", "ID_ASEGURAMIENTO", "ID_TITULACION_PERSONAL_SANITARIO", "FECHAS", "TERRITORIO", "EDAD_SUJETO_ASISTENCIA", "ID_CONTACTO_ASISTENCIAL", "ID_SUJETO_ASISTENCIA", "PAIS", "SEXO_SUJETO_ASISTENCIA" ]
Pedro is a NOMBRE_SUJETO_ASISTENCIA, Iglesias Pastor is a NOMBRE_SUJETO_ASISTENCIA, 1149404 is a ID_SUJETO_ASISTENCIA, 343551107164 is a ID_ASEGURAMIENTO, A Coruña is a TERRITORIO, 15003 is a TERRITORIO, 09/05/1945 is a FECHAS, España is a PAIS, 67 años is a EDAD_SUJETO_ASISTENCIA, 02/04/2013 is a FECHAS, 1287103 is a ID_CONTACTO_ASISTENCIAL, José Manuel Janeiro Pais is a NOMBRE_PERSONAL_SANITARIO, 15 15 65203 is a ID_TITULACION_PERSONAL_SANITARIO, Varón is a SEXO_SUJETO_ASISTENCIA, 67 años is a EDAD_SUJETO_ASISTENCIA, José Manuel Janeiro Pais is a NOMBRE_PERSONAL_SANITARIO, Avda . Lázaro Cárdenas , 23 - 1ºE is a CALLE, 15009 is a TERRITORIO, La Coruña is a TERRITORIO, España is a PAIS, janeiropais@canalejo.org is a CORREO_ELECTRONICO	185_task1	Sentence: Datos del paciente. Nombre: Pedro . Apellidos: Iglesias Pastor. NHC: 1149404. NASS: 343551107164. Domicilio: Rúa Comandante Fontanes, 19, 2 B. Localidad/ Provincia: A Coruña. CP: 15003. Datos asistenciales. Fecha de nacimiento: 09/05/1945. País de nacimiento: España. Edad: 67 años Sexo: H. Fecha de Ingreso: 02/04/2013. Episodio: 1287103. Médico: José Manuel Janeiro Pais NºCol: 15 15 65203. Informe clínico del paciente: Varón, de 67 años, con agudeza visual de 0,6 y 0,5 con cataratas nucleares grado 3 en ambos ojos. El ojo izquierdo mostraba un pterigión nasal grado I y diversas lesiones con forma de islotes corneales epiteliales con distribución semicircular inferior, no afectando al eje visual. No presentaba signos inflamatorios en el segmento anterior y el resto de la exploración es normal. Se instauró tratamiento con Mitomicina-C 0,02% preoperatorio (1), con reducción de la lesión a 1/3 de su tamaño. Se realizó intervención de cataratas en ambos ojos mediante técnica MICS, exéresis del pterigión del ojo izquierdo y exéresis de la lesión corneal, remitiéndose a estudio anatomopatológico, el cual informa: epitelio conjuntival con focos de atipia leve de las células de la capa basal, llegando a ocupar la atipia, a nivel del limbo, hasta 2/3 del espesor total, observándose escaso pleomorfismo. Degeneración elastótica actínica del corión y escaso infiltrado inflamatorio crónico linfocitario subepitelial. A los 6 meses se evidenció la presencia de islotes aislados recidivantes, tratándose nuevamente con Mitomicina-C, regresando la lesión, no evidenciándose nuevas recidivas en su seguimiento durante 1 año. Responsable clínico: Dr. José Manuel Janeiro Pais, Avda. Lázaro Cárdenas, 23 - 1ºE 15009 La Coruña (España). janeiropais@canalejo.org Instructions: please typing these entity words according to sentence: Pedro, Iglesias Pastor, 1149404, 343551107164, A Coruña, 15003, 09/05/1945, España, 67 años, 02/04/2013, 1287103, José Manuel Janeiro Pais, 15 15 65203, Varón, 67 años, José Manuel Janeiro Pais, Avda . Lázaro Cárdenas , 23 - 1ºE, 15009, La Coruña, España, janeiropais@canalejo.org Options: TERRITORIO, SEXO_SUJETO_ASISTENCIA, ID_SUJETO_ASISTENCIA, FECHAS, CALLE, CORREO_ELECTRONICO, PAIS, EDAD_SUJETO_ASISTENCIA, ID_CONTACTO_ASISTENCIAL, ID_ASEGURAMIENTO, ID_TITULACION_PERSONAL_SANITARIO, NOMBRE_SUJETO_ASISTENCIA, NOMBRE_PERSONAL_SANITARIO	[ "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_ASEGURAMIENTO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "I-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-ID_CONTACTO_ASISTENCIAL", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "B-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "B-TERRITORIO", "B-TERRITORIO", "I-TERRITORIO", "O", "B-PAIS", "O", "O", "B-CORREO_ELECTRONICO", "O" ]	Datos del paciente. Nombre: Pedro . Apellidos: Iglesias Pastor. NHC: 1149404. NASS: 343551107164. Domicilio: Rúa Comandante Fontanes, 19, 2 B. Localidad/ Provincia: A Coruña. CP: 15003. Datos asistenciales. Fecha de nacimiento: 09/05/1945. País de nacimiento: España. Edad: 67 años Sexo: H. Fecha de Ingreso: 02/04/2013. Episodio: 1287103. Médico: José Manuel Janeiro Pais NºCol: 15 15 65203. Informe clínico del paciente: Varón, de 67 años, con agudeza visual de 0,6 y 0,5 con cataratas nucleares grado 3 en ambos ojos. El ojo izquierdo mostraba un pterigión nasal grado I y diversas lesiones con forma de islotes corneales epiteliales con distribución semicircular inferior, no afectando al eje visual. No presentaba signos inflamatorios en el segmento anterior y el resto de la exploración es normal. Se instauró tratamiento con Mitomicina-C 0,02% preoperatorio (1), con reducción de la lesión a 1/3 de su tamaño. Se realizó intervención de cataratas en ambos ojos mediante técnica MICS, exéresis del pterigión del ojo izquierdo y exéresis de la lesión corneal, remitiéndose a estudio anatomopatológico, el cual informa: epitelio conjuntival con focos de atipia leve de las células de la capa basal, llegando a ocupar la atipia, a nivel del limbo, hasta 2/3 del espesor total, observándose escaso pleomorfismo. Degeneración elastótica actínica del corión y escaso infiltrado inflamatorio crónico linfocitario subepitelial. A los 6 meses se evidenció la presencia de islotes aislados recidivantes, tratándose nuevamente con Mitomicina-C, regresando la lesión, no evidenciándose nuevas recidivas en su seguimiento durante 1 año. Responsable clínico: Dr. José Manuel Janeiro Pais, Avda. Lázaro Cárdenas, 23 - 1ºE 15009 La Coruña (España). janeiropais@canalejo.org	[ "Datos", "del", "paciente", ".", "\n", "Nombre", ":", "Pedro", ".", "\n", "Apellidos", ":", "Iglesias", "Pastor", ".", "\n", "NHC", ":", "1149404", ".", "\n", "NASS", ":", "343551107164", ".", "\n", "Domicilio", ":", "Rúa", "Comandante", "Fontanes", ",", "19", ",", "2", "B.", "\n", "Localidad/", "Provincia", ":", "A", "Coruña", ".", "\n", "CP", ":", "15003", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "09/05/1945", ".", "\n", "País", "de", "nacimiento", ":", "España", ".", "\n", "Edad", ":", "67", "años", "Sexo", ":", "H.", "\n", "Fecha", "de", "Ingreso", ":", "02/04/2013", ".", "\n", "Episodio", ":", "1287103", ".", "\n", "Médico", ":", "José", "Manuel", "Janeiro", "Pais", " ", "NºCol", ":", "15", "15", "65203", ".", "\n", "Informe", "clínico", "del", "paciente", ":", "Varón", ",", "de", "67", "años", ",", "con", "agudeza", "visual", "de", "0,6", "y", "0,5", "con", "cataratas", "nucleares", "grado", "3", "en", "ambos", "ojos", ".", "El", "ojo", "izquierdo", "mostraba", "un", "pterigión", "nasal", "grado", "I", "y", "diversas", "lesiones", "con", "forma", "de", "islotes", "corneales", "epiteliales", "con", "distribución", "semicircular", "inferior", ",", "no", "afectando", "al", "eje", "visual", ".", "No", "presentaba", "signos", "inflamatorios", "en", "el", "segmento", "anterior", "y", "el", "resto", "de", "la", "exploración", "es", "normal", ".", "\n", "Se", "instauró", "tratamiento", "con", "Mitomicina", "-", "C", "0,02", "%", "preoperatorio", "(", "1", ")", ",", "con", "reducción", "de", "la", "lesión", "a", "1/3", "de", "su", "tamaño", ".", "\n", "Se", "realizó", "intervención", "de", "cataratas", "en", "ambos", "ojos", "mediante", "técnica", "MICS", ",", "exéresis", "del", "pterigión", "del", "ojo", "izquierdo", "y", "exéresis", "de", "la", "lesión", "corneal", ",", "remitiéndose", "a", "estudio", "anatomopatológico", ",", "el", "cual", "informa", ":", "epitelio", "conjuntival", "con", "focos", "de", "atipia", "leve", "de", "las", "células", "de", "la", "capa", "basal", ",", "llegando", "a", "ocupar", "la", "atipia", ",", "a", "nivel", "del", "limbo", ",", "hasta", "2/3", "del", "espesor", "total", ",", "observándose", "escaso", "pleomorfismo", ".", "Degeneración", "elastótica", "actínica", "del", "corión", "y", "escaso", "infiltrado", "inflamatorio", "crónico", "linfocitario", "subepitelial", ".", "\n", "A", "los", "6", "meses", "se", "evidenció", "la", "presencia", "de", "islotes", "aislados", "recidivantes", ",", "tratándose", "nuevamente", "con", "Mitomicina", "-", "C", ",", "regresando", "la", "lesión", ",", "no", "evidenciándose", "nuevas", "recidivas", "en", "su", "seguimiento", "durante", "1", "año", ".", "\n", "Responsable", "clínico", ":", "Dr", ".", "José", "Manuel", "Janeiro", "Pais", ",", "Avda", ".", "Lázaro", "Cárdenas", ",", "23", "-", "1ºE", "15009", "La", "Coruña", "(", "España", ")", ".", "janeiropais@canalejo.org", "\n" ]	[ "CALLE", "CORREO_ELECTRONICO", "NOMBRE_PERSONAL_SANITARIO", "NOMBRE_SUJETO_ASISTENCIA", "ID_ASEGURAMIENTO", "ID_TITULACION_PERSONAL_SANITARIO", "FECHAS", "TERRITORIO", "EDAD_SUJETO_ASISTENCIA", "ID_CONTACTO_ASISTENCIAL", "ID_SUJETO_ASISTENCIA", "PAIS", "SEXO_SUJETO_ASISTENCIA" ]

Nuclear is a Entity, beta - catenin is a Protein, lymphoid enhancer factor 1 is a Protein, beta - catenin is a Protein, nucleus is a Entity, beta - catenin is a Protein, beta - catenin is a Protein, nucleus is a Entity, beta - catenin is a Protein, LEF-1 is a Protein, E - cadherin is a Protein, APC is a Protein, axin is a Protein, beta - catenin is a Protein, beta - catenin is a Protein, nucleus is a Entity, beta - Catenin is a Protein, LEF-1 is a Protein, nuclear is a Entity, nucleus is a Entity, beta - catenin is a Protein, VP16 is a Protein

10330189_task1

Sentence: Nuclear localization and formation of beta-catenin-lymphoid enhancer factor 1 complexes are not sufficient for activation of gene expression. In response to activation of the Wnt signaling pathway, beta-catenin accumulates in the nucleus, where it cooperates with LEF/TCF (for lymphoid enhancer factor and T-cell factor) transcription factors to activate gene expression. The mechanisms by which beta-catenin undergoes this shift in location and participates in activation of gene transcription are unknown. We demonstrate here that beta-catenin can be imported into the nucleus independently of LEF/TCF binding, and it may also be exported from nuclei. We have introduced a small deletion within beta-catenin (Delta19) that disrupts binding to LEF-1, E-cadherin, and APC but not axin. This Delta19 beta-catenin mutant localizes to the nucleus because it may not be efficiently sequestered in the cytoplasm. The nuclear localization of Delta19 definitively demonstrates that the mechanisms by which beta-catenin localizes in the nucleus are completely independent of LEF/TCF factors. beta-Catenin and LEF-1 complexes can activate reporter gene expression in a transformed T-lymphocyte cell line (Jurkat) but not in normal T lymphocytes, even though both factors are nuclear. Thus, localization of both factors to the nucleus is not sufficient for activation of gene expression. Excess beta-catenin can squelch reporter gene activation by LEF-1-beta-catenin complexes but not activation by the transcription factor VP16. Taken together, these data suggest that a third component is necessary for gene activation and that this third component may vary with cell type. Instructions: please typing these entity words according to sentence: Nuclear, beta - catenin, lymphoid enhancer factor 1, beta - catenin, nucleus, beta - catenin, beta - catenin, nucleus, beta - catenin, LEF-1, E - cadherin, APC, axin, beta - catenin, beta - catenin, nucleus, beta - Catenin, LEF-1, nuclear, nucleus, beta - catenin, VP16 Options: Entity, Protein

[ "B-Entity", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "B-Protein", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Nuclear localization and formation of beta-catenin-lymphoid enhancer factor 1 complexes are not sufficient for activation of gene expression. In response to activation of the Wnt signaling pathway, beta-catenin accumulates in the nucleus, where it cooperates with LEF/TCF (for lymphoid enhancer factor and T-cell factor) transcription factors to activate gene expression. The mechanisms by which beta-catenin undergoes this shift in location and participates in activation of gene transcription are unknown. We demonstrate here that beta-catenin can be imported into the nucleus independently of LEF/TCF binding, and it may also be exported from nuclei. We have introduced a small deletion within beta-catenin (Delta19) that disrupts binding to LEF-1, E-cadherin, and APC but not axin. This Delta19 beta-catenin mutant localizes to the nucleus because it may not be efficiently sequestered in the cytoplasm. The nuclear localization of Delta19 definitively demonstrates that the mechanisms by which beta-catenin localizes in the nucleus are completely independent of LEF/TCF factors. beta-Catenin and LEF-1 complexes can activate reporter gene expression in a transformed T-lymphocyte cell line (Jurkat) but not in normal T lymphocytes, even though both factors are nuclear. Thus, localization of both factors to the nucleus is not sufficient for activation of gene expression. Excess beta-catenin can squelch reporter gene activation by LEF-1-beta-catenin complexes but not activation by the transcription factor VP16. Taken together, these data suggest that a third component is necessary for gene activation and that this third component may vary with cell type.

[ "Nuclear", "localization", "and", "formation", "of", "beta", "-", "catenin", "-", "lymphoid", "enhancer", "factor", "1", "complexes", "are", "not", "sufficient", "for", "activation", "of", "gene", "expression", ".", "\n", "In", "response", "to", "activation", "of", "the", "Wnt", "signaling", "pathway", ",", "beta", "-", "catenin", "accumulates", "in", "the", "nucleus", ",", "where", "it", "cooperates", "with", "LEF", "/", "TCF", "(", "for", "lymphoid", "enhancer", "factor", "and", "T", "-", "cell", "factor", ")", "transcription", "factors", "to", "activate", "gene", "expression", ".", "The", "mechanisms", "by", "which", "beta", "-", "catenin", "undergoes", "this", "shift", "in", "location", "and", "participates", "in", "activation", "of", "gene", "transcription", "are", "unknown", ".", "We", "demonstrate", "here", "that", "beta", "-", "catenin", "can", "be", "imported", "into", "the", "nucleus", "independently", "of", "LEF", "/", "TCF", "binding", ",", "and", "it", "may", "also", "be", "exported", "from", "nuclei", ".", "We", "have", "introduced", "a", "small", "deletion", "within", "beta", "-", "catenin", "(", "Delta19", ")", "that", "disrupts", "binding", "to", "LEF-1", ",", "E", "-", "cadherin", ",", "and", "APC", "but", "not", "axin", ".", "This", "Delta19", "beta", "-", "catenin", "mutant", "localizes", "to", "the", "nucleus", "because", "it", "may", "not", "be", "efficiently", "sequestered", "in", "the", "cytoplasm", ".", "The", "nuclear", "localization", "of", "Delta19", "definitively", "demonstrates", "that", "the", "mechanisms", "by", "which", "beta", "-", "catenin", "localizes", "in", "the", "nucleus", "are", "completely", "independent", "of", "LEF", "/", "TCF", "factors", ".", "beta", "-", "Catenin", "and", "LEF-1", "complexes", "can", "activate", "reporter", "gene", "expression", "in", "a", "transformed", "T", "-", "lymphocyte", "cell", "line", "(", "Jurkat", ")", "but", "not", "in", "normal", "T", "lymphocytes", ",", "even", "though", "both", "factors", "are", "nuclear", ".", "Thus", ",", "localization", "of", "both", "factors", "to", "the", "nucleus", "is", "not", "sufficient", "for", "activation", "of", "gene", "expression", ".", "Excess", "beta", "-", "catenin", "can", "squelch", "reporter", "gene", "activation", "by", "LEF-1-beta", "-", "catenin", "complexes", "but", "not", "activation", "by", "the", "transcription", "factor", "VP16", ".", "Taken", "together", ",", "these", "data", "suggest", "that", "a", "third", "component", "is", "necessary", "for", "gene", "activation", "and", "that", "this", "third", "component", "may", "vary", "with", "cell", "type", "." ]

[ "Protein", "Entity" ]

Nuclear, beta - catenin, lymphoid enhancer factor 1, beta - catenin, nucleus, beta - catenin, beta - catenin, nucleus, beta - catenin, LEF-1, E - cadherin, APC, axin, beta - catenin, beta - catenin, nucleus, beta - Catenin, LEF-1, nuclear, nucleus, beta - catenin, VP16

10330189_task2

Sentence: Nuclear localization and formation of beta-catenin-lymphoid enhancer factor 1 complexes are not sufficient for activation of gene expression. In response to activation of the Wnt signaling pathway, beta-catenin accumulates in the nucleus, where it cooperates with LEF/TCF (for lymphoid enhancer factor and T-cell factor) transcription factors to activate gene expression. The mechanisms by which beta-catenin undergoes this shift in location and participates in activation of gene transcription are unknown. We demonstrate here that beta-catenin can be imported into the nucleus independently of LEF/TCF binding, and it may also be exported from nuclei. We have introduced a small deletion within beta-catenin (Delta19) that disrupts binding to LEF-1, E-cadherin, and APC but not axin. This Delta19 beta-catenin mutant localizes to the nucleus because it may not be efficiently sequestered in the cytoplasm. The nuclear localization of Delta19 definitively demonstrates that the mechanisms by which beta-catenin localizes in the nucleus are completely independent of LEF/TCF factors. beta-Catenin and LEF-1 complexes can activate reporter gene expression in a transformed T-lymphocyte cell line (Jurkat) but not in normal T lymphocytes, even though both factors are nuclear. Thus, localization of both factors to the nucleus is not sufficient for activation of gene expression. Excess beta-catenin can squelch reporter gene activation by LEF-1-beta-catenin complexes but not activation by the transcription factor VP16. Taken together, these data suggest that a third component is necessary for gene activation and that this third component may vary with cell type. Instructions: please extract entity words from the input sentence

[ "B-Entity", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "B-Protein", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Nuclear localization and formation of beta-catenin-lymphoid enhancer factor 1 complexes are not sufficient for activation of gene expression. In response to activation of the Wnt signaling pathway, beta-catenin accumulates in the nucleus, where it cooperates with LEF/TCF (for lymphoid enhancer factor and T-cell factor) transcription factors to activate gene expression. The mechanisms by which beta-catenin undergoes this shift in location and participates in activation of gene transcription are unknown. We demonstrate here that beta-catenin can be imported into the nucleus independently of LEF/TCF binding, and it may also be exported from nuclei. We have introduced a small deletion within beta-catenin (Delta19) that disrupts binding to LEF-1, E-cadherin, and APC but not axin. This Delta19 beta-catenin mutant localizes to the nucleus because it may not be efficiently sequestered in the cytoplasm. The nuclear localization of Delta19 definitively demonstrates that the mechanisms by which beta-catenin localizes in the nucleus are completely independent of LEF/TCF factors. beta-Catenin and LEF-1 complexes can activate reporter gene expression in a transformed T-lymphocyte cell line (Jurkat) but not in normal T lymphocytes, even though both factors are nuclear. Thus, localization of both factors to the nucleus is not sufficient for activation of gene expression. Excess beta-catenin can squelch reporter gene activation by LEF-1-beta-catenin complexes but not activation by the transcription factor VP16. Taken together, these data suggest that a third component is necessary for gene activation and that this third component may vary with cell type.

[ "Nuclear", "localization", "and", "formation", "of", "beta", "-", "catenin", "-", "lymphoid", "enhancer", "factor", "1", "complexes", "are", "not", "sufficient", "for", "activation", "of", "gene", "expression", ".", "\n", "In", "response", "to", "activation", "of", "the", "Wnt", "signaling", "pathway", ",", "beta", "-", "catenin", "accumulates", "in", "the", "nucleus", ",", "where", "it", "cooperates", "with", "LEF", "/", "TCF", "(", "for", "lymphoid", "enhancer", "factor", "and", "T", "-", "cell", "factor", ")", "transcription", "factors", "to", "activate", "gene", "expression", ".", "The", "mechanisms", "by", "which", "beta", "-", "catenin", "undergoes", "this", "shift", "in", "location", "and", "participates", "in", "activation", "of", "gene", "transcription", "are", "unknown", ".", "We", "demonstrate", "here", "that", "beta", "-", "catenin", "can", "be", "imported", "into", "the", "nucleus", "independently", "of", "LEF", "/", "TCF", "binding", ",", "and", "it", "may", "also", "be", "exported", "from", "nuclei", ".", "We", "have", "introduced", "a", "small", "deletion", "within", "beta", "-", "catenin", "(", "Delta19", ")", "that", "disrupts", "binding", "to", "LEF-1", ",", "E", "-", "cadherin", ",", "and", "APC", "but", "not", "axin", ".", "This", "Delta19", "beta", "-", "catenin", "mutant", "localizes", "to", "the", "nucleus", "because", "it", "may", "not", "be", "efficiently", "sequestered", "in", "the", "cytoplasm", ".", "The", "nuclear", "localization", "of", "Delta19", "definitively", "demonstrates", "that", "the", "mechanisms", "by", "which", "beta", "-", "catenin", "localizes", "in", "the", "nucleus", "are", "completely", "independent", "of", "LEF", "/", "TCF", "factors", ".", "beta", "-", "Catenin", "and", "LEF-1", "complexes", "can", "activate", "reporter", "gene", "expression", "in", "a", "transformed", "T", "-", "lymphocyte", "cell", "line", "(", "Jurkat", ")", "but", "not", "in", "normal", "T", "lymphocytes", ",", "even", "though", "both", "factors", "are", "nuclear", ".", "Thus", ",", "localization", "of", "both", "factors", "to", "the", "nucleus", "is", "not", "sufficient", "for", "activation", "of", "gene", "expression", ".", "Excess", "beta", "-", "catenin", "can", "squelch", "reporter", "gene", "activation", "by", "LEF-1-beta", "-", "catenin", "complexes", "but", "not", "activation", "by", "the", "transcription", "factor", "VP16", ".", "Taken", "together", ",", "these", "data", "suggest", "that", "a", "third", "component", "is", "necessary", "for", "gene", "activation", "and", "that", "this", "third", "component", "may", "vary", "with", "cell", "type", "." ]

[ "Protein", "Entity" ]

vitamin D3-binding protein is a Protein, alpha - N - acetylgalactosaminidase is a Protein, Gc is a Protein, vitamin D3-binding protein is a Protein, beta - galactosidase is a Protein, Gc is a Protein, Gc is a Protein, beta - galactosidase is a Protein, Gc is a Protein, Gc is a Protein, alpha - N - acetylgalactosaminidase is a Protein, alpha - N - acetylgalactosaminidase is a Protein, Gc is a Protein, Gc is a Protein, alpha - N - acetylgalactosaminidase is a Protein

570_task0

Sentence: Deglycosylation of serum vitamin D3-binding protein by alpha-N-acetylgalactosaminidase detected in the plasma of patients with systemic lupus erythematosus. A serum glycoprotein, Gc protein (vitamin D3-binding protein), can be converted by beta-galactosidase of B cells and sialidase of T cells to a potent macrophage-activating factor (MAF), a protein with N-acetylgalactosamine as the remaining sugar moiety. Thus, Gc protein is the precursor for MAF. Treatment of Gc protein with immobilized beta-galactosidase and sialidase generates a remarkably high titered macrophage-activating factor (GcMAF). When peripheral blood monocytes/ macrophages (designated macrophages) of 33 systemic lupus erythematosus patients were incubated with GcMAF (100 pg/ml), the macrophages of all patients were activated as determined by superoxide generation. However, the precursor activity of patient plasma Gc protein was lost or reduced in these patients. Loss of the precursor activity was the result of deglycosylation of plasma Gc protein by alpha-N-acetylgalactosaminidase activity found in the patient plasma. Levels of plasma alpha-N-acetylgalactosaminidase activity in individual patients had an inverse correlation with the MAF precursor activity of their plasma Gc protein. Deglycosylated Gc protein cannot be converted to macro-phage-activating factor. The resulting defect in macro-phage activation may lead to an inability to clear pathogenic immune complexes. Thus, elevated plasma alpha-N-acetylgalactosaminidase activity resulting in the loss of MAF precursor activity and reduced macro-phage activity may play a role in the pathogenesis of systemic lupus erythematosus. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein

[ "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Deglycosylation of serum vitamin D3-binding protein by alpha-N-acetylgalactosaminidase detected in the plasma of patients with systemic lupus erythematosus. A serum glycoprotein, Gc protein (vitamin D3-binding protein), can be converted by beta-galactosidase of B cells and sialidase of T cells to a potent macrophage-activating factor (MAF), a protein with N-acetylgalactosamine as the remaining sugar moiety. Thus, Gc protein is the precursor for MAF. Treatment of Gc protein with immobilized beta-galactosidase and sialidase generates a remarkably high titered macrophage-activating factor (GcMAF). When peripheral blood monocytes/ macrophages (designated macrophages) of 33 systemic lupus erythematosus patients were incubated with GcMAF (100 pg/ml), the macrophages of all patients were activated as determined by superoxide generation. However, the precursor activity of patient plasma Gc protein was lost or reduced in these patients. Loss of the precursor activity was the result of deglycosylation of plasma Gc protein by alpha-N-acetylgalactosaminidase activity found in the patient plasma. Levels of plasma alpha-N-acetylgalactosaminidase activity in individual patients had an inverse correlation with the MAF precursor activity of their plasma Gc protein. Deglycosylated Gc protein cannot be converted to macro-phage-activating factor. The resulting defect in macro-phage activation may lead to an inability to clear pathogenic immune complexes. Thus, elevated plasma alpha-N-acetylgalactosaminidase activity resulting in the loss of MAF precursor activity and reduced macro-phage activity may play a role in the pathogenesis of systemic lupus erythematosus.

[ "Deglycosylation", "of", "serum", "vitamin", "D3-binding", "protein", "by", "alpha", "-", "N", "-", "acetylgalactosaminidase", "detected", "in", "the", "plasma", "of", "patients", "with", "systemic", "lupus", "erythematosus", ".", "\n", "A", "serum", "glycoprotein", ",", "Gc", "protein", "(", "vitamin", "D3-binding", "protein", ")", ",", "can", "be", "converted", "by", "beta", "-", "galactosidase", "of", "B", "cells", "and", "sialidase", "of", "T", "cells", "to", "a", "potent", "macrophage", "-", "activating", "factor", "(", "MAF", ")", ",", "a", "protein", "with", "N", "-", "acetylgalactosamine", "as", "the", "remaining", "sugar", "moiety", ".", "Thus", ",", "Gc", "protein", "is", "the", "precursor", "for", "MAF", ".", "Treatment", "of", "Gc", "protein", "with", "immobilized", "beta", "-", "galactosidase", "and", "sialidase", "generates", "a", "remarkably", "high", "titered", "macrophage", "-", "activating", "factor", "(", "GcMAF", ")", ".", "When", "peripheral", "blood", "monocytes/", "macrophages", "(", "designated", "macrophages", ")", "of", "33", "systemic", "lupus", "erythematosus", "patients", "were", "incubated", "with", "GcMAF", "(", "100", "pg", "/", "ml", ")", ",", "the", "macrophages", "of", "all", "patients", "were", "activated", "as", "determined", "by", "superoxide", "generation", ".", "However", ",", "the", "precursor", "activity", "of", "patient", "plasma", "Gc", "protein", "was", "lost", "or", "reduced", "in", "these", "patients", ".", "Loss", "of", "the", "precursor", "activity", "was", "the", "result", "of", "deglycosylation", "of", "plasma", "Gc", "protein", "by", "alpha", "-", "N", "-", "acetylgalactosaminidase", "activity", "found", "in", "the", "patient", "plasma", ".", "Levels", "of", "plasma", "alpha", "-", "N", "-", "acetylgalactosaminidase", "activity", "in", "individual", "patients", "had", "an", "inverse", "correlation", "with", "the", "MAF", "precursor", "activity", "of", "their", "plasma", "Gc", "protein", ".", "Deglycosylated", "Gc", "protein", "cannot", "be", "converted", "to", "macro", "-", "phage", "-", "activating", "factor", ".", "The", "resulting", "defect", "in", "macro", "-", "phage", "activation", "may", "lead", "to", "an", "inability", "to", "clear", "pathogenic", "immune", "complexes", ".", "Thus", ",", "elevated", "plasma", "alpha", "-", "N", "-", "acetylgalactosaminidase", "activity", "resulting", "in", "the", "loss", "of", "MAF", "precursor", "activity", "and", "reduced", "macro", "-", "phage", "activity", "may", "play", "a", "role", "in", "the", "pathogenesis", "of", "systemic", "lupus", "erythematosus", ".", "\n" ]

[ "Protein" ]

vitamin D3-binding protein is a Protein, alpha - N - acetylgalactosaminidase is a Protein, Gc is a Protein, vitamin D3-binding protein is a Protein, beta - galactosidase is a Protein, Gc is a Protein, Gc is a Protein, beta - galactosidase is a Protein, Gc is a Protein, Gc is a Protein, alpha - N - acetylgalactosaminidase is a Protein, alpha - N - acetylgalactosaminidase is a Protein, Gc is a Protein, Gc is a Protein, alpha - N - acetylgalactosaminidase is a Protein

570_task1

Sentence: Deglycosylation of serum vitamin D3-binding protein by alpha-N-acetylgalactosaminidase detected in the plasma of patients with systemic lupus erythematosus. A serum glycoprotein, Gc protein (vitamin D3-binding protein), can be converted by beta-galactosidase of B cells and sialidase of T cells to a potent macrophage-activating factor (MAF), a protein with N-acetylgalactosamine as the remaining sugar moiety. Thus, Gc protein is the precursor for MAF. Treatment of Gc protein with immobilized beta-galactosidase and sialidase generates a remarkably high titered macrophage-activating factor (GcMAF). When peripheral blood monocytes/ macrophages (designated macrophages) of 33 systemic lupus erythematosus patients were incubated with GcMAF (100 pg/ml), the macrophages of all patients were activated as determined by superoxide generation. However, the precursor activity of patient plasma Gc protein was lost or reduced in these patients. Loss of the precursor activity was the result of deglycosylation of plasma Gc protein by alpha-N-acetylgalactosaminidase activity found in the patient plasma. Levels of plasma alpha-N-acetylgalactosaminidase activity in individual patients had an inverse correlation with the MAF precursor activity of their plasma Gc protein. Deglycosylated Gc protein cannot be converted to macro-phage-activating factor. The resulting defect in macro-phage activation may lead to an inability to clear pathogenic immune complexes. Thus, elevated plasma alpha-N-acetylgalactosaminidase activity resulting in the loss of MAF precursor activity and reduced macro-phage activity may play a role in the pathogenesis of systemic lupus erythematosus. Instructions: please typing these entity words according to sentence: vitamin D3-binding protein, alpha - N - acetylgalactosaminidase, Gc, vitamin D3-binding protein, beta - galactosidase, Gc, Gc, beta - galactosidase, Gc, Gc, alpha - N - acetylgalactosaminidase, alpha - N - acetylgalactosaminidase, Gc, Gc, alpha - N - acetylgalactosaminidase Options: Protein

[ "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Deglycosylation of serum vitamin D3-binding protein by alpha-N-acetylgalactosaminidase detected in the plasma of patients with systemic lupus erythematosus. A serum glycoprotein, Gc protein (vitamin D3-binding protein), can be converted by beta-galactosidase of B cells and sialidase of T cells to a potent macrophage-activating factor (MAF), a protein with N-acetylgalactosamine as the remaining sugar moiety. Thus, Gc protein is the precursor for MAF. Treatment of Gc protein with immobilized beta-galactosidase and sialidase generates a remarkably high titered macrophage-activating factor (GcMAF). When peripheral blood monocytes/ macrophages (designated macrophages) of 33 systemic lupus erythematosus patients were incubated with GcMAF (100 pg/ml), the macrophages of all patients were activated as determined by superoxide generation. However, the precursor activity of patient plasma Gc protein was lost or reduced in these patients. Loss of the precursor activity was the result of deglycosylation of plasma Gc protein by alpha-N-acetylgalactosaminidase activity found in the patient plasma. Levels of plasma alpha-N-acetylgalactosaminidase activity in individual patients had an inverse correlation with the MAF precursor activity of their plasma Gc protein. Deglycosylated Gc protein cannot be converted to macro-phage-activating factor. The resulting defect in macro-phage activation may lead to an inability to clear pathogenic immune complexes. Thus, elevated plasma alpha-N-acetylgalactosaminidase activity resulting in the loss of MAF precursor activity and reduced macro-phage activity may play a role in the pathogenesis of systemic lupus erythematosus.

[ "Deglycosylation", "of", "serum", "vitamin", "D3-binding", "protein", "by", "alpha", "-", "N", "-", "acetylgalactosaminidase", "detected", "in", "the", "plasma", "of", "patients", "with", "systemic", "lupus", "erythematosus", ".", "\n", "A", "serum", "glycoprotein", ",", "Gc", "protein", "(", "vitamin", "D3-binding", "protein", ")", ",", "can", "be", "converted", "by", "beta", "-", "galactosidase", "of", "B", "cells", "and", "sialidase", "of", "T", "cells", "to", "a", "potent", "macrophage", "-", "activating", "factor", "(", "MAF", ")", ",", "a", "protein", "with", "N", "-", "acetylgalactosamine", "as", "the", "remaining", "sugar", "moiety", ".", "Thus", ",", "Gc", "protein", "is", "the", "precursor", "for", "MAF", ".", "Treatment", "of", "Gc", "protein", "with", "immobilized", "beta", "-", "galactosidase", "and", "sialidase", "generates", "a", "remarkably", "high", "titered", "macrophage", "-", "activating", "factor", "(", "GcMAF", ")", ".", "When", "peripheral", "blood", "monocytes/", "macrophages", "(", "designated", "macrophages", ")", "of", "33", "systemic", "lupus", "erythematosus", "patients", "were", "incubated", "with", "GcMAF", "(", "100", "pg", "/", "ml", ")", ",", "the", "macrophages", "of", "all", "patients", "were", "activated", "as", "determined", "by", "superoxide", "generation", ".", "However", ",", "the", "precursor", "activity", "of", "patient", "plasma", "Gc", "protein", "was", "lost", "or", "reduced", "in", "these", "patients", ".", "Loss", "of", "the", "precursor", "activity", "was", "the", "result", "of", "deglycosylation", "of", "plasma", "Gc", "protein", "by", "alpha", "-", "N", "-", "acetylgalactosaminidase", "activity", "found", "in", "the", "patient", "plasma", ".", "Levels", "of", "plasma", "alpha", "-", "N", "-", "acetylgalactosaminidase", "activity", "in", "individual", "patients", "had", "an", "inverse", "correlation", "with", "the", "MAF", "precursor", "activity", "of", "their", "plasma", "Gc", "protein", ".", "Deglycosylated", "Gc", "protein", "cannot", "be", "converted", "to", "macro", "-", "phage", "-", "activating", "factor", ".", "The", "resulting", "defect", "in", "macro", "-", "phage", "activation", "may", "lead", "to", "an", "inability", "to", "clear", "pathogenic", "immune", "complexes", ".", "Thus", ",", "elevated", "plasma", "alpha", "-", "N", "-", "acetylgalactosaminidase", "activity", "resulting", "in", "the", "loss", "of", "MAF", "precursor", "activity", "and", "reduced", "macro", "-", "phage", "activity", "may", "play", "a", "role", "in", "the", "pathogenesis", "of", "systemic", "lupus", "erythematosus", ".", "\n" ]

[ "Protein" ]

vitamin D3-binding protein, alpha - N - acetylgalactosaminidase, Gc, vitamin D3-binding protein, beta - galactosidase, Gc, Gc, beta - galactosidase, Gc, Gc, alpha - N - acetylgalactosaminidase, alpha - N - acetylgalactosaminidase, Gc, Gc, alpha - N - acetylgalactosaminidase

570_task2

Sentence: Deglycosylation of serum vitamin D3-binding protein by alpha-N-acetylgalactosaminidase detected in the plasma of patients with systemic lupus erythematosus. A serum glycoprotein, Gc protein (vitamin D3-binding protein), can be converted by beta-galactosidase of B cells and sialidase of T cells to a potent macrophage-activating factor (MAF), a protein with N-acetylgalactosamine as the remaining sugar moiety. Thus, Gc protein is the precursor for MAF. Treatment of Gc protein with immobilized beta-galactosidase and sialidase generates a remarkably high titered macrophage-activating factor (GcMAF). When peripheral blood monocytes/ macrophages (designated macrophages) of 33 systemic lupus erythematosus patients were incubated with GcMAF (100 pg/ml), the macrophages of all patients were activated as determined by superoxide generation. However, the precursor activity of patient plasma Gc protein was lost or reduced in these patients. Loss of the precursor activity was the result of deglycosylation of plasma Gc protein by alpha-N-acetylgalactosaminidase activity found in the patient plasma. Levels of plasma alpha-N-acetylgalactosaminidase activity in individual patients had an inverse correlation with the MAF precursor activity of their plasma Gc protein. Deglycosylated Gc protein cannot be converted to macro-phage-activating factor. The resulting defect in macro-phage activation may lead to an inability to clear pathogenic immune complexes. Thus, elevated plasma alpha-N-acetylgalactosaminidase activity resulting in the loss of MAF precursor activity and reduced macro-phage activity may play a role in the pathogenesis of systemic lupus erythematosus. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Deglycosylation of serum vitamin D3-binding protein by alpha-N-acetylgalactosaminidase detected in the plasma of patients with systemic lupus erythematosus. A serum glycoprotein, Gc protein (vitamin D3-binding protein), can be converted by beta-galactosidase of B cells and sialidase of T cells to a potent macrophage-activating factor (MAF), a protein with N-acetylgalactosamine as the remaining sugar moiety. Thus, Gc protein is the precursor for MAF. Treatment of Gc protein with immobilized beta-galactosidase and sialidase generates a remarkably high titered macrophage-activating factor (GcMAF). When peripheral blood monocytes/ macrophages (designated macrophages) of 33 systemic lupus erythematosus patients were incubated with GcMAF (100 pg/ml), the macrophages of all patients were activated as determined by superoxide generation. However, the precursor activity of patient plasma Gc protein was lost or reduced in these patients. Loss of the precursor activity was the result of deglycosylation of plasma Gc protein by alpha-N-acetylgalactosaminidase activity found in the patient plasma. Levels of plasma alpha-N-acetylgalactosaminidase activity in individual patients had an inverse correlation with the MAF precursor activity of their plasma Gc protein. Deglycosylated Gc protein cannot be converted to macro-phage-activating factor. The resulting defect in macro-phage activation may lead to an inability to clear pathogenic immune complexes. Thus, elevated plasma alpha-N-acetylgalactosaminidase activity resulting in the loss of MAF precursor activity and reduced macro-phage activity may play a role in the pathogenesis of systemic lupus erythematosus.

[ "Deglycosylation", "of", "serum", "vitamin", "D3-binding", "protein", "by", "alpha", "-", "N", "-", "acetylgalactosaminidase", "detected", "in", "the", "plasma", "of", "patients", "with", "systemic", "lupus", "erythematosus", ".", "\n", "A", "serum", "glycoprotein", ",", "Gc", "protein", "(", "vitamin", "D3-binding", "protein", ")", ",", "can", "be", "converted", "by", "beta", "-", "galactosidase", "of", "B", "cells", "and", "sialidase", "of", "T", "cells", "to", "a", "potent", "macrophage", "-", "activating", "factor", "(", "MAF", ")", ",", "a", "protein", "with", "N", "-", "acetylgalactosamine", "as", "the", "remaining", "sugar", "moiety", ".", "Thus", ",", "Gc", "protein", "is", "the", "precursor", "for", "MAF", ".", "Treatment", "of", "Gc", "protein", "with", "immobilized", "beta", "-", "galactosidase", "and", "sialidase", "generates", "a", "remarkably", "high", "titered", "macrophage", "-", "activating", "factor", "(", "GcMAF", ")", ".", "When", "peripheral", "blood", "monocytes/", "macrophages", "(", "designated", "macrophages", ")", "of", "33", "systemic", "lupus", "erythematosus", "patients", "were", "incubated", "with", "GcMAF", "(", "100", "pg", "/", "ml", ")", ",", "the", "macrophages", "of", "all", "patients", "were", "activated", "as", "determined", "by", "superoxide", "generation", ".", "However", ",", "the", "precursor", "activity", "of", "patient", "plasma", "Gc", "protein", "was", "lost", "or", "reduced", "in", "these", "patients", ".", "Loss", "of", "the", "precursor", "activity", "was", "the", "result", "of", "deglycosylation", "of", "plasma", "Gc", "protein", "by", "alpha", "-", "N", "-", "acetylgalactosaminidase", "activity", "found", "in", "the", "patient", "plasma", ".", "Levels", "of", "plasma", "alpha", "-", "N", "-", "acetylgalactosaminidase", "activity", "in", "individual", "patients", "had", "an", "inverse", "correlation", "with", "the", "MAF", "precursor", "activity", "of", "their", "plasma", "Gc", "protein", ".", "Deglycosylated", "Gc", "protein", "cannot", "be", "converted", "to", "macro", "-", "phage", "-", "activating", "factor", ".", "The", "resulting", "defect", "in", "macro", "-", "phage", "activation", "may", "lead", "to", "an", "inability", "to", "clear", "pathogenic", "immune", "complexes", ".", "Thus", ",", "elevated", "plasma", "alpha", "-", "N", "-", "acetylgalactosaminidase", "activity", "resulting", "in", "the", "loss", "of", "MAF", "precursor", "activity", "and", "reduced", "macro", "-", "phage", "activity", "may", "play", "a", "role", "in", "the", "pathogenesis", "of", "systemic", "lupus", "erythematosus", ".", "\n" ]

[ "Protein" ]

amprenavir is a DRUG, rifabutin is a DRUG, rifampin is a DRUG, amprenavir is a DRUG, rifabutin is a DRUG, rifampin is a DRUG, amprenavir is a DRUG, rifabutin is a DRUG, rifampin is a DRUG, amprenavir is a DRUG, rifabutin is a DRUG, amprenavir is a DRUG, rifampin is a DRUG, amprenavir is a DRUG, rifabutin is a DRUG, rifampin is a DRUG, 25-O - desacetyl metabolites is a DRUG_N, Rifabutin is a DRUG, amprenavir is a DRUG, Amprenavir is a DRUG, rifabutin is a DRUG, 25-O - desacetylrifabutin is a DRUG_N, Rifampin is a DRUG, amprenavir is a DRUG, amprenavir is a DRUG, rifampin is a DRUG, Amprenavir is a DRUG, rifabutin is a DRUG, rifampin is a DRUG, Amprenavir is a DRUG, rifampin is a DRUG, Amprenavir is a DRUG, rifabutin is a DRUG, Rifampin is a DRUG, amprenavir is a DRUG, Amprenavir is a DRUG, rifabutin is a DRUG, 25-O - desacetylrifabutin is a DRUG_N, Amprenavir is a DRUG, rifampin is a DRUG, rifabutin is a DRUG

11158747_task0

Sentence: Pharmacokinetic Interaction between amprenavir and rifabutin or rifampin in healthy males. The objective of this study was to determine if there is a pharmacokinetic interaction when amprenavir is given with rifabutin or rifampin and to determine the effects of these drugs on the erythromycin breath test (ERMBT). Twenty-four healthy male subjects were randomized to one of two cohorts. All subjects received amprenavir (1,200 mg twice a day) for 4 days, followed by a 7-day washout period, followed by either rifabutin (300 mg once a day [QD]) (cohort 1) or rifampin (600 mg QD) (cohort 2) for 14 days. Cohort 1 then received amprenavir plus rifabutin for 10 days, and cohort 2 received amprenavir plus rifampin for 4 days. Serial plasma and urine samples for measurement of amprenavir, rifabutin, and rifampin and their 25-O-desacetyl metabolites, were measured by high-performance liquid chromatography. Rifabutin did not significantly affect amprenavir's pharmacokinetics. Amprenavir significantly increased the area under the curve at steady state (AUC(ss)) of rifabutin by 2.93-fold and the AUC(ss) of 25-O-desacetylrifabutin by 13.3-fold. Rifampin significantly decreased the AUC(ss) of amprenavir by 82%, but amprenavir had no effect on rifampin pharmacokinetics. Amprenavir decreased the results of the ERMBT by 83%. The results of the ERMBT after 2 weeks of rifabutin and rifampin therapy were increased 187 and 156%, respectively. Amprenavir plus rifampin was well tolerated. Amprenavir plus rifabutin was poorly tolerated, and 5 of 11 subjects discontinued therapy. Rifampin markedly increases the metabolic clearance of amprenavir, and coadministration is contraindicated. Amprenavir significantly decreases clearance of rifabutin and 25-O-desacetylrifabutin, and the combination is poorly tolerated. Amprenavir inhibits the ERMBT, and rifampin and rifabutin are equipotent inducers of the ERMBT. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: DRUG_N, DRUG

[ "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "O", "B-DRUG_N", "I-DRUG_N", "I-DRUG_N", "I-DRUG_N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "B-DRUG_N", "I-DRUG_N", "I-DRUG_N", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG_N", "I-DRUG_N", "I-DRUG_N", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O" ]

Pharmacokinetic Interaction between amprenavir and rifabutin or rifampin in healthy males. The objective of this study was to determine if there is a pharmacokinetic interaction when amprenavir is given with rifabutin or rifampin and to determine the effects of these drugs on the erythromycin breath test (ERMBT). Twenty-four healthy male subjects were randomized to one of two cohorts. All subjects received amprenavir (1,200 mg twice a day) for 4 days, followed by a 7-day washout period, followed by either rifabutin (300 mg once a day [QD]) (cohort 1) or rifampin (600 mg QD) (cohort 2) for 14 days. Cohort 1 then received amprenavir plus rifabutin for 10 days, and cohort 2 received amprenavir plus rifampin for 4 days. Serial plasma and urine samples for measurement of amprenavir, rifabutin, and rifampin and their 25-O-desacetyl metabolites, were measured by high-performance liquid chromatography. Rifabutin did not significantly affect amprenavir's pharmacokinetics. Amprenavir significantly increased the area under the curve at steady state (AUC(ss)) of rifabutin by 2.93-fold and the AUC(ss) of 25-O-desacetylrifabutin by 13.3-fold. Rifampin significantly decreased the AUC(ss) of amprenavir by 82%, but amprenavir had no effect on rifampin pharmacokinetics. Amprenavir decreased the results of the ERMBT by 83%. The results of the ERMBT after 2 weeks of rifabutin and rifampin therapy were increased 187 and 156%, respectively. Amprenavir plus rifampin was well tolerated. Amprenavir plus rifabutin was poorly tolerated, and 5 of 11 subjects discontinued therapy. Rifampin markedly increases the metabolic clearance of amprenavir, and coadministration is contraindicated. Amprenavir significantly decreases clearance of rifabutin and 25-O-desacetylrifabutin, and the combination is poorly tolerated. Amprenavir inhibits the ERMBT, and rifampin and rifabutin are equipotent inducers of the ERMBT.

[ "Pharmacokinetic", "Interaction", "between", "amprenavir", "and", "rifabutin", "or", "rifampin", "in", "healthy", "males", ".", "The", "objective", "of", "this", "study", "was", "to", "determine", "if", "there", "is", "a", "pharmacokinetic", "interaction", "when", "amprenavir", "is", "given", "with", "rifabutin", "or", "rifampin", "and", "to", "determine", "the", "effects", "of", "these", "drugs", "on", "the", "erythromycin", "breath", "test", "(", "ERMBT", ")", ".", "Twenty", "-", "four", "healthy", "male", "subjects", "were", "randomized", "to", "one", "of", "two", "cohorts", ".", "All", "subjects", "received", "amprenavir", "(", "1,200", "mg", "twice", "a", "day", ")", "for", "4", "days", ",", "followed", "by", "a", "7-day", "washout", "period", ",", "followed", "by", "either", "rifabutin", "(", "300", "mg", "once", "a", "day", "[", "QD", "]", ")", "(", "cohort", "1", ")", "or", "rifampin", "(", "600", "mg", "QD", ")", "(", "cohort", "2", ")", "for", "14", "days", ".", "Cohort", "1", "then", "received", "amprenavir", "plus", "rifabutin", "for", "10", "days", ",", "and", "cohort", "2", "received", "amprenavir", "plus", "rifampin", "for", "4", "days", ".", "Serial", "plasma", "and", "urine", "samples", "for", "measurement", "of", "amprenavir", ",", "rifabutin", ",", "and", "rifampin", "and", "their", "25-O", "-", "desacetyl", "metabolites", ",", "were", "measured", "by", "high", "-", "performance", "liquid", "chromatography", ".", "Rifabutin", "did", "not", "significantly", "affect", "amprenavir", "'s", "pharmacokinetics", ".", "Amprenavir", "significantly", "increased", "the", "area", "under", "the", "curve", "at", "steady", "state", "(", "AUC(ss", ")", ")", "of", "rifabutin", "by", "2.93-fold", "and", "the", "AUC(ss", ")", "of", "25-O", "-", "desacetylrifabutin", "by", "13.3-fold", ".", "Rifampin", "significantly", "decreased", "the", "AUC(ss", ")", "of", "amprenavir", "by", "82", "%", ",", "but", "amprenavir", "had", "no", "effect", "on", "rifampin", "pharmacokinetics", ".", "Amprenavir", "decreased", "the", "results", "of", "the", "ERMBT", "by", "83", "%", ".", "The", "results", "of", "the", "ERMBT", "after", "2", "weeks", "of", "rifabutin", "and", "rifampin", "therapy", "were", "increased", "187", "and", "156", "%", ",", "respectively", ".", "Amprenavir", "plus", "rifampin", "was", "well", "tolerated", ".", "Amprenavir", "plus", "rifabutin", "was", "poorly", "tolerated", ",", "and", "5", "of", "11", "subjects", "discontinued", "therapy", ".", "Rifampin", "markedly", "increases", "the", "metabolic", "clearance", "of", "amprenavir", ",", "and", "coadministration", "is", "contraindicated", ".", "Amprenavir", "significantly", "decreases", "clearance", "of", "rifabutin", "and", "25-O", "-", "desacetylrifabutin", ",", "and", "the", "combination", "is", "poorly", "tolerated", ".", "Amprenavir", "inhibits", "the", "ERMBT", ",", "and", "rifampin", "and", "rifabutin", "are", "equipotent", "inducers", "of", "the", "ERMBT", "." ]

[ "DRUG_N", "DRUG" ]

amprenavir is a DRUG, rifabutin is a DRUG, rifampin is a DRUG, amprenavir is a DRUG, rifabutin is a DRUG, rifampin is a DRUG, amprenavir is a DRUG, rifabutin is a DRUG, rifampin is a DRUG, amprenavir is a DRUG, rifabutin is a DRUG, amprenavir is a DRUG, rifampin is a DRUG, amprenavir is a DRUG, rifabutin is a DRUG, rifampin is a DRUG, 25-O - desacetyl metabolites is a DRUG_N, Rifabutin is a DRUG, amprenavir is a DRUG, Amprenavir is a DRUG, rifabutin is a DRUG, 25-O - desacetylrifabutin is a DRUG_N, Rifampin is a DRUG, amprenavir is a DRUG, amprenavir is a DRUG, rifampin is a DRUG, Amprenavir is a DRUG, rifabutin is a DRUG, rifampin is a DRUG, Amprenavir is a DRUG, rifampin is a DRUG, Amprenavir is a DRUG, rifabutin is a DRUG, Rifampin is a DRUG, amprenavir is a DRUG, Amprenavir is a DRUG, rifabutin is a DRUG, 25-O - desacetylrifabutin is a DRUG_N, Amprenavir is a DRUG, rifampin is a DRUG, rifabutin is a DRUG

11158747_task1

Sentence: Pharmacokinetic Interaction between amprenavir and rifabutin or rifampin in healthy males. The objective of this study was to determine if there is a pharmacokinetic interaction when amprenavir is given with rifabutin or rifampin and to determine the effects of these drugs on the erythromycin breath test (ERMBT). Twenty-four healthy male subjects were randomized to one of two cohorts. All subjects received amprenavir (1,200 mg twice a day) for 4 days, followed by a 7-day washout period, followed by either rifabutin (300 mg once a day [QD]) (cohort 1) or rifampin (600 mg QD) (cohort 2) for 14 days. Cohort 1 then received amprenavir plus rifabutin for 10 days, and cohort 2 received amprenavir plus rifampin for 4 days. Serial plasma and urine samples for measurement of amprenavir, rifabutin, and rifampin and their 25-O-desacetyl metabolites, were measured by high-performance liquid chromatography. Rifabutin did not significantly affect amprenavir's pharmacokinetics. Amprenavir significantly increased the area under the curve at steady state (AUC(ss)) of rifabutin by 2.93-fold and the AUC(ss) of 25-O-desacetylrifabutin by 13.3-fold. Rifampin significantly decreased the AUC(ss) of amprenavir by 82%, but amprenavir had no effect on rifampin pharmacokinetics. Amprenavir decreased the results of the ERMBT by 83%. The results of the ERMBT after 2 weeks of rifabutin and rifampin therapy were increased 187 and 156%, respectively. Amprenavir plus rifampin was well tolerated. Amprenavir plus rifabutin was poorly tolerated, and 5 of 11 subjects discontinued therapy. Rifampin markedly increases the metabolic clearance of amprenavir, and coadministration is contraindicated. Amprenavir significantly decreases clearance of rifabutin and 25-O-desacetylrifabutin, and the combination is poorly tolerated. Amprenavir inhibits the ERMBT, and rifampin and rifabutin are equipotent inducers of the ERMBT. Instructions: please typing these entity words according to sentence: amprenavir, rifabutin, rifampin, amprenavir, rifabutin, rifampin, amprenavir, rifabutin, rifampin, amprenavir, rifabutin, amprenavir, rifampin, amprenavir, rifabutin, rifampin, 25-O - desacetyl metabolites, Rifabutin, amprenavir, Amprenavir, rifabutin, 25-O - desacetylrifabutin, Rifampin, amprenavir, amprenavir, rifampin, Amprenavir, rifabutin, rifampin, Amprenavir, rifampin, Amprenavir, rifabutin, Rifampin, amprenavir, Amprenavir, rifabutin, 25-O - desacetylrifabutin, Amprenavir, rifampin, rifabutin Options: DRUG_N, DRUG

[ "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "O", "B-DRUG_N", "I-DRUG_N", "I-DRUG_N", "I-DRUG_N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "B-DRUG_N", "I-DRUG_N", "I-DRUG_N", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG_N", "I-DRUG_N", "I-DRUG_N", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O" ]

Pharmacokinetic Interaction between amprenavir and rifabutin or rifampin in healthy males. The objective of this study was to determine if there is a pharmacokinetic interaction when amprenavir is given with rifabutin or rifampin and to determine the effects of these drugs on the erythromycin breath test (ERMBT). Twenty-four healthy male subjects were randomized to one of two cohorts. All subjects received amprenavir (1,200 mg twice a day) for 4 days, followed by a 7-day washout period, followed by either rifabutin (300 mg once a day [QD]) (cohort 1) or rifampin (600 mg QD) (cohort 2) for 14 days. Cohort 1 then received amprenavir plus rifabutin for 10 days, and cohort 2 received amprenavir plus rifampin for 4 days. Serial plasma and urine samples for measurement of amprenavir, rifabutin, and rifampin and their 25-O-desacetyl metabolites, were measured by high-performance liquid chromatography. Rifabutin did not significantly affect amprenavir's pharmacokinetics. Amprenavir significantly increased the area under the curve at steady state (AUC(ss)) of rifabutin by 2.93-fold and the AUC(ss) of 25-O-desacetylrifabutin by 13.3-fold. Rifampin significantly decreased the AUC(ss) of amprenavir by 82%, but amprenavir had no effect on rifampin pharmacokinetics. Amprenavir decreased the results of the ERMBT by 83%. The results of the ERMBT after 2 weeks of rifabutin and rifampin therapy were increased 187 and 156%, respectively. Amprenavir plus rifampin was well tolerated. Amprenavir plus rifabutin was poorly tolerated, and 5 of 11 subjects discontinued therapy. Rifampin markedly increases the metabolic clearance of amprenavir, and coadministration is contraindicated. Amprenavir significantly decreases clearance of rifabutin and 25-O-desacetylrifabutin, and the combination is poorly tolerated. Amprenavir inhibits the ERMBT, and rifampin and rifabutin are equipotent inducers of the ERMBT.

[ "Pharmacokinetic", "Interaction", "between", "amprenavir", "and", "rifabutin", "or", "rifampin", "in", "healthy", "males", ".", "The", "objective", "of", "this", "study", "was", "to", "determine", "if", "there", "is", "a", "pharmacokinetic", "interaction", "when", "amprenavir", "is", "given", "with", "rifabutin", "or", "rifampin", "and", "to", "determine", "the", "effects", "of", "these", "drugs", "on", "the", "erythromycin", "breath", "test", "(", "ERMBT", ")", ".", "Twenty", "-", "four", "healthy", "male", "subjects", "were", "randomized", "to", "one", "of", "two", "cohorts", ".", "All", "subjects", "received", "amprenavir", "(", "1,200", "mg", "twice", "a", "day", ")", "for", "4", "days", ",", "followed", "by", "a", "7-day", "washout", "period", ",", "followed", "by", "either", "rifabutin", "(", "300", "mg", "once", "a", "day", "[", "QD", "]", ")", "(", "cohort", "1", ")", "or", "rifampin", "(", "600", "mg", "QD", ")", "(", "cohort", "2", ")", "for", "14", "days", ".", "Cohort", "1", "then", "received", "amprenavir", "plus", "rifabutin", "for", "10", "days", ",", "and", "cohort", "2", "received", "amprenavir", "plus", "rifampin", "for", "4", "days", ".", "Serial", "plasma", "and", "urine", "samples", "for", "measurement", "of", "amprenavir", ",", "rifabutin", ",", "and", "rifampin", "and", "their", "25-O", "-", "desacetyl", "metabolites", ",", "were", "measured", "by", "high", "-", "performance", "liquid", "chromatography", ".", "Rifabutin", "did", "not", "significantly", "affect", "amprenavir", "'s", "pharmacokinetics", ".", "Amprenavir", "significantly", "increased", "the", "area", "under", "the", "curve", "at", "steady", "state", "(", "AUC(ss", ")", ")", "of", "rifabutin", "by", "2.93-fold", "and", "the", "AUC(ss", ")", "of", "25-O", "-", "desacetylrifabutin", "by", "13.3-fold", ".", "Rifampin", "significantly", "decreased", "the", "AUC(ss", ")", "of", "amprenavir", "by", "82", "%", ",", "but", "amprenavir", "had", "no", "effect", "on", "rifampin", "pharmacokinetics", ".", "Amprenavir", "decreased", "the", "results", "of", "the", "ERMBT", "by", "83", "%", ".", "The", "results", "of", "the", "ERMBT", "after", "2", "weeks", "of", "rifabutin", "and", "rifampin", "therapy", "were", "increased", "187", "and", "156", "%", ",", "respectively", ".", "Amprenavir", "plus", "rifampin", "was", "well", "tolerated", ".", "Amprenavir", "plus", "rifabutin", "was", "poorly", "tolerated", ",", "and", "5", "of", "11", "subjects", "discontinued", "therapy", ".", "Rifampin", "markedly", "increases", "the", "metabolic", "clearance", "of", "amprenavir", ",", "and", "coadministration", "is", "contraindicated", ".", "Amprenavir", "significantly", "decreases", "clearance", "of", "rifabutin", "and", "25-O", "-", "desacetylrifabutin", ",", "and", "the", "combination", "is", "poorly", "tolerated", ".", "Amprenavir", "inhibits", "the", "ERMBT", ",", "and", "rifampin", "and", "rifabutin", "are", "equipotent", "inducers", "of", "the", "ERMBT", "." ]

[ "DRUG_N", "DRUG" ]

amprenavir, rifabutin, rifampin, amprenavir, rifabutin, rifampin, amprenavir, rifabutin, rifampin, amprenavir, rifabutin, amprenavir, rifampin, amprenavir, rifabutin, rifampin, 25-O - desacetyl metabolites, Rifabutin, amprenavir, Amprenavir, rifabutin, 25-O - desacetylrifabutin, Rifampin, amprenavir, amprenavir, rifampin, Amprenavir, rifabutin, rifampin, Amprenavir, rifampin, Amprenavir, rifabutin, Rifampin, amprenavir, Amprenavir, rifabutin, 25-O - desacetylrifabutin, Amprenavir, rifampin, rifabutin

11158747_task2

Sentence: Pharmacokinetic Interaction between amprenavir and rifabutin or rifampin in healthy males. The objective of this study was to determine if there is a pharmacokinetic interaction when amprenavir is given with rifabutin or rifampin and to determine the effects of these drugs on the erythromycin breath test (ERMBT). Twenty-four healthy male subjects were randomized to one of two cohorts. All subjects received amprenavir (1,200 mg twice a day) for 4 days, followed by a 7-day washout period, followed by either rifabutin (300 mg once a day [QD]) (cohort 1) or rifampin (600 mg QD) (cohort 2) for 14 days. Cohort 1 then received amprenavir plus rifabutin for 10 days, and cohort 2 received amprenavir plus rifampin for 4 days. Serial plasma and urine samples for measurement of amprenavir, rifabutin, and rifampin and their 25-O-desacetyl metabolites, were measured by high-performance liquid chromatography. Rifabutin did not significantly affect amprenavir's pharmacokinetics. Amprenavir significantly increased the area under the curve at steady state (AUC(ss)) of rifabutin by 2.93-fold and the AUC(ss) of 25-O-desacetylrifabutin by 13.3-fold. Rifampin significantly decreased the AUC(ss) of amprenavir by 82%, but amprenavir had no effect on rifampin pharmacokinetics. Amprenavir decreased the results of the ERMBT by 83%. The results of the ERMBT after 2 weeks of rifabutin and rifampin therapy were increased 187 and 156%, respectively. Amprenavir plus rifampin was well tolerated. Amprenavir plus rifabutin was poorly tolerated, and 5 of 11 subjects discontinued therapy. Rifampin markedly increases the metabolic clearance of amprenavir, and coadministration is contraindicated. Amprenavir significantly decreases clearance of rifabutin and 25-O-desacetylrifabutin, and the combination is poorly tolerated. Amprenavir inhibits the ERMBT, and rifampin and rifabutin are equipotent inducers of the ERMBT. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "O", "B-DRUG_N", "I-DRUG_N", "I-DRUG_N", "I-DRUG_N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "B-DRUG_N", "I-DRUG_N", "I-DRUG_N", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG_N", "I-DRUG_N", "I-DRUG_N", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O" ]

Pharmacokinetic Interaction between amprenavir and rifabutin or rifampin in healthy males. The objective of this study was to determine if there is a pharmacokinetic interaction when amprenavir is given with rifabutin or rifampin and to determine the effects of these drugs on the erythromycin breath test (ERMBT). Twenty-four healthy male subjects were randomized to one of two cohorts. All subjects received amprenavir (1,200 mg twice a day) for 4 days, followed by a 7-day washout period, followed by either rifabutin (300 mg once a day [QD]) (cohort 1) or rifampin (600 mg QD) (cohort 2) for 14 days. Cohort 1 then received amprenavir plus rifabutin for 10 days, and cohort 2 received amprenavir plus rifampin for 4 days. Serial plasma and urine samples for measurement of amprenavir, rifabutin, and rifampin and their 25-O-desacetyl metabolites, were measured by high-performance liquid chromatography. Rifabutin did not significantly affect amprenavir's pharmacokinetics. Amprenavir significantly increased the area under the curve at steady state (AUC(ss)) of rifabutin by 2.93-fold and the AUC(ss) of 25-O-desacetylrifabutin by 13.3-fold. Rifampin significantly decreased the AUC(ss) of amprenavir by 82%, but amprenavir had no effect on rifampin pharmacokinetics. Amprenavir decreased the results of the ERMBT by 83%. The results of the ERMBT after 2 weeks of rifabutin and rifampin therapy were increased 187 and 156%, respectively. Amprenavir plus rifampin was well tolerated. Amprenavir plus rifabutin was poorly tolerated, and 5 of 11 subjects discontinued therapy. Rifampin markedly increases the metabolic clearance of amprenavir, and coadministration is contraindicated. Amprenavir significantly decreases clearance of rifabutin and 25-O-desacetylrifabutin, and the combination is poorly tolerated. Amprenavir inhibits the ERMBT, and rifampin and rifabutin are equipotent inducers of the ERMBT.

[ "Pharmacokinetic", "Interaction", "between", "amprenavir", "and", "rifabutin", "or", "rifampin", "in", "healthy", "males", ".", "The", "objective", "of", "this", "study", "was", "to", "determine", "if", "there", "is", "a", "pharmacokinetic", "interaction", "when", "amprenavir", "is", "given", "with", "rifabutin", "or", "rifampin", "and", "to", "determine", "the", "effects", "of", "these", "drugs", "on", "the", "erythromycin", "breath", "test", "(", "ERMBT", ")", ".", "Twenty", "-", "four", "healthy", "male", "subjects", "were", "randomized", "to", "one", "of", "two", "cohorts", ".", "All", "subjects", "received", "amprenavir", "(", "1,200", "mg", "twice", "a", "day", ")", "for", "4", "days", ",", "followed", "by", "a", "7-day", "washout", "period", ",", "followed", "by", "either", "rifabutin", "(", "300", "mg", "once", "a", "day", "[", "QD", "]", ")", "(", "cohort", "1", ")", "or", "rifampin", "(", "600", "mg", "QD", ")", "(", "cohort", "2", ")", "for", "14", "days", ".", "Cohort", "1", "then", "received", "amprenavir", "plus", "rifabutin", "for", "10", "days", ",", "and", "cohort", "2", "received", "amprenavir", "plus", "rifampin", "for", "4", "days", ".", "Serial", "plasma", "and", "urine", "samples", "for", "measurement", "of", "amprenavir", ",", "rifabutin", ",", "and", "rifampin", "and", "their", "25-O", "-", "desacetyl", "metabolites", ",", "were", "measured", "by", "high", "-", "performance", "liquid", "chromatography", ".", "Rifabutin", "did", "not", "significantly", "affect", "amprenavir", "'s", "pharmacokinetics", ".", "Amprenavir", "significantly", "increased", "the", "area", "under", "the", "curve", "at", "steady", "state", "(", "AUC(ss", ")", ")", "of", "rifabutin", "by", "2.93-fold", "and", "the", "AUC(ss", ")", "of", "25-O", "-", "desacetylrifabutin", "by", "13.3-fold", ".", "Rifampin", "significantly", "decreased", "the", "AUC(ss", ")", "of", "amprenavir", "by", "82", "%", ",", "but", "amprenavir", "had", "no", "effect", "on", "rifampin", "pharmacokinetics", ".", "Amprenavir", "decreased", "the", "results", "of", "the", "ERMBT", "by", "83", "%", ".", "The", "results", "of", "the", "ERMBT", "after", "2", "weeks", "of", "rifabutin", "and", "rifampin", "therapy", "were", "increased", "187", "and", "156", "%", ",", "respectively", ".", "Amprenavir", "plus", "rifampin", "was", "well", "tolerated", ".", "Amprenavir", "plus", "rifabutin", "was", "poorly", "tolerated", ",", "and", "5", "of", "11", "subjects", "discontinued", "therapy", ".", "Rifampin", "markedly", "increases", "the", "metabolic", "clearance", "of", "amprenavir", ",", "and", "coadministration", "is", "contraindicated", ".", "Amprenavir", "significantly", "decreases", "clearance", "of", "rifabutin", "and", "25-O", "-", "desacetylrifabutin", ",", "and", "the", "combination", "is", "poorly", "tolerated", ".", "Amprenavir", "inhibits", "the", "ERMBT", ",", "and", "rifampin", "and", "rifabutin", "are", "equipotent", "inducers", "of", "the", "ERMBT", "." ]

[ "DRUG_N", "DRUG" ]

profilin is a Individual_protein, actin is a Individual_protein

487_task0

Sentence: Involvement of profilin in the actin-based motility of L. monocytogenes in cells and in cell-free extracts. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Individual_protein

[ "O", "O", "B-Individual_protein", "O", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Involvement of profilin in the actin-based motility of L. monocytogenes in cells and in cell-free extracts.

[ "Involvement", "of", "profilin", "in", "the", "actin", "-", "based", "motility", "of", "L.", "monocytogenes", "in", "cells", "and", "in", "cell", "-", "free", "extracts", "." ]

[ "Individual_protein" ]

profilin is a Individual_protein, actin is a Individual_protein

487_task1

Sentence: Involvement of profilin in the actin-based motility of L. monocytogenes in cells and in cell-free extracts. Instructions: please typing these entity words according to sentence: profilin, actin Options: Individual_protein

[ "O", "O", "B-Individual_protein", "O", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Involvement of profilin in the actin-based motility of L. monocytogenes in cells and in cell-free extracts.

[ "Involvement", "of", "profilin", "in", "the", "actin", "-", "based", "motility", "of", "L.", "monocytogenes", "in", "cells", "and", "in", "cell", "-", "free", "extracts", "." ]

[ "Individual_protein" ]

profilin, actin

487_task2

Sentence: Involvement of profilin in the actin-based motility of L. monocytogenes in cells and in cell-free extracts. Instructions: please extract entity words from the input sentence

[ "O", "O", "B-Individual_protein", "O", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Involvement of profilin in the actin-based motility of L. monocytogenes in cells and in cell-free extracts.

[ "Involvement", "of", "profilin", "in", "the", "actin", "-", "based", "motility", "of", "L.", "monocytogenes", "in", "cells", "and", "in", "cell", "-", "free", "extracts", "." ]

[ "Individual_protein" ]

L - Carnitine is a Simple_chemical, methotrexate is a Simple_chemical, organ is a Organ, leukocyte is a Cell, Methotrexate is a Simple_chemical, MTX is a Simple_chemical, folic acid is a Simple_chemical, tumors is a Cancer, normal tissues is a Tissue, hematopoietic cells is a Cell, bone marrow is a Multi-tissue_structure, gastrointestinal mucosal cells is a Cell, leukocytes is a Cell, MTX is a Simple_chemical, organ is a Organ, L - carnitine is a Simple_chemical, L - Car is a Simple_chemical, Wistar albino rats is a Organism, MTX is a Simple_chemical, saline is a Simple_chemical, L - Car is a Simple_chemical, rats is a Organism, trunk blood is a Organism_substance, ileum is a Multi-tissue_structure, liver is a Organ, kidney is a Organ, malondialdehyde is a Simple_chemical, MDA is a Simple_chemical, glutathione is a Simple_chemical, GSH is a Simple_chemical, myeloperoxidase is a Simple_chemical, MPO is a Simple_chemical, collagen is a Gene_or_gene_product, MTX is a Simple_chemical, MDA is a Simple_chemical, MPO is a Simple_chemical, collagen is a Gene_or_gene_product, GSH is a Simple_chemical, tissues is a Tissue, L - Car is a Simple_chemical, serum is a Organism_substance, TNF - alpha is a Gene_or_gene_product, MTX is a Simple_chemical, L - Car is a Simple_chemical, neutrophils is a Cell, Annexin V is a Gene_or_gene_product, saline is a Simple_chemical, MTX is a Simple_chemical, L - Car is a Simple_chemical, leukocyte is a Cell, MTX is a Simple_chemical, L - Car is a Simple_chemical, intestinal mucosa is a Multi-tissue_structure, liver parenchyma is a Multi-tissue_structure, glomerular is a Tissue, tubular epithelium is a Tissue, saline is a Simple_chemical, MTX is a Simple_chemical, L - Car is a Simple_chemical, L - Car is a Simple_chemical, MTX is a Simple_chemical, organ is a Organ, leukocyte is a Cell, L - Carnitine is a Simple_chemical

63_task0

Sentence: L-Carnitine ameliorates methotrexate-induced oxidative organ injury and inhibits leukocyte death. Methotrexate (MTX), a folic acid antagonist widely used for the treatment of a variety of tumors and inflammatory diseases, affects normal tissues that have a high rate of proliferation, including the hematopoietic cells of the bone marrow and the gastrointestinal mucosal cells. To elucidate the role of free radicals and leukocytes in MTX-induced oxidative organ damage and the putative protective effect of L-carnitine (L-Car), Wistar albino rats were administered a single dose of MTX (20 mg/kg) followed by either saline or L-Car (500 mg/kg) for 5 days. After decapitation of the rats, trunk blood was obtained, and the ileum, liver, and kidney were removed for histological examination and for the measurement of malondialdehyde (MDA) and glutathione (GSH) levels, myeloperoxidase (MPO) activity, and collagen content. Our results showed that MTX administration increased the MDA and MPO activities and collagen content and decreased GSH levels in all tissues, while these alterations were reversed in L-Car-treated group. The elevated serum TNF-alpha level observed following MTX treatment was depressed with L-Car. The oxidative burst of neutrophils stimulated by Annexin V was reduced in the saline-treated MTX group, while L-Car abolished this inhibition. Similarly, flow cytometric measurements revealed that leukocyte apoptosis was increased in MTX-treated animals, while L-Car reversed these effects. Severe degeneration of the intestinal mucosa, liver parenchyma, and glomerular and tubular epithelium observed in the saline-treated MTX group was improved by L-Car treatment. These results suggest that L-Car, possibly via its free radical scavenging and antioxidant properties, ameliorates MTX-induced oxidative organ injury and inhibits leukocyte apoptosis. Thus, supplementation with L-Carnitine as an adjuvant therapy may be promising in alleviating the systemic side-effects of chemotherapeutics. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Tissue, Organ, Organism_substance, Gene_or_gene_product, Organism, Simple_chemical, Cancer, Multi-tissue_structure, Cell

[ "B-Simple_chemical", "I-Simple_chemical", "I-Simple_chemical", "O", "B-Simple_chemical", "O", "O", "O", "B-Organ", "O", "O", "O", "B-Cell", "O", "O", "O", "B-Simple_chemical", "O", "B-Simple_chemical", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "B-Tissue", "I-Tissue", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "B-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "B-Simple_chemical", "O", "O", "O", "B-Organ", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "I-Simple_chemical", "O", "B-Simple_chemical", "I-Simple_chemical", "I-Simple_chemical", "O", "O", "B-Organism", "I-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "B-Simple_chemical", "I-Simple_chemical", "I-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "B-Organism_substance", "I-Organism_substance", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "B-Organ", "O", "O", "B-Organ", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "B-Simple_chemical", "O", "O", "B-Simple_chemical", "O", "B-Simple_chemical", "O", "O", "O", "B-Simple_chemical", "O", "B-Simple_chemical", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "B-Simple_chemical", "O", "B-Simple_chemical", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "B-Tissue", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "I-Simple_chemical", "O", "O", "O", "O", "O", "O", "B-Organism_substance", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "I-Simple_chemical", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "B-Simple_chemical", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "I-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "I-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "B-Tissue", "O", "B-Tissue", "I-Tissue", "O", "O", "O", "B-Simple_chemical", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "I-Simple_chemical", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "I-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "B-Organ", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "I-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

L-Carnitine ameliorates methotrexate-induced oxidative organ injury and inhibits leukocyte death. Methotrexate (MTX), a folic acid antagonist widely used for the treatment of a variety of tumors and inflammatory diseases, affects normal tissues that have a high rate of proliferation, including the hematopoietic cells of the bone marrow and the gastrointestinal mucosal cells. To elucidate the role of free radicals and leukocytes in MTX-induced oxidative organ damage and the putative protective effect of L-carnitine (L-Car), Wistar albino rats were administered a single dose of MTX (20 mg/kg) followed by either saline or L-Car (500 mg/kg) for 5 days. After decapitation of the rats, trunk blood was obtained, and the ileum, liver, and kidney were removed for histological examination and for the measurement of malondialdehyde (MDA) and glutathione (GSH) levels, myeloperoxidase (MPO) activity, and collagen content. Our results showed that MTX administration increased the MDA and MPO activities and collagen content and decreased GSH levels in all tissues, while these alterations were reversed in L-Car-treated group. The elevated serum TNF-alpha level observed following MTX treatment was depressed with L-Car. The oxidative burst of neutrophils stimulated by Annexin V was reduced in the saline-treated MTX group, while L-Car abolished this inhibition. Similarly, flow cytometric measurements revealed that leukocyte apoptosis was increased in MTX-treated animals, while L-Car reversed these effects. Severe degeneration of the intestinal mucosa, liver parenchyma, and glomerular and tubular epithelium observed in the saline-treated MTX group was improved by L-Car treatment. These results suggest that L-Car, possibly via its free radical scavenging and antioxidant properties, ameliorates MTX-induced oxidative organ injury and inhibits leukocyte apoptosis. Thus, supplementation with L-Carnitine as an adjuvant therapy may be promising in alleviating the systemic side-effects of chemotherapeutics.

[ "L", "-", "Carnitine", "ameliorates", "methotrexate", "-", "induced", "oxidative", "organ", "injury", "and", "inhibits", "leukocyte", "death", ".", "\n", "Methotrexate", "(", "MTX", ")", ",", "a", "folic", "acid", "antagonist", "widely", "used", "for", "the", "treatment", "of", "a", "variety", "of", "tumors", "and", "inflammatory", "diseases", ",", "affects", "normal", "tissues", "that", "have", "a", "high", "rate", "of", "proliferation", ",", "including", "the", "hematopoietic", "cells", "of", "the", "bone", "marrow", "and", "the", "gastrointestinal", "mucosal", "cells", ".", "To", "elucidate", "the", "role", "of", "free", "radicals", "and", "leukocytes", "in", "MTX", "-", "induced", "oxidative", "organ", "damage", "and", "the", "putative", "protective", "effect", "of", "L", "-", "carnitine", "(", "L", "-", "Car", ")", ",", "Wistar", "albino", "rats", "were", "administered", "a", "single", "dose", "of", "MTX", "(", "20", "mg", "/", "kg", ")", "followed", "by", "either", "saline", "or", "L", "-", "Car", "(", "500", "mg", "/", "kg", ")", "for", "5", "days", ".", "After", "decapitation", "of", "the", "rats", ",", "trunk", "blood", "was", "obtained", ",", "and", "the", "ileum", ",", "liver", ",", "and", "kidney", "were", "removed", "for", "histological", "examination", "and", "for", "the", "measurement", "of", "malondialdehyde", "(", "MDA", ")", "and", "glutathione", "(", "GSH", ")", "levels", ",", "myeloperoxidase", "(", "MPO", ")", "activity", ",", "and", "collagen", "content", ".", "Our", "results", "showed", "that", "MTX", "administration", "increased", "the", "MDA", "and", "MPO", "activities", "and", "collagen", "content", "and", "decreased", "GSH", "levels", "in", "all", "tissues", ",", "while", "these", "alterations", "were", "reversed", "in", "L", "-", "Car", "-", "treated", "group", ".", "The", "elevated", "serum", "TNF", "-", "alpha", "level", "observed", "following", "MTX", "treatment", "was", "depressed", "with", "L", "-", "Car", ".", "The", "oxidative", "burst", "of", "neutrophils", "stimulated", "by", "Annexin", "V", "was", "reduced", "in", "the", "saline", "-", "treated", "MTX", "group", ",", "while", "L", "-", "Car", "abolished", "this", "inhibition", ".", "Similarly", ",", "flow", "cytometric", "measurements", "revealed", "that", "leukocyte", "apoptosis", "was", "increased", "in", "MTX", "-", "treated", "animals", ",", "while", "L", "-", "Car", "reversed", "these", "effects", ".", "Severe", "degeneration", "of", "the", "intestinal", "mucosa", ",", "liver", "parenchyma", ",", "and", "glomerular", "and", "tubular", "epithelium", "observed", "in", "the", "saline", "-", "treated", "MTX", "group", "was", "improved", "by", "L", "-", "Car", "treatment", ".", "These", "results", "suggest", "that", "L", "-", "Car", ",", "possibly", "via", "its", "free", "radical", "scavenging", "and", "antioxidant", "properties", ",", "ameliorates", "MTX", "-", "induced", "oxidative", "organ", "injury", "and", "inhibits", "leukocyte", "apoptosis", ".", "Thus", ",", "supplementation", "with", "L", "-", "Carnitine", "as", "an", "adjuvant", "therapy", "may", "be", "promising", "in", "alleviating", "the", "systemic", "side", "-", "effects", "of", "chemotherapeutics", ".", "\n" ]

[ "Cell", "Organism", "Tissue", "Multi-tissue_structure", "Simple_chemical", "Organism_substance", "Gene_or_gene_product", "Cancer", "Organ" ]

L - Carnitine is a Simple_chemical, methotrexate is a Simple_chemical, organ is a Organ, leukocyte is a Cell, Methotrexate is a Simple_chemical, MTX is a Simple_chemical, folic acid is a Simple_chemical, tumors is a Cancer, normal tissues is a Tissue, hematopoietic cells is a Cell, bone marrow is a Multi-tissue_structure, gastrointestinal mucosal cells is a Cell, leukocytes is a Cell, MTX is a Simple_chemical, organ is a Organ, L - carnitine is a Simple_chemical, L - Car is a Simple_chemical, Wistar albino rats is a Organism, MTX is a Simple_chemical, saline is a Simple_chemical, L - Car is a Simple_chemical, rats is a Organism, trunk blood is a Organism_substance, ileum is a Multi-tissue_structure, liver is a Organ, kidney is a Organ, malondialdehyde is a Simple_chemical, MDA is a Simple_chemical, glutathione is a Simple_chemical, GSH is a Simple_chemical, myeloperoxidase is a Simple_chemical, MPO is a Simple_chemical, collagen is a Gene_or_gene_product, MTX is a Simple_chemical, MDA is a Simple_chemical, MPO is a Simple_chemical, collagen is a Gene_or_gene_product, GSH is a Simple_chemical, tissues is a Tissue, L - Car is a Simple_chemical, serum is a Organism_substance, TNF - alpha is a Gene_or_gene_product, MTX is a Simple_chemical, L - Car is a Simple_chemical, neutrophils is a Cell, Annexin V is a Gene_or_gene_product, saline is a Simple_chemical, MTX is a Simple_chemical, L - Car is a Simple_chemical, leukocyte is a Cell, MTX is a Simple_chemical, L - Car is a Simple_chemical, intestinal mucosa is a Multi-tissue_structure, liver parenchyma is a Multi-tissue_structure, glomerular is a Tissue, tubular epithelium is a Tissue, saline is a Simple_chemical, MTX is a Simple_chemical, L - Car is a Simple_chemical, L - Car is a Simple_chemical, MTX is a Simple_chemical, organ is a Organ, leukocyte is a Cell, L - Carnitine is a Simple_chemical

63_task1

Sentence: L-Carnitine ameliorates methotrexate-induced oxidative organ injury and inhibits leukocyte death. Methotrexate (MTX), a folic acid antagonist widely used for the treatment of a variety of tumors and inflammatory diseases, affects normal tissues that have a high rate of proliferation, including the hematopoietic cells of the bone marrow and the gastrointestinal mucosal cells. To elucidate the role of free radicals and leukocytes in MTX-induced oxidative organ damage and the putative protective effect of L-carnitine (L-Car), Wistar albino rats were administered a single dose of MTX (20 mg/kg) followed by either saline or L-Car (500 mg/kg) for 5 days. After decapitation of the rats, trunk blood was obtained, and the ileum, liver, and kidney were removed for histological examination and for the measurement of malondialdehyde (MDA) and glutathione (GSH) levels, myeloperoxidase (MPO) activity, and collagen content. Our results showed that MTX administration increased the MDA and MPO activities and collagen content and decreased GSH levels in all tissues, while these alterations were reversed in L-Car-treated group. The elevated serum TNF-alpha level observed following MTX treatment was depressed with L-Car. The oxidative burst of neutrophils stimulated by Annexin V was reduced in the saline-treated MTX group, while L-Car abolished this inhibition. Similarly, flow cytometric measurements revealed that leukocyte apoptosis was increased in MTX-treated animals, while L-Car reversed these effects. Severe degeneration of the intestinal mucosa, liver parenchyma, and glomerular and tubular epithelium observed in the saline-treated MTX group was improved by L-Car treatment. These results suggest that L-Car, possibly via its free radical scavenging and antioxidant properties, ameliorates MTX-induced oxidative organ injury and inhibits leukocyte apoptosis. Thus, supplementation with L-Carnitine as an adjuvant therapy may be promising in alleviating the systemic side-effects of chemotherapeutics. Instructions: please typing these entity words according to sentence: L - Carnitine, methotrexate, organ, leukocyte, Methotrexate, MTX, folic acid, tumors, normal tissues, hematopoietic cells, bone marrow, gastrointestinal mucosal cells, leukocytes, MTX, organ, L - carnitine, L - Car, Wistar albino rats, MTX, saline, L - Car, rats, trunk blood, ileum, liver, kidney, malondialdehyde, MDA, glutathione, GSH, myeloperoxidase, MPO, collagen, MTX, MDA, MPO, collagen, GSH, tissues, L - Car, serum, TNF - alpha, MTX, L - Car, neutrophils, Annexin V, saline, MTX, L - Car, leukocyte, MTX, L - Car, intestinal mucosa, liver parenchyma, glomerular, tubular epithelium, saline, MTX, L - Car, L - Car, MTX, organ, leukocyte, L - Carnitine Options: Tissue, Organ, Organism_substance, Gene_or_gene_product, Organism, Simple_chemical, Cancer, Multi-tissue_structure, Cell

[ "B-Simple_chemical", "I-Simple_chemical", "I-Simple_chemical", "O", "B-Simple_chemical", "O", "O", "O", "B-Organ", "O", "O", "O", "B-Cell", "O", "O", "O", "B-Simple_chemical", "O", "B-Simple_chemical", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "B-Tissue", "I-Tissue", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "B-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "B-Simple_chemical", "O", "O", "O", "B-Organ", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "I-Simple_chemical", "O", "B-Simple_chemical", "I-Simple_chemical", "I-Simple_chemical", "O", "O", "B-Organism", "I-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "B-Simple_chemical", "I-Simple_chemical", "I-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "B-Organism_substance", "I-Organism_substance", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "B-Organ", "O", "O", "B-Organ", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "B-Simple_chemical", "O", "O", "B-Simple_chemical", "O", "B-Simple_chemical", "O", "O", "O", "B-Simple_chemical", "O", "B-Simple_chemical", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "B-Simple_chemical", "O", "B-Simple_chemical", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "B-Tissue", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "I-Simple_chemical", "O", "O", "O", "O", "O", "O", "B-Organism_substance", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "I-Simple_chemical", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "B-Simple_chemical", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "I-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "I-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "B-Tissue", "O", "B-Tissue", "I-Tissue", "O", "O", "O", "B-Simple_chemical", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "I-Simple_chemical", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "I-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "B-Organ", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "I-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

L-Carnitine ameliorates methotrexate-induced oxidative organ injury and inhibits leukocyte death. Methotrexate (MTX), a folic acid antagonist widely used for the treatment of a variety of tumors and inflammatory diseases, affects normal tissues that have a high rate of proliferation, including the hematopoietic cells of the bone marrow and the gastrointestinal mucosal cells. To elucidate the role of free radicals and leukocytes in MTX-induced oxidative organ damage and the putative protective effect of L-carnitine (L-Car), Wistar albino rats were administered a single dose of MTX (20 mg/kg) followed by either saline or L-Car (500 mg/kg) for 5 days. After decapitation of the rats, trunk blood was obtained, and the ileum, liver, and kidney were removed for histological examination and for the measurement of malondialdehyde (MDA) and glutathione (GSH) levels, myeloperoxidase (MPO) activity, and collagen content. Our results showed that MTX administration increased the MDA and MPO activities and collagen content and decreased GSH levels in all tissues, while these alterations were reversed in L-Car-treated group. The elevated serum TNF-alpha level observed following MTX treatment was depressed with L-Car. The oxidative burst of neutrophils stimulated by Annexin V was reduced in the saline-treated MTX group, while L-Car abolished this inhibition. Similarly, flow cytometric measurements revealed that leukocyte apoptosis was increased in MTX-treated animals, while L-Car reversed these effects. Severe degeneration of the intestinal mucosa, liver parenchyma, and glomerular and tubular epithelium observed in the saline-treated MTX group was improved by L-Car treatment. These results suggest that L-Car, possibly via its free radical scavenging and antioxidant properties, ameliorates MTX-induced oxidative organ injury and inhibits leukocyte apoptosis. Thus, supplementation with L-Carnitine as an adjuvant therapy may be promising in alleviating the systemic side-effects of chemotherapeutics.

[ "L", "-", "Carnitine", "ameliorates", "methotrexate", "-", "induced", "oxidative", "organ", "injury", "and", "inhibits", "leukocyte", "death", ".", "\n", "Methotrexate", "(", "MTX", ")", ",", "a", "folic", "acid", "antagonist", "widely", "used", "for", "the", "treatment", "of", "a", "variety", "of", "tumors", "and", "inflammatory", "diseases", ",", "affects", "normal", "tissues", "that", "have", "a", "high", "rate", "of", "proliferation", ",", "including", "the", "hematopoietic", "cells", "of", "the", "bone", "marrow", "and", "the", "gastrointestinal", "mucosal", "cells", ".", "To", "elucidate", "the", "role", "of", "free", "radicals", "and", "leukocytes", "in", "MTX", "-", "induced", "oxidative", "organ", "damage", "and", "the", "putative", "protective", "effect", "of", "L", "-", "carnitine", "(", "L", "-", "Car", ")", ",", "Wistar", "albino", "rats", "were", "administered", "a", "single", "dose", "of", "MTX", "(", "20", "mg", "/", "kg", ")", "followed", "by", "either", "saline", "or", "L", "-", "Car", "(", "500", "mg", "/", "kg", ")", "for", "5", "days", ".", "After", "decapitation", "of", "the", "rats", ",", "trunk", "blood", "was", "obtained", ",", "and", "the", "ileum", ",", "liver", ",", "and", "kidney", "were", "removed", "for", "histological", "examination", "and", "for", "the", "measurement", "of", "malondialdehyde", "(", "MDA", ")", "and", "glutathione", "(", "GSH", ")", "levels", ",", "myeloperoxidase", "(", "MPO", ")", "activity", ",", "and", "collagen", "content", ".", "Our", "results", "showed", "that", "MTX", "administration", "increased", "the", "MDA", "and", "MPO", "activities", "and", "collagen", "content", "and", "decreased", "GSH", "levels", "in", "all", "tissues", ",", "while", "these", "alterations", "were", "reversed", "in", "L", "-", "Car", "-", "treated", "group", ".", "The", "elevated", "serum", "TNF", "-", "alpha", "level", "observed", "following", "MTX", "treatment", "was", "depressed", "with", "L", "-", "Car", ".", "The", "oxidative", "burst", "of", "neutrophils", "stimulated", "by", "Annexin", "V", "was", "reduced", "in", "the", "saline", "-", "treated", "MTX", "group", ",", "while", "L", "-", "Car", "abolished", "this", "inhibition", ".", "Similarly", ",", "flow", "cytometric", "measurements", "revealed", "that", "leukocyte", "apoptosis", "was", "increased", "in", "MTX", "-", "treated", "animals", ",", "while", "L", "-", "Car", "reversed", "these", "effects", ".", "Severe", "degeneration", "of", "the", "intestinal", "mucosa", ",", "liver", "parenchyma", ",", "and", "glomerular", "and", "tubular", "epithelium", "observed", "in", "the", "saline", "-", "treated", "MTX", "group", "was", "improved", "by", "L", "-", "Car", "treatment", ".", "These", "results", "suggest", "that", "L", "-", "Car", ",", "possibly", "via", "its", "free", "radical", "scavenging", "and", "antioxidant", "properties", ",", "ameliorates", "MTX", "-", "induced", "oxidative", "organ", "injury", "and", "inhibits", "leukocyte", "apoptosis", ".", "Thus", ",", "supplementation", "with", "L", "-", "Carnitine", "as", "an", "adjuvant", "therapy", "may", "be", "promising", "in", "alleviating", "the", "systemic", "side", "-", "effects", "of", "chemotherapeutics", ".", "\n" ]

[ "Cell", "Organism", "Tissue", "Multi-tissue_structure", "Simple_chemical", "Organism_substance", "Gene_or_gene_product", "Cancer", "Organ" ]

L - Carnitine, methotrexate, organ, leukocyte, Methotrexate, MTX, folic acid, tumors, normal tissues, hematopoietic cells, bone marrow, gastrointestinal mucosal cells, leukocytes, MTX, organ, L - carnitine, L - Car, Wistar albino rats, MTX, saline, L - Car, rats, trunk blood, ileum, liver, kidney, malondialdehyde, MDA, glutathione, GSH, myeloperoxidase, MPO, collagen, MTX, MDA, MPO, collagen, GSH, tissues, L - Car, serum, TNF - alpha, MTX, L - Car, neutrophils, Annexin V, saline, MTX, L - Car, leukocyte, MTX, L - Car, intestinal mucosa, liver parenchyma, glomerular, tubular epithelium, saline, MTX, L - Car, L - Car, MTX, organ, leukocyte, L - Carnitine

63_task2

Sentence: L-Carnitine ameliorates methotrexate-induced oxidative organ injury and inhibits leukocyte death. Methotrexate (MTX), a folic acid antagonist widely used for the treatment of a variety of tumors and inflammatory diseases, affects normal tissues that have a high rate of proliferation, including the hematopoietic cells of the bone marrow and the gastrointestinal mucosal cells. To elucidate the role of free radicals and leukocytes in MTX-induced oxidative organ damage and the putative protective effect of L-carnitine (L-Car), Wistar albino rats were administered a single dose of MTX (20 mg/kg) followed by either saline or L-Car (500 mg/kg) for 5 days. After decapitation of the rats, trunk blood was obtained, and the ileum, liver, and kidney were removed for histological examination and for the measurement of malondialdehyde (MDA) and glutathione (GSH) levels, myeloperoxidase (MPO) activity, and collagen content. Our results showed that MTX administration increased the MDA and MPO activities and collagen content and decreased GSH levels in all tissues, while these alterations were reversed in L-Car-treated group. The elevated serum TNF-alpha level observed following MTX treatment was depressed with L-Car. The oxidative burst of neutrophils stimulated by Annexin V was reduced in the saline-treated MTX group, while L-Car abolished this inhibition. Similarly, flow cytometric measurements revealed that leukocyte apoptosis was increased in MTX-treated animals, while L-Car reversed these effects. Severe degeneration of the intestinal mucosa, liver parenchyma, and glomerular and tubular epithelium observed in the saline-treated MTX group was improved by L-Car treatment. These results suggest that L-Car, possibly via its free radical scavenging and antioxidant properties, ameliorates MTX-induced oxidative organ injury and inhibits leukocyte apoptosis. Thus, supplementation with L-Carnitine as an adjuvant therapy may be promising in alleviating the systemic side-effects of chemotherapeutics. Instructions: please extract entity words from the input sentence

[ "B-Simple_chemical", "I-Simple_chemical", "I-Simple_chemical", "O", "B-Simple_chemical", "O", "O", "O", "B-Organ", "O", "O", "O", "B-Cell", "O", "O", "O", "B-Simple_chemical", "O", "B-Simple_chemical", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "B-Tissue", "I-Tissue", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "B-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "B-Simple_chemical", "O", "O", "O", "B-Organ", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "I-Simple_chemical", "O", "B-Simple_chemical", "I-Simple_chemical", "I-Simple_chemical", "O", "O", "B-Organism", "I-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "B-Simple_chemical", "I-Simple_chemical", "I-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "B-Organism_substance", "I-Organism_substance", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "B-Organ", "O", "O", "B-Organ", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "B-Simple_chemical", "O", "O", "B-Simple_chemical", "O", "B-Simple_chemical", "O", "O", "O", "B-Simple_chemical", "O", "B-Simple_chemical", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "B-Simple_chemical", "O", "B-Simple_chemical", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "B-Tissue", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "I-Simple_chemical", "O", "O", "O", "O", "O", "O", "B-Organism_substance", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "I-Simple_chemical", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "B-Simple_chemical", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "I-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "I-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "B-Tissue", "O", "B-Tissue", "I-Tissue", "O", "O", "O", "B-Simple_chemical", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "I-Simple_chemical", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "I-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "B-Organ", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "I-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

L-Carnitine ameliorates methotrexate-induced oxidative organ injury and inhibits leukocyte death. Methotrexate (MTX), a folic acid antagonist widely used for the treatment of a variety of tumors and inflammatory diseases, affects normal tissues that have a high rate of proliferation, including the hematopoietic cells of the bone marrow and the gastrointestinal mucosal cells. To elucidate the role of free radicals and leukocytes in MTX-induced oxidative organ damage and the putative protective effect of L-carnitine (L-Car), Wistar albino rats were administered a single dose of MTX (20 mg/kg) followed by either saline or L-Car (500 mg/kg) for 5 days. After decapitation of the rats, trunk blood was obtained, and the ileum, liver, and kidney were removed for histological examination and for the measurement of malondialdehyde (MDA) and glutathione (GSH) levels, myeloperoxidase (MPO) activity, and collagen content. Our results showed that MTX administration increased the MDA and MPO activities and collagen content and decreased GSH levels in all tissues, while these alterations were reversed in L-Car-treated group. The elevated serum TNF-alpha level observed following MTX treatment was depressed with L-Car. The oxidative burst of neutrophils stimulated by Annexin V was reduced in the saline-treated MTX group, while L-Car abolished this inhibition. Similarly, flow cytometric measurements revealed that leukocyte apoptosis was increased in MTX-treated animals, while L-Car reversed these effects. Severe degeneration of the intestinal mucosa, liver parenchyma, and glomerular and tubular epithelium observed in the saline-treated MTX group was improved by L-Car treatment. These results suggest that L-Car, possibly via its free radical scavenging and antioxidant properties, ameliorates MTX-induced oxidative organ injury and inhibits leukocyte apoptosis. Thus, supplementation with L-Carnitine as an adjuvant therapy may be promising in alleviating the systemic side-effects of chemotherapeutics.

[ "L", "-", "Carnitine", "ameliorates", "methotrexate", "-", "induced", "oxidative", "organ", "injury", "and", "inhibits", "leukocyte", "death", ".", "\n", "Methotrexate", "(", "MTX", ")", ",", "a", "folic", "acid", "antagonist", "widely", "used", "for", "the", "treatment", "of", "a", "variety", "of", "tumors", "and", "inflammatory", "diseases", ",", "affects", "normal", "tissues", "that", "have", "a", "high", "rate", "of", "proliferation", ",", "including", "the", "hematopoietic", "cells", "of", "the", "bone", "marrow", "and", "the", "gastrointestinal", "mucosal", "cells", ".", "To", "elucidate", "the", "role", "of", "free", "radicals", "and", "leukocytes", "in", "MTX", "-", "induced", "oxidative", "organ", "damage", "and", "the", "putative", "protective", "effect", "of", "L", "-", "carnitine", "(", "L", "-", "Car", ")", ",", "Wistar", "albino", "rats", "were", "administered", "a", "single", "dose", "of", "MTX", "(", "20", "mg", "/", "kg", ")", "followed", "by", "either", "saline", "or", "L", "-", "Car", "(", "500", "mg", "/", "kg", ")", "for", "5", "days", ".", "After", "decapitation", "of", "the", "rats", ",", "trunk", "blood", "was", "obtained", ",", "and", "the", "ileum", ",", "liver", ",", "and", "kidney", "were", "removed", "for", "histological", "examination", "and", "for", "the", "measurement", "of", "malondialdehyde", "(", "MDA", ")", "and", "glutathione", "(", "GSH", ")", "levels", ",", "myeloperoxidase", "(", "MPO", ")", "activity", ",", "and", "collagen", "content", ".", "Our", "results", "showed", "that", "MTX", "administration", "increased", "the", "MDA", "and", "MPO", "activities", "and", "collagen", "content", "and", "decreased", "GSH", "levels", "in", "all", "tissues", ",", "while", "these", "alterations", "were", "reversed", "in", "L", "-", "Car", "-", "treated", "group", ".", "The", "elevated", "serum", "TNF", "-", "alpha", "level", "observed", "following", "MTX", "treatment", "was", "depressed", "with", "L", "-", "Car", ".", "The", "oxidative", "burst", "of", "neutrophils", "stimulated", "by", "Annexin", "V", "was", "reduced", "in", "the", "saline", "-", "treated", "MTX", "group", ",", "while", "L", "-", "Car", "abolished", "this", "inhibition", ".", "Similarly", ",", "flow", "cytometric", "measurements", "revealed", "that", "leukocyte", "apoptosis", "was", "increased", "in", "MTX", "-", "treated", "animals", ",", "while", "L", "-", "Car", "reversed", "these", "effects", ".", "Severe", "degeneration", "of", "the", "intestinal", "mucosa", ",", "liver", "parenchyma", ",", "and", "glomerular", "and", "tubular", "epithelium", "observed", "in", "the", "saline", "-", "treated", "MTX", "group", "was", "improved", "by", "L", "-", "Car", "treatment", ".", "These", "results", "suggest", "that", "L", "-", "Car", ",", "possibly", "via", "its", "free", "radical", "scavenging", "and", "antioxidant", "properties", ",", "ameliorates", "MTX", "-", "induced", "oxidative", "organ", "injury", "and", "inhibits", "leukocyte", "apoptosis", ".", "Thus", ",", "supplementation", "with", "L", "-", "Carnitine", "as", "an", "adjuvant", "therapy", "may", "be", "promising", "in", "alleviating", "the", "systemic", "side", "-", "effects", "of", "chemotherapeutics", ".", "\n" ]

[ "Cell", "Organism", "Tissue", "Multi-tissue_structure", "Simple_chemical", "Organism_substance", "Gene_or_gene_product", "Cancer", "Organ" ]

Clinically significant is a Qualifier, new is a Qualifier, illness is a Condition, within 1 month before randomization is a Temporal, may affect the participant 's ability to fulfill the study requirements or significantly confound the assessments is a Scope, cannot swallow is a Observation, investigational products is a Drug, T2DM is a Condition, hypoglycemia unawareness is a Condition, Aortic regurgitation is a Condition, mild or greater is a Qualifier, Mitral regurgitation is a Condition, moderate or greater is a Qualifier, Mitral or aortic valve stenosis greater than mild is a Scope, aortic stenosis : jet > 3.0 meters per second [ m / s ] , mean gradient > 25 millimeters of mercury [ mmHg ] , and aortic valve area < 1.5 centimeters squared [ cm^2 ] ; mitral stenosis : mean gradient > 5 mmHg and mitral valve area < 1.5 cm^2 is a Scope, Systolic pulmonary artery pressure ( SPAP ) is a Measurement, > 40 mmHg is a Value, tricuspid regurgitation [ TR ] jet velocity is a Measurement, > 2.9 m / s is a Value, RVOTAT is a Measurement, = 100 milliseconds ( msec ) is a Value, Left ventricular ejection fraction is a Measurement, < 45 % is a Value, Intracardiac mass is a Condition, tumor is a Condition, thrombus is a Condition, Evidence of is a Mood, congenital heart disease is a Condition, Clinically significant is a Qualifier, pericardial effusion is a Condition, moderate or larger or with hemodynamic compromise is a Scope, Significant is a Qualifier, renal or hepatic disease is a Scope, serum creatinine greater than 1.5× upper limit of normal ( ULN ) , serum transaminases greater than 3× ULN , or total bilirubin greater than 1.5× ULN in absence of Gilbert 's syndrome is a Scope, suicidal ideation is a Condition, with intent is a Qualifier, with or without a plan is a Scope, at the time of or within 6 months of Screening is a Scope, Yes is a Value, questions 4 or 5 is a Scope, Suicidal Ideation section of the Columbia - Suicide Severity Rating Scale ( C - SSRS ) is a Procedure, suicidal behavior is a Condition, in the past is a Temporal, C - SSRS is a Procedure, history is a Observation, anorexia or bulimia is a Scope, within 2 years before Screening is a Temporal, Attention Deficit Hyperactivity Disorder is a Condition, Diagnostic and Statistical Manual of Mental Disorders , 5th Edition is a Qualifier, depressive disorder , bipolar disorder , or schizophrenia is a Scope, secondary causes ( genetic , endocrine , or metabolic ) for obesity is a Scope, Prader - Willi syndrome , Bardet Biedl syndrome , Down 's Syndrome , untreated hypothyroidism , Cushing 's syndrome , daily systemic corticosteroid exposure for longer than 30 days , history of significant exposure to corticosteroids for chronic illness during the past year ; inhaled steroids will be allowed is a Scope, products intended for weight loss is a Drug, prescription drugs , over - the - counter ( OTC ) drugs , and herbal is a Scope, within 1 month before Screening is a Temporal, selective serotonin reuptake inhibitors is a Drug, serotonin norepinephrine reuptake inhibitors is a Drug, tricyclic antidepressants is a Drug, bupropion is a Drug, triptans is a Drug, St . John 's Wort is a Drug, tryptophan is a Drug, linezolid is a Drug, dextromethorphan is a Drug, any form is a Qualifier, lithium is a Drug, tramadol is a Drug, antipsychotics is a Drug, dopamine antagonists is a Drug, antiseizure medications is a Drug, valproic acid , zonisamide , topiramate , and lamotrigine is a Scope, oral steroids is a Drug, topical and inhaled steroids is a Scope, acceptable is a Negation, stimulant medications is a Drug, Ritalin , Concerta , Biphetamine , and Dexedrine is a Scope, benzodiazepines is a Drug, drugs known to increase the risk for cardiac valvulopathy is a Scope, within 6 months before Screening is a Temporal, pergolide , ergotamine , methysergide , and cabergoline is a Scope, History or evidence of clinically significant disease is a Scope, malignancy ; cardiac , respiratory , gastrointestinal , renal , or psychiatric disease is a Scope, other than is a Negation, prediabetes is a Condition, impaired fasting glucose or impaired glucose tolerance ) is a Scope, type 2 diabetes is a Condition, oral anti - diabetic agents ( excluding sulfonylurea ) or non - insulin injectable antidiabetic agents is a Scope, obstructive sleep apnea is a Condition, dyslipidemia is a Condition, nonalcoholic fatty liver disease is a Condition, within 6 months before Screening is a Temporal, hypersensitivity is a Condition, Belviq XR is a Drug, or any of the excipients is a Qualifier, Significant is a Qualifier, change in diet or level of physical activity is a Scope, within 1 month before dosing is a Temporal, change in weight is a Observation, more than 5 kg is a Value, within 3 months before Screening is a Temporal, < 1000 calories / day is a Value, within 6 months before Screening is a Temporal, History is a Observation, alcohol or drug dependence or abuse is a Scope, Recreational drug use is a Observation, within 2 years before Screening is a Temporal, human immunodeficiency virus positive is a Condition, active is a Qualifier, viral hepatitis is a Condition, B or C is a Scope, Malignancy is a Condition, within 5 years before Screening is a Temporal, Unable to attend scheduled visits is a Observation, lack of transportation is a Observation, lack of a caregiver is a Observation, Special needs is a Observation, unable to comprehend study - related instructions is a Scope, mild to profound mental retardation [ intelligence quotient < 70 ] , moderate to severe cognitive developmental delay , pervasive development disorders , autism is a Scope, Ongoing is a Temporal, epilepsy is a Condition, other is a Qualifier, medications is a Drug, seizure disorder is a Condition, within 6 months of screening or any time between screening and randomization is a Scope, blood pressure is a Measurement, 95th percentile or greater is a Value, for age is a Qualifier, 2 separate readings is a Multiplier, 2 separate days is a Qualifier, Currently is a Temporal, another is a Qualifier, investigational drug or device is a Scope, within 30 days before providing informed consent is a Temporal, Planned is a Mood, bariatric surgery is a Procedure, during the study is a Temporal, prior is a Temporal, bariatric surgical procedures is a Procedure, the study is a Reference_point, Female is a Person, breastfeeding or pregnant is a Scope, at Screening or Baseline is a Scope, positive beta - human chorionic gonadotropin test is a Scope, separate Baseline assessment is required if a negative screening pregnancy test was obtained more than 72 hours before the first dose of study drug is a Scope, unprotected sexual intercourse is a Condition, within 30 days before study entry is a Temporal, do not agree is a Observation, highly effective method of contraception is a Scope, total abstinence , an intrauterine device , a double - barrier method [ such as condom plus diaphragm with spermicide ] , a contraceptive implant , an oral contraceptive , or have a vasectomized partner with confirmed azoospermia is a Scope, throughout the entire study period is a Temporal, for 28 days after study drug discontinuation is a Temporal, currently is a Temporal, abstinent is a Condition, do not agree is a Observation, double - barrier method ( as described above ) or refrain from sexual activity is a Scope, during the study period and for 28 days after study drug discontinuation is a Scope, hormonal contraceptives is a Drug, not is a Negation, stable dose is a Qualifier, hormonal contraceptive is a Drug, for at least 4 weeks before dosing is a Temporal, do not agree is a Observation, the same is a Qualifier, contraceptive is a Drug, during the study is a Temporal, for 28 days after study drug discontinuation is a Temporal

NCT03338296_exc_task0

Sentence: Clinically significant new illness within 1 month before randomization that may affect the participant's ability to fulfill the study requirements or significantly confound the assessments Participants who cannot swallow investigational products Participants with T2DM who have hypoglycemia unawareness Aortic regurgitation mild or greater Mitral regurgitation moderate or greater Mitral or aortic valve stenosis greater than mild (ie, aortic stenosis: jet >3.0 meters per second [m/s], mean gradient >25 millimeters of mercury [mmHg], and aortic valve area <1.5 centimeters squared [cm^2]; mitral stenosis: mean gradient >5 mmHg and mitral valve area <1.5 cm^2) Systolic pulmonary artery pressure (SPAP) >40 mmHg (and/or tricuspid regurgitation [TR] jet velocity >2.9 m/s) In cases where an actual SPAP value is not measurable due to lack of adequate TR jet, the pulmonary flow acceleration time measured at the right ventricular outflow tract (RVOTAT) will be used to assess eligibility. Participants with a RVOTAT =100 milliseconds (msec) will be excluded, suggesting an elevated mean SPAP; eligibility for the those participants with RVOTAT between 100 and 120 msec will be determined based on combined assessment of the TR jet, septal motion, and right ventricular size. Left ventricular ejection fraction <45% Intracardiac mass, tumor, or thrombus Evidence of congenital heart disease Clinically significant pericardial effusion (eg, moderate or larger or with hemodynamic compromise) Significant renal or hepatic disease as evidenced by a serum creatinine greater than 1.5× upper limit of normal (ULN), serum transaminases greater than 3× ULN, or total bilirubin greater than 1.5× ULN in absence of Gilbert's syndrome Any suicidal ideation with intent with or without a plan, at the time of or within 6 months of Screening, as indicated by answering "Yes" to questions 4 or 5 on the Suicidal Ideation section of the Columbia-Suicide Severity Rating Scale (C-SSRS) Any suicidal behavior in the past based on the C-SSRS Any history of anorexia or bulimia within 2 years before Screening, Attention Deficit Hyperactivity Disorder, any Diagnostic and Statistical Manual of Mental Disorders, 5th Edition depressive disorder, bipolar disorder, or schizophrenia Known secondary causes (genetic, endocrine, or metabolic) for obesity (eg, Prader-Willi syndrome, Bardet Biedl syndrome, Down's Syndrome, untreated hypothyroidism, Cushing's syndrome, daily systemic corticosteroid exposure for longer than 30 days, history of significant exposure to corticosteroids for chronic illness during the past year; inhaled steroids will be allowed) Use of other products intended for weight loss including prescription drugs, over-the-counter (OTC) drugs, and herbal preparations within 1 month before Screening selective serotonin reuptake inhibitors serotonin norepinephrine reuptake inhibitors tricyclic antidepressants bupropion triptans St. John's Wort tryptophan linezolid dextromethorphan in any form (eg, OTC cold medicines) lithium tramadol antipsychotics or other dopamine antagonists antiseizure medications including valproic acid, zonisamide, topiramate, and lamotrigine oral steroids (topical and inhaled steroids are acceptable) stimulant medications (eg, Ritalin, Concerta, Biphetamine, and Dexedrine) benzodiazepines Use of drugs known to increase the risk for cardiac valvulopathy within 6 months before Screening, including but not limited to pergolide, ergotamine, methysergide, and cabergoline History or evidence of clinically significant disease (eg, malignancy; cardiac, respiratory, gastrointestinal, renal, or psychiatric disease) other than prediabetes (impaired fasting glucose or impaired glucose tolerance), type 2 diabetes treated with oral anti-diabetic agents (excluding sulfonylurea) or non-insulin injectable antidiabetic agents, obstructive sleep apnea, dyslipidemia, and nonalcoholic fatty liver disease Use of Belviq XR within 6 months before Screening or hypersensitivity to Belviq XR or any of the excipients Significant change in diet or level of physical activity within 1 month before dosing or change in weight of more than 5 kg within 3 months before Screening Any use of a very-low-calorie (<1000 calories/day) weight loss diet within 6 months before Screening History of alcohol or drug dependence or abuse Recreational drug use within 2 years before Screening Known to be human immunodeficiency virus positive Known to have active viral hepatitis (B or C) Malignancy within 5 years before Screening Unable to attend scheduled visits (eg, lack of transportation) or lack of a caregiver or guardian to supervise study participation Special needs participants who are unable to comprehend study-related instructions (eg, mild to profound mental retardation [intelligence quotient <70], moderate to severe cognitive developmental delay, pervasive development disorders, autism) Ongoing epilepsy or other seizure disorder, or use of medications for a seizure disorder within 6 months of screening or any time between screening and randomization Participants with a blood pressure in the 95th percentile or greater for age, sex, and height on 2 separate readings recorded on 2 separate days. Those participants who had uncontrolled hypertension at Screening can be rescreened more than 1 month after initiation or adjustment of antihypertensive therapy 1 time. Currently enrolled in another clinical study or has used any investigational drug or device within 30 days before providing informed consent Planned bariatric surgery during the study or prior bariatric surgical procedures Not suitable to participate in the study in the opinion of the investigator, including consideration of any existing physical, medical, or mental condition that prevents compliance with the protocol Female participants who are breastfeeding or pregnant at Screening or Baseline (as documented by a positive beta-human chorionic gonadotropin test). A separate Baseline assessment is required if a negative screening pregnancy test was obtained more than 72 hours before the first dose of study drug. Had unprotected sexual intercourse within 30 days before study entry and who do not agree to use a highly effective method of contraception (eg, total abstinence, an intrauterine device, a double-barrier method [such as condom plus diaphragm with spermicide], a contraceptive implant, an oral contraceptive, or have a vasectomized partner with confirmed azoospermia) throughout the entire study period and for 28 days after study drug discontinuation Are currently abstinent and do not agree to use a double-barrier method (as described above) or refrain from sexual activity during the study period and for 28 days after study drug discontinuation Are using hormonal contraceptives, but are not on a stable dose of the same hormonal contraceptive product for at least 4 weeks before dosing and who do not agree to use the same contraceptive during the study and for 28 days after study drug discontinuation (Note: All female participants will be considered to be of childbearing potential unless they have been sterilized surgically [ie, bilateral tubal ligation, total hysterectomy, or bilateral oophorectomy, all with surgery at least 1 month before dosing]). Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Temporal, Condition, Qualifier, Value, Person, Observation, Multiplier, Procedure, Negation, Reference_point, Scope, Measurement, Mood, Drug

[ "B-Qualifier", "I-Qualifier", "B-Qualifier", "B-Condition", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Observation", "I-Observation", "B-Drug", "I-Drug", "O", "O", "O", "B-Condition", "O", "O", "B-Condition", "I-Condition", "O", "B-Condition", "I-Condition", "B-Qualifier", "I-Qualifier", "I-Qualifier", "O", "B-Condition", "I-Condition", "B-Qualifier", "I-Qualifier", "I-Qualifier", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "O", "O", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "O", "B-Condition", "I-Condition", "O", "B-Condition", "O", "O", "B-Condition", "O", "B-Mood", "I-Mood", "B-Condition", "I-Condition", "I-Condition", "O", "B-Qualifier", "I-Qualifier", "B-Condition", "I-Condition", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Qualifier", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Condition", "I-Condition", "B-Qualifier", "I-Qualifier", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "B-Value", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "O", "O", "B-Condition", "I-Condition", "B-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "B-Procedure", "I-Procedure", "I-Procedure", "O", "O", "B-Observation", "O", "B-Scope", "I-Scope", "I-Scope", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "O", "O", "B-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "B-Drug", "I-Drug", "I-Drug", "I-Drug", "I-Drug", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Drug", "I-Drug", "I-Drug", "I-Drug", "O", "B-Drug", "I-Drug", "I-Drug", "I-Drug", "O", "B-Drug", "I-Drug", "O", "B-Drug", "O", "B-Drug", "O", "B-Drug", "I-Drug", "I-Drug", "I-Drug", "I-Drug", "O", "B-Drug", "O", "B-Drug", "O", "B-Drug", "O", "B-Qualifier", "I-Qualifier", "O", "O", "O", "O", "O", "O", "O", "O", "B-Drug", "O", "B-Drug", "O", "B-Drug", "O", "O", "B-Drug", "I-Drug", "O", "B-Drug", "I-Drug", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Drug", "I-Drug", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Negation", "O", "O", "B-Drug", "I-Drug", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Drug", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Negation", "I-Negation", "B-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Condition", "I-Condition", "I-Condition", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Condition", "I-Condition", "I-Condition", "O", "B-Condition", "O", "O", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "O", "O", "O", "O", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Condition", "O", "B-Drug", "I-Drug", "B-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "O", "B-Qualifier", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Observation", "I-Observation", "I-Observation", "O", "B-Value", "I-Value", "I-Value", "I-Value", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "O", "O", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Observation", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Observation", "I-Observation", "I-Observation", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "O", "O", "O", "O", "B-Qualifier", "B-Condition", "I-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "O", "O", "B-Condition", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Observation", "I-Observation", "I-Observation", "I-Observation", "I-Observation", "O", "O", "O", "B-Observation", "I-Observation", "I-Observation", "O", "O", "B-Observation", "I-Observation", "I-Observation", "I-Observation", "O", "O", "O", "O", "O", "O", "O", "B-Observation", "I-Observation", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Temporal", "B-Condition", "O", "B-Qualifier", "O", "O", "O", "O", "O", "O", "B-Drug", "O", "O", "B-Condition", "I-Condition", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "B-Measurement", "I-Measurement", "O", "O", "B-Value", "I-Value", "I-Value", "I-Value", "B-Qualifier", "I-Qualifier", "O", "O", "O", "O", "O", "O", "B-Multiplier", "I-Multiplier", "I-Multiplier", "O", "O", "B-Qualifier", "I-Qualifier", "I-Qualifier", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Temporal", "O", "O", "B-Qualifier", "O", "O", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Mood", "B-Procedure", "I-Procedure", "B-Temporal", "I-Temporal", "I-Temporal", "O", "B-Temporal", "B-Procedure", "I-Procedure", "I-Procedure", "O", "O", "O", "O", "O", "O", "B-Reference_point", "I-Reference_point", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Person", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Condition", "I-Condition", "I-Condition", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "B-Observation", "I-Observation", "I-Observation", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "B-Temporal", "B-Condition", "O", "B-Observation", "I-Observation", "I-Observation", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Drug", "I-Drug", "O", "O", "O", "B-Negation", "O", "O", "B-Qualifier", "I-Qualifier", "O", "O", "O", "B-Drug", "I-Drug", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "B-Observation", "I-Observation", "I-Observation", "O", "O", "B-Qualifier", "I-Qualifier", "B-Drug", "B-Temporal", "I-Temporal", "I-Temporal", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Clinically significant new illness within 1 month before randomization that may affect the participant's ability to fulfill the study requirements or significantly confound the assessments Participants who cannot swallow investigational products Participants with T2DM who have hypoglycemia unawareness Aortic regurgitation mild or greater Mitral regurgitation moderate or greater Mitral or aortic valve stenosis greater than mild (ie, aortic stenosis: jet >3.0 meters per second [m/s], mean gradient >25 millimeters of mercury [mmHg], and aortic valve area <1.5 centimeters squared [cm^2]; mitral stenosis: mean gradient >5 mmHg and mitral valve area <1.5 cm^2) Systolic pulmonary artery pressure (SPAP) >40 mmHg (and/or tricuspid regurgitation [TR] jet velocity >2.9 m/s) In cases where an actual SPAP value is not measurable due to lack of adequate TR jet, the pulmonary flow acceleration time measured at the right ventricular outflow tract (RVOTAT) will be used to assess eligibility. Participants with a RVOTAT =100 milliseconds (msec) will be excluded, suggesting an elevated mean SPAP; eligibility for the those participants with RVOTAT between 100 and 120 msec will be determined based on combined assessment of the TR jet, septal motion, and right ventricular size. Left ventricular ejection fraction <45% Intracardiac mass, tumor, or thrombus Evidence of congenital heart disease Clinically significant pericardial effusion (eg, moderate or larger or with hemodynamic compromise) Significant renal or hepatic disease as evidenced by a serum creatinine greater than 1.5× upper limit of normal (ULN), serum transaminases greater than 3× ULN, or total bilirubin greater than 1.5× ULN in absence of Gilbert's syndrome Any suicidal ideation with intent with or without a plan, at the time of or within 6 months of Screening, as indicated by answering "Yes" to questions 4 or 5 on the Suicidal Ideation section of the Columbia-Suicide Severity Rating Scale (C-SSRS) Any suicidal behavior in the past based on the C-SSRS Any history of anorexia or bulimia within 2 years before Screening, Attention Deficit Hyperactivity Disorder, any Diagnostic and Statistical Manual of Mental Disorders, 5th Edition depressive disorder, bipolar disorder, or schizophrenia Known secondary causes (genetic, endocrine, or metabolic) for obesity (eg, Prader-Willi syndrome, Bardet Biedl syndrome, Down's Syndrome, untreated hypothyroidism, Cushing's syndrome, daily systemic corticosteroid exposure for longer than 30 days, history of significant exposure to corticosteroids for chronic illness during the past year; inhaled steroids will be allowed) Use of other products intended for weight loss including prescription drugs, over-the-counter (OTC) drugs, and herbal preparations within 1 month before Screening selective serotonin reuptake inhibitors serotonin norepinephrine reuptake inhibitors tricyclic antidepressants bupropion triptans St. John's Wort tryptophan linezolid dextromethorphan in any form (eg, OTC cold medicines) lithium tramadol antipsychotics or other dopamine antagonists antiseizure medications including valproic acid, zonisamide, topiramate, and lamotrigine oral steroids (topical and inhaled steroids are acceptable) stimulant medications (eg, Ritalin, Concerta, Biphetamine, and Dexedrine) benzodiazepines Use of drugs known to increase the risk for cardiac valvulopathy within 6 months before Screening, including but not limited to pergolide, ergotamine, methysergide, and cabergoline History or evidence of clinically significant disease (eg, malignancy; cardiac, respiratory, gastrointestinal, renal, or psychiatric disease) other than prediabetes (impaired fasting glucose or impaired glucose tolerance), type 2 diabetes treated with oral anti-diabetic agents (excluding sulfonylurea) or non-insulin injectable antidiabetic agents, obstructive sleep apnea, dyslipidemia, and nonalcoholic fatty liver disease Use of Belviq XR within 6 months before Screening or hypersensitivity to Belviq XR or any of the excipients Significant change in diet or level of physical activity within 1 month before dosing or change in weight of more than 5 kg within 3 months before Screening Any use of a very-low-calorie (<1000 calories/day) weight loss diet within 6 months before Screening History of alcohol or drug dependence or abuse Recreational drug use within 2 years before Screening Known to be human immunodeficiency virus positive Known to have active viral hepatitis (B or C) Malignancy within 5 years before Screening Unable to attend scheduled visits (eg, lack of transportation) or lack of a caregiver or guardian to supervise study participation Special needs participants who are unable to comprehend study-related instructions (eg, mild to profound mental retardation [intelligence quotient <70], moderate to severe cognitive developmental delay, pervasive development disorders, autism) Ongoing epilepsy or other seizure disorder, or use of medications for a seizure disorder within 6 months of screening or any time between screening and randomization Participants with a blood pressure in the 95th percentile or greater for age, sex, and height on 2 separate readings recorded on 2 separate days. Those participants who had uncontrolled hypertension at Screening can be rescreened more than 1 month after initiation or adjustment of antihypertensive therapy 1 time. Currently enrolled in another clinical study or has used any investigational drug or device within 30 days before providing informed consent Planned bariatric surgery during the study or prior bariatric surgical procedures Not suitable to participate in the study in the opinion of the investigator, including consideration of any existing physical, medical, or mental condition that prevents compliance with the protocol Female participants who are breastfeeding or pregnant at Screening or Baseline (as documented by a positive beta-human chorionic gonadotropin test). A separate Baseline assessment is required if a negative screening pregnancy test was obtained more than 72 hours before the first dose of study drug. Had unprotected sexual intercourse within 30 days before study entry and who do not agree to use a highly effective method of contraception (eg, total abstinence, an intrauterine device, a double-barrier method [such as condom plus diaphragm with spermicide], a contraceptive implant, an oral contraceptive, or have a vasectomized partner with confirmed azoospermia) throughout the entire study period and for 28 days after study drug discontinuation Are currently abstinent and do not agree to use a double-barrier method (as described above) or refrain from sexual activity during the study period and for 28 days after study drug discontinuation Are using hormonal contraceptives, but are not on a stable dose of the same hormonal contraceptive product for at least 4 weeks before dosing and who do not agree to use the same contraceptive during the study and for 28 days after study drug discontinuation (Note: All female participants will be considered to be of childbearing potential unless they have been sterilized surgically [ie, bilateral tubal ligation, total hysterectomy, or bilateral oophorectomy, all with surgery at least 1 month before dosing]).

[ "Clinically", "significant", "new", "illness", "within", "1", "month", "before", "randomization", "that", "may", "affect", "the", "participant", "'s", "ability", "to", "fulfill", "the", "study", "requirements", "or", "significantly", "confound", "the", "assessments", "\n", "Participants", "who", "cannot", "swallow", "investigational", "products", "\n", "Participants", "with", "T2DM", "who", "have", "hypoglycemia", "unawareness", "\n", "Aortic", "regurgitation", "mild", "or", "greater", "\n", "Mitral", "regurgitation", "moderate", "or", "greater", "\n", "Mitral", "or", "aortic", "valve", "stenosis", "greater", "than", "mild", "(", "ie", ",", "aortic", "stenosis", ":", "jet", ">", "3.0", "meters", "per", "second", "[", "m", "/", "s", "]", ",", "mean", "gradient", ">", "25", "millimeters", "of", "mercury", "[", "mmHg", "]", ",", "and", "aortic", "valve", "area", "<", "1.5", "centimeters", "squared", "[", "cm^2", "]", ";", "mitral", "stenosis", ":", "mean", "gradient", ">", "5", "mmHg", "and", "mitral", "valve", "area", "<", "1.5", "cm^2", ")", "\n", "Systolic", "pulmonary", "artery", "pressure", "(", "SPAP", ")", ">", "40", "mmHg", "(", "and", "/", "or", "tricuspid", "regurgitation", "[", "TR", "]", "jet", "velocity", ">", "2.9", "m", "/", "s", ")", "In", "cases", "where", "an", "actual", "SPAP", "value", "is", "not", "measurable", "due", "to", "lack", "of", "adequate", "TR", "jet", ",", "the", "pulmonary", "flow", "acceleration", "time", "measured", "at", "the", "right", "ventricular", "outflow", "tract", "(", "RVOTAT", ")", "will", "be", "used", "to", "assess", "eligibility", ".", "Participants", "with", "a", "RVOTAT", "=", "100", "milliseconds", "(", "msec", ")", "will", "be", "excluded", ",", "suggesting", "an", "elevated", "mean", "SPAP", ";", "eligibility", "for", "the", "those", "participants", "with", "RVOTAT", "between", "100", "and", "120", "msec", "will", "be", "determined", "based", "on", "combined", "assessment", "of", "the", "TR", "jet", ",", "septal", "motion", ",", "and", "right", "ventricular", "size", ".", "\n", "Left", "ventricular", "ejection", "fraction", "<", "45", "%", "\n", "Intracardiac", "mass", ",", "tumor", ",", "or", "thrombus", "\n", "Evidence", "of", "congenital", "heart", "disease", "\n", "Clinically", "significant", "pericardial", "effusion", "(", "eg", ",", "moderate", "or", "larger", "or", "with", "hemodynamic", "compromise", ")", "\n", "Significant", "renal", "or", "hepatic", "disease", "as", "evidenced", "by", "a", "serum", "creatinine", "greater", "than", "1.5×", "upper", "limit", "of", "normal", "(", "ULN", ")", ",", "serum", "transaminases", "greater", "than", "3×", "ULN", ",", "or", "total", "bilirubin", "greater", "than", "1.5×", "ULN", "in", "absence", "of", "Gilbert", "'s", "syndrome", "\n", "Any", "suicidal", "ideation", "with", "intent", "with", "or", "without", "a", "plan", ",", "at", "the", "time", "of", "or", "within", "6", "months", "of", "Screening", ",", "as", "indicated", "by", "answering", "\"", "Yes", "\"", "to", "questions", "4", "or", "5", "on", "the", "Suicidal", "Ideation", "section", "of", "the", "Columbia", "-", "Suicide", "Severity", "Rating", "Scale", "(", "C", "-", "SSRS", ")", "\n", "Any", "suicidal", "behavior", "in", "the", "past", "based", "on", "the", "C", "-", "SSRS", "\n", "Any", "history", "of", "anorexia", "or", "bulimia", "within", "2", "years", "before", "Screening", ",", "Attention", "Deficit", "Hyperactivity", "Disorder", ",", "any", "Diagnostic", "and", "Statistical", "Manual", "of", "Mental", "Disorders", ",", "5th", "Edition", "depressive", "disorder", ",", "bipolar", "disorder", ",", "or", "schizophrenia", "\n", "Known", "secondary", "causes", "(", "genetic", ",", "endocrine", ",", "or", "metabolic", ")", "for", "obesity", "(", "eg", ",", "Prader", "-", "Willi", "syndrome", ",", "Bardet", "Biedl", "syndrome", ",", "Down", "'s", "Syndrome", ",", "untreated", "hypothyroidism", ",", "Cushing", "'s", "syndrome", ",", "daily", "systemic", "corticosteroid", "exposure", "for", "longer", "than", "30", "days", ",", "history", "of", "significant", "exposure", "to", "corticosteroids", "for", "chronic", "illness", "during", "the", "past", "year", ";", "inhaled", "steroids", "will", "be", "allowed", ")", "\n", "Use", "of", "other", "products", "intended", "for", "weight", "loss", "including", "prescription", "drugs", ",", "over", "-", "the", "-", "counter", "(", "OTC", ")", "drugs", ",", "and", "herbal", "preparations", "within", "1", "month", "before", "Screening", "\n", "selective", "serotonin", "reuptake", "inhibitors", "\n", "serotonin", "norepinephrine", "reuptake", "inhibitors", "\n", "tricyclic", "antidepressants", "\n", "bupropion", "\n", "triptans", "\n", "St", ".", "John", "'s", "Wort", "\n", "tryptophan", "\n", "linezolid", "\n", "dextromethorphan", "in", "any", "form", "(", "eg", ",", "OTC", "cold", "medicines", ")", "\n", "lithium", "\n", "tramadol", "\n", "antipsychotics", "or", "other", "dopamine", "antagonists", "\t\n", "antiseizure", "medications", "including", "valproic", "acid", ",", "zonisamide", ",", "topiramate", ",", "and", "lamotrigine", "\n", "oral", "steroids", "(", "topical", "and", "inhaled", "steroids", "are", "acceptable", ")", "\n", "stimulant", "medications", "(", "eg", ",", "Ritalin", ",", "Concerta", ",", "Biphetamine", ",", "and", "Dexedrine", ")", "\n", "benzodiazepines", "\n", "Use", "of", "drugs", "known", "to", "increase", "the", "risk", "for", "cardiac", "valvulopathy", "within", "6", "months", "before", "Screening", ",", "including", "but", "not", "limited", "to", "pergolide", ",", "ergotamine", ",", "methysergide", ",", "and", "cabergoline", "\n", "History", "or", "evidence", "of", "clinically", "significant", "disease", "(", "eg", ",", "malignancy", ";", "cardiac", ",", "respiratory", ",", "gastrointestinal", ",", "renal", ",", "or", "psychiatric", "disease", ")", "other", "than", "prediabetes", "(", "impaired", "fasting", "glucose", "or", "impaired", "glucose", "tolerance", ")", ",", "type", "2", "diabetes", "treated", "with", "oral", "anti", "-", "diabetic", "agents", "(", "excluding", "sulfonylurea", ")", "or", "non", "-", "insulin", "injectable", "antidiabetic", "agents", ",", "obstructive", "sleep", "apnea", ",", "dyslipidemia", ",", "and", "nonalcoholic", "fatty", "liver", "disease", "\n", "Use", "of", "Belviq", "XR", "within", "6", "months", "before", "Screening", "or", "hypersensitivity", "to", "Belviq", "XR", "or", "any", "of", "the", "excipients", "\n", "Significant", "change", "in", "diet", "or", "level", "of", "physical", "activity", "within", "1", "month", "before", "dosing", "or", "change", "in", "weight", "of", "more", "than", "5", "kg", "within", "3", "months", "before", "Screening", "\n", "Any", "use", "of", "a", "very", "-", "low", "-", "calorie", "(", "<", "1000", "calories", "/", "day", ")", "weight", "loss", "diet", "within", "6", "months", "before", "Screening", "\n", "History", "of", "alcohol", "or", "drug", "dependence", "or", "abuse", "\n", "Recreational", "drug", "use", "within", "2", "years", "before", "Screening", "\n", "Known", "to", "be", "human", "immunodeficiency", "virus", "positive", "\n", "Known", "to", "have", "active", "viral", "hepatitis", "(", "B", "or", "C", ")", "\n", "Malignancy", "within", "5", "years", "before", "Screening", "\n", "Unable", "to", "attend", "scheduled", "visits", "(", "eg", ",", "lack", "of", "transportation", ")", "or", "lack", "of", "a", "caregiver", "or", "guardian", "to", "supervise", "study", "participation", "\n", "Special", "needs", "participants", "who", "are", "unable", "to", "comprehend", "study", "-", "related", "instructions", "(", "eg", ",", "mild", "to", "profound", "mental", "retardation", "[", "intelligence", "quotient", "<", "70", "]", ",", "moderate", "to", "severe", "cognitive", "developmental", "delay", ",", "pervasive", "development", "disorders", ",", "autism", ")", "\n", "Ongoing", "epilepsy", "or", "other", "seizure", "disorder", ",", "or", "use", "of", "medications", "for", "a", "seizure", "disorder", "within", "6", "months", "of", "screening", "or", "any", "time", "between", "screening", "and", "randomization", "\n", "Participants", "with", "a", "blood", "pressure", "in", "the", "95th", "percentile", "or", "greater", "for", "age", ",", "sex", ",", "and", "height", "on", "2", "separate", "readings", "recorded", "on", "2", "separate", "days", ".", "Those", "participants", "who", "had", "uncontrolled", "hypertension", "at", "Screening", "can", "be", "rescreened", "more", "than", "1", "month", "after", "initiation", "or", "adjustment", "of", "antihypertensive", "therapy", "1", "time", ".", "\n", "Currently", "enrolled", "in", "another", "clinical", "study", "or", "has", "used", "any", "investigational", "drug", "or", "device", "within", "30", "days", "before", "providing", "informed", "consent", "\n", "Planned", "bariatric", "surgery", "during", "the", "study", "or", "prior", "bariatric", "surgical", "procedures", "\n", "Not", "suitable", "to", "participate", "in", "the", "study", "in", "the", "opinion", "of", "the", "investigator", ",", "including", "consideration", "of", "any", "existing", "physical", ",", "medical", ",", "or", "mental", "condition", "that", "prevents", "compliance", "with", "the", "protocol", "\n", "Female", "participants", "who", "are", "breastfeeding", "or", "pregnant", "at", "Screening", "or", "Baseline", "(", "as", "documented", "by", "a", "positive", "beta", "-", "human", "chorionic", "gonadotropin", "test", ")", ".", "A", "separate", "Baseline", "assessment", "is", "required", "if", "a", "negative", "screening", "pregnancy", "test", "was", "obtained", "more", "than", "72", "hours", "before", "the", "first", "dose", "of", "study", "drug", ".", "\n", "Had", "unprotected", "sexual", "intercourse", "within", "30", "days", "before", "study", "entry", "and", "who", "do", "not", "agree", "to", "use", "a", "highly", "effective", "method", "of", "contraception", "(", "eg", ",", "total", "abstinence", ",", "an", "intrauterine", "device", ",", "a", "double", "-", "barrier", "method", "[", "such", "as", "condom", "plus", "diaphragm", "with", "spermicide", "]", ",", "a", "contraceptive", "implant", ",", "an", "oral", "contraceptive", ",", "or", "have", "a", "vasectomized", "partner", "with", "confirmed", "azoospermia", ")", "throughout", "the", "entire", "study", "period", "and", "for", "28", "days", "after", "study", "drug", "discontinuation", "\n", "Are", "currently", "abstinent", "and", "do", "not", "agree", "to", "use", "a", "double", "-", "barrier", "method", "(", "as", "described", "above", ")", "or", "refrain", "from", "sexual", "activity", "during", "the", "study", "period", "and", "for", "28", "days", "after", "study", "drug", "discontinuation", "\n", "Are", "using", "hormonal", "contraceptives", ",", "but", "are", "not", "on", "a", "stable", "dose", "of", "the", "same", "hormonal", "contraceptive", "product", "for", "at", "least", "4", "weeks", "before", "dosing", "and", "who", "do", "not", "agree", "to", "use", "the", "same", "contraceptive", "during", "the", "study", "and", "for", "28", "days", "after", "study", "drug", "discontinuation", "(", "Note", ":", "All", "female", "participants", "will", "be", "considered", "to", "be", "of", "childbearing", "potential", "unless", "they", "have", "been", "sterilized", "surgically", "[", "ie", ",", "bilateral", "tubal", "ligation", ",", "total", "hysterectomy", ",", "or", "bilateral", "oophorectomy", ",", "all", "with", "surgery", "at", "least", "1", "month", "before", "dosing", "]", ")", ".", "\n" ]

[ "Scope", "Procedure", "Observation", "Qualifier", "Temporal", "Value", "Drug", "Measurement", "Condition", "Reference_point", "Device", "Multiplier", "Mood", "Negation", "Person" ]

Clinically significant is a Qualifier, new is a Qualifier, illness is a Condition, within 1 month before randomization is a Temporal, may affect the participant 's ability to fulfill the study requirements or significantly confound the assessments is a Scope, cannot swallow is a Observation, investigational products is a Drug, T2DM is a Condition, hypoglycemia unawareness is a Condition, Aortic regurgitation is a Condition, mild or greater is a Qualifier, Mitral regurgitation is a Condition, moderate or greater is a Qualifier, Mitral or aortic valve stenosis greater than mild is a Scope, aortic stenosis : jet > 3.0 meters per second [ m / s ] , mean gradient > 25 millimeters of mercury [ mmHg ] , and aortic valve area < 1.5 centimeters squared [ cm^2 ] ; mitral stenosis : mean gradient > 5 mmHg and mitral valve area < 1.5 cm^2 is a Scope, Systolic pulmonary artery pressure ( SPAP ) is a Measurement, > 40 mmHg is a Value, tricuspid regurgitation [ TR ] jet velocity is a Measurement, > 2.9 m / s is a Value, RVOTAT is a Measurement, = 100 milliseconds ( msec ) is a Value, Left ventricular ejection fraction is a Measurement, < 45 % is a Value, Intracardiac mass is a Condition, tumor is a Condition, thrombus is a Condition, Evidence of is a Mood, congenital heart disease is a Condition, Clinically significant is a Qualifier, pericardial effusion is a Condition, moderate or larger or with hemodynamic compromise is a Scope, Significant is a Qualifier, renal or hepatic disease is a Scope, serum creatinine greater than 1.5× upper limit of normal ( ULN ) , serum transaminases greater than 3× ULN , or total bilirubin greater than 1.5× ULN in absence of Gilbert 's syndrome is a Scope, suicidal ideation is a Condition, with intent is a Qualifier, with or without a plan is a Scope, at the time of or within 6 months of Screening is a Scope, Yes is a Value, questions 4 or 5 is a Scope, Suicidal Ideation section of the Columbia - Suicide Severity Rating Scale ( C - SSRS ) is a Procedure, suicidal behavior is a Condition, in the past is a Temporal, C - SSRS is a Procedure, history is a Observation, anorexia or bulimia is a Scope, within 2 years before Screening is a Temporal, Attention Deficit Hyperactivity Disorder is a Condition, Diagnostic and Statistical Manual of Mental Disorders , 5th Edition is a Qualifier, depressive disorder , bipolar disorder , or schizophrenia is a Scope, secondary causes ( genetic , endocrine , or metabolic ) for obesity is a Scope, Prader - Willi syndrome , Bardet Biedl syndrome , Down 's Syndrome , untreated hypothyroidism , Cushing 's syndrome , daily systemic corticosteroid exposure for longer than 30 days , history of significant exposure to corticosteroids for chronic illness during the past year ; inhaled steroids will be allowed is a Scope, products intended for weight loss is a Drug, prescription drugs , over - the - counter ( OTC ) drugs , and herbal is a Scope, within 1 month before Screening is a Temporal, selective serotonin reuptake inhibitors is a Drug, serotonin norepinephrine reuptake inhibitors is a Drug, tricyclic antidepressants is a Drug, bupropion is a Drug, triptans is a Drug, St . John 's Wort is a Drug, tryptophan is a Drug, linezolid is a Drug, dextromethorphan is a Drug, any form is a Qualifier, lithium is a Drug, tramadol is a Drug, antipsychotics is a Drug, dopamine antagonists is a Drug, antiseizure medications is a Drug, valproic acid , zonisamide , topiramate , and lamotrigine is a Scope, oral steroids is a Drug, topical and inhaled steroids is a Scope, acceptable is a Negation, stimulant medications is a Drug, Ritalin , Concerta , Biphetamine , and Dexedrine is a Scope, benzodiazepines is a Drug, drugs known to increase the risk for cardiac valvulopathy is a Scope, within 6 months before Screening is a Temporal, pergolide , ergotamine , methysergide , and cabergoline is a Scope, History or evidence of clinically significant disease is a Scope, malignancy ; cardiac , respiratory , gastrointestinal , renal , or psychiatric disease is a Scope, other than is a Negation, prediabetes is a Condition, impaired fasting glucose or impaired glucose tolerance ) is a Scope, type 2 diabetes is a Condition, oral anti - diabetic agents ( excluding sulfonylurea ) or non - insulin injectable antidiabetic agents is a Scope, obstructive sleep apnea is a Condition, dyslipidemia is a Condition, nonalcoholic fatty liver disease is a Condition, within 6 months before Screening is a Temporal, hypersensitivity is a Condition, Belviq XR is a Drug, or any of the excipients is a Qualifier, Significant is a Qualifier, change in diet or level of physical activity is a Scope, within 1 month before dosing is a Temporal, change in weight is a Observation, more than 5 kg is a Value, within 3 months before Screening is a Temporal, < 1000 calories / day is a Value, within 6 months before Screening is a Temporal, History is a Observation, alcohol or drug dependence or abuse is a Scope, Recreational drug use is a Observation, within 2 years before Screening is a Temporal, human immunodeficiency virus positive is a Condition, active is a Qualifier, viral hepatitis is a Condition, B or C is a Scope, Malignancy is a Condition, within 5 years before Screening is a Temporal, Unable to attend scheduled visits is a Observation, lack of transportation is a Observation, lack of a caregiver is a Observation, Special needs is a Observation, unable to comprehend study - related instructions is a Scope, mild to profound mental retardation [ intelligence quotient < 70 ] , moderate to severe cognitive developmental delay , pervasive development disorders , autism is a Scope, Ongoing is a Temporal, epilepsy is a Condition, other is a Qualifier, medications is a Drug, seizure disorder is a Condition, within 6 months of screening or any time between screening and randomization is a Scope, blood pressure is a Measurement, 95th percentile or greater is a Value, for age is a Qualifier, 2 separate readings is a Multiplier, 2 separate days is a Qualifier, Currently is a Temporal, another is a Qualifier, investigational drug or device is a Scope, within 30 days before providing informed consent is a Temporal, Planned is a Mood, bariatric surgery is a Procedure, during the study is a Temporal, prior is a Temporal, bariatric surgical procedures is a Procedure, the study is a Reference_point, Female is a Person, breastfeeding or pregnant is a Scope, at Screening or Baseline is a Scope, positive beta - human chorionic gonadotropin test is a Scope, separate Baseline assessment is required if a negative screening pregnancy test was obtained more than 72 hours before the first dose of study drug is a Scope, unprotected sexual intercourse is a Condition, within 30 days before study entry is a Temporal, do not agree is a Observation, highly effective method of contraception is a Scope, total abstinence , an intrauterine device , a double - barrier method [ such as condom plus diaphragm with spermicide ] , a contraceptive implant , an oral contraceptive , or have a vasectomized partner with confirmed azoospermia is a Scope, throughout the entire study period is a Temporal, for 28 days after study drug discontinuation is a Temporal, currently is a Temporal, abstinent is a Condition, do not agree is a Observation, double - barrier method ( as described above ) or refrain from sexual activity is a Scope, during the study period and for 28 days after study drug discontinuation is a Scope, hormonal contraceptives is a Drug, not is a Negation, stable dose is a Qualifier, hormonal contraceptive is a Drug, for at least 4 weeks before dosing is a Temporal, do not agree is a Observation, the same is a Qualifier, contraceptive is a Drug, during the study is a Temporal, for 28 days after study drug discontinuation is a Temporal

NCT03338296_exc_task1

Sentence: Clinically significant new illness within 1 month before randomization that may affect the participant's ability to fulfill the study requirements or significantly confound the assessments Participants who cannot swallow investigational products Participants with T2DM who have hypoglycemia unawareness Aortic regurgitation mild or greater Mitral regurgitation moderate or greater Mitral or aortic valve stenosis greater than mild (ie, aortic stenosis: jet >3.0 meters per second [m/s], mean gradient >25 millimeters of mercury [mmHg], and aortic valve area <1.5 centimeters squared [cm^2]; mitral stenosis: mean gradient >5 mmHg and mitral valve area <1.5 cm^2) Systolic pulmonary artery pressure (SPAP) >40 mmHg (and/or tricuspid regurgitation [TR] jet velocity >2.9 m/s) In cases where an actual SPAP value is not measurable due to lack of adequate TR jet, the pulmonary flow acceleration time measured at the right ventricular outflow tract (RVOTAT) will be used to assess eligibility. Participants with a RVOTAT =100 milliseconds (msec) will be excluded, suggesting an elevated mean SPAP; eligibility for the those participants with RVOTAT between 100 and 120 msec will be determined based on combined assessment of the TR jet, septal motion, and right ventricular size. Left ventricular ejection fraction <45% Intracardiac mass, tumor, or thrombus Evidence of congenital heart disease Clinically significant pericardial effusion (eg, moderate or larger or with hemodynamic compromise) Significant renal or hepatic disease as evidenced by a serum creatinine greater than 1.5× upper limit of normal (ULN), serum transaminases greater than 3× ULN, or total bilirubin greater than 1.5× ULN in absence of Gilbert's syndrome Any suicidal ideation with intent with or without a plan, at the time of or within 6 months of Screening, as indicated by answering "Yes" to questions 4 or 5 on the Suicidal Ideation section of the Columbia-Suicide Severity Rating Scale (C-SSRS) Any suicidal behavior in the past based on the C-SSRS Any history of anorexia or bulimia within 2 years before Screening, Attention Deficit Hyperactivity Disorder, any Diagnostic and Statistical Manual of Mental Disorders, 5th Edition depressive disorder, bipolar disorder, or schizophrenia Known secondary causes (genetic, endocrine, or metabolic) for obesity (eg, Prader-Willi syndrome, Bardet Biedl syndrome, Down's Syndrome, untreated hypothyroidism, Cushing's syndrome, daily systemic corticosteroid exposure for longer than 30 days, history of significant exposure to corticosteroids for chronic illness during the past year; inhaled steroids will be allowed) Use of other products intended for weight loss including prescription drugs, over-the-counter (OTC) drugs, and herbal preparations within 1 month before Screening selective serotonin reuptake inhibitors serotonin norepinephrine reuptake inhibitors tricyclic antidepressants bupropion triptans St. John's Wort tryptophan linezolid dextromethorphan in any form (eg, OTC cold medicines) lithium tramadol antipsychotics or other dopamine antagonists antiseizure medications including valproic acid, zonisamide, topiramate, and lamotrigine oral steroids (topical and inhaled steroids are acceptable) stimulant medications (eg, Ritalin, Concerta, Biphetamine, and Dexedrine) benzodiazepines Use of drugs known to increase the risk for cardiac valvulopathy within 6 months before Screening, including but not limited to pergolide, ergotamine, methysergide, and cabergoline History or evidence of clinically significant disease (eg, malignancy; cardiac, respiratory, gastrointestinal, renal, or psychiatric disease) other than prediabetes (impaired fasting glucose or impaired glucose tolerance), type 2 diabetes treated with oral anti-diabetic agents (excluding sulfonylurea) or non-insulin injectable antidiabetic agents, obstructive sleep apnea, dyslipidemia, and nonalcoholic fatty liver disease Use of Belviq XR within 6 months before Screening or hypersensitivity to Belviq XR or any of the excipients Significant change in diet or level of physical activity within 1 month before dosing or change in weight of more than 5 kg within 3 months before Screening Any use of a very-low-calorie (<1000 calories/day) weight loss diet within 6 months before Screening History of alcohol or drug dependence or abuse Recreational drug use within 2 years before Screening Known to be human immunodeficiency virus positive Known to have active viral hepatitis (B or C) Malignancy within 5 years before Screening Unable to attend scheduled visits (eg, lack of transportation) or lack of a caregiver or guardian to supervise study participation Special needs participants who are unable to comprehend study-related instructions (eg, mild to profound mental retardation [intelligence quotient <70], moderate to severe cognitive developmental delay, pervasive development disorders, autism) Ongoing epilepsy or other seizure disorder, or use of medications for a seizure disorder within 6 months of screening or any time between screening and randomization Participants with a blood pressure in the 95th percentile or greater for age, sex, and height on 2 separate readings recorded on 2 separate days. Those participants who had uncontrolled hypertension at Screening can be rescreened more than 1 month after initiation or adjustment of antihypertensive therapy 1 time. Currently enrolled in another clinical study or has used any investigational drug or device within 30 days before providing informed consent Planned bariatric surgery during the study or prior bariatric surgical procedures Not suitable to participate in the study in the opinion of the investigator, including consideration of any existing physical, medical, or mental condition that prevents compliance with the protocol Female participants who are breastfeeding or pregnant at Screening or Baseline (as documented by a positive beta-human chorionic gonadotropin test). A separate Baseline assessment is required if a negative screening pregnancy test was obtained more than 72 hours before the first dose of study drug. Had unprotected sexual intercourse within 30 days before study entry and who do not agree to use a highly effective method of contraception (eg, total abstinence, an intrauterine device, a double-barrier method [such as condom plus diaphragm with spermicide], a contraceptive implant, an oral contraceptive, or have a vasectomized partner with confirmed azoospermia) throughout the entire study period and for 28 days after study drug discontinuation Are currently abstinent and do not agree to use a double-barrier method (as described above) or refrain from sexual activity during the study period and for 28 days after study drug discontinuation Are using hormonal contraceptives, but are not on a stable dose of the same hormonal contraceptive product for at least 4 weeks before dosing and who do not agree to use the same contraceptive during the study and for 28 days after study drug discontinuation (Note: All female participants will be considered to be of childbearing potential unless they have been sterilized surgically [ie, bilateral tubal ligation, total hysterectomy, or bilateral oophorectomy, all with surgery at least 1 month before dosing]). Instructions: please typing these entity words according to sentence: Clinically significant, new, illness, within 1 month before randomization, may affect the participant 's ability to fulfill the study requirements or significantly confound the assessments, cannot swallow, investigational products, T2DM, hypoglycemia unawareness, Aortic regurgitation, mild or greater, Mitral regurgitation, moderate or greater, Mitral or aortic valve stenosis greater than mild, aortic stenosis : jet > 3.0 meters per second [ m / s ] , mean gradient > 25 millimeters of mercury [ mmHg ] , and aortic valve area < 1.5 centimeters squared [ cm^2 ] ; mitral stenosis : mean gradient > 5 mmHg and mitral valve area < 1.5 cm^2, Systolic pulmonary artery pressure ( SPAP ), > 40 mmHg, tricuspid regurgitation [ TR ] jet velocity, > 2.9 m / s, RVOTAT, = 100 milliseconds ( msec ), Left ventricular ejection fraction, < 45 %, Intracardiac mass, tumor, thrombus, Evidence of, congenital heart disease, Clinically significant, pericardial effusion, moderate or larger or with hemodynamic compromise, Significant, renal or hepatic disease, serum creatinine greater than 1.5× upper limit of normal ( ULN ) , serum transaminases greater than 3× ULN , or total bilirubin greater than 1.5× ULN in absence of Gilbert 's syndrome, suicidal ideation, with intent, with or without a plan, at the time of or within 6 months of Screening, Yes, questions 4 or 5, Suicidal Ideation section of the Columbia - Suicide Severity Rating Scale ( C - SSRS ), suicidal behavior, in the past, C - SSRS, history, anorexia or bulimia, within 2 years before Screening, Attention Deficit Hyperactivity Disorder, Diagnostic and Statistical Manual of Mental Disorders , 5th Edition, depressive disorder , bipolar disorder , or schizophrenia, secondary causes ( genetic , endocrine , or metabolic ) for obesity, Prader - Willi syndrome , Bardet Biedl syndrome , Down 's Syndrome , untreated hypothyroidism , Cushing 's syndrome , daily systemic corticosteroid exposure for longer than 30 days , history of significant exposure to corticosteroids for chronic illness during the past year ; inhaled steroids will be allowed, products intended for weight loss, prescription drugs , over - the - counter ( OTC ) drugs , and herbal, within 1 month before Screening, selective serotonin reuptake inhibitors, serotonin norepinephrine reuptake inhibitors, tricyclic antidepressants, bupropion, triptans, St . John 's Wort, tryptophan, linezolid, dextromethorphan, any form, lithium, tramadol, antipsychotics, dopamine antagonists, antiseizure medications, valproic acid , zonisamide , topiramate , and lamotrigine, oral steroids, topical and inhaled steroids, acceptable, stimulant medications, Ritalin , Concerta , Biphetamine , and Dexedrine, benzodiazepines, drugs known to increase the risk for cardiac valvulopathy, within 6 months before Screening, pergolide , ergotamine , methysergide , and cabergoline, History or evidence of clinically significant disease, malignancy ; cardiac , respiratory , gastrointestinal , renal , or psychiatric disease, other than, prediabetes, impaired fasting glucose or impaired glucose tolerance ), type 2 diabetes, oral anti - diabetic agents ( excluding sulfonylurea ) or non - insulin injectable antidiabetic agents, obstructive sleep apnea, dyslipidemia, nonalcoholic fatty liver disease, within 6 months before Screening, hypersensitivity, Belviq XR, or any of the excipients, Significant, change in diet or level of physical activity, within 1 month before dosing, change in weight, more than 5 kg, within 3 months before Screening, < 1000 calories / day, within 6 months before Screening, History, alcohol or drug dependence or abuse, Recreational drug use, within 2 years before Screening, human immunodeficiency virus positive, active, viral hepatitis, B or C, Malignancy, within 5 years before Screening, Unable to attend scheduled visits, lack of transportation, lack of a caregiver, Special needs, unable to comprehend study - related instructions, mild to profound mental retardation [ intelligence quotient < 70 ] , moderate to severe cognitive developmental delay , pervasive development disorders , autism, Ongoing, epilepsy, other, medications, seizure disorder, within 6 months of screening or any time between screening and randomization, blood pressure, 95th percentile or greater, for age, 2 separate readings, 2 separate days, Currently, another, investigational drug or device, within 30 days before providing informed consent, Planned, bariatric surgery, during the study, prior, bariatric surgical procedures, the study, Female, breastfeeding or pregnant, at Screening or Baseline, positive beta - human chorionic gonadotropin test, separate Baseline assessment is required if a negative screening pregnancy test was obtained more than 72 hours before the first dose of study drug, unprotected sexual intercourse, within 30 days before study entry, do not agree, highly effective method of contraception, total abstinence , an intrauterine device , a double - barrier method [ such as condom plus diaphragm with spermicide ] , a contraceptive implant , an oral contraceptive , or have a vasectomized partner with confirmed azoospermia, throughout the entire study period, for 28 days after study drug discontinuation, currently, abstinent, do not agree, double - barrier method ( as described above ) or refrain from sexual activity, during the study period and for 28 days after study drug discontinuation, hormonal contraceptives, not, stable dose, hormonal contraceptive, for at least 4 weeks before dosing, do not agree, the same, contraceptive, during the study, for 28 days after study drug discontinuation Options: Temporal, Condition, Qualifier, Value, Person, Observation, Multiplier, Procedure, Negation, Reference_point, Scope, Measurement, Mood, Drug

[ "B-Qualifier", "I-Qualifier", "B-Qualifier", "B-Condition", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Observation", "I-Observation", "B-Drug", "I-Drug", "O", "O", "O", "B-Condition", "O", "O", "B-Condition", "I-Condition", "O", "B-Condition", "I-Condition", "B-Qualifier", "I-Qualifier", "I-Qualifier", "O", "B-Condition", "I-Condition", "B-Qualifier", "I-Qualifier", "I-Qualifier", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "O", "O", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "O", "B-Condition", "I-Condition", "O", "B-Condition", "O", "O", "B-Condition", "O", "B-Mood", "I-Mood", "B-Condition", "I-Condition", "I-Condition", "O", "B-Qualifier", "I-Qualifier", "B-Condition", "I-Condition", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Qualifier", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Condition", "I-Condition", "B-Qualifier", "I-Qualifier", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "B-Value", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "O", "O", "B-Condition", "I-Condition", "B-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "B-Procedure", "I-Procedure", "I-Procedure", "O", "O", "B-Observation", "O", "B-Scope", "I-Scope", "I-Scope", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "O", "O", "B-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "B-Drug", "I-Drug", "I-Drug", "I-Drug", "I-Drug", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Drug", "I-Drug", "I-Drug", "I-Drug", "O", "B-Drug", "I-Drug", "I-Drug", "I-Drug", "O", "B-Drug", "I-Drug", "O", "B-Drug", "O", "B-Drug", "O", "B-Drug", "I-Drug", "I-Drug", "I-Drug", "I-Drug", "O", "B-Drug", "O", "B-Drug", "O", "B-Drug", "O", "B-Qualifier", "I-Qualifier", "O", "O", "O", "O", "O", "O", "O", "O", "B-Drug", "O", "B-Drug", "O", "B-Drug", "O", "O", "B-Drug", "I-Drug", "O", "B-Drug", "I-Drug", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Drug", "I-Drug", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Negation", "O", "O", "B-Drug", "I-Drug", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Drug", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Negation", "I-Negation", "B-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Condition", "I-Condition", "I-Condition", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Condition", "I-Condition", "I-Condition", "O", "B-Condition", "O", "O", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "O", "O", "O", "O", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Condition", "O", "B-Drug", "I-Drug", "B-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "O", "B-Qualifier", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Observation", "I-Observation", "I-Observation", "O", "B-Value", "I-Value", "I-Value", "I-Value", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "O", "O", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Observation", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Observation", "I-Observation", "I-Observation", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "O", "O", "O", "O", "B-Qualifier", "B-Condition", "I-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "O", "O", "B-Condition", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Observation", "I-Observation", "I-Observation", "I-Observation", "I-Observation", "O", "O", "O", "B-Observation", "I-Observation", "I-Observation", "O", "O", "B-Observation", "I-Observation", "I-Observation", "I-Observation", "O", "O", "O", "O", "O", "O", "O", "B-Observation", "I-Observation", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Temporal", "B-Condition", "O", "B-Qualifier", "O", "O", "O", "O", "O", "O", "B-Drug", "O", "O", "B-Condition", "I-Condition", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "B-Measurement", "I-Measurement", "O", "O", "B-Value", "I-Value", "I-Value", "I-Value", "B-Qualifier", "I-Qualifier", "O", "O", "O", "O", "O", "O", "B-Multiplier", "I-Multiplier", "I-Multiplier", "O", "O", "B-Qualifier", "I-Qualifier", "I-Qualifier", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Temporal", "O", "O", "B-Qualifier", "O", "O", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Mood", "B-Procedure", "I-Procedure", "B-Temporal", "I-Temporal", "I-Temporal", "O", "B-Temporal", "B-Procedure", "I-Procedure", "I-Procedure", "O", "O", "O", "O", "O", "O", "B-Reference_point", "I-Reference_point", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Person", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Condition", "I-Condition", "I-Condition", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "B-Observation", "I-Observation", "I-Observation", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "B-Temporal", "B-Condition", "O", "B-Observation", "I-Observation", "I-Observation", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Drug", "I-Drug", "O", "O", "O", "B-Negation", "O", "O", "B-Qualifier", "I-Qualifier", "O", "O", "O", "B-Drug", "I-Drug", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "B-Observation", "I-Observation", "I-Observation", "O", "O", "B-Qualifier", "I-Qualifier", "B-Drug", "B-Temporal", "I-Temporal", "I-Temporal", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Clinically significant new illness within 1 month before randomization that may affect the participant's ability to fulfill the study requirements or significantly confound the assessments Participants who cannot swallow investigational products Participants with T2DM who have hypoglycemia unawareness Aortic regurgitation mild or greater Mitral regurgitation moderate or greater Mitral or aortic valve stenosis greater than mild (ie, aortic stenosis: jet >3.0 meters per second [m/s], mean gradient >25 millimeters of mercury [mmHg], and aortic valve area <1.5 centimeters squared [cm^2]; mitral stenosis: mean gradient >5 mmHg and mitral valve area <1.5 cm^2) Systolic pulmonary artery pressure (SPAP) >40 mmHg (and/or tricuspid regurgitation [TR] jet velocity >2.9 m/s) In cases where an actual SPAP value is not measurable due to lack of adequate TR jet, the pulmonary flow acceleration time measured at the right ventricular outflow tract (RVOTAT) will be used to assess eligibility. Participants with a RVOTAT =100 milliseconds (msec) will be excluded, suggesting an elevated mean SPAP; eligibility for the those participants with RVOTAT between 100 and 120 msec will be determined based on combined assessment of the TR jet, septal motion, and right ventricular size. Left ventricular ejection fraction <45% Intracardiac mass, tumor, or thrombus Evidence of congenital heart disease Clinically significant pericardial effusion (eg, moderate or larger or with hemodynamic compromise) Significant renal or hepatic disease as evidenced by a serum creatinine greater than 1.5× upper limit of normal (ULN), serum transaminases greater than 3× ULN, or total bilirubin greater than 1.5× ULN in absence of Gilbert's syndrome Any suicidal ideation with intent with or without a plan, at the time of or within 6 months of Screening, as indicated by answering "Yes" to questions 4 or 5 on the Suicidal Ideation section of the Columbia-Suicide Severity Rating Scale (C-SSRS) Any suicidal behavior in the past based on the C-SSRS Any history of anorexia or bulimia within 2 years before Screening, Attention Deficit Hyperactivity Disorder, any Diagnostic and Statistical Manual of Mental Disorders, 5th Edition depressive disorder, bipolar disorder, or schizophrenia Known secondary causes (genetic, endocrine, or metabolic) for obesity (eg, Prader-Willi syndrome, Bardet Biedl syndrome, Down's Syndrome, untreated hypothyroidism, Cushing's syndrome, daily systemic corticosteroid exposure for longer than 30 days, history of significant exposure to corticosteroids for chronic illness during the past year; inhaled steroids will be allowed) Use of other products intended for weight loss including prescription drugs, over-the-counter (OTC) drugs, and herbal preparations within 1 month before Screening selective serotonin reuptake inhibitors serotonin norepinephrine reuptake inhibitors tricyclic antidepressants bupropion triptans St. John's Wort tryptophan linezolid dextromethorphan in any form (eg, OTC cold medicines) lithium tramadol antipsychotics or other dopamine antagonists antiseizure medications including valproic acid, zonisamide, topiramate, and lamotrigine oral steroids (topical and inhaled steroids are acceptable) stimulant medications (eg, Ritalin, Concerta, Biphetamine, and Dexedrine) benzodiazepines Use of drugs known to increase the risk for cardiac valvulopathy within 6 months before Screening, including but not limited to pergolide, ergotamine, methysergide, and cabergoline History or evidence of clinically significant disease (eg, malignancy; cardiac, respiratory, gastrointestinal, renal, or psychiatric disease) other than prediabetes (impaired fasting glucose or impaired glucose tolerance), type 2 diabetes treated with oral anti-diabetic agents (excluding sulfonylurea) or non-insulin injectable antidiabetic agents, obstructive sleep apnea, dyslipidemia, and nonalcoholic fatty liver disease Use of Belviq XR within 6 months before Screening or hypersensitivity to Belviq XR or any of the excipients Significant change in diet or level of physical activity within 1 month before dosing or change in weight of more than 5 kg within 3 months before Screening Any use of a very-low-calorie (<1000 calories/day) weight loss diet within 6 months before Screening History of alcohol or drug dependence or abuse Recreational drug use within 2 years before Screening Known to be human immunodeficiency virus positive Known to have active viral hepatitis (B or C) Malignancy within 5 years before Screening Unable to attend scheduled visits (eg, lack of transportation) or lack of a caregiver or guardian to supervise study participation Special needs participants who are unable to comprehend study-related instructions (eg, mild to profound mental retardation [intelligence quotient <70], moderate to severe cognitive developmental delay, pervasive development disorders, autism) Ongoing epilepsy or other seizure disorder, or use of medications for a seizure disorder within 6 months of screening or any time between screening and randomization Participants with a blood pressure in the 95th percentile or greater for age, sex, and height on 2 separate readings recorded on 2 separate days. Those participants who had uncontrolled hypertension at Screening can be rescreened more than 1 month after initiation or adjustment of antihypertensive therapy 1 time. Currently enrolled in another clinical study or has used any investigational drug or device within 30 days before providing informed consent Planned bariatric surgery during the study or prior bariatric surgical procedures Not suitable to participate in the study in the opinion of the investigator, including consideration of any existing physical, medical, or mental condition that prevents compliance with the protocol Female participants who are breastfeeding or pregnant at Screening or Baseline (as documented by a positive beta-human chorionic gonadotropin test). A separate Baseline assessment is required if a negative screening pregnancy test was obtained more than 72 hours before the first dose of study drug. Had unprotected sexual intercourse within 30 days before study entry and who do not agree to use a highly effective method of contraception (eg, total abstinence, an intrauterine device, a double-barrier method [such as condom plus diaphragm with spermicide], a contraceptive implant, an oral contraceptive, or have a vasectomized partner with confirmed azoospermia) throughout the entire study period and for 28 days after study drug discontinuation Are currently abstinent and do not agree to use a double-barrier method (as described above) or refrain from sexual activity during the study period and for 28 days after study drug discontinuation Are using hormonal contraceptives, but are not on a stable dose of the same hormonal contraceptive product for at least 4 weeks before dosing and who do not agree to use the same contraceptive during the study and for 28 days after study drug discontinuation (Note: All female participants will be considered to be of childbearing potential unless they have been sterilized surgically [ie, bilateral tubal ligation, total hysterectomy, or bilateral oophorectomy, all with surgery at least 1 month before dosing]).

[ "Clinically", "significant", "new", "illness", "within", "1", "month", "before", "randomization", "that", "may", "affect", "the", "participant", "'s", "ability", "to", "fulfill", "the", "study", "requirements", "or", "significantly", "confound", "the", "assessments", "\n", "Participants", "who", "cannot", "swallow", "investigational", "products", "\n", "Participants", "with", "T2DM", "who", "have", "hypoglycemia", "unawareness", "\n", "Aortic", "regurgitation", "mild", "or", "greater", "\n", "Mitral", "regurgitation", "moderate", "or", "greater", "\n", "Mitral", "or", "aortic", "valve", "stenosis", "greater", "than", "mild", "(", "ie", ",", "aortic", "stenosis", ":", "jet", ">", "3.0", "meters", "per", "second", "[", "m", "/", "s", "]", ",", "mean", "gradient", ">", "25", "millimeters", "of", "mercury", "[", "mmHg", "]", ",", "and", "aortic", "valve", "area", "<", "1.5", "centimeters", "squared", "[", "cm^2", "]", ";", "mitral", "stenosis", ":", "mean", "gradient", ">", "5", "mmHg", "and", "mitral", "valve", "area", "<", "1.5", "cm^2", ")", "\n", "Systolic", "pulmonary", "artery", "pressure", "(", "SPAP", ")", ">", "40", "mmHg", "(", "and", "/", "or", "tricuspid", "regurgitation", "[", "TR", "]", "jet", "velocity", ">", "2.9", "m", "/", "s", ")", "In", "cases", "where", "an", "actual", "SPAP", "value", "is", "not", "measurable", "due", "to", "lack", "of", "adequate", "TR", "jet", ",", "the", "pulmonary", "flow", "acceleration", "time", "measured", "at", "the", "right", "ventricular", "outflow", "tract", "(", "RVOTAT", ")", "will", "be", "used", "to", "assess", "eligibility", ".", "Participants", "with", "a", "RVOTAT", "=", "100", "milliseconds", "(", "msec", ")", "will", "be", "excluded", ",", "suggesting", "an", "elevated", "mean", "SPAP", ";", "eligibility", "for", "the", "those", "participants", "with", "RVOTAT", "between", "100", "and", "120", "msec", "will", "be", "determined", "based", "on", "combined", "assessment", "of", "the", "TR", "jet", ",", "septal", "motion", ",", "and", "right", "ventricular", "size", ".", "\n", "Left", "ventricular", "ejection", "fraction", "<", "45", "%", "\n", "Intracardiac", "mass", ",", "tumor", ",", "or", "thrombus", "\n", "Evidence", "of", "congenital", "heart", "disease", "\n", "Clinically", "significant", "pericardial", "effusion", "(", "eg", ",", "moderate", "or", "larger", "or", "with", "hemodynamic", "compromise", ")", "\n", "Significant", "renal", "or", "hepatic", "disease", "as", "evidenced", "by", "a", "serum", "creatinine", "greater", "than", "1.5×", "upper", "limit", "of", "normal", "(", "ULN", ")", ",", "serum", "transaminases", "greater", "than", "3×", "ULN", ",", "or", "total", "bilirubin", "greater", "than", "1.5×", "ULN", "in", "absence", "of", "Gilbert", "'s", "syndrome", "\n", "Any", "suicidal", "ideation", "with", "intent", "with", "or", "without", "a", "plan", ",", "at", "the", "time", "of", "or", "within", "6", "months", "of", "Screening", ",", "as", "indicated", "by", "answering", "\"", "Yes", "\"", "to", "questions", "4", "or", "5", "on", "the", "Suicidal", "Ideation", "section", "of", "the", "Columbia", "-", "Suicide", "Severity", "Rating", "Scale", "(", "C", "-", "SSRS", ")", "\n", "Any", "suicidal", "behavior", "in", "the", "past", "based", "on", "the", "C", "-", "SSRS", "\n", "Any", "history", "of", "anorexia", "or", "bulimia", "within", "2", "years", "before", "Screening", ",", "Attention", "Deficit", "Hyperactivity", "Disorder", ",", "any", "Diagnostic", "and", "Statistical", "Manual", "of", "Mental", "Disorders", ",", "5th", "Edition", "depressive", "disorder", ",", "bipolar", "disorder", ",", "or", "schizophrenia", "\n", "Known", "secondary", "causes", "(", "genetic", ",", "endocrine", ",", "or", "metabolic", ")", "for", "obesity", "(", "eg", ",", "Prader", "-", "Willi", "syndrome", ",", "Bardet", "Biedl", "syndrome", ",", "Down", "'s", "Syndrome", ",", "untreated", "hypothyroidism", ",", "Cushing", "'s", "syndrome", ",", "daily", "systemic", "corticosteroid", "exposure", "for", "longer", "than", "30", "days", ",", "history", "of", "significant", "exposure", "to", "corticosteroids", "for", "chronic", "illness", "during", "the", "past", "year", ";", "inhaled", "steroids", "will", "be", "allowed", ")", "\n", "Use", "of", "other", "products", "intended", "for", "weight", "loss", "including", "prescription", "drugs", ",", "over", "-", "the", "-", "counter", "(", "OTC", ")", "drugs", ",", "and", "herbal", "preparations", "within", "1", "month", "before", "Screening", "\n", "selective", "serotonin", "reuptake", "inhibitors", "\n", "serotonin", "norepinephrine", "reuptake", "inhibitors", "\n", "tricyclic", "antidepressants", "\n", "bupropion", "\n", "triptans", "\n", "St", ".", "John", "'s", "Wort", "\n", "tryptophan", "\n", "linezolid", "\n", "dextromethorphan", "in", "any", "form", "(", "eg", ",", "OTC", "cold", "medicines", ")", "\n", "lithium", "\n", "tramadol", "\n", "antipsychotics", "or", "other", "dopamine", "antagonists", "\t\n", "antiseizure", "medications", "including", "valproic", "acid", ",", "zonisamide", ",", "topiramate", ",", "and", "lamotrigine", "\n", "oral", "steroids", "(", "topical", "and", "inhaled", "steroids", "are", "acceptable", ")", "\n", "stimulant", "medications", "(", "eg", ",", "Ritalin", ",", "Concerta", ",", "Biphetamine", ",", "and", "Dexedrine", ")", "\n", "benzodiazepines", "\n", "Use", "of", "drugs", "known", "to", "increase", "the", "risk", "for", "cardiac", "valvulopathy", "within", "6", "months", "before", "Screening", ",", "including", "but", "not", "limited", "to", "pergolide", ",", "ergotamine", ",", "methysergide", ",", "and", "cabergoline", "\n", "History", "or", "evidence", "of", "clinically", "significant", "disease", "(", "eg", ",", "malignancy", ";", "cardiac", ",", "respiratory", ",", "gastrointestinal", ",", "renal", ",", "or", "psychiatric", "disease", ")", "other", "than", "prediabetes", "(", "impaired", "fasting", "glucose", "or", "impaired", "glucose", "tolerance", ")", ",", "type", "2", "diabetes", "treated", "with", "oral", "anti", "-", "diabetic", "agents", "(", "excluding", "sulfonylurea", ")", "or", "non", "-", "insulin", "injectable", "antidiabetic", "agents", ",", "obstructive", "sleep", "apnea", ",", "dyslipidemia", ",", "and", "nonalcoholic", "fatty", "liver", "disease", "\n", "Use", "of", "Belviq", "XR", "within", "6", "months", "before", "Screening", "or", "hypersensitivity", "to", "Belviq", "XR", "or", "any", "of", "the", "excipients", "\n", "Significant", "change", "in", "diet", "or", "level", "of", "physical", "activity", "within", "1", "month", "before", "dosing", "or", "change", "in", "weight", "of", "more", "than", "5", "kg", "within", "3", "months", "before", "Screening", "\n", "Any", "use", "of", "a", "very", "-", "low", "-", "calorie", "(", "<", "1000", "calories", "/", "day", ")", "weight", "loss", "diet", "within", "6", "months", "before", "Screening", "\n", "History", "of", "alcohol", "or", "drug", "dependence", "or", "abuse", "\n", "Recreational", "drug", "use", "within", "2", "years", "before", "Screening", "\n", "Known", "to", "be", "human", "immunodeficiency", "virus", "positive", "\n", "Known", "to", "have", "active", "viral", "hepatitis", "(", "B", "or", "C", ")", "\n", "Malignancy", "within", "5", "years", "before", "Screening", "\n", "Unable", "to", "attend", "scheduled", "visits", "(", "eg", ",", "lack", "of", "transportation", ")", "or", "lack", "of", "a", "caregiver", "or", "guardian", "to", "supervise", "study", "participation", "\n", "Special", "needs", "participants", "who", "are", "unable", "to", "comprehend", "study", "-", "related", "instructions", "(", "eg", ",", "mild", "to", "profound", "mental", "retardation", "[", "intelligence", "quotient", "<", "70", "]", ",", "moderate", "to", "severe", "cognitive", "developmental", "delay", ",", "pervasive", "development", "disorders", ",", "autism", ")", "\n", "Ongoing", "epilepsy", "or", "other", "seizure", "disorder", ",", "or", "use", "of", "medications", "for", "a", "seizure", "disorder", "within", "6", "months", "of", "screening", "or", "any", "time", "between", "screening", "and", "randomization", "\n", "Participants", "with", "a", "blood", "pressure", "in", "the", "95th", "percentile", "or", "greater", "for", "age", ",", "sex", ",", "and", "height", "on", "2", "separate", "readings", "recorded", "on", "2", "separate", "days", ".", "Those", "participants", "who", "had", "uncontrolled", "hypertension", "at", "Screening", "can", "be", "rescreened", "more", "than", "1", "month", "after", "initiation", "or", "adjustment", "of", "antihypertensive", "therapy", "1", "time", ".", "\n", "Currently", "enrolled", "in", "another", "clinical", "study", "or", "has", "used", "any", "investigational", "drug", "or", "device", "within", "30", "days", "before", "providing", "informed", "consent", "\n", "Planned", "bariatric", "surgery", "during", "the", "study", "or", "prior", "bariatric", "surgical", "procedures", "\n", "Not", "suitable", "to", "participate", "in", "the", "study", "in", "the", "opinion", "of", "the", "investigator", ",", "including", "consideration", "of", "any", "existing", "physical", ",", "medical", ",", "or", "mental", "condition", "that", "prevents", "compliance", "with", "the", "protocol", "\n", "Female", "participants", "who", "are", "breastfeeding", "or", "pregnant", "at", "Screening", "or", "Baseline", "(", "as", "documented", "by", "a", "positive", "beta", "-", "human", "chorionic", "gonadotropin", "test", ")", ".", "A", "separate", "Baseline", "assessment", "is", "required", "if", "a", "negative", "screening", "pregnancy", "test", "was", "obtained", "more", "than", "72", "hours", "before", "the", "first", "dose", "of", "study", "drug", ".", "\n", "Had", "unprotected", "sexual", "intercourse", "within", "30", "days", "before", "study", "entry", "and", "who", "do", "not", "agree", "to", "use", "a", "highly", "effective", "method", "of", "contraception", "(", "eg", ",", "total", "abstinence", ",", "an", "intrauterine", "device", ",", "a", "double", "-", "barrier", "method", "[", "such", "as", "condom", "plus", "diaphragm", "with", "spermicide", "]", ",", "a", "contraceptive", "implant", ",", "an", "oral", "contraceptive", ",", "or", "have", "a", "vasectomized", "partner", "with", "confirmed", "azoospermia", ")", "throughout", "the", "entire", "study", "period", "and", "for", "28", "days", "after", "study", "drug", "discontinuation", "\n", "Are", "currently", "abstinent", "and", "do", "not", "agree", "to", "use", "a", "double", "-", "barrier", "method", "(", "as", "described", "above", ")", "or", "refrain", "from", "sexual", "activity", "during", "the", "study", "period", "and", "for", "28", "days", "after", "study", "drug", "discontinuation", "\n", "Are", "using", "hormonal", "contraceptives", ",", "but", "are", "not", "on", "a", "stable", "dose", "of", "the", "same", "hormonal", "contraceptive", "product", "for", "at", "least", "4", "weeks", "before", "dosing", "and", "who", "do", "not", "agree", "to", "use", "the", "same", "contraceptive", "during", "the", "study", "and", "for", "28", "days", "after", "study", "drug", "discontinuation", "(", "Note", ":", "All", "female", "participants", "will", "be", "considered", "to", "be", "of", "childbearing", "potential", "unless", "they", "have", "been", "sterilized", "surgically", "[", "ie", ",", "bilateral", "tubal", "ligation", ",", "total", "hysterectomy", ",", "or", "bilateral", "oophorectomy", ",", "all", "with", "surgery", "at", "least", "1", "month", "before", "dosing", "]", ")", ".", "\n" ]

[ "Scope", "Procedure", "Observation", "Qualifier", "Temporal", "Value", "Drug", "Measurement", "Condition", "Reference_point", "Device", "Multiplier", "Mood", "Negation", "Person" ]

Clinically significant, new, illness, within 1 month before randomization, may affect the participant 's ability to fulfill the study requirements or significantly confound the assessments, cannot swallow, investigational products, T2DM, hypoglycemia unawareness, Aortic regurgitation, mild or greater, Mitral regurgitation, moderate or greater, Mitral or aortic valve stenosis greater than mild, aortic stenosis : jet > 3.0 meters per second [ m / s ] , mean gradient > 25 millimeters of mercury [ mmHg ] , and aortic valve area < 1.5 centimeters squared [ cm^2 ] ; mitral stenosis : mean gradient > 5 mmHg and mitral valve area < 1.5 cm^2, Systolic pulmonary artery pressure ( SPAP ), > 40 mmHg, tricuspid regurgitation [ TR ] jet velocity, > 2.9 m / s, RVOTAT, = 100 milliseconds ( msec ), Left ventricular ejection fraction, < 45 %, Intracardiac mass, tumor, thrombus, Evidence of, congenital heart disease, Clinically significant, pericardial effusion, moderate or larger or with hemodynamic compromise, Significant, renal or hepatic disease, serum creatinine greater than 1.5× upper limit of normal ( ULN ) , serum transaminases greater than 3× ULN , or total bilirubin greater than 1.5× ULN in absence of Gilbert 's syndrome, suicidal ideation, with intent, with or without a plan, at the time of or within 6 months of Screening, Yes, questions 4 or 5, Suicidal Ideation section of the Columbia - Suicide Severity Rating Scale ( C - SSRS ), suicidal behavior, in the past, C - SSRS, history, anorexia or bulimia, within 2 years before Screening, Attention Deficit Hyperactivity Disorder, Diagnostic and Statistical Manual of Mental Disorders , 5th Edition, depressive disorder , bipolar disorder , or schizophrenia, secondary causes ( genetic , endocrine , or metabolic ) for obesity, Prader - Willi syndrome , Bardet Biedl syndrome , Down 's Syndrome , untreated hypothyroidism , Cushing 's syndrome , daily systemic corticosteroid exposure for longer than 30 days , history of significant exposure to corticosteroids for chronic illness during the past year ; inhaled steroids will be allowed, products intended for weight loss, prescription drugs , over - the - counter ( OTC ) drugs , and herbal, within 1 month before Screening, selective serotonin reuptake inhibitors, serotonin norepinephrine reuptake inhibitors, tricyclic antidepressants, bupropion, triptans, St . John 's Wort, tryptophan, linezolid, dextromethorphan, any form, lithium, tramadol, antipsychotics, dopamine antagonists, antiseizure medications, valproic acid , zonisamide , topiramate , and lamotrigine, oral steroids, topical and inhaled steroids, acceptable, stimulant medications, Ritalin , Concerta , Biphetamine , and Dexedrine, benzodiazepines, drugs known to increase the risk for cardiac valvulopathy, within 6 months before Screening, pergolide , ergotamine , methysergide , and cabergoline, History or evidence of clinically significant disease, malignancy ; cardiac , respiratory , gastrointestinal , renal , or psychiatric disease, other than, prediabetes, impaired fasting glucose or impaired glucose tolerance ), type 2 diabetes, oral anti - diabetic agents ( excluding sulfonylurea ) or non - insulin injectable antidiabetic agents, obstructive sleep apnea, dyslipidemia, nonalcoholic fatty liver disease, within 6 months before Screening, hypersensitivity, Belviq XR, or any of the excipients, Significant, change in diet or level of physical activity, within 1 month before dosing, change in weight, more than 5 kg, within 3 months before Screening, < 1000 calories / day, within 6 months before Screening, History, alcohol or drug dependence or abuse, Recreational drug use, within 2 years before Screening, human immunodeficiency virus positive, active, viral hepatitis, B or C, Malignancy, within 5 years before Screening, Unable to attend scheduled visits, lack of transportation, lack of a caregiver, Special needs, unable to comprehend study - related instructions, mild to profound mental retardation [ intelligence quotient < 70 ] , moderate to severe cognitive developmental delay , pervasive development disorders , autism, Ongoing, epilepsy, other, medications, seizure disorder, within 6 months of screening or any time between screening and randomization, blood pressure, 95th percentile or greater, for age, 2 separate readings, 2 separate days, Currently, another, investigational drug or device, within 30 days before providing informed consent, Planned, bariatric surgery, during the study, prior, bariatric surgical procedures, the study, Female, breastfeeding or pregnant, at Screening or Baseline, positive beta - human chorionic gonadotropin test, separate Baseline assessment is required if a negative screening pregnancy test was obtained more than 72 hours before the first dose of study drug, unprotected sexual intercourse, within 30 days before study entry, do not agree, highly effective method of contraception, total abstinence , an intrauterine device , a double - barrier method [ such as condom plus diaphragm with spermicide ] , a contraceptive implant , an oral contraceptive , or have a vasectomized partner with confirmed azoospermia, throughout the entire study period, for 28 days after study drug discontinuation, currently, abstinent, do not agree, double - barrier method ( as described above ) or refrain from sexual activity, during the study period and for 28 days after study drug discontinuation, hormonal contraceptives, not, stable dose, hormonal contraceptive, for at least 4 weeks before dosing, do not agree, the same, contraceptive, during the study, for 28 days after study drug discontinuation

NCT03338296_exc_task2

Sentence: Clinically significant new illness within 1 month before randomization that may affect the participant's ability to fulfill the study requirements or significantly confound the assessments Participants who cannot swallow investigational products Participants with T2DM who have hypoglycemia unawareness Aortic regurgitation mild or greater Mitral regurgitation moderate or greater Mitral or aortic valve stenosis greater than mild (ie, aortic stenosis: jet >3.0 meters per second [m/s], mean gradient >25 millimeters of mercury [mmHg], and aortic valve area <1.5 centimeters squared [cm^2]; mitral stenosis: mean gradient >5 mmHg and mitral valve area <1.5 cm^2) Systolic pulmonary artery pressure (SPAP) >40 mmHg (and/or tricuspid regurgitation [TR] jet velocity >2.9 m/s) In cases where an actual SPAP value is not measurable due to lack of adequate TR jet, the pulmonary flow acceleration time measured at the right ventricular outflow tract (RVOTAT) will be used to assess eligibility. Participants with a RVOTAT =100 milliseconds (msec) will be excluded, suggesting an elevated mean SPAP; eligibility for the those participants with RVOTAT between 100 and 120 msec will be determined based on combined assessment of the TR jet, septal motion, and right ventricular size. Left ventricular ejection fraction <45% Intracardiac mass, tumor, or thrombus Evidence of congenital heart disease Clinically significant pericardial effusion (eg, moderate or larger or with hemodynamic compromise) Significant renal or hepatic disease as evidenced by a serum creatinine greater than 1.5× upper limit of normal (ULN), serum transaminases greater than 3× ULN, or total bilirubin greater than 1.5× ULN in absence of Gilbert's syndrome Any suicidal ideation with intent with or without a plan, at the time of or within 6 months of Screening, as indicated by answering "Yes" to questions 4 or 5 on the Suicidal Ideation section of the Columbia-Suicide Severity Rating Scale (C-SSRS) Any suicidal behavior in the past based on the C-SSRS Any history of anorexia or bulimia within 2 years before Screening, Attention Deficit Hyperactivity Disorder, any Diagnostic and Statistical Manual of Mental Disorders, 5th Edition depressive disorder, bipolar disorder, or schizophrenia Known secondary causes (genetic, endocrine, or metabolic) for obesity (eg, Prader-Willi syndrome, Bardet Biedl syndrome, Down's Syndrome, untreated hypothyroidism, Cushing's syndrome, daily systemic corticosteroid exposure for longer than 30 days, history of significant exposure to corticosteroids for chronic illness during the past year; inhaled steroids will be allowed) Use of other products intended for weight loss including prescription drugs, over-the-counter (OTC) drugs, and herbal preparations within 1 month before Screening selective serotonin reuptake inhibitors serotonin norepinephrine reuptake inhibitors tricyclic antidepressants bupropion triptans St. John's Wort tryptophan linezolid dextromethorphan in any form (eg, OTC cold medicines) lithium tramadol antipsychotics or other dopamine antagonists antiseizure medications including valproic acid, zonisamide, topiramate, and lamotrigine oral steroids (topical and inhaled steroids are acceptable) stimulant medications (eg, Ritalin, Concerta, Biphetamine, and Dexedrine) benzodiazepines Use of drugs known to increase the risk for cardiac valvulopathy within 6 months before Screening, including but not limited to pergolide, ergotamine, methysergide, and cabergoline History or evidence of clinically significant disease (eg, malignancy; cardiac, respiratory, gastrointestinal, renal, or psychiatric disease) other than prediabetes (impaired fasting glucose or impaired glucose tolerance), type 2 diabetes treated with oral anti-diabetic agents (excluding sulfonylurea) or non-insulin injectable antidiabetic agents, obstructive sleep apnea, dyslipidemia, and nonalcoholic fatty liver disease Use of Belviq XR within 6 months before Screening or hypersensitivity to Belviq XR or any of the excipients Significant change in diet or level of physical activity within 1 month before dosing or change in weight of more than 5 kg within 3 months before Screening Any use of a very-low-calorie (<1000 calories/day) weight loss diet within 6 months before Screening History of alcohol or drug dependence or abuse Recreational drug use within 2 years before Screening Known to be human immunodeficiency virus positive Known to have active viral hepatitis (B or C) Malignancy within 5 years before Screening Unable to attend scheduled visits (eg, lack of transportation) or lack of a caregiver or guardian to supervise study participation Special needs participants who are unable to comprehend study-related instructions (eg, mild to profound mental retardation [intelligence quotient <70], moderate to severe cognitive developmental delay, pervasive development disorders, autism) Ongoing epilepsy or other seizure disorder, or use of medications for a seizure disorder within 6 months of screening or any time between screening and randomization Participants with a blood pressure in the 95th percentile or greater for age, sex, and height on 2 separate readings recorded on 2 separate days. Those participants who had uncontrolled hypertension at Screening can be rescreened more than 1 month after initiation or adjustment of antihypertensive therapy 1 time. Currently enrolled in another clinical study or has used any investigational drug or device within 30 days before providing informed consent Planned bariatric surgery during the study or prior bariatric surgical procedures Not suitable to participate in the study in the opinion of the investigator, including consideration of any existing physical, medical, or mental condition that prevents compliance with the protocol Female participants who are breastfeeding or pregnant at Screening or Baseline (as documented by a positive beta-human chorionic gonadotropin test). A separate Baseline assessment is required if a negative screening pregnancy test was obtained more than 72 hours before the first dose of study drug. Had unprotected sexual intercourse within 30 days before study entry and who do not agree to use a highly effective method of contraception (eg, total abstinence, an intrauterine device, a double-barrier method [such as condom plus diaphragm with spermicide], a contraceptive implant, an oral contraceptive, or have a vasectomized partner with confirmed azoospermia) throughout the entire study period and for 28 days after study drug discontinuation Are currently abstinent and do not agree to use a double-barrier method (as described above) or refrain from sexual activity during the study period and for 28 days after study drug discontinuation Are using hormonal contraceptives, but are not on a stable dose of the same hormonal contraceptive product for at least 4 weeks before dosing and who do not agree to use the same contraceptive during the study and for 28 days after study drug discontinuation (Note: All female participants will be considered to be of childbearing potential unless they have been sterilized surgically [ie, bilateral tubal ligation, total hysterectomy, or bilateral oophorectomy, all with surgery at least 1 month before dosing]). Instructions: please extract entity words from the input sentence

[ "B-Qualifier", "I-Qualifier", "B-Qualifier", "B-Condition", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Observation", "I-Observation", "B-Drug", "I-Drug", "O", "O", "O", "B-Condition", "O", "O", "B-Condition", "I-Condition", "O", "B-Condition", "I-Condition", "B-Qualifier", "I-Qualifier", "I-Qualifier", "O", "B-Condition", "I-Condition", "B-Qualifier", "I-Qualifier", "I-Qualifier", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "O", "O", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "O", "B-Condition", "I-Condition", "O", "B-Condition", "O", "O", "B-Condition", "O", "B-Mood", "I-Mood", "B-Condition", "I-Condition", "I-Condition", "O", "B-Qualifier", "I-Qualifier", "B-Condition", "I-Condition", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Qualifier", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Condition", "I-Condition", "B-Qualifier", "I-Qualifier", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "B-Value", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "O", "O", "B-Condition", "I-Condition", "B-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "B-Procedure", "I-Procedure", "I-Procedure", "O", "O", "B-Observation", "O", "B-Scope", "I-Scope", "I-Scope", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "O", "O", "B-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "B-Drug", "I-Drug", "I-Drug", "I-Drug", "I-Drug", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Drug", "I-Drug", "I-Drug", "I-Drug", "O", "B-Drug", "I-Drug", "I-Drug", "I-Drug", "O", "B-Drug", "I-Drug", "O", "B-Drug", "O", "B-Drug", "O", "B-Drug", "I-Drug", "I-Drug", "I-Drug", "I-Drug", "O", "B-Drug", "O", "B-Drug", "O", "B-Drug", "O", "B-Qualifier", "I-Qualifier", "O", "O", "O", "O", "O", "O", "O", "O", "B-Drug", "O", "B-Drug", "O", "B-Drug", "O", "O", "B-Drug", "I-Drug", "O", "B-Drug", "I-Drug", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Drug", "I-Drug", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Negation", "O", "O", "B-Drug", "I-Drug", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Drug", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Negation", "I-Negation", "B-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Condition", "I-Condition", "I-Condition", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Condition", "I-Condition", "I-Condition", "O", "B-Condition", "O", "O", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "O", "O", "O", "O", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Condition", "O", "B-Drug", "I-Drug", "B-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "O", "B-Qualifier", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Observation", "I-Observation", "I-Observation", "O", "B-Value", "I-Value", "I-Value", "I-Value", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "O", "O", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Observation", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Observation", "I-Observation", "I-Observation", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "O", "O", "O", "O", "B-Qualifier", "B-Condition", "I-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "O", "O", "B-Condition", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Observation", "I-Observation", "I-Observation", "I-Observation", "I-Observation", "O", "O", "O", "B-Observation", "I-Observation", "I-Observation", "O", "O", "B-Observation", "I-Observation", "I-Observation", "I-Observation", "O", "O", "O", "O", "O", "O", "O", "B-Observation", "I-Observation", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Temporal", "B-Condition", "O", "B-Qualifier", "O", "O", "O", "O", "O", "O", "B-Drug", "O", "O", "B-Condition", "I-Condition", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "B-Measurement", "I-Measurement", "O", "O", "B-Value", "I-Value", "I-Value", "I-Value", "B-Qualifier", "I-Qualifier", "O", "O", "O", "O", "O", "O", "B-Multiplier", "I-Multiplier", "I-Multiplier", "O", "O", "B-Qualifier", "I-Qualifier", "I-Qualifier", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Temporal", "O", "O", "B-Qualifier", "O", "O", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Mood", "B-Procedure", "I-Procedure", "B-Temporal", "I-Temporal", "I-Temporal", "O", "B-Temporal", "B-Procedure", "I-Procedure", "I-Procedure", "O", "O", "O", "O", "O", "O", "B-Reference_point", "I-Reference_point", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Person", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Condition", "I-Condition", "I-Condition", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "B-Observation", "I-Observation", "I-Observation", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "B-Temporal", "B-Condition", "O", "B-Observation", "I-Observation", "I-Observation", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Drug", "I-Drug", "O", "O", "O", "B-Negation", "O", "O", "B-Qualifier", "I-Qualifier", "O", "O", "O", "B-Drug", "I-Drug", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "B-Observation", "I-Observation", "I-Observation", "O", "O", "B-Qualifier", "I-Qualifier", "B-Drug", "B-Temporal", "I-Temporal", "I-Temporal", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Clinically significant new illness within 1 month before randomization that may affect the participant's ability to fulfill the study requirements or significantly confound the assessments Participants who cannot swallow investigational products Participants with T2DM who have hypoglycemia unawareness Aortic regurgitation mild or greater Mitral regurgitation moderate or greater Mitral or aortic valve stenosis greater than mild (ie, aortic stenosis: jet >3.0 meters per second [m/s], mean gradient >25 millimeters of mercury [mmHg], and aortic valve area <1.5 centimeters squared [cm^2]; mitral stenosis: mean gradient >5 mmHg and mitral valve area <1.5 cm^2) Systolic pulmonary artery pressure (SPAP) >40 mmHg (and/or tricuspid regurgitation [TR] jet velocity >2.9 m/s) In cases where an actual SPAP value is not measurable due to lack of adequate TR jet, the pulmonary flow acceleration time measured at the right ventricular outflow tract (RVOTAT) will be used to assess eligibility. Participants with a RVOTAT =100 milliseconds (msec) will be excluded, suggesting an elevated mean SPAP; eligibility for the those participants with RVOTAT between 100 and 120 msec will be determined based on combined assessment of the TR jet, septal motion, and right ventricular size. Left ventricular ejection fraction <45% Intracardiac mass, tumor, or thrombus Evidence of congenital heart disease Clinically significant pericardial effusion (eg, moderate or larger or with hemodynamic compromise) Significant renal or hepatic disease as evidenced by a serum creatinine greater than 1.5× upper limit of normal (ULN), serum transaminases greater than 3× ULN, or total bilirubin greater than 1.5× ULN in absence of Gilbert's syndrome Any suicidal ideation with intent with or without a plan, at the time of or within 6 months of Screening, as indicated by answering "Yes" to questions 4 or 5 on the Suicidal Ideation section of the Columbia-Suicide Severity Rating Scale (C-SSRS) Any suicidal behavior in the past based on the C-SSRS Any history of anorexia or bulimia within 2 years before Screening, Attention Deficit Hyperactivity Disorder, any Diagnostic and Statistical Manual of Mental Disorders, 5th Edition depressive disorder, bipolar disorder, or schizophrenia Known secondary causes (genetic, endocrine, or metabolic) for obesity (eg, Prader-Willi syndrome, Bardet Biedl syndrome, Down's Syndrome, untreated hypothyroidism, Cushing's syndrome, daily systemic corticosteroid exposure for longer than 30 days, history of significant exposure to corticosteroids for chronic illness during the past year; inhaled steroids will be allowed) Use of other products intended for weight loss including prescription drugs, over-the-counter (OTC) drugs, and herbal preparations within 1 month before Screening selective serotonin reuptake inhibitors serotonin norepinephrine reuptake inhibitors tricyclic antidepressants bupropion triptans St. John's Wort tryptophan linezolid dextromethorphan in any form (eg, OTC cold medicines) lithium tramadol antipsychotics or other dopamine antagonists antiseizure medications including valproic acid, zonisamide, topiramate, and lamotrigine oral steroids (topical and inhaled steroids are acceptable) stimulant medications (eg, Ritalin, Concerta, Biphetamine, and Dexedrine) benzodiazepines Use of drugs known to increase the risk for cardiac valvulopathy within 6 months before Screening, including but not limited to pergolide, ergotamine, methysergide, and cabergoline History or evidence of clinically significant disease (eg, malignancy; cardiac, respiratory, gastrointestinal, renal, or psychiatric disease) other than prediabetes (impaired fasting glucose or impaired glucose tolerance), type 2 diabetes treated with oral anti-diabetic agents (excluding sulfonylurea) or non-insulin injectable antidiabetic agents, obstructive sleep apnea, dyslipidemia, and nonalcoholic fatty liver disease Use of Belviq XR within 6 months before Screening or hypersensitivity to Belviq XR or any of the excipients Significant change in diet or level of physical activity within 1 month before dosing or change in weight of more than 5 kg within 3 months before Screening Any use of a very-low-calorie (<1000 calories/day) weight loss diet within 6 months before Screening History of alcohol or drug dependence or abuse Recreational drug use within 2 years before Screening Known to be human immunodeficiency virus positive Known to have active viral hepatitis (B or C) Malignancy within 5 years before Screening Unable to attend scheduled visits (eg, lack of transportation) or lack of a caregiver or guardian to supervise study participation Special needs participants who are unable to comprehend study-related instructions (eg, mild to profound mental retardation [intelligence quotient <70], moderate to severe cognitive developmental delay, pervasive development disorders, autism) Ongoing epilepsy or other seizure disorder, or use of medications for a seizure disorder within 6 months of screening or any time between screening and randomization Participants with a blood pressure in the 95th percentile or greater for age, sex, and height on 2 separate readings recorded on 2 separate days. Those participants who had uncontrolled hypertension at Screening can be rescreened more than 1 month after initiation or adjustment of antihypertensive therapy 1 time. Currently enrolled in another clinical study or has used any investigational drug or device within 30 days before providing informed consent Planned bariatric surgery during the study or prior bariatric surgical procedures Not suitable to participate in the study in the opinion of the investigator, including consideration of any existing physical, medical, or mental condition that prevents compliance with the protocol Female participants who are breastfeeding or pregnant at Screening or Baseline (as documented by a positive beta-human chorionic gonadotropin test). A separate Baseline assessment is required if a negative screening pregnancy test was obtained more than 72 hours before the first dose of study drug. Had unprotected sexual intercourse within 30 days before study entry and who do not agree to use a highly effective method of contraception (eg, total abstinence, an intrauterine device, a double-barrier method [such as condom plus diaphragm with spermicide], a contraceptive implant, an oral contraceptive, or have a vasectomized partner with confirmed azoospermia) throughout the entire study period and for 28 days after study drug discontinuation Are currently abstinent and do not agree to use a double-barrier method (as described above) or refrain from sexual activity during the study period and for 28 days after study drug discontinuation Are using hormonal contraceptives, but are not on a stable dose of the same hormonal contraceptive product for at least 4 weeks before dosing and who do not agree to use the same contraceptive during the study and for 28 days after study drug discontinuation (Note: All female participants will be considered to be of childbearing potential unless they have been sterilized surgically [ie, bilateral tubal ligation, total hysterectomy, or bilateral oophorectomy, all with surgery at least 1 month before dosing]).

[ "Clinically", "significant", "new", "illness", "within", "1", "month", "before", "randomization", "that", "may", "affect", "the", "participant", "'s", "ability", "to", "fulfill", "the", "study", "requirements", "or", "significantly", "confound", "the", "assessments", "\n", "Participants", "who", "cannot", "swallow", "investigational", "products", "\n", "Participants", "with", "T2DM", "who", "have", "hypoglycemia", "unawareness", "\n", "Aortic", "regurgitation", "mild", "or", "greater", "\n", "Mitral", "regurgitation", "moderate", "or", "greater", "\n", "Mitral", "or", "aortic", "valve", "stenosis", "greater", "than", "mild", "(", "ie", ",", "aortic", "stenosis", ":", "jet", ">", "3.0", "meters", "per", "second", "[", "m", "/", "s", "]", ",", "mean", "gradient", ">", "25", "millimeters", "of", "mercury", "[", "mmHg", "]", ",", "and", "aortic", "valve", "area", "<", "1.5", "centimeters", "squared", "[", "cm^2", "]", ";", "mitral", "stenosis", ":", "mean", "gradient", ">", "5", "mmHg", "and", "mitral", "valve", "area", "<", "1.5", "cm^2", ")", "\n", "Systolic", "pulmonary", "artery", "pressure", "(", "SPAP", ")", ">", "40", "mmHg", "(", "and", "/", "or", "tricuspid", "regurgitation", "[", "TR", "]", "jet", "velocity", ">", "2.9", "m", "/", "s", ")", "In", "cases", "where", "an", "actual", "SPAP", "value", "is", "not", "measurable", "due", "to", "lack", "of", "adequate", "TR", "jet", ",", "the", "pulmonary", "flow", "acceleration", "time", "measured", "at", "the", "right", "ventricular", "outflow", "tract", "(", "RVOTAT", ")", "will", "be", "used", "to", "assess", "eligibility", ".", "Participants", "with", "a", "RVOTAT", "=", "100", "milliseconds", "(", "msec", ")", "will", "be", "excluded", ",", "suggesting", "an", "elevated", "mean", "SPAP", ";", "eligibility", "for", "the", "those", "participants", "with", "RVOTAT", "between", "100", "and", "120", "msec", "will", "be", "determined", "based", "on", "combined", "assessment", "of", "the", "TR", "jet", ",", "septal", "motion", ",", "and", "right", "ventricular", "size", ".", "\n", "Left", "ventricular", "ejection", "fraction", "<", "45", "%", "\n", "Intracardiac", "mass", ",", "tumor", ",", "or", "thrombus", "\n", "Evidence", "of", "congenital", "heart", "disease", "\n", "Clinically", "significant", "pericardial", "effusion", "(", "eg", ",", "moderate", "or", "larger", "or", "with", "hemodynamic", "compromise", ")", "\n", "Significant", "renal", "or", "hepatic", "disease", "as", "evidenced", "by", "a", "serum", "creatinine", "greater", "than", "1.5×", "upper", "limit", "of", "normal", "(", "ULN", ")", ",", "serum", "transaminases", "greater", "than", "3×", "ULN", ",", "or", "total", "bilirubin", "greater", "than", "1.5×", "ULN", "in", "absence", "of", "Gilbert", "'s", "syndrome", "\n", "Any", "suicidal", "ideation", "with", "intent", "with", "or", "without", "a", "plan", ",", "at", "the", "time", "of", "or", "within", "6", "months", "of", "Screening", ",", "as", "indicated", "by", "answering", "\"", "Yes", "\"", "to", "questions", "4", "or", "5", "on", "the", "Suicidal", "Ideation", "section", "of", "the", "Columbia", "-", "Suicide", "Severity", "Rating", "Scale", "(", "C", "-", "SSRS", ")", "\n", "Any", "suicidal", "behavior", "in", "the", "past", "based", "on", "the", "C", "-", "SSRS", "\n", "Any", "history", "of", "anorexia", "or", "bulimia", "within", "2", "years", "before", "Screening", ",", "Attention", "Deficit", "Hyperactivity", "Disorder", ",", "any", "Diagnostic", "and", "Statistical", "Manual", "of", "Mental", "Disorders", ",", "5th", "Edition", "depressive", "disorder", ",", "bipolar", "disorder", ",", "or", "schizophrenia", "\n", "Known", "secondary", "causes", "(", "genetic", ",", "endocrine", ",", "or", "metabolic", ")", "for", "obesity", "(", "eg", ",", "Prader", "-", "Willi", "syndrome", ",", "Bardet", "Biedl", "syndrome", ",", "Down", "'s", "Syndrome", ",", "untreated", "hypothyroidism", ",", "Cushing", "'s", "syndrome", ",", "daily", "systemic", "corticosteroid", "exposure", "for", "longer", "than", "30", "days", ",", "history", "of", "significant", "exposure", "to", "corticosteroids", "for", "chronic", "illness", "during", "the", "past", "year", ";", "inhaled", "steroids", "will", "be", "allowed", ")", "\n", "Use", "of", "other", "products", "intended", "for", "weight", "loss", "including", "prescription", "drugs", ",", "over", "-", "the", "-", "counter", "(", "OTC", ")", "drugs", ",", "and", "herbal", "preparations", "within", "1", "month", "before", "Screening", "\n", "selective", "serotonin", "reuptake", "inhibitors", "\n", "serotonin", "norepinephrine", "reuptake", "inhibitors", "\n", "tricyclic", "antidepressants", "\n", "bupropion", "\n", "triptans", "\n", "St", ".", "John", "'s", "Wort", "\n", "tryptophan", "\n", "linezolid", "\n", "dextromethorphan", "in", "any", "form", "(", "eg", ",", "OTC", "cold", "medicines", ")", "\n", "lithium", "\n", "tramadol", "\n", "antipsychotics", "or", "other", "dopamine", "antagonists", "\t\n", "antiseizure", "medications", "including", "valproic", "acid", ",", "zonisamide", ",", "topiramate", ",", "and", "lamotrigine", "\n", "oral", "steroids", "(", "topical", "and", "inhaled", "steroids", "are", "acceptable", ")", "\n", "stimulant", "medications", "(", "eg", ",", "Ritalin", ",", "Concerta", ",", "Biphetamine", ",", "and", "Dexedrine", ")", "\n", "benzodiazepines", "\n", "Use", "of", "drugs", "known", "to", "increase", "the", "risk", "for", "cardiac", "valvulopathy", "within", "6", "months", "before", "Screening", ",", "including", "but", "not", "limited", "to", "pergolide", ",", "ergotamine", ",", "methysergide", ",", "and", "cabergoline", "\n", "History", "or", "evidence", "of", "clinically", "significant", "disease", "(", "eg", ",", "malignancy", ";", "cardiac", ",", "respiratory", ",", "gastrointestinal", ",", "renal", ",", "or", "psychiatric", "disease", ")", "other", "than", "prediabetes", "(", "impaired", "fasting", "glucose", "or", "impaired", "glucose", "tolerance", ")", ",", "type", "2", "diabetes", "treated", "with", "oral", "anti", "-", "diabetic", "agents", "(", "excluding", "sulfonylurea", ")", "or", "non", "-", "insulin", "injectable", "antidiabetic", "agents", ",", "obstructive", "sleep", "apnea", ",", "dyslipidemia", ",", "and", "nonalcoholic", "fatty", "liver", "disease", "\n", "Use", "of", "Belviq", "XR", "within", "6", "months", "before", "Screening", "or", "hypersensitivity", "to", "Belviq", "XR", "or", "any", "of", "the", "excipients", "\n", "Significant", "change", "in", "diet", "or", "level", "of", "physical", "activity", "within", "1", "month", "before", "dosing", "or", "change", "in", "weight", "of", "more", "than", "5", "kg", "within", "3", "months", "before", "Screening", "\n", "Any", "use", "of", "a", "very", "-", "low", "-", "calorie", "(", "<", "1000", "calories", "/", "day", ")", "weight", "loss", "diet", "within", "6", "months", "before", "Screening", "\n", "History", "of", "alcohol", "or", "drug", "dependence", "or", "abuse", "\n", "Recreational", "drug", "use", "within", "2", "years", "before", "Screening", "\n", "Known", "to", "be", "human", "immunodeficiency", "virus", "positive", "\n", "Known", "to", "have", "active", "viral", "hepatitis", "(", "B", "or", "C", ")", "\n", "Malignancy", "within", "5", "years", "before", "Screening", "\n", "Unable", "to", "attend", "scheduled", "visits", "(", "eg", ",", "lack", "of", "transportation", ")", "or", "lack", "of", "a", "caregiver", "or", "guardian", "to", "supervise", "study", "participation", "\n", "Special", "needs", "participants", "who", "are", "unable", "to", "comprehend", "study", "-", "related", "instructions", "(", "eg", ",", "mild", "to", "profound", "mental", "retardation", "[", "intelligence", "quotient", "<", "70", "]", ",", "moderate", "to", "severe", "cognitive", "developmental", "delay", ",", "pervasive", "development", "disorders", ",", "autism", ")", "\n", "Ongoing", "epilepsy", "or", "other", "seizure", "disorder", ",", "or", "use", "of", "medications", "for", "a", "seizure", "disorder", "within", "6", "months", "of", "screening", "or", "any", "time", "between", "screening", "and", "randomization", "\n", "Participants", "with", "a", "blood", "pressure", "in", "the", "95th", "percentile", "or", "greater", "for", "age", ",", "sex", ",", "and", "height", "on", "2", "separate", "readings", "recorded", "on", "2", "separate", "days", ".", "Those", "participants", "who", "had", "uncontrolled", "hypertension", "at", "Screening", "can", "be", "rescreened", "more", "than", "1", "month", "after", "initiation", "or", "adjustment", "of", "antihypertensive", "therapy", "1", "time", ".", "\n", "Currently", "enrolled", "in", "another", "clinical", "study", "or", "has", "used", "any", "investigational", "drug", "or", "device", "within", "30", "days", "before", "providing", "informed", "consent", "\n", "Planned", "bariatric", "surgery", "during", "the", "study", "or", "prior", "bariatric", "surgical", "procedures", "\n", "Not", "suitable", "to", "participate", "in", "the", "study", "in", "the", "opinion", "of", "the", "investigator", ",", "including", "consideration", "of", "any", "existing", "physical", ",", "medical", ",", "or", "mental", "condition", "that", "prevents", "compliance", "with", "the", "protocol", "\n", "Female", "participants", "who", "are", "breastfeeding", "or", "pregnant", "at", "Screening", "or", "Baseline", "(", "as", "documented", "by", "a", "positive", "beta", "-", "human", "chorionic", "gonadotropin", "test", ")", ".", "A", "separate", "Baseline", "assessment", "is", "required", "if", "a", "negative", "screening", "pregnancy", "test", "was", "obtained", "more", "than", "72", "hours", "before", "the", "first", "dose", "of", "study", "drug", ".", "\n", "Had", "unprotected", "sexual", "intercourse", "within", "30", "days", "before", "study", "entry", "and", "who", "do", "not", "agree", "to", "use", "a", "highly", "effective", "method", "of", "contraception", "(", "eg", ",", "total", "abstinence", ",", "an", "intrauterine", "device", ",", "a", "double", "-", "barrier", "method", "[", "such", "as", "condom", "plus", "diaphragm", "with", "spermicide", "]", ",", "a", "contraceptive", "implant", ",", "an", "oral", "contraceptive", ",", "or", "have", "a", "vasectomized", "partner", "with", "confirmed", "azoospermia", ")", "throughout", "the", "entire", "study", "period", "and", "for", "28", "days", "after", "study", "drug", "discontinuation", "\n", "Are", "currently", "abstinent", "and", "do", "not", "agree", "to", "use", "a", "double", "-", "barrier", "method", "(", "as", "described", "above", ")", "or", "refrain", "from", "sexual", "activity", "during", "the", "study", "period", "and", "for", "28", "days", "after", "study", "drug", "discontinuation", "\n", "Are", "using", "hormonal", "contraceptives", ",", "but", "are", "not", "on", "a", "stable", "dose", "of", "the", "same", "hormonal", "contraceptive", "product", "for", "at", "least", "4", "weeks", "before", "dosing", "and", "who", "do", "not", "agree", "to", "use", "the", "same", "contraceptive", "during", "the", "study", "and", "for", "28", "days", "after", "study", "drug", "discontinuation", "(", "Note", ":", "All", "female", "participants", "will", "be", "considered", "to", "be", "of", "childbearing", "potential", "unless", "they", "have", "been", "sterilized", "surgically", "[", "ie", ",", "bilateral", "tubal", "ligation", ",", "total", "hysterectomy", ",", "or", "bilateral", "oophorectomy", ",", "all", "with", "surgery", "at", "least", "1", "month", "before", "dosing", "]", ")", ".", "\n" ]

[ "Scope", "Procedure", "Observation", "Qualifier", "Temporal", "Value", "Drug", "Measurement", "Condition", "Reference_point", "Device", "Multiplier", "Mood", "Negation", "Person" ]

Ca2 + is a CHEMICAL

20566645_task0

Sentence: Predicting cardiomyopathic phenotypes by altering Ca2+ affinity of cardiac troponin C. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: CHEMICAL

[ "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O" ]

Predicting cardiomyopathic phenotypes by altering Ca2+ affinity of cardiac troponin C.

[ "Predicting", "cardiomyopathic", "phenotypes", "by", "altering", "Ca2", "+", "affinity", "of", "cardiac", "troponin", "C." ]

[ "GENE-Y", "GENE-N", "CHEMICAL" ]

Ca2 + is a CHEMICAL

20566645_task1

Sentence: Predicting cardiomyopathic phenotypes by altering Ca2+ affinity of cardiac troponin C. Instructions: please typing these entity words according to sentence: Ca2 + Options: CHEMICAL

[ "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O" ]

Predicting cardiomyopathic phenotypes by altering Ca2+ affinity of cardiac troponin C.

[ "Predicting", "cardiomyopathic", "phenotypes", "by", "altering", "Ca2", "+", "affinity", "of", "cardiac", "troponin", "C." ]

[ "GENE-Y", "GENE-N", "CHEMICAL" ]

Ca2 +

20566645_task2

Sentence: Predicting cardiomyopathic phenotypes by altering Ca2+ affinity of cardiac troponin C. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O" ]

Predicting cardiomyopathic phenotypes by altering Ca2+ affinity of cardiac troponin C.

[ "Predicting", "cardiomyopathic", "phenotypes", "by", "altering", "Ca2", "+", "affinity", "of", "cardiac", "troponin", "C." ]

[ "GENE-Y", "GENE-N", "CHEMICAL" ]

placebo - controlled is a Intervention_Control, melatonin treatment is a Intervention_Pharmacological, delayed sleep phase syndrome is a Participant_Condition, impaired sleep maintenance is a Outcome_Physical, children is a Participant_Age, neurodevelopmental disabilities is a Participant_Condition, efficacy is a Outcome_Other, autistic spectrum disorders is a Participant_Condition, CR melatonin is a Intervention_Pharmacological, Sleep characteristics is a Outcome_Physical, Clinician rating is a Outcome_Other, caregiver ratings is a Outcome_Other, Fifty - one is a Participant_Sample-size, children ( age range 2 - 18 years ) is a Participant_Age, total night - time sleep is a Outcome_Physical, sleep latency is a Outcome_Physical, clinician and parent ratings . is a Outcome_Other, open - label somnolog measures is a Outcome_Physical, sleep efficiency is a Outcome_Physical, the longest sleep episode is a Outcome_Physical, improved the sleep is a Outcome_Physical, effective in reducing family stress is a Outcome_Mental, Children is a Participant_Age, treatment resistant chronic delayed sleep phase syndrome is a Outcome_Physical, melatonin therapy . is a Intervention_Pharmacological

33945_task0

Sentence: A randomized , placebo-controlled trial of controlled release melatonin treatment of delayed sleep phase syndrome and impaired sleep maintenance in children with neurodevelopmental disabilities . The purpose of this study was to determine the efficacy of controlled-release ( CR ) melatonin in the treatment of delayed sleep phase syndrome and impaired sleep maintenance of children with neurodevelopmental disabilities including autistic spectrum disorders . A randomized double-blind , placebo-controlled crossover trial of CR melatonin ( 5 mg ) followed by a 3-month open-label study was conducted during which the dose was gradually increased until the therapy showed optimal beneficial effects . Sleep characteristics were measured by caregiver who completed somnologs and wrist actigraphs . Clinician rating of severity of the sleep disorder and improvement from baseline , along with caregiver ratings of global functioning and family stress were also obtained . Fifty-one children ( age range 2-18 years ) who did not respond to sleep hygiene intervention were enrolled . Fifty patients completed the crossover trial and 47 completed the open-label phase . Recordings of total night-time sleep and sleep latency showed significant improvement of approximately 30 min . Similarly , significant improvement was observed in clinician and parent ratings . There was additional improvement in the open-label somnolog measures of sleep efficiency and the longest sleep episode in the open-label phase . Overall , the therapy improved the sleep of 47 children and was effective in reducing family stress . Children with neurodevelopmental disabilities , who had treatment resistant chronic delayed sleep phase syndrome and impaired sleep maintenance , showed improvement in melatonin therapy . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Participant_Condition, Intervention_Control, Participant_Age, Outcome_Physical, Participant_Sample-size, Outcome_Other, Outcome_Mental

[ "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Participant_Age", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "B-Participant_Age", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological" ]

A randomized , placebo-controlled trial of controlled release melatonin treatment of delayed sleep phase syndrome and impaired sleep maintenance in children with neurodevelopmental disabilities . The purpose of this study was to determine the efficacy of controlled-release ( CR ) melatonin in the treatment of delayed sleep phase syndrome and impaired sleep maintenance of children with neurodevelopmental disabilities including autistic spectrum disorders . A randomized double-blind , placebo-controlled crossover trial of CR melatonin ( 5 mg ) followed by a 3-month open-label study was conducted during which the dose was gradually increased until the therapy showed optimal beneficial effects . Sleep characteristics were measured by caregiver who completed somnologs and wrist actigraphs . Clinician rating of severity of the sleep disorder and improvement from baseline , along with caregiver ratings of global functioning and family stress were also obtained . Fifty-one children ( age range 2-18 years ) who did not respond to sleep hygiene intervention were enrolled . Fifty patients completed the crossover trial and 47 completed the open-label phase . Recordings of total night-time sleep and sleep latency showed significant improvement of approximately 30 min . Similarly , significant improvement was observed in clinician and parent ratings . There was additional improvement in the open-label somnolog measures of sleep efficiency and the longest sleep episode in the open-label phase . Overall , the therapy improved the sleep of 47 children and was effective in reducing family stress . Children with neurodevelopmental disabilities , who had treatment resistant chronic delayed sleep phase syndrome and impaired sleep maintenance , showed improvement in melatonin therapy .

[ "A", "randomized", ",", "placebo", "-", "controlled", "trial", "of", "controlled", "release", "melatonin", "treatment", "of", "delayed", "sleep", "phase", "syndrome", "and", "impaired", "sleep", "maintenance", "in", "children", "with", "neurodevelopmental", "disabilities", ".", "The", "purpose", "of", "this", "study", "was", "to", "determine", "the", "efficacy", "of", "controlled", "-", "release", "(", "CR", ")", "melatonin", "in", "the", "treatment", "of", "delayed", "sleep", "phase", "syndrome", "and", "impaired", "sleep", "maintenance", "of", "children", "with", "neurodevelopmental", "disabilities", "including", "autistic", "spectrum", "disorders", ".", "A", "randomized", "double", "-", "blind", ",", "placebo", "-", "controlled", "crossover", "trial", "of", "CR", "melatonin", "(", "5", "mg", ")", "followed", "by", "a", "3-month", "open", "-", "label", "study", "was", "conducted", "during", "which", "the", "dose", "was", "gradually", "increased", "until", "the", "therapy", "showed", "optimal", "beneficial", "effects", ".", "Sleep", "characteristics", "were", "measured", "by", "caregiver", "who", "completed", "somnologs", "and", "wrist", "actigraphs", ".", "Clinician", "rating", "of", "severity", "of", "the", "sleep", "disorder", "and", "improvement", "from", "baseline", ",", "along", "with", "caregiver", "ratings", "of", "global", "functioning", "and", "family", "stress", "were", "also", "obtained", ".", "Fifty", "-", "one", "children", "(", "age", "range", "2", "-", "18", "years", ")", "who", "did", "not", "respond", "to", "sleep", "hygiene", "intervention", "were", "enrolled", ".", "Fifty", "patients", "completed", "the", "crossover", "trial", "and", "47", "completed", "the", "open", "-", "label", "phase", ".", "Recordings", "of", "total", "night", "-", "time", "sleep", "and", "sleep", "latency", "showed", "significant", "improvement", "of", "approximately", "30", "min", ".", "Similarly", ",", "significant", "improvement", "was", "observed", "in", "clinician", "and", "parent", "ratings", ".", "There", "was", "additional", "improvement", "in", "the", "open", "-", "label", "somnolog", "measures", "of", "sleep", "efficiency", "and", "the", "longest", "sleep", "episode", "in", "the", "open", "-", "label", "phase", ".", "Overall", ",", "the", "therapy", "improved", "the", "sleep", "of", "47", "children", "and", "was", "effective", "in", "reducing", "family", "stress", ".", "Children", "with", "neurodevelopmental", "disabilities", ",", "who", "had", "treatment", "resistant", "chronic", "delayed", "sleep", "phase", "syndrome", "and", "impaired", "sleep", "maintenance", ",", "showed", "improvement", "in", "melatonin", "therapy", "." ]

[ "Outcome_Physical", "Participant_Condition", "Outcome_Mental", "Participant_Age", "Outcome_Other", "Intervention_Pharmacological", "Intervention_Control", "Participant_Sample-size" ]

placebo - controlled is a Intervention_Control, melatonin treatment is a Intervention_Pharmacological, delayed sleep phase syndrome is a Participant_Condition, impaired sleep maintenance is a Outcome_Physical, children is a Participant_Age, neurodevelopmental disabilities is a Participant_Condition, efficacy is a Outcome_Other, autistic spectrum disorders is a Participant_Condition, CR melatonin is a Intervention_Pharmacological, Sleep characteristics is a Outcome_Physical, Clinician rating is a Outcome_Other, caregiver ratings is a Outcome_Other, Fifty - one is a Participant_Sample-size, children ( age range 2 - 18 years ) is a Participant_Age, total night - time sleep is a Outcome_Physical, sleep latency is a Outcome_Physical, clinician and parent ratings . is a Outcome_Other, open - label somnolog measures is a Outcome_Physical, sleep efficiency is a Outcome_Physical, the longest sleep episode is a Outcome_Physical, improved the sleep is a Outcome_Physical, effective in reducing family stress is a Outcome_Mental, Children is a Participant_Age, treatment resistant chronic delayed sleep phase syndrome is a Outcome_Physical, melatonin therapy . is a Intervention_Pharmacological

33945_task1

Sentence: A randomized , placebo-controlled trial of controlled release melatonin treatment of delayed sleep phase syndrome and impaired sleep maintenance in children with neurodevelopmental disabilities . The purpose of this study was to determine the efficacy of controlled-release ( CR ) melatonin in the treatment of delayed sleep phase syndrome and impaired sleep maintenance of children with neurodevelopmental disabilities including autistic spectrum disorders . A randomized double-blind , placebo-controlled crossover trial of CR melatonin ( 5 mg ) followed by a 3-month open-label study was conducted during which the dose was gradually increased until the therapy showed optimal beneficial effects . Sleep characteristics were measured by caregiver who completed somnologs and wrist actigraphs . Clinician rating of severity of the sleep disorder and improvement from baseline , along with caregiver ratings of global functioning and family stress were also obtained . Fifty-one children ( age range 2-18 years ) who did not respond to sleep hygiene intervention were enrolled . Fifty patients completed the crossover trial and 47 completed the open-label phase . Recordings of total night-time sleep and sleep latency showed significant improvement of approximately 30 min . Similarly , significant improvement was observed in clinician and parent ratings . There was additional improvement in the open-label somnolog measures of sleep efficiency and the longest sleep episode in the open-label phase . Overall , the therapy improved the sleep of 47 children and was effective in reducing family stress . Children with neurodevelopmental disabilities , who had treatment resistant chronic delayed sleep phase syndrome and impaired sleep maintenance , showed improvement in melatonin therapy . Instructions: please typing these entity words according to sentence: placebo - controlled, melatonin treatment, delayed sleep phase syndrome, impaired sleep maintenance, children, neurodevelopmental disabilities, efficacy, autistic spectrum disorders, CR melatonin, Sleep characteristics, Clinician rating, caregiver ratings, Fifty - one, children ( age range 2 - 18 years ), total night - time sleep, sleep latency, clinician and parent ratings ., open - label somnolog measures, sleep efficiency, the longest sleep episode, improved the sleep, effective in reducing family stress, Children, treatment resistant chronic delayed sleep phase syndrome, melatonin therapy . Options: Intervention_Pharmacological, Participant_Condition, Intervention_Control, Participant_Age, Outcome_Physical, Participant_Sample-size, Outcome_Other, Outcome_Mental

[ "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Participant_Age", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "B-Participant_Age", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological" ]

A randomized , placebo-controlled trial of controlled release melatonin treatment of delayed sleep phase syndrome and impaired sleep maintenance in children with neurodevelopmental disabilities . The purpose of this study was to determine the efficacy of controlled-release ( CR ) melatonin in the treatment of delayed sleep phase syndrome and impaired sleep maintenance of children with neurodevelopmental disabilities including autistic spectrum disorders . A randomized double-blind , placebo-controlled crossover trial of CR melatonin ( 5 mg ) followed by a 3-month open-label study was conducted during which the dose was gradually increased until the therapy showed optimal beneficial effects . Sleep characteristics were measured by caregiver who completed somnologs and wrist actigraphs . Clinician rating of severity of the sleep disorder and improvement from baseline , along with caregiver ratings of global functioning and family stress were also obtained . Fifty-one children ( age range 2-18 years ) who did not respond to sleep hygiene intervention were enrolled . Fifty patients completed the crossover trial and 47 completed the open-label phase . Recordings of total night-time sleep and sleep latency showed significant improvement of approximately 30 min . Similarly , significant improvement was observed in clinician and parent ratings . There was additional improvement in the open-label somnolog measures of sleep efficiency and the longest sleep episode in the open-label phase . Overall , the therapy improved the sleep of 47 children and was effective in reducing family stress . Children with neurodevelopmental disabilities , who had treatment resistant chronic delayed sleep phase syndrome and impaired sleep maintenance , showed improvement in melatonin therapy .

[ "A", "randomized", ",", "placebo", "-", "controlled", "trial", "of", "controlled", "release", "melatonin", "treatment", "of", "delayed", "sleep", "phase", "syndrome", "and", "impaired", "sleep", "maintenance", "in", "children", "with", "neurodevelopmental", "disabilities", ".", "The", "purpose", "of", "this", "study", "was", "to", "determine", "the", "efficacy", "of", "controlled", "-", "release", "(", "CR", ")", "melatonin", "in", "the", "treatment", "of", "delayed", "sleep", "phase", "syndrome", "and", "impaired", "sleep", "maintenance", "of", "children", "with", "neurodevelopmental", "disabilities", "including", "autistic", "spectrum", "disorders", ".", "A", "randomized", "double", "-", "blind", ",", "placebo", "-", "controlled", "crossover", "trial", "of", "CR", "melatonin", "(", "5", "mg", ")", "followed", "by", "a", "3-month", "open", "-", "label", "study", "was", "conducted", "during", "which", "the", "dose", "was", "gradually", "increased", "until", "the", "therapy", "showed", "optimal", "beneficial", "effects", ".", "Sleep", "characteristics", "were", "measured", "by", "caregiver", "who", "completed", "somnologs", "and", "wrist", "actigraphs", ".", "Clinician", "rating", "of", "severity", "of", "the", "sleep", "disorder", "and", "improvement", "from", "baseline", ",", "along", "with", "caregiver", "ratings", "of", "global", "functioning", "and", "family", "stress", "were", "also", "obtained", ".", "Fifty", "-", "one", "children", "(", "age", "range", "2", "-", "18", "years", ")", "who", "did", "not", "respond", "to", "sleep", "hygiene", "intervention", "were", "enrolled", ".", "Fifty", "patients", "completed", "the", "crossover", "trial", "and", "47", "completed", "the", "open", "-", "label", "phase", ".", "Recordings", "of", "total", "night", "-", "time", "sleep", "and", "sleep", "latency", "showed", "significant", "improvement", "of", "approximately", "30", "min", ".", "Similarly", ",", "significant", "improvement", "was", "observed", "in", "clinician", "and", "parent", "ratings", ".", "There", "was", "additional", "improvement", "in", "the", "open", "-", "label", "somnolog", "measures", "of", "sleep", "efficiency", "and", "the", "longest", "sleep", "episode", "in", "the", "open", "-", "label", "phase", ".", "Overall", ",", "the", "therapy", "improved", "the", "sleep", "of", "47", "children", "and", "was", "effective", "in", "reducing", "family", "stress", ".", "Children", "with", "neurodevelopmental", "disabilities", ",", "who", "had", "treatment", "resistant", "chronic", "delayed", "sleep", "phase", "syndrome", "and", "impaired", "sleep", "maintenance", ",", "showed", "improvement", "in", "melatonin", "therapy", "." ]

[ "Outcome_Physical", "Participant_Condition", "Outcome_Mental", "Participant_Age", "Outcome_Other", "Intervention_Pharmacological", "Intervention_Control", "Participant_Sample-size" ]

placebo - controlled, melatonin treatment, delayed sleep phase syndrome, impaired sleep maintenance, children, neurodevelopmental disabilities, efficacy, autistic spectrum disorders, CR melatonin, Sleep characteristics, Clinician rating, caregiver ratings, Fifty - one, children ( age range 2 - 18 years ), total night - time sleep, sleep latency, clinician and parent ratings ., open - label somnolog measures, sleep efficiency, the longest sleep episode, improved the sleep, effective in reducing family stress, Children, treatment resistant chronic delayed sleep phase syndrome, melatonin therapy .

33945_task2

Sentence: A randomized , placebo-controlled trial of controlled release melatonin treatment of delayed sleep phase syndrome and impaired sleep maintenance in children with neurodevelopmental disabilities . The purpose of this study was to determine the efficacy of controlled-release ( CR ) melatonin in the treatment of delayed sleep phase syndrome and impaired sleep maintenance of children with neurodevelopmental disabilities including autistic spectrum disorders . A randomized double-blind , placebo-controlled crossover trial of CR melatonin ( 5 mg ) followed by a 3-month open-label study was conducted during which the dose was gradually increased until the therapy showed optimal beneficial effects . Sleep characteristics were measured by caregiver who completed somnologs and wrist actigraphs . Clinician rating of severity of the sleep disorder and improvement from baseline , along with caregiver ratings of global functioning and family stress were also obtained . Fifty-one children ( age range 2-18 years ) who did not respond to sleep hygiene intervention were enrolled . Fifty patients completed the crossover trial and 47 completed the open-label phase . Recordings of total night-time sleep and sleep latency showed significant improvement of approximately 30 min . Similarly , significant improvement was observed in clinician and parent ratings . There was additional improvement in the open-label somnolog measures of sleep efficiency and the longest sleep episode in the open-label phase . Overall , the therapy improved the sleep of 47 children and was effective in reducing family stress . Children with neurodevelopmental disabilities , who had treatment resistant chronic delayed sleep phase syndrome and impaired sleep maintenance , showed improvement in melatonin therapy . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Participant_Age", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "B-Participant_Age", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological" ]

A randomized , placebo-controlled trial of controlled release melatonin treatment of delayed sleep phase syndrome and impaired sleep maintenance in children with neurodevelopmental disabilities . The purpose of this study was to determine the efficacy of controlled-release ( CR ) melatonin in the treatment of delayed sleep phase syndrome and impaired sleep maintenance of children with neurodevelopmental disabilities including autistic spectrum disorders . A randomized double-blind , placebo-controlled crossover trial of CR melatonin ( 5 mg ) followed by a 3-month open-label study was conducted during which the dose was gradually increased until the therapy showed optimal beneficial effects . Sleep characteristics were measured by caregiver who completed somnologs and wrist actigraphs . Clinician rating of severity of the sleep disorder and improvement from baseline , along with caregiver ratings of global functioning and family stress were also obtained . Fifty-one children ( age range 2-18 years ) who did not respond to sleep hygiene intervention were enrolled . Fifty patients completed the crossover trial and 47 completed the open-label phase . Recordings of total night-time sleep and sleep latency showed significant improvement of approximately 30 min . Similarly , significant improvement was observed in clinician and parent ratings . There was additional improvement in the open-label somnolog measures of sleep efficiency and the longest sleep episode in the open-label phase . Overall , the therapy improved the sleep of 47 children and was effective in reducing family stress . Children with neurodevelopmental disabilities , who had treatment resistant chronic delayed sleep phase syndrome and impaired sleep maintenance , showed improvement in melatonin therapy .

[ "A", "randomized", ",", "placebo", "-", "controlled", "trial", "of", "controlled", "release", "melatonin", "treatment", "of", "delayed", "sleep", "phase", "syndrome", "and", "impaired", "sleep", "maintenance", "in", "children", "with", "neurodevelopmental", "disabilities", ".", "The", "purpose", "of", "this", "study", "was", "to", "determine", "the", "efficacy", "of", "controlled", "-", "release", "(", "CR", ")", "melatonin", "in", "the", "treatment", "of", "delayed", "sleep", "phase", "syndrome", "and", "impaired", "sleep", "maintenance", "of", "children", "with", "neurodevelopmental", "disabilities", "including", "autistic", "spectrum", "disorders", ".", "A", "randomized", "double", "-", "blind", ",", "placebo", "-", "controlled", "crossover", "trial", "of", "CR", "melatonin", "(", "5", "mg", ")", "followed", "by", "a", "3-month", "open", "-", "label", "study", "was", "conducted", "during", "which", "the", "dose", "was", "gradually", "increased", "until", "the", "therapy", "showed", "optimal", "beneficial", "effects", ".", "Sleep", "characteristics", "were", "measured", "by", "caregiver", "who", "completed", "somnologs", "and", "wrist", "actigraphs", ".", "Clinician", "rating", "of", "severity", "of", "the", "sleep", "disorder", "and", "improvement", "from", "baseline", ",", "along", "with", "caregiver", "ratings", "of", "global", "functioning", "and", "family", "stress", "were", "also", "obtained", ".", "Fifty", "-", "one", "children", "(", "age", "range", "2", "-", "18", "years", ")", "who", "did", "not", "respond", "to", "sleep", "hygiene", "intervention", "were", "enrolled", ".", "Fifty", "patients", "completed", "the", "crossover", "trial", "and", "47", "completed", "the", "open", "-", "label", "phase", ".", "Recordings", "of", "total", "night", "-", "time", "sleep", "and", "sleep", "latency", "showed", "significant", "improvement", "of", "approximately", "30", "min", ".", "Similarly", ",", "significant", "improvement", "was", "observed", "in", "clinician", "and", "parent", "ratings", ".", "There", "was", "additional", "improvement", "in", "the", "open", "-", "label", "somnolog", "measures", "of", "sleep", "efficiency", "and", "the", "longest", "sleep", "episode", "in", "the", "open", "-", "label", "phase", ".", "Overall", ",", "the", "therapy", "improved", "the", "sleep", "of", "47", "children", "and", "was", "effective", "in", "reducing", "family", "stress", ".", "Children", "with", "neurodevelopmental", "disabilities", ",", "who", "had", "treatment", "resistant", "chronic", "delayed", "sleep", "phase", "syndrome", "and", "impaired", "sleep", "maintenance", ",", "showed", "improvement", "in", "melatonin", "therapy", "." ]

[ "Outcome_Physical", "Participant_Condition", "Outcome_Mental", "Participant_Age", "Outcome_Other", "Intervention_Pharmacological", "Intervention_Control", "Participant_Sample-size" ]

PDGF(B ) is a Protein, c - fos is a Protein, c - jun is a Protein, EGR2 is a Protein, platelet - derived growth factor B subunit is a Protein, PDGF[B ] is a Protein, transforming growth factor - beta is a Protein, TGF - beta is a Protein, PDGF(B ) is a Protein, TGF - beta is a Protein, PDGF(B ) is a Protein, PDGF(B ) is a Protein, fibronectin is a Protein, PDGF(B ) is a Protein, PDGF(B ) is a Protein, c - fos is a Protein, c - jun is a Protein, EGR2 is a Protein, c - jun is a Protein, EGR2 is a Protein, c - fos is a Protein, c - fos is a Protein, c - jun is a Protein, EGR2 is a Protein, PDGF(B ) is a Protein, c - jun is a Protein, EGR2 is a Protein, PDGF(B ) is a Protein

328_task0

Sentence: Adherence-dependent increase in human monocyte PDGF(B) mRNA is associated with increases in c-fos, c-jun, and EGR2 mRNA. Adherence is an important initial step in the transition of a circulating monocyte to a tissue macrophage. This differentiation is accompanied by an augmented capacity to generate growth factors. We hypothesized that adherence itself might be an important trigger for a sequence of gene activation culminating in cells with increased mRNA encoding profibrotic growth factors such as platelet-derived growth factor B subunit (PDGF[B]) and transforming growth factor-beta (TGF-beta). After in vitro adherence, human monocytes had a biphasic increase in PDGF(B) mRNA with peaks at 6 h and 13 d. No increase in TGF-beta mRNA was observed. The 6-h increase in PDGF(B) mRNA was adherence dependent, and in addition, was abrogated when the cytoskeletal integrity was compromised by cytochalasin D. The 6-h increase in PDGF(B) mRNA was unaltered by adherence in the presence of the monocyte stimulus lipopolysaccharide. Adherence to either fibronectin or collagen-coated plastic had little consistent effect on PDGF(B) mRNA accumulation. The increased PDGF(B) mRNA observed in adherent monocytes was accompanied by increases in mRNAs of the early growth response genes c-fos (maximal at 20 min), c-jun, and EGR2 (maximal at 6-24 h). The increase in c-jun and EGR2, but not c-fos, mRNA was also abrogated by cytochalasin D. These observations suggest that adherence results in increases of c-fos, c-jun, EGR2, and PDGF(B) mRNA. In addition, the increases in c-jun, EGR2, and PDGF(B) may depend on cytoskeletal rearrangement. Modulation of these events at the time of adherence offers a mechanism by which differential priming of the cells may be accomplished. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein

[ "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Adherence-dependent increase in human monocyte PDGF(B) mRNA is associated with increases in c-fos, c-jun, and EGR2 mRNA. Adherence is an important initial step in the transition of a circulating monocyte to a tissue macrophage. This differentiation is accompanied by an augmented capacity to generate growth factors. We hypothesized that adherence itself might be an important trigger for a sequence of gene activation culminating in cells with increased mRNA encoding profibrotic growth factors such as platelet-derived growth factor B subunit (PDGF[B]) and transforming growth factor-beta (TGF-beta). After in vitro adherence, human monocytes had a biphasic increase in PDGF(B) mRNA with peaks at 6 h and 13 d. No increase in TGF-beta mRNA was observed. The 6-h increase in PDGF(B) mRNA was adherence dependent, and in addition, was abrogated when the cytoskeletal integrity was compromised by cytochalasin D. The 6-h increase in PDGF(B) mRNA was unaltered by adherence in the presence of the monocyte stimulus lipopolysaccharide. Adherence to either fibronectin or collagen-coated plastic had little consistent effect on PDGF(B) mRNA accumulation. The increased PDGF(B) mRNA observed in adherent monocytes was accompanied by increases in mRNAs of the early growth response genes c-fos (maximal at 20 min), c-jun, and EGR2 (maximal at 6-24 h). The increase in c-jun and EGR2, but not c-fos, mRNA was also abrogated by cytochalasin D. These observations suggest that adherence results in increases of c-fos, c-jun, EGR2, and PDGF(B) mRNA. In addition, the increases in c-jun, EGR2, and PDGF(B) may depend on cytoskeletal rearrangement. Modulation of these events at the time of adherence offers a mechanism by which differential priming of the cells may be accomplished.

[ "Adherence", "-", "dependent", "increase", "in", "human", "monocyte", "PDGF(B", ")", "mRNA", "is", "associated", "with", "increases", "in", "c", "-", "fos", ",", "c", "-", "jun", ",", "and", "EGR2", "mRNA", ".", "\n", "Adherence", "is", "an", "important", "initial", "step", "in", "the", "transition", "of", "a", "circulating", "monocyte", "to", "a", "tissue", "macrophage", ".", "This", "differentiation", "is", "accompanied", "by", "an", "augmented", "capacity", "to", "generate", "growth", "factors", ".", "We", "hypothesized", "that", "adherence", "itself", "might", "be", "an", "important", "trigger", "for", "a", "sequence", "of", "gene", "activation", "culminating", "in", "cells", "with", "increased", "mRNA", "encoding", "profibrotic", "growth", "factors", "such", "as", "platelet", "-", "derived", "growth", "factor", "B", "subunit", "(", "PDGF[B", "]", ")", "and", "transforming", "growth", "factor", "-", "beta", "(", "TGF", "-", "beta", ")", ".", "After", "in", "vitro", "adherence", ",", "human", "monocytes", "had", "a", "biphasic", "increase", "in", "PDGF(B", ")", "mRNA", "with", "peaks", "at", "6", "h", "and", "13", "d.", "No", "increase", "in", "TGF", "-", "beta", "mRNA", "was", "observed", ".", "The", "6-h", "increase", "in", "PDGF(B", ")", "mRNA", "was", "adherence", "dependent", ",", "and", "in", "addition", ",", "was", "abrogated", "when", "the", "cytoskeletal", "integrity", "was", "compromised", "by", "cytochalasin", "D.", "The", "6-h", "increase", "in", "PDGF(B", ")", "mRNA", "was", "unaltered", "by", "adherence", "in", "the", "presence", "of", "the", "monocyte", "stimulus", "lipopolysaccharide", ".", "Adherence", "to", "either", "fibronectin", "or", "collagen", "-", "coated", "plastic", "had", "little", "consistent", "effect", "on", "PDGF(B", ")", "mRNA", "accumulation", ".", "The", "increased", "PDGF(B", ")", "mRNA", "observed", "in", "adherent", "monocytes", "was", "accompanied", "by", "increases", "in", "mRNAs", "of", "the", "early", "growth", "response", "genes", "c", "-", "fos", "(", "maximal", "at", "20", "min", ")", ",", "c", "-", "jun", ",", "and", "EGR2", "(", "maximal", "at", "6", "-", "24", "h", ")", ".", "The", "increase", "in", "c", "-", "jun", "and", "EGR2", ",", "but", "not", "c", "-", "fos", ",", "mRNA", "was", "also", "abrogated", "by", "cytochalasin", "D.", "These", "observations", "suggest", "that", "adherence", "results", "in", "increases", "of", "c", "-", "fos", ",", "c", "-", "jun", ",", "EGR2", ",", "and", "PDGF(B", ")", "mRNA", ".", "In", "addition", ",", "the", "increases", "in", "c", "-", "jun", ",", "EGR2", ",", "and", "PDGF(B", ")", "may", "depend", "on", "cytoskeletal", "rearrangement", ".", "Modulation", "of", "these", "events", "at", "the", "time", "of", "adherence", "offers", "a", "mechanism", "by", "which", "differential", "priming", "of", "the", "cells", "may", "be", "accomplished", "." ]

[ "Protein" ]

PDGF(B ) is a Protein, c - fos is a Protein, c - jun is a Protein, EGR2 is a Protein, platelet - derived growth factor B subunit is a Protein, PDGF[B ] is a Protein, transforming growth factor - beta is a Protein, TGF - beta is a Protein, PDGF(B ) is a Protein, TGF - beta is a Protein, PDGF(B ) is a Protein, PDGF(B ) is a Protein, fibronectin is a Protein, PDGF(B ) is a Protein, PDGF(B ) is a Protein, c - fos is a Protein, c - jun is a Protein, EGR2 is a Protein, c - jun is a Protein, EGR2 is a Protein, c - fos is a Protein, c - fos is a Protein, c - jun is a Protein, EGR2 is a Protein, PDGF(B ) is a Protein, c - jun is a Protein, EGR2 is a Protein, PDGF(B ) is a Protein

328_task1

Sentence: Adherence-dependent increase in human monocyte PDGF(B) mRNA is associated with increases in c-fos, c-jun, and EGR2 mRNA. Adherence is an important initial step in the transition of a circulating monocyte to a tissue macrophage. This differentiation is accompanied by an augmented capacity to generate growth factors. We hypothesized that adherence itself might be an important trigger for a sequence of gene activation culminating in cells with increased mRNA encoding profibrotic growth factors such as platelet-derived growth factor B subunit (PDGF[B]) and transforming growth factor-beta (TGF-beta). After in vitro adherence, human monocytes had a biphasic increase in PDGF(B) mRNA with peaks at 6 h and 13 d. No increase in TGF-beta mRNA was observed. The 6-h increase in PDGF(B) mRNA was adherence dependent, and in addition, was abrogated when the cytoskeletal integrity was compromised by cytochalasin D. The 6-h increase in PDGF(B) mRNA was unaltered by adherence in the presence of the monocyte stimulus lipopolysaccharide. Adherence to either fibronectin or collagen-coated plastic had little consistent effect on PDGF(B) mRNA accumulation. The increased PDGF(B) mRNA observed in adherent monocytes was accompanied by increases in mRNAs of the early growth response genes c-fos (maximal at 20 min), c-jun, and EGR2 (maximal at 6-24 h). The increase in c-jun and EGR2, but not c-fos, mRNA was also abrogated by cytochalasin D. These observations suggest that adherence results in increases of c-fos, c-jun, EGR2, and PDGF(B) mRNA. In addition, the increases in c-jun, EGR2, and PDGF(B) may depend on cytoskeletal rearrangement. Modulation of these events at the time of adherence offers a mechanism by which differential priming of the cells may be accomplished. Instructions: please typing these entity words according to sentence: PDGF(B ), c - fos, c - jun, EGR2, platelet - derived growth factor B subunit, PDGF[B ], transforming growth factor - beta, TGF - beta, PDGF(B ), TGF - beta, PDGF(B ), PDGF(B ), fibronectin, PDGF(B ), PDGF(B ), c - fos, c - jun, EGR2, c - jun, EGR2, c - fos, c - fos, c - jun, EGR2, PDGF(B ), c - jun, EGR2, PDGF(B ) Options: Protein

[ "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Adherence-dependent increase in human monocyte PDGF(B) mRNA is associated with increases in c-fos, c-jun, and EGR2 mRNA. Adherence is an important initial step in the transition of a circulating monocyte to a tissue macrophage. This differentiation is accompanied by an augmented capacity to generate growth factors. We hypothesized that adherence itself might be an important trigger for a sequence of gene activation culminating in cells with increased mRNA encoding profibrotic growth factors such as platelet-derived growth factor B subunit (PDGF[B]) and transforming growth factor-beta (TGF-beta). After in vitro adherence, human monocytes had a biphasic increase in PDGF(B) mRNA with peaks at 6 h and 13 d. No increase in TGF-beta mRNA was observed. The 6-h increase in PDGF(B) mRNA was adherence dependent, and in addition, was abrogated when the cytoskeletal integrity was compromised by cytochalasin D. The 6-h increase in PDGF(B) mRNA was unaltered by adherence in the presence of the monocyte stimulus lipopolysaccharide. Adherence to either fibronectin or collagen-coated plastic had little consistent effect on PDGF(B) mRNA accumulation. The increased PDGF(B) mRNA observed in adherent monocytes was accompanied by increases in mRNAs of the early growth response genes c-fos (maximal at 20 min), c-jun, and EGR2 (maximal at 6-24 h). The increase in c-jun and EGR2, but not c-fos, mRNA was also abrogated by cytochalasin D. These observations suggest that adherence results in increases of c-fos, c-jun, EGR2, and PDGF(B) mRNA. In addition, the increases in c-jun, EGR2, and PDGF(B) may depend on cytoskeletal rearrangement. Modulation of these events at the time of adherence offers a mechanism by which differential priming of the cells may be accomplished.

[ "Adherence", "-", "dependent", "increase", "in", "human", "monocyte", "PDGF(B", ")", "mRNA", "is", "associated", "with", "increases", "in", "c", "-", "fos", ",", "c", "-", "jun", ",", "and", "EGR2", "mRNA", ".", "\n", "Adherence", "is", "an", "important", "initial", "step", "in", "the", "transition", "of", "a", "circulating", "monocyte", "to", "a", "tissue", "macrophage", ".", "This", "differentiation", "is", "accompanied", "by", "an", "augmented", "capacity", "to", "generate", "growth", "factors", ".", "We", "hypothesized", "that", "adherence", "itself", "might", "be", "an", "important", "trigger", "for", "a", "sequence", "of", "gene", "activation", "culminating", "in", "cells", "with", "increased", "mRNA", "encoding", "profibrotic", "growth", "factors", "such", "as", "platelet", "-", "derived", "growth", "factor", "B", "subunit", "(", "PDGF[B", "]", ")", "and", "transforming", "growth", "factor", "-", "beta", "(", "TGF", "-", "beta", ")", ".", "After", "in", "vitro", "adherence", ",", "human", "monocytes", "had", "a", "biphasic", "increase", "in", "PDGF(B", ")", "mRNA", "with", "peaks", "at", "6", "h", "and", "13", "d.", "No", "increase", "in", "TGF", "-", "beta", "mRNA", "was", "observed", ".", "The", "6-h", "increase", "in", "PDGF(B", ")", "mRNA", "was", "adherence", "dependent", ",", "and", "in", "addition", ",", "was", "abrogated", "when", "the", "cytoskeletal", "integrity", "was", "compromised", "by", "cytochalasin", "D.", "The", "6-h", "increase", "in", "PDGF(B", ")", "mRNA", "was", "unaltered", "by", "adherence", "in", "the", "presence", "of", "the", "monocyte", "stimulus", "lipopolysaccharide", ".", "Adherence", "to", "either", "fibronectin", "or", "collagen", "-", "coated", "plastic", "had", "little", "consistent", "effect", "on", "PDGF(B", ")", "mRNA", "accumulation", ".", "The", "increased", "PDGF(B", ")", "mRNA", "observed", "in", "adherent", "monocytes", "was", "accompanied", "by", "increases", "in", "mRNAs", "of", "the", "early", "growth", "response", "genes", "c", "-", "fos", "(", "maximal", "at", "20", "min", ")", ",", "c", "-", "jun", ",", "and", "EGR2", "(", "maximal", "at", "6", "-", "24", "h", ")", ".", "The", "increase", "in", "c", "-", "jun", "and", "EGR2", ",", "but", "not", "c", "-", "fos", ",", "mRNA", "was", "also", "abrogated", "by", "cytochalasin", "D.", "These", "observations", "suggest", "that", "adherence", "results", "in", "increases", "of", "c", "-", "fos", ",", "c", "-", "jun", ",", "EGR2", ",", "and", "PDGF(B", ")", "mRNA", ".", "In", "addition", ",", "the", "increases", "in", "c", "-", "jun", ",", "EGR2", ",", "and", "PDGF(B", ")", "may", "depend", "on", "cytoskeletal", "rearrangement", ".", "Modulation", "of", "these", "events", "at", "the", "time", "of", "adherence", "offers", "a", "mechanism", "by", "which", "differential", "priming", "of", "the", "cells", "may", "be", "accomplished", "." ]

[ "Protein" ]

PDGF(B ), c - fos, c - jun, EGR2, platelet - derived growth factor B subunit, PDGF[B ], transforming growth factor - beta, TGF - beta, PDGF(B ), TGF - beta, PDGF(B ), PDGF(B ), fibronectin, PDGF(B ), PDGF(B ), c - fos, c - jun, EGR2, c - jun, EGR2, c - fos, c - fos, c - jun, EGR2, PDGF(B ), c - jun, EGR2, PDGF(B )

328_task2

Sentence: Adherence-dependent increase in human monocyte PDGF(B) mRNA is associated with increases in c-fos, c-jun, and EGR2 mRNA. Adherence is an important initial step in the transition of a circulating monocyte to a tissue macrophage. This differentiation is accompanied by an augmented capacity to generate growth factors. We hypothesized that adherence itself might be an important trigger for a sequence of gene activation culminating in cells with increased mRNA encoding profibrotic growth factors such as platelet-derived growth factor B subunit (PDGF[B]) and transforming growth factor-beta (TGF-beta). After in vitro adherence, human monocytes had a biphasic increase in PDGF(B) mRNA with peaks at 6 h and 13 d. No increase in TGF-beta mRNA was observed. The 6-h increase in PDGF(B) mRNA was adherence dependent, and in addition, was abrogated when the cytoskeletal integrity was compromised by cytochalasin D. The 6-h increase in PDGF(B) mRNA was unaltered by adherence in the presence of the monocyte stimulus lipopolysaccharide. Adherence to either fibronectin or collagen-coated plastic had little consistent effect on PDGF(B) mRNA accumulation. The increased PDGF(B) mRNA observed in adherent monocytes was accompanied by increases in mRNAs of the early growth response genes c-fos (maximal at 20 min), c-jun, and EGR2 (maximal at 6-24 h). The increase in c-jun and EGR2, but not c-fos, mRNA was also abrogated by cytochalasin D. These observations suggest that adherence results in increases of c-fos, c-jun, EGR2, and PDGF(B) mRNA. In addition, the increases in c-jun, EGR2, and PDGF(B) may depend on cytoskeletal rearrangement. Modulation of these events at the time of adherence offers a mechanism by which differential priming of the cells may be accomplished. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Adherence-dependent increase in human monocyte PDGF(B) mRNA is associated with increases in c-fos, c-jun, and EGR2 mRNA. Adherence is an important initial step in the transition of a circulating monocyte to a tissue macrophage. This differentiation is accompanied by an augmented capacity to generate growth factors. We hypothesized that adherence itself might be an important trigger for a sequence of gene activation culminating in cells with increased mRNA encoding profibrotic growth factors such as platelet-derived growth factor B subunit (PDGF[B]) and transforming growth factor-beta (TGF-beta). After in vitro adherence, human monocytes had a biphasic increase in PDGF(B) mRNA with peaks at 6 h and 13 d. No increase in TGF-beta mRNA was observed. The 6-h increase in PDGF(B) mRNA was adherence dependent, and in addition, was abrogated when the cytoskeletal integrity was compromised by cytochalasin D. The 6-h increase in PDGF(B) mRNA was unaltered by adherence in the presence of the monocyte stimulus lipopolysaccharide. Adherence to either fibronectin or collagen-coated plastic had little consistent effect on PDGF(B) mRNA accumulation. The increased PDGF(B) mRNA observed in adherent monocytes was accompanied by increases in mRNAs of the early growth response genes c-fos (maximal at 20 min), c-jun, and EGR2 (maximal at 6-24 h). The increase in c-jun and EGR2, but not c-fos, mRNA was also abrogated by cytochalasin D. These observations suggest that adherence results in increases of c-fos, c-jun, EGR2, and PDGF(B) mRNA. In addition, the increases in c-jun, EGR2, and PDGF(B) may depend on cytoskeletal rearrangement. Modulation of these events at the time of adherence offers a mechanism by which differential priming of the cells may be accomplished.

[ "Adherence", "-", "dependent", "increase", "in", "human", "monocyte", "PDGF(B", ")", "mRNA", "is", "associated", "with", "increases", "in", "c", "-", "fos", ",", "c", "-", "jun", ",", "and", "EGR2", "mRNA", ".", "\n", "Adherence", "is", "an", "important", "initial", "step", "in", "the", "transition", "of", "a", "circulating", "monocyte", "to", "a", "tissue", "macrophage", ".", "This", "differentiation", "is", "accompanied", "by", "an", "augmented", "capacity", "to", "generate", "growth", "factors", ".", "We", "hypothesized", "that", "adherence", "itself", "might", "be", "an", "important", "trigger", "for", "a", "sequence", "of", "gene", "activation", "culminating", "in", "cells", "with", "increased", "mRNA", "encoding", "profibrotic", "growth", "factors", "such", "as", "platelet", "-", "derived", "growth", "factor", "B", "subunit", "(", "PDGF[B", "]", ")", "and", "transforming", "growth", "factor", "-", "beta", "(", "TGF", "-", "beta", ")", ".", "After", "in", "vitro", "adherence", ",", "human", "monocytes", "had", "a", "biphasic", "increase", "in", "PDGF(B", ")", "mRNA", "with", "peaks", "at", "6", "h", "and", "13", "d.", "No", "increase", "in", "TGF", "-", "beta", "mRNA", "was", "observed", ".", "The", "6-h", "increase", "in", "PDGF(B", ")", "mRNA", "was", "adherence", "dependent", ",", "and", "in", "addition", ",", "was", "abrogated", "when", "the", "cytoskeletal", "integrity", "was", "compromised", "by", "cytochalasin", "D.", "The", "6-h", "increase", "in", "PDGF(B", ")", "mRNA", "was", "unaltered", "by", "adherence", "in", "the", "presence", "of", "the", "monocyte", "stimulus", "lipopolysaccharide", ".", "Adherence", "to", "either", "fibronectin", "or", "collagen", "-", "coated", "plastic", "had", "little", "consistent", "effect", "on", "PDGF(B", ")", "mRNA", "accumulation", ".", "The", "increased", "PDGF(B", ")", "mRNA", "observed", "in", "adherent", "monocytes", "was", "accompanied", "by", "increases", "in", "mRNAs", "of", "the", "early", "growth", "response", "genes", "c", "-", "fos", "(", "maximal", "at", "20", "min", ")", ",", "c", "-", "jun", ",", "and", "EGR2", "(", "maximal", "at", "6", "-", "24", "h", ")", ".", "The", "increase", "in", "c", "-", "jun", "and", "EGR2", ",", "but", "not", "c", "-", "fos", ",", "mRNA", "was", "also", "abrogated", "by", "cytochalasin", "D.", "These", "observations", "suggest", "that", "adherence", "results", "in", "increases", "of", "c", "-", "fos", ",", "c", "-", "jun", ",", "EGR2", ",", "and", "PDGF(B", ")", "mRNA", ".", "In", "addition", ",", "the", "increases", "in", "c", "-", "jun", ",", "EGR2", ",", "and", "PDGF(B", ")", "may", "depend", "on", "cytoskeletal", "rearrangement", ".", "Modulation", "of", "these", "events", "at", "the", "time", "of", "adherence", "offers", "a", "mechanism", "by", "which", "differential", "priming", "of", "the", "cells", "may", "be", "accomplished", "." ]

[ "Protein" ]

benefit / disadvantage is a Outcome_Other, granulocyte colony - stimulating factor therapy is a Intervention_Pharmacological, children is a Participant_Age, PBSCT is a Intervention_Pharmacological, 74 is a Participant_Sample-size, high - dose chemotherapy is a Intervention_Pharmacological, autologous peripheral blood stem cell transplantation ( PBSCT ) is a Participant_Condition, effectiveness is a Outcome_Other, G - CSF is a Intervention_Pharmacological, hematopoietic recovery is a Outcome_Physical, acute lymphoblastic leukemia is a Participant_Condition, 27 is a Participant_Sample-size, neuroblastoma is a Participant_Condition, 29 is a Participant_Sample-size, miscellaneous solid tumors is a Participant_Condition, 18 is a Participant_Sample-size, primary PBSCT is a Intervention_Pharmacological, chemotherapy - responsive disease is a Participant_Condition, collected cell number > 1 x 10 ( 5 ) colony - forming unit - granulocyte - macrophage ( CFU - GM ) /kg and > 1 x 10 ( 6 ) CD34 ( + ) cells / kg is a Participant_Condition, 11 is a Participant_Sample-size, 63 is a Participant_Sample-size, 32 is a Participant_Sample-size, control group is a Intervention_Control, high - dose regimens without total body irradiation consisted of the MCVAC regimen using ranimustine ( MCNU , 450 mg / m2 ) , cytosine arabinoside ( 16 g / m2 ) , etoposide ( 1.6 g / m2 ) , and cyclophosphamide is a Intervention_Pharmacological, Hi - MEC regimen using melphalan is a Intervention_Pharmacological, carboplatinum is a Intervention_Pharmacological, Five is a Participant_Sample-size, two is a Participant_Sample-size, three is a Participant_Sample-size, survived is a Outcome_Mortality, median numbers of transfused mononuclear cells ( MNC ) is a Outcome_Physical, time to achieve an absolute neutrophil count ( ANC ) of > 0.5 x 10 ( 9 ) /L is a Outcome_Other, duration of febrile days is a Outcome_Other, platelet recovery to > 20 x 10 ( 9 ) /L is a Outcome_Other, platelet transfusion - dependent days is a Outcome_Other, engraftment kinetics is a Outcome_Physical, recovery of granulocytes is a Outcome_Physical, recovery of platelets . is a Outcome_Physical

93229_task0

Sentence: Marginal benefit/disadvantage of granulocyte colony-stimulating factor therapy after autologous blood stem cell transplantation in children : results of a prospective randomized trial . The Japanese Cooperative Study Group of PBSCT . In this prospective trial , a total of 74 children who were scheduled to undergo high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation ( PBSCT ) were prospectively randomized at diagnosis to evaluate the effectiveness of exogenous granulocyte colony-stimulating factor ( G-CSF ) treatment in accelerating hematopoietic recovery after PBSCT . The diagnosis included acute lymphoblastic leukemia ( ALL ) ( n = 27 ) , neuroblastoma ( n = 29 ) , and miscellaneous solid tumors ( n = 18 ) . Eligibility criteria included ( 1 ) primary PBSCT , ( 2 ) chemotherapy-responsive disease , and ( 3 ) collected cell number > 1 x 10 ( 5 ) colony-forming unit-granulocyte-macrophage ( CFU-GM ) /kg and > 1 x 10 ( 6 ) CD34 ( + ) cells/kg patient 's body weight . After applying the above criteria , 11 patients were excluded due to disease progression before PBSCT ( n = 6 ) or a low number of harvested cells ( n = 5 ) , leaving 63 patients for analysis ; 32 patients in the treatment group ( 300 microg/m2 of G-CSF intravenously over 1 hour from day 1 of PBSCT ) and 31 in the control group without treatment . Two distinct disease-oriented high-dose regimens without total body irradiation consisted of the MCVAC regimen using ranimustine ( MCNU , 450 mg/m2 ) , cytosine arabinoside ( 16 g/m2 ) , etoposide ( 1.6 g/m2 ) , and cyclophosphamide ( 100 mg/kg ) for patients with ALL , and the Hi-MEC regimen using melphalan ( 180 mg/m2 ) , etoposide ( 1.6 g/m2 ) , and carboplatinum ( 1.6 g/m2 ) for those with solid tumors . Five patients ( two in the treatment group and three in the control group ) were subsequently removed due to protocol violations . All patients survived PBSCT . The median numbers of transfused mononuclear cells ( MNC ) , CD34 ( + ) cells , and CFU-GM were , respectively , 4.5 ( range , 1 to 19 ) x 10 ( 8 ) /kg , 8.0 ( 1.1 to 25 ) x 10 ( 6 ) /kg , and 3.7 ( 1.2 to 23 ) x 10 ( 5 ) /kg in the treatment group ( n = 30 ) and 2.9 ( 0.8 to 21 ) x 10 ( 8 ) /kg , 6.3 ( 1.1 to 34 ) x 10 ( 6 ) /kg , and 5.5 ( 1.3 to 37 ) x 10 ( 5 ) /kg , respectively , in the control group ( n = 28 ) , with no significant difference . After PBSCT , the time to achieve an absolute neutrophil count ( ANC ) of > 0.5 x 10 ( 9 ) /L in the treatment group was less than that in the control group ( median , 11 v 12 days ; the log-rank test , P =.046 ) , although the last day of red blood cell ( RBC ) transfusion ( day 11 v day 10 ) and the duration of febrile days ( > 38 degrees C ) after PBSCT ( 4 v 4 days ) were identical in both groups . However , platelet recovery to > 20 x 10 ( 9 ) /L was significantly longer in treatment group than control group ( 26 v 16 days ; P =.009 ) and > 50 x 10 ( 9 ) /L tended to take longer in the treatment group ( 29 v 26 days ; P =.126 ) , with significantly more platelet transfusion-dependent days ( 27 v 13 days ; t-test , P =.037 ) . When patients were divided into two different disease cohorts , ALL patients showed no difference in engraftment kinetics between the G-CSF treatment and control groups , while differences were seen in those with solid tumors . We concluded that the marginal clinical benefit of 1 day earlier recovery of granulocytes could be offset by the delayed recovery of platelets . We recommend that the routine application of costly G-CSF therapy in children undergoing PBSCT should be seriously reconsidered . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Participant_Condition, Intervention_Control, Outcome_Mortality, Participant_Age, Outcome_Physical, Participant_Sample-size, Outcome_Other

[ "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "B-Participant_Condition", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Marginal benefit/disadvantage of granulocyte colony-stimulating factor therapy after autologous blood stem cell transplantation in children : results of a prospective randomized trial . The Japanese Cooperative Study Group of PBSCT . In this prospective trial , a total of 74 children who were scheduled to undergo high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation ( PBSCT ) were prospectively randomized at diagnosis to evaluate the effectiveness of exogenous granulocyte colony-stimulating factor ( G-CSF ) treatment in accelerating hematopoietic recovery after PBSCT . The diagnosis included acute lymphoblastic leukemia ( ALL ) ( n = 27 ) , neuroblastoma ( n = 29 ) , and miscellaneous solid tumors ( n = 18 ) . Eligibility criteria included ( 1 ) primary PBSCT , ( 2 ) chemotherapy-responsive disease , and ( 3 ) collected cell number > 1 x 10 ( 5 ) colony-forming unit-granulocyte-macrophage ( CFU-GM ) /kg and > 1 x 10 ( 6 ) CD34 ( + ) cells/kg patient 's body weight . After applying the above criteria , 11 patients were excluded due to disease progression before PBSCT ( n = 6 ) or a low number of harvested cells ( n = 5 ) , leaving 63 patients for analysis ; 32 patients in the treatment group ( 300 microg/m2 of G-CSF intravenously over 1 hour from day 1 of PBSCT ) and 31 in the control group without treatment . Two distinct disease-oriented high-dose regimens without total body irradiation consisted of the MCVAC regimen using ranimustine ( MCNU , 450 mg/m2 ) , cytosine arabinoside ( 16 g/m2 ) , etoposide ( 1.6 g/m2 ) , and cyclophosphamide ( 100 mg/kg ) for patients with ALL , and the Hi-MEC regimen using melphalan ( 180 mg/m2 ) , etoposide ( 1.6 g/m2 ) , and carboplatinum ( 1.6 g/m2 ) for those with solid tumors . Five patients ( two in the treatment group and three in the control group ) were subsequently removed due to protocol violations . All patients survived PBSCT . The median numbers of transfused mononuclear cells ( MNC ) , CD34 ( + ) cells , and CFU-GM were , respectively , 4.5 ( range , 1 to 19 ) x 10 ( 8 ) /kg , 8.0 ( 1.1 to 25 ) x 10 ( 6 ) /kg , and 3.7 ( 1.2 to 23 ) x 10 ( 5 ) /kg in the treatment group ( n = 30 ) and 2.9 ( 0.8 to 21 ) x 10 ( 8 ) /kg , 6.3 ( 1.1 to 34 ) x 10 ( 6 ) /kg , and 5.5 ( 1.3 to 37 ) x 10 ( 5 ) /kg , respectively , in the control group ( n = 28 ) , with no significant difference . After PBSCT , the time to achieve an absolute neutrophil count ( ANC ) of > 0.5 x 10 ( 9 ) /L in the treatment group was less than that in the control group ( median , 11 v 12 days ; the log-rank test , P =.046 ) , although the last day of red blood cell ( RBC ) transfusion ( day 11 v day 10 ) and the duration of febrile days ( > 38 degrees C ) after PBSCT ( 4 v 4 days ) were identical in both groups . However , platelet recovery to > 20 x 10 ( 9 ) /L was significantly longer in treatment group than control group ( 26 v 16 days ; P =.009 ) and > 50 x 10 ( 9 ) /L tended to take longer in the treatment group ( 29 v 26 days ; P =.126 ) , with significantly more platelet transfusion-dependent days ( 27 v 13 days ; t-test , P =.037 ) . When patients were divided into two different disease cohorts , ALL patients showed no difference in engraftment kinetics between the G-CSF treatment and control groups , while differences were seen in those with solid tumors . We concluded that the marginal clinical benefit of 1 day earlier recovery of granulocytes could be offset by the delayed recovery of platelets . We recommend that the routine application of costly G-CSF therapy in children undergoing PBSCT should be seriously reconsidered .

[ "Marginal", "benefit", "/", "disadvantage", "of", "granulocyte", "colony", "-", "stimulating", "factor", "therapy", "after", "autologous", "blood", "stem", "cell", "transplantation", "in", "children", ":", "results", "of", "a", "prospective", "randomized", "trial", ".", "The", "Japanese", "Cooperative", "Study", "Group", "of", "PBSCT", ".", "In", "this", "prospective", "trial", ",", "a", "total", "of", "74", "children", "who", "were", "scheduled", "to", "undergo", "high", "-", "dose", "chemotherapy", "followed", "by", "autologous", "peripheral", "blood", "stem", "cell", "transplantation", "(", "PBSCT", ")", "were", "prospectively", "randomized", "at", "diagnosis", "to", "evaluate", "the", "effectiveness", "of", "exogenous", "granulocyte", "colony", "-", "stimulating", "factor", "(", "G", "-", "CSF", ")", "treatment", "in", "accelerating", "hematopoietic", "recovery", "after", "PBSCT", ".", "The", "diagnosis", "included", "acute", "lymphoblastic", "leukemia", "(", "ALL", ")", "(", "n", "=", "27", ")", ",", "neuroblastoma", "(", "n", "=", "29", ")", ",", "and", "miscellaneous", "solid", "tumors", "(", "n", "=", "18", ")", ".", "Eligibility", "criteria", "included", "(", "1", ")", "primary", "PBSCT", ",", "(", "2", ")", "chemotherapy", "-", "responsive", "disease", ",", "and", "(", "3", ")", "collected", "cell", "number", ">", "1", "x", "10", "(", "5", ")", "colony", "-", "forming", "unit", "-", "granulocyte", "-", "macrophage", "(", "CFU", "-", "GM", ")", "/kg", "and", ">", "1", "x", "10", "(", "6", ")", "CD34", "(", "+", ")", "cells", "/", "kg", "patient", "'", "s", "body", "weight", ".", "After", "applying", "the", "above", "criteria", ",", "11", "patients", "were", "excluded", "due", "to", "disease", "progression", "before", "PBSCT", "(", "n", "=", "6", ")", "or", "a", "low", "number", "of", "harvested", "cells", "(", "n", "=", "5", ")", ",", "leaving", "63", "patients", "for", "analysis", ";", "32", "patients", "in", "the", "treatment", "group", "(", "300", "microg", "/", "m2", "of", "G", "-", "CSF", "intravenously", "over", "1", "hour", "from", "day", "1", "of", "PBSCT", ")", "and", "31", "in", "the", "control", "group", "without", "treatment", ".", "Two", "distinct", "disease", "-", "oriented", "high", "-", "dose", "regimens", "without", "total", "body", "irradiation", "consisted", "of", "the", "MCVAC", "regimen", "using", "ranimustine", "(", "MCNU", ",", "450", "mg", "/", "m2", ")", ",", "cytosine", "arabinoside", "(", "16", "g", "/", "m2", ")", ",", "etoposide", "(", "1.6", "g", "/", "m2", ")", ",", "and", "cyclophosphamide", "(", "100", "mg", "/", "kg", ")", "for", "patients", "with", "ALL", ",", "and", "the", "Hi", "-", "MEC", "regimen", "using", "melphalan", "(", "180", "mg", "/", "m2", ")", ",", "etoposide", "(", "1.6", "g", "/", "m2", ")", ",", "and", "carboplatinum", "(", "1.6", "g", "/", "m2", ")", "for", "those", "with", "solid", "tumors", ".", "Five", "patients", "(", "two", "in", "the", "treatment", "group", "and", "three", "in", "the", "control", "group", ")", "were", "subsequently", "removed", "due", "to", "protocol", "violations", ".", "All", "patients", "survived", "PBSCT", ".", "The", "median", "numbers", "of", "transfused", "mononuclear", "cells", "(", "MNC", ")", ",", "CD34", "(", "+", ")", "cells", ",", "and", "CFU", "-", "GM", "were", ",", "respectively", ",", "4.5", "(", "range", ",", "1", "to", "19", ")", "x", "10", "(", "8", ")", "/kg", ",", "8.0", "(", "1.1", "to", "25", ")", "x", "10", "(", "6", ")", "/kg", ",", "and", "3.7", "(", "1.2", "to", "23", ")", "x", "10", "(", "5", ")", "/kg", "in", "the", "treatment", "group", "(", "n", "=", "30", ")", "and", "2.9", "(", "0.8", "to", "21", ")", "x", "10", "(", "8", ")", "/kg", ",", "6.3", "(", "1.1", "to", "34", ")", "x", "10", "(", "6", ")", "/kg", ",", "and", "5.5", "(", "1.3", "to", "37", ")", "x", "10", "(", "5", ")", "/kg", ",", "respectively", ",", "in", "the", "control", "group", "(", "n", "=", "28", ")", ",", "with", "no", "significant", "difference", ".", "After", "PBSCT", ",", "the", "time", "to", "achieve", "an", "absolute", "neutrophil", "count", "(", "ANC", ")", "of", ">", "0.5", "x", "10", "(", "9", ")", "/L", "in", "the", "treatment", "group", "was", "less", "than", "that", "in", "the", "control", "group", "(", "median", ",", "11", "v", "12", "days", ";", "the", "log", "-", "rank", "test", ",", "P", "=", ".046", ")", ",", "although", "the", "last", "day", "of", "red", "blood", "cell", "(", "RBC", ")", "transfusion", "(", "day", "11", "v", "day", "10", ")", "and", "the", "duration", "of", "febrile", "days", "(", ">", "38", "degrees", "C", ")", "after", "PBSCT", "(", "4", "v", "4", "days", ")", "were", "identical", "in", "both", "groups", ".", "However", ",", "platelet", "recovery", "to", ">", "20", "x", "10", "(", "9", ")", "/L", "was", "significantly", "longer", "in", "treatment", "group", "than", "control", "group", "(", "26", "v", "16", "days", ";", "P", "=", ".009", ")", "and", ">", "50", "x", "10", "(", "9", ")", "/L", "tended", "to", "take", "longer", "in", "the", "treatment", "group", "(", "29", "v", "26", "days", ";", "P", "=", ".126", ")", ",", "with", "significantly", "more", "platelet", "transfusion", "-", "dependent", "days", "(", "27", "v", "13", "days", ";", "t", "-", "test", ",", "P", "=", ".037", ")", ".", "When", "patients", "were", "divided", "into", "two", "different", "disease", "cohorts", ",", "ALL", "patients", "showed", "no", "difference", "in", "engraftment", "kinetics", "between", "the", "G", "-", "CSF", "treatment", "and", "control", "groups", ",", "while", "differences", "were", "seen", "in", "those", "with", "solid", "tumors", ".", "We", "concluded", "that", "the", "marginal", "clinical", "benefit", "of", "1", "day", "earlier", "recovery", "of", "granulocytes", "could", "be", "offset", "by", "the", "delayed", "recovery", "of", "platelets", ".", "We", "recommend", "that", "the", "routine", "application", "of", "costly", "G", "-", "CSF", "therapy", "in", "children", "undergoing", "PBSCT", "should", "be", "seriously", "reconsidered", "." ]

[ "Intervention_Pharmacological", "Participant_Condition", "Outcome_Other", "Outcome_Physical", "Intervention_Control", "Outcome_Mortality", "Participant_Age", "Participant_Sample-size" ]

benefit / disadvantage is a Outcome_Other, granulocyte colony - stimulating factor therapy is a Intervention_Pharmacological, children is a Participant_Age, PBSCT is a Intervention_Pharmacological, 74 is a Participant_Sample-size, high - dose chemotherapy is a Intervention_Pharmacological, autologous peripheral blood stem cell transplantation ( PBSCT ) is a Participant_Condition, effectiveness is a Outcome_Other, G - CSF is a Intervention_Pharmacological, hematopoietic recovery is a Outcome_Physical, acute lymphoblastic leukemia is a Participant_Condition, 27 is a Participant_Sample-size, neuroblastoma is a Participant_Condition, 29 is a Participant_Sample-size, miscellaneous solid tumors is a Participant_Condition, 18 is a Participant_Sample-size, primary PBSCT is a Intervention_Pharmacological, chemotherapy - responsive disease is a Participant_Condition, collected cell number > 1 x 10 ( 5 ) colony - forming unit - granulocyte - macrophage ( CFU - GM ) /kg and > 1 x 10 ( 6 ) CD34 ( + ) cells / kg is a Participant_Condition, 11 is a Participant_Sample-size, 63 is a Participant_Sample-size, 32 is a Participant_Sample-size, control group is a Intervention_Control, high - dose regimens without total body irradiation consisted of the MCVAC regimen using ranimustine ( MCNU , 450 mg / m2 ) , cytosine arabinoside ( 16 g / m2 ) , etoposide ( 1.6 g / m2 ) , and cyclophosphamide is a Intervention_Pharmacological, Hi - MEC regimen using melphalan is a Intervention_Pharmacological, carboplatinum is a Intervention_Pharmacological, Five is a Participant_Sample-size, two is a Participant_Sample-size, three is a Participant_Sample-size, survived is a Outcome_Mortality, median numbers of transfused mononuclear cells ( MNC ) is a Outcome_Physical, time to achieve an absolute neutrophil count ( ANC ) of > 0.5 x 10 ( 9 ) /L is a Outcome_Other, duration of febrile days is a Outcome_Other, platelet recovery to > 20 x 10 ( 9 ) /L is a Outcome_Other, platelet transfusion - dependent days is a Outcome_Other, engraftment kinetics is a Outcome_Physical, recovery of granulocytes is a Outcome_Physical, recovery of platelets . is a Outcome_Physical

93229_task1

Sentence: Marginal benefit/disadvantage of granulocyte colony-stimulating factor therapy after autologous blood stem cell transplantation in children : results of a prospective randomized trial . The Japanese Cooperative Study Group of PBSCT . In this prospective trial , a total of 74 children who were scheduled to undergo high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation ( PBSCT ) were prospectively randomized at diagnosis to evaluate the effectiveness of exogenous granulocyte colony-stimulating factor ( G-CSF ) treatment in accelerating hematopoietic recovery after PBSCT . The diagnosis included acute lymphoblastic leukemia ( ALL ) ( n = 27 ) , neuroblastoma ( n = 29 ) , and miscellaneous solid tumors ( n = 18 ) . Eligibility criteria included ( 1 ) primary PBSCT , ( 2 ) chemotherapy-responsive disease , and ( 3 ) collected cell number > 1 x 10 ( 5 ) colony-forming unit-granulocyte-macrophage ( CFU-GM ) /kg and > 1 x 10 ( 6 ) CD34 ( + ) cells/kg patient 's body weight . After applying the above criteria , 11 patients were excluded due to disease progression before PBSCT ( n = 6 ) or a low number of harvested cells ( n = 5 ) , leaving 63 patients for analysis ; 32 patients in the treatment group ( 300 microg/m2 of G-CSF intravenously over 1 hour from day 1 of PBSCT ) and 31 in the control group without treatment . Two distinct disease-oriented high-dose regimens without total body irradiation consisted of the MCVAC regimen using ranimustine ( MCNU , 450 mg/m2 ) , cytosine arabinoside ( 16 g/m2 ) , etoposide ( 1.6 g/m2 ) , and cyclophosphamide ( 100 mg/kg ) for patients with ALL , and the Hi-MEC regimen using melphalan ( 180 mg/m2 ) , etoposide ( 1.6 g/m2 ) , and carboplatinum ( 1.6 g/m2 ) for those with solid tumors . Five patients ( two in the treatment group and three in the control group ) were subsequently removed due to protocol violations . All patients survived PBSCT . The median numbers of transfused mononuclear cells ( MNC ) , CD34 ( + ) cells , and CFU-GM were , respectively , 4.5 ( range , 1 to 19 ) x 10 ( 8 ) /kg , 8.0 ( 1.1 to 25 ) x 10 ( 6 ) /kg , and 3.7 ( 1.2 to 23 ) x 10 ( 5 ) /kg in the treatment group ( n = 30 ) and 2.9 ( 0.8 to 21 ) x 10 ( 8 ) /kg , 6.3 ( 1.1 to 34 ) x 10 ( 6 ) /kg , and 5.5 ( 1.3 to 37 ) x 10 ( 5 ) /kg , respectively , in the control group ( n = 28 ) , with no significant difference . After PBSCT , the time to achieve an absolute neutrophil count ( ANC ) of > 0.5 x 10 ( 9 ) /L in the treatment group was less than that in the control group ( median , 11 v 12 days ; the log-rank test , P =.046 ) , although the last day of red blood cell ( RBC ) transfusion ( day 11 v day 10 ) and the duration of febrile days ( > 38 degrees C ) after PBSCT ( 4 v 4 days ) were identical in both groups . However , platelet recovery to > 20 x 10 ( 9 ) /L was significantly longer in treatment group than control group ( 26 v 16 days ; P =.009 ) and > 50 x 10 ( 9 ) /L tended to take longer in the treatment group ( 29 v 26 days ; P =.126 ) , with significantly more platelet transfusion-dependent days ( 27 v 13 days ; t-test , P =.037 ) . When patients were divided into two different disease cohorts , ALL patients showed no difference in engraftment kinetics between the G-CSF treatment and control groups , while differences were seen in those with solid tumors . We concluded that the marginal clinical benefit of 1 day earlier recovery of granulocytes could be offset by the delayed recovery of platelets . We recommend that the routine application of costly G-CSF therapy in children undergoing PBSCT should be seriously reconsidered . Instructions: please typing these entity words according to sentence: benefit / disadvantage, granulocyte colony - stimulating factor therapy, children, PBSCT, 74, high - dose chemotherapy, autologous peripheral blood stem cell transplantation ( PBSCT ), effectiveness, G - CSF, hematopoietic recovery, acute lymphoblastic leukemia, 27, neuroblastoma, 29, miscellaneous solid tumors, 18, primary PBSCT, chemotherapy - responsive disease, collected cell number > 1 x 10 ( 5 ) colony - forming unit - granulocyte - macrophage ( CFU - GM ) /kg and > 1 x 10 ( 6 ) CD34 ( + ) cells / kg, 11, 63, 32, control group, high - dose regimens without total body irradiation consisted of the MCVAC regimen using ranimustine ( MCNU , 450 mg / m2 ) , cytosine arabinoside ( 16 g / m2 ) , etoposide ( 1.6 g / m2 ) , and cyclophosphamide, Hi - MEC regimen using melphalan, carboplatinum, Five, two, three, survived, median numbers of transfused mononuclear cells ( MNC ), time to achieve an absolute neutrophil count ( ANC ) of > 0.5 x 10 ( 9 ) /L, duration of febrile days, platelet recovery to > 20 x 10 ( 9 ) /L, platelet transfusion - dependent days, engraftment kinetics, recovery of granulocytes, recovery of platelets . Options: Intervention_Pharmacological, Participant_Condition, Intervention_Control, Outcome_Mortality, Participant_Age, Outcome_Physical, Participant_Sample-size, Outcome_Other

[ "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "B-Participant_Condition", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Marginal benefit/disadvantage of granulocyte colony-stimulating factor therapy after autologous blood stem cell transplantation in children : results of a prospective randomized trial . The Japanese Cooperative Study Group of PBSCT . In this prospective trial , a total of 74 children who were scheduled to undergo high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation ( PBSCT ) were prospectively randomized at diagnosis to evaluate the effectiveness of exogenous granulocyte colony-stimulating factor ( G-CSF ) treatment in accelerating hematopoietic recovery after PBSCT . The diagnosis included acute lymphoblastic leukemia ( ALL ) ( n = 27 ) , neuroblastoma ( n = 29 ) , and miscellaneous solid tumors ( n = 18 ) . Eligibility criteria included ( 1 ) primary PBSCT , ( 2 ) chemotherapy-responsive disease , and ( 3 ) collected cell number > 1 x 10 ( 5 ) colony-forming unit-granulocyte-macrophage ( CFU-GM ) /kg and > 1 x 10 ( 6 ) CD34 ( + ) cells/kg patient 's body weight . After applying the above criteria , 11 patients were excluded due to disease progression before PBSCT ( n = 6 ) or a low number of harvested cells ( n = 5 ) , leaving 63 patients for analysis ; 32 patients in the treatment group ( 300 microg/m2 of G-CSF intravenously over 1 hour from day 1 of PBSCT ) and 31 in the control group without treatment . Two distinct disease-oriented high-dose regimens without total body irradiation consisted of the MCVAC regimen using ranimustine ( MCNU , 450 mg/m2 ) , cytosine arabinoside ( 16 g/m2 ) , etoposide ( 1.6 g/m2 ) , and cyclophosphamide ( 100 mg/kg ) for patients with ALL , and the Hi-MEC regimen using melphalan ( 180 mg/m2 ) , etoposide ( 1.6 g/m2 ) , and carboplatinum ( 1.6 g/m2 ) for those with solid tumors . Five patients ( two in the treatment group and three in the control group ) were subsequently removed due to protocol violations . All patients survived PBSCT . The median numbers of transfused mononuclear cells ( MNC ) , CD34 ( + ) cells , and CFU-GM were , respectively , 4.5 ( range , 1 to 19 ) x 10 ( 8 ) /kg , 8.0 ( 1.1 to 25 ) x 10 ( 6 ) /kg , and 3.7 ( 1.2 to 23 ) x 10 ( 5 ) /kg in the treatment group ( n = 30 ) and 2.9 ( 0.8 to 21 ) x 10 ( 8 ) /kg , 6.3 ( 1.1 to 34 ) x 10 ( 6 ) /kg , and 5.5 ( 1.3 to 37 ) x 10 ( 5 ) /kg , respectively , in the control group ( n = 28 ) , with no significant difference . After PBSCT , the time to achieve an absolute neutrophil count ( ANC ) of > 0.5 x 10 ( 9 ) /L in the treatment group was less than that in the control group ( median , 11 v 12 days ; the log-rank test , P =.046 ) , although the last day of red blood cell ( RBC ) transfusion ( day 11 v day 10 ) and the duration of febrile days ( > 38 degrees C ) after PBSCT ( 4 v 4 days ) were identical in both groups . However , platelet recovery to > 20 x 10 ( 9 ) /L was significantly longer in treatment group than control group ( 26 v 16 days ; P =.009 ) and > 50 x 10 ( 9 ) /L tended to take longer in the treatment group ( 29 v 26 days ; P =.126 ) , with significantly more platelet transfusion-dependent days ( 27 v 13 days ; t-test , P =.037 ) . When patients were divided into two different disease cohorts , ALL patients showed no difference in engraftment kinetics between the G-CSF treatment and control groups , while differences were seen in those with solid tumors . We concluded that the marginal clinical benefit of 1 day earlier recovery of granulocytes could be offset by the delayed recovery of platelets . We recommend that the routine application of costly G-CSF therapy in children undergoing PBSCT should be seriously reconsidered .

[ "Marginal", "benefit", "/", "disadvantage", "of", "granulocyte", "colony", "-", "stimulating", "factor", "therapy", "after", "autologous", "blood", "stem", "cell", "transplantation", "in", "children", ":", "results", "of", "a", "prospective", "randomized", "trial", ".", "The", "Japanese", "Cooperative", "Study", "Group", "of", "PBSCT", ".", "In", "this", "prospective", "trial", ",", "a", "total", "of", "74", "children", "who", "were", "scheduled", "to", "undergo", "high", "-", "dose", "chemotherapy", "followed", "by", "autologous", "peripheral", "blood", "stem", "cell", "transplantation", "(", "PBSCT", ")", "were", "prospectively", "randomized", "at", "diagnosis", "to", "evaluate", "the", "effectiveness", "of", "exogenous", "granulocyte", "colony", "-", "stimulating", "factor", "(", "G", "-", "CSF", ")", "treatment", "in", "accelerating", "hematopoietic", "recovery", "after", "PBSCT", ".", "The", "diagnosis", "included", "acute", "lymphoblastic", "leukemia", "(", "ALL", ")", "(", "n", "=", "27", ")", ",", "neuroblastoma", "(", "n", "=", "29", ")", ",", "and", "miscellaneous", "solid", "tumors", "(", "n", "=", "18", ")", ".", "Eligibility", "criteria", "included", "(", "1", ")", "primary", "PBSCT", ",", "(", "2", ")", "chemotherapy", "-", "responsive", "disease", ",", "and", "(", "3", ")", "collected", "cell", "number", ">", "1", "x", "10", "(", "5", ")", "colony", "-", "forming", "unit", "-", "granulocyte", "-", "macrophage", "(", "CFU", "-", "GM", ")", "/kg", "and", ">", "1", "x", "10", "(", "6", ")", "CD34", "(", "+", ")", "cells", "/", "kg", "patient", "'", "s", "body", "weight", ".", "After", "applying", "the", "above", "criteria", ",", "11", "patients", "were", "excluded", "due", "to", "disease", "progression", "before", "PBSCT", "(", "n", "=", "6", ")", "or", "a", "low", "number", "of", "harvested", "cells", "(", "n", "=", "5", ")", ",", "leaving", "63", "patients", "for", "analysis", ";", "32", "patients", "in", "the", "treatment", "group", "(", "300", "microg", "/", "m2", "of", "G", "-", "CSF", "intravenously", "over", "1", "hour", "from", "day", "1", "of", "PBSCT", ")", "and", "31", "in", "the", "control", "group", "without", "treatment", ".", "Two", "distinct", "disease", "-", "oriented", "high", "-", "dose", "regimens", "without", "total", "body", "irradiation", "consisted", "of", "the", "MCVAC", "regimen", "using", "ranimustine", "(", "MCNU", ",", "450", "mg", "/", "m2", ")", ",", "cytosine", "arabinoside", "(", "16", "g", "/", "m2", ")", ",", "etoposide", "(", "1.6", "g", "/", "m2", ")", ",", "and", "cyclophosphamide", "(", "100", "mg", "/", "kg", ")", "for", "patients", "with", "ALL", ",", "and", "the", "Hi", "-", "MEC", "regimen", "using", "melphalan", "(", "180", "mg", "/", "m2", ")", ",", "etoposide", "(", "1.6", "g", "/", "m2", ")", ",", "and", "carboplatinum", "(", "1.6", "g", "/", "m2", ")", "for", "those", "with", "solid", "tumors", ".", "Five", "patients", "(", "two", "in", "the", "treatment", "group", "and", "three", "in", "the", "control", "group", ")", "were", "subsequently", "removed", "due", "to", "protocol", "violations", ".", "All", "patients", "survived", "PBSCT", ".", "The", "median", "numbers", "of", "transfused", "mononuclear", "cells", "(", "MNC", ")", ",", "CD34", "(", "+", ")", "cells", ",", "and", "CFU", "-", "GM", "were", ",", "respectively", ",", "4.5", "(", "range", ",", "1", "to", "19", ")", "x", "10", "(", "8", ")", "/kg", ",", "8.0", "(", "1.1", "to", "25", ")", "x", "10", "(", "6", ")", "/kg", ",", "and", "3.7", "(", "1.2", "to", "23", ")", "x", "10", "(", "5", ")", "/kg", "in", "the", "treatment", "group", "(", "n", "=", "30", ")", "and", "2.9", "(", "0.8", "to", "21", ")", "x", "10", "(", "8", ")", "/kg", ",", "6.3", "(", "1.1", "to", "34", ")", "x", "10", "(", "6", ")", "/kg", ",", "and", "5.5", "(", "1.3", "to", "37", ")", "x", "10", "(", "5", ")", "/kg", ",", "respectively", ",", "in", "the", "control", "group", "(", "n", "=", "28", ")", ",", "with", "no", "significant", "difference", ".", "After", "PBSCT", ",", "the", "time", "to", "achieve", "an", "absolute", "neutrophil", "count", "(", "ANC", ")", "of", ">", "0.5", "x", "10", "(", "9", ")", "/L", "in", "the", "treatment", "group", "was", "less", "than", "that", "in", "the", "control", "group", "(", "median", ",", "11", "v", "12", "days", ";", "the", "log", "-", "rank", "test", ",", "P", "=", ".046", ")", ",", "although", "the", "last", "day", "of", "red", "blood", "cell", "(", "RBC", ")", "transfusion", "(", "day", "11", "v", "day", "10", ")", "and", "the", "duration", "of", "febrile", "days", "(", ">", "38", "degrees", "C", ")", "after", "PBSCT", "(", "4", "v", "4", "days", ")", "were", "identical", "in", "both", "groups", ".", "However", ",", "platelet", "recovery", "to", ">", "20", "x", "10", "(", "9", ")", "/L", "was", "significantly", "longer", "in", "treatment", "group", "than", "control", "group", "(", "26", "v", "16", "days", ";", "P", "=", ".009", ")", "and", ">", "50", "x", "10", "(", "9", ")", "/L", "tended", "to", "take", "longer", "in", "the", "treatment", "group", "(", "29", "v", "26", "days", ";", "P", "=", ".126", ")", ",", "with", "significantly", "more", "platelet", "transfusion", "-", "dependent", "days", "(", "27", "v", "13", "days", ";", "t", "-", "test", ",", "P", "=", ".037", ")", ".", "When", "patients", "were", "divided", "into", "two", "different", "disease", "cohorts", ",", "ALL", "patients", "showed", "no", "difference", "in", "engraftment", "kinetics", "between", "the", "G", "-", "CSF", "treatment", "and", "control", "groups", ",", "while", "differences", "were", "seen", "in", "those", "with", "solid", "tumors", ".", "We", "concluded", "that", "the", "marginal", "clinical", "benefit", "of", "1", "day", "earlier", "recovery", "of", "granulocytes", "could", "be", "offset", "by", "the", "delayed", "recovery", "of", "platelets", ".", "We", "recommend", "that", "the", "routine", "application", "of", "costly", "G", "-", "CSF", "therapy", "in", "children", "undergoing", "PBSCT", "should", "be", "seriously", "reconsidered", "." ]

[ "Intervention_Pharmacological", "Participant_Condition", "Outcome_Other", "Outcome_Physical", "Intervention_Control", "Outcome_Mortality", "Participant_Age", "Participant_Sample-size" ]

benefit / disadvantage, granulocyte colony - stimulating factor therapy, children, PBSCT, 74, high - dose chemotherapy, autologous peripheral blood stem cell transplantation ( PBSCT ), effectiveness, G - CSF, hematopoietic recovery, acute lymphoblastic leukemia, 27, neuroblastoma, 29, miscellaneous solid tumors, 18, primary PBSCT, chemotherapy - responsive disease, collected cell number > 1 x 10 ( 5 ) colony - forming unit - granulocyte - macrophage ( CFU - GM ) /kg and > 1 x 10 ( 6 ) CD34 ( + ) cells / kg, 11, 63, 32, control group, high - dose regimens without total body irradiation consisted of the MCVAC regimen using ranimustine ( MCNU , 450 mg / m2 ) , cytosine arabinoside ( 16 g / m2 ) , etoposide ( 1.6 g / m2 ) , and cyclophosphamide, Hi - MEC regimen using melphalan, carboplatinum, Five, two, three, survived, median numbers of transfused mononuclear cells ( MNC ), time to achieve an absolute neutrophil count ( ANC ) of > 0.5 x 10 ( 9 ) /L, duration of febrile days, platelet recovery to > 20 x 10 ( 9 ) /L, platelet transfusion - dependent days, engraftment kinetics, recovery of granulocytes, recovery of platelets .

93229_task2

Sentence: Marginal benefit/disadvantage of granulocyte colony-stimulating factor therapy after autologous blood stem cell transplantation in children : results of a prospective randomized trial . The Japanese Cooperative Study Group of PBSCT . In this prospective trial , a total of 74 children who were scheduled to undergo high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation ( PBSCT ) were prospectively randomized at diagnosis to evaluate the effectiveness of exogenous granulocyte colony-stimulating factor ( G-CSF ) treatment in accelerating hematopoietic recovery after PBSCT . The diagnosis included acute lymphoblastic leukemia ( ALL ) ( n = 27 ) , neuroblastoma ( n = 29 ) , and miscellaneous solid tumors ( n = 18 ) . Eligibility criteria included ( 1 ) primary PBSCT , ( 2 ) chemotherapy-responsive disease , and ( 3 ) collected cell number > 1 x 10 ( 5 ) colony-forming unit-granulocyte-macrophage ( CFU-GM ) /kg and > 1 x 10 ( 6 ) CD34 ( + ) cells/kg patient 's body weight . After applying the above criteria , 11 patients were excluded due to disease progression before PBSCT ( n = 6 ) or a low number of harvested cells ( n = 5 ) , leaving 63 patients for analysis ; 32 patients in the treatment group ( 300 microg/m2 of G-CSF intravenously over 1 hour from day 1 of PBSCT ) and 31 in the control group without treatment . Two distinct disease-oriented high-dose regimens without total body irradiation consisted of the MCVAC regimen using ranimustine ( MCNU , 450 mg/m2 ) , cytosine arabinoside ( 16 g/m2 ) , etoposide ( 1.6 g/m2 ) , and cyclophosphamide ( 100 mg/kg ) for patients with ALL , and the Hi-MEC regimen using melphalan ( 180 mg/m2 ) , etoposide ( 1.6 g/m2 ) , and carboplatinum ( 1.6 g/m2 ) for those with solid tumors . Five patients ( two in the treatment group and three in the control group ) were subsequently removed due to protocol violations . All patients survived PBSCT . The median numbers of transfused mononuclear cells ( MNC ) , CD34 ( + ) cells , and CFU-GM were , respectively , 4.5 ( range , 1 to 19 ) x 10 ( 8 ) /kg , 8.0 ( 1.1 to 25 ) x 10 ( 6 ) /kg , and 3.7 ( 1.2 to 23 ) x 10 ( 5 ) /kg in the treatment group ( n = 30 ) and 2.9 ( 0.8 to 21 ) x 10 ( 8 ) /kg , 6.3 ( 1.1 to 34 ) x 10 ( 6 ) /kg , and 5.5 ( 1.3 to 37 ) x 10 ( 5 ) /kg , respectively , in the control group ( n = 28 ) , with no significant difference . After PBSCT , the time to achieve an absolute neutrophil count ( ANC ) of > 0.5 x 10 ( 9 ) /L in the treatment group was less than that in the control group ( median , 11 v 12 days ; the log-rank test , P =.046 ) , although the last day of red blood cell ( RBC ) transfusion ( day 11 v day 10 ) and the duration of febrile days ( > 38 degrees C ) after PBSCT ( 4 v 4 days ) were identical in both groups . However , platelet recovery to > 20 x 10 ( 9 ) /L was significantly longer in treatment group than control group ( 26 v 16 days ; P =.009 ) and > 50 x 10 ( 9 ) /L tended to take longer in the treatment group ( 29 v 26 days ; P =.126 ) , with significantly more platelet transfusion-dependent days ( 27 v 13 days ; t-test , P =.037 ) . When patients were divided into two different disease cohorts , ALL patients showed no difference in engraftment kinetics between the G-CSF treatment and control groups , while differences were seen in those with solid tumors . We concluded that the marginal clinical benefit of 1 day earlier recovery of granulocytes could be offset by the delayed recovery of platelets . We recommend that the routine application of costly G-CSF therapy in children undergoing PBSCT should be seriously reconsidered . Instructions: please extract entity words from the input sentence

[ "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "B-Participant_Condition", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Marginal benefit/disadvantage of granulocyte colony-stimulating factor therapy after autologous blood stem cell transplantation in children : results of a prospective randomized trial . The Japanese Cooperative Study Group of PBSCT . In this prospective trial , a total of 74 children who were scheduled to undergo high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation ( PBSCT ) were prospectively randomized at diagnosis to evaluate the effectiveness of exogenous granulocyte colony-stimulating factor ( G-CSF ) treatment in accelerating hematopoietic recovery after PBSCT . The diagnosis included acute lymphoblastic leukemia ( ALL ) ( n = 27 ) , neuroblastoma ( n = 29 ) , and miscellaneous solid tumors ( n = 18 ) . Eligibility criteria included ( 1 ) primary PBSCT , ( 2 ) chemotherapy-responsive disease , and ( 3 ) collected cell number > 1 x 10 ( 5 ) colony-forming unit-granulocyte-macrophage ( CFU-GM ) /kg and > 1 x 10 ( 6 ) CD34 ( + ) cells/kg patient 's body weight . After applying the above criteria , 11 patients were excluded due to disease progression before PBSCT ( n = 6 ) or a low number of harvested cells ( n = 5 ) , leaving 63 patients for analysis ; 32 patients in the treatment group ( 300 microg/m2 of G-CSF intravenously over 1 hour from day 1 of PBSCT ) and 31 in the control group without treatment . Two distinct disease-oriented high-dose regimens without total body irradiation consisted of the MCVAC regimen using ranimustine ( MCNU , 450 mg/m2 ) , cytosine arabinoside ( 16 g/m2 ) , etoposide ( 1.6 g/m2 ) , and cyclophosphamide ( 100 mg/kg ) for patients with ALL , and the Hi-MEC regimen using melphalan ( 180 mg/m2 ) , etoposide ( 1.6 g/m2 ) , and carboplatinum ( 1.6 g/m2 ) for those with solid tumors . Five patients ( two in the treatment group and three in the control group ) were subsequently removed due to protocol violations . All patients survived PBSCT . The median numbers of transfused mononuclear cells ( MNC ) , CD34 ( + ) cells , and CFU-GM were , respectively , 4.5 ( range , 1 to 19 ) x 10 ( 8 ) /kg , 8.0 ( 1.1 to 25 ) x 10 ( 6 ) /kg , and 3.7 ( 1.2 to 23 ) x 10 ( 5 ) /kg in the treatment group ( n = 30 ) and 2.9 ( 0.8 to 21 ) x 10 ( 8 ) /kg , 6.3 ( 1.1 to 34 ) x 10 ( 6 ) /kg , and 5.5 ( 1.3 to 37 ) x 10 ( 5 ) /kg , respectively , in the control group ( n = 28 ) , with no significant difference . After PBSCT , the time to achieve an absolute neutrophil count ( ANC ) of > 0.5 x 10 ( 9 ) /L in the treatment group was less than that in the control group ( median , 11 v 12 days ; the log-rank test , P =.046 ) , although the last day of red blood cell ( RBC ) transfusion ( day 11 v day 10 ) and the duration of febrile days ( > 38 degrees C ) after PBSCT ( 4 v 4 days ) were identical in both groups . However , platelet recovery to > 20 x 10 ( 9 ) /L was significantly longer in treatment group than control group ( 26 v 16 days ; P =.009 ) and > 50 x 10 ( 9 ) /L tended to take longer in the treatment group ( 29 v 26 days ; P =.126 ) , with significantly more platelet transfusion-dependent days ( 27 v 13 days ; t-test , P =.037 ) . When patients were divided into two different disease cohorts , ALL patients showed no difference in engraftment kinetics between the G-CSF treatment and control groups , while differences were seen in those with solid tumors . We concluded that the marginal clinical benefit of 1 day earlier recovery of granulocytes could be offset by the delayed recovery of platelets . We recommend that the routine application of costly G-CSF therapy in children undergoing PBSCT should be seriously reconsidered .

[ "Marginal", "benefit", "/", "disadvantage", "of", "granulocyte", "colony", "-", "stimulating", "factor", "therapy", "after", "autologous", "blood", "stem", "cell", "transplantation", "in", "children", ":", "results", "of", "a", "prospective", "randomized", "trial", ".", "The", "Japanese", "Cooperative", "Study", "Group", "of", "PBSCT", ".", "In", "this", "prospective", "trial", ",", "a", "total", "of", "74", "children", "who", "were", "scheduled", "to", "undergo", "high", "-", "dose", "chemotherapy", "followed", "by", "autologous", "peripheral", "blood", "stem", "cell", "transplantation", "(", "PBSCT", ")", "were", "prospectively", "randomized", "at", "diagnosis", "to", "evaluate", "the", "effectiveness", "of", "exogenous", "granulocyte", "colony", "-", "stimulating", "factor", "(", "G", "-", "CSF", ")", "treatment", "in", "accelerating", "hematopoietic", "recovery", "after", "PBSCT", ".", "The", "diagnosis", "included", "acute", "lymphoblastic", "leukemia", "(", "ALL", ")", "(", "n", "=", "27", ")", ",", "neuroblastoma", "(", "n", "=", "29", ")", ",", "and", "miscellaneous", "solid", "tumors", "(", "n", "=", "18", ")", ".", "Eligibility", "criteria", "included", "(", "1", ")", "primary", "PBSCT", ",", "(", "2", ")", "chemotherapy", "-", "responsive", "disease", ",", "and", "(", "3", ")", "collected", "cell", "number", ">", "1", "x", "10", "(", "5", ")", "colony", "-", "forming", "unit", "-", "granulocyte", "-", "macrophage", "(", "CFU", "-", "GM", ")", "/kg", "and", ">", "1", "x", "10", "(", "6", ")", "CD34", "(", "+", ")", "cells", "/", "kg", "patient", "'", "s", "body", "weight", ".", "After", "applying", "the", "above", "criteria", ",", "11", "patients", "were", "excluded", "due", "to", "disease", "progression", "before", "PBSCT", "(", "n", "=", "6", ")", "or", "a", "low", "number", "of", "harvested", "cells", "(", "n", "=", "5", ")", ",", "leaving", "63", "patients", "for", "analysis", ";", "32", "patients", "in", "the", "treatment", "group", "(", "300", "microg", "/", "m2", "of", "G", "-", "CSF", "intravenously", "over", "1", "hour", "from", "day", "1", "of", "PBSCT", ")", "and", "31", "in", "the", "control", "group", "without", "treatment", ".", "Two", "distinct", "disease", "-", "oriented", "high", "-", "dose", "regimens", "without", "total", "body", "irradiation", "consisted", "of", "the", "MCVAC", "regimen", "using", "ranimustine", "(", "MCNU", ",", "450", "mg", "/", "m2", ")", ",", "cytosine", "arabinoside", "(", "16", "g", "/", "m2", ")", ",", "etoposide", "(", "1.6", "g", "/", "m2", ")", ",", "and", "cyclophosphamide", "(", "100", "mg", "/", "kg", ")", "for", "patients", "with", "ALL", ",", "and", "the", "Hi", "-", "MEC", "regimen", "using", "melphalan", "(", "180", "mg", "/", "m2", ")", ",", "etoposide", "(", "1.6", "g", "/", "m2", ")", ",", "and", "carboplatinum", "(", "1.6", "g", "/", "m2", ")", "for", "those", "with", "solid", "tumors", ".", "Five", "patients", "(", "two", "in", "the", "treatment", "group", "and", "three", "in", "the", "control", "group", ")", "were", "subsequently", "removed", "due", "to", "protocol", "violations", ".", "All", "patients", "survived", "PBSCT", ".", "The", "median", "numbers", "of", "transfused", "mononuclear", "cells", "(", "MNC", ")", ",", "CD34", "(", "+", ")", "cells", ",", "and", "CFU", "-", "GM", "were", ",", "respectively", ",", "4.5", "(", "range", ",", "1", "to", "19", ")", "x", "10", "(", "8", ")", "/kg", ",", "8.0", "(", "1.1", "to", "25", ")", "x", "10", "(", "6", ")", "/kg", ",", "and", "3.7", "(", "1.2", "to", "23", ")", "x", "10", "(", "5", ")", "/kg", "in", "the", "treatment", "group", "(", "n", "=", "30", ")", "and", "2.9", "(", "0.8", "to", "21", ")", "x", "10", "(", "8", ")", "/kg", ",", "6.3", "(", "1.1", "to", "34", ")", "x", "10", "(", "6", ")", "/kg", ",", "and", "5.5", "(", "1.3", "to", "37", ")", "x", "10", "(", "5", ")", "/kg", ",", "respectively", ",", "in", "the", "control", "group", "(", "n", "=", "28", ")", ",", "with", "no", "significant", "difference", ".", "After", "PBSCT", ",", "the", "time", "to", "achieve", "an", "absolute", "neutrophil", "count", "(", "ANC", ")", "of", ">", "0.5", "x", "10", "(", "9", ")", "/L", "in", "the", "treatment", "group", "was", "less", "than", "that", "in", "the", "control", "group", "(", "median", ",", "11", "v", "12", "days", ";", "the", "log", "-", "rank", "test", ",", "P", "=", ".046", ")", ",", "although", "the", "last", "day", "of", "red", "blood", "cell", "(", "RBC", ")", "transfusion", "(", "day", "11", "v", "day", "10", ")", "and", "the", "duration", "of", "febrile", "days", "(", ">", "38", "degrees", "C", ")", "after", "PBSCT", "(", "4", "v", "4", "days", ")", "were", "identical", "in", "both", "groups", ".", "However", ",", "platelet", "recovery", "to", ">", "20", "x", "10", "(", "9", ")", "/L", "was", "significantly", "longer", "in", "treatment", "group", "than", "control", "group", "(", "26", "v", "16", "days", ";", "P", "=", ".009", ")", "and", ">", "50", "x", "10", "(", "9", ")", "/L", "tended", "to", "take", "longer", "in", "the", "treatment", "group", "(", "29", "v", "26", "days", ";", "P", "=", ".126", ")", ",", "with", "significantly", "more", "platelet", "transfusion", "-", "dependent", "days", "(", "27", "v", "13", "days", ";", "t", "-", "test", ",", "P", "=", ".037", ")", ".", "When", "patients", "were", "divided", "into", "two", "different", "disease", "cohorts", ",", "ALL", "patients", "showed", "no", "difference", "in", "engraftment", "kinetics", "between", "the", "G", "-", "CSF", "treatment", "and", "control", "groups", ",", "while", "differences", "were", "seen", "in", "those", "with", "solid", "tumors", ".", "We", "concluded", "that", "the", "marginal", "clinical", "benefit", "of", "1", "day", "earlier", "recovery", "of", "granulocytes", "could", "be", "offset", "by", "the", "delayed", "recovery", "of", "platelets", ".", "We", "recommend", "that", "the", "routine", "application", "of", "costly", "G", "-", "CSF", "therapy", "in", "children", "undergoing", "PBSCT", "should", "be", "seriously", "reconsidered", "." ]

[ "Intervention_Pharmacological", "Participant_Condition", "Outcome_Other", "Outcome_Physical", "Intervention_Control", "Outcome_Mortality", "Participant_Age", "Participant_Sample-size" ]

Jedet is a NOMBRE_SUJETO_ASISTENCIA, Sanchez Garcia is a NOMBRE_SUJETO_ASISTENCIA, 7845123 is a ID_SUJETO_ASISTENCIA, 23 56487946 12 is a ID_ASEGURAMIENTO, Girona is a TERRITORIO, 17002 is a TERRITORIO, 14/09/1986 is a FECHAS, España is a PAIS, 31 años is a EDAD_SUJETO_ASISTENCIA, 11/12/2017 is a FECHAS, Paula Ortiz Ballujera is a NOMBRE_PERSONAL_SANITARIO, 17 17 85236 is a ID_TITULACION_PERSONAL_SANITARIO, varón is a SEXO_SUJETO_ASISTENCIA, 31 años is a EDAD_SUJETO_ASISTENCIA, Paula Ortiz Ballujera is a NOMBRE_PERSONAL_SANITARIO, Hospital Universitari de Girona Doctor Josep Trueta is a HOSPITAL, 17007 is a TERRITORIO, Girona is a TERRITORIO, España is a PAIS, ballujera@hotmail.com is a CORREO_ELECTRONICO

97_task0

Sentence: Nombre: Jedet. Apellidos: Sanchez Garcia. NHC: 7845123. NASS: 23 56487946 12. Domicilio: Carrer del Dr. Castany 28, 8A. Localidad/ Provincia: Girona. CP: 17002. Datos asistenciales. Fecha de nacimiento: 14/09/1986. País: España. Edad: 31 años Sexo: H. Fecha de Ingreso: 11/12/2017. Servicio: Medicina intensiva. Médico:Paula Ortiz Ballujera NºCol: 17 17 85236. Historia Actual: El paciente era un varón de 31 años de edad que sufrió un accidente de motocicleta. La radiografía de tórax mostraba un ensanchamiento mediastínico. La TACHT al ingreso mostró un seudoaneurisma de aorta torácica distal a la salida de la arteria subclavia izquierda con un importante hematoma periaórtico y mediastínico asociado con hemotórax bilateral. Ingresó en la UCI, donde se consiguió un control estricto de la tensión arterial. A las 8 horas del traumatismo se colocó una endoprótesis en la aorta torácica descendente por vía ilíaca izquierda. La arteria subclavia izquierda quedó parcialmente ocluida sin repercusión clínica. A las 24 horas fue dado de alta a planta y a la semana se le dio el alta hospitalaria, ya que estaba asintomático. Remitido por: Dirección para correspondencia: Dra. Paula Ortiz Ballujera. Servicio de Medicina Intensiva (UCI). Hospital Universitari de Girona Doctor Josep Trueta. Avda. de França, s/n. 17007 Girona. España. Correo electrónico: ballujera@hotmail.com Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: TERRITORIO, SEXO_SUJETO_ASISTENCIA, ID_SUJETO_ASISTENCIA, FECHAS, HOSPITAL, CORREO_ELECTRONICO, PAIS, EDAD_SUJETO_ASISTENCIA, ID_ASEGURAMIENTO, ID_TITULACION_PERSONAL_SANITARIO, NOMBRE_SUJETO_ASISTENCIA, NOMBRE_PERSONAL_SANITARIO

[ "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "B-TERRITORIO", "O", "B-PAIS", "O", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]

Nombre: Jedet. Apellidos: Sanchez Garcia. NHC: 7845123. NASS: 23 56487946 12. Domicilio: Carrer del Dr. Castany 28, 8A. Localidad/ Provincia: Girona. CP: 17002. Datos asistenciales. Fecha de nacimiento: 14/09/1986. País: España. Edad: 31 años Sexo: H. Fecha de Ingreso: 11/12/2017. Servicio: Medicina intensiva. Médico:Paula Ortiz Ballujera NºCol: 17 17 85236. Historia Actual: El paciente era un varón de 31 años de edad que sufrió un accidente de motocicleta. La radiografía de tórax mostraba un ensanchamiento mediastínico. La TACHT al ingreso mostró un seudoaneurisma de aorta torácica distal a la salida de la arteria subclavia izquierda con un importante hematoma periaórtico y mediastínico asociado con hemotórax bilateral. Ingresó en la UCI, donde se consiguió un control estricto de la tensión arterial. A las 8 horas del traumatismo se colocó una endoprótesis en la aorta torácica descendente por vía ilíaca izquierda. La arteria subclavia izquierda quedó parcialmente ocluida sin repercusión clínica. A las 24 horas fue dado de alta a planta y a la semana se le dio el alta hospitalaria, ya que estaba asintomático. Remitido por: Dirección para correspondencia: Dra. Paula Ortiz Ballujera. Servicio de Medicina Intensiva (UCI). Hospital Universitari de Girona Doctor Josep Trueta. Avda. de França, s/n. 17007 Girona. España. Correo electrónico: ballujera@hotmail.com

[ "Nombre", ":", "Jedet", ".", "\n", "Apellidos", ":", "Sanchez", "Garcia", ".", "\n", "NHC", ":", "7845123", ".", "\n", "NASS", ":", "23", "56487946", "12", ".", "\n", "Domicilio", ":", "Carrer", "del", "Dr", ".", "Castany", "28", ",", "8A.", "\n", "Localidad/", "Provincia", ":", "Girona", ".", "\n", "CP", ":", "17002", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "14/09/1986", ".", "\n", "País", ":", "España", ".", "\n", "Edad", ":", "31", "años", "Sexo", ":", "H.", "\n", "Fecha", "de", "Ingreso", ":", "11/12/2017", ".", "\n", "Servicio", ":", "Medicina", "intensiva", ".", "\n", "Médico", ":", "Paula", "Ortiz", "Ballujera", "NºCol", ":", "17", "17", "85236", ".", "\n", "Historia", "Actual", ":", "El", "paciente", "era", "un", "varón", "de", "31", "años", "de", "edad", "que", "sufrió", "un", "accidente", "de", "motocicleta", ".", "La", "radiografía", "de", "tórax", "mostraba", "un", "ensanchamiento", "mediastínico", ".", "La", "TACHT", "al", "ingreso", "mostró", "un", "seudoaneurisma", "de", "aorta", "torácica", "distal", "a", "la", "salida", "de", "la", "arteria", "subclavia", "izquierda", "con", "un", "importante", "hematoma", "periaórtico", "y", "mediastínico", "asociado", "con", "hemotórax", "bilateral", ".", "\n", "Ingresó", "en", "la", "UCI", ",", "donde", "se", "consiguió", "un", "control", "estricto", "de", "la", "tensión", "arterial", ".", "A", "las", "8", "horas", "del", "traumatismo", "se", "colocó", "una", "endoprótesis", "en", "la", "aorta", "torácica", "descendente", "por", "vía", "ilíaca", "izquierda", ".", "La", "arteria", "subclavia", "izquierda", "quedó", "parcialmente", "ocluida", "sin", "repercusión", "clínica", ".", "A", "las", "24", "horas", "fue", "dado", "de", "alta", "a", "planta", "y", "a", "la", "semana", "se", "le", "dio", "el", "alta", "hospitalaria", ",", "ya", "que", "estaba", "asintomático", ".", "\n", "Remitido", "por", ":", "Dirección", "para", "correspondencia", ":", "Dra", ".", "Paula", "Ortiz", "Ballujera", ".", "Servicio", "de", "Medicina", "Intensiva", "(", "UCI", ")", ".", "Hospital", "Universitari", "de", "Girona", "Doctor", "Josep", "Trueta", ".", "Avda", ".", "de", "França", ",", "s", "/", "n.", "17007", "Girona", ".", "España", ".", "Correo", "electrónico", ":", "ballujera@hotmail.com", "\n" ]

[ "HOSPITAL", "CALLE", "CORREO_ELECTRONICO", "NOMBRE_PERSONAL_SANITARIO", "ID_ASEGURAMIENTO", "NOMBRE_SUJETO_ASISTENCIA", "ID_TITULACION_PERSONAL_SANITARIO", "FECHAS", "EDAD_SUJETO_ASISTENCIA", "ID_SUJETO_ASISTENCIA", "PAIS", "TERRITORIO", "SEXO_SUJETO_ASISTENCIA" ]

Jedet is a NOMBRE_SUJETO_ASISTENCIA, Sanchez Garcia is a NOMBRE_SUJETO_ASISTENCIA, 7845123 is a ID_SUJETO_ASISTENCIA, 23 56487946 12 is a ID_ASEGURAMIENTO, Girona is a TERRITORIO, 17002 is a TERRITORIO, 14/09/1986 is a FECHAS, España is a PAIS, 31 años is a EDAD_SUJETO_ASISTENCIA, 11/12/2017 is a FECHAS, Paula Ortiz Ballujera is a NOMBRE_PERSONAL_SANITARIO, 17 17 85236 is a ID_TITULACION_PERSONAL_SANITARIO, varón is a SEXO_SUJETO_ASISTENCIA, 31 años is a EDAD_SUJETO_ASISTENCIA, Paula Ortiz Ballujera is a NOMBRE_PERSONAL_SANITARIO, Hospital Universitari de Girona Doctor Josep Trueta is a HOSPITAL, 17007 is a TERRITORIO, Girona is a TERRITORIO, España is a PAIS, ballujera@hotmail.com is a CORREO_ELECTRONICO

97_task1

Sentence: Nombre: Jedet. Apellidos: Sanchez Garcia. NHC: 7845123. NASS: 23 56487946 12. Domicilio: Carrer del Dr. Castany 28, 8A. Localidad/ Provincia: Girona. CP: 17002. Datos asistenciales. Fecha de nacimiento: 14/09/1986. País: España. Edad: 31 años Sexo: H. Fecha de Ingreso: 11/12/2017. Servicio: Medicina intensiva. Médico:Paula Ortiz Ballujera NºCol: 17 17 85236. Historia Actual: El paciente era un varón de 31 años de edad que sufrió un accidente de motocicleta. La radiografía de tórax mostraba un ensanchamiento mediastínico. La TACHT al ingreso mostró un seudoaneurisma de aorta torácica distal a la salida de la arteria subclavia izquierda con un importante hematoma periaórtico y mediastínico asociado con hemotórax bilateral. Ingresó en la UCI, donde se consiguió un control estricto de la tensión arterial. A las 8 horas del traumatismo se colocó una endoprótesis en la aorta torácica descendente por vía ilíaca izquierda. La arteria subclavia izquierda quedó parcialmente ocluida sin repercusión clínica. A las 24 horas fue dado de alta a planta y a la semana se le dio el alta hospitalaria, ya que estaba asintomático. Remitido por: Dirección para correspondencia: Dra. Paula Ortiz Ballujera. Servicio de Medicina Intensiva (UCI). Hospital Universitari de Girona Doctor Josep Trueta. Avda. de França, s/n. 17007 Girona. España. Correo electrónico: ballujera@hotmail.com Instructions: please typing these entity words according to sentence: Jedet, Sanchez Garcia, 7845123, 23 56487946 12, Girona, 17002, 14/09/1986, España, 31 años, 11/12/2017, Paula Ortiz Ballujera, 17 17 85236, varón, 31 años, Paula Ortiz Ballujera, Hospital Universitari de Girona Doctor Josep Trueta, 17007, Girona, España, ballujera@hotmail.com Options: TERRITORIO, SEXO_SUJETO_ASISTENCIA, ID_SUJETO_ASISTENCIA, FECHAS, HOSPITAL, CORREO_ELECTRONICO, PAIS, EDAD_SUJETO_ASISTENCIA, ID_ASEGURAMIENTO, ID_TITULACION_PERSONAL_SANITARIO, NOMBRE_SUJETO_ASISTENCIA, NOMBRE_PERSONAL_SANITARIO

[ "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "B-TERRITORIO", "O", "B-PAIS", "O", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]

Nombre: Jedet. Apellidos: Sanchez Garcia. NHC: 7845123. NASS: 23 56487946 12. Domicilio: Carrer del Dr. Castany 28, 8A. Localidad/ Provincia: Girona. CP: 17002. Datos asistenciales. Fecha de nacimiento: 14/09/1986. País: España. Edad: 31 años Sexo: H. Fecha de Ingreso: 11/12/2017. Servicio: Medicina intensiva. Médico:Paula Ortiz Ballujera NºCol: 17 17 85236. Historia Actual: El paciente era un varón de 31 años de edad que sufrió un accidente de motocicleta. La radiografía de tórax mostraba un ensanchamiento mediastínico. La TACHT al ingreso mostró un seudoaneurisma de aorta torácica distal a la salida de la arteria subclavia izquierda con un importante hematoma periaórtico y mediastínico asociado con hemotórax bilateral. Ingresó en la UCI, donde se consiguió un control estricto de la tensión arterial. A las 8 horas del traumatismo se colocó una endoprótesis en la aorta torácica descendente por vía ilíaca izquierda. La arteria subclavia izquierda quedó parcialmente ocluida sin repercusión clínica. A las 24 horas fue dado de alta a planta y a la semana se le dio el alta hospitalaria, ya que estaba asintomático. Remitido por: Dirección para correspondencia: Dra. Paula Ortiz Ballujera. Servicio de Medicina Intensiva (UCI). Hospital Universitari de Girona Doctor Josep Trueta. Avda. de França, s/n. 17007 Girona. España. Correo electrónico: ballujera@hotmail.com

[ "Nombre", ":", "Jedet", ".", "\n", "Apellidos", ":", "Sanchez", "Garcia", ".", "\n", "NHC", ":", "7845123", ".", "\n", "NASS", ":", "23", "56487946", "12", ".", "\n", "Domicilio", ":", "Carrer", "del", "Dr", ".", "Castany", "28", ",", "8A.", "\n", "Localidad/", "Provincia", ":", "Girona", ".", "\n", "CP", ":", "17002", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "14/09/1986", ".", "\n", "País", ":", "España", ".", "\n", "Edad", ":", "31", "años", "Sexo", ":", "H.", "\n", "Fecha", "de", "Ingreso", ":", "11/12/2017", ".", "\n", "Servicio", ":", "Medicina", "intensiva", ".", "\n", "Médico", ":", "Paula", "Ortiz", "Ballujera", "NºCol", ":", "17", "17", "85236", ".", "\n", "Historia", "Actual", ":", "El", "paciente", "era", "un", "varón", "de", "31", "años", "de", "edad", "que", "sufrió", "un", "accidente", "de", "motocicleta", ".", "La", "radiografía", "de", "tórax", "mostraba", "un", "ensanchamiento", "mediastínico", ".", "La", "TACHT", "al", "ingreso", "mostró", "un", "seudoaneurisma", "de", "aorta", "torácica", "distal", "a", "la", "salida", "de", "la", "arteria", "subclavia", "izquierda", "con", "un", "importante", "hematoma", "periaórtico", "y", "mediastínico", "asociado", "con", "hemotórax", "bilateral", ".", "\n", "Ingresó", "en", "la", "UCI", ",", "donde", "se", "consiguió", "un", "control", "estricto", "de", "la", "tensión", "arterial", ".", "A", "las", "8", "horas", "del", "traumatismo", "se", "colocó", "una", "endoprótesis", "en", "la", "aorta", "torácica", "descendente", "por", "vía", "ilíaca", "izquierda", ".", "La", "arteria", "subclavia", "izquierda", "quedó", "parcialmente", "ocluida", "sin", "repercusión", "clínica", ".", "A", "las", "24", "horas", "fue", "dado", "de", "alta", "a", "planta", "y", "a", "la", "semana", "se", "le", "dio", "el", "alta", "hospitalaria", ",", "ya", "que", "estaba", "asintomático", ".", "\n", "Remitido", "por", ":", "Dirección", "para", "correspondencia", ":", "Dra", ".", "Paula", "Ortiz", "Ballujera", ".", "Servicio", "de", "Medicina", "Intensiva", "(", "UCI", ")", ".", "Hospital", "Universitari", "de", "Girona", "Doctor", "Josep", "Trueta", ".", "Avda", ".", "de", "França", ",", "s", "/", "n.", "17007", "Girona", ".", "España", ".", "Correo", "electrónico", ":", "ballujera@hotmail.com", "\n" ]

[ "HOSPITAL", "CALLE", "CORREO_ELECTRONICO", "NOMBRE_PERSONAL_SANITARIO", "ID_ASEGURAMIENTO", "NOMBRE_SUJETO_ASISTENCIA", "ID_TITULACION_PERSONAL_SANITARIO", "FECHAS", "EDAD_SUJETO_ASISTENCIA", "ID_SUJETO_ASISTENCIA", "PAIS", "TERRITORIO", "SEXO_SUJETO_ASISTENCIA" ]

Jedet, Sanchez Garcia, 7845123, 23 56487946 12, Girona, 17002, 14/09/1986, España, 31 años, 11/12/2017, Paula Ortiz Ballujera, 17 17 85236, varón, 31 años, Paula Ortiz Ballujera, Hospital Universitari de Girona Doctor Josep Trueta, 17007, Girona, España, ballujera@hotmail.com

97_task2

Sentence: Nombre: Jedet. Apellidos: Sanchez Garcia. NHC: 7845123. NASS: 23 56487946 12. Domicilio: Carrer del Dr. Castany 28, 8A. Localidad/ Provincia: Girona. CP: 17002. Datos asistenciales. Fecha de nacimiento: 14/09/1986. País: España. Edad: 31 años Sexo: H. Fecha de Ingreso: 11/12/2017. Servicio: Medicina intensiva. Médico:Paula Ortiz Ballujera NºCol: 17 17 85236. Historia Actual: El paciente era un varón de 31 años de edad que sufrió un accidente de motocicleta. La radiografía de tórax mostraba un ensanchamiento mediastínico. La TACHT al ingreso mostró un seudoaneurisma de aorta torácica distal a la salida de la arteria subclavia izquierda con un importante hematoma periaórtico y mediastínico asociado con hemotórax bilateral. Ingresó en la UCI, donde se consiguió un control estricto de la tensión arterial. A las 8 horas del traumatismo se colocó una endoprótesis en la aorta torácica descendente por vía ilíaca izquierda. La arteria subclavia izquierda quedó parcialmente ocluida sin repercusión clínica. A las 24 horas fue dado de alta a planta y a la semana se le dio el alta hospitalaria, ya que estaba asintomático. Remitido por: Dirección para correspondencia: Dra. Paula Ortiz Ballujera. Servicio de Medicina Intensiva (UCI). Hospital Universitari de Girona Doctor Josep Trueta. Avda. de França, s/n. 17007 Girona. España. Correo electrónico: ballujera@hotmail.com Instructions: please extract entity words from the input sentence

[ "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "B-TERRITORIO", "O", "B-PAIS", "O", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]

Nombre: Jedet. Apellidos: Sanchez Garcia. NHC: 7845123. NASS: 23 56487946 12. Domicilio: Carrer del Dr. Castany 28, 8A. Localidad/ Provincia: Girona. CP: 17002. Datos asistenciales. Fecha de nacimiento: 14/09/1986. País: España. Edad: 31 años Sexo: H. Fecha de Ingreso: 11/12/2017. Servicio: Medicina intensiva. Médico:Paula Ortiz Ballujera NºCol: 17 17 85236. Historia Actual: El paciente era un varón de 31 años de edad que sufrió un accidente de motocicleta. La radiografía de tórax mostraba un ensanchamiento mediastínico. La TACHT al ingreso mostró un seudoaneurisma de aorta torácica distal a la salida de la arteria subclavia izquierda con un importante hematoma periaórtico y mediastínico asociado con hemotórax bilateral. Ingresó en la UCI, donde se consiguió un control estricto de la tensión arterial. A las 8 horas del traumatismo se colocó una endoprótesis en la aorta torácica descendente por vía ilíaca izquierda. La arteria subclavia izquierda quedó parcialmente ocluida sin repercusión clínica. A las 24 horas fue dado de alta a planta y a la semana se le dio el alta hospitalaria, ya que estaba asintomático. Remitido por: Dirección para correspondencia: Dra. Paula Ortiz Ballujera. Servicio de Medicina Intensiva (UCI). Hospital Universitari de Girona Doctor Josep Trueta. Avda. de França, s/n. 17007 Girona. España. Correo electrónico: ballujera@hotmail.com

[ "Nombre", ":", "Jedet", ".", "\n", "Apellidos", ":", "Sanchez", "Garcia", ".", "\n", "NHC", ":", "7845123", ".", "\n", "NASS", ":", "23", "56487946", "12", ".", "\n", "Domicilio", ":", "Carrer", "del", "Dr", ".", "Castany", "28", ",", "8A.", "\n", "Localidad/", "Provincia", ":", "Girona", ".", "\n", "CP", ":", "17002", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "14/09/1986", ".", "\n", "País", ":", "España", ".", "\n", "Edad", ":", "31", "años", "Sexo", ":", "H.", "\n", "Fecha", "de", "Ingreso", ":", "11/12/2017", ".", "\n", "Servicio", ":", "Medicina", "intensiva", ".", "\n", "Médico", ":", "Paula", "Ortiz", "Ballujera", "NºCol", ":", "17", "17", "85236", ".", "\n", "Historia", "Actual", ":", "El", "paciente", "era", "un", "varón", "de", "31", "años", "de", "edad", "que", "sufrió", "un", "accidente", "de", "motocicleta", ".", "La", "radiografía", "de", "tórax", "mostraba", "un", "ensanchamiento", "mediastínico", ".", "La", "TACHT", "al", "ingreso", "mostró", "un", "seudoaneurisma", "de", "aorta", "torácica", "distal", "a", "la", "salida", "de", "la", "arteria", "subclavia", "izquierda", "con", "un", "importante", "hematoma", "periaórtico", "y", "mediastínico", "asociado", "con", "hemotórax", "bilateral", ".", "\n", "Ingresó", "en", "la", "UCI", ",", "donde", "se", "consiguió", "un", "control", "estricto", "de", "la", "tensión", "arterial", ".", "A", "las", "8", "horas", "del", "traumatismo", "se", "colocó", "una", "endoprótesis", "en", "la", "aorta", "torácica", "descendente", "por", "vía", "ilíaca", "izquierda", ".", "La", "arteria", "subclavia", "izquierda", "quedó", "parcialmente", "ocluida", "sin", "repercusión", "clínica", ".", "A", "las", "24", "horas", "fue", "dado", "de", "alta", "a", "planta", "y", "a", "la", "semana", "se", "le", "dio", "el", "alta", "hospitalaria", ",", "ya", "que", "estaba", "asintomático", ".", "\n", "Remitido", "por", ":", "Dirección", "para", "correspondencia", ":", "Dra", ".", "Paula", "Ortiz", "Ballujera", ".", "Servicio", "de", "Medicina", "Intensiva", "(", "UCI", ")", ".", "Hospital", "Universitari", "de", "Girona", "Doctor", "Josep", "Trueta", ".", "Avda", ".", "de", "França", ",", "s", "/", "n.", "17007", "Girona", ".", "España", ".", "Correo", "electrónico", ":", "ballujera@hotmail.com", "\n" ]

[ "HOSPITAL", "CALLE", "CORREO_ELECTRONICO", "NOMBRE_PERSONAL_SANITARIO", "ID_ASEGURAMIENTO", "NOMBRE_SUJETO_ASISTENCIA", "ID_TITULACION_PERSONAL_SANITARIO", "FECHAS", "EDAD_SUJETO_ASISTENCIA", "ID_SUJETO_ASISTENCIA", "PAIS", "TERRITORIO", "SEXO_SUJETO_ASISTENCIA" ]

review is an umlsterm, pediatrics is an umlsterm, war is an umlsterm, touch is an umlsterm, pediatrics is an umlsterm, standard is an umlsterm, the changing is an umlsterm, needs is an umlsterm, pediatrics is an umlsterm, pediatrics is an umlsterm, economic is an umlsterm, National is an umlsterm, population is an umlsterm, preventive is an umlsterm, care is an umlsterm, program is an umlsterm, public health is an umlsterm, plan is an umlsterm, need is an umlsterm, evaluation is an umlsterm, program is an umlsterm, need is an umlsterm, communication is an umlsterm

MonatsschriftKinderheilkunde.01480573.eng.abstr_task0

Sentence: This review summarizes some aspects of German pediatrics as it developed after world war II . Having lost its touch with international pediatrics regained its high standard during the late forties and fifties and now develops in concordance with the changing needs and the advances of pediatrics in a highly industialoized nation . As in other countries , the practice and structure of pediatrics have been influenced by changes in social attidudes and expectations , and by economic restrictions . National specifics are the high number of practicing pediatric population and emphasis on a highly structured and formalized preventive care program under a public health plan . The need for critical evaluation of this program is emphasized as is the need for better communication among subspecialties . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O" ]

This review summarizes some aspects of German pediatrics as it developed after world war II . Having lost its touch with international pediatrics regained its high standard during the late forties and fifties and now develops in concordance with the changing needs and the advances of pediatrics in a highly industialoized nation . As in other countries , the practice and structure of pediatrics have been influenced by changes in social attidudes and expectations , and by economic restrictions . National specifics are the high number of practicing pediatric population and emphasis on a highly structured and formalized preventive care program under a public health plan . The need for critical evaluation of this program is emphasized as is the need for better communication among subspecialties .

[ "This", "review", "summarizes", "some", "aspects", "of", "German", "pediatrics", "as", "it", "developed", "after", "world", "war", "II", ".", "Having", "lost", "its", "touch", "with", "international", "pediatrics", "regained", "its", "high", "standard", "during", "the", "late", "forties", "and", "fifties", "and", "now", "develops", "in", "concordance", "with", "the", "changing", "needs", "and", "the", "advances", "of", "pediatrics", "in", "a", "highly", "industialoized", "nation", ".", "As", "in", "other", "countries", ",", "the", "practice", "and", "structure", "of", "pediatrics", "have", "been", "influenced", "by", "changes", "in", "social", "attidudes", "and", "expectations", ",", "and", "by", "economic", "restrictions", ".", "National", "specifics", "are", "the", "high", "number", "of", "practicing", "pediatric", "population", "and", "emphasis", "on", "a", "highly", "structured", "and", "formalized", "preventive", "care", "program", "under", "a", "public", "health", "plan", ".", "The", "need", "for", "critical", "evaluation", "of", "this", "program", "is", "emphasized", "as", "is", "the", "need", "for", "better", "communication", "among", "subspecialties", "." ]

[ "umlsterm" ]

review is an umlsterm, pediatrics is an umlsterm, war is an umlsterm, touch is an umlsterm, pediatrics is an umlsterm, standard is an umlsterm, the changing is an umlsterm, needs is an umlsterm, pediatrics is an umlsterm, pediatrics is an umlsterm, economic is an umlsterm, National is an umlsterm, population is an umlsterm, preventive is an umlsterm, care is an umlsterm, program is an umlsterm, public health is an umlsterm, plan is an umlsterm, need is an umlsterm, evaluation is an umlsterm, program is an umlsterm, need is an umlsterm, communication is an umlsterm

MonatsschriftKinderheilkunde.01480573.eng.abstr_task1

Sentence: This review summarizes some aspects of German pediatrics as it developed after world war II . Having lost its touch with international pediatrics regained its high standard during the late forties and fifties and now develops in concordance with the changing needs and the advances of pediatrics in a highly industialoized nation . As in other countries , the practice and structure of pediatrics have been influenced by changes in social attidudes and expectations , and by economic restrictions . National specifics are the high number of practicing pediatric population and emphasis on a highly structured and formalized preventive care program under a public health plan . The need for critical evaluation of this program is emphasized as is the need for better communication among subspecialties . Instructions: please typing these entity words according to sentence: review, pediatrics, war, touch, pediatrics, standard, the changing, needs, pediatrics, pediatrics, economic, National, population, preventive, care, program, public health, plan, need, evaluation, program, need, communication Options: umlsterm

[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O" ]

This review summarizes some aspects of German pediatrics as it developed after world war II . Having lost its touch with international pediatrics regained its high standard during the late forties and fifties and now develops in concordance with the changing needs and the advances of pediatrics in a highly industialoized nation . As in other countries , the practice and structure of pediatrics have been influenced by changes in social attidudes and expectations , and by economic restrictions . National specifics are the high number of practicing pediatric population and emphasis on a highly structured and formalized preventive care program under a public health plan . The need for critical evaluation of this program is emphasized as is the need for better communication among subspecialties .

[ "This", "review", "summarizes", "some", "aspects", "of", "German", "pediatrics", "as", "it", "developed", "after", "world", "war", "II", ".", "Having", "lost", "its", "touch", "with", "international", "pediatrics", "regained", "its", "high", "standard", "during", "the", "late", "forties", "and", "fifties", "and", "now", "develops", "in", "concordance", "with", "the", "changing", "needs", "and", "the", "advances", "of", "pediatrics", "in", "a", "highly", "industialoized", "nation", ".", "As", "in", "other", "countries", ",", "the", "practice", "and", "structure", "of", "pediatrics", "have", "been", "influenced", "by", "changes", "in", "social", "attidudes", "and", "expectations", ",", "and", "by", "economic", "restrictions", ".", "National", "specifics", "are", "the", "high", "number", "of", "practicing", "pediatric", "population", "and", "emphasis", "on", "a", "highly", "structured", "and", "formalized", "preventive", "care", "program", "under", "a", "public", "health", "plan", ".", "The", "need", "for", "critical", "evaluation", "of", "this", "program", "is", "emphasized", "as", "is", "the", "need", "for", "better", "communication", "among", "subspecialties", "." ]

[ "umlsterm" ]

review, pediatrics, war, touch, pediatrics, standard, the changing, needs, pediatrics, pediatrics, economic, National, population, preventive, care, program, public health, plan, need, evaluation, program, need, communication

MonatsschriftKinderheilkunde.01480573.eng.abstr_task2

Sentence: This review summarizes some aspects of German pediatrics as it developed after world war II . Having lost its touch with international pediatrics regained its high standard during the late forties and fifties and now develops in concordance with the changing needs and the advances of pediatrics in a highly industialoized nation . As in other countries , the practice and structure of pediatrics have been influenced by changes in social attidudes and expectations , and by economic restrictions . National specifics are the high number of practicing pediatric population and emphasis on a highly structured and formalized preventive care program under a public health plan . The need for critical evaluation of this program is emphasized as is the need for better communication among subspecialties . Instructions: please extract entity words from the input sentence

[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O" ]

This review summarizes some aspects of German pediatrics as it developed after world war II . Having lost its touch with international pediatrics regained its high standard during the late forties and fifties and now develops in concordance with the changing needs and the advances of pediatrics in a highly industialoized nation . As in other countries , the practice and structure of pediatrics have been influenced by changes in social attidudes and expectations , and by economic restrictions . National specifics are the high number of practicing pediatric population and emphasis on a highly structured and formalized preventive care program under a public health plan . The need for critical evaluation of this program is emphasized as is the need for better communication among subspecialties .

[ "This", "review", "summarizes", "some", "aspects", "of", "German", "pediatrics", "as", "it", "developed", "after", "world", "war", "II", ".", "Having", "lost", "its", "touch", "with", "international", "pediatrics", "regained", "its", "high", "standard", "during", "the", "late", "forties", "and", "fifties", "and", "now", "develops", "in", "concordance", "with", "the", "changing", "needs", "and", "the", "advances", "of", "pediatrics", "in", "a", "highly", "industialoized", "nation", ".", "As", "in", "other", "countries", ",", "the", "practice", "and", "structure", "of", "pediatrics", "have", "been", "influenced", "by", "changes", "in", "social", "attidudes", "and", "expectations", ",", "and", "by", "economic", "restrictions", ".", "National", "specifics", "are", "the", "high", "number", "of", "practicing", "pediatric", "population", "and", "emphasis", "on", "a", "highly", "structured", "and", "formalized", "preventive", "care", "program", "under", "a", "public", "health", "plan", ".", "The", "need", "for", "critical", "evaluation", "of", "this", "program", "is", "emphasized", "as", "is", "the", "need", "for", "better", "communication", "among", "subspecialties", "." ]

[ "umlsterm" ]

patients is an umlsterm, operations is an umlsterm, arthritis is an umlsterm, os calcis is an umlsterm, fracture is an umlsterm, evaluation is an umlsterm, overall is an umlsterm, Outcome - questionnaire is an umlsterm, severity - symptom is an umlsterm, scale is an umlsterm, Carpaltunnel - syndrome is an umlsterm, evaluation is an umlsterm, analysis of variance is an umlsterm, ANOVA is an umlsterm, Pearson 's is an umlsterm, Os calcis is an umlsterm, fracture is an umlsterm, cause is an umlsterm, arthritis is an umlsterm, patients is an umlsterm, males is an umlsterm, females is an umlsterm, treatment is an umlsterm, fracture is an umlsterm, patients is an umlsterm, patients is an umlsterm, open is an umlsterm, plate is an umlsterm, trauma is an umlsterm, age is an umlsterm, time is an umlsterm, pain is an umlsterm, patients is an umlsterm, range of motion is an umlsterm, ankle joint is an umlsterm, patients is an umlsterm, evaluation is an umlsterm, arthritis is an umlsterm, ankle joint is an umlsterm, joint is an umlsterm, patients is an umlsterm, joint is an umlsterm, patients is an umlsterm, analysis is an umlsterm, os calcis is an umlsterm, fracture is an umlsterm, evaluation is an umlsterm, clinical - radiological is an umlsterm, evaluation is an umlsterm

DerUnfallchirurg.91020013.eng.abstr_task0

Sentence: In a long-term follow-up we evaluated 40 patients out of 55 ( 73 % ) with a subtalar fusion . The operations took place from 5/84 to 5/91 . In all cases the indication for the fusion was a post-traumatic arthritis after an intra-articular os calcis fracture . The evaluation of the overall results was carried out with three different scoring systems : a. The Hannover Scoring System . b. The Outcome-questionnaire , rating patient's complaints and the functional status based on the severity-symptom scale and functional status described for Carpaltunnel-syndrome by Levine et al. c . The clinical rating system ( CRS ) described by Kitaoka et al. The statistical evaluation was performed by analysis of variance ( ANOVA ) . Level of significance was based on P = 0.05 and calculation of Pearson's correlation coefficient . The Os calcis fracture was the cause for the subtalar arthritis in all 40 patients ( 33 males and 7 females ) . The primary treatment of the calcaneal fracture was conservative ( cons . ) using a plaster in 23 patients ( 57.5 % ) , while 17 patients ( 42.5 % ) underwent open reduction and plate fixation ( op . ) . The interval between trauma and subtalar fusion averaged 3.5 years ( 3 months to 20 years ) . The interval between subtalar fusion and follow-up averaged 5.2 years ( 4-14 years ) . The mean age at the time of reexamination was 47 years ( 26-61 years ) . In the present study , complete pain relief could be achieved in 21 ( 52.5 % ; 58 % op . , 50 % cons . ) patients . A relevant restriction in the range of motion in the ankle joint was found in 26 ( 65 % ; 76 % op . , 58 % cons . ) . In 23 patients ( 62 % ; 65 % op . , 59 % cons . ) the radiological evaluation revealed a grade 1 ° arthritis of the ankle joint , in the talonavicular joint in 17 patients ( 42.5 % ; 41 % op . , 45 % cons . ) , and in the calcaneo-cuboid joint in 14 patients ( 35 % ; 47 % . , 27 % cons . ) . The statistical analysis revealed a better outcome in the operative group compared with the conservative group , although the operated os calcis fractures in the majority were the more severe fracture types . In all evaluation systems a score between 61 and 69 points could be achieved with no significant difference between the operatively and conservatively treated groups and between the newly developed questionaire and the clinical-radiological scoring systems . For the questionaire this fulfills the requirements for a reliable outcome evaluation . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]

In a long-term follow-up we evaluated 40 patients out of 55 ( 73 % ) with a subtalar fusion . The operations took place from 5/84 to 5/91 . In all cases the indication for the fusion was a post-traumatic arthritis after an intra-articular os calcis fracture . The evaluation of the overall results was carried out with three different scoring systems : a. The Hannover Scoring System . b. The Outcome-questionnaire , rating patient's complaints and the functional status based on the severity-symptom scale and functional status described for Carpaltunnel-syndrome by Levine et al. c . The clinical rating system ( CRS ) described by Kitaoka et al. The statistical evaluation was performed by analysis of variance ( ANOVA ) . Level of significance was based on P = 0.05 and calculation of Pearson's correlation coefficient . The Os calcis fracture was the cause for the subtalar arthritis in all 40 patients ( 33 males and 7 females ) . The primary treatment of the calcaneal fracture was conservative ( cons . ) using a plaster in 23 patients ( 57.5 % ) , while 17 patients ( 42.5 % ) underwent open reduction and plate fixation ( op . ) . The interval between trauma and subtalar fusion averaged 3.5 years ( 3 months to 20 years ) . The interval between subtalar fusion and follow-up averaged 5.2 years ( 4-14 years ) . The mean age at the time of reexamination was 47 years ( 26-61 years ) . In the present study , complete pain relief could be achieved in 21 ( 52.5 % ; 58 % op . , 50 % cons . ) patients . A relevant restriction in the range of motion in the ankle joint was found in 26 ( 65 % ; 76 % op . , 58 % cons . ) . In 23 patients ( 62 % ; 65 % op . , 59 % cons . ) the radiological evaluation revealed a grade 1 ° arthritis of the ankle joint , in the talonavicular joint in 17 patients ( 42.5 % ; 41 % op . , 45 % cons . ) , and in the calcaneo-cuboid joint in 14 patients ( 35 % ; 47 % . , 27 % cons . ) . The statistical analysis revealed a better outcome in the operative group compared with the conservative group , although the operated os calcis fractures in the majority were the more severe fracture types . In all evaluation systems a score between 61 and 69 points could be achieved with no significant difference between the operatively and conservatively treated groups and between the newly developed questionaire and the clinical-radiological scoring systems . For the questionaire this fulfills the requirements for a reliable outcome evaluation .

[ "In", "a", "long", "-", "term", "follow", "-", "up", "we", "evaluated", "40", "patients", "out", "of", "55", "(", "73", "%", ")", "with", "a", "subtalar", "fusion", ".", "The", "operations", "took", "place", "from", "5/84", "to", "5/91", ".", "In", "all", "cases", "the", "indication", "for", "the", "fusion", "was", "a", "post", "-", "traumatic", "arthritis", "after", "an", "intra", "-", "articular", "os", "calcis", "fracture", ".", "The", "evaluation", "of", "the", "overall", "results", "was", "carried", "out", "with", "three", "different", "scoring", "systems", ":", "a.", "The", "Hannover", "Scoring", "System", ".", "b.", "The", "Outcome", "-", "questionnaire", ",", "rating", "patient", "'s", "complaints", "and", "the", "functional", "status", "based", "on", "the", "severity", "-", "symptom", "scale", "and", "functional", "status", "described", "for", "Carpaltunnel", "-", "syndrome", "by", "Levine", "et", "al", ".", "c", ".", "The", "clinical", "rating", "system", "(", "CRS", ")", "described", "by", "Kitaoka", "et", "al", ".", "The", "statistical", "evaluation", "was", "performed", "by", "analysis", "of", "variance", "(", "ANOVA", ")", ".", "Level", "of", "significance", "was", "based", "on", "P", "=", "0.05", "and", "calculation", "of", "Pearson", "'s", "correlation", "coefficient", ".", "The", "Os", "calcis", "fracture", "was", "the", "cause", "for", "the", "subtalar", "arthritis", "in", "all", "40", "patients", "(", "33", "males", "and", "7", "females", ")", ".", "The", "primary", "treatment", "of", "the", "calcaneal", "fracture", "was", "conservative", "(", "cons", ".", ")", "using", "a", "plaster", "in", "23", "patients", "(", "57.5", "%", ")", ",", "while", "17", "patients", "(", "42.5", "%", ")", "underwent", "open", "reduction", "and", "plate", "fixation", "(", "op", ".", ")", ".", "The", "interval", "between", "trauma", "and", "subtalar", "fusion", "averaged", "3.5", "years", "(", "3", "months", "to", "20", "years", ")", ".", "The", "interval", "between", "subtalar", "fusion", "and", "follow", "-", "up", "averaged", "5.2", "years", "(", "4", "-", "14", "years", ")", ".", "The", "mean", "age", "at", "the", "time", "of", "reexamination", "was", "47", "years", "(", "26", "-", "61", "years", ")", ".", "In", "the", "present", "study", ",", "complete", "pain", "relief", "could", "be", "achieved", "in", "21", "(", "52.5", "%", ";", "58", "%", "op", ".", ",", "50", "%", "cons", ".", ")", "patients", ".", "A", "relevant", "restriction", "in", "the", "range", "of", "motion", "in", "the", "ankle", "joint", "was", "found", "in", "26", "(", "65", "%", ";", "76", "%", "op", ".", ",", "58", "%", "cons", ".", ")", ".", "In", "23", "patients", "(", "62", "%", ";", "65", "%", "op", ".", ",", "59", "%", "cons", ".", ")", "the", "radiological", "evaluation", "revealed", "a", "grade", "1", "°", "arthritis", "of", "the", "ankle", "joint", ",", "in", "the", "talonavicular", "joint", "in", "17", "patients", "(", "42.5", "%", ";", "41", "%", "op", ".", ",", "45", "%", "cons", ".", ")", ",", "and", "in", "the", "calcaneo", "-", "cuboid", "joint", "in", "14", "patients", "(", "35", "%", ";", "47", "%", ".", ",", "27", "%", "cons", ".", ")", ".", "The", "statistical", "analysis", "revealed", "a", "better", "outcome", "in", "the", "operative", "group", "compared", "with", "the", "conservative", "group", ",", "although", "the", "operated", "os", "calcis", "fractures", "in", "the", "majority", "were", "the", "more", "severe", "fracture", "types", ".", "In", "all", "evaluation", "systems", "a", "score", "between", "61", "and", "69", "points", "could", "be", "achieved", "with", "no", "significant", "difference", "between", "the", "operatively", "and", "conservatively", "treated", "groups", "and", "between", "the", "newly", "developed", "questionaire", "and", "the", "clinical", "-", "radiological", "scoring", "systems", ".", "For", "the", "questionaire", "this", "fulfills", "the", "requirements", "for", "a", "reliable", "outcome", "evaluation", "." ]

[ "umlsterm" ]

patients is an umlsterm, operations is an umlsterm, arthritis is an umlsterm, os calcis is an umlsterm, fracture is an umlsterm, evaluation is an umlsterm, overall is an umlsterm, Outcome - questionnaire is an umlsterm, severity - symptom is an umlsterm, scale is an umlsterm, Carpaltunnel - syndrome is an umlsterm, evaluation is an umlsterm, analysis of variance is an umlsterm, ANOVA is an umlsterm, Pearson 's is an umlsterm, Os calcis is an umlsterm, fracture is an umlsterm, cause is an umlsterm, arthritis is an umlsterm, patients is an umlsterm, males is an umlsterm, females is an umlsterm, treatment is an umlsterm, fracture is an umlsterm, patients is an umlsterm, patients is an umlsterm, open is an umlsterm, plate is an umlsterm, trauma is an umlsterm, age is an umlsterm, time is an umlsterm, pain is an umlsterm, patients is an umlsterm, range of motion is an umlsterm, ankle joint is an umlsterm, patients is an umlsterm, evaluation is an umlsterm, arthritis is an umlsterm, ankle joint is an umlsterm, joint is an umlsterm, patients is an umlsterm, joint is an umlsterm, patients is an umlsterm, analysis is an umlsterm, os calcis is an umlsterm, fracture is an umlsterm, evaluation is an umlsterm, clinical - radiological is an umlsterm, evaluation is an umlsterm

DerUnfallchirurg.91020013.eng.abstr_task1

Sentence: In a long-term follow-up we evaluated 40 patients out of 55 ( 73 % ) with a subtalar fusion . The operations took place from 5/84 to 5/91 . In all cases the indication for the fusion was a post-traumatic arthritis after an intra-articular os calcis fracture . The evaluation of the overall results was carried out with three different scoring systems : a. The Hannover Scoring System . b. The Outcome-questionnaire , rating patient's complaints and the functional status based on the severity-symptom scale and functional status described for Carpaltunnel-syndrome by Levine et al. c . The clinical rating system ( CRS ) described by Kitaoka et al. The statistical evaluation was performed by analysis of variance ( ANOVA ) . Level of significance was based on P = 0.05 and calculation of Pearson's correlation coefficient . The Os calcis fracture was the cause for the subtalar arthritis in all 40 patients ( 33 males and 7 females ) . The primary treatment of the calcaneal fracture was conservative ( cons . ) using a plaster in 23 patients ( 57.5 % ) , while 17 patients ( 42.5 % ) underwent open reduction and plate fixation ( op . ) . The interval between trauma and subtalar fusion averaged 3.5 years ( 3 months to 20 years ) . The interval between subtalar fusion and follow-up averaged 5.2 years ( 4-14 years ) . The mean age at the time of reexamination was 47 years ( 26-61 years ) . In the present study , complete pain relief could be achieved in 21 ( 52.5 % ; 58 % op . , 50 % cons . ) patients . A relevant restriction in the range of motion in the ankle joint was found in 26 ( 65 % ; 76 % op . , 58 % cons . ) . In 23 patients ( 62 % ; 65 % op . , 59 % cons . ) the radiological evaluation revealed a grade 1 ° arthritis of the ankle joint , in the talonavicular joint in 17 patients ( 42.5 % ; 41 % op . , 45 % cons . ) , and in the calcaneo-cuboid joint in 14 patients ( 35 % ; 47 % . , 27 % cons . ) . The statistical analysis revealed a better outcome in the operative group compared with the conservative group , although the operated os calcis fractures in the majority were the more severe fracture types . In all evaluation systems a score between 61 and 69 points could be achieved with no significant difference between the operatively and conservatively treated groups and between the newly developed questionaire and the clinical-radiological scoring systems . For the questionaire this fulfills the requirements for a reliable outcome evaluation . Instructions: please typing these entity words according to sentence: patients, operations, arthritis, os calcis, fracture, evaluation, overall, Outcome - questionnaire, severity - symptom, scale, Carpaltunnel - syndrome, evaluation, analysis of variance, ANOVA, Pearson 's, Os calcis, fracture, cause, arthritis, patients, males, females, treatment, fracture, patients, patients, open, plate, trauma, age, time, pain, patients, range of motion, ankle joint, patients, evaluation, arthritis, ankle joint, joint, patients, joint, patients, analysis, os calcis, fracture, evaluation, clinical - radiological, evaluation Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]

In a long-term follow-up we evaluated 40 patients out of 55 ( 73 % ) with a subtalar fusion . The operations took place from 5/84 to 5/91 . In all cases the indication for the fusion was a post-traumatic arthritis after an intra-articular os calcis fracture . The evaluation of the overall results was carried out with three different scoring systems : a. The Hannover Scoring System . b. The Outcome-questionnaire , rating patient's complaints and the functional status based on the severity-symptom scale and functional status described for Carpaltunnel-syndrome by Levine et al. c . The clinical rating system ( CRS ) described by Kitaoka et al. The statistical evaluation was performed by analysis of variance ( ANOVA ) . Level of significance was based on P = 0.05 and calculation of Pearson's correlation coefficient . The Os calcis fracture was the cause for the subtalar arthritis in all 40 patients ( 33 males and 7 females ) . The primary treatment of the calcaneal fracture was conservative ( cons . ) using a plaster in 23 patients ( 57.5 % ) , while 17 patients ( 42.5 % ) underwent open reduction and plate fixation ( op . ) . The interval between trauma and subtalar fusion averaged 3.5 years ( 3 months to 20 years ) . The interval between subtalar fusion and follow-up averaged 5.2 years ( 4-14 years ) . The mean age at the time of reexamination was 47 years ( 26-61 years ) . In the present study , complete pain relief could be achieved in 21 ( 52.5 % ; 58 % op . , 50 % cons . ) patients . A relevant restriction in the range of motion in the ankle joint was found in 26 ( 65 % ; 76 % op . , 58 % cons . ) . In 23 patients ( 62 % ; 65 % op . , 59 % cons . ) the radiological evaluation revealed a grade 1 ° arthritis of the ankle joint , in the talonavicular joint in 17 patients ( 42.5 % ; 41 % op . , 45 % cons . ) , and in the calcaneo-cuboid joint in 14 patients ( 35 % ; 47 % . , 27 % cons . ) . The statistical analysis revealed a better outcome in the operative group compared with the conservative group , although the operated os calcis fractures in the majority were the more severe fracture types . In all evaluation systems a score between 61 and 69 points could be achieved with no significant difference between the operatively and conservatively treated groups and between the newly developed questionaire and the clinical-radiological scoring systems . For the questionaire this fulfills the requirements for a reliable outcome evaluation .

[ "In", "a", "long", "-", "term", "follow", "-", "up", "we", "evaluated", "40", "patients", "out", "of", "55", "(", "73", "%", ")", "with", "a", "subtalar", "fusion", ".", "The", "operations", "took", "place", "from", "5/84", "to", "5/91", ".", "In", "all", "cases", "the", "indication", "for", "the", "fusion", "was", "a", "post", "-", "traumatic", "arthritis", "after", "an", "intra", "-", "articular", "os", "calcis", "fracture", ".", "The", "evaluation", "of", "the", "overall", "results", "was", "carried", "out", "with", "three", "different", "scoring", "systems", ":", "a.", "The", "Hannover", "Scoring", "System", ".", "b.", "The", "Outcome", "-", "questionnaire", ",", "rating", "patient", "'s", "complaints", "and", "the", "functional", "status", "based", "on", "the", "severity", "-", "symptom", "scale", "and", "functional", "status", "described", "for", "Carpaltunnel", "-", "syndrome", "by", "Levine", "et", "al", ".", "c", ".", "The", "clinical", "rating", "system", "(", "CRS", ")", "described", "by", "Kitaoka", "et", "al", ".", "The", "statistical", "evaluation", "was", "performed", "by", "analysis", "of", "variance", "(", "ANOVA", ")", ".", "Level", "of", "significance", "was", "based", "on", "P", "=", "0.05", "and", "calculation", "of", "Pearson", "'s", "correlation", "coefficient", ".", "The", "Os", "calcis", "fracture", "was", "the", "cause", "for", "the", "subtalar", "arthritis", "in", "all", "40", "patients", "(", "33", "males", "and", "7", "females", ")", ".", "The", "primary", "treatment", "of", "the", "calcaneal", "fracture", "was", "conservative", "(", "cons", ".", ")", "using", "a", "plaster", "in", "23", "patients", "(", "57.5", "%", ")", ",", "while", "17", "patients", "(", "42.5", "%", ")", "underwent", "open", "reduction", "and", "plate", "fixation", "(", "op", ".", ")", ".", "The", "interval", "between", "trauma", "and", "subtalar", "fusion", "averaged", "3.5", "years", "(", "3", "months", "to", "20", "years", ")", ".", "The", "interval", "between", "subtalar", "fusion", "and", "follow", "-", "up", "averaged", "5.2", "years", "(", "4", "-", "14", "years", ")", ".", "The", "mean", "age", "at", "the", "time", "of", "reexamination", "was", "47", "years", "(", "26", "-", "61", "years", ")", ".", "In", "the", "present", "study", ",", "complete", "pain", "relief", "could", "be", "achieved", "in", "21", "(", "52.5", "%", ";", "58", "%", "op", ".", ",", "50", "%", "cons", ".", ")", "patients", ".", "A", "relevant", "restriction", "in", "the", "range", "of", "motion", "in", "the", "ankle", "joint", "was", "found", "in", "26", "(", "65", "%", ";", "76", "%", "op", ".", ",", "58", "%", "cons", ".", ")", ".", "In", "23", "patients", "(", "62", "%", ";", "65", "%", "op", ".", ",", "59", "%", "cons", ".", ")", "the", "radiological", "evaluation", "revealed", "a", "grade", "1", "°", "arthritis", "of", "the", "ankle", "joint", ",", "in", "the", "talonavicular", "joint", "in", "17", "patients", "(", "42.5", "%", ";", "41", "%", "op", ".", ",", "45", "%", "cons", ".", ")", ",", "and", "in", "the", "calcaneo", "-", "cuboid", "joint", "in", "14", "patients", "(", "35", "%", ";", "47", "%", ".", ",", "27", "%", "cons", ".", ")", ".", "The", "statistical", "analysis", "revealed", "a", "better", "outcome", "in", "the", "operative", "group", "compared", "with", "the", "conservative", "group", ",", "although", "the", "operated", "os", "calcis", "fractures", "in", "the", "majority", "were", "the", "more", "severe", "fracture", "types", ".", "In", "all", "evaluation", "systems", "a", "score", "between", "61", "and", "69", "points", "could", "be", "achieved", "with", "no", "significant", "difference", "between", "the", "operatively", "and", "conservatively", "treated", "groups", "and", "between", "the", "newly", "developed", "questionaire", "and", "the", "clinical", "-", "radiological", "scoring", "systems", ".", "For", "the", "questionaire", "this", "fulfills", "the", "requirements", "for", "a", "reliable", "outcome", "evaluation", "." ]

[ "umlsterm" ]

patients, operations, arthritis, os calcis, fracture, evaluation, overall, Outcome - questionnaire, severity - symptom, scale, Carpaltunnel - syndrome, evaluation, analysis of variance, ANOVA, Pearson 's, Os calcis, fracture, cause, arthritis, patients, males, females, treatment, fracture, patients, patients, open, plate, trauma, age, time, pain, patients, range of motion, ankle joint, patients, evaluation, arthritis, ankle joint, joint, patients, joint, patients, analysis, os calcis, fracture, evaluation, clinical - radiological, evaluation

DerUnfallchirurg.91020013.eng.abstr_task2

Sentence: In a long-term follow-up we evaluated 40 patients out of 55 ( 73 % ) with a subtalar fusion . The operations took place from 5/84 to 5/91 . In all cases the indication for the fusion was a post-traumatic arthritis after an intra-articular os calcis fracture . The evaluation of the overall results was carried out with three different scoring systems : a. The Hannover Scoring System . b. The Outcome-questionnaire , rating patient's complaints and the functional status based on the severity-symptom scale and functional status described for Carpaltunnel-syndrome by Levine et al. c . The clinical rating system ( CRS ) described by Kitaoka et al. The statistical evaluation was performed by analysis of variance ( ANOVA ) . Level of significance was based on P = 0.05 and calculation of Pearson's correlation coefficient . The Os calcis fracture was the cause for the subtalar arthritis in all 40 patients ( 33 males and 7 females ) . The primary treatment of the calcaneal fracture was conservative ( cons . ) using a plaster in 23 patients ( 57.5 % ) , while 17 patients ( 42.5 % ) underwent open reduction and plate fixation ( op . ) . The interval between trauma and subtalar fusion averaged 3.5 years ( 3 months to 20 years ) . The interval between subtalar fusion and follow-up averaged 5.2 years ( 4-14 years ) . The mean age at the time of reexamination was 47 years ( 26-61 years ) . In the present study , complete pain relief could be achieved in 21 ( 52.5 % ; 58 % op . , 50 % cons . ) patients . A relevant restriction in the range of motion in the ankle joint was found in 26 ( 65 % ; 76 % op . , 58 % cons . ) . In 23 patients ( 62 % ; 65 % op . , 59 % cons . ) the radiological evaluation revealed a grade 1 ° arthritis of the ankle joint , in the talonavicular joint in 17 patients ( 42.5 % ; 41 % op . , 45 % cons . ) , and in the calcaneo-cuboid joint in 14 patients ( 35 % ; 47 % . , 27 % cons . ) . The statistical analysis revealed a better outcome in the operative group compared with the conservative group , although the operated os calcis fractures in the majority were the more severe fracture types . In all evaluation systems a score between 61 and 69 points could be achieved with no significant difference between the operatively and conservatively treated groups and between the newly developed questionaire and the clinical-radiological scoring systems . For the questionaire this fulfills the requirements for a reliable outcome evaluation . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]

In a long-term follow-up we evaluated 40 patients out of 55 ( 73 % ) with a subtalar fusion . The operations took place from 5/84 to 5/91 . In all cases the indication for the fusion was a post-traumatic arthritis after an intra-articular os calcis fracture . The evaluation of the overall results was carried out with three different scoring systems : a. The Hannover Scoring System . b. The Outcome-questionnaire , rating patient's complaints and the functional status based on the severity-symptom scale and functional status described for Carpaltunnel-syndrome by Levine et al. c . The clinical rating system ( CRS ) described by Kitaoka et al. The statistical evaluation was performed by analysis of variance ( ANOVA ) . Level of significance was based on P = 0.05 and calculation of Pearson's correlation coefficient . The Os calcis fracture was the cause for the subtalar arthritis in all 40 patients ( 33 males and 7 females ) . The primary treatment of the calcaneal fracture was conservative ( cons . ) using a plaster in 23 patients ( 57.5 % ) , while 17 patients ( 42.5 % ) underwent open reduction and plate fixation ( op . ) . The interval between trauma and subtalar fusion averaged 3.5 years ( 3 months to 20 years ) . The interval between subtalar fusion and follow-up averaged 5.2 years ( 4-14 years ) . The mean age at the time of reexamination was 47 years ( 26-61 years ) . In the present study , complete pain relief could be achieved in 21 ( 52.5 % ; 58 % op . , 50 % cons . ) patients . A relevant restriction in the range of motion in the ankle joint was found in 26 ( 65 % ; 76 % op . , 58 % cons . ) . In 23 patients ( 62 % ; 65 % op . , 59 % cons . ) the radiological evaluation revealed a grade 1 ° arthritis of the ankle joint , in the talonavicular joint in 17 patients ( 42.5 % ; 41 % op . , 45 % cons . ) , and in the calcaneo-cuboid joint in 14 patients ( 35 % ; 47 % . , 27 % cons . ) . The statistical analysis revealed a better outcome in the operative group compared with the conservative group , although the operated os calcis fractures in the majority were the more severe fracture types . In all evaluation systems a score between 61 and 69 points could be achieved with no significant difference between the operatively and conservatively treated groups and between the newly developed questionaire and the clinical-radiological scoring systems . For the questionaire this fulfills the requirements for a reliable outcome evaluation .

[ "In", "a", "long", "-", "term", "follow", "-", "up", "we", "evaluated", "40", "patients", "out", "of", "55", "(", "73", "%", ")", "with", "a", "subtalar", "fusion", ".", "The", "operations", "took", "place", "from", "5/84", "to", "5/91", ".", "In", "all", "cases", "the", "indication", "for", "the", "fusion", "was", "a", "post", "-", "traumatic", "arthritis", "after", "an", "intra", "-", "articular", "os", "calcis", "fracture", ".", "The", "evaluation", "of", "the", "overall", "results", "was", "carried", "out", "with", "three", "different", "scoring", "systems", ":", "a.", "The", "Hannover", "Scoring", "System", ".", "b.", "The", "Outcome", "-", "questionnaire", ",", "rating", "patient", "'s", "complaints", "and", "the", "functional", "status", "based", "on", "the", "severity", "-", "symptom", "scale", "and", "functional", "status", "described", "for", "Carpaltunnel", "-", "syndrome", "by", "Levine", "et", "al", ".", "c", ".", "The", "clinical", "rating", "system", "(", "CRS", ")", "described", "by", "Kitaoka", "et", "al", ".", "The", "statistical", "evaluation", "was", "performed", "by", "analysis", "of", "variance", "(", "ANOVA", ")", ".", "Level", "of", "significance", "was", "based", "on", "P", "=", "0.05", "and", "calculation", "of", "Pearson", "'s", "correlation", "coefficient", ".", "The", "Os", "calcis", "fracture", "was", "the", "cause", "for", "the", "subtalar", "arthritis", "in", "all", "40", "patients", "(", "33", "males", "and", "7", "females", ")", ".", "The", "primary", "treatment", "of", "the", "calcaneal", "fracture", "was", "conservative", "(", "cons", ".", ")", "using", "a", "plaster", "in", "23", "patients", "(", "57.5", "%", ")", ",", "while", "17", "patients", "(", "42.5", "%", ")", "underwent", "open", "reduction", "and", "plate", "fixation", "(", "op", ".", ")", ".", "The", "interval", "between", "trauma", "and", "subtalar", "fusion", "averaged", "3.5", "years", "(", "3", "months", "to", "20", "years", ")", ".", "The", "interval", "between", "subtalar", "fusion", "and", "follow", "-", "up", "averaged", "5.2", "years", "(", "4", "-", "14", "years", ")", ".", "The", "mean", "age", "at", "the", "time", "of", "reexamination", "was", "47", "years", "(", "26", "-", "61", "years", ")", ".", "In", "the", "present", "study", ",", "complete", "pain", "relief", "could", "be", "achieved", "in", "21", "(", "52.5", "%", ";", "58", "%", "op", ".", ",", "50", "%", "cons", ".", ")", "patients", ".", "A", "relevant", "restriction", "in", "the", "range", "of", "motion", "in", "the", "ankle", "joint", "was", "found", "in", "26", "(", "65", "%", ";", "76", "%", "op", ".", ",", "58", "%", "cons", ".", ")", ".", "In", "23", "patients", "(", "62", "%", ";", "65", "%", "op", ".", ",", "59", "%", "cons", ".", ")", "the", "radiological", "evaluation", "revealed", "a", "grade", "1", "°", "arthritis", "of", "the", "ankle", "joint", ",", "in", "the", "talonavicular", "joint", "in", "17", "patients", "(", "42.5", "%", ";", "41", "%", "op", ".", ",", "45", "%", "cons", ".", ")", ",", "and", "in", "the", "calcaneo", "-", "cuboid", "joint", "in", "14", "patients", "(", "35", "%", ";", "47", "%", ".", ",", "27", "%", "cons", ".", ")", ".", "The", "statistical", "analysis", "revealed", "a", "better", "outcome", "in", "the", "operative", "group", "compared", "with", "the", "conservative", "group", ",", "although", "the", "operated", "os", "calcis", "fractures", "in", "the", "majority", "were", "the", "more", "severe", "fracture", "types", ".", "In", "all", "evaluation", "systems", "a", "score", "between", "61", "and", "69", "points", "could", "be", "achieved", "with", "no", "significant", "difference", "between", "the", "operatively", "and", "conservatively", "treated", "groups", "and", "between", "the", "newly", "developed", "questionaire", "and", "the", "clinical", "-", "radiological", "scoring", "systems", ".", "For", "the", "questionaire", "this", "fulfills", "the", "requirements", "for", "a", "reliable", "outcome", "evaluation", "." ]

[ "umlsterm" ]

2,3-dihydrobenzofuran is a IUPAC, analogues is a MODIFIER, amphetamines is a FAMILY, LSD tartrate is a IUPAC, [ 125I]-(R)-DOI is a IUPAC, ( 125I]-(R)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane ) is a IUPAC, 1-(5-methoxy-2,3-dihydrobenzofuran-4-yl)-2-aminopropane is a IUPAC, 7-brominated is a PARTIUPAC, analogue is a MODIFIER, 1-(2,5-dimethoxyphenyl)-2-aminopropane is a IUPAC, 4-bromo is a PARTIUPAC, derivative is a MODIFIER, DOB is a ABBREVIATION, dihydrofuran is a TRIVIAL, 5-methoxy is a PARTIUPAC, groups is a MODIFIER, bromine is a TRIVIAL, bromine is a TRIVIAL, atom is a MODIFIER, 5-methoxy is a PARTIUPAC

example-61_task0

Sentence: Two 2,3-dihydrobenzofuran analogues of hallucinogenic amphetamines were prepared and evaluated for activity in the two-lever drug-discrimination paradigm in rats trained to discriminate saline from LSD tartrate (0.08 mg/kg) and for the ability to displace [125I]-(R)-DOI [( 125I]-(R)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane) from rat cortical homogenate 5-HT2 receptors. The compounds, 1-(5-methoxy-2,3-dihydrobenzofuran-4-yl)-2-aminopropane (6a) and its 7-brominated analogue 6b, possessed activity comparable to their conformationally flexible counterparts 1-(2,5-dimethoxyphenyl)-2-aminopropane (3) and its 4-bromo derivative DOB (5), respectively. The results suggest that the dihydrofuran ring in 6a and 6b models the active conformation of the 5-methoxy groups in 3 and 5. Free energy of binding, derived from radioligand displacement KA values, indicated that addition of the bromine in either series contributes 2.4-3.2 kcal/mol of binding energy. On the basis of surface area of the bromine atom, this value is 2-3 times higher than would be expected on the basis of hydrophobic binding. Thus, hydrophobicity of the para substituent alone cannot account for the dramatic enhancement of hallucinogenic activity. Although this substituent may play a minor role in orienting the conformation of the 5-methoxy groupin derivatives such as 4 and 5, there appears to be some other, as yet unknown, critical receptor interaction. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: IUPAC, TRIVIAL, FAMILY, PARTIUPAC, MODIFIER, ABBREVIATION

[ "O", "B-IUPAC", "B-MODIFIER", "O", "O", "B-FAMILY", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-IUPAC", "I-IUPAC", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-IUPAC", "I-IUPAC", "O", "B-IUPAC", "I-IUPAC", "I-IUPAC", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-IUPAC", "O", "O", "O", "O", "O", "B-PARTIUPAC", "B-MODIFIER", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-IUPAC", "O", "O", "O", "O", "O", "B-PARTIUPAC", "B-MODIFIER", "B-ABBREVIATION", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PARTIUPAC", "B-MODIFIER", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "B-MODIFIER", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PARTIUPAC", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Two 2,3-dihydrobenzofuran analogues of hallucinogenic amphetamines were prepared and evaluated for activity in the two-lever drug-discrimination paradigm in rats trained to discriminate saline from LSD tartrate (0.08 mg/kg) and for the ability to displace [125I]-(R)-DOI [( 125I]-(R)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane) from rat cortical homogenate 5-HT2 receptors. The compounds, 1-(5-methoxy-2,3-dihydrobenzofuran-4-yl)-2-aminopropane (6a) and its 7-brominated analogue 6b, possessed activity comparable to their conformationally flexible counterparts 1-(2,5-dimethoxyphenyl)-2-aminopropane (3) and its 4-bromo derivative DOB (5), respectively. The results suggest that the dihydrofuran ring in 6a and 6b models the active conformation of the 5-methoxy groups in 3 and 5. Free energy of binding, derived from radioligand displacement KA values, indicated that addition of the bromine in either series contributes 2.4-3.2 kcal/mol of binding energy. On the basis of surface area of the bromine atom, this value is 2-3 times higher than would be expected on the basis of hydrophobic binding. Thus, hydrophobicity of the para substituent alone cannot account for the dramatic enhancement of hallucinogenic activity. Although this substituent may play a minor role in orienting the conformation of the 5-methoxy groupin derivatives such as 4 and 5, there appears to be some other, as yet unknown, critical receptor interaction.

[ "Two", "2,3-dihydrobenzofuran", "analogues", "of", "hallucinogenic", "amphetamines", "were", "prepared", "and", "evaluated", "for", "activity", "in", "the", "two", "-", "lever", "drug", "-", "discrimination", "paradigm", "in", "rats", "trained", "to", "discriminate", "saline", "from", "LSD", "tartrate", "(", "0.08", "mg", "/", "kg", ")", "and", "for", "the", "ability", "to", "displace", "[", "125I]-(R)-DOI", "[", "(", "125I]-(R)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane", ")", "from", "rat", "cortical", "homogenate", "5-HT2", "receptors", ".", "The", "compounds", ",", "1-(5-methoxy-2,3-dihydrobenzofuran-4-yl)-2-aminopropane", "(", "6a", ")", "and", "its", "7-brominated", "analogue", "6b", ",", "possessed", "activity", "comparable", "to", "their", "conformationally", "flexible", "counterparts", "1-(2,5-dimethoxyphenyl)-2-aminopropane", "(", "3", ")", "and", "its", "4-bromo", "derivative", "DOB", "(", "5", ")", ",", "respectively", ".", "The", "results", "suggest", "that", "the", "dihydrofuran", "ring", "in", "6a", "and", "6b", "models", "the", "active", "conformation", "of", "the", "5-methoxy", "groups", "in", "3", "and", "5", ".", "Free", "energy", "of", "binding", ",", "derived", "from", "radioligand", "displacement", "KA", "values", ",", "indicated", "that", "addition", "of", "the", "bromine", "in", "either", "series", "contributes", "2.4", "-", "3.2", "kcal", "/", "mol", "of", "binding", "energy", ".", "On", "the", "basis", "of", "surface", "area", "of", "the", "bromine", "atom", ",", "this", "value", "is", "2", "-", "3", "times", "higher", "than", "would", "be", "expected", "on", "the", "basis", "of", "hydrophobic", "binding", ".", "Thus", ",", "hydrophobicity", "of", "the", "para", "substituent", "alone", "cannot", "account", "for", "the", "dramatic", "enhancement", "of", "hallucinogenic", "activity", ".", "Although", "this", "substituent", "may", "play", "a", "minor", "role", "in", "orienting", "the", "conformation", "of", "the", "5-methoxy", "groupin", " ", "derivatives", "such", "as", "4", "and", "5", ",", "there", "appears", "to", "be", "some", "other", ",", "as", "yet", "unknown", ",", "critical", "receptor", "interaction", "." ]

[ "IUPAC", "FAMILY", "PARTIUPAC", "TRIVIAL", "MODIFIER", "ABBREVIATION" ]

2,3-dihydrobenzofuran is a IUPAC, analogues is a MODIFIER, amphetamines is a FAMILY, LSD tartrate is a IUPAC, [ 125I]-(R)-DOI is a IUPAC, ( 125I]-(R)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane ) is a IUPAC, 1-(5-methoxy-2,3-dihydrobenzofuran-4-yl)-2-aminopropane is a IUPAC, 7-brominated is a PARTIUPAC, analogue is a MODIFIER, 1-(2,5-dimethoxyphenyl)-2-aminopropane is a IUPAC, 4-bromo is a PARTIUPAC, derivative is a MODIFIER, DOB is a ABBREVIATION, dihydrofuran is a TRIVIAL, 5-methoxy is a PARTIUPAC, groups is a MODIFIER, bromine is a TRIVIAL, bromine is a TRIVIAL, atom is a MODIFIER, 5-methoxy is a PARTIUPAC

example-61_task1

Sentence: Two 2,3-dihydrobenzofuran analogues of hallucinogenic amphetamines were prepared and evaluated for activity in the two-lever drug-discrimination paradigm in rats trained to discriminate saline from LSD tartrate (0.08 mg/kg) and for the ability to displace [125I]-(R)-DOI [( 125I]-(R)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane) from rat cortical homogenate 5-HT2 receptors. The compounds, 1-(5-methoxy-2,3-dihydrobenzofuran-4-yl)-2-aminopropane (6a) and its 7-brominated analogue 6b, possessed activity comparable to their conformationally flexible counterparts 1-(2,5-dimethoxyphenyl)-2-aminopropane (3) and its 4-bromo derivative DOB (5), respectively. The results suggest that the dihydrofuran ring in 6a and 6b models the active conformation of the 5-methoxy groups in 3 and 5. Free energy of binding, derived from radioligand displacement KA values, indicated that addition of the bromine in either series contributes 2.4-3.2 kcal/mol of binding energy. On the basis of surface area of the bromine atom, this value is 2-3 times higher than would be expected on the basis of hydrophobic binding. Thus, hydrophobicity of the para substituent alone cannot account for the dramatic enhancement of hallucinogenic activity. Although this substituent may play a minor role in orienting the conformation of the 5-methoxy groupin derivatives such as 4 and 5, there appears to be some other, as yet unknown, critical receptor interaction. Instructions: please typing these entity words according to sentence: 2,3-dihydrobenzofuran, analogues, amphetamines, LSD tartrate, [ 125I]-(R)-DOI, ( 125I]-(R)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane ), 1-(5-methoxy-2,3-dihydrobenzofuran-4-yl)-2-aminopropane, 7-brominated, analogue, 1-(2,5-dimethoxyphenyl)-2-aminopropane, 4-bromo, derivative, DOB, dihydrofuran, 5-methoxy, groups, bromine, bromine, atom, 5-methoxy Options: IUPAC, TRIVIAL, FAMILY, PARTIUPAC, MODIFIER, ABBREVIATION

[ "O", "B-IUPAC", "B-MODIFIER", "O", "O", "B-FAMILY", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-IUPAC", "I-IUPAC", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-IUPAC", "I-IUPAC", "O", "B-IUPAC", "I-IUPAC", "I-IUPAC", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-IUPAC", "O", "O", "O", "O", "O", "B-PARTIUPAC", "B-MODIFIER", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-IUPAC", "O", "O", "O", "O", "O", "B-PARTIUPAC", "B-MODIFIER", "B-ABBREVIATION", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PARTIUPAC", "B-MODIFIER", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "B-MODIFIER", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PARTIUPAC", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Two 2,3-dihydrobenzofuran analogues of hallucinogenic amphetamines were prepared and evaluated for activity in the two-lever drug-discrimination paradigm in rats trained to discriminate saline from LSD tartrate (0.08 mg/kg) and for the ability to displace [125I]-(R)-DOI [( 125I]-(R)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane) from rat cortical homogenate 5-HT2 receptors. The compounds, 1-(5-methoxy-2,3-dihydrobenzofuran-4-yl)-2-aminopropane (6a) and its 7-brominated analogue 6b, possessed activity comparable to their conformationally flexible counterparts 1-(2,5-dimethoxyphenyl)-2-aminopropane (3) and its 4-bromo derivative DOB (5), respectively. The results suggest that the dihydrofuran ring in 6a and 6b models the active conformation of the 5-methoxy groups in 3 and 5. Free energy of binding, derived from radioligand displacement KA values, indicated that addition of the bromine in either series contributes 2.4-3.2 kcal/mol of binding energy. On the basis of surface area of the bromine atom, this value is 2-3 times higher than would be expected on the basis of hydrophobic binding. Thus, hydrophobicity of the para substituent alone cannot account for the dramatic enhancement of hallucinogenic activity. Although this substituent may play a minor role in orienting the conformation of the 5-methoxy groupin derivatives such as 4 and 5, there appears to be some other, as yet unknown, critical receptor interaction.

[ "Two", "2,3-dihydrobenzofuran", "analogues", "of", "hallucinogenic", "amphetamines", "were", "prepared", "and", "evaluated", "for", "activity", "in", "the", "two", "-", "lever", "drug", "-", "discrimination", "paradigm", "in", "rats", "trained", "to", "discriminate", "saline", "from", "LSD", "tartrate", "(", "0.08", "mg", "/", "kg", ")", "and", "for", "the", "ability", "to", "displace", "[", "125I]-(R)-DOI", "[", "(", "125I]-(R)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane", ")", "from", "rat", "cortical", "homogenate", "5-HT2", "receptors", ".", "The", "compounds", ",", "1-(5-methoxy-2,3-dihydrobenzofuran-4-yl)-2-aminopropane", "(", "6a", ")", "and", "its", "7-brominated", "analogue", "6b", ",", "possessed", "activity", "comparable", "to", "their", "conformationally", "flexible", "counterparts", "1-(2,5-dimethoxyphenyl)-2-aminopropane", "(", "3", ")", "and", "its", "4-bromo", "derivative", "DOB", "(", "5", ")", ",", "respectively", ".", "The", "results", "suggest", "that", "the", "dihydrofuran", "ring", "in", "6a", "and", "6b", "models", "the", "active", "conformation", "of", "the", "5-methoxy", "groups", "in", "3", "and", "5", ".", "Free", "energy", "of", "binding", ",", "derived", "from", "radioligand", "displacement", "KA", "values", ",", "indicated", "that", "addition", "of", "the", "bromine", "in", "either", "series", "contributes", "2.4", "-", "3.2", "kcal", "/", "mol", "of", "binding", "energy", ".", "On", "the", "basis", "of", "surface", "area", "of", "the", "bromine", "atom", ",", "this", "value", "is", "2", "-", "3", "times", "higher", "than", "would", "be", "expected", "on", "the", "basis", "of", "hydrophobic", "binding", ".", "Thus", ",", "hydrophobicity", "of", "the", "para", "substituent", "alone", "cannot", "account", "for", "the", "dramatic", "enhancement", "of", "hallucinogenic", "activity", ".", "Although", "this", "substituent", "may", "play", "a", "minor", "role", "in", "orienting", "the", "conformation", "of", "the", "5-methoxy", "groupin", " ", "derivatives", "such", "as", "4", "and", "5", ",", "there", "appears", "to", "be", "some", "other", ",", "as", "yet", "unknown", ",", "critical", "receptor", "interaction", "." ]

[ "IUPAC", "FAMILY", "PARTIUPAC", "TRIVIAL", "MODIFIER", "ABBREVIATION" ]

2,3-dihydrobenzofuran, analogues, amphetamines, LSD tartrate, [ 125I]-(R)-DOI, ( 125I]-(R)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane ), 1-(5-methoxy-2,3-dihydrobenzofuran-4-yl)-2-aminopropane, 7-brominated, analogue, 1-(2,5-dimethoxyphenyl)-2-aminopropane, 4-bromo, derivative, DOB, dihydrofuran, 5-methoxy, groups, bromine, bromine, atom, 5-methoxy

example-61_task2

Sentence: Two 2,3-dihydrobenzofuran analogues of hallucinogenic amphetamines were prepared and evaluated for activity in the two-lever drug-discrimination paradigm in rats trained to discriminate saline from LSD tartrate (0.08 mg/kg) and for the ability to displace [125I]-(R)-DOI [( 125I]-(R)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane) from rat cortical homogenate 5-HT2 receptors. The compounds, 1-(5-methoxy-2,3-dihydrobenzofuran-4-yl)-2-aminopropane (6a) and its 7-brominated analogue 6b, possessed activity comparable to their conformationally flexible counterparts 1-(2,5-dimethoxyphenyl)-2-aminopropane (3) and its 4-bromo derivative DOB (5), respectively. The results suggest that the dihydrofuran ring in 6a and 6b models the active conformation of the 5-methoxy groups in 3 and 5. Free energy of binding, derived from radioligand displacement KA values, indicated that addition of the bromine in either series contributes 2.4-3.2 kcal/mol of binding energy. On the basis of surface area of the bromine atom, this value is 2-3 times higher than would be expected on the basis of hydrophobic binding. Thus, hydrophobicity of the para substituent alone cannot account for the dramatic enhancement of hallucinogenic activity. Although this substituent may play a minor role in orienting the conformation of the 5-methoxy groupin derivatives such as 4 and 5, there appears to be some other, as yet unknown, critical receptor interaction. Instructions: please extract entity words from the input sentence

[ "O", "B-IUPAC", "B-MODIFIER", "O", "O", "B-FAMILY", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-IUPAC", "I-IUPAC", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-IUPAC", "I-IUPAC", "O", "B-IUPAC", "I-IUPAC", "I-IUPAC", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-IUPAC", "O", "O", "O", "O", "O", "B-PARTIUPAC", "B-MODIFIER", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-IUPAC", "O", "O", "O", "O", "O", "B-PARTIUPAC", "B-MODIFIER", "B-ABBREVIATION", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PARTIUPAC", "B-MODIFIER", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "B-MODIFIER", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PARTIUPAC", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Two 2,3-dihydrobenzofuran analogues of hallucinogenic amphetamines were prepared and evaluated for activity in the two-lever drug-discrimination paradigm in rats trained to discriminate saline from LSD tartrate (0.08 mg/kg) and for the ability to displace [125I]-(R)-DOI [( 125I]-(R)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane) from rat cortical homogenate 5-HT2 receptors. The compounds, 1-(5-methoxy-2,3-dihydrobenzofuran-4-yl)-2-aminopropane (6a) and its 7-brominated analogue 6b, possessed activity comparable to their conformationally flexible counterparts 1-(2,5-dimethoxyphenyl)-2-aminopropane (3) and its 4-bromo derivative DOB (5), respectively. The results suggest that the dihydrofuran ring in 6a and 6b models the active conformation of the 5-methoxy groups in 3 and 5. Free energy of binding, derived from radioligand displacement KA values, indicated that addition of the bromine in either series contributes 2.4-3.2 kcal/mol of binding energy. On the basis of surface area of the bromine atom, this value is 2-3 times higher than would be expected on the basis of hydrophobic binding. Thus, hydrophobicity of the para substituent alone cannot account for the dramatic enhancement of hallucinogenic activity. Although this substituent may play a minor role in orienting the conformation of the 5-methoxy groupin derivatives such as 4 and 5, there appears to be some other, as yet unknown, critical receptor interaction.

[ "Two", "2,3-dihydrobenzofuran", "analogues", "of", "hallucinogenic", "amphetamines", "were", "prepared", "and", "evaluated", "for", "activity", "in", "the", "two", "-", "lever", "drug", "-", "discrimination", "paradigm", "in", "rats", "trained", "to", "discriminate", "saline", "from", "LSD", "tartrate", "(", "0.08", "mg", "/", "kg", ")", "and", "for", "the", "ability", "to", "displace", "[", "125I]-(R)-DOI", "[", "(", "125I]-(R)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane", ")", "from", "rat", "cortical", "homogenate", "5-HT2", "receptors", ".", "The", "compounds", ",", "1-(5-methoxy-2,3-dihydrobenzofuran-4-yl)-2-aminopropane", "(", "6a", ")", "and", "its", "7-brominated", "analogue", "6b", ",", "possessed", "activity", "comparable", "to", "their", "conformationally", "flexible", "counterparts", "1-(2,5-dimethoxyphenyl)-2-aminopropane", "(", "3", ")", "and", "its", "4-bromo", "derivative", "DOB", "(", "5", ")", ",", "respectively", ".", "The", "results", "suggest", "that", "the", "dihydrofuran", "ring", "in", "6a", "and", "6b", "models", "the", "active", "conformation", "of", "the", "5-methoxy", "groups", "in", "3", "and", "5", ".", "Free", "energy", "of", "binding", ",", "derived", "from", "radioligand", "displacement", "KA", "values", ",", "indicated", "that", "addition", "of", "the", "bromine", "in", "either", "series", "contributes", "2.4", "-", "3.2", "kcal", "/", "mol", "of", "binding", "energy", ".", "On", "the", "basis", "of", "surface", "area", "of", "the", "bromine", "atom", ",", "this", "value", "is", "2", "-", "3", "times", "higher", "than", "would", "be", "expected", "on", "the", "basis", "of", "hydrophobic", "binding", ".", "Thus", ",", "hydrophobicity", "of", "the", "para", "substituent", "alone", "cannot", "account", "for", "the", "dramatic", "enhancement", "of", "hallucinogenic", "activity", ".", "Although", "this", "substituent", "may", "play", "a", "minor", "role", "in", "orienting", "the", "conformation", "of", "the", "5-methoxy", "groupin", " ", "derivatives", "such", "as", "4", "and", "5", ",", "there", "appears", "to", "be", "some", "other", ",", "as", "yet", "unknown", ",", "critical", "receptor", "interaction", "." ]

[ "IUPAC", "FAMILY", "PARTIUPAC", "TRIVIAL", "MODIFIER", "ABBREVIATION" ]

pseudoexfoliation syndrome is an umlsterm, Evaluation is an umlsterm, cell is an umlsterm, cataract extraction is an umlsterm, eyes is an umlsterm

DerOpthalmologe.70940332.eng.abstr_task0

Sentence: Introduction : Corneal endothelial involvement can be found in pseudoexfoliation syndrome ( PEX ) . Evaluation of possible differences in endothelial cell loss following cataract extraction was compared to normal eyes . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O" ]

Introduction : Corneal endothelial involvement can be found in pseudoexfoliation syndrome ( PEX ) . Evaluation of possible differences in endothelial cell loss following cataract extraction was compared to normal eyes .

[ "Introduction", ":", "Corneal", "endothelial", "involvement", "can", "be", "found", "in", "pseudoexfoliation", "syndrome", "(", "PEX", ")", ".", "Evaluation", "of", "possible", "differences", "in", "endothelial", "cell", "loss", "following", "cataract", "extraction", "was", "compared", "to", "normal", "eyes", "." ]

[ "umlsterm" ]

pseudoexfoliation syndrome is an umlsterm, Evaluation is an umlsterm, cell is an umlsterm, cataract extraction is an umlsterm, eyes is an umlsterm

DerOpthalmologe.70940332.eng.abstr_task1

Sentence: Introduction : Corneal endothelial involvement can be found in pseudoexfoliation syndrome ( PEX ) . Evaluation of possible differences in endothelial cell loss following cataract extraction was compared to normal eyes . Instructions: please typing these entity words according to sentence: pseudoexfoliation syndrome, Evaluation, cell, cataract extraction, eyes Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O" ]

Introduction : Corneal endothelial involvement can be found in pseudoexfoliation syndrome ( PEX ) . Evaluation of possible differences in endothelial cell loss following cataract extraction was compared to normal eyes .

[ "Introduction", ":", "Corneal", "endothelial", "involvement", "can", "be", "found", "in", "pseudoexfoliation", "syndrome", "(", "PEX", ")", ".", "Evaluation", "of", "possible", "differences", "in", "endothelial", "cell", "loss", "following", "cataract", "extraction", "was", "compared", "to", "normal", "eyes", "." ]

[ "umlsterm" ]

pseudoexfoliation syndrome, Evaluation, cell, cataract extraction, eyes

DerOpthalmologe.70940332.eng.abstr_task2

Sentence: Introduction : Corneal endothelial involvement can be found in pseudoexfoliation syndrome ( PEX ) . Evaluation of possible differences in endothelial cell loss following cataract extraction was compared to normal eyes . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O" ]

Introduction : Corneal endothelial involvement can be found in pseudoexfoliation syndrome ( PEX ) . Evaluation of possible differences in endothelial cell loss following cataract extraction was compared to normal eyes .

[ "Introduction", ":", "Corneal", "endothelial", "involvement", "can", "be", "found", "in", "pseudoexfoliation", "syndrome", "(", "PEX", ")", ".", "Evaluation", "of", "possible", "differences", "in", "endothelial", "cell", "loss", "following", "cataract", "extraction", "was", "compared", "to", "normal", "eyes", "." ]

[ "umlsterm" ]

DICO is a CHEMICAL, flavonoid is a CHEMICAL

23567243_task0

Sentence: DICO, a novel nonaromatic B-ring flavonoid, induces G2/M cell cycle arrest and apoptosis in human hepatoma cells. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: CHEMICAL

[ "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

DICO, a novel nonaromatic B-ring flavonoid, induces G2/M cell cycle arrest and apoptosis in human hepatoma cells.

[ "DICO", ",", "a", "novel", "nonaromatic", "B", "-", "ring", "flavonoid", ",", "induces", "G2", "/", "M", "cell", "cycle", "arrest", "and", "apoptosis", "in", "human", "hepatoma", "cells", "." ]

[ "GENE-N", "GENE-Y", "CHEMICAL" ]

DICO is a CHEMICAL, flavonoid is a CHEMICAL

23567243_task1

Sentence: DICO, a novel nonaromatic B-ring flavonoid, induces G2/M cell cycle arrest and apoptosis in human hepatoma cells. Instructions: please typing these entity words according to sentence: DICO, flavonoid Options: CHEMICAL

[ "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

DICO, a novel nonaromatic B-ring flavonoid, induces G2/M cell cycle arrest and apoptosis in human hepatoma cells.

[ "DICO", ",", "a", "novel", "nonaromatic", "B", "-", "ring", "flavonoid", ",", "induces", "G2", "/", "M", "cell", "cycle", "arrest", "and", "apoptosis", "in", "human", "hepatoma", "cells", "." ]

[ "GENE-N", "GENE-Y", "CHEMICAL" ]

DICO, flavonoid

23567243_task2

Sentence: DICO, a novel nonaromatic B-ring flavonoid, induces G2/M cell cycle arrest and apoptosis in human hepatoma cells. Instructions: please extract entity words from the input sentence

[ "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

DICO, a novel nonaromatic B-ring flavonoid, induces G2/M cell cycle arrest and apoptosis in human hepatoma cells.

[ "DICO", ",", "a", "novel", "nonaromatic", "B", "-", "ring", "flavonoid", ",", "induces", "G2", "/", "M", "cell", "cycle", "arrest", "and", "apoptosis", "in", "human", "hepatoma", "cells", "." ]

[ "GENE-N", "GENE-Y", "CHEMICAL" ]

PU.1 is a Protein, spi-1 is a Protein, promoter is a Entity, PU.1 is a Protein, spi-1 is a Protein, PU.1 is a Protein, promoter is a Entity, PU.1 is a Protein, PU.1 is a Protein, Oct-1 is a Protein, Oct-2 is a Protein, Sp1 is a Protein, PU.1 is a Protein, OBF-1 is a Protein, Bob1 is a Protein, OCA - B is a Protein, OBF-1 is a Protein, Bob1 is a Protein, OCA - B is a Protein, PU.1 is a Protein, promoter is a Entity, PU.1 is a Protein

8663022_task0

Sentence: Octamer binding factors and their coactivator can activate the murine PU.1 (spi-1) promoter. PU.1 (spi-1), a member of the Ets transcription factor family, is predominantly expressed in myeloid and B cells, activates many B cell and myeloid genes, and is critical for development of both of these lineages. Our previous studies (Chen, H.M., Ray-Gallet, D., Zhang, P., Hetherington, C.J., Gonzalez, D.A., Zhang, D.-E., Moreau-Gachelin, F., and Tenen, D.G.(1995) Oncogene 11, 1549-1560) demonstrate that the PU.1 promoter directs cell type-specific reporter gene expression in myeloid cell lines, and that PU.1 activates its own promoter in an autoregulatory loop. Here we show that the murine PU.1 promoter is also specifically and highly functional in B cell lines as well. Oct-1 and Oct-2 can bind specifically to a site at base pair -55 in vitro, and this site is specifically protected in B cells in vivo. We also demonstrate that two other sites contribute to promoter activity in B cells; an Sp1 binding site adjacent to the octamer site, and the PU.1 autoregulatory site. Finally, we show that the B cell coactivator OBF-1/Bob1/OCA-B is only expressed in B cells and not in myeloid cells, and that OBF-1/Bob1/OCA-B can transactivate the PU.1 promoter in HeLa and myeloid cells. This B cell restricted coactivator may be responsible for the B cell specific expression of PU.1 mediated by the octamer site. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "B-Entity", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O" ]

Octamer binding factors and their coactivator can activate the murine PU.1 (spi-1) promoter. PU.1 (spi-1), a member of the Ets transcription factor family, is predominantly expressed in myeloid and B cells, activates many B cell and myeloid genes, and is critical for development of both of these lineages. Our previous studies (Chen, H.M., Ray-Gallet, D., Zhang, P., Hetherington, C.J., Gonzalez, D.A., Zhang, D.-E., Moreau-Gachelin, F., and Tenen, D.G.(1995) Oncogene 11, 1549-1560) demonstrate that the PU.1 promoter directs cell type-specific reporter gene expression in myeloid cell lines, and that PU.1 activates its own promoter in an autoregulatory loop. Here we show that the murine PU.1 promoter is also specifically and highly functional in B cell lines as well. Oct-1 and Oct-2 can bind specifically to a site at base pair -55 in vitro, and this site is specifically protected in B cells in vivo. We also demonstrate that two other sites contribute to promoter activity in B cells; an Sp1 binding site adjacent to the octamer site, and the PU.1 autoregulatory site. Finally, we show that the B cell coactivator OBF-1/Bob1/OCA-B is only expressed in B cells and not in myeloid cells, and that OBF-1/Bob1/OCA-B can transactivate the PU.1 promoter in HeLa and myeloid cells. This B cell restricted coactivator may be responsible for the B cell specific expression of PU.1 mediated by the octamer site.

[ "Octamer", "binding", "factors", "and", "their", "coactivator", "can", "activate", "the", "murine", "PU.1", "(", "spi-1", ")", "promoter", ".", "\n", "PU.1", "(", "spi-1", ")", ",", "a", "member", "of", "the", "Ets", "transcription", "factor", "family", ",", "is", "predominantly", "expressed", "in", "myeloid", "and", "B", "cells", ",", "activates", "many", "B", "cell", "and", "myeloid", "genes", ",", "and", "is", "critical", "for", "development", "of", "both", "of", "these", "lineages", ".", "Our", "previous", "studies", "(", "Chen", ",", "H.M.", ",", "Ray", "-", "Gallet", ",", "D.", ",", "Zhang", ",", "P.", ",", "Hetherington", ",", "C.J.", ",", "Gonzalez", ",", "D.A.", ",", "Zhang", ",", "D.-E.", ",", "Moreau", "-", "Gachelin", ",", "F.", ",", "and", "Tenen", ",", "D.G.(1995", ")", "Oncogene", "11", ",", "1549", "-", "1560", ")", "demonstrate", "that", "the", "PU.1", "promoter", "directs", "cell", "type", "-", "specific", "reporter", "gene", "expression", "in", "myeloid", "cell", "lines", ",", "and", "that", "PU.1", "activates", "its", "own", "promoter", "in", "an", "autoregulatory", "loop", ".", "Here", "we", "show", "that", "the", "murine", "PU.1", "promoter", "is", "also", "specifically", "and", "highly", "functional", "in", "B", "cell", "lines", "as", "well", ".", "Oct-1", "and", "Oct-2", "can", "bind", "specifically", "to", "a", "site", "at", "base", "pair", "-55", "in", "vitro", ",", "and", "this", "site", "is", "specifically", "protected", "in", "B", "cells", "in", "vivo", ".", "We", "also", "demonstrate", "that", "two", "other", "sites", "contribute", "to", "promoter", "activity", "in", "B", "cells", ";", "an", "Sp1", "binding", "site", "adjacent", "to", "the", "octamer", "site", ",", "and", "the", "PU.1", "autoregulatory", "site", ".", "Finally", ",", "we", "show", "that", "the", "B", "cell", "coactivator", "OBF-1", "/", "Bob1", "/", "OCA", "-", "B", "is", "only", "expressed", "in", "B", "cells", "and", "not", "in", "myeloid", "cells", ",", "and", "that", "OBF-1", "/", "Bob1", "/", "OCA", "-", "B", "can", "transactivate", "the", "PU.1", "promoter", "in", "HeLa", "and", "myeloid", "cells", ".", "This", "B", "cell", "restricted", "coactivator", "may", "be", "responsible", "for", "the", "B", "cell", "specific", "expression", "of", "PU.1", "mediated", "by", "the", "octamer", "site", "." ]

[ "Entity", "Protein" ]

PU.1 is a Protein, spi-1 is a Protein, promoter is a Entity, PU.1 is a Protein, spi-1 is a Protein, PU.1 is a Protein, promoter is a Entity, PU.1 is a Protein, PU.1 is a Protein, Oct-1 is a Protein, Oct-2 is a Protein, Sp1 is a Protein, PU.1 is a Protein, OBF-1 is a Protein, Bob1 is a Protein, OCA - B is a Protein, OBF-1 is a Protein, Bob1 is a Protein, OCA - B is a Protein, PU.1 is a Protein, promoter is a Entity, PU.1 is a Protein

8663022_task1

Sentence: Octamer binding factors and their coactivator can activate the murine PU.1 (spi-1) promoter. PU.1 (spi-1), a member of the Ets transcription factor family, is predominantly expressed in myeloid and B cells, activates many B cell and myeloid genes, and is critical for development of both of these lineages. Our previous studies (Chen, H.M., Ray-Gallet, D., Zhang, P., Hetherington, C.J., Gonzalez, D.A., Zhang, D.-E., Moreau-Gachelin, F., and Tenen, D.G.(1995) Oncogene 11, 1549-1560) demonstrate that the PU.1 promoter directs cell type-specific reporter gene expression in myeloid cell lines, and that PU.1 activates its own promoter in an autoregulatory loop. Here we show that the murine PU.1 promoter is also specifically and highly functional in B cell lines as well. Oct-1 and Oct-2 can bind specifically to a site at base pair -55 in vitro, and this site is specifically protected in B cells in vivo. We also demonstrate that two other sites contribute to promoter activity in B cells; an Sp1 binding site adjacent to the octamer site, and the PU.1 autoregulatory site. Finally, we show that the B cell coactivator OBF-1/Bob1/OCA-B is only expressed in B cells and not in myeloid cells, and that OBF-1/Bob1/OCA-B can transactivate the PU.1 promoter in HeLa and myeloid cells. This B cell restricted coactivator may be responsible for the B cell specific expression of PU.1 mediated by the octamer site. Instructions: please typing these entity words according to sentence: PU.1, spi-1, promoter, PU.1, spi-1, PU.1, promoter, PU.1, PU.1, Oct-1, Oct-2, Sp1, PU.1, OBF-1, Bob1, OCA - B, OBF-1, Bob1, OCA - B, PU.1, promoter, PU.1 Options: Entity, Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "B-Entity", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O" ]

Octamer binding factors and their coactivator can activate the murine PU.1 (spi-1) promoter. PU.1 (spi-1), a member of the Ets transcription factor family, is predominantly expressed in myeloid and B cells, activates many B cell and myeloid genes, and is critical for development of both of these lineages. Our previous studies (Chen, H.M., Ray-Gallet, D., Zhang, P., Hetherington, C.J., Gonzalez, D.A., Zhang, D.-E., Moreau-Gachelin, F., and Tenen, D.G.(1995) Oncogene 11, 1549-1560) demonstrate that the PU.1 promoter directs cell type-specific reporter gene expression in myeloid cell lines, and that PU.1 activates its own promoter in an autoregulatory loop. Here we show that the murine PU.1 promoter is also specifically and highly functional in B cell lines as well. Oct-1 and Oct-2 can bind specifically to a site at base pair -55 in vitro, and this site is specifically protected in B cells in vivo. We also demonstrate that two other sites contribute to promoter activity in B cells; an Sp1 binding site adjacent to the octamer site, and the PU.1 autoregulatory site. Finally, we show that the B cell coactivator OBF-1/Bob1/OCA-B is only expressed in B cells and not in myeloid cells, and that OBF-1/Bob1/OCA-B can transactivate the PU.1 promoter in HeLa and myeloid cells. This B cell restricted coactivator may be responsible for the B cell specific expression of PU.1 mediated by the octamer site.

[ "Octamer", "binding", "factors", "and", "their", "coactivator", "can", "activate", "the", "murine", "PU.1", "(", "spi-1", ")", "promoter", ".", "\n", "PU.1", "(", "spi-1", ")", ",", "a", "member", "of", "the", "Ets", "transcription", "factor", "family", ",", "is", "predominantly", "expressed", "in", "myeloid", "and", "B", "cells", ",", "activates", "many", "B", "cell", "and", "myeloid", "genes", ",", "and", "is", "critical", "for", "development", "of", "both", "of", "these", "lineages", ".", "Our", "previous", "studies", "(", "Chen", ",", "H.M.", ",", "Ray", "-", "Gallet", ",", "D.", ",", "Zhang", ",", "P.", ",", "Hetherington", ",", "C.J.", ",", "Gonzalez", ",", "D.A.", ",", "Zhang", ",", "D.-E.", ",", "Moreau", "-", "Gachelin", ",", "F.", ",", "and", "Tenen", ",", "D.G.(1995", ")", "Oncogene", "11", ",", "1549", "-", "1560", ")", "demonstrate", "that", "the", "PU.1", "promoter", "directs", "cell", "type", "-", "specific", "reporter", "gene", "expression", "in", "myeloid", "cell", "lines", ",", "and", "that", "PU.1", "activates", "its", "own", "promoter", "in", "an", "autoregulatory", "loop", ".", "Here", "we", "show", "that", "the", "murine", "PU.1", "promoter", "is", "also", "specifically", "and", "highly", "functional", "in", "B", "cell", "lines", "as", "well", ".", "Oct-1", "and", "Oct-2", "can", "bind", "specifically", "to", "a", "site", "at", "base", "pair", "-55", "in", "vitro", ",", "and", "this", "site", "is", "specifically", "protected", "in", "B", "cells", "in", "vivo", ".", "We", "also", "demonstrate", "that", "two", "other", "sites", "contribute", "to", "promoter", "activity", "in", "B", "cells", ";", "an", "Sp1", "binding", "site", "adjacent", "to", "the", "octamer", "site", ",", "and", "the", "PU.1", "autoregulatory", "site", ".", "Finally", ",", "we", "show", "that", "the", "B", "cell", "coactivator", "OBF-1", "/", "Bob1", "/", "OCA", "-", "B", "is", "only", "expressed", "in", "B", "cells", "and", "not", "in", "myeloid", "cells", ",", "and", "that", "OBF-1", "/", "Bob1", "/", "OCA", "-", "B", "can", "transactivate", "the", "PU.1", "promoter", "in", "HeLa", "and", "myeloid", "cells", ".", "This", "B", "cell", "restricted", "coactivator", "may", "be", "responsible", "for", "the", "B", "cell", "specific", "expression", "of", "PU.1", "mediated", "by", "the", "octamer", "site", "." ]

[ "Entity", "Protein" ]

PU.1, spi-1, promoter, PU.1, spi-1, PU.1, promoter, PU.1, PU.1, Oct-1, Oct-2, Sp1, PU.1, OBF-1, Bob1, OCA - B, OBF-1, Bob1, OCA - B, PU.1, promoter, PU.1

8663022_task2

Sentence: Octamer binding factors and their coactivator can activate the murine PU.1 (spi-1) promoter. PU.1 (spi-1), a member of the Ets transcription factor family, is predominantly expressed in myeloid and B cells, activates many B cell and myeloid genes, and is critical for development of both of these lineages. Our previous studies (Chen, H.M., Ray-Gallet, D., Zhang, P., Hetherington, C.J., Gonzalez, D.A., Zhang, D.-E., Moreau-Gachelin, F., and Tenen, D.G.(1995) Oncogene 11, 1549-1560) demonstrate that the PU.1 promoter directs cell type-specific reporter gene expression in myeloid cell lines, and that PU.1 activates its own promoter in an autoregulatory loop. Here we show that the murine PU.1 promoter is also specifically and highly functional in B cell lines as well. Oct-1 and Oct-2 can bind specifically to a site at base pair -55 in vitro, and this site is specifically protected in B cells in vivo. We also demonstrate that two other sites contribute to promoter activity in B cells; an Sp1 binding site adjacent to the octamer site, and the PU.1 autoregulatory site. Finally, we show that the B cell coactivator OBF-1/Bob1/OCA-B is only expressed in B cells and not in myeloid cells, and that OBF-1/Bob1/OCA-B can transactivate the PU.1 promoter in HeLa and myeloid cells. This B cell restricted coactivator may be responsible for the B cell specific expression of PU.1 mediated by the octamer site. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "B-Entity", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O" ]

Octamer binding factors and their coactivator can activate the murine PU.1 (spi-1) promoter. PU.1 (spi-1), a member of the Ets transcription factor family, is predominantly expressed in myeloid and B cells, activates many B cell and myeloid genes, and is critical for development of both of these lineages. Our previous studies (Chen, H.M., Ray-Gallet, D., Zhang, P., Hetherington, C.J., Gonzalez, D.A., Zhang, D.-E., Moreau-Gachelin, F., and Tenen, D.G.(1995) Oncogene 11, 1549-1560) demonstrate that the PU.1 promoter directs cell type-specific reporter gene expression in myeloid cell lines, and that PU.1 activates its own promoter in an autoregulatory loop. Here we show that the murine PU.1 promoter is also specifically and highly functional in B cell lines as well. Oct-1 and Oct-2 can bind specifically to a site at base pair -55 in vitro, and this site is specifically protected in B cells in vivo. We also demonstrate that two other sites contribute to promoter activity in B cells; an Sp1 binding site adjacent to the octamer site, and the PU.1 autoregulatory site. Finally, we show that the B cell coactivator OBF-1/Bob1/OCA-B is only expressed in B cells and not in myeloid cells, and that OBF-1/Bob1/OCA-B can transactivate the PU.1 promoter in HeLa and myeloid cells. This B cell restricted coactivator may be responsible for the B cell specific expression of PU.1 mediated by the octamer site.

[ "Octamer", "binding", "factors", "and", "their", "coactivator", "can", "activate", "the", "murine", "PU.1", "(", "spi-1", ")", "promoter", ".", "\n", "PU.1", "(", "spi-1", ")", ",", "a", "member", "of", "the", "Ets", "transcription", "factor", "family", ",", "is", "predominantly", "expressed", "in", "myeloid", "and", "B", "cells", ",", "activates", "many", "B", "cell", "and", "myeloid", "genes", ",", "and", "is", "critical", "for", "development", "of", "both", "of", "these", "lineages", ".", "Our", "previous", "studies", "(", "Chen", ",", "H.M.", ",", "Ray", "-", "Gallet", ",", "D.", ",", "Zhang", ",", "P.", ",", "Hetherington", ",", "C.J.", ",", "Gonzalez", ",", "D.A.", ",", "Zhang", ",", "D.-E.", ",", "Moreau", "-", "Gachelin", ",", "F.", ",", "and", "Tenen", ",", "D.G.(1995", ")", "Oncogene", "11", ",", "1549", "-", "1560", ")", "demonstrate", "that", "the", "PU.1", "promoter", "directs", "cell", "type", "-", "specific", "reporter", "gene", "expression", "in", "myeloid", "cell", "lines", ",", "and", "that", "PU.1", "activates", "its", "own", "promoter", "in", "an", "autoregulatory", "loop", ".", "Here", "we", "show", "that", "the", "murine", "PU.1", "promoter", "is", "also", "specifically", "and", "highly", "functional", "in", "B", "cell", "lines", "as", "well", ".", "Oct-1", "and", "Oct-2", "can", "bind", "specifically", "to", "a", "site", "at", "base", "pair", "-55", "in", "vitro", ",", "and", "this", "site", "is", "specifically", "protected", "in", "B", "cells", "in", "vivo", ".", "We", "also", "demonstrate", "that", "two", "other", "sites", "contribute", "to", "promoter", "activity", "in", "B", "cells", ";", "an", "Sp1", "binding", "site", "adjacent", "to", "the", "octamer", "site", ",", "and", "the", "PU.1", "autoregulatory", "site", ".", "Finally", ",", "we", "show", "that", "the", "B", "cell", "coactivator", "OBF-1", "/", "Bob1", "/", "OCA", "-", "B", "is", "only", "expressed", "in", "B", "cells", "and", "not", "in", "myeloid", "cells", ",", "and", "that", "OBF-1", "/", "Bob1", "/", "OCA", "-", "B", "can", "transactivate", "the", "PU.1", "promoter", "in", "HeLa", "and", "myeloid", "cells", ".", "This", "B", "cell", "restricted", "coactivator", "may", "be", "responsible", "for", "the", "B", "cell", "specific", "expression", "of", "PU.1", "mediated", "by", "the", "octamer", "site", "." ]

[ "Entity", "Protein" ]

vessels is a Multi-tissue_structure, tissue is a Tissue, Vascular is a Multi-tissue_structure, arterial is a Multi-tissue_structure, venous is a Multi-tissue_structure, stroma is a Tissue, tissues is a Tissue, hierarchic network is a Tissue, pericytes is a Cell, arterial is a Multi-tissue_structure, extracellular is a Immaterial_anatomical_entity, vascular is a Multi-tissue_structure, vessels is a Multi-tissue_structure, caliber is a Immaterial_anatomical_entity, vessel lumen is a Immaterial_anatomical_entity, pericyte is a Cell, vascular is a Multi-tissue_structure, vascular is a Multi-tissue_structure, tumor is a Cancer, tumor is a Cancer, tumors is a Cancer

PMID-17311993_task0

Sentence: Inhibition of Dll4-mediated signaling induces proliferation of immature vessels and results in poor tissue perfusion. Vascular development is dependent on various growth factors and certain modifiers critical for providing arterial or venous identity, interaction with the surrounding stroma and tissues, hierarchic network formation, and recruitment of pericytes. Notch receptors and ligands (Jagged and Delta-like) play a critical role in this process in addition to VEGF. Dll4 is one of the Notch ligands that regulates arterial specification and maturation events. In the current study, we have shown that loss of function by either targeted allele deletion or use of a soluble form of Dll4 extracellular domain leads to inhibition of Notch signaling, resulting in increased vascular proliferation but defective maturation. Newly forming vessels have thin caliber, a markedly reduced vessel lumen, markedly reduced pericyte recruitment, and deficient vascular perfusion. sDll4 similarly induced defective vascular response in tumor implants leading to reduced tumor growth. Interference with Dll4-Notch signaling may be particularly desirable in tumors that have highly induced Dll4-Notch pathway. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Tissue, Immaterial_anatomical_entity, Cancer, Multi-tissue_structure, Cell

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "O", "O", "B-Tissue", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "B-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "B-Tissue", "O", "B-Tissue", "O", "B-Tissue", "I-Tissue", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Immaterial_anatomical_entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "B-Immaterial_anatomical_entity", "O", "O", "O", "O", "B-Immaterial_anatomical_entity", "I-Immaterial_anatomical_entity", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "B-Cancer", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O" ]

Inhibition of Dll4-mediated signaling induces proliferation of immature vessels and results in poor tissue perfusion. Vascular development is dependent on various growth factors and certain modifiers critical for providing arterial or venous identity, interaction with the surrounding stroma and tissues, hierarchic network formation, and recruitment of pericytes. Notch receptors and ligands (Jagged and Delta-like) play a critical role in this process in addition to VEGF. Dll4 is one of the Notch ligands that regulates arterial specification and maturation events. In the current study, we have shown that loss of function by either targeted allele deletion or use of a soluble form of Dll4 extracellular domain leads to inhibition of Notch signaling, resulting in increased vascular proliferation but defective maturation. Newly forming vessels have thin caliber, a markedly reduced vessel lumen, markedly reduced pericyte recruitment, and deficient vascular perfusion. sDll4 similarly induced defective vascular response in tumor implants leading to reduced tumor growth. Interference with Dll4-Notch signaling may be particularly desirable in tumors that have highly induced Dll4-Notch pathway.

[ "Inhibition", "of", "Dll4-mediated", "signaling", "induces", "proliferation", "of", "immature", "vessels", "and", "results", "in", "poor", "tissue", "perfusion", ".", "\n", "Vascular", "development", "is", "dependent", "on", "various", "growth", "factors", "and", "certain", "modifiers", "critical", "for", "providing", "arterial", "or", "venous", "identity", ",", "interaction", "with", "the", "surrounding", "stroma", "and", "tissues", ",", "hierarchic", "network", "formation", ",", "and", "recruitment", "of", "pericytes", ".", "Notch", "receptors", "and", "ligands", "(", "Jagged", "and", "Delta", "-", "like", ")", "play", "a", "critical", "role", "in", "this", "process", "in", "addition", "to", "VEGF", ".", "Dll4", "is", "one", "of", "the", "Notch", "ligands", "that", "regulates", "arterial", "specification", "and", "maturation", "events", ".", "In", "the", "current", "study", ",", "we", "have", "shown", "that", "loss", "of", "function", "by", "either", "targeted", "allele", "deletion", "or", "use", "of", "a", "soluble", "form", "of", "Dll4", "extracellular", "domain", "leads", "to", "inhibition", "of", "Notch", "signaling", ",", "resulting", "in", "increased", "vascular", "proliferation", "but", "defective", "maturation", ".", "Newly", "forming", "vessels", "have", "thin", "caliber", ",", "a", "markedly", "reduced", "vessel", "lumen", ",", "markedly", "reduced", "pericyte", "recruitment", ",", "and", "deficient", "vascular", "perfusion", ".", "sDll4", "similarly", "induced", "defective", "vascular", "response", "in", "tumor", "implants", "leading", "to", "reduced", "tumor", "growth", ".", "Interference", "with", "Dll4-Notch", "signaling", "may", "be", "particularly", "desirable", "in", "tumors", "that", "have", "highly", "induced", "Dll4-Notch", "pathway", ".", "\n" ]

[ "Tissue", "Immaterial_anatomical_entity", "Cell", "Multi-tissue_structure", "Cancer" ]

vessels is a Multi-tissue_structure, tissue is a Tissue, Vascular is a Multi-tissue_structure, arterial is a Multi-tissue_structure, venous is a Multi-tissue_structure, stroma is a Tissue, tissues is a Tissue, hierarchic network is a Tissue, pericytes is a Cell, arterial is a Multi-tissue_structure, extracellular is a Immaterial_anatomical_entity, vascular is a Multi-tissue_structure, vessels is a Multi-tissue_structure, caliber is a Immaterial_anatomical_entity, vessel lumen is a Immaterial_anatomical_entity, pericyte is a Cell, vascular is a Multi-tissue_structure, vascular is a Multi-tissue_structure, tumor is a Cancer, tumor is a Cancer, tumors is a Cancer

PMID-17311993_task1

Sentence: Inhibition of Dll4-mediated signaling induces proliferation of immature vessels and results in poor tissue perfusion. Vascular development is dependent on various growth factors and certain modifiers critical for providing arterial or venous identity, interaction with the surrounding stroma and tissues, hierarchic network formation, and recruitment of pericytes. Notch receptors and ligands (Jagged and Delta-like) play a critical role in this process in addition to VEGF. Dll4 is one of the Notch ligands that regulates arterial specification and maturation events. In the current study, we have shown that loss of function by either targeted allele deletion or use of a soluble form of Dll4 extracellular domain leads to inhibition of Notch signaling, resulting in increased vascular proliferation but defective maturation. Newly forming vessels have thin caliber, a markedly reduced vessel lumen, markedly reduced pericyte recruitment, and deficient vascular perfusion. sDll4 similarly induced defective vascular response in tumor implants leading to reduced tumor growth. Interference with Dll4-Notch signaling may be particularly desirable in tumors that have highly induced Dll4-Notch pathway. Instructions: please typing these entity words according to sentence: vessels, tissue, Vascular, arterial, venous, stroma, tissues, hierarchic network, pericytes, arterial, extracellular, vascular, vessels, caliber, vessel lumen, pericyte, vascular, vascular, tumor, tumor, tumors Options: Tissue, Immaterial_anatomical_entity, Cancer, Multi-tissue_structure, Cell

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "O", "O", "B-Tissue", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "B-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "B-Tissue", "O", "B-Tissue", "O", "B-Tissue", "I-Tissue", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Immaterial_anatomical_entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "B-Immaterial_anatomical_entity", "O", "O", "O", "O", "B-Immaterial_anatomical_entity", "I-Immaterial_anatomical_entity", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "B-Cancer", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O" ]

Inhibition of Dll4-mediated signaling induces proliferation of immature vessels and results in poor tissue perfusion. Vascular development is dependent on various growth factors and certain modifiers critical for providing arterial or venous identity, interaction with the surrounding stroma and tissues, hierarchic network formation, and recruitment of pericytes. Notch receptors and ligands (Jagged and Delta-like) play a critical role in this process in addition to VEGF. Dll4 is one of the Notch ligands that regulates arterial specification and maturation events. In the current study, we have shown that loss of function by either targeted allele deletion or use of a soluble form of Dll4 extracellular domain leads to inhibition of Notch signaling, resulting in increased vascular proliferation but defective maturation. Newly forming vessels have thin caliber, a markedly reduced vessel lumen, markedly reduced pericyte recruitment, and deficient vascular perfusion. sDll4 similarly induced defective vascular response in tumor implants leading to reduced tumor growth. Interference with Dll4-Notch signaling may be particularly desirable in tumors that have highly induced Dll4-Notch pathway.

[ "Inhibition", "of", "Dll4-mediated", "signaling", "induces", "proliferation", "of", "immature", "vessels", "and", "results", "in", "poor", "tissue", "perfusion", ".", "\n", "Vascular", "development", "is", "dependent", "on", "various", "growth", "factors", "and", "certain", "modifiers", "critical", "for", "providing", "arterial", "or", "venous", "identity", ",", "interaction", "with", "the", "surrounding", "stroma", "and", "tissues", ",", "hierarchic", "network", "formation", ",", "and", "recruitment", "of", "pericytes", ".", "Notch", "receptors", "and", "ligands", "(", "Jagged", "and", "Delta", "-", "like", ")", "play", "a", "critical", "role", "in", "this", "process", "in", "addition", "to", "VEGF", ".", "Dll4", "is", "one", "of", "the", "Notch", "ligands", "that", "regulates", "arterial", "specification", "and", "maturation", "events", ".", "In", "the", "current", "study", ",", "we", "have", "shown", "that", "loss", "of", "function", "by", "either", "targeted", "allele", "deletion", "or", "use", "of", "a", "soluble", "form", "of", "Dll4", "extracellular", "domain", "leads", "to", "inhibition", "of", "Notch", "signaling", ",", "resulting", "in", "increased", "vascular", "proliferation", "but", "defective", "maturation", ".", "Newly", "forming", "vessels", "have", "thin", "caliber", ",", "a", "markedly", "reduced", "vessel", "lumen", ",", "markedly", "reduced", "pericyte", "recruitment", ",", "and", "deficient", "vascular", "perfusion", ".", "sDll4", "similarly", "induced", "defective", "vascular", "response", "in", "tumor", "implants", "leading", "to", "reduced", "tumor", "growth", ".", "Interference", "with", "Dll4-Notch", "signaling", "may", "be", "particularly", "desirable", "in", "tumors", "that", "have", "highly", "induced", "Dll4-Notch", "pathway", ".", "\n" ]

[ "Tissue", "Immaterial_anatomical_entity", "Cell", "Multi-tissue_structure", "Cancer" ]

vessels, tissue, Vascular, arterial, venous, stroma, tissues, hierarchic network, pericytes, arterial, extracellular, vascular, vessels, caliber, vessel lumen, pericyte, vascular, vascular, tumor, tumor, tumors

PMID-17311993_task2

Sentence: Inhibition of Dll4-mediated signaling induces proliferation of immature vessels and results in poor tissue perfusion. Vascular development is dependent on various growth factors and certain modifiers critical for providing arterial or venous identity, interaction with the surrounding stroma and tissues, hierarchic network formation, and recruitment of pericytes. Notch receptors and ligands (Jagged and Delta-like) play a critical role in this process in addition to VEGF. Dll4 is one of the Notch ligands that regulates arterial specification and maturation events. In the current study, we have shown that loss of function by either targeted allele deletion or use of a soluble form of Dll4 extracellular domain leads to inhibition of Notch signaling, resulting in increased vascular proliferation but defective maturation. Newly forming vessels have thin caliber, a markedly reduced vessel lumen, markedly reduced pericyte recruitment, and deficient vascular perfusion. sDll4 similarly induced defective vascular response in tumor implants leading to reduced tumor growth. Interference with Dll4-Notch signaling may be particularly desirable in tumors that have highly induced Dll4-Notch pathway. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "O", "O", "B-Tissue", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "B-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "B-Tissue", "O", "B-Tissue", "O", "B-Tissue", "I-Tissue", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Immaterial_anatomical_entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "B-Immaterial_anatomical_entity", "O", "O", "O", "O", "B-Immaterial_anatomical_entity", "I-Immaterial_anatomical_entity", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "B-Cancer", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O" ]

Inhibition of Dll4-mediated signaling induces proliferation of immature vessels and results in poor tissue perfusion. Vascular development is dependent on various growth factors and certain modifiers critical for providing arterial or venous identity, interaction with the surrounding stroma and tissues, hierarchic network formation, and recruitment of pericytes. Notch receptors and ligands (Jagged and Delta-like) play a critical role in this process in addition to VEGF. Dll4 is one of the Notch ligands that regulates arterial specification and maturation events. In the current study, we have shown that loss of function by either targeted allele deletion or use of a soluble form of Dll4 extracellular domain leads to inhibition of Notch signaling, resulting in increased vascular proliferation but defective maturation. Newly forming vessels have thin caliber, a markedly reduced vessel lumen, markedly reduced pericyte recruitment, and deficient vascular perfusion. sDll4 similarly induced defective vascular response in tumor implants leading to reduced tumor growth. Interference with Dll4-Notch signaling may be particularly desirable in tumors that have highly induced Dll4-Notch pathway.

[ "Inhibition", "of", "Dll4-mediated", "signaling", "induces", "proliferation", "of", "immature", "vessels", "and", "results", "in", "poor", "tissue", "perfusion", ".", "\n", "Vascular", "development", "is", "dependent", "on", "various", "growth", "factors", "and", "certain", "modifiers", "critical", "for", "providing", "arterial", "or", "venous", "identity", ",", "interaction", "with", "the", "surrounding", "stroma", "and", "tissues", ",", "hierarchic", "network", "formation", ",", "and", "recruitment", "of", "pericytes", ".", "Notch", "receptors", "and", "ligands", "(", "Jagged", "and", "Delta", "-", "like", ")", "play", "a", "critical", "role", "in", "this", "process", "in", "addition", "to", "VEGF", ".", "Dll4", "is", "one", "of", "the", "Notch", "ligands", "that", "regulates", "arterial", "specification", "and", "maturation", "events", ".", "In", "the", "current", "study", ",", "we", "have", "shown", "that", "loss", "of", "function", "by", "either", "targeted", "allele", "deletion", "or", "use", "of", "a", "soluble", "form", "of", "Dll4", "extracellular", "domain", "leads", "to", "inhibition", "of", "Notch", "signaling", ",", "resulting", "in", "increased", "vascular", "proliferation", "but", "defective", "maturation", ".", "Newly", "forming", "vessels", "have", "thin", "caliber", ",", "a", "markedly", "reduced", "vessel", "lumen", ",", "markedly", "reduced", "pericyte", "recruitment", ",", "and", "deficient", "vascular", "perfusion", ".", "sDll4", "similarly", "induced", "defective", "vascular", "response", "in", "tumor", "implants", "leading", "to", "reduced", "tumor", "growth", ".", "Interference", "with", "Dll4-Notch", "signaling", "may", "be", "particularly", "desirable", "in", "tumors", "that", "have", "highly", "induced", "Dll4-Notch", "pathway", ".", "\n" ]

[ "Tissue", "Immaterial_anatomical_entity", "Cell", "Multi-tissue_structure", "Cancer" ]

Porphyrine is an umlsterm, Tumoren is an umlsterm, Arbeit is an umlsterm, Melanomen is an umlsterm, Hauttumors is an umlsterm

DerRadiologe.90390422.ger.abstr_task0

Sentence: Ziel : Fuer Porphyrine wird eine selektive Anreicherung in malignen Tumoren beschrieben . In dieser Arbeit soll mittels der hochaufloesenden MRT das Enhancement in melanotischen Melanomen nach Applikation von Mn-TPPS4 untersucht werden , um eine bessere Charakterisierung dieses malignen Hauttumors zu erreichen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]

Ziel : Fuer Porphyrine wird eine selektive Anreicherung in malignen Tumoren beschrieben . In dieser Arbeit soll mittels der hochaufloesenden MRT das Enhancement in melanotischen Melanomen nach Applikation von Mn-TPPS4 untersucht werden , um eine bessere Charakterisierung dieses malignen Hauttumors zu erreichen .

[ "Ziel", ":", "Fuer", "Porphyrine", "wird", "eine", "selektive", "Anreicherung", "in", "malignen", "Tumoren", "beschrieben", ".", "In", "dieser", "Arbeit", "soll", "mittels", "der", "hochaufloesenden", "MRT", "das", "Enhancement", "in", "melanotischen", "Melanomen", "nach", "Applikation", "von", "Mn", "-", "TPPS4", "untersucht", "werden", ",", "um", "eine", "bessere", "Charakterisierung", "dieses", "malignen", "Hauttumors", "zu", "erreichen", "." ]

[ "umlsterm" ]

Porphyrine is an umlsterm, Tumoren is an umlsterm, Arbeit is an umlsterm, Melanomen is an umlsterm, Hauttumors is an umlsterm

DerRadiologe.90390422.ger.abstr_task1

Sentence: Ziel : Fuer Porphyrine wird eine selektive Anreicherung in malignen Tumoren beschrieben . In dieser Arbeit soll mittels der hochaufloesenden MRT das Enhancement in melanotischen Melanomen nach Applikation von Mn-TPPS4 untersucht werden , um eine bessere Charakterisierung dieses malignen Hauttumors zu erreichen . Instructions: please typing these entity words according to sentence: Porphyrine, Tumoren, Arbeit, Melanomen, Hauttumors Options: umlsterm

[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]

Ziel : Fuer Porphyrine wird eine selektive Anreicherung in malignen Tumoren beschrieben . In dieser Arbeit soll mittels der hochaufloesenden MRT das Enhancement in melanotischen Melanomen nach Applikation von Mn-TPPS4 untersucht werden , um eine bessere Charakterisierung dieses malignen Hauttumors zu erreichen .

[ "Ziel", ":", "Fuer", "Porphyrine", "wird", "eine", "selektive", "Anreicherung", "in", "malignen", "Tumoren", "beschrieben", ".", "In", "dieser", "Arbeit", "soll", "mittels", "der", "hochaufloesenden", "MRT", "das", "Enhancement", "in", "melanotischen", "Melanomen", "nach", "Applikation", "von", "Mn", "-", "TPPS4", "untersucht", "werden", ",", "um", "eine", "bessere", "Charakterisierung", "dieses", "malignen", "Hauttumors", "zu", "erreichen", "." ]

[ "umlsterm" ]

Porphyrine, Tumoren, Arbeit, Melanomen, Hauttumors

DerRadiologe.90390422.ger.abstr_task2

Sentence: Ziel : Fuer Porphyrine wird eine selektive Anreicherung in malignen Tumoren beschrieben . In dieser Arbeit soll mittels der hochaufloesenden MRT das Enhancement in melanotischen Melanomen nach Applikation von Mn-TPPS4 untersucht werden , um eine bessere Charakterisierung dieses malignen Hauttumors zu erreichen . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]

Ziel : Fuer Porphyrine wird eine selektive Anreicherung in malignen Tumoren beschrieben . In dieser Arbeit soll mittels der hochaufloesenden MRT das Enhancement in melanotischen Melanomen nach Applikation von Mn-TPPS4 untersucht werden , um eine bessere Charakterisierung dieses malignen Hauttumors zu erreichen .

[ "Ziel", ":", "Fuer", "Porphyrine", "wird", "eine", "selektive", "Anreicherung", "in", "malignen", "Tumoren", "beschrieben", ".", "In", "dieser", "Arbeit", "soll", "mittels", "der", "hochaufloesenden", "MRT", "das", "Enhancement", "in", "melanotischen", "Melanomen", "nach", "Applikation", "von", "Mn", "-", "TPPS4", "untersucht", "werden", ",", "um", "eine", "bessere", "Charakterisierung", "dieses", "malignen", "Hauttumors", "zu", "erreichen", "." ]

[ "umlsterm" ]

Peptid is an umlsterm, Patienten is an umlsterm

DerAnaesthesist.90480395.ger.abstr_task0

Sentence: Der Syntheseort fuer das inflammatorische Peptid Procalcitonin ( PCT ) ist bisher nicht bekannt . In der vorliegenden Studie wurde bei kardiochirurgischen Patienten nach Hinweisen fuer einen Syntheseort nach extrakorporaler Zirkulation ( EKZ ) gesucht . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Der Syntheseort fuer das inflammatorische Peptid Procalcitonin ( PCT ) ist bisher nicht bekannt . In der vorliegenden Studie wurde bei kardiochirurgischen Patienten nach Hinweisen fuer einen Syntheseort nach extrakorporaler Zirkulation ( EKZ ) gesucht .

[ "Der", "Syntheseort", "fuer", "das", "inflammatorische", "Peptid", "Procalcitonin", "(", "PCT", ")", "ist", "bisher", "nicht", "bekannt", ".", "In", "der", "vorliegenden", "Studie", "wurde", "bei", "kardiochirurgischen", "Patienten", "nach", "Hinweisen", "fuer", "einen", "Syntheseort", "nach", "extrakorporaler", "Zirkulation", "(", "EKZ", ")", "gesucht", "." ]

[ "umlsterm" ]

Peptid is an umlsterm, Patienten is an umlsterm

DerAnaesthesist.90480395.ger.abstr_task1

Sentence: Der Syntheseort fuer das inflammatorische Peptid Procalcitonin ( PCT ) ist bisher nicht bekannt . In der vorliegenden Studie wurde bei kardiochirurgischen Patienten nach Hinweisen fuer einen Syntheseort nach extrakorporaler Zirkulation ( EKZ ) gesucht . Instructions: please typing these entity words according to sentence: Peptid, Patienten Options: umlsterm

[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Der Syntheseort fuer das inflammatorische Peptid Procalcitonin ( PCT ) ist bisher nicht bekannt . In der vorliegenden Studie wurde bei kardiochirurgischen Patienten nach Hinweisen fuer einen Syntheseort nach extrakorporaler Zirkulation ( EKZ ) gesucht .

[ "Der", "Syntheseort", "fuer", "das", "inflammatorische", "Peptid", "Procalcitonin", "(", "PCT", ")", "ist", "bisher", "nicht", "bekannt", ".", "In", "der", "vorliegenden", "Studie", "wurde", "bei", "kardiochirurgischen", "Patienten", "nach", "Hinweisen", "fuer", "einen", "Syntheseort", "nach", "extrakorporaler", "Zirkulation", "(", "EKZ", ")", "gesucht", "." ]

[ "umlsterm" ]

Peptid, Patienten

DerAnaesthesist.90480395.ger.abstr_task2

Sentence: Der Syntheseort fuer das inflammatorische Peptid Procalcitonin ( PCT ) ist bisher nicht bekannt . In der vorliegenden Studie wurde bei kardiochirurgischen Patienten nach Hinweisen fuer einen Syntheseort nach extrakorporaler Zirkulation ( EKZ ) gesucht . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Der Syntheseort fuer das inflammatorische Peptid Procalcitonin ( PCT ) ist bisher nicht bekannt . In der vorliegenden Studie wurde bei kardiochirurgischen Patienten nach Hinweisen fuer einen Syntheseort nach extrakorporaler Zirkulation ( EKZ ) gesucht .

[ "Der", "Syntheseort", "fuer", "das", "inflammatorische", "Peptid", "Procalcitonin", "(", "PCT", ")", "ist", "bisher", "nicht", "bekannt", ".", "In", "der", "vorliegenden", "Studie", "wurde", "bei", "kardiochirurgischen", "Patienten", "nach", "Hinweisen", "fuer", "einen", "Syntheseort", "nach", "extrakorporaler", "Zirkulation", "(", "EKZ", ")", "gesucht", "." ]

[ "umlsterm" ]

Progesterone is a compound, microtubule - associated protein 2 is a protein, MAP2 is a protein

DS.d395_task0

Sentence: Progesterone effects on neuronal ultrastructure and expression of microtubule-associated protein 2 (MAP2) in rats with acute spinal cord injury. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: compound, protein

[ "B-compound", "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "I-protein", "I-protein", "I-protein", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Progesterone effects on neuronal ultrastructure and expression of microtubule-associated protein 2 (MAP2) in rats with acute spinal cord injury.

[ "Progesterone", "effects", "on", "neuronal", "ultrastructure", "and", "expression", "of", "microtubule", "-", "associated", "protein", "2", "(", "MAP2", ")", "in", "rats", "with", "acute", "spinal", "cord", "injury", "." ]

[ "protein", "compound" ]

Progesterone is a compound, microtubule - associated protein 2 is a protein, MAP2 is a protein

DS.d395_task1

Sentence: Progesterone effects on neuronal ultrastructure and expression of microtubule-associated protein 2 (MAP2) in rats with acute spinal cord injury. Instructions: please typing these entity words according to sentence: Progesterone, microtubule - associated protein 2, MAP2 Options: compound, protein

[ "B-compound", "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "I-protein", "I-protein", "I-protein", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Progesterone effects on neuronal ultrastructure and expression of microtubule-associated protein 2 (MAP2) in rats with acute spinal cord injury.

[ "Progesterone", "effects", "on", "neuronal", "ultrastructure", "and", "expression", "of", "microtubule", "-", "associated", "protein", "2", "(", "MAP2", ")", "in", "rats", "with", "acute", "spinal", "cord", "injury", "." ]

[ "protein", "compound" ]

Progesterone, microtubule - associated protein 2, MAP2

DS.d395_task2

Sentence: Progesterone effects on neuronal ultrastructure and expression of microtubule-associated protein 2 (MAP2) in rats with acute spinal cord injury. Instructions: please extract entity words from the input sentence

[ "B-compound", "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "I-protein", "I-protein", "I-protein", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Progesterone effects on neuronal ultrastructure and expression of microtubule-associated protein 2 (MAP2) in rats with acute spinal cord injury.

[ "Progesterone", "effects", "on", "neuronal", "ultrastructure", "and", "expression", "of", "microtubule", "-", "associated", "protein", "2", "(", "MAP2", ")", "in", "rats", "with", "acute", "spinal", "cord", "injury", "." ]

[ "protein", "compound" ]

diabetes mellitus according to World Health Organization criteria is a Scope, treatment with insulin or an oral hypoglycemic agent , twice random glucose measurements major than 200 mg / dl , or a fasting glucose major than 140 mg / dl is a Scope, Ulcer is a Condition, legs or feet is a Scope, stage is a Measurement, III or IV is a Value, Wagner Classification System is a Qualifier

NCT02742233_inc_task0

Sentence: Diagnosis of diabetes mellitus according to World Health Organization criteria ( treatment with insulin or an oral hypoglycemic agent, twice random glucose measurements major than 200 mg/dl, or a fasting glucose major than 140 mg/dl) Ulcer located on the legs or feet, stage III or IV (Wagner Classification System) The subject agrees to comply with study protocol requirements and all follow up visit requirements. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Condition, Qualifier, Value, Scope, Measurement

[ "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Condition", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "O", "B-Measurement", "B-Value", "I-Value", "I-Value", "O", "B-Qualifier", "I-Qualifier", "I-Qualifier", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Diagnosis of diabetes mellitus according to World Health Organization criteria ( treatment with insulin or an oral hypoglycemic agent, twice random glucose measurements major than 200 mg/dl, or a fasting glucose major than 140 mg/dl) Ulcer located on the legs or feet, stage III or IV (Wagner Classification System) The subject agrees to comply with study protocol requirements and all follow up visit requirements.

[ "Diagnosis", "of", "diabetes", "mellitus", "according", "to", "World", "Health", "Organization", "criteria", "(", "treatment", "with", "insulin", "or", "an", "oral", "hypoglycemic", "agent", ",", "twice", "random", "glucose", "measurements", "major", "than", "200", "mg", "/", "dl", ",", "or", "a", "fasting", "glucose", "major", "than", "140", "mg", "/", "dl", ")", "\n", "Ulcer", "located", "on", "the", "legs", "or", "feet", ",", "stage", "III", "or", "IV", "(", "Wagner", "Classification", "System", ")", "\n", "The", "subject", "agrees", "to", "comply", "with", "study", "protocol", "requirements", "and", "all", "follow", "up", "visit", "requirements", ".", "\n" ]

[ "Scope", "Qualifier", "Measurement", "Drug", "Value", "Condition", "Procedure", "Multiplier" ]

diabetes mellitus according to World Health Organization criteria is a Scope, treatment with insulin or an oral hypoglycemic agent , twice random glucose measurements major than 200 mg / dl , or a fasting glucose major than 140 mg / dl is a Scope, Ulcer is a Condition, legs or feet is a Scope, stage is a Measurement, III or IV is a Value, Wagner Classification System is a Qualifier

NCT02742233_inc_task1

Sentence: Diagnosis of diabetes mellitus according to World Health Organization criteria ( treatment with insulin or an oral hypoglycemic agent, twice random glucose measurements major than 200 mg/dl, or a fasting glucose major than 140 mg/dl) Ulcer located on the legs or feet, stage III or IV (Wagner Classification System) The subject agrees to comply with study protocol requirements and all follow up visit requirements. Instructions: please typing these entity words according to sentence: diabetes mellitus according to World Health Organization criteria, treatment with insulin or an oral hypoglycemic agent , twice random glucose measurements major than 200 mg / dl , or a fasting glucose major than 140 mg / dl, Ulcer, legs or feet, stage, III or IV, Wagner Classification System Options: Condition, Qualifier, Value, Scope, Measurement

[ "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Condition", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "O", "B-Measurement", "B-Value", "I-Value", "I-Value", "O", "B-Qualifier", "I-Qualifier", "I-Qualifier", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Diagnosis of diabetes mellitus according to World Health Organization criteria ( treatment with insulin or an oral hypoglycemic agent, twice random glucose measurements major than 200 mg/dl, or a fasting glucose major than 140 mg/dl) Ulcer located on the legs or feet, stage III or IV (Wagner Classification System) The subject agrees to comply with study protocol requirements and all follow up visit requirements.

[ "Diagnosis", "of", "diabetes", "mellitus", "according", "to", "World", "Health", "Organization", "criteria", "(", "treatment", "with", "insulin", "or", "an", "oral", "hypoglycemic", "agent", ",", "twice", "random", "glucose", "measurements", "major", "than", "200", "mg", "/", "dl", ",", "or", "a", "fasting", "glucose", "major", "than", "140", "mg", "/", "dl", ")", "\n", "Ulcer", "located", "on", "the", "legs", "or", "feet", ",", "stage", "III", "or", "IV", "(", "Wagner", "Classification", "System", ")", "\n", "The", "subject", "agrees", "to", "comply", "with", "study", "protocol", "requirements", "and", "all", "follow", "up", "visit", "requirements", ".", "\n" ]

[ "Scope", "Qualifier", "Measurement", "Drug", "Value", "Condition", "Procedure", "Multiplier" ]

diabetes mellitus according to World Health Organization criteria, treatment with insulin or an oral hypoglycemic agent , twice random glucose measurements major than 200 mg / dl , or a fasting glucose major than 140 mg / dl, Ulcer, legs or feet, stage, III or IV, Wagner Classification System

NCT02742233_inc_task2

Sentence: Diagnosis of diabetes mellitus according to World Health Organization criteria ( treatment with insulin or an oral hypoglycemic agent, twice random glucose measurements major than 200 mg/dl, or a fasting glucose major than 140 mg/dl) Ulcer located on the legs or feet, stage III or IV (Wagner Classification System) The subject agrees to comply with study protocol requirements and all follow up visit requirements. Instructions: please extract entity words from the input sentence

[ "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Condition", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "O", "B-Measurement", "B-Value", "I-Value", "I-Value", "O", "B-Qualifier", "I-Qualifier", "I-Qualifier", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Diagnosis of diabetes mellitus according to World Health Organization criteria ( treatment with insulin or an oral hypoglycemic agent, twice random glucose measurements major than 200 mg/dl, or a fasting glucose major than 140 mg/dl) Ulcer located on the legs or feet, stage III or IV (Wagner Classification System) The subject agrees to comply with study protocol requirements and all follow up visit requirements.

[ "Diagnosis", "of", "diabetes", "mellitus", "according", "to", "World", "Health", "Organization", "criteria", "(", "treatment", "with", "insulin", "or", "an", "oral", "hypoglycemic", "agent", ",", "twice", "random", "glucose", "measurements", "major", "than", "200", "mg", "/", "dl", ",", "or", "a", "fasting", "glucose", "major", "than", "140", "mg", "/", "dl", ")", "\n", "Ulcer", "located", "on", "the", "legs", "or", "feet", ",", "stage", "III", "or", "IV", "(", "Wagner", "Classification", "System", ")", "\n", "The", "subject", "agrees", "to", "comply", "with", "study", "protocol", "requirements", "and", "all", "follow", "up", "visit", "requirements", ".", "\n" ]

[ "Scope", "Qualifier", "Measurement", "Drug", "Value", "Condition", "Procedure", "Multiplier" ]

Osteoporose is an umlsterm, Knochenmassenverlust is an umlsterm, Knochenstruktur is an umlsterm, Frakturgefaehrdung is an umlsterm, Osteoporosediagnostik is an umlsterm, bildgebende is an umlsterm, Computertomographie is an umlsterm, Magnetresonanztomographie is an umlsterm, Knochendichte is an umlsterm, Knochenstabilitaet is an umlsterm, Patienten is an umlsterm, Frakturen is an umlsterm

DerRadiologe.80380853.ger.abstr_task0

Sentence: Bei der Osteoporose kommt es zu einem Knochenmassenverlust und zu einem Umbau der trabekulaeren Knochenstruktur mit erhoehter Frakturgefaehrdung . Ziel der vorliegenden Uebersicht ist es , den Stellenwert strukturanalytischer Verfahren im Rahmen der Osteoporosediagnostik zu analysieren . Als bildgebende Verfahren zur Strukturanalyse wurden konventionelle Radiographie , hochaufloesende Computertomographie ( HR-CT ) und hochaufloesende Magnetresonanztomographie ( HR-MRT ) eingesetzt . Die besten Ergebnisse wurden mit hochaufloesenden tomographischen Verfahren erzielt , wobei die hochaufloesende MRT die beste Ortsaufloesung erzielte . Die vorliegenden Untersuchungen zeigen , dass Texturparameter und Knochendichte sich komplementaer zueinander verhalten . Die Kombination beider Verfahren erzielt die beste Praediktion der biomechanisch bestimmten Knochenstabilitaet und die beste Differenzierung von Patienten mit und ohne osteoporotische Frakturen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O" ]

Bei der Osteoporose kommt es zu einem Knochenmassenverlust und zu einem Umbau der trabekulaeren Knochenstruktur mit erhoehter Frakturgefaehrdung . Ziel der vorliegenden Uebersicht ist es , den Stellenwert strukturanalytischer Verfahren im Rahmen der Osteoporosediagnostik zu analysieren . Als bildgebende Verfahren zur Strukturanalyse wurden konventionelle Radiographie , hochaufloesende Computertomographie ( HR-CT ) und hochaufloesende Magnetresonanztomographie ( HR-MRT ) eingesetzt . Die besten Ergebnisse wurden mit hochaufloesenden tomographischen Verfahren erzielt , wobei die hochaufloesende MRT die beste Ortsaufloesung erzielte . Die vorliegenden Untersuchungen zeigen , dass Texturparameter und Knochendichte sich komplementaer zueinander verhalten . Die Kombination beider Verfahren erzielt die beste Praediktion der biomechanisch bestimmten Knochenstabilitaet und die beste Differenzierung von Patienten mit und ohne osteoporotische Frakturen .

[ "Bei", "der", "Osteoporose", "kommt", "es", "zu", "einem", "Knochenmassenverlust", "und", "zu", "einem", "Umbau", "der", "trabekulaeren", "Knochenstruktur", "mit", "erhoehter", "Frakturgefaehrdung", ".", "Ziel", "der", "vorliegenden", "Uebersicht", "ist", "es", ",", "den", "Stellenwert", "strukturanalytischer", "Verfahren", "im", "Rahmen", "der", "Osteoporosediagnostik", "zu", "analysieren", ".", "Als", "bildgebende", "Verfahren", "zur", "Strukturanalyse", "wurden", "konventionelle", "Radiographie", ",", "hochaufloesende", "Computertomographie", "(", "HR", "-", "CT", ")", "und", "hochaufloesende", "Magnetresonanztomographie", "(", "HR", "-", "MRT", ")", "eingesetzt", ".", "Die", "besten", "Ergebnisse", "wurden", "mit", "hochaufloesenden", "tomographischen", "Verfahren", "erzielt", ",", "wobei", "die", "hochaufloesende", "MRT", "die", "beste", "Ortsaufloesung", "erzielte", ".", "Die", "vorliegenden", "Untersuchungen", "zeigen", ",", "dass", "Texturparameter", "und", "Knochendichte", "sich", "komplementaer", "zueinander", "verhalten", ".", "Die", "Kombination", "beider", "Verfahren", "erzielt", "die", "beste", "Praediktion", "der", "biomechanisch", "bestimmten", "Knochenstabilitaet", "und", "die", "beste", "Differenzierung", "von", "Patienten", "mit", "und", "ohne", "osteoporotische", "Frakturen", "." ]

[ "umlsterm" ]

Osteoporose is an umlsterm, Knochenmassenverlust is an umlsterm, Knochenstruktur is an umlsterm, Frakturgefaehrdung is an umlsterm, Osteoporosediagnostik is an umlsterm, bildgebende is an umlsterm, Computertomographie is an umlsterm, Magnetresonanztomographie is an umlsterm, Knochendichte is an umlsterm, Knochenstabilitaet is an umlsterm, Patienten is an umlsterm, Frakturen is an umlsterm

DerRadiologe.80380853.ger.abstr_task1

Sentence: Bei der Osteoporose kommt es zu einem Knochenmassenverlust und zu einem Umbau der trabekulaeren Knochenstruktur mit erhoehter Frakturgefaehrdung . Ziel der vorliegenden Uebersicht ist es , den Stellenwert strukturanalytischer Verfahren im Rahmen der Osteoporosediagnostik zu analysieren . Als bildgebende Verfahren zur Strukturanalyse wurden konventionelle Radiographie , hochaufloesende Computertomographie ( HR-CT ) und hochaufloesende Magnetresonanztomographie ( HR-MRT ) eingesetzt . Die besten Ergebnisse wurden mit hochaufloesenden tomographischen Verfahren erzielt , wobei die hochaufloesende MRT die beste Ortsaufloesung erzielte . Die vorliegenden Untersuchungen zeigen , dass Texturparameter und Knochendichte sich komplementaer zueinander verhalten . Die Kombination beider Verfahren erzielt die beste Praediktion der biomechanisch bestimmten Knochenstabilitaet und die beste Differenzierung von Patienten mit und ohne osteoporotische Frakturen . Instructions: please typing these entity words according to sentence: Osteoporose, Knochenmassenverlust, Knochenstruktur, Frakturgefaehrdung, Osteoporosediagnostik, bildgebende, Computertomographie, Magnetresonanztomographie, Knochendichte, Knochenstabilitaet, Patienten, Frakturen Options: umlsterm

[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O" ]

Bei der Osteoporose kommt es zu einem Knochenmassenverlust und zu einem Umbau der trabekulaeren Knochenstruktur mit erhoehter Frakturgefaehrdung . Ziel der vorliegenden Uebersicht ist es , den Stellenwert strukturanalytischer Verfahren im Rahmen der Osteoporosediagnostik zu analysieren . Als bildgebende Verfahren zur Strukturanalyse wurden konventionelle Radiographie , hochaufloesende Computertomographie ( HR-CT ) und hochaufloesende Magnetresonanztomographie ( HR-MRT ) eingesetzt . Die besten Ergebnisse wurden mit hochaufloesenden tomographischen Verfahren erzielt , wobei die hochaufloesende MRT die beste Ortsaufloesung erzielte . Die vorliegenden Untersuchungen zeigen , dass Texturparameter und Knochendichte sich komplementaer zueinander verhalten . Die Kombination beider Verfahren erzielt die beste Praediktion der biomechanisch bestimmten Knochenstabilitaet und die beste Differenzierung von Patienten mit und ohne osteoporotische Frakturen .

[ "Bei", "der", "Osteoporose", "kommt", "es", "zu", "einem", "Knochenmassenverlust", "und", "zu", "einem", "Umbau", "der", "trabekulaeren", "Knochenstruktur", "mit", "erhoehter", "Frakturgefaehrdung", ".", "Ziel", "der", "vorliegenden", "Uebersicht", "ist", "es", ",", "den", "Stellenwert", "strukturanalytischer", "Verfahren", "im", "Rahmen", "der", "Osteoporosediagnostik", "zu", "analysieren", ".", "Als", "bildgebende", "Verfahren", "zur", "Strukturanalyse", "wurden", "konventionelle", "Radiographie", ",", "hochaufloesende", "Computertomographie", "(", "HR", "-", "CT", ")", "und", "hochaufloesende", "Magnetresonanztomographie", "(", "HR", "-", "MRT", ")", "eingesetzt", ".", "Die", "besten", "Ergebnisse", "wurden", "mit", "hochaufloesenden", "tomographischen", "Verfahren", "erzielt", ",", "wobei", "die", "hochaufloesende", "MRT", "die", "beste", "Ortsaufloesung", "erzielte", ".", "Die", "vorliegenden", "Untersuchungen", "zeigen", ",", "dass", "Texturparameter", "und", "Knochendichte", "sich", "komplementaer", "zueinander", "verhalten", ".", "Die", "Kombination", "beider", "Verfahren", "erzielt", "die", "beste", "Praediktion", "der", "biomechanisch", "bestimmten", "Knochenstabilitaet", "und", "die", "beste", "Differenzierung", "von", "Patienten", "mit", "und", "ohne", "osteoporotische", "Frakturen", "." ]

[ "umlsterm" ]

Osteoporose, Knochenmassenverlust, Knochenstruktur, Frakturgefaehrdung, Osteoporosediagnostik, bildgebende, Computertomographie, Magnetresonanztomographie, Knochendichte, Knochenstabilitaet, Patienten, Frakturen

DerRadiologe.80380853.ger.abstr_task2

Sentence: Bei der Osteoporose kommt es zu einem Knochenmassenverlust und zu einem Umbau der trabekulaeren Knochenstruktur mit erhoehter Frakturgefaehrdung . Ziel der vorliegenden Uebersicht ist es , den Stellenwert strukturanalytischer Verfahren im Rahmen der Osteoporosediagnostik zu analysieren . Als bildgebende Verfahren zur Strukturanalyse wurden konventionelle Radiographie , hochaufloesende Computertomographie ( HR-CT ) und hochaufloesende Magnetresonanztomographie ( HR-MRT ) eingesetzt . Die besten Ergebnisse wurden mit hochaufloesenden tomographischen Verfahren erzielt , wobei die hochaufloesende MRT die beste Ortsaufloesung erzielte . Die vorliegenden Untersuchungen zeigen , dass Texturparameter und Knochendichte sich komplementaer zueinander verhalten . Die Kombination beider Verfahren erzielt die beste Praediktion der biomechanisch bestimmten Knochenstabilitaet und die beste Differenzierung von Patienten mit und ohne osteoporotische Frakturen . Instructions: please extract entity words from the input sentence

[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O" ]

Bei der Osteoporose kommt es zu einem Knochenmassenverlust und zu einem Umbau der trabekulaeren Knochenstruktur mit erhoehter Frakturgefaehrdung . Ziel der vorliegenden Uebersicht ist es , den Stellenwert strukturanalytischer Verfahren im Rahmen der Osteoporosediagnostik zu analysieren . Als bildgebende Verfahren zur Strukturanalyse wurden konventionelle Radiographie , hochaufloesende Computertomographie ( HR-CT ) und hochaufloesende Magnetresonanztomographie ( HR-MRT ) eingesetzt . Die besten Ergebnisse wurden mit hochaufloesenden tomographischen Verfahren erzielt , wobei die hochaufloesende MRT die beste Ortsaufloesung erzielte . Die vorliegenden Untersuchungen zeigen , dass Texturparameter und Knochendichte sich komplementaer zueinander verhalten . Die Kombination beider Verfahren erzielt die beste Praediktion der biomechanisch bestimmten Knochenstabilitaet und die beste Differenzierung von Patienten mit und ohne osteoporotische Frakturen .

[ "Bei", "der", "Osteoporose", "kommt", "es", "zu", "einem", "Knochenmassenverlust", "und", "zu", "einem", "Umbau", "der", "trabekulaeren", "Knochenstruktur", "mit", "erhoehter", "Frakturgefaehrdung", ".", "Ziel", "der", "vorliegenden", "Uebersicht", "ist", "es", ",", "den", "Stellenwert", "strukturanalytischer", "Verfahren", "im", "Rahmen", "der", "Osteoporosediagnostik", "zu", "analysieren", ".", "Als", "bildgebende", "Verfahren", "zur", "Strukturanalyse", "wurden", "konventionelle", "Radiographie", ",", "hochaufloesende", "Computertomographie", "(", "HR", "-", "CT", ")", "und", "hochaufloesende", "Magnetresonanztomographie", "(", "HR", "-", "MRT", ")", "eingesetzt", ".", "Die", "besten", "Ergebnisse", "wurden", "mit", "hochaufloesenden", "tomographischen", "Verfahren", "erzielt", ",", "wobei", "die", "hochaufloesende", "MRT", "die", "beste", "Ortsaufloesung", "erzielte", ".", "Die", "vorliegenden", "Untersuchungen", "zeigen", ",", "dass", "Texturparameter", "und", "Knochendichte", "sich", "komplementaer", "zueinander", "verhalten", ".", "Die", "Kombination", "beider", "Verfahren", "erzielt", "die", "beste", "Praediktion", "der", "biomechanisch", "bestimmten", "Knochenstabilitaet", "und", "die", "beste", "Differenzierung", "von", "Patienten", "mit", "und", "ohne", "osteoporotische", "Frakturen", "." ]

[ "umlsterm" ]

Gliclazide is a compound, gliclazide is a compound, CYP2C9 is a protein, CYP2C19 is a protein

DS.d305_task0

Sentence: Gliclazide can change the conformation of the active sites and decrease obviously the affinities between gliclazide in the active site and enzymes when it is docked in the second active sites in CYP2C9 and CYP2C19. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: compound, protein

[ "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "B-protein", "O" ]

Gliclazide can change the conformation of the active sites and decrease obviously the affinities between gliclazide in the active site and enzymes when it is docked in the second active sites in CYP2C9 and CYP2C19.

[ "Gliclazide", "can", "change", "the", "conformation", "of", "the", "active", "sites", "and", "decrease", "obviously", "the", "affinities", "between", "gliclazide", "in", "the", "active", "site", "and", "enzymes", "when", "it", "is", "docked", "in", "the", "second", "active", "sites", "in", "CYP2C9", "and", "CYP2C19", "." ]

[ "compound", "protein" ]

Gliclazide is a compound, gliclazide is a compound, CYP2C9 is a protein, CYP2C19 is a protein

DS.d305_task1

Sentence: Gliclazide can change the conformation of the active sites and decrease obviously the affinities between gliclazide in the active site and enzymes when it is docked in the second active sites in CYP2C9 and CYP2C19. Instructions: please typing these entity words according to sentence: Gliclazide, gliclazide, CYP2C9, CYP2C19 Options: compound, protein

[ "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "B-protein", "O" ]

Gliclazide can change the conformation of the active sites and decrease obviously the affinities between gliclazide in the active site and enzymes when it is docked in the second active sites in CYP2C9 and CYP2C19.

[ "Gliclazide", "can", "change", "the", "conformation", "of", "the", "active", "sites", "and", "decrease", "obviously", "the", "affinities", "between", "gliclazide", "in", "the", "active", "site", "and", "enzymes", "when", "it", "is", "docked", "in", "the", "second", "active", "sites", "in", "CYP2C9", "and", "CYP2C19", "." ]

[ "compound", "protein" ]

Gliclazide, gliclazide, CYP2C9, CYP2C19

DS.d305_task2

Sentence: Gliclazide can change the conformation of the active sites and decrease obviously the affinities between gliclazide in the active site and enzymes when it is docked in the second active sites in CYP2C9 and CYP2C19. Instructions: please extract entity words from the input sentence

[ "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "B-protein", "O" ]

Gliclazide can change the conformation of the active sites and decrease obviously the affinities between gliclazide in the active site and enzymes when it is docked in the second active sites in CYP2C9 and CYP2C19.

[ "Gliclazide", "can", "change", "the", "conformation", "of", "the", "active", "sites", "and", "decrease", "obviously", "the", "affinities", "between", "gliclazide", "in", "the", "active", "site", "and", "enzymes", "when", "it", "is", "docked", "in", "the", "second", "active", "sites", "in", "CYP2C9", "and", "CYP2C19", "." ]

[ "compound", "protein" ]

supine BP is a Measurement, > 140 mm Hg systolic or > 90 mm Hg diastolic or < 100 mm Hg systolic or < 60 mm Hg diastolic is a Scope, Serum potassium is a Measurement, > = 5.1 mmol / L or < 3.5 mmol / L is a Scope, at screening is a Temporal, Estimated GFR is a Measurement, < 60 mL / min/1.73 m2 is a Value, Cockcroft - Gault formula is a Observation

NCT01314898_exc_task0

Sentence: Subjects with a supine BP >140 mm Hg systolic or >90 mm Hg diastolic or <100 mm Hg systolic or <60 mm Hg diastolic based on the average of the triplicate Serum potassium >=5.1 mmol/L or <3.5 mmol/L at screening, confirmed by a single repeat if deemed necessary. Estimated GFR <60 mL/min/1.73 m2 using the Cockcroft-Gault formula measurement of the individual parameters following at least 5 minutes of rest at Screening. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Temporal, Value, Observation, Scope, Measurement

[ "O", "O", "O", "B-Measurement", "I-Measurement", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "O", "O", "B-Measurement", "I-Measurement", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "O", "B-Observation", "I-Observation", "I-Observation", "I-Observation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Subjects with a supine BP >140 mm Hg systolic or >90 mm Hg diastolic or <100 mm Hg systolic or <60 mm Hg diastolic based on the average of the triplicate Serum potassium >=5.1 mmol/L or <3.5 mmol/L at screening, confirmed by a single repeat if deemed necessary. Estimated GFR <60 mL/min/1.73 m2 using the Cockcroft-Gault formula measurement of the individual parameters following at least 5 minutes of rest at Screening.

[ "Subjects", "with", "a", "supine", "BP", ">", "140", "mm", "Hg", "systolic", "or", ">", "90", "mm", "Hg", "diastolic", "or", "<", "100", "mm", "Hg", "systolic", "or", "<", "60", "mm", "Hg", "diastolic", "based", "on", "the", "average", "of", "the", "triplicate", "\n", "Serum", "potassium", ">", "=", "5.1", "mmol", "/", "L", "or", "<", "3.5", "mmol", "/", "L", "at", "screening", ",", "confirmed", "by", "a", "single", "repeat", "if", "deemed", "necessary", ".", "\n", "Estimated", "GFR", "<", "60", "mL", "/", "min/1.73", "m2", "using", "the", "Cockcroft", "-", "Gault", "formula", "measurement", "of", "the", "individual", "parameters", "following", "at", "least", "5", "minutes", "of", "rest", "at", "Screening", ".", " \n \n" ]

[ "Scope", "Observation", "Value", "Measurement", "Temporal" ]

supine BP is a Measurement, > 140 mm Hg systolic or > 90 mm Hg diastolic or < 100 mm Hg systolic or < 60 mm Hg diastolic is a Scope, Serum potassium is a Measurement, > = 5.1 mmol / L or < 3.5 mmol / L is a Scope, at screening is a Temporal, Estimated GFR is a Measurement, < 60 mL / min/1.73 m2 is a Value, Cockcroft - Gault formula is a Observation

NCT01314898_exc_task1

Sentence: Subjects with a supine BP >140 mm Hg systolic or >90 mm Hg diastolic or <100 mm Hg systolic or <60 mm Hg diastolic based on the average of the triplicate Serum potassium >=5.1 mmol/L or <3.5 mmol/L at screening, confirmed by a single repeat if deemed necessary. Estimated GFR <60 mL/min/1.73 m2 using the Cockcroft-Gault formula measurement of the individual parameters following at least 5 minutes of rest at Screening. Instructions: please typing these entity words according to sentence: supine BP, > 140 mm Hg systolic or > 90 mm Hg diastolic or < 100 mm Hg systolic or < 60 mm Hg diastolic, Serum potassium, > = 5.1 mmol / L or < 3.5 mmol / L, at screening, Estimated GFR, < 60 mL / min/1.73 m2, Cockcroft - Gault formula Options: Temporal, Value, Observation, Scope, Measurement

[ "O", "O", "O", "B-Measurement", "I-Measurement", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "O", "O", "B-Measurement", "I-Measurement", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "O", "B-Observation", "I-Observation", "I-Observation", "I-Observation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Subjects with a supine BP >140 mm Hg systolic or >90 mm Hg diastolic or <100 mm Hg systolic or <60 mm Hg diastolic based on the average of the triplicate Serum potassium >=5.1 mmol/L or <3.5 mmol/L at screening, confirmed by a single repeat if deemed necessary. Estimated GFR <60 mL/min/1.73 m2 using the Cockcroft-Gault formula measurement of the individual parameters following at least 5 minutes of rest at Screening.

[ "Subjects", "with", "a", "supine", "BP", ">", "140", "mm", "Hg", "systolic", "or", ">", "90", "mm", "Hg", "diastolic", "or", "<", "100", "mm", "Hg", "systolic", "or", "<", "60", "mm", "Hg", "diastolic", "based", "on", "the", "average", "of", "the", "triplicate", "\n", "Serum", "potassium", ">", "=", "5.1", "mmol", "/", "L", "or", "<", "3.5", "mmol", "/", "L", "at", "screening", ",", "confirmed", "by", "a", "single", "repeat", "if", "deemed", "necessary", ".", "\n", "Estimated", "GFR", "<", "60", "mL", "/", "min/1.73", "m2", "using", "the", "Cockcroft", "-", "Gault", "formula", "measurement", "of", "the", "individual", "parameters", "following", "at", "least", "5", "minutes", "of", "rest", "at", "Screening", ".", " \n \n" ]

[ "Scope", "Observation", "Value", "Measurement", "Temporal" ]

supine BP, > 140 mm Hg systolic or > 90 mm Hg diastolic or < 100 mm Hg systolic or < 60 mm Hg diastolic, Serum potassium, > = 5.1 mmol / L or < 3.5 mmol / L, at screening, Estimated GFR, < 60 mL / min/1.73 m2, Cockcroft - Gault formula

NCT01314898_exc_task2

Sentence: Subjects with a supine BP >140 mm Hg systolic or >90 mm Hg diastolic or <100 mm Hg systolic or <60 mm Hg diastolic based on the average of the triplicate Serum potassium >=5.1 mmol/L or <3.5 mmol/L at screening, confirmed by a single repeat if deemed necessary. Estimated GFR <60 mL/min/1.73 m2 using the Cockcroft-Gault formula measurement of the individual parameters following at least 5 minutes of rest at Screening. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-Measurement", "I-Measurement", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "O", "O", "B-Measurement", "I-Measurement", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "O", "B-Observation", "I-Observation", "I-Observation", "I-Observation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Subjects with a supine BP >140 mm Hg systolic or >90 mm Hg diastolic or <100 mm Hg systolic or <60 mm Hg diastolic based on the average of the triplicate Serum potassium >=5.1 mmol/L or <3.5 mmol/L at screening, confirmed by a single repeat if deemed necessary. Estimated GFR <60 mL/min/1.73 m2 using the Cockcroft-Gault formula measurement of the individual parameters following at least 5 minutes of rest at Screening.

[ "Subjects", "with", "a", "supine", "BP", ">", "140", "mm", "Hg", "systolic", "or", ">", "90", "mm", "Hg", "diastolic", "or", "<", "100", "mm", "Hg", "systolic", "or", "<", "60", "mm", "Hg", "diastolic", "based", "on", "the", "average", "of", "the", "triplicate", "\n", "Serum", "potassium", ">", "=", "5.1", "mmol", "/", "L", "or", "<", "3.5", "mmol", "/", "L", "at", "screening", ",", "confirmed", "by", "a", "single", "repeat", "if", "deemed", "necessary", ".", "\n", "Estimated", "GFR", "<", "60", "mL", "/", "min/1.73", "m2", "using", "the", "Cockcroft", "-", "Gault", "formula", "measurement", "of", "the", "individual", "parameters", "following", "at", "least", "5", "minutes", "of", "rest", "at", "Screening", ".", " \n \n" ]

[ "Scope", "Observation", "Value", "Measurement", "Temporal" ]

Zehe is an umlsterm, Druckstellen is an umlsterm, Schuhversorgung is an umlsterm

OperativeOrthopaedie.00120068.ger.abstr_task0

Sentence: Das Problem Sechsjaehriger Junge mit einseitigem Spaltfuss vom Typ II mit Oligodaktylie und Klinodaktylie der zweiten Zehe . Wegen ungewoehnlicher Vorfussbreite bestehen schmerzhafte Druckstellen und grosse Schwierigkeiten bei der Schuhversorgung . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]

Das Problem Sechsjaehriger Junge mit einseitigem Spaltfuss vom Typ II mit Oligodaktylie und Klinodaktylie der zweiten Zehe . Wegen ungewoehnlicher Vorfussbreite bestehen schmerzhafte Druckstellen und grosse Schwierigkeiten bei der Schuhversorgung .

[ "Das", "Problem", "Sechsjaehriger", "Junge", "mit", "einseitigem", "Spaltfuss", "vom", "Typ", "II", "mit", "Oligodaktylie", "und", "Klinodaktylie", "der", "zweiten", "Zehe", ".", "Wegen", "ungewoehnlicher", "Vorfussbreite", "bestehen", "schmerzhafte", "Druckstellen", "und", "grosse", "Schwierigkeiten", "bei", "der", "Schuhversorgung", "." ]

[ "umlsterm" ]

Zehe is an umlsterm, Druckstellen is an umlsterm, Schuhversorgung is an umlsterm

OperativeOrthopaedie.00120068.ger.abstr_task1

Sentence: Das Problem Sechsjaehriger Junge mit einseitigem Spaltfuss vom Typ II mit Oligodaktylie und Klinodaktylie der zweiten Zehe . Wegen ungewoehnlicher Vorfussbreite bestehen schmerzhafte Druckstellen und grosse Schwierigkeiten bei der Schuhversorgung . Instructions: please typing these entity words according to sentence: Zehe, Druckstellen, Schuhversorgung Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]

Das Problem Sechsjaehriger Junge mit einseitigem Spaltfuss vom Typ II mit Oligodaktylie und Klinodaktylie der zweiten Zehe . Wegen ungewoehnlicher Vorfussbreite bestehen schmerzhafte Druckstellen und grosse Schwierigkeiten bei der Schuhversorgung .

[ "Das", "Problem", "Sechsjaehriger", "Junge", "mit", "einseitigem", "Spaltfuss", "vom", "Typ", "II", "mit", "Oligodaktylie", "und", "Klinodaktylie", "der", "zweiten", "Zehe", ".", "Wegen", "ungewoehnlicher", "Vorfussbreite", "bestehen", "schmerzhafte", "Druckstellen", "und", "grosse", "Schwierigkeiten", "bei", "der", "Schuhversorgung", "." ]

[ "umlsterm" ]

Zehe, Druckstellen, Schuhversorgung

OperativeOrthopaedie.00120068.ger.abstr_task2

Sentence: Das Problem Sechsjaehriger Junge mit einseitigem Spaltfuss vom Typ II mit Oligodaktylie und Klinodaktylie der zweiten Zehe . Wegen ungewoehnlicher Vorfussbreite bestehen schmerzhafte Druckstellen und grosse Schwierigkeiten bei der Schuhversorgung . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]

Das Problem Sechsjaehriger Junge mit einseitigem Spaltfuss vom Typ II mit Oligodaktylie und Klinodaktylie der zweiten Zehe . Wegen ungewoehnlicher Vorfussbreite bestehen schmerzhafte Druckstellen und grosse Schwierigkeiten bei der Schuhversorgung .

[ "Das", "Problem", "Sechsjaehriger", "Junge", "mit", "einseitigem", "Spaltfuss", "vom", "Typ", "II", "mit", "Oligodaktylie", "und", "Klinodaktylie", "der", "zweiten", "Zehe", ".", "Wegen", "ungewoehnlicher", "Vorfussbreite", "bestehen", "schmerzhafte", "Druckstellen", "und", "grosse", "Schwierigkeiten", "bei", "der", "Schuhversorgung", "." ]

[ "umlsterm" ]

Myc is a Protein, Max is a Protein, heterodimer is a Entity, antisense oligonucleotides is a Entity, c - Myc is a Protein, c - Myc is a Protein, Max is a Protein, Myc is a Protein, heterodimers is a Entity, Max is a Protein, Myc is a Protein, Max is a Protein

610_task0

Sentence: Functional Myc-Max heterodimer is required for activation-induced apoptosis in T cell hybridomas. T cell hybridomas respond to activation signals by undergoing apoptotic cell death, and this is likely to represent comparable events related to tolerance induction in immature and mature T cells in vivo. Previous studies using antisense oligonucleotides implicated the c-Myc protein in the phenomenon of activation-induced apoptosis. This role for c-Myc in apoptosis is now confirmed in studies using a dominant negative form of its heterodimeric binding partner, Max, which we show here inhibits activation-induced apoptosis. Further, coexpression of a reciprocally mutant Myc protein capable of forming functional heterodimers with the mutant Max can compensate for the dominant negative activity and restore activation-induced apoptosis. These results imply that Myc promotes activation-induced apoptosis by obligatory heterodimerization with Max, and therefore, by regulating gene transcription. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein

[ "O", "B-Protein", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Functional Myc-Max heterodimer is required for activation-induced apoptosis in T cell hybridomas. T cell hybridomas respond to activation signals by undergoing apoptotic cell death, and this is likely to represent comparable events related to tolerance induction in immature and mature T cells in vivo. Previous studies using antisense oligonucleotides implicated the c-Myc protein in the phenomenon of activation-induced apoptosis. This role for c-Myc in apoptosis is now confirmed in studies using a dominant negative form of its heterodimeric binding partner, Max, which we show here inhibits activation-induced apoptosis. Further, coexpression of a reciprocally mutant Myc protein capable of forming functional heterodimers with the mutant Max can compensate for the dominant negative activity and restore activation-induced apoptosis. These results imply that Myc promotes activation-induced apoptosis by obligatory heterodimerization with Max, and therefore, by regulating gene transcription.

[ "Functional", "Myc", "-", "Max", "heterodimer", "is", "required", "for", "activation", "-", "induced", "apoptosis", "in", "T", "cell", "hybridomas", ".", "\n", "T", "cell", "hybridomas", "respond", "to", "activation", "signals", "by", "undergoing", "apoptotic", "cell", "death", ",", "and", "this", "is", "likely", "to", "represent", "comparable", "events", "related", "to", "tolerance", "induction", "in", "immature", "and", "mature", "T", "cells", "in", "vivo", ".", "Previous", "studies", "using", "antisense", "oligonucleotides", "implicated", "the", "c", "-", "Myc", "protein", "in", "the", "phenomenon", "of", "activation", "-", "induced", "apoptosis", ".", "This", "role", "for", "c", "-", "Myc", "in", "apoptosis", "is", "now", "confirmed", "in", "studies", "using", "a", "dominant", "negative", "form", "of", "its", "heterodimeric", "binding", "partner", ",", "Max", ",", "which", "we", "show", "here", "inhibits", "activation", "-", "induced", "apoptosis", ".", "Further", ",", "coexpression", "of", "a", "reciprocally", "mutant", "Myc", "protein", "capable", "of", "forming", "functional", "heterodimers", "with", "the", "mutant", "Max", "can", "compensate", "for", "the", "dominant", "negative", "activity", "and", "restore", "activation", "-", "induced", "apoptosis", ".", "These", "results", "imply", "that", "Myc", "promotes", "activation", "-", "induced", "apoptosis", "by", "obligatory", "heterodimerization", "with", "Max", ",", "and", "therefore", ",", "by", "regulating", "gene", "transcription", ".", "\n" ]

[ "Entity", "Protein" ]

Myc is a Protein, Max is a Protein, heterodimer is a Entity, antisense oligonucleotides is a Entity, c - Myc is a Protein, c - Myc is a Protein, Max is a Protein, Myc is a Protein, heterodimers is a Entity, Max is a Protein, Myc is a Protein, Max is a Protein

610_task1

Sentence: Functional Myc-Max heterodimer is required for activation-induced apoptosis in T cell hybridomas. T cell hybridomas respond to activation signals by undergoing apoptotic cell death, and this is likely to represent comparable events related to tolerance induction in immature and mature T cells in vivo. Previous studies using antisense oligonucleotides implicated the c-Myc protein in the phenomenon of activation-induced apoptosis. This role for c-Myc in apoptosis is now confirmed in studies using a dominant negative form of its heterodimeric binding partner, Max, which we show here inhibits activation-induced apoptosis. Further, coexpression of a reciprocally mutant Myc protein capable of forming functional heterodimers with the mutant Max can compensate for the dominant negative activity and restore activation-induced apoptosis. These results imply that Myc promotes activation-induced apoptosis by obligatory heterodimerization with Max, and therefore, by regulating gene transcription. Instructions: please typing these entity words according to sentence: Myc, Max, heterodimer, antisense oligonucleotides, c - Myc, c - Myc, Max, Myc, heterodimers, Max, Myc, Max Options: Entity, Protein

[ "O", "B-Protein", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Functional Myc-Max heterodimer is required for activation-induced apoptosis in T cell hybridomas. T cell hybridomas respond to activation signals by undergoing apoptotic cell death, and this is likely to represent comparable events related to tolerance induction in immature and mature T cells in vivo. Previous studies using antisense oligonucleotides implicated the c-Myc protein in the phenomenon of activation-induced apoptosis. This role for c-Myc in apoptosis is now confirmed in studies using a dominant negative form of its heterodimeric binding partner, Max, which we show here inhibits activation-induced apoptosis. Further, coexpression of a reciprocally mutant Myc protein capable of forming functional heterodimers with the mutant Max can compensate for the dominant negative activity and restore activation-induced apoptosis. These results imply that Myc promotes activation-induced apoptosis by obligatory heterodimerization with Max, and therefore, by regulating gene transcription.

[ "Functional", "Myc", "-", "Max", "heterodimer", "is", "required", "for", "activation", "-", "induced", "apoptosis", "in", "T", "cell", "hybridomas", ".", "\n", "T", "cell", "hybridomas", "respond", "to", "activation", "signals", "by", "undergoing", "apoptotic", "cell", "death", ",", "and", "this", "is", "likely", "to", "represent", "comparable", "events", "related", "to", "tolerance", "induction", "in", "immature", "and", "mature", "T", "cells", "in", "vivo", ".", "Previous", "studies", "using", "antisense", "oligonucleotides", "implicated", "the", "c", "-", "Myc", "protein", "in", "the", "phenomenon", "of", "activation", "-", "induced", "apoptosis", ".", "This", "role", "for", "c", "-", "Myc", "in", "apoptosis", "is", "now", "confirmed", "in", "studies", "using", "a", "dominant", "negative", "form", "of", "its", "heterodimeric", "binding", "partner", ",", "Max", ",", "which", "we", "show", "here", "inhibits", "activation", "-", "induced", "apoptosis", ".", "Further", ",", "coexpression", "of", "a", "reciprocally", "mutant", "Myc", "protein", "capable", "of", "forming", "functional", "heterodimers", "with", "the", "mutant", "Max", "can", "compensate", "for", "the", "dominant", "negative", "activity", "and", "restore", "activation", "-", "induced", "apoptosis", ".", "These", "results", "imply", "that", "Myc", "promotes", "activation", "-", "induced", "apoptosis", "by", "obligatory", "heterodimerization", "with", "Max", ",", "and", "therefore", ",", "by", "regulating", "gene", "transcription", ".", "\n" ]

[ "Entity", "Protein" ]

Myc, Max, heterodimer, antisense oligonucleotides, c - Myc, c - Myc, Max, Myc, heterodimers, Max, Myc, Max

610_task2

Sentence: Functional Myc-Max heterodimer is required for activation-induced apoptosis in T cell hybridomas. T cell hybridomas respond to activation signals by undergoing apoptotic cell death, and this is likely to represent comparable events related to tolerance induction in immature and mature T cells in vivo. Previous studies using antisense oligonucleotides implicated the c-Myc protein in the phenomenon of activation-induced apoptosis. This role for c-Myc in apoptosis is now confirmed in studies using a dominant negative form of its heterodimeric binding partner, Max, which we show here inhibits activation-induced apoptosis. Further, coexpression of a reciprocally mutant Myc protein capable of forming functional heterodimers with the mutant Max can compensate for the dominant negative activity and restore activation-induced apoptosis. These results imply that Myc promotes activation-induced apoptosis by obligatory heterodimerization with Max, and therefore, by regulating gene transcription. Instructions: please extract entity words from the input sentence

[ "O", "B-Protein", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Functional Myc-Max heterodimer is required for activation-induced apoptosis in T cell hybridomas. T cell hybridomas respond to activation signals by undergoing apoptotic cell death, and this is likely to represent comparable events related to tolerance induction in immature and mature T cells in vivo. Previous studies using antisense oligonucleotides implicated the c-Myc protein in the phenomenon of activation-induced apoptosis. This role for c-Myc in apoptosis is now confirmed in studies using a dominant negative form of its heterodimeric binding partner, Max, which we show here inhibits activation-induced apoptosis. Further, coexpression of a reciprocally mutant Myc protein capable of forming functional heterodimers with the mutant Max can compensate for the dominant negative activity and restore activation-induced apoptosis. These results imply that Myc promotes activation-induced apoptosis by obligatory heterodimerization with Max, and therefore, by regulating gene transcription.

[ "Functional", "Myc", "-", "Max", "heterodimer", "is", "required", "for", "activation", "-", "induced", "apoptosis", "in", "T", "cell", "hybridomas", ".", "\n", "T", "cell", "hybridomas", "respond", "to", "activation", "signals", "by", "undergoing", "apoptotic", "cell", "death", ",", "and", "this", "is", "likely", "to", "represent", "comparable", "events", "related", "to", "tolerance", "induction", "in", "immature", "and", "mature", "T", "cells", "in", "vivo", ".", "Previous", "studies", "using", "antisense", "oligonucleotides", "implicated", "the", "c", "-", "Myc", "protein", "in", "the", "phenomenon", "of", "activation", "-", "induced", "apoptosis", ".", "This", "role", "for", "c", "-", "Myc", "in", "apoptosis", "is", "now", "confirmed", "in", "studies", "using", "a", "dominant", "negative", "form", "of", "its", "heterodimeric", "binding", "partner", ",", "Max", ",", "which", "we", "show", "here", "inhibits", "activation", "-", "induced", "apoptosis", ".", "Further", ",", "coexpression", "of", "a", "reciprocally", "mutant", "Myc", "protein", "capable", "of", "forming", "functional", "heterodimers", "with", "the", "mutant", "Max", "can", "compensate", "for", "the", "dominant", "negative", "activity", "and", "restore", "activation", "-", "induced", "apoptosis", ".", "These", "results", "imply", "that", "Myc", "promotes", "activation", "-", "induced", "apoptosis", "by", "obligatory", "heterodimerization", "with", "Max", ",", "and", "therefore", ",", "by", "regulating", "gene", "transcription", ".", "\n" ]

[ "Entity", "Protein" ]

Methicillin - resistant is an umlsterm, S. aureus is an umlsterm, cause is an umlsterm, infection is an umlsterm, patients is an umlsterm, Germany is an umlsterm, nosocomial infections is an umlsterm, elderly is an umlsterm, patients is an umlsterm, chronic illnesses is an umlsterm, risk of is an umlsterm, epidemiology is an umlsterm, therapy is an umlsterm, recommendations is an umlsterm, prevention is an umlsterm, hospitals is an umlsterm, nursing homes is an umlsterm

ZfuerGerontologie+Geriatrie.00330367.eng.abstr_task0

Sentence: Methicillin-resistant S. aureus ( MRSA ) has become an important cause of severe infection in hospitalized patients all over the world . In Germany a significant increase of nosocomial infections due to MRSA has occurred during the last 10 years . Especially elderly patients with chronic illnesses are at increased risk of becoming colonized or infected with MRSA . This report focuses on epidemiology and therapy of MRSA , and on the recommendations concerning management and prevention of spread of MRSA in hospitals and nursing homes . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O" ]

Methicillin-resistant S. aureus ( MRSA ) has become an important cause of severe infection in hospitalized patients all over the world . In Germany a significant increase of nosocomial infections due to MRSA has occurred during the last 10 years . Especially elderly patients with chronic illnesses are at increased risk of becoming colonized or infected with MRSA . This report focuses on epidemiology and therapy of MRSA , and on the recommendations concerning management and prevention of spread of MRSA in hospitals and nursing homes .

[ "Methicillin", "-", "resistant", "S.", "aureus", "(", "MRSA", ")", "has", "become", "an", "important", "cause", "of", "severe", "infection", "in", "hospitalized", "patients", "all", "over", "the", "world", ".", "In", "Germany", "a", "significant", "increase", "of", "nosocomial", "infections", "due", "to", "MRSA", "has", "occurred", "during", "the", "last", "10", "years", ".", "Especially", "elderly", "patients", "with", "chronic", "illnesses", "are", "at", "increased", "risk", "of", "becoming", "colonized", "or", "infected", "with", "MRSA", ".", "This", "report", "focuses", "on", "epidemiology", "and", "therapy", "of", "MRSA", ",", "and", "on", "the", "recommendations", "concerning", "management", "and", "prevention", "of", "spread", "of", "MRSA", "in", "hospitals", "and", "nursing", "homes", "." ]

[ "umlsterm" ]

Methicillin - resistant is an umlsterm, S. aureus is an umlsterm, cause is an umlsterm, infection is an umlsterm, patients is an umlsterm, Germany is an umlsterm, nosocomial infections is an umlsterm, elderly is an umlsterm, patients is an umlsterm, chronic illnesses is an umlsterm, risk of is an umlsterm, epidemiology is an umlsterm, therapy is an umlsterm, recommendations is an umlsterm, prevention is an umlsterm, hospitals is an umlsterm, nursing homes is an umlsterm

ZfuerGerontologie+Geriatrie.00330367.eng.abstr_task1

Sentence: Methicillin-resistant S. aureus ( MRSA ) has become an important cause of severe infection in hospitalized patients all over the world . In Germany a significant increase of nosocomial infections due to MRSA has occurred during the last 10 years . Especially elderly patients with chronic illnesses are at increased risk of becoming colonized or infected with MRSA . This report focuses on epidemiology and therapy of MRSA , and on the recommendations concerning management and prevention of spread of MRSA in hospitals and nursing homes . Instructions: please typing these entity words according to sentence: Methicillin - resistant, S. aureus, cause, infection, patients, Germany, nosocomial infections, elderly, patients, chronic illnesses, risk of, epidemiology, therapy, recommendations, prevention, hospitals, nursing homes Options: umlsterm

[ "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O" ]

Methicillin-resistant S. aureus ( MRSA ) has become an important cause of severe infection in hospitalized patients all over the world . In Germany a significant increase of nosocomial infections due to MRSA has occurred during the last 10 years . Especially elderly patients with chronic illnesses are at increased risk of becoming colonized or infected with MRSA . This report focuses on epidemiology and therapy of MRSA , and on the recommendations concerning management and prevention of spread of MRSA in hospitals and nursing homes .

[ "Methicillin", "-", "resistant", "S.", "aureus", "(", "MRSA", ")", "has", "become", "an", "important", "cause", "of", "severe", "infection", "in", "hospitalized", "patients", "all", "over", "the", "world", ".", "In", "Germany", "a", "significant", "increase", "of", "nosocomial", "infections", "due", "to", "MRSA", "has", "occurred", "during", "the", "last", "10", "years", ".", "Especially", "elderly", "patients", "with", "chronic", "illnesses", "are", "at", "increased", "risk", "of", "becoming", "colonized", "or", "infected", "with", "MRSA", ".", "This", "report", "focuses", "on", "epidemiology", "and", "therapy", "of", "MRSA", ",", "and", "on", "the", "recommendations", "concerning", "management", "and", "prevention", "of", "spread", "of", "MRSA", "in", "hospitals", "and", "nursing", "homes", "." ]

[ "umlsterm" ]

Methicillin - resistant, S. aureus, cause, infection, patients, Germany, nosocomial infections, elderly, patients, chronic illnesses, risk of, epidemiology, therapy, recommendations, prevention, hospitals, nursing homes

ZfuerGerontologie+Geriatrie.00330367.eng.abstr_task2

Sentence: Methicillin-resistant S. aureus ( MRSA ) has become an important cause of severe infection in hospitalized patients all over the world . In Germany a significant increase of nosocomial infections due to MRSA has occurred during the last 10 years . Especially elderly patients with chronic illnesses are at increased risk of becoming colonized or infected with MRSA . This report focuses on epidemiology and therapy of MRSA , and on the recommendations concerning management and prevention of spread of MRSA in hospitals and nursing homes . Instructions: please extract entity words from the input sentence

[ "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O" ]

Methicillin-resistant S. aureus ( MRSA ) has become an important cause of severe infection in hospitalized patients all over the world . In Germany a significant increase of nosocomial infections due to MRSA has occurred during the last 10 years . Especially elderly patients with chronic illnesses are at increased risk of becoming colonized or infected with MRSA . This report focuses on epidemiology and therapy of MRSA , and on the recommendations concerning management and prevention of spread of MRSA in hospitals and nursing homes .

[ "Methicillin", "-", "resistant", "S.", "aureus", "(", "MRSA", ")", "has", "become", "an", "important", "cause", "of", "severe", "infection", "in", "hospitalized", "patients", "all", "over", "the", "world", ".", "In", "Germany", "a", "significant", "increase", "of", "nosocomial", "infections", "due", "to", "MRSA", "has", "occurred", "during", "the", "last", "10", "years", ".", "Especially", "elderly", "patients", "with", "chronic", "illnesses", "are", "at", "increased", "risk", "of", "becoming", "colonized", "or", "infected", "with", "MRSA", ".", "This", "report", "focuses", "on", "epidemiology", "and", "therapy", "of", "MRSA", ",", "and", "on", "the", "recommendations", "concerning", "management", "and", "prevention", "of", "spread", "of", "MRSA", "in", "hospitals", "and", "nursing", "homes", "." ]

[ "umlsterm" ]

history is an umlsterm, patients is an umlsterm, surgical treatment is an umlsterm, face is an umlsterm, surgical is an umlsterm, flap is an umlsterm, skin grafting is an umlsterm, techniques is an umlsterm, nose is an umlsterm, eyelids is an umlsterm, skin is an umlsterm, defect is an umlsterm, histologic is an umlsterm, control is an umlsterm, tumor is an umlsterm, tumor is an umlsterm, judgement is an umlsterm, procedure is an umlsterm, repair is an umlsterm, Recurrences is an umlsterm, histologic is an umlsterm, growth is an umlsterm, predisposition is an umlsterm, time is an umlsterm, surgical is an umlsterm, face is an umlsterm, techniques is an umlsterm

DerChirurg.90700265.eng.abstr_task0

Sentence: The present investigation reviews the history of 673 patients having undergone surgical treatment for 1301 BCC of the face between 1977 and 1992 at our department . Based on this series the features with bearing on the surgical strategy , such as type , size and location of the lesions , will be outlined . Emphasis is put on the variants of local flap reconstruction and skin grafting techniques , particularly in the problem zones of the nose and eyelids , where no excess skin for closure of the defect is available . Throughout the whole series histologic control of the adequacy of marginal and deep tumor resection was performed . It became obvious that the required ranges for clearance to tumor edges and removal in depth cannot be predefined arbitrarily or on pure clinical judgement . Frequently a two-stage procedure of resection and repair will be necessitated . Recurrences during the mandatory follow-up were thoroughly reassessed to identify the reason for failure ( e . g . accuracy of histologic category , multifocal growth , predisposition ) and related to the time span from primary excision . Our series confirms that morphologically controlled surgical excision of the BCC of the face and subsequent application of reconstructive techniques produces both safe oncologic and esthetic results . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O" ]

The present investigation reviews the history of 673 patients having undergone surgical treatment for 1301 BCC of the face between 1977 and 1992 at our department . Based on this series the features with bearing on the surgical strategy , such as type , size and location of the lesions , will be outlined . Emphasis is put on the variants of local flap reconstruction and skin grafting techniques , particularly in the problem zones of the nose and eyelids , where no excess skin for closure of the defect is available . Throughout the whole series histologic control of the adequacy of marginal and deep tumor resection was performed . It became obvious that the required ranges for clearance to tumor edges and removal in depth cannot be predefined arbitrarily or on pure clinical judgement . Frequently a two-stage procedure of resection and repair will be necessitated . Recurrences during the mandatory follow-up were thoroughly reassessed to identify the reason for failure ( e . g . accuracy of histologic category , multifocal growth , predisposition ) and related to the time span from primary excision . Our series confirms that morphologically controlled surgical excision of the BCC of the face and subsequent application of reconstructive techniques produces both safe oncologic and esthetic results .

[ "The", "present", "investigation", "reviews", "the", "history", "of", "673", "patients", "having", "undergone", "surgical", "treatment", "for", "1301", "BCC", "of", "the", "face", "between", "1977", "and", "1992", "at", "our", "department", ".", "Based", "on", "this", "series", "the", "features", "with", "bearing", "on", "the", "surgical", "strategy", ",", "such", "as", "type", ",", "size", "and", "location", "of", "the", "lesions", ",", "will", "be", "outlined", ".", "Emphasis", "is", "put", "on", "the", "variants", "of", "local", "flap", "reconstruction", "and", "skin", "grafting", "techniques", ",", "particularly", "in", "the", "problem", "zones", "of", "the", "nose", "and", "eyelids", ",", "where", "no", "excess", "skin", "for", "closure", "of", "the", "defect", "is", "available", ".", "Throughout", "the", "whole", "series", "histologic", "control", "of", "the", "adequacy", "of", "marginal", "and", "deep", "tumor", "resection", "was", "performed", ".", "It", "became", "obvious", "that", "the", "required", "ranges", "for", "clearance", "to", "tumor", "edges", "and", "removal", "in", "depth", "cannot", "be", "predefined", "arbitrarily", "or", "on", "pure", "clinical", "judgement", ".", "Frequently", "a", "two", "-", "stage", "procedure", "of", "resection", "and", "repair", "will", "be", "necessitated", ".", "Recurrences", "during", "the", "mandatory", "follow", "-", "up", "were", "thoroughly", "reassessed", "to", "identify", "the", "reason", "for", "failure", "(", "e", ".", "g", ".", "accuracy", "of", "histologic", "category", ",", "multifocal", "growth", ",", "predisposition", ")", "and", "related", "to", "the", "time", "span", "from", "primary", "excision", ".", "Our", "series", "confirms", "that", "morphologically", "controlled", "surgical", "excision", "of", "the", "BCC", "of", "the", "face", "and", "subsequent", "application", "of", "reconstructive", "techniques", "produces", "both", "safe", "oncologic", "and", "esthetic", "results", "." ]

[ "umlsterm" ]

history is an umlsterm, patients is an umlsterm, surgical treatment is an umlsterm, face is an umlsterm, surgical is an umlsterm, flap is an umlsterm, skin grafting is an umlsterm, techniques is an umlsterm, nose is an umlsterm, eyelids is an umlsterm, skin is an umlsterm, defect is an umlsterm, histologic is an umlsterm, control is an umlsterm, tumor is an umlsterm, tumor is an umlsterm, judgement is an umlsterm, procedure is an umlsterm, repair is an umlsterm, Recurrences is an umlsterm, histologic is an umlsterm, growth is an umlsterm, predisposition is an umlsterm, time is an umlsterm, surgical is an umlsterm, face is an umlsterm, techniques is an umlsterm

DerChirurg.90700265.eng.abstr_task1

Sentence: The present investigation reviews the history of 673 patients having undergone surgical treatment for 1301 BCC of the face between 1977 and 1992 at our department . Based on this series the features with bearing on the surgical strategy , such as type , size and location of the lesions , will be outlined . Emphasis is put on the variants of local flap reconstruction and skin grafting techniques , particularly in the problem zones of the nose and eyelids , where no excess skin for closure of the defect is available . Throughout the whole series histologic control of the adequacy of marginal and deep tumor resection was performed . It became obvious that the required ranges for clearance to tumor edges and removal in depth cannot be predefined arbitrarily or on pure clinical judgement . Frequently a two-stage procedure of resection and repair will be necessitated . Recurrences during the mandatory follow-up were thoroughly reassessed to identify the reason for failure ( e . g . accuracy of histologic category , multifocal growth , predisposition ) and related to the time span from primary excision . Our series confirms that morphologically controlled surgical excision of the BCC of the face and subsequent application of reconstructive techniques produces both safe oncologic and esthetic results . Instructions: please typing these entity words according to sentence: history, patients, surgical treatment, face, surgical, flap, skin grafting, techniques, nose, eyelids, skin, defect, histologic, control, tumor, tumor, judgement, procedure, repair, Recurrences, histologic, growth, predisposition, time, surgical, face, techniques Options: umlsterm

[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O" ]

The present investigation reviews the history of 673 patients having undergone surgical treatment for 1301 BCC of the face between 1977 and 1992 at our department . Based on this series the features with bearing on the surgical strategy , such as type , size and location of the lesions , will be outlined . Emphasis is put on the variants of local flap reconstruction and skin grafting techniques , particularly in the problem zones of the nose and eyelids , where no excess skin for closure of the defect is available . Throughout the whole series histologic control of the adequacy of marginal and deep tumor resection was performed . It became obvious that the required ranges for clearance to tumor edges and removal in depth cannot be predefined arbitrarily or on pure clinical judgement . Frequently a two-stage procedure of resection and repair will be necessitated . Recurrences during the mandatory follow-up were thoroughly reassessed to identify the reason for failure ( e . g . accuracy of histologic category , multifocal growth , predisposition ) and related to the time span from primary excision . Our series confirms that morphologically controlled surgical excision of the BCC of the face and subsequent application of reconstructive techniques produces both safe oncologic and esthetic results .

[ "The", "present", "investigation", "reviews", "the", "history", "of", "673", "patients", "having", "undergone", "surgical", "treatment", "for", "1301", "BCC", "of", "the", "face", "between", "1977", "and", "1992", "at", "our", "department", ".", "Based", "on", "this", "series", "the", "features", "with", "bearing", "on", "the", "surgical", "strategy", ",", "such", "as", "type", ",", "size", "and", "location", "of", "the", "lesions", ",", "will", "be", "outlined", ".", "Emphasis", "is", "put", "on", "the", "variants", "of", "local", "flap", "reconstruction", "and", "skin", "grafting", "techniques", ",", "particularly", "in", "the", "problem", "zones", "of", "the", "nose", "and", "eyelids", ",", "where", "no", "excess", "skin", "for", "closure", "of", "the", "defect", "is", "available", ".", "Throughout", "the", "whole", "series", "histologic", "control", "of", "the", "adequacy", "of", "marginal", "and", "deep", "tumor", "resection", "was", "performed", ".", "It", "became", "obvious", "that", "the", "required", "ranges", "for", "clearance", "to", "tumor", "edges", "and", "removal", "in", "depth", "cannot", "be", "predefined", "arbitrarily", "or", "on", "pure", "clinical", "judgement", ".", "Frequently", "a", "two", "-", "stage", "procedure", "of", "resection", "and", "repair", "will", "be", "necessitated", ".", "Recurrences", "during", "the", "mandatory", "follow", "-", "up", "were", "thoroughly", "reassessed", "to", "identify", "the", "reason", "for", "failure", "(", "e", ".", "g", ".", "accuracy", "of", "histologic", "category", ",", "multifocal", "growth", ",", "predisposition", ")", "and", "related", "to", "the", "time", "span", "from", "primary", "excision", ".", "Our", "series", "confirms", "that", "morphologically", "controlled", "surgical", "excision", "of", "the", "BCC", "of", "the", "face", "and", "subsequent", "application", "of", "reconstructive", "techniques", "produces", "both", "safe", "oncologic", "and", "esthetic", "results", "." ]

[ "umlsterm" ]

history, patients, surgical treatment, face, surgical, flap, skin grafting, techniques, nose, eyelids, skin, defect, histologic, control, tumor, tumor, judgement, procedure, repair, Recurrences, histologic, growth, predisposition, time, surgical, face, techniques

DerChirurg.90700265.eng.abstr_task2

Sentence: The present investigation reviews the history of 673 patients having undergone surgical treatment for 1301 BCC of the face between 1977 and 1992 at our department . Based on this series the features with bearing on the surgical strategy , such as type , size and location of the lesions , will be outlined . Emphasis is put on the variants of local flap reconstruction and skin grafting techniques , particularly in the problem zones of the nose and eyelids , where no excess skin for closure of the defect is available . Throughout the whole series histologic control of the adequacy of marginal and deep tumor resection was performed . It became obvious that the required ranges for clearance to tumor edges and removal in depth cannot be predefined arbitrarily or on pure clinical judgement . Frequently a two-stage procedure of resection and repair will be necessitated . Recurrences during the mandatory follow-up were thoroughly reassessed to identify the reason for failure ( e . g . accuracy of histologic category , multifocal growth , predisposition ) and related to the time span from primary excision . Our series confirms that morphologically controlled surgical excision of the BCC of the face and subsequent application of reconstructive techniques produces both safe oncologic and esthetic results . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O" ]

The present investigation reviews the history of 673 patients having undergone surgical treatment for 1301 BCC of the face between 1977 and 1992 at our department . Based on this series the features with bearing on the surgical strategy , such as type , size and location of the lesions , will be outlined . Emphasis is put on the variants of local flap reconstruction and skin grafting techniques , particularly in the problem zones of the nose and eyelids , where no excess skin for closure of the defect is available . Throughout the whole series histologic control of the adequacy of marginal and deep tumor resection was performed . It became obvious that the required ranges for clearance to tumor edges and removal in depth cannot be predefined arbitrarily or on pure clinical judgement . Frequently a two-stage procedure of resection and repair will be necessitated . Recurrences during the mandatory follow-up were thoroughly reassessed to identify the reason for failure ( e . g . accuracy of histologic category , multifocal growth , predisposition ) and related to the time span from primary excision . Our series confirms that morphologically controlled surgical excision of the BCC of the face and subsequent application of reconstructive techniques produces both safe oncologic and esthetic results .

[ "The", "present", "investigation", "reviews", "the", "history", "of", "673", "patients", "having", "undergone", "surgical", "treatment", "for", "1301", "BCC", "of", "the", "face", "between", "1977", "and", "1992", "at", "our", "department", ".", "Based", "on", "this", "series", "the", "features", "with", "bearing", "on", "the", "surgical", "strategy", ",", "such", "as", "type", ",", "size", "and", "location", "of", "the", "lesions", ",", "will", "be", "outlined", ".", "Emphasis", "is", "put", "on", "the", "variants", "of", "local", "flap", "reconstruction", "and", "skin", "grafting", "techniques", ",", "particularly", "in", "the", "problem", "zones", "of", "the", "nose", "and", "eyelids", ",", "where", "no", "excess", "skin", "for", "closure", "of", "the", "defect", "is", "available", ".", "Throughout", "the", "whole", "series", "histologic", "control", "of", "the", "adequacy", "of", "marginal", "and", "deep", "tumor", "resection", "was", "performed", ".", "It", "became", "obvious", "that", "the", "required", "ranges", "for", "clearance", "to", "tumor", "edges", "and", "removal", "in", "depth", "cannot", "be", "predefined", "arbitrarily", "or", "on", "pure", "clinical", "judgement", ".", "Frequently", "a", "two", "-", "stage", "procedure", "of", "resection", "and", "repair", "will", "be", "necessitated", ".", "Recurrences", "during", "the", "mandatory", "follow", "-", "up", "were", "thoroughly", "reassessed", "to", "identify", "the", "reason", "for", "failure", "(", "e", ".", "g", ".", "accuracy", "of", "histologic", "category", ",", "multifocal", "growth", ",", "predisposition", ")", "and", "related", "to", "the", "time", "span", "from", "primary", "excision", ".", "Our", "series", "confirms", "that", "morphologically", "controlled", "surgical", "excision", "of", "the", "BCC", "of", "the", "face", "and", "subsequent", "application", "of", "reconstructive", "techniques", "produces", "both", "safe", "oncologic", "and", "esthetic", "results", "." ]

[ "umlsterm" ]

diagnosis is an umlsterm, neonate is an umlsterm, neonatal hypotonia is an umlsterm, asphyxia is an umlsterm, Craniofacial abnormalities is an umlsterm, fissures is an umlsterm, mouth is an umlsterm, treatment is an umlsterm, Hypogonadism is an umlsterm, cryptorchism is an umlsterm, signs is an umlsterm, age is an umlsterm, obesity is an umlsterm, hyperphagia is an umlsterm, hands is an umlsterm, feet is an umlsterm, neonate is an umlsterm, Diagnostic is an umlsterm, criteria is an umlsterm, therapeutic is an umlsterm, Hydrops fetalis is an umlsterm

MonatsschriftKinderheilkunde.71450515.eng.abstr_task0

Sentence: The diagnosis Prader-Willi-Syndrome ( PWS ) in the neonate is difficult because features like neonatal hypotonia and feeding problems are easily misdiagnosed as a consequence of peripartal asphyxia . Craniofacial abnormalities like narrow bifrontal diameter , almond shaped palpebral fissures and openend downturned mouth are underdiagnosed especially if respiratory treatment is necessary . Hypogonadism in girls and in milder expression in boys ( for example cryptorchism ) are common and unspecific signs at that age . Typical features like obesity and hyperphagia , small hands and feet and small stature are not expressed until the second year . The clinical course of PWS in the neonate is demonstrated in two cases . Diagnostic criteria and therapeutic intervention are discussed . Hydrops fetalis as a seldom feature in PWS has to be taken into consideration . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

The diagnosis Prader-Willi-Syndrome ( PWS ) in the neonate is difficult because features like neonatal hypotonia and feeding problems are easily misdiagnosed as a consequence of peripartal asphyxia . Craniofacial abnormalities like narrow bifrontal diameter , almond shaped palpebral fissures and openend downturned mouth are underdiagnosed especially if respiratory treatment is necessary . Hypogonadism in girls and in milder expression in boys ( for example cryptorchism ) are common and unspecific signs at that age . Typical features like obesity and hyperphagia , small hands and feet and small stature are not expressed until the second year . The clinical course of PWS in the neonate is demonstrated in two cases . Diagnostic criteria and therapeutic intervention are discussed . Hydrops fetalis as a seldom feature in PWS has to be taken into consideration .

[ "The", "diagnosis", "Prader", "-", "Willi", "-", "Syndrome", "(", "PWS", ")", "in", "the", "neonate", "is", "difficult", "because", "features", "like", "neonatal", "hypotonia", "and", "feeding", "problems", "are", "easily", "misdiagnosed", "as", "a", "consequence", "of", "peripartal", "asphyxia", ".", "Craniofacial", "abnormalities", "like", "narrow", "bifrontal", "diameter", ",", "almond", "shaped", "palpebral", "fissures", "and", "openend", "downturned", "mouth", "are", "underdiagnosed", "especially", "if", "respiratory", "treatment", "is", "necessary", ".", "Hypogonadism", "in", "girls", "and", "in", "milder", "expression", "in", "boys", "(", "for", "example", "cryptorchism", ")", "are", "common", "and", "unspecific", "signs", "at", "that", "age", ".", "Typical", "features", "like", "obesity", "and", "hyperphagia", ",", "small", "hands", "and", "feet", "and", "small", "stature", "are", "not", "expressed", "until", "the", "second", "year", ".", "The", "clinical", "course", "of", "PWS", "in", "the", "neonate", "is", "demonstrated", "in", "two", "cases", ".", "Diagnostic", "criteria", "and", "therapeutic", "intervention", "are", "discussed", ".", "Hydrops", "fetalis", "as", "a", "seldom", "feature", "in", "PWS", "has", "to", "be", "taken", "into", "consideration", "." ]

[ "umlsterm" ]

diagnosis is an umlsterm, neonate is an umlsterm, neonatal hypotonia is an umlsterm, asphyxia is an umlsterm, Craniofacial abnormalities is an umlsterm, fissures is an umlsterm, mouth is an umlsterm, treatment is an umlsterm, Hypogonadism is an umlsterm, cryptorchism is an umlsterm, signs is an umlsterm, age is an umlsterm, obesity is an umlsterm, hyperphagia is an umlsterm, hands is an umlsterm, feet is an umlsterm, neonate is an umlsterm, Diagnostic is an umlsterm, criteria is an umlsterm, therapeutic is an umlsterm, Hydrops fetalis is an umlsterm

MonatsschriftKinderheilkunde.71450515.eng.abstr_task1

Sentence: The diagnosis Prader-Willi-Syndrome ( PWS ) in the neonate is difficult because features like neonatal hypotonia and feeding problems are easily misdiagnosed as a consequence of peripartal asphyxia . Craniofacial abnormalities like narrow bifrontal diameter , almond shaped palpebral fissures and openend downturned mouth are underdiagnosed especially if respiratory treatment is necessary . Hypogonadism in girls and in milder expression in boys ( for example cryptorchism ) are common and unspecific signs at that age . Typical features like obesity and hyperphagia , small hands and feet and small stature are not expressed until the second year . The clinical course of PWS in the neonate is demonstrated in two cases . Diagnostic criteria and therapeutic intervention are discussed . Hydrops fetalis as a seldom feature in PWS has to be taken into consideration . Instructions: please typing these entity words according to sentence: diagnosis, neonate, neonatal hypotonia, asphyxia, Craniofacial abnormalities, fissures, mouth, treatment, Hypogonadism, cryptorchism, signs, age, obesity, hyperphagia, hands, feet, neonate, Diagnostic, criteria, therapeutic, Hydrops fetalis Options: umlsterm

[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

The diagnosis Prader-Willi-Syndrome ( PWS ) in the neonate is difficult because features like neonatal hypotonia and feeding problems are easily misdiagnosed as a consequence of peripartal asphyxia . Craniofacial abnormalities like narrow bifrontal diameter , almond shaped palpebral fissures and openend downturned mouth are underdiagnosed especially if respiratory treatment is necessary . Hypogonadism in girls and in milder expression in boys ( for example cryptorchism ) are common and unspecific signs at that age . Typical features like obesity and hyperphagia , small hands and feet and small stature are not expressed until the second year . The clinical course of PWS in the neonate is demonstrated in two cases . Diagnostic criteria and therapeutic intervention are discussed . Hydrops fetalis as a seldom feature in PWS has to be taken into consideration .

[ "The", "diagnosis", "Prader", "-", "Willi", "-", "Syndrome", "(", "PWS", ")", "in", "the", "neonate", "is", "difficult", "because", "features", "like", "neonatal", "hypotonia", "and", "feeding", "problems", "are", "easily", "misdiagnosed", "as", "a", "consequence", "of", "peripartal", "asphyxia", ".", "Craniofacial", "abnormalities", "like", "narrow", "bifrontal", "diameter", ",", "almond", "shaped", "palpebral", "fissures", "and", "openend", "downturned", "mouth", "are", "underdiagnosed", "especially", "if", "respiratory", "treatment", "is", "necessary", ".", "Hypogonadism", "in", "girls", "and", "in", "milder", "expression", "in", "boys", "(", "for", "example", "cryptorchism", ")", "are", "common", "and", "unspecific", "signs", "at", "that", "age", ".", "Typical", "features", "like", "obesity", "and", "hyperphagia", ",", "small", "hands", "and", "feet", "and", "small", "stature", "are", "not", "expressed", "until", "the", "second", "year", ".", "The", "clinical", "course", "of", "PWS", "in", "the", "neonate", "is", "demonstrated", "in", "two", "cases", ".", "Diagnostic", "criteria", "and", "therapeutic", "intervention", "are", "discussed", ".", "Hydrops", "fetalis", "as", "a", "seldom", "feature", "in", "PWS", "has", "to", "be", "taken", "into", "consideration", "." ]

[ "umlsterm" ]

diagnosis, neonate, neonatal hypotonia, asphyxia, Craniofacial abnormalities, fissures, mouth, treatment, Hypogonadism, cryptorchism, signs, age, obesity, hyperphagia, hands, feet, neonate, Diagnostic, criteria, therapeutic, Hydrops fetalis

MonatsschriftKinderheilkunde.71450515.eng.abstr_task2

Sentence: The diagnosis Prader-Willi-Syndrome ( PWS ) in the neonate is difficult because features like neonatal hypotonia and feeding problems are easily misdiagnosed as a consequence of peripartal asphyxia . Craniofacial abnormalities like narrow bifrontal diameter , almond shaped palpebral fissures and openend downturned mouth are underdiagnosed especially if respiratory treatment is necessary . Hypogonadism in girls and in milder expression in boys ( for example cryptorchism ) are common and unspecific signs at that age . Typical features like obesity and hyperphagia , small hands and feet and small stature are not expressed until the second year . The clinical course of PWS in the neonate is demonstrated in two cases . Diagnostic criteria and therapeutic intervention are discussed . Hydrops fetalis as a seldom feature in PWS has to be taken into consideration . Instructions: please extract entity words from the input sentence

[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

The diagnosis Prader-Willi-Syndrome ( PWS ) in the neonate is difficult because features like neonatal hypotonia and feeding problems are easily misdiagnosed as a consequence of peripartal asphyxia . Craniofacial abnormalities like narrow bifrontal diameter , almond shaped palpebral fissures and openend downturned mouth are underdiagnosed especially if respiratory treatment is necessary . Hypogonadism in girls and in milder expression in boys ( for example cryptorchism ) are common and unspecific signs at that age . Typical features like obesity and hyperphagia , small hands and feet and small stature are not expressed until the second year . The clinical course of PWS in the neonate is demonstrated in two cases . Diagnostic criteria and therapeutic intervention are discussed . Hydrops fetalis as a seldom feature in PWS has to be taken into consideration .

[ "The", "diagnosis", "Prader", "-", "Willi", "-", "Syndrome", "(", "PWS", ")", "in", "the", "neonate", "is", "difficult", "because", "features", "like", "neonatal", "hypotonia", "and", "feeding", "problems", "are", "easily", "misdiagnosed", "as", "a", "consequence", "of", "peripartal", "asphyxia", ".", "Craniofacial", "abnormalities", "like", "narrow", "bifrontal", "diameter", ",", "almond", "shaped", "palpebral", "fissures", "and", "openend", "downturned", "mouth", "are", "underdiagnosed", "especially", "if", "respiratory", "treatment", "is", "necessary", ".", "Hypogonadism", "in", "girls", "and", "in", "milder", "expression", "in", "boys", "(", "for", "example", "cryptorchism", ")", "are", "common", "and", "unspecific", "signs", "at", "that", "age", ".", "Typical", "features", "like", "obesity", "and", "hyperphagia", ",", "small", "hands", "and", "feet", "and", "small", "stature", "are", "not", "expressed", "until", "the", "second", "year", ".", "The", "clinical", "course", "of", "PWS", "in", "the", "neonate", "is", "demonstrated", "in", "two", "cases", ".", "Diagnostic", "criteria", "and", "therapeutic", "intervention", "are", "discussed", ".", "Hydrops", "fetalis", "as", "a", "seldom", "feature", "in", "PWS", "has", "to", "be", "taken", "into", "consideration", "." ]

[ "umlsterm" ]

15S)-HPETE is a compound, 15S)-HETE is a compound, Fas ligand is a protein, FADD is a protein, BH3-interacting domain death agonist is a protein, cytochrome c is a protein, PARP-1 is a protein

DS.d237_task0

Sentence: The cells exposed to 10 microM (15S)-HPETE for 3 h or to 40 microM (15S)-HETE for 6 h showed increased expression of Fas ligand and FADD (Fas-associated death domain), caspase 8 activation, Bid (BH3-interacting domain death agonist) cleavage, decrease in mitochondrial membrane potential, cytochrome c release, caspase 3 activation, PARP-1 (poly(ADP-ribose) polymerase-1) cleavage and DNA fragmentation, suggesting the involvement of both extrinsic and intrinsic death pathways. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: compound, protein

[ "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "I-protein", "I-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

The cells exposed to 10 microM (15S)-HPETE for 3 h or to 40 microM (15S)-HETE for 6 h showed increased expression of Fas ligand and FADD (Fas-associated death domain), caspase 8 activation, Bid (BH3-interacting domain death agonist) cleavage, decrease in mitochondrial membrane potential, cytochrome c release, caspase 3 activation, PARP-1 (poly(ADP-ribose) polymerase-1) cleavage and DNA fragmentation, suggesting the involvement of both extrinsic and intrinsic death pathways.

[ "The", "cells", "exposed", "to", "10", "microM", "(", "15S)-HPETE", "for", "3", "h", "or", "to", "40", "microM", "(", "15S)-HETE", "for", "6", "h", "showed", "increased", "expression", "of", "Fas", "ligand", "and", "FADD", "(", "Fas", "-", "associated", "death", "domain", ")", ",", "caspase", "8", "activation", ",", "Bid", "(", "BH3-interacting", "domain", "death", "agonist", ")", "cleavage", ",", "decrease", "in", "mitochondrial", "membrane", "potential", ",", "cytochrome", "c", "release", ",", "caspase", "3", "activation", ",", "PARP-1", "(", "poly(ADP", "-", "ribose", ")", "polymerase-1", ")", "cleavage", "and", "DNA", "fragmentation", ",", "suggesting", "the", "involvement", "of", "both", "extrinsic", "and", "intrinsic", "death", "pathways", "." ]

[ "protein", "compound" ]

15S)-HPETE is a compound, 15S)-HETE is a compound, Fas ligand is a protein, FADD is a protein, BH3-interacting domain death agonist is a protein, cytochrome c is a protein, PARP-1 is a protein

DS.d237_task1

Sentence: The cells exposed to 10 microM (15S)-HPETE for 3 h or to 40 microM (15S)-HETE for 6 h showed increased expression of Fas ligand and FADD (Fas-associated death domain), caspase 8 activation, Bid (BH3-interacting domain death agonist) cleavage, decrease in mitochondrial membrane potential, cytochrome c release, caspase 3 activation, PARP-1 (poly(ADP-ribose) polymerase-1) cleavage and DNA fragmentation, suggesting the involvement of both extrinsic and intrinsic death pathways. Instructions: please typing these entity words according to sentence: 15S)-HPETE, 15S)-HETE, Fas ligand, FADD, BH3-interacting domain death agonist, cytochrome c, PARP-1 Options: compound, protein

[ "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "I-protein", "I-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

The cells exposed to 10 microM (15S)-HPETE for 3 h or to 40 microM (15S)-HETE for 6 h showed increased expression of Fas ligand and FADD (Fas-associated death domain), caspase 8 activation, Bid (BH3-interacting domain death agonist) cleavage, decrease in mitochondrial membrane potential, cytochrome c release, caspase 3 activation, PARP-1 (poly(ADP-ribose) polymerase-1) cleavage and DNA fragmentation, suggesting the involvement of both extrinsic and intrinsic death pathways.

[ "The", "cells", "exposed", "to", "10", "microM", "(", "15S)-HPETE", "for", "3", "h", "or", "to", "40", "microM", "(", "15S)-HETE", "for", "6", "h", "showed", "increased", "expression", "of", "Fas", "ligand", "and", "FADD", "(", "Fas", "-", "associated", "death", "domain", ")", ",", "caspase", "8", "activation", ",", "Bid", "(", "BH3-interacting", "domain", "death", "agonist", ")", "cleavage", ",", "decrease", "in", "mitochondrial", "membrane", "potential", ",", "cytochrome", "c", "release", ",", "caspase", "3", "activation", ",", "PARP-1", "(", "poly(ADP", "-", "ribose", ")", "polymerase-1", ")", "cleavage", "and", "DNA", "fragmentation", ",", "suggesting", "the", "involvement", "of", "both", "extrinsic", "and", "intrinsic", "death", "pathways", "." ]

[ "protein", "compound" ]

15S)-HPETE, 15S)-HETE, Fas ligand, FADD, BH3-interacting domain death agonist, cytochrome c, PARP-1

DS.d237_task2

Sentence: The cells exposed to 10 microM (15S)-HPETE for 3 h or to 40 microM (15S)-HETE for 6 h showed increased expression of Fas ligand and FADD (Fas-associated death domain), caspase 8 activation, Bid (BH3-interacting domain death agonist) cleavage, decrease in mitochondrial membrane potential, cytochrome c release, caspase 3 activation, PARP-1 (poly(ADP-ribose) polymerase-1) cleavage and DNA fragmentation, suggesting the involvement of both extrinsic and intrinsic death pathways. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "I-protein", "I-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

The cells exposed to 10 microM (15S)-HPETE for 3 h or to 40 microM (15S)-HETE for 6 h showed increased expression of Fas ligand and FADD (Fas-associated death domain), caspase 8 activation, Bid (BH3-interacting domain death agonist) cleavage, decrease in mitochondrial membrane potential, cytochrome c release, caspase 3 activation, PARP-1 (poly(ADP-ribose) polymerase-1) cleavage and DNA fragmentation, suggesting the involvement of both extrinsic and intrinsic death pathways.

[ "The", "cells", "exposed", "to", "10", "microM", "(", "15S)-HPETE", "for", "3", "h", "or", "to", "40", "microM", "(", "15S)-HETE", "for", "6", "h", "showed", "increased", "expression", "of", "Fas", "ligand", "and", "FADD", "(", "Fas", "-", "associated", "death", "domain", ")", ",", "caspase", "8", "activation", ",", "Bid", "(", "BH3-interacting", "domain", "death", "agonist", ")", "cleavage", ",", "decrease", "in", "mitochondrial", "membrane", "potential", ",", "cytochrome", "c", "release", ",", "caspase", "3", "activation", ",", "PARP-1", "(", "poly(ADP", "-", "ribose", ")", "polymerase-1", ")", "cleavage", "and", "DNA", "fragmentation", ",", "suggesting", "the", "involvement", "of", "both", "extrinsic", "and", "intrinsic", "death", "pathways", "." ]

[ "protein", "compound" ]

fumarylacetoacetate hydrolase is a Gene, FAH is a Gene, G158D is a SNP, P261L is a SNP, F405H is a SNP, DEL366S is a SNP, IVS2 + 1(g - t ) is a SNP, IVS6 - 1(g - c ) is a SNP, IVS8 - 1(g - c ) is a SNP, IVS6 - 1(g - t ) is a SNP, IVS12 + 5(g - a ) is a SNP

487_task0

Sentence: Spectrum of mutations in the fumarylacetoacetate hydrolase gene of tyrosinemia type 1 patients in northwestern Europe and Mediterranean countries. Hereditary tyrosinemia type 1 (HT1) is a rare metabolic disease caused by a deficient activity of the enzyme fumarylacetoacetase (FAH). To investigate the molecular heterogeneity of tyrosinemia, the geographic distribution and the genotype-phenotype relationship, we have analyzed the FAH genotype of 25 HT1 patients. Mutation screening was performed by PCR amplification of exons 1-14 of the FAH gene, followed by SSCP analysis and direct sequencing of the amplified exons. Fourteen different mutations were found, of which seven were novel, viz. three missense mutations (G158D, P261L, F405H), a deletion of three nucleotides causing a deletion of serine (DEL366S) and three splice site mutations: IVS2+1(g-t), IVS6-1(g-c), IVS8-1(g-c). The splice site mutations IVS6-1(g-t) and IVS12+5(g-a) were frequently found in countries around the Mediterranean and northwestern Europe, respectively. No clear correlation between the genotype and the three major HT1 subtypes could be established. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Gene, SNP

[ "O", "O", "O", "O", "O", "B-Gene", "I-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-SNP", "O", "B-SNP", "O", "B-SNP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-SNP", "O", "O", "O", "O", "O", "O", "O", "B-SNP", "I-SNP", "I-SNP", "I-SNP", "I-SNP", "I-SNP", "O", "B-SNP", "I-SNP", "I-SNP", "I-SNP", "I-SNP", "I-SNP", "O", "B-SNP", "I-SNP", "I-SNP", "I-SNP", "I-SNP", "I-SNP", "O", "O", "O", "O", "O", "B-SNP", "I-SNP", "I-SNP", "I-SNP", "I-SNP", "I-SNP", "O", "B-SNP", "I-SNP", "I-SNP", "I-SNP", "I-SNP", "I-SNP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Spectrum of mutations in the fumarylacetoacetate hydrolase gene of tyrosinemia type 1 patients in northwestern Europe and Mediterranean countries. Hereditary tyrosinemia type 1 (HT1) is a rare metabolic disease caused by a deficient activity of the enzyme fumarylacetoacetase (FAH). To investigate the molecular heterogeneity of tyrosinemia, the geographic distribution and the genotype-phenotype relationship, we have analyzed the FAH genotype of 25 HT1 patients. Mutation screening was performed by PCR amplification of exons 1-14 of the FAH gene, followed by SSCP analysis and direct sequencing of the amplified exons. Fourteen different mutations were found, of which seven were novel, viz. three missense mutations (G158D, P261L, F405H), a deletion of three nucleotides causing a deletion of serine (DEL366S) and three splice site mutations: IVS2+1(g-t), IVS6-1(g-c), IVS8-1(g-c). The splice site mutations IVS6-1(g-t) and IVS12+5(g-a) were frequently found in countries around the Mediterranean and northwestern Europe, respectively. No clear correlation between the genotype and the three major HT1 subtypes could be established.

[ "Spectrum", "of", "mutations", "in", "the", "fumarylacetoacetate", "hydrolase", "gene", "of", "tyrosinemia", "type", "1", "patients", "in", "northwestern", "Europe", "and", "Mediterranean", "countries", ".", "Hereditary", "tyrosinemia", "type", "1", "(", "HT1", ")", "is", "a", "rare", "metabolic", "disease", "caused", "by", "a", "deficient", "activity", "of", "the", "enzyme", "fumarylacetoacetase", "(", "FAH", ")", ".", "To", "investigate", "the", "molecular", "heterogeneity", "of", "tyrosinemia", ",", "the", "geographic", "distribution", "and", "the", "genotype", "-", "phenotype", "relationship", ",", "we", "have", "analyzed", "the", "FAH", "genotype", "of", "25", "HT1", "patients", ".", "Mutation", "screening", "was", "performed", "by", "PCR", "amplification", "of", "exons", "1", "-", "14", "of", "the", "FAH", "gene", ",", "followed", "by", "SSCP", "analysis", "and", "direct", "sequencing", "of", "the", "amplified", "exons", ".", "Fourteen", "different", "mutations", "were", "found", ",", "of", "which", "seven", "were", "novel", ",", "viz", ".", "three", "missense", "mutations", "(", "G158D", ",", "P261L", ",", "F405H", ")", ",", "a", "deletion", "of", "three", "nucleotides", "causing", "a", "deletion", "of", "serine", "(", "DEL366S", ")", "and", "three", "splice", "site", "mutations", ":", "IVS2", "+", "1(g", "-", "t", ")", ",", "IVS6", "-", "1(g", "-", "c", ")", ",", "IVS8", "-", "1(g", "-", "c", ")", ".", "The", "splice", "site", "mutations", "IVS6", "-", "1(g", "-", "t", ")", "and", "IVS12", "+", "5(g", "-", "a", ")", "were", "frequently", "found", "in", "countries", "around", "the", "Mediterranean", "and", "northwestern", "Europe", ",", "respectively", ".", "No", "clear", "correlation", "between", "the", "genotype", "and", "the", "three", "major", "HT1", "subtypes", "could", "be", "established", ".", "\n" ]

[ "Gene", "SNP" ]

fumarylacetoacetate hydrolase is a Gene, FAH is a Gene, G158D is a SNP, P261L is a SNP, F405H is a SNP, DEL366S is a SNP, IVS2 + 1(g - t ) is a SNP, IVS6 - 1(g - c ) is a SNP, IVS8 - 1(g - c ) is a SNP, IVS6 - 1(g - t ) is a SNP, IVS12 + 5(g - a ) is a SNP

487_task1

Sentence: Spectrum of mutations in the fumarylacetoacetate hydrolase gene of tyrosinemia type 1 patients in northwestern Europe and Mediterranean countries. Hereditary tyrosinemia type 1 (HT1) is a rare metabolic disease caused by a deficient activity of the enzyme fumarylacetoacetase (FAH). To investigate the molecular heterogeneity of tyrosinemia, the geographic distribution and the genotype-phenotype relationship, we have analyzed the FAH genotype of 25 HT1 patients. Mutation screening was performed by PCR amplification of exons 1-14 of the FAH gene, followed by SSCP analysis and direct sequencing of the amplified exons. Fourteen different mutations were found, of which seven were novel, viz. three missense mutations (G158D, P261L, F405H), a deletion of three nucleotides causing a deletion of serine (DEL366S) and three splice site mutations: IVS2+1(g-t), IVS6-1(g-c), IVS8-1(g-c). The splice site mutations IVS6-1(g-t) and IVS12+5(g-a) were frequently found in countries around the Mediterranean and northwestern Europe, respectively. No clear correlation between the genotype and the three major HT1 subtypes could be established. Instructions: please typing these entity words according to sentence: fumarylacetoacetate hydrolase, FAH, G158D, P261L, F405H, DEL366S, IVS2 + 1(g - t ), IVS6 - 1(g - c ), IVS8 - 1(g - c ), IVS6 - 1(g - t ), IVS12 + 5(g - a ) Options: Gene, SNP

[ "O", "O", "O", "O", "O", "B-Gene", "I-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-SNP", "O", "B-SNP", "O", "B-SNP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-SNP", "O", "O", "O", "O", "O", "O", "O", "B-SNP", "I-SNP", "I-SNP", "I-SNP", "I-SNP", "I-SNP", "O", "B-SNP", "I-SNP", "I-SNP", "I-SNP", "I-SNP", "I-SNP", "O", "B-SNP", "I-SNP", "I-SNP", "I-SNP", "I-SNP", "I-SNP", "O", "O", "O", "O", "O", "B-SNP", "I-SNP", "I-SNP", "I-SNP", "I-SNP", "I-SNP", "O", "B-SNP", "I-SNP", "I-SNP", "I-SNP", "I-SNP", "I-SNP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Spectrum of mutations in the fumarylacetoacetate hydrolase gene of tyrosinemia type 1 patients in northwestern Europe and Mediterranean countries. Hereditary tyrosinemia type 1 (HT1) is a rare metabolic disease caused by a deficient activity of the enzyme fumarylacetoacetase (FAH). To investigate the molecular heterogeneity of tyrosinemia, the geographic distribution and the genotype-phenotype relationship, we have analyzed the FAH genotype of 25 HT1 patients. Mutation screening was performed by PCR amplification of exons 1-14 of the FAH gene, followed by SSCP analysis and direct sequencing of the amplified exons. Fourteen different mutations were found, of which seven were novel, viz. three missense mutations (G158D, P261L, F405H), a deletion of three nucleotides causing a deletion of serine (DEL366S) and three splice site mutations: IVS2+1(g-t), IVS6-1(g-c), IVS8-1(g-c). The splice site mutations IVS6-1(g-t) and IVS12+5(g-a) were frequently found in countries around the Mediterranean and northwestern Europe, respectively. No clear correlation between the genotype and the three major HT1 subtypes could be established.

[ "Spectrum", "of", "mutations", "in", "the", "fumarylacetoacetate", "hydrolase", "gene", "of", "tyrosinemia", "type", "1", "patients", "in", "northwestern", "Europe", "and", "Mediterranean", "countries", ".", "Hereditary", "tyrosinemia", "type", "1", "(", "HT1", ")", "is", "a", "rare", "metabolic", "disease", "caused", "by", "a", "deficient", "activity", "of", "the", "enzyme", "fumarylacetoacetase", "(", "FAH", ")", ".", "To", "investigate", "the", "molecular", "heterogeneity", "of", "tyrosinemia", ",", "the", "geographic", "distribution", "and", "the", "genotype", "-", "phenotype", "relationship", ",", "we", "have", "analyzed", "the", "FAH", "genotype", "of", "25", "HT1", "patients", ".", "Mutation", "screening", "was", "performed", "by", "PCR", "amplification", "of", "exons", "1", "-", "14", "of", "the", "FAH", "gene", ",", "followed", "by", "SSCP", "analysis", "and", "direct", "sequencing", "of", "the", "amplified", "exons", ".", "Fourteen", "different", "mutations", "were", "found", ",", "of", "which", "seven", "were", "novel", ",", "viz", ".", "three", "missense", "mutations", "(", "G158D", ",", "P261L", ",", "F405H", ")", ",", "a", "deletion", "of", "three", "nucleotides", "causing", "a", "deletion", "of", "serine", "(", "DEL366S", ")", "and", "three", "splice", "site", "mutations", ":", "IVS2", "+", "1(g", "-", "t", ")", ",", "IVS6", "-", "1(g", "-", "c", ")", ",", "IVS8", "-", "1(g", "-", "c", ")", ".", "The", "splice", "site", "mutations", "IVS6", "-", "1(g", "-", "t", ")", "and", "IVS12", "+", "5(g", "-", "a", ")", "were", "frequently", "found", "in", "countries", "around", "the", "Mediterranean", "and", "northwestern", "Europe", ",", "respectively", ".", "No", "clear", "correlation", "between", "the", "genotype", "and", "the", "three", "major", "HT1", "subtypes", "could", "be", "established", ".", "\n" ]

[ "Gene", "SNP" ]

fumarylacetoacetate hydrolase, FAH, G158D, P261L, F405H, DEL366S, IVS2 + 1(g - t ), IVS6 - 1(g - c ), IVS8 - 1(g - c ), IVS6 - 1(g - t ), IVS12 + 5(g - a )

487_task2

Sentence: Spectrum of mutations in the fumarylacetoacetate hydrolase gene of tyrosinemia type 1 patients in northwestern Europe and Mediterranean countries. Hereditary tyrosinemia type 1 (HT1) is a rare metabolic disease caused by a deficient activity of the enzyme fumarylacetoacetase (FAH). To investigate the molecular heterogeneity of tyrosinemia, the geographic distribution and the genotype-phenotype relationship, we have analyzed the FAH genotype of 25 HT1 patients. Mutation screening was performed by PCR amplification of exons 1-14 of the FAH gene, followed by SSCP analysis and direct sequencing of the amplified exons. Fourteen different mutations were found, of which seven were novel, viz. three missense mutations (G158D, P261L, F405H), a deletion of three nucleotides causing a deletion of serine (DEL366S) and three splice site mutations: IVS2+1(g-t), IVS6-1(g-c), IVS8-1(g-c). The splice site mutations IVS6-1(g-t) and IVS12+5(g-a) were frequently found in countries around the Mediterranean and northwestern Europe, respectively. No clear correlation between the genotype and the three major HT1 subtypes could be established. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "B-Gene", "I-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-SNP", "O", "B-SNP", "O", "B-SNP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-SNP", "O", "O", "O", "O", "O", "O", "O", "B-SNP", "I-SNP", "I-SNP", "I-SNP", "I-SNP", "I-SNP", "O", "B-SNP", "I-SNP", "I-SNP", "I-SNP", "I-SNP", "I-SNP", "O", "B-SNP", "I-SNP", "I-SNP", "I-SNP", "I-SNP", "I-SNP", "O", "O", "O", "O", "O", "B-SNP", "I-SNP", "I-SNP", "I-SNP", "I-SNP", "I-SNP", "O", "B-SNP", "I-SNP", "I-SNP", "I-SNP", "I-SNP", "I-SNP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Spectrum of mutations in the fumarylacetoacetate hydrolase gene of tyrosinemia type 1 patients in northwestern Europe and Mediterranean countries. Hereditary tyrosinemia type 1 (HT1) is a rare metabolic disease caused by a deficient activity of the enzyme fumarylacetoacetase (FAH). To investigate the molecular heterogeneity of tyrosinemia, the geographic distribution and the genotype-phenotype relationship, we have analyzed the FAH genotype of 25 HT1 patients. Mutation screening was performed by PCR amplification of exons 1-14 of the FAH gene, followed by SSCP analysis and direct sequencing of the amplified exons. Fourteen different mutations were found, of which seven were novel, viz. three missense mutations (G158D, P261L, F405H), a deletion of three nucleotides causing a deletion of serine (DEL366S) and three splice site mutations: IVS2+1(g-t), IVS6-1(g-c), IVS8-1(g-c). The splice site mutations IVS6-1(g-t) and IVS12+5(g-a) were frequently found in countries around the Mediterranean and northwestern Europe, respectively. No clear correlation between the genotype and the three major HT1 subtypes could be established.

[ "Spectrum", "of", "mutations", "in", "the", "fumarylacetoacetate", "hydrolase", "gene", "of", "tyrosinemia", "type", "1", "patients", "in", "northwestern", "Europe", "and", "Mediterranean", "countries", ".", "Hereditary", "tyrosinemia", "type", "1", "(", "HT1", ")", "is", "a", "rare", "metabolic", "disease", "caused", "by", "a", "deficient", "activity", "of", "the", "enzyme", "fumarylacetoacetase", "(", "FAH", ")", ".", "To", "investigate", "the", "molecular", "heterogeneity", "of", "tyrosinemia", ",", "the", "geographic", "distribution", "and", "the", "genotype", "-", "phenotype", "relationship", ",", "we", "have", "analyzed", "the", "FAH", "genotype", "of", "25", "HT1", "patients", ".", "Mutation", "screening", "was", "performed", "by", "PCR", "amplification", "of", "exons", "1", "-", "14", "of", "the", "FAH", "gene", ",", "followed", "by", "SSCP", "analysis", "and", "direct", "sequencing", "of", "the", "amplified", "exons", ".", "Fourteen", "different", "mutations", "were", "found", ",", "of", "which", "seven", "were", "novel", ",", "viz", ".", "three", "missense", "mutations", "(", "G158D", ",", "P261L", ",", "F405H", ")", ",", "a", "deletion", "of", "three", "nucleotides", "causing", "a", "deletion", "of", "serine", "(", "DEL366S", ")", "and", "three", "splice", "site", "mutations", ":", "IVS2", "+", "1(g", "-", "t", ")", ",", "IVS6", "-", "1(g", "-", "c", ")", ",", "IVS8", "-", "1(g", "-", "c", ")", ".", "The", "splice", "site", "mutations", "IVS6", "-", "1(g", "-", "t", ")", "and", "IVS12", "+", "5(g", "-", "a", ")", "were", "frequently", "found", "in", "countries", "around", "the", "Mediterranean", "and", "northwestern", "Europe", ",", "respectively", ".", "No", "clear", "correlation", "between", "the", "genotype", "and", "the", "three", "major", "HT1", "subtypes", "could", "be", "established", ".", "\n" ]

[ "Gene", "SNP" ]

maennliche is an umlsterm, Patienten is an umlsterm, Diagnose is an umlsterm, Aortenisthmusstenose is an umlsterm, Patienten is an umlsterm, lebensbedrohlichen is an umlsterm, Komplikation is an umlsterm, Aortenisthmusstenose is an umlsterm, Subarachnoidalblutung is an umlsterm, zerebrales Aneurysma is an umlsterm, Patienten is an umlsterm, Aortenruptur is an umlsterm, Erweiterung is an umlsterm, Aorta ascendens is an umlsterm, Patienten is an umlsterm, Ruptur is an umlsterm, Aorta descendens is an umlsterm, Oesophagus is an umlsterm, Patienten is an umlsterm, Diagnose is an umlsterm, Diagnose is an umlsterm, Aortenisthmusstenose is an umlsterm

MonatsschriftKinderheilkunde.71450477.ger.abstr_task0

Sentence: Wir berichten ueber 4 maennliche Patienten im Alter zwischen 11 Jahren und 14 Jahren , 9 Monaten , bei denen verspaetet die Diagnose einer Aortenisthmusstenose gestellt wurde . Drei der Patienten kamen primaer mit einer lebensbedrohlichen Komplikation der zuvor nicht erkannten Aortenisthmusstenose zur stationaeren Aufnahme . Es handelte sich hierbei 1 mal um eine Subarachnoidalblutung durch ein rupturiertes zerebrales Aneurysma , bei 1 anderen Patienten um eine Aortenruptur bei aneurysmatischer Erweiterung der Aorta ascendens , die von einer Aortendissektion gefolgt wurde sowie bei 1 Patienten um die Ruptur eines poststenotischen Aneurysmas der Aorta descendens in den Oesophagus . Alle 4 Patienten konnten erfolgreich operiert werden . Der postoperative Verlauf war jedoch immer durch einen schwer einstellbaren Hypertonus gekennzeichnet . Diskussion : Die verspaetete Diagnose dieser Aortenisthmusstenosen ist auf die fehlende Symptomatik zurueckzufuehren , die auf der Entwicklung eines meist ausgepraegten Kollateralkreislaufs beruht . Prognostisch entscheidend ist die fruehzeitige Diagnose . Die Korrekturoperation der asymptomatischen Aortenisthmusstenose sollte im 2. Lebensjahr erfolgen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O" ]

Wir berichten ueber 4 maennliche Patienten im Alter zwischen 11 Jahren und 14 Jahren , 9 Monaten , bei denen verspaetet die Diagnose einer Aortenisthmusstenose gestellt wurde . Drei der Patienten kamen primaer mit einer lebensbedrohlichen Komplikation der zuvor nicht erkannten Aortenisthmusstenose zur stationaeren Aufnahme . Es handelte sich hierbei 1 mal um eine Subarachnoidalblutung durch ein rupturiertes zerebrales Aneurysma , bei 1 anderen Patienten um eine Aortenruptur bei aneurysmatischer Erweiterung der Aorta ascendens , die von einer Aortendissektion gefolgt wurde sowie bei 1 Patienten um die Ruptur eines poststenotischen Aneurysmas der Aorta descendens in den Oesophagus . Alle 4 Patienten konnten erfolgreich operiert werden . Der postoperative Verlauf war jedoch immer durch einen schwer einstellbaren Hypertonus gekennzeichnet . Diskussion : Die verspaetete Diagnose dieser Aortenisthmusstenosen ist auf die fehlende Symptomatik zurueckzufuehren , die auf der Entwicklung eines meist ausgepraegten Kollateralkreislaufs beruht . Prognostisch entscheidend ist die fruehzeitige Diagnose . Die Korrekturoperation der asymptomatischen Aortenisthmusstenose sollte im 2. Lebensjahr erfolgen .

[ "Wir", "berichten", "ueber", "4", "maennliche", "Patienten", "im", "Alter", "zwischen", "11", "Jahren", "und", "14", "Jahren", ",", "9", "Monaten", ",", "bei", "denen", "verspaetet", "die", "Diagnose", "einer", "Aortenisthmusstenose", "gestellt", "wurde", ".", "Drei", "der", "Patienten", "kamen", "primaer", "mit", "einer", "lebensbedrohlichen", "Komplikation", "der", "zuvor", "nicht", "erkannten", "Aortenisthmusstenose", "zur", "stationaeren", "Aufnahme", ".", "Es", "handelte", "sich", "hierbei", "1", "mal", "um", "eine", "Subarachnoidalblutung", "durch", "ein", "rupturiertes", "zerebrales", "Aneurysma", ",", "bei", "1", "anderen", "Patienten", "um", "eine", "Aortenruptur", "bei", "aneurysmatischer", "Erweiterung", "der", "Aorta", "ascendens", ",", "die", "von", "einer", "Aortendissektion", "gefolgt", "wurde", "sowie", "bei", "1", "Patienten", "um", "die", "Ruptur", "eines", "poststenotischen", "Aneurysmas", "der", "Aorta", "descendens", "in", "den", "Oesophagus", ".", "Alle", "4", "Patienten", "konnten", "erfolgreich", "operiert", "werden", ".", "Der", "postoperative", "Verlauf", "war", "jedoch", "immer", "durch", "einen", "schwer", "einstellbaren", "Hypertonus", "gekennzeichnet", ".", "Diskussion", ":", "Die", "verspaetete", "Diagnose", "dieser", "Aortenisthmusstenosen", "ist", "auf", "die", "fehlende", "Symptomatik", "zurueckzufuehren", ",", "die", "auf", "der", "Entwicklung", "eines", "meist", "ausgepraegten", "Kollateralkreislaufs", "beruht", ".", "Prognostisch", "entscheidend", "ist", "die", "fruehzeitige", "Diagnose", ".", "Die", "Korrekturoperation", "der", "asymptomatischen", "Aortenisthmusstenose", "sollte", "im", "2", ".", "Lebensjahr", "erfolgen", "." ]

[ "umlsterm" ]

maennliche is an umlsterm, Patienten is an umlsterm, Diagnose is an umlsterm, Aortenisthmusstenose is an umlsterm, Patienten is an umlsterm, lebensbedrohlichen is an umlsterm, Komplikation is an umlsterm, Aortenisthmusstenose is an umlsterm, Subarachnoidalblutung is an umlsterm, zerebrales Aneurysma is an umlsterm, Patienten is an umlsterm, Aortenruptur is an umlsterm, Erweiterung is an umlsterm, Aorta ascendens is an umlsterm, Patienten is an umlsterm, Ruptur is an umlsterm, Aorta descendens is an umlsterm, Oesophagus is an umlsterm, Patienten is an umlsterm, Diagnose is an umlsterm, Diagnose is an umlsterm, Aortenisthmusstenose is an umlsterm

MonatsschriftKinderheilkunde.71450477.ger.abstr_task1

Sentence: Wir berichten ueber 4 maennliche Patienten im Alter zwischen 11 Jahren und 14 Jahren , 9 Monaten , bei denen verspaetet die Diagnose einer Aortenisthmusstenose gestellt wurde . Drei der Patienten kamen primaer mit einer lebensbedrohlichen Komplikation der zuvor nicht erkannten Aortenisthmusstenose zur stationaeren Aufnahme . Es handelte sich hierbei 1 mal um eine Subarachnoidalblutung durch ein rupturiertes zerebrales Aneurysma , bei 1 anderen Patienten um eine Aortenruptur bei aneurysmatischer Erweiterung der Aorta ascendens , die von einer Aortendissektion gefolgt wurde sowie bei 1 Patienten um die Ruptur eines poststenotischen Aneurysmas der Aorta descendens in den Oesophagus . Alle 4 Patienten konnten erfolgreich operiert werden . Der postoperative Verlauf war jedoch immer durch einen schwer einstellbaren Hypertonus gekennzeichnet . Diskussion : Die verspaetete Diagnose dieser Aortenisthmusstenosen ist auf die fehlende Symptomatik zurueckzufuehren , die auf der Entwicklung eines meist ausgepraegten Kollateralkreislaufs beruht . Prognostisch entscheidend ist die fruehzeitige Diagnose . Die Korrekturoperation der asymptomatischen Aortenisthmusstenose sollte im 2. Lebensjahr erfolgen . Instructions: please typing these entity words according to sentence: maennliche, Patienten, Diagnose, Aortenisthmusstenose, Patienten, lebensbedrohlichen, Komplikation, Aortenisthmusstenose, Subarachnoidalblutung, zerebrales Aneurysma, Patienten, Aortenruptur, Erweiterung, Aorta ascendens, Patienten, Ruptur, Aorta descendens, Oesophagus, Patienten, Diagnose, Diagnose, Aortenisthmusstenose Options: umlsterm

[ "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O" ]

Wir berichten ueber 4 maennliche Patienten im Alter zwischen 11 Jahren und 14 Jahren , 9 Monaten , bei denen verspaetet die Diagnose einer Aortenisthmusstenose gestellt wurde . Drei der Patienten kamen primaer mit einer lebensbedrohlichen Komplikation der zuvor nicht erkannten Aortenisthmusstenose zur stationaeren Aufnahme . Es handelte sich hierbei 1 mal um eine Subarachnoidalblutung durch ein rupturiertes zerebrales Aneurysma , bei 1 anderen Patienten um eine Aortenruptur bei aneurysmatischer Erweiterung der Aorta ascendens , die von einer Aortendissektion gefolgt wurde sowie bei 1 Patienten um die Ruptur eines poststenotischen Aneurysmas der Aorta descendens in den Oesophagus . Alle 4 Patienten konnten erfolgreich operiert werden . Der postoperative Verlauf war jedoch immer durch einen schwer einstellbaren Hypertonus gekennzeichnet . Diskussion : Die verspaetete Diagnose dieser Aortenisthmusstenosen ist auf die fehlende Symptomatik zurueckzufuehren , die auf der Entwicklung eines meist ausgepraegten Kollateralkreislaufs beruht . Prognostisch entscheidend ist die fruehzeitige Diagnose . Die Korrekturoperation der asymptomatischen Aortenisthmusstenose sollte im 2. Lebensjahr erfolgen .

[ "Wir", "berichten", "ueber", "4", "maennliche", "Patienten", "im", "Alter", "zwischen", "11", "Jahren", "und", "14", "Jahren", ",", "9", "Monaten", ",", "bei", "denen", "verspaetet", "die", "Diagnose", "einer", "Aortenisthmusstenose", "gestellt", "wurde", ".", "Drei", "der", "Patienten", "kamen", "primaer", "mit", "einer", "lebensbedrohlichen", "Komplikation", "der", "zuvor", "nicht", "erkannten", "Aortenisthmusstenose", "zur", "stationaeren", "Aufnahme", ".", "Es", "handelte", "sich", "hierbei", "1", "mal", "um", "eine", "Subarachnoidalblutung", "durch", "ein", "rupturiertes", "zerebrales", "Aneurysma", ",", "bei", "1", "anderen", "Patienten", "um", "eine", "Aortenruptur", "bei", "aneurysmatischer", "Erweiterung", "der", "Aorta", "ascendens", ",", "die", "von", "einer", "Aortendissektion", "gefolgt", "wurde", "sowie", "bei", "1", "Patienten", "um", "die", "Ruptur", "eines", "poststenotischen", "Aneurysmas", "der", "Aorta", "descendens", "in", "den", "Oesophagus", ".", "Alle", "4", "Patienten", "konnten", "erfolgreich", "operiert", "werden", ".", "Der", "postoperative", "Verlauf", "war", "jedoch", "immer", "durch", "einen", "schwer", "einstellbaren", "Hypertonus", "gekennzeichnet", ".", "Diskussion", ":", "Die", "verspaetete", "Diagnose", "dieser", "Aortenisthmusstenosen", "ist", "auf", "die", "fehlende", "Symptomatik", "zurueckzufuehren", ",", "die", "auf", "der", "Entwicklung", "eines", "meist", "ausgepraegten", "Kollateralkreislaufs", "beruht", ".", "Prognostisch", "entscheidend", "ist", "die", "fruehzeitige", "Diagnose", ".", "Die", "Korrekturoperation", "der", "asymptomatischen", "Aortenisthmusstenose", "sollte", "im", "2", ".", "Lebensjahr", "erfolgen", "." ]

[ "umlsterm" ]

maennliche, Patienten, Diagnose, Aortenisthmusstenose, Patienten, lebensbedrohlichen, Komplikation, Aortenisthmusstenose, Subarachnoidalblutung, zerebrales Aneurysma, Patienten, Aortenruptur, Erweiterung, Aorta ascendens, Patienten, Ruptur, Aorta descendens, Oesophagus, Patienten, Diagnose, Diagnose, Aortenisthmusstenose

MonatsschriftKinderheilkunde.71450477.ger.abstr_task2

Sentence: Wir berichten ueber 4 maennliche Patienten im Alter zwischen 11 Jahren und 14 Jahren , 9 Monaten , bei denen verspaetet die Diagnose einer Aortenisthmusstenose gestellt wurde . Drei der Patienten kamen primaer mit einer lebensbedrohlichen Komplikation der zuvor nicht erkannten Aortenisthmusstenose zur stationaeren Aufnahme . Es handelte sich hierbei 1 mal um eine Subarachnoidalblutung durch ein rupturiertes zerebrales Aneurysma , bei 1 anderen Patienten um eine Aortenruptur bei aneurysmatischer Erweiterung der Aorta ascendens , die von einer Aortendissektion gefolgt wurde sowie bei 1 Patienten um die Ruptur eines poststenotischen Aneurysmas der Aorta descendens in den Oesophagus . Alle 4 Patienten konnten erfolgreich operiert werden . Der postoperative Verlauf war jedoch immer durch einen schwer einstellbaren Hypertonus gekennzeichnet . Diskussion : Die verspaetete Diagnose dieser Aortenisthmusstenosen ist auf die fehlende Symptomatik zurueckzufuehren , die auf der Entwicklung eines meist ausgepraegten Kollateralkreislaufs beruht . Prognostisch entscheidend ist die fruehzeitige Diagnose . Die Korrekturoperation der asymptomatischen Aortenisthmusstenose sollte im 2. Lebensjahr erfolgen . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O" ]

Wir berichten ueber 4 maennliche Patienten im Alter zwischen 11 Jahren und 14 Jahren , 9 Monaten , bei denen verspaetet die Diagnose einer Aortenisthmusstenose gestellt wurde . Drei der Patienten kamen primaer mit einer lebensbedrohlichen Komplikation der zuvor nicht erkannten Aortenisthmusstenose zur stationaeren Aufnahme . Es handelte sich hierbei 1 mal um eine Subarachnoidalblutung durch ein rupturiertes zerebrales Aneurysma , bei 1 anderen Patienten um eine Aortenruptur bei aneurysmatischer Erweiterung der Aorta ascendens , die von einer Aortendissektion gefolgt wurde sowie bei 1 Patienten um die Ruptur eines poststenotischen Aneurysmas der Aorta descendens in den Oesophagus . Alle 4 Patienten konnten erfolgreich operiert werden . Der postoperative Verlauf war jedoch immer durch einen schwer einstellbaren Hypertonus gekennzeichnet . Diskussion : Die verspaetete Diagnose dieser Aortenisthmusstenosen ist auf die fehlende Symptomatik zurueckzufuehren , die auf der Entwicklung eines meist ausgepraegten Kollateralkreislaufs beruht . Prognostisch entscheidend ist die fruehzeitige Diagnose . Die Korrekturoperation der asymptomatischen Aortenisthmusstenose sollte im 2. Lebensjahr erfolgen .

[ "Wir", "berichten", "ueber", "4", "maennliche", "Patienten", "im", "Alter", "zwischen", "11", "Jahren", "und", "14", "Jahren", ",", "9", "Monaten", ",", "bei", "denen", "verspaetet", "die", "Diagnose", "einer", "Aortenisthmusstenose", "gestellt", "wurde", ".", "Drei", "der", "Patienten", "kamen", "primaer", "mit", "einer", "lebensbedrohlichen", "Komplikation", "der", "zuvor", "nicht", "erkannten", "Aortenisthmusstenose", "zur", "stationaeren", "Aufnahme", ".", "Es", "handelte", "sich", "hierbei", "1", "mal", "um", "eine", "Subarachnoidalblutung", "durch", "ein", "rupturiertes", "zerebrales", "Aneurysma", ",", "bei", "1", "anderen", "Patienten", "um", "eine", "Aortenruptur", "bei", "aneurysmatischer", "Erweiterung", "der", "Aorta", "ascendens", ",", "die", "von", "einer", "Aortendissektion", "gefolgt", "wurde", "sowie", "bei", "1", "Patienten", "um", "die", "Ruptur", "eines", "poststenotischen", "Aneurysmas", "der", "Aorta", "descendens", "in", "den", "Oesophagus", ".", "Alle", "4", "Patienten", "konnten", "erfolgreich", "operiert", "werden", ".", "Der", "postoperative", "Verlauf", "war", "jedoch", "immer", "durch", "einen", "schwer", "einstellbaren", "Hypertonus", "gekennzeichnet", ".", "Diskussion", ":", "Die", "verspaetete", "Diagnose", "dieser", "Aortenisthmusstenosen", "ist", "auf", "die", "fehlende", "Symptomatik", "zurueckzufuehren", ",", "die", "auf", "der", "Entwicklung", "eines", "meist", "ausgepraegten", "Kollateralkreislaufs", "beruht", ".", "Prognostisch", "entscheidend", "ist", "die", "fruehzeitige", "Diagnose", ".", "Die", "Korrekturoperation", "der", "asymptomatischen", "Aortenisthmusstenose", "sollte", "im", "2", ".", "Lebensjahr", "erfolgen", "." ]

[ "umlsterm" ]

Pedro is a NOMBRE_SUJETO_ASISTENCIA, Iglesias Pastor is a NOMBRE_SUJETO_ASISTENCIA, 1149404 is a ID_SUJETO_ASISTENCIA, 343551107164 is a ID_ASEGURAMIENTO, A Coruña is a TERRITORIO, 15003 is a TERRITORIO, 09/05/1945 is a FECHAS, España is a PAIS, 67 años is a EDAD_SUJETO_ASISTENCIA, 02/04/2013 is a FECHAS, 1287103 is a ID_CONTACTO_ASISTENCIAL, José Manuel Janeiro Pais is a NOMBRE_PERSONAL_SANITARIO, 15 15 65203 is a ID_TITULACION_PERSONAL_SANITARIO, Varón is a SEXO_SUJETO_ASISTENCIA, 67 años is a EDAD_SUJETO_ASISTENCIA, José Manuel Janeiro Pais is a NOMBRE_PERSONAL_SANITARIO, Avda . Lázaro Cárdenas , 23 - 1ºE is a CALLE, 15009 is a TERRITORIO, La Coruña is a TERRITORIO, España is a PAIS, janeiropais@canalejo.org is a CORREO_ELECTRONICO

185_task0

Sentence: Datos del paciente. Nombre: Pedro . Apellidos: Iglesias Pastor. NHC: 1149404. NASS: 343551107164. Domicilio: Rúa Comandante Fontanes, 19, 2 B. Localidad/ Provincia: A Coruña. CP: 15003. Datos asistenciales. Fecha de nacimiento: 09/05/1945. País de nacimiento: España. Edad: 67 años Sexo: H. Fecha de Ingreso: 02/04/2013. Episodio: 1287103. Médico: José Manuel Janeiro Pais NºCol: 15 15 65203. Informe clínico del paciente: Varón, de 67 años, con agudeza visual de 0,6 y 0,5 con cataratas nucleares grado 3 en ambos ojos. El ojo izquierdo mostraba un pterigión nasal grado I y diversas lesiones con forma de islotes corneales epiteliales con distribución semicircular inferior, no afectando al eje visual. No presentaba signos inflamatorios en el segmento anterior y el resto de la exploración es normal. Se instauró tratamiento con Mitomicina-C 0,02% preoperatorio (1), con reducción de la lesión a 1/3 de su tamaño. Se realizó intervención de cataratas en ambos ojos mediante técnica MICS, exéresis del pterigión del ojo izquierdo y exéresis de la lesión corneal, remitiéndose a estudio anatomopatológico, el cual informa: epitelio conjuntival con focos de atipia leve de las células de la capa basal, llegando a ocupar la atipia, a nivel del limbo, hasta 2/3 del espesor total, observándose escaso pleomorfismo. Degeneración elastótica actínica del corión y escaso infiltrado inflamatorio crónico linfocitario subepitelial. A los 6 meses se evidenció la presencia de islotes aislados recidivantes, tratándose nuevamente con Mitomicina-C, regresando la lesión, no evidenciándose nuevas recidivas en su seguimiento durante 1 año. Responsable clínico: Dr. José Manuel Janeiro Pais, Avda. Lázaro Cárdenas, 23 - 1ºE 15009 La Coruña (España). janeiropais@canalejo.org Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: TERRITORIO, SEXO_SUJETO_ASISTENCIA, ID_SUJETO_ASISTENCIA, FECHAS, CALLE, CORREO_ELECTRONICO, PAIS, EDAD_SUJETO_ASISTENCIA, ID_CONTACTO_ASISTENCIAL, ID_ASEGURAMIENTO, ID_TITULACION_PERSONAL_SANITARIO, NOMBRE_SUJETO_ASISTENCIA, NOMBRE_PERSONAL_SANITARIO

[ "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_ASEGURAMIENTO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "I-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-ID_CONTACTO_ASISTENCIAL", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "B-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "B-TERRITORIO", "B-TERRITORIO", "I-TERRITORIO", "O", "B-PAIS", "O", "O", "B-CORREO_ELECTRONICO", "O" ]

Datos del paciente. Nombre: Pedro . Apellidos: Iglesias Pastor. NHC: 1149404. NASS: 343551107164. Domicilio: Rúa Comandante Fontanes, 19, 2 B. Localidad/ Provincia: A Coruña. CP: 15003. Datos asistenciales. Fecha de nacimiento: 09/05/1945. País de nacimiento: España. Edad: 67 años Sexo: H. Fecha de Ingreso: 02/04/2013. Episodio: 1287103. Médico: José Manuel Janeiro Pais NºCol: 15 15 65203. Informe clínico del paciente: Varón, de 67 años, con agudeza visual de 0,6 y 0,5 con cataratas nucleares grado 3 en ambos ojos. El ojo izquierdo mostraba un pterigión nasal grado I y diversas lesiones con forma de islotes corneales epiteliales con distribución semicircular inferior, no afectando al eje visual. No presentaba signos inflamatorios en el segmento anterior y el resto de la exploración es normal. Se instauró tratamiento con Mitomicina-C 0,02% preoperatorio (1), con reducción de la lesión a 1/3 de su tamaño. Se realizó intervención de cataratas en ambos ojos mediante técnica MICS, exéresis del pterigión del ojo izquierdo y exéresis de la lesión corneal, remitiéndose a estudio anatomopatológico, el cual informa: epitelio conjuntival con focos de atipia leve de las células de la capa basal, llegando a ocupar la atipia, a nivel del limbo, hasta 2/3 del espesor total, observándose escaso pleomorfismo. Degeneración elastótica actínica del corión y escaso infiltrado inflamatorio crónico linfocitario subepitelial. A los 6 meses se evidenció la presencia de islotes aislados recidivantes, tratándose nuevamente con Mitomicina-C, regresando la lesión, no evidenciándose nuevas recidivas en su seguimiento durante 1 año. Responsable clínico: Dr. José Manuel Janeiro Pais, Avda. Lázaro Cárdenas, 23 - 1ºE 15009 La Coruña (España). janeiropais@canalejo.org

[ "Datos", "del", "paciente", ".", "\n", "Nombre", ":", "Pedro", ".", "\n", "Apellidos", ":", "Iglesias", "Pastor", ".", "\n", "NHC", ":", "1149404", ".", "\n", "NASS", ":", "343551107164", ".", "\n", "Domicilio", ":", "Rúa", "Comandante", "Fontanes", ",", "19", ",", "2", "B.", "\n", "Localidad/", "Provincia", ":", "A", "Coruña", ".", "\n", "CP", ":", "15003", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "09/05/1945", ".", "\n", "País", "de", "nacimiento", ":", "España", ".", "\n", "Edad", ":", "67", "años", "Sexo", ":", "H.", "\n", "Fecha", "de", "Ingreso", ":", "02/04/2013", ".", "\n", "Episodio", ":", "1287103", ".", "\n", "Médico", ":", "José", "Manuel", "Janeiro", "Pais", " ", "NºCol", ":", "15", "15", "65203", ".", "\n", "Informe", "clínico", "del", "paciente", ":", "Varón", ",", "de", "67", "años", ",", "con", "agudeza", "visual", "de", "0,6", "y", "0,5", "con", "cataratas", "nucleares", "grado", "3", "en", "ambos", "ojos", ".", "El", "ojo", "izquierdo", "mostraba", "un", "pterigión", "nasal", "grado", "I", "y", "diversas", "lesiones", "con", "forma", "de", "islotes", "corneales", "epiteliales", "con", "distribución", "semicircular", "inferior", ",", "no", "afectando", "al", "eje", "visual", ".", "No", "presentaba", "signos", "inflamatorios", "en", "el", "segmento", "anterior", "y", "el", "resto", "de", "la", "exploración", "es", "normal", ".", "\n", "Se", "instauró", "tratamiento", "con", "Mitomicina", "-", "C", "0,02", "%", "preoperatorio", "(", "1", ")", ",", "con", "reducción", "de", "la", "lesión", "a", "1/3", "de", "su", "tamaño", ".", "\n", "Se", "realizó", "intervención", "de", "cataratas", "en", "ambos", "ojos", "mediante", "técnica", "MICS", ",", "exéresis", "del", "pterigión", "del", "ojo", "izquierdo", "y", "exéresis", "de", "la", "lesión", "corneal", ",", "remitiéndose", "a", "estudio", "anatomopatológico", ",", "el", "cual", "informa", ":", "epitelio", "conjuntival", "con", "focos", "de", "atipia", "leve", "de", "las", "células", "de", "la", "capa", "basal", ",", "llegando", "a", "ocupar", "la", "atipia", ",", "a", "nivel", "del", "limbo", ",", "hasta", "2/3", "del", "espesor", "total", ",", "observándose", "escaso", "pleomorfismo", ".", "Degeneración", "elastótica", "actínica", "del", "corión", "y", "escaso", "infiltrado", "inflamatorio", "crónico", "linfocitario", "subepitelial", ".", "\n", "A", "los", "6", "meses", "se", "evidenció", "la", "presencia", "de", "islotes", "aislados", "recidivantes", ",", "tratándose", "nuevamente", "con", "Mitomicina", "-", "C", ",", "regresando", "la", "lesión", ",", "no", "evidenciándose", "nuevas", "recidivas", "en", "su", "seguimiento", "durante", "1", "año", ".", "\n", "Responsable", "clínico", ":", "Dr", ".", "José", "Manuel", "Janeiro", "Pais", ",", "Avda", ".", "Lázaro", "Cárdenas", ",", "23", "-", "1ºE", "15009", "La", "Coruña", "(", "España", ")", ".", "janeiropais@canalejo.org", "\n" ]

[ "CALLE", "CORREO_ELECTRONICO", "NOMBRE_PERSONAL_SANITARIO", "NOMBRE_SUJETO_ASISTENCIA", "ID_ASEGURAMIENTO", "ID_TITULACION_PERSONAL_SANITARIO", "FECHAS", "TERRITORIO", "EDAD_SUJETO_ASISTENCIA", "ID_CONTACTO_ASISTENCIAL", "ID_SUJETO_ASISTENCIA", "PAIS", "SEXO_SUJETO_ASISTENCIA" ]

Pedro is a NOMBRE_SUJETO_ASISTENCIA, Iglesias Pastor is a NOMBRE_SUJETO_ASISTENCIA, 1149404 is a ID_SUJETO_ASISTENCIA, 343551107164 is a ID_ASEGURAMIENTO, A Coruña is a TERRITORIO, 15003 is a TERRITORIO, 09/05/1945 is a FECHAS, España is a PAIS, 67 años is a EDAD_SUJETO_ASISTENCIA, 02/04/2013 is a FECHAS, 1287103 is a ID_CONTACTO_ASISTENCIAL, José Manuel Janeiro Pais is a NOMBRE_PERSONAL_SANITARIO, 15 15 65203 is a ID_TITULACION_PERSONAL_SANITARIO, Varón is a SEXO_SUJETO_ASISTENCIA, 67 años is a EDAD_SUJETO_ASISTENCIA, José Manuel Janeiro Pais is a NOMBRE_PERSONAL_SANITARIO, Avda . Lázaro Cárdenas , 23 - 1ºE is a CALLE, 15009 is a TERRITORIO, La Coruña is a TERRITORIO, España is a PAIS, janeiropais@canalejo.org is a CORREO_ELECTRONICO

185_task1

Sentence: Datos del paciente. Nombre: Pedro . Apellidos: Iglesias Pastor. NHC: 1149404. NASS: 343551107164. Domicilio: Rúa Comandante Fontanes, 19, 2 B. Localidad/ Provincia: A Coruña. CP: 15003. Datos asistenciales. Fecha de nacimiento: 09/05/1945. País de nacimiento: España. Edad: 67 años Sexo: H. Fecha de Ingreso: 02/04/2013. Episodio: 1287103. Médico: José Manuel Janeiro Pais NºCol: 15 15 65203. Informe clínico del paciente: Varón, de 67 años, con agudeza visual de 0,6 y 0,5 con cataratas nucleares grado 3 en ambos ojos. El ojo izquierdo mostraba un pterigión nasal grado I y diversas lesiones con forma de islotes corneales epiteliales con distribución semicircular inferior, no afectando al eje visual. No presentaba signos inflamatorios en el segmento anterior y el resto de la exploración es normal. Se instauró tratamiento con Mitomicina-C 0,02% preoperatorio (1), con reducción de la lesión a 1/3 de su tamaño. Se realizó intervención de cataratas en ambos ojos mediante técnica MICS, exéresis del pterigión del ojo izquierdo y exéresis de la lesión corneal, remitiéndose a estudio anatomopatológico, el cual informa: epitelio conjuntival con focos de atipia leve de las células de la capa basal, llegando a ocupar la atipia, a nivel del limbo, hasta 2/3 del espesor total, observándose escaso pleomorfismo. Degeneración elastótica actínica del corión y escaso infiltrado inflamatorio crónico linfocitario subepitelial. A los 6 meses se evidenció la presencia de islotes aislados recidivantes, tratándose nuevamente con Mitomicina-C, regresando la lesión, no evidenciándose nuevas recidivas en su seguimiento durante 1 año. Responsable clínico: Dr. José Manuel Janeiro Pais, Avda. Lázaro Cárdenas, 23 - 1ºE 15009 La Coruña (España). janeiropais@canalejo.org Instructions: please typing these entity words according to sentence: Pedro, Iglesias Pastor, 1149404, 343551107164, A Coruña, 15003, 09/05/1945, España, 67 años, 02/04/2013, 1287103, José Manuel Janeiro Pais, 15 15 65203, Varón, 67 años, José Manuel Janeiro Pais, Avda . Lázaro Cárdenas , 23 - 1ºE, 15009, La Coruña, España, janeiropais@canalejo.org Options: TERRITORIO, SEXO_SUJETO_ASISTENCIA, ID_SUJETO_ASISTENCIA, FECHAS, CALLE, CORREO_ELECTRONICO, PAIS, EDAD_SUJETO_ASISTENCIA, ID_CONTACTO_ASISTENCIAL, ID_ASEGURAMIENTO, ID_TITULACION_PERSONAL_SANITARIO, NOMBRE_SUJETO_ASISTENCIA, NOMBRE_PERSONAL_SANITARIO

[ "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_ASEGURAMIENTO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "I-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-ID_CONTACTO_ASISTENCIAL", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "B-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "B-TERRITORIO", "B-TERRITORIO", "I-TERRITORIO", "O", "B-PAIS", "O", "O", "B-CORREO_ELECTRONICO", "O" ]

Datos del paciente. Nombre: Pedro . Apellidos: Iglesias Pastor. NHC: 1149404. NASS: 343551107164. Domicilio: Rúa Comandante Fontanes, 19, 2 B. Localidad/ Provincia: A Coruña. CP: 15003. Datos asistenciales. Fecha de nacimiento: 09/05/1945. País de nacimiento: España. Edad: 67 años Sexo: H. Fecha de Ingreso: 02/04/2013. Episodio: 1287103. Médico: José Manuel Janeiro Pais NºCol: 15 15 65203. Informe clínico del paciente: Varón, de 67 años, con agudeza visual de 0,6 y 0,5 con cataratas nucleares grado 3 en ambos ojos. El ojo izquierdo mostraba un pterigión nasal grado I y diversas lesiones con forma de islotes corneales epiteliales con distribución semicircular inferior, no afectando al eje visual. No presentaba signos inflamatorios en el segmento anterior y el resto de la exploración es normal. Se instauró tratamiento con Mitomicina-C 0,02% preoperatorio (1), con reducción de la lesión a 1/3 de su tamaño. Se realizó intervención de cataratas en ambos ojos mediante técnica MICS, exéresis del pterigión del ojo izquierdo y exéresis de la lesión corneal, remitiéndose a estudio anatomopatológico, el cual informa: epitelio conjuntival con focos de atipia leve de las células de la capa basal, llegando a ocupar la atipia, a nivel del limbo, hasta 2/3 del espesor total, observándose escaso pleomorfismo. Degeneración elastótica actínica del corión y escaso infiltrado inflamatorio crónico linfocitario subepitelial. A los 6 meses se evidenció la presencia de islotes aislados recidivantes, tratándose nuevamente con Mitomicina-C, regresando la lesión, no evidenciándose nuevas recidivas en su seguimiento durante 1 año. Responsable clínico: Dr. José Manuel Janeiro Pais, Avda. Lázaro Cárdenas, 23 - 1ºE 15009 La Coruña (España). janeiropais@canalejo.org

[ "Datos", "del", "paciente", ".", "\n", "Nombre", ":", "Pedro", ".", "\n", "Apellidos", ":", "Iglesias", "Pastor", ".", "\n", "NHC", ":", "1149404", ".", "\n", "NASS", ":", "343551107164", ".", "\n", "Domicilio", ":", "Rúa", "Comandante", "Fontanes", ",", "19", ",", "2", "B.", "\n", "Localidad/", "Provincia", ":", "A", "Coruña", ".", "\n", "CP", ":", "15003", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "09/05/1945", ".", "\n", "País", "de", "nacimiento", ":", "España", ".", "\n", "Edad", ":", "67", "años", "Sexo", ":", "H.", "\n", "Fecha", "de", "Ingreso", ":", "02/04/2013", ".", "\n", "Episodio", ":", "1287103", ".", "\n", "Médico", ":", "José", "Manuel", "Janeiro", "Pais", " ", "NºCol", ":", "15", "15", "65203", ".", "\n", "Informe", "clínico", "del", "paciente", ":", "Varón", ",", "de", "67", "años", ",", "con", "agudeza", "visual", "de", "0,6", "y", "0,5", "con", "cataratas", "nucleares", "grado", "3", "en", "ambos", "ojos", ".", "El", "ojo", "izquierdo", "mostraba", "un", "pterigión", "nasal", "grado", "I", "y", "diversas", "lesiones", "con", "forma", "de", "islotes", "corneales", "epiteliales", "con", "distribución", "semicircular", "inferior", ",", "no", "afectando", "al", "eje", "visual", ".", "No", "presentaba", "signos", "inflamatorios", "en", "el", "segmento", "anterior", "y", "el", "resto", "de", "la", "exploración", "es", "normal", ".", "\n", "Se", "instauró", "tratamiento", "con", "Mitomicina", "-", "C", "0,02", "%", "preoperatorio", "(", "1", ")", ",", "con", "reducción", "de", "la", "lesión", "a", "1/3", "de", "su", "tamaño", ".", "\n", "Se", "realizó", "intervención", "de", "cataratas", "en", "ambos", "ojos", "mediante", "técnica", "MICS", ",", "exéresis", "del", "pterigión", "del", "ojo", "izquierdo", "y", "exéresis", "de", "la", "lesión", "corneal", ",", "remitiéndose", "a", "estudio", "anatomopatológico", ",", "el", "cual", "informa", ":", "epitelio", "conjuntival", "con", "focos", "de", "atipia", "leve", "de", "las", "células", "de", "la", "capa", "basal", ",", "llegando", "a", "ocupar", "la", "atipia", ",", "a", "nivel", "del", "limbo", ",", "hasta", "2/3", "del", "espesor", "total", ",", "observándose", "escaso", "pleomorfismo", ".", "Degeneración", "elastótica", "actínica", "del", "corión", "y", "escaso", "infiltrado", "inflamatorio", "crónico", "linfocitario", "subepitelial", ".", "\n", "A", "los", "6", "meses", "se", "evidenció", "la", "presencia", "de", "islotes", "aislados", "recidivantes", ",", "tratándose", "nuevamente", "con", "Mitomicina", "-", "C", ",", "regresando", "la", "lesión", ",", "no", "evidenciándose", "nuevas", "recidivas", "en", "su", "seguimiento", "durante", "1", "año", ".", "\n", "Responsable", "clínico", ":", "Dr", ".", "José", "Manuel", "Janeiro", "Pais", ",", "Avda", ".", "Lázaro", "Cárdenas", ",", "23", "-", "1ºE", "15009", "La", "Coruña", "(", "España", ")", ".", "janeiropais@canalejo.org", "\n" ]

[ "CALLE", "CORREO_ELECTRONICO", "NOMBRE_PERSONAL_SANITARIO", "NOMBRE_SUJETO_ASISTENCIA", "ID_ASEGURAMIENTO", "ID_TITULACION_PERSONAL_SANITARIO", "FECHAS", "TERRITORIO", "EDAD_SUJETO_ASISTENCIA", "ID_CONTACTO_ASISTENCIAL", "ID_SUJETO_ASISTENCIA", "PAIS", "SEXO_SUJETO_ASISTENCIA" ]